PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	BUCHWALD, D; UMALI, P; UMALI, J; KITH, P; PEARLMAN, T; KOMAROFF, AL				BUCHWALD, D; UMALI, P; UMALI, J; KITH, P; PEARLMAN, T; KOMAROFF, AL			CHRONIC FATIGUE AND THE CHRONIC-FATIGUE-SYNDROME - PREVALENCE IN A PACIFIC-NORTHWEST HEALTH-CARE SYSTEM	ANNALS OF INTERNAL MEDICINE			English	Article						FATIGUE; FATIGUE SYNDROME, CHRONIC; HEALTH STATUS INDICATORS; LYMPHADENITIS; PSYCHOPHYSIOLOGICAL DISORDERS	GENERAL-PRACTICE; FOLLOW-UP; SYMPTOMS; EPIDEMIOLOGY; DEFINITION; POPULATION	Objectives: To investigate the point prevalence of the chronic fatigue syndrome and unexplained debilitating chronic fatigue in a community-based sample of persons and to describe demographic, clinical, and psychosocial differences among those with the chronic fatigue syndrome, those with chronic fatigue, and healthy controls. Design: Prospective cohort study. Setting: A health maintenance organization in Seattle, Washington. Participants: A random sample of 4000 members of the health maintenance organization was surveyed by mail for the presence of chronic fatigue. Measurements: Persons with chronic fatigue were evaluated using a questionnaire that requested information about medical history and fatigue and related symptoms; validated measures of functional status and psychological distress; a physical examination; and standardized blood tests. A structured psychiatric interview was done in persons who appeared to meet the original Centers for Disease Control and Prevention (CDC) criteria for the chronic fatigue syndrome. Participants completed self-report measures at 12 and 24 months. Those with chronic fatigue were reevaluated in person 1 year after study enrollment. Results. 3066 (77%) of the 4000 members surveyed responded. Chronic fatigue was reported by 590 persons (19%). Of these, 388 (66%) had a medical or psychiatric condition that could account for the fatigue. Of the 74 persons (37%) with chronic fatigue who were enrolled in the study, only 3 met the CDC criteria for the chronic fatigue syndrome. The remaining 71 persons were designated as having chronic fatigue alone. Seventy-four healthy, age- and sex-matched controls who were drawn from the same sample but who denied having chronic fatigue were also studied. Demographic characteristics were similar in persons with the chronic fatigue syndrome, persons with chronic fatigue atone, and controls. Those with the chronic fatigue syndrome or chronic fatigue alone had more frequent cervical and axillary adenopathy, poorer functional status, and greater psychological distress than controls. Women and minorities were not overrepresented among cases with chronic fatigue. Conclusions: Using different assumptions about the likelihood that persons who did not participate in the study had the chronic fatigue syndrome, the estimated crude point prevalence of the syndrome in this community ranged from 75 to 267 cases per 100 000 persons. The point prevalence of chronic fatigue alone was strikingly higher; it ranged from 1775 to 6321 cases per 100 000 persons.	HARVARD UNIV, SCH MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, BOSTON, MA USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	BUCHWALD, D (corresponding author), UNIV WASHINGTON, HARBORVIEW MED CTR, 325 9TH AVE ZA-60, SEATTLE, WA 98104 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI032246, R01AI026788, R01AI027314] Funding Source: NIH RePORTER; NIAID NIH HHS [UO1 AI32246, R01 AI27314, R01 AI26788] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATES DW, 1993, ARCH INTERN MED, V153, P2759, DOI 10.1001/archinte.153.24.2759; BUCHWALD D, 1987, JAMA-J AM MED ASSOC, V257, P2303, DOI 10.1001/jama.257.17.2303; CATHEBRAS PJ, 1992, J GEN INTERN MED, V7, P276, DOI 10.1007/BF02598083; CHEN MK, 1986, PREV MED, V15, P74, DOI 10.1016/0091-7435(86)90037-X; CLARK MR, 1995, AM J MED, V98, P187, DOI 10.1016/S0002-9343(99)80403-3; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; GOLD D, 1990, JAMA-J AM MED ASSOC, V264, P48, DOI 10.1001/jama.264.1.48; Gore, 1987, HLTH LIFESTYLE SURVE; GUNN WJ, 1993, CIBA F SYMP, V173, P83; HAMMOND EC, 1964, AM J PUBLIC HEALTH N, V54, P11, DOI 10.2105/AJPH.54.1.11; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; HOYEN DO, 1991, BRIT J GEN PRACT, V41, P324; HOYEN DO, 1988, SCOT MED J, V33, P368, DOI 10.1177/003693308803300607; JERRETT WA, 1981, PRACTITIONER, V225, P731; KELLNER R, 1973, AM J PSYCHIAT, V130, P102, DOI 10.1176/ajp.130.1.102; KROENKE K, 1988, JAMA-J AM MED ASSOC, V260, P929, DOI 10.1001/jama.260.7.929; KROENKE K, 1990, ARCH INTERN MED, V150, P1685, DOI 10.1001/archinte.150.8.1685; LLOYD AR, 1990, MED J AUSTRALIA, V153, P522, DOI 10.5694/j.1326-5377.1990.tb126191.x; MATTHEWS DA, 1990, CLIN RES, V38, pA699; MCDONALD E, 1993, PSYCHOL MED, V23, P987, DOI 10.1017/S0033291700026453; MORRISON JD, 1980, J FAM PRACTICE, V10, P795; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; PRICE RK, 1992, PUBLIC HEALTH REP, V107, P514; REIDENBERG MM, 1968, NEW ENGL J MED, V279, P678, DOI 10.1056/NEJM196809262791304; Robins L.N., 1985, DIAGNOSTIC INTERVIEW; SCHLUEDERBERG A, 1992, ANN INTERN MED, V117, P325, DOI 10.7326/0003-4819-117-4-325; SHARPE M, 1992, BRIT MED J, V305, P147, DOI 10.1136/bmj.305.6846.147; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; TARNOPOLSKY A, 1980, PSYCHOL MED, V10, P683, DOI 10.1017/S0033291700054982; VALDINI AF, 1988, J FAM PRACTICE, V26, P33; 1987, DIAGNOSTIC STATISTIC	34	173	177	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1995	123	2					81	88		10.7326/0003-4819-123-2-199507150-00001	http://dx.doi.org/10.7326/0003-4819-123-2-199507150-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM435	7778839				2022-12-24	WOS:A1995RM43500001
J	NIGHTINGALE, SL				NIGHTINGALE, SL			ONE-DAY COURSE ON CLINICAL-TRIALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1897	1897						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783288				2022-12-24	WOS:A1995RE35400007
J	ALLABY, MAK				ALLABY, MAK			CONTRACEPTIVE SERVICES FOR TEENAGERS - DO WE NEED FAMILY-PLANNING CLINICS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether the effectiveness of contraceptive services for teenagers is related to the balance of service provision between general practitioners and specialist family planning services. Design-Cross sectional study with routinely collected data from family planning clinics and family health services authorities and published data on births and abortions. Setting-Eight health districts in the former Oxford region. Subjects-Girls aged under 16 and women aged 16-19 who attended a contraceptive service during 1991-2 or who gave birth or had an abortion during 1990-2. Main outcome measures-Attenders at family planning clinics as a percentage of all users of contraceptive services. The conception rate:uptake of contraceptive services ratio was used as a measure of effectiveness. Results-In comparisons between districts the percentage of all users of contraceptive services who attended a clinic varied fi om 38% (95% confidence interval 28% to 48%) to 79% (72% to 86%) among 13-15 year olds and from 14% (12% to 15%) to 44% (42% to 46%) among women aged 16-19 years. The conception rate:uptake of contraceptive services ratio varied twofold in the older age group and more than threefold in the younger age group. It was lowest in districts where clinic attenders comprised a large percentage of all users of contraceptive services. Conclusion-Contraceptive services for teenagers may be more effective in districts where clinics play a large part in delivering the service, particularly for girls aged under 16.			ALLABY, MAK (corresponding author), NORTHAMPTONSHIRE HLTH AUTHOR,DEPT PUBL HLTH MED,NORTHAMPTON NN1 5DN,ENGLAND.							ALLEN I, 1991, FAMILY PLANNING PREG; IBBOTSON S, 1992, BRIT MED J, V305, P835, DOI 10.1136/bmj.305.6857.835-b; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; ROXBY M, 1992, HLTH NEEDS ASSESSMEN; SHEPHERD M, 1988, CONSUMER PREFERENCES; 1992, GUIDELINES REVIEWING; 1992, ABORTION STATISTICS; 1992, HLTH NATION STRATEGY; 1992, FM1 OFF POP CENS SUR; 1990, FM1 OFF POP CENS SUR; 1990, ABORTION STATISTICS; 1994, 37 FAC PUBL HLTH MED; 1991, ABORTION STATISTICS; 1991, FM1 OFF POP CENS SUR	14	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1641	1643		10.1136/bmj.310.6995.1641	http://dx.doi.org/10.1136/bmj.310.6995.1641			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RF698	7795452	Green Published			2022-12-24	WOS:A1995RF69800024
J	WINKLER, J; SUHR, ST; GAGE, FH; THAL, LJ; FISHER, LJ				WINKLER, J; SUHR, ST; GAGE, FH; THAL, LJ; FISHER, LJ			ESSENTIAL ROLE OF NEOCORTICAL ACETYLCHOLINE IN SPATIAL MEMORY	NATURE			English	Article							NUCLEUS BASALIS MAGNOCELLULARIS; EXCITOTOXIC LESIONS; CHOLINERGIC SYSTEM; SENILE DEMENTIA; IBOTENIC ACID; FOREBRAIN; RATS; NEURONS; ACETYLTRANSFERASE; PHYSOSTIGMINE	THE cholinergic system plays a crucial role in learning and memory. Lesions of cholinergic nuclei(1-4), pharmacological manipulations of cholinergic systems(5-8), intracerebral transplantation of fetal tissue(9-11) and anatomical changes in cholinergic pathways during ageing(12-14) have all been correlated with altered cognitive behaviour. However, it has not been proved that regional acetylcholine is causally required for learning and memory. Here we describe how we achieved a permanent and selective impairment of learning and memory by damaging the nucleus basalis magnocellularis, a nucleus that provides the major cholinergic innervation of the neocortex(15,16), in adult rats. To test the hypothesis that acetylcholine is essential for restoration of cognitive function, we implanted genetically modified cells that produce acetylcholine(17) into denervated neocortical target regions. After grafting, rats with increased neocortical acetylcholine levels showed a significant improvement in a spatial navigation task. Acetylcholine is thus not only necessary for learning and memory, as previously argued, but its presence within the neocortex is also sufficient to ameliorate learning deficits and restore memory following damage to the nucleus basalis.	UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; VET AFFAIRS MED CTR,DEPT NEUROL,SAN DIEGO,CA 92161	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)								ALKON DL, 1991, BRAIN RES REV, V16, P193, DOI 10.1016/0165-0173(91)90005-S; ARENDT T, 1989, NEUROSCIENCE, V33, P435, DOI 10.1016/0306-4522(89)90397-7; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BERGERSWEENEY J, 1994, J NEUROSCI, V14, P4507; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOEGMAN RJ, 1992, NEUROSCIENCE, V51, P129, DOI 10.1016/0306-4522(92)90477-J; CONNOR DJ, 1991, BRAIN RES, V555, P84, DOI 10.1016/0006-8993(91)90863-Q; DECKER MW, 1991, SYNAPSE, V7, P151, DOI 10.1002/syn.890070209; DEKKER AJAM, 1991, NEUROSCI BIOBEHAV R, V15, P299, DOI 10.1016/S0149-7634(05)80008-9; DUNNETT SB, 1985, NEUROSCIENCE, V16, P787, DOI 10.1016/0306-4522(85)90094-6; DUNNETT SB, 1991, TRENDS NEUROSCI, V14, P494, DOI 10.1016/0166-2236(91)90061-X; FIBIGER HC, 1982, BRAIN RES REV, V4, P327, DOI 10.1016/0165-0173(82)90011-X; FISHER LJ, 1993, J NEUROCHEM, V61, P1323, DOI 10.1111/j.1471-4159.1993.tb13625.x; FREED WJ, 1990, EXP NEUROL, V110, P139, DOI 10.1016/0014-4886(90)90026-O; GAGE FH, 1986, J NEUROSCI, V6, P2837; GAGE FH, 1991, NEURON, V6, P1, DOI 10.1016/0896-6273(91)90116-H; GIROD R, IN PRESS J NEUROSCI; GRANT SGN, 1994, TRENDS NEUROSCI, V17, P71, DOI 10.1016/0166-2236(94)90077-9; MANDEL RJ, 1988, PSYCHOPHARMACOLOGY, V96, P421, DOI 10.1007/BF00216074; MANDEL RJ, 1989, BEHAV BRAIN RES, V31, P221, DOI 10.1016/0166-4328(89)90004-1; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; MUIR JL, 1993, BEHAV BRAIN RES, V57, P123, DOI 10.1016/0166-4328(93)90128-D; MURRAY CL, 1985, NEUROSCIENCE, V14, P1025, DOI 10.1016/0306-4522(85)90273-8; NILSSON OG, 1987, EXP BRAIN RES, V67, P195, DOI 10.1007/BF00269466; PAGE KJ, 1991, NEUROSCIENCE, V43, P457, DOI 10.1016/0306-4522(91)90308-B; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; PERRY EK, 1978, BRIT MED J, V2, P1457, DOI 10.1136/bmj.2.6150.1457; TAKAHASHI JS, 1994, SCIENCE, V264, P1724, DOI 10.1126/science.8209253; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341	29	246	255	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					484	487		10.1038/375484a0	http://dx.doi.org/10.1038/375484a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777056				2022-12-24	WOS:A1995RC18800047
J	KOCH, WJ; ROCKMAN, HA; SAMAMA, P; HAMILTON, RA; BOND, RA; MILANO, CA; LEFKOWITZ, RJ				KOCH, WJ; ROCKMAN, HA; SAMAMA, P; HAMILTON, RA; BOND, RA; MILANO, CA; LEFKOWITZ, RJ			CARDIAC-FUNCTION IN MICE OVEREXPRESSING THE BETA-ADRENERGIC-RECEPTOR KINASE OR A BETA-ARK INHIBITOR	SCIENCE			English	Article							BETA-2-ADRENERGIC RECEPTORS; GAMMA-SUBUNITS; G-PROTEINS; BINDING; DESENSITIZATION; PATHWAYS; LIGAND; HEART	Transgenic mice were created with cardiac-specific overexpression of the beta-adrenergic receptor kinase-1 (beta ARK1) or a beta ARK inhibitor. Animals overexpressing beta ARK1 demonstrated attenuation of isoproterenol-stimulated left ventricular contractility in vivo, dampening of myocardial adenylyl cyclase activity, and reduced functional coupling of beta-adrenergic receptors. Conversely, mice expressing the beta ARK inhibitor displayed enhanced cardiac contractility in vivo with or without isoproterenol. These animals demonstrate the important role of beta ARK in modulating in vivo myocardial function. Because increased amounts of beta ARK1 and diminished cardiac beta-adrenergic responsiveness characterize heart failure, these animals may provide experimental models to study the role of beta ARK in heart disease.	DUKE UNIV,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,DEPT SURG,DURHAM,NC 27710; UNIV HOUSTON,DEPT PHARMACOL & PHARMACEUT SCI,HOUSTON,TX 77204	Duke University; Howard Hughes Medical Institute; Duke University; University of Houston System; University of Houston	KOCH, WJ (corresponding author), DUKE UNIV,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710, USA.		Lefkowitz, Robert/AAW-2649-2021		NATIONAL CANCER INSTITUTE [F32CA009350] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NCI NIH HHS [5F32-CA09350] Funding Source: Medline; NHLBI NIH HHS [HL-16037] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOEKHOFF I, 1994, J BIOL CHEM, V269, P37; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISTOW MR, 1985, J MOL CELL CARDIOL, V17, P41, DOI 10.1016/0022-2828(85)90007-0; BRISTOW MR, 1990, CIRCULATION, V82, P12; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; BRODDE OE, 1993, PHARMACOL THERAPEUT, V60, P405, DOI 10.1016/0163-7258(93)90030-H; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELEAN A, 1980, J BIOL CHEM, V255, P7106; FREEDMAN NJ, UNPUB; GREEN SA, 1992, MOL PHARMACOL, V41, P889; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; INGLESE J, 1993, J BIOL CHEM, V268, P23735; INGLESE J, 1992, NATURE, V359, P149; KENT RS, 1980, MOL PHARMACOL, V17, P14; KOCH W, UNPUB; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; ROCKMAN HA, 1994, P NATL ACAD SCI USA, V91, P2694, DOI 10.1073/pnas.91.7.2694; ROCKMAN HA, UNPUB; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454	30	620	643	0	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1350	1353		10.1126/science.7761854	http://dx.doi.org/10.1126/science.7761854			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761854				2022-12-24	WOS:A1995RB19800039
J	WIRTZ, E; CLAYTON, C				WIRTZ, E; CLAYTON, C			INDUCIBLE GENE-EXPRESSION IN TRYPANOSOMES MEDIATED BY A PROKARYOTIC REPRESSOR	SCIENCE			English	Article							RNA-POLYMERASE-I; AMANITIN-RESISTANT TRANSCRIPTION; TN10-ENCODED TET-REPRESSOR; PROTEIN-CODING GENES; COLI LAC REPRESSOR; CAMV 35S PROMOTER; REPETITIVE PROTEIN; HOMOLOGOUS RECOMBINATION; DISCONTINUOUS TRANSCRIPTION; DEVELOPMENTAL REGULATION	An inducible expression system was developed for the protozoan parasite Trypanosoma brucei. Transgenic trypanosomes expressing the tetracycline repressor of Escherichia coli exhibited inducer (tetracycline)-dependent expression of chromosomally integrated reporter genes under the control of a procyclic acidic repetitive protein (PARP) promoter bearing a fet operator. Reporter expression could be controlled over a range of four orders of magnitude in response to tetracycline concentration, a degree of regulation that exceeds those exhibited by other eukaryotic repression-based systems. The tet repressor-controlled PARP promoter should be a valuable tool for the study of trypanosome biochemistry, pathogenicity, and cell and molecular biology.	UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg			Clayton, Christine/K-7700-2019	Clayton, Christine/0000-0002-6384-0731				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; ALTSCHMIED L, 1988, EMBO J, V7, P4011, DOI 10.1002/j.1460-2075.1988.tb03290.x; ANZ L, 1994, MOL CELL BIOL, V14, P5804; Beverley S. M., 1993, PROTOCOLS MOL PARASI, P333; BEVERLEY SM, UNPUB; BONIN A, 1994, THESIS U HEIDELBERG; BROWN M, 1987, CELL, V49, P603, DOI 10.1016/0092-8674(87)90536-8; BROWN SD, 1992, MOL CELL BIOL, V12, P2644, DOI 10.1128/MCB.12.6.2644; CHUNG HM, 1992, PARASITOL TODAY, V8, P414, DOI 10.1016/0169-4758(92)90194-7; CHUNG HMM, 1993, MOL CELL BIOL, V13, P3734, DOI 10.1128/MCB.13.6.3734; CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036; CLAYTON CE, 1992, PROGR NUCLEIC ACID R, P37; DINGERMANN T, 1992, EMBO J, V11, P1487, DOI 10.1002/j.1460-2075.1992.tb05193.x; DINGERMANN T, 1992, MOL CELL BIOL, V12, P4038, DOI 10.1128/MCB.12.9.4038; EID J, 1991, P NATL ACAD SCI USA, V88, P2118, DOI 10.1073/pnas.88.6.2118; EID JE, 1991, GENE DEV, V5, P2024, DOI 10.1101/gad.5.11.2024; FIGGE J, 1988, CELL, V52, P713, DOI 10.1016/0092-8674(88)90409-6; FLASPOHLER J, UNPUB; GATZ C, 1991, MOL GEN GENET, V227, P229, DOI 10.1007/BF00259675; GATZ C, 1988, P NATL ACAD SCI USA, V85, P1394, DOI 10.1073/pnas.85.5.1394; GATZ C, 1992, PLANT J, V2, P397, DOI 10.1046/j.1365-313X.1992.t01-37-00999.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAMM B, 1990, MOL BIOCHEM PARASIT, V40, P13, DOI 10.1016/0166-6851(90)90075-W; HEINS L, 1992, MOL GEN GENET, V232, P328, DOI 10.1007/BF00280013; Hillen W., 1989, TOPICS MOL STRUCTURA, V10, P143; HU MCT, 1991, GENE, V99, P141, DOI 10.1016/0378-1119(91)90120-Z; HU MCT, 1987, CELL, V48, P555, DOI 10.1016/0092-8674(87)90234-0; HUG M, 1993, MOL BIOCHEM PARASIT, V61, P87, DOI 10.1016/0166-6851(93)90161-P; KONIG E, 1989, NUCLEIC ACIDS RES, V17, P8727, DOI 10.1093/nar/17.21.8727; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; LEE MGS, 1991, GENE, V105, P255, DOI 10.1016/0378-1119(91)90159-9; MOWATT MR, 1987, MOL CELL BIOL, V7, P2838, DOI 10.1128/MCB.7.8.2838; NILSEN TW, 1994, SCIENCE, V264, P1868, DOI 10.1126/science.7912006; PAYS E, 1990, EMBO J, V9, P3145, DOI 10.1002/j.1460-2075.1990.tb07512.x; PAYS E, 1992, SOC GENERL MICROBIOL, V50, P127; RODITI I, 1987, NATURE, V325, P272, DOI 10.1038/325272a0; RUDENKO G, 1991, EMBO J, V10, P3387, DOI 10.1002/j.1460-2075.1991.tb04903.x; RUDENKO G, 1992, NUCLEIC ACIDS RES, V20, P303, DOI 10.1093/nar/20.2.303; RUDENKO G, 1990, MOL CELL BIOL, V10, P3492, DOI 10.1128/MCB.10.7.3492; RUDENKO G, 1994, EMBO J, V13, P5470, DOI 10.1002/j.1460-2075.1994.tb06882.x; RUDENKO G, 1989, EMBO J, V8, P4259, DOI 10.1002/j.1460-2075.1989.tb08611.x; SHERMAN DR, 1991, EMBO J, V10, P3379, DOI 10.1002/j.1460-2075.1991.tb04902.x; SIMPSON L, 1994, SCIENCE, V264, P1870, DOI 10.1126/science.8009214; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; VANDERPLOEG LHT, 1986, CELL, V47, P479, DOI 10.1016/0092-8674(86)90608-2; WHITE TC, 1986, NUCLEIC ACIDS RES, V14, P9471, DOI 10.1093/nar/14.23.9471; WIRTZ E, 1994, NUCLEIC ACIDS RES, V22, P3887, DOI 10.1093/nar/22.19.3887; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153; ZOMERDIJK JCBM, 1991, NATURE, V353, P772, DOI 10.1038/353772a0; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x	54	195	201	0	16	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1179	1183		10.1126/science.7761835	http://dx.doi.org/10.1126/science.7761835			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761835				2022-12-24	WOS:A1995RA60400038
J	FERGUSON, AE; GIBSON, NA; AITCHISON, TC; PATON, JY				FERGUSON, AE; GIBSON, NA; AITCHISON, TC; PATON, JY			MEASURED BRONCHODILATOR USE IN PRESCHOOL-CHILDREN WITH ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							MEDICATION	Objective-To investigate how parents use bronchodilator treatment for relief of symptoms when treating their asthmatic preschool children. Design-A commercial electromechanical timer device was attached to a large volume spacer to record the time and date of each use of inhaled bronchodilator over two months. The recorded time and dates were compared with symptoms noted in an asthma diary card. Setting-Large paediatric teaching hospital in Glasgow. Subjects-29 preschool children with moderately severe asthma attending a specialist paediatric asthma clinic. Main outcome measures-Inhaler use measured by the timer device; symptoms and inhaler use recorded by parents in a daily asthma diary. Results-Satisfactory data were obtained in 22 of the 29 children; the median number of study days was 53 (range 18-77). Asthmatic symptoms were recorded on a median of 30 (3-77) days. Bronchodilator was used on a median of 19 (2-73) days, or on 63% (7-100%) of days when symptoms occurred. The median number of puffs used in a day was 1 (range 0-100) and was significantly related to symptom severity in only 14 of the 22 children. In only two of the 22 children was bronchodilator given more frequently than four hourly, and only five children ever used more than 12 puffs a day. Conclusions-The frequency of parental administration of bronchodilator treatment was variable and not closely related to the parent's record of symptom severity. Parents often recorded symptoms in their children but did not treat them.	UNIV GLASGOW,DEPT STAT,GLASGOW G12 8QQ,LANARK,SCOTLAND	University of Glasgow	FERGUSON, AE (corresponding author), ROYAL HOSP SICK CHILDREN,DEPT CHILD HLTH,GLASGOW G3 8SJ,LANARK,SCOTLAND.							[Anonymous], 1993, THORAX, V48, pS1; ARCHER LNJ, 1985, ARCH DIS CHILD, V60, P473, DOI 10.1136/adc.60.5.473; BOSLEY CM, 1994, EUR RESPIR J, V7, P504, DOI 10.1183/09031936.94.07030504; COUTTS JAP, 1992, ARCH DIS CHILD, V67, P332, DOI 10.1136/adc.67.3.332; GLEESON JGA, 1988, BRIT J DIS CHEST, V82, P172, DOI 10.1016/0007-0971(88)90039-3; Lenny W, 1994, EUR RESPIR REV, V4, P49; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; Sears M R, 1991, Bull Int Union Tuberc Lung Dis, V66, P79; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPECTOR SL, 1986, J ALLERGY CLIN IMMUN, V77, P65, DOI 10.1016/0091-6749(86)90325-8	10	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1161	1164		10.1136/bmj.310.6988.1161	http://dx.doi.org/10.1136/bmj.310.6988.1161			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX566	7767149	Green Published			2022-12-24	WOS:A1995QX56600019
J	SATO, S; SUZUKI, K; AKAHANE, Y; AKAMATSU, K; AKIYAMA, K; YUNOMURA, K; TSUDA, F; TANAKA, T; OKAMOTO, H; MIYAKAWA, Y; MAYUMI, M				SATO, S; SUZUKI, K; AKAHANE, Y; AKAMATSU, K; AKIYAMA, K; YUNOMURA, K; TSUDA, F; TANAKA, T; OKAMOTO, H; MIYAKAWA, Y; MAYUMI, M			HEPATITIS-B VIRUS-STRAINS WITH MUTATIONS IN THE CORE PROMOTER IN PATIENTS WITH FULMINANT-HEPATITIS	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B E ANTIGENS; GENETIC CODE	COMPLETE NUCLEOTIDE-SEQUENCE; PRECORE-REGION DEFECTS; E-ANTIGEN; PREGENOME ENCAPSIDATION; HBV-DNA; PROTEIN; EXPRESSION; ANTIBODY; MUTANTS; INFECTION	Objective: Fulminant hepatitis B can be induced by hepatitis B virus (HBV) strains with mutations in the precore region that cannot encode hepatitis B e antigen (HBeAg). Such mutations are rarely seen in HBV DNA clones from patients with fulminant hepatitis B in the United States and France. Thus, the other mutations in HBV strains causing fulminant hepatitis B need to be identified. Design: Retrospective clinical, serologic, and molecular biological studies of patients with fulminant hepatitis B. Setting: University and city hospitals in Japan. Patients: 43 patients with fulminant hepatitis B. Measurements: The precore region coding fora part of the HBeAg precursor and the core promoter regulating the transcription of precore messenger RNA were sequenced in HBV DNA clones. Results: A point mutation from G to A at nucleotide 1896 in the precore region was detected in 519 (98%) of 529 HBV DNA clones from 38 patients. Two point mutations in the core promoter, from A to T at nucleotide 1762 and from G to A at nucleotide 1764, were detected in all 130 clones from the remaining 5 patients, who did not have mutations in the precore region, and in 20 (63%) of 32 clones from a patient with chronic hepatitis B who had transmitted HBV to 1 of these other 5 patients. Mutations in the core promoter were also detected in clones from 26 (68%) of the 38 patients with the precore mutation at nucleotide 1896. Neither HBeAg nor antibody to HBeAg was detected in 37 (90%) of the 41 patients tested. Conclusions: In Japan, fulminant hepatitis B is closely associated with HBV strains that do not produce HBeAg because of mutations in the precore region, which affect translation of HBeAg, or because of mutations in the core promoter, which affect transcription of the HBeAg coding region.	JICHI MED SCH, DIV IMMUNOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; IWATE MED UNIV, SCH MED, DEPT INTERNAL MED 1, MORIOKA, IWATE 020, JAPAN; YAMANASHI MED UNIV, DEPT INTERNAL MED 1, TAMAHO, YAMANASHI 40938, JAPAN; EHIME UNIV, SCH MED, DEPT INTERNAL MED 3, SHIGENOBU, EHIME 79102, JAPAN; ASAHIKAWA MED COLL, DEPT INTERNAL MED 2, ASAHIKAWA, HOKKAIDO 078, JAPAN; DOKKYO UNIV, SCH MED, DEPT INTERNAL MED 2, MIBU, TOCHIGI 32102, JAPAN; TOSHIBA GEN HOSP, DEPT MED SCI, TOKYO 140, JAPAN; MITA INST, TOKYO 108, JAPAN; JAPANESE RED CROSS, SAITAMA BLOOD CTR, URAWA, SAITAMA 338, JAPAN	Jichi Medical University; Iwate Medical University; University of Yamanashi; Ehime University; Asahikawa Medical College; Dokkyo Medical University; Toshiba Corporation; Japanese Red Cross Medical Center			Okamoto, Hiroaki/H-4371-2011	Okamoto, Hiroaki/0000-0003-0827-0964				BRUNETTO MR, 1991, P NATL ACAD SCI USA, V88, P4186, DOI 10.1073/pnas.88.10.4186; BRUSS V, 1988, VIROLOGY, V163, P268, DOI 10.1016/0042-6822(88)90266-8; CARMAN WF, 1989, LANCET, V2, P588; CARMAN WF, 1991, HEPATOLOGY, V14, P219, DOI 10.1002/hep.1840140203; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; FERAY C, 1993, J HEPATOL, V18, P119, DOI 10.1016/S0168-8278(05)80019-4; GIMSON AES, 1983, GUT, V24, P615, DOI 10.1136/gut.24.7.615; IIZUKA H, 1992, VOX SANG, V63, P107, DOI 10.1111/j.1423-0410.1992.tb02495.x; JUNKERNIEPMANN M, 1990, EMBO J, V9, P3389, DOI 10.1002/j.1460-2075.1990.tb07540.x; KOJIMA M, 1991, VOX SANG, V60, P34, DOI 10.1111/j.1423-0410.1991.tb00868.x; KOSAKA Y, 1991, GASTROENTEROLOGY, V100, P1087, DOI 10.1016/0016-5085(91)90286-T; LASKUS T, 1993, GASTROENTEROLOGY, V105, P1173, DOI 10.1016/0016-5085(93)90964-E; LASKUS T, 1994, J HEPATOL, V20, P837, DOI 10.1016/S0168-8278(05)80158-8; LI JS, 1993, J VIROL, V67, P5402, DOI 10.1128/JVI.67.9.5402-5410.1993; LIANG TJ, 1991, NEW ENGL J MED, V324, P1705, DOI 10.1056/NEJM199106133242405; MCLACHLAN A, 1987, J VIROL, V61, P683, DOI 10.1128/JVI.61.3.683-692.1987; MILICH DR, 1990, P NATL ACAD SCI USA, V87, P6599, DOI 10.1073/pnas.87.17.6599; MISKA S, 1993, J HEPATOL, V18, P53, DOI 10.1016/S0168-8278(05)80009-1; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; OGATA N, 1993, VIROLOGY, V194, P263, DOI 10.1006/viro.1993.1257; OKAMOTO H, 1988, J GEN VIROL, V69, P2575, DOI 10.1099/0022-1317-69-10-2575; OKAMOTO H, 1990, J VIROL, V64, P1298, DOI 10.1128/JVI.64.3.1298-1303.1990; OMATA M, 1991, NEW ENGL J MED, V324, P1699, DOI 10.1056/NEJM199106133242404; PREISLERADAMS S, 1994, GASTROENTEROLOGY, V106, pA965; TAKAHASHI K, 1983, J IMMUNOL, V130, P2903; TERAZAWA S, 1991, PEDIATR RES, V29, P5, DOI 10.1203/00006450-199101000-00002; TONG SP, 1993, J VIROL, V67, P5651, DOI 10.1128/JVI.67.9.5651-5655.1993; TREPO CG, 1976, GUT, V17, P10, DOI 10.1136/gut.17.1.10; TREY C, 1968, NEW ENGL J MED, V279, P798, DOI 10.1056/NEJM196810102791504; TSUDA F, 1984, GASTROENTEROLOGY, V87, P159; VAUDIN M, 1988, J GEN VIROL, V69, P1383, DOI 10.1099/0022-1317-69-6-1383; WANG Y, 1990, J VIROL, V64, P3977, DOI 10.1128/JVI.64.8.3977-3981.1990; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WILL H, 1987, J VIROL, V61, P904, DOI 10.1128/JVI.61.3.904-911.1987; WOOLF IL, 1976, BMJ-BRIT MED J, V2, P669, DOI 10.1136/bmj.2.6037.669; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678; YOTSUMOTO S, 1992, HEPATOLOGY, V16, P31, DOI 10.1002/hep.1840160107; YUH CH, 1992, J VIROL, V66, P4073, DOI 10.1128/JVI.66.7.4073-4084.1992	38	257	279	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					241	248		10.7326/0003-4819-122-4-199502150-00001	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825758				2022-12-24	WOS:A1995QF76900001
J	WESTLEY, MS; BARAGIOLA, RA; JOHNSON, RE; BARATTA, GA				WESTLEY, MS; BARAGIOLA, RA; JOHNSON, RE; BARATTA, GA			PHOTODESORPTION FROM LOW-TEMPERATURE WATER ICE IN INTERSTELLAR AND CIRCUMSOLAR GRAINS	NATURE			English	Article							MOLECULAR CLOUDS; RADIATION-FIELD; DENSE CLOUDS; LIGHT-IONS; DUST; MAGNETOSPHERE; DESORPTION	Dust grains in the interstellar medium(1) and the outer Solar System(2-4) commonly have a coating of water ice, which affects their optical properties and surface chemistry, The thickness of these icy mantles may be determined in part by the extent of photodesorption (photosputtering) by background ultraviolet radiation, But this process is poorly understood, with theoretical estimates of the photodesorption rate spanning several orders of magnitude(5,6). Here we report measurements of the absolute ultraviolet photodesorption yield of low-temperature water ice, Our results indicate that the rate of photodesorption is appreciable. In particular, it can account for the absence of icy mantles on grains in diffuse interstellar clouds, it exceeds solar-wind ion erosion and sublimation in the outer Solar System, and it is important in determining the lifetimes of icy mantles in dense molecular clouds.	UNIV CATANIA,OSSERVATORIO ASTROFIS,CATANIA,ITALY	Istituto Nazionale Astrofisica (INAF); University of Catania	WESTLEY, MS (corresponding author), UNIV VIRGINIA,THORNTON HALL,CHARLOTTESVILLE,VA 22901, USA.		Baratta, Giuseppe/AAY-6188-2021	Baratta, Giuseppe/0000-0002-3688-160X				BROWN WL, 1980, PHYS REV LETT, V45, P1632, DOI 10.1103/PhysRevLett.45.1632; BROWN WL, 1982, SCIENCE, V218, P525, DOI 10.1126/science.218.4572.525; BROWN WL, 1978, PHYS REV LETT, V40, P1027, DOI 10.1103/PhysRevLett.40.1027; CARLSON RW, 1980, NATURE, V283, P461, DOI 10.1038/283461a0; COMBI MR, 1987, ICARUS, V71, P178, DOI 10.1016/0019-1035(87)90171-0; DHENDECOURT LB, 1982, ASTRON ASTROPHYS, V109, pL12; DRAINE BT, 1979, ASTROPHYS J, V231, P438, DOI 10.1086/157206; EVIATAR A, 1986, ASTRON J, V300, pL9; FLOURNOY JM, 1962, J CHEM PHYS, V36, P2229, DOI 10.1063/1.1732861; HAMILTON DP, 1994, SCIENCE, V264, P550, DOI 10.1126/science.264.5158.550; HARRISON H, 1967, SCIENCE, V157, P1175, DOI 10.1126/science.157.3793.1175; HARTQUIST TW, 1990, MON NOT R ASTRON SOC, V247, P343; HEIDE HG, 1984, ULTRAMICROSCOPY, V14, P271, DOI 10.1016/0304-3991(84)90095-0; Johnson R. E., 1993, EOS, V74, P572; JOHNSON RE, 1990, ENERGETIC PARTICLE I; LEGER A, 1985, ASTRON ASTROPHYS, V144, P147; MATHIS JS, 1983, ASTRON ASTROPHYS, V128, P212; MORFILL GE, 1993, J GEOPHYS RES-SPACE, V98, P11285, DOI 10.1029/93JA00308; NISHI N, 1984, J CHEM PHYS, V80, P3898, DOI 10.1063/1.447172; NORMAN C, 1980, ASTROPHYS J, V238, P158, DOI 10.1086/157969; PRASAD SS, 1983, ASTROPHYS J, V267, P603, DOI 10.1086/160896; SACK NJ, 1993, PHYS REV B, V48, P9973, DOI 10.1103/PhysRevB.48.9973; SHEMANSKY DE, 1993, NATURE, V363, P329, DOI 10.1038/363329a0; SMITH RG, 1993, MON NOT R ASTRON SOC, V263, P749, DOI 10.1093/mnras/263.3.749; STERNBERG A, 1987, ASTROPHYS J, V320, P676, DOI 10.1086/165585; TAUB IA, 1968, J CHEM PHYS, V49, P2499, DOI 10.1063/1.1670446; WARREN SG, 1984, APPL OPTICS, V23, P1206, DOI 10.1364/AO.23.001206; WATSON WD, 1972, ASTROPHYS J, V174, P321, DOI 10.1086/151492; Whittet D. C. B., 1992, DUST GALACTIC ENV	29	219	220	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					405	407		10.1038/373405a0	http://dx.doi.org/10.1038/373405a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830792				2022-12-24	WOS:A1995QE67000048
J	CHANG, MW; BARR, E; SELTZER, J; JIANG, YQ; NABEL, GJ; NABEL, EG; PARMACEK, MS; LEIDEN, JM				CHANG, MW; BARR, E; SELTZER, J; JIANG, YQ; NABEL, GJ; NABEL, EG; PARMACEK, MS; LEIDEN, JM			CYTOSTATIC GENE-THERAPY FOR VASCULAR PROLIFERATIVE DISORDERS WITH A CONSTITUTIVELY ACTIVE FORM OF THE RETINOBLASTOMA GENE-PRODUCT	SCIENCE			English	Article							MUSCLE CELL-PROLIFERATION; TRANSCRIPTION FACTOR; CYCLE; ATHEROSCLEROSIS; RESTENOSIS; PROTEIN; P53; OLIGONUCLEOTIDES; BINDING; INJURY	Vascular smooth muscle cell (SMC) proliferation in response to injury is an important etiologic factor in vascular proliferative disorders such as atherosclerosis and restenosis after balloon angioplasty. The retinoblastoma gene product (Rb) is present in the unphosphorylated and active form in quiescent primary arterial SMCs, but is rapidly inactivated by phosphorylation in response to growth factor stimulation in vitro, A replication-defective adenovirus encoding a nonphosphorylatable, constitutively active form of Rb was constructed. Infection of cultured primary rat aortic SMCs with this virus inhibited growth factor-stimulated cell proliferation in vitro. Localized arterial infection with the virus at the time of balloon angioplasty significantly reduced SMC proliferation and neointima formation in both the rat carotid and porcine femoral artery models of restenosis, These results demonstrate the role of Rb in regulating vascular SMC proliferation and suggest a gene therapy approach for vascular proliferative disorders associated with arterial injury.	UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PATHOL, CHICAGO, IL 60637 USA; UNIV MICHIGAN, MED CTR, DEPT MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA	University of Chicago; University of Chicago; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan				Parmacek, Michael/0000-0003-1449-4665				BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARR E, 1994, GENE THER, V1, P51; BARR E, 1994, TRENDS CARDIOVAS MED, V4, P57, DOI 10.1016/1050-1738(94)90010-8; BLANK RS, 1988, J CELL BIOL, V107, P299, DOI 10.1083/jcb.107.1.299; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Chang M.-W., UNPUB; CHANG MW, IN PRESS MOL MED; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CLOWES AW, 1983, LAB INVEST, V49, P327; COHEN AJ, 1990, AIDS, V4, P807, DOI 10.1097/00002030-199008000-00014; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EPSTEIN SE, 1993, CIRCULATION, V88, P1351, DOI 10.1161/01.CIR.88.3.1351; FAULDS D, 1990, DRUGS, V39, P597, DOI 10.2165/00003495-199039040-00008; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; FORRESTER JS, 1991, J AM COLL CARDIOL, V17, P758, DOI 10.1016/S0735-1097(10)80196-2; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GUZMAN LA, 1994, CIRCULATION, V90, P147; GUZMAN PJ, 1993, CIRCULATION, V88, P2838, DOI 10.1161/01.CIR.88.6.2838; GUZMAN RJ, 1994, P NATL ACAD SCI USA, V91, P10732, DOI 10.1073/pnas.91.22.10732; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KARPINSKI BA, 1989, MOL CELL BIOL, V9, P2588, DOI 10.1128/MCB.9.6.2588; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KIM DW, 1993, GENE, V134, P307; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KOZARSKY K, 1993, SOMAT CELL MOLEC GEN, V19, P449, DOI 10.1007/BF01233250; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LIBBY P, 1992, CIRCULATION, V86, P47; LINDNER V, 1992, J CLIN INVEST, V90, P2044, DOI 10.1172/JCI116085; LIU MW, 1989, CIRCULATION, V79, P1374, DOI 10.1161/01.CIR.79.6.1374; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PRESCOTT MF, 1991, AM J PATHOL, V139, P139; REITMAN JS, 1982, ATHEROSCLEROSIS, V43, P119, DOI 10.1016/0021-9150(82)90104-6; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHWARTZ RS, 1992, J AM COLL CARDIOL, V20, P1284, DOI 10.1016/0735-1097(92)90389-5; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; TRIPATHY SK, 1994, P NATL ACAD SCI USA, V91, P11557, DOI 10.1073/pnas.91.24.11557; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINER BH, 1985, CIRCULATION, V72, P1081, DOI 10.1161/01.CIR.72.5.1081; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480	57	417	455	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	1995	267	5197					518	522		10.1126/science.7824950	http://dx.doi.org/10.1126/science.7824950			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824950				2022-12-24	WOS:A1995QD40300040
J	LEFKOWITZ, RJ				LEFKOWITZ, RJ			CLINICAL IMPLICATIONS OF BASIC RESEARCH - G-PROTEINS IN MEDICINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIGNAL-TRANSDUCTION				LEFKOWITZ, RJ (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.		Lefkowitz, Robert/AAW-2649-2021					IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LINDER ME, 1992, SCI AM, V267, P56; LINDER ME, 1992, SCI AM, V267, P64; RODBELL M, 1992, CURR TOP CELL REGUL, V32, P1; SPIEGEL AM, 1993, J CLIN INVEST, V92, P1119, DOI 10.1172/JCI116680	6	23	24	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	1995	332	3					186	187		10.1056/NEJM199501193320312	http://dx.doi.org/10.1056/NEJM199501193320312			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB160	7800014				2022-12-24	WOS:A1995QB16000012
J	MACKALL, CL; FLEISHER, TA; BROWN, MR; ANDRICH, MP; CHEN, CC; FEUERSTEIN, IM; HOROWITZ, ME; MAGRATH, IT; SHAD, AT; STEINBERG, SM; WEXLER, LH; GRESS, RE				MACKALL, CL; FLEISHER, TA; BROWN, MR; ANDRICH, MP; CHEN, CC; FEUERSTEIN, IM; HOROWITZ, ME; MAGRATH, IT; SHAD, AT; STEINBERG, SM; WEXLER, LH; GRESS, RE			AGE, THYMOPOIESIS, AND CD4+ T-LYMPHOCYTE REGENERATION AFTER INTENSIVE CHEMOTHERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; IMMUNODEFICIENCY-VIRUS INFECTION; ISOFORM EXPRESSION; CELL REGENERATION; SUBSETS; THYMECTOMY; DEPLETION; PROGENY; THERAPY; THYMUS	Background. Inadequate reconstitution of CD4+ T lymphocytes is an important clinical problem complicating chemotherapy, human immunodeficiency virus infection, and bone marrow transplantation, but relatively little is known about how CD4+ T lymphocytes regenerate. There are two main possibilities: bone marrow-derived progenitors could reconstitute the lymphocyte population using a thymus-dependent pathway, or thymus-independent pathways could predominate. Previous studies have suggested that the CD45RA glycoprotein on CD4+ T lymphocytes is a marker for progeny generated by a thymus-dependent pathway. Methods. We studied 15 patients 1 to 24 years of age who had undergone intensive chemotherapy for cancer. The absolute numbers of CD4+ T lymphocytes in peripheral blood and the expression of CD45 isoforms (CD45RA and CD45RO) on these lymphocytes were studied serially during lymphocyte regeneration after the completion of therapy. Radiographic imaging of the thymus was performed concomitantly. Results. There was an inverse relation between the patients' ages and the CD4+ T-lymphocyte counts six months after therapy was completed (r=-0.92). The CD4+ recovery correlated quantitatively with the appearance of CD45RA+CD4+ T lymphocytes in the blood (r=0.64). There was a higher proportion of CD45RA+CD4+ T lymphocytes in patients with thymic enlargement after chemotherapy than in patients without such enlargement (two-sided P=0.015). Conclusions. Thymus-dependent regeneration of CD4+ T lymphocytes occurs primarily in children, whereas even young adults have deficiencies in this pathway. Our results suggest that rapid T-cell regeneration requires residual thymic function in patients receiving high-dose chemotherapy.	NCI, DIV CANC BIOL DIAG & CTR, EXPTL IMMUNOL BRANCH, BETHESDA, MD USA; NCI, DIV CANC TREATMENT, MED BRANCH, BETHESDA, MD USA; NCI, DIV CANC TREATMENT, PEDIAT BRANCH, BETHESDA, MD USA; NCI, BIOSTAT & DATA MANAGEMENT SECT, BETHESDA, MD USA; NIH, CTR CLIN, DEPT NUCL MED, BETHESDA, MD 20892 USA; NIH, CTR CLIN, DEPT CLIN PATHOL, BETHESDA, MD 20892 USA; UNIFORMED SERV UNIV HLTH SCI, HENRY M JACKSON FDN ADV MIL MED, BETHESDA, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; Uniformed Services University of the Health Sciences - USA	MACKALL, CL (corresponding author), NIH, CTR CLIN, DEPT RADIOL, BLDG 10, RM 4B14, BETHESDA, MD 20892 USA.							ALTMAN S, 1993, P NATL ACAD SCI USA, V90, P10898, DOI 10.1073/pnas.90.23.10898; ATKINSON K, 1982, BLOOD, V59, P1292; BREARLEY S, 1987, CLIN EXP IMMUNOL, V70, P322; BUCHSCHACHER GL, 1993, JAMA-J AM MED ASSOC, V269, P2880, DOI 10.1001/jama.269.22.2880; CHOYKE PL, 1987, AM J ROENTGENOL, V149, P269, DOI 10.2214/ajr.149.2.269; Civin C I, 1992, Prog Clin Biol Res, V377, P461; DEGAST GC, 1985, BLOOD, V66, P428; ERKELLERYUKSEL FM, 1992, J PEDIATR-US, V120, P216, DOI 10.1016/S0022-3476(05)80430-5; FANCI AS, 1988, SCIENCE, V239, P617; FAVROT M, 1983, CLIN EXP IMMUNOL, V54, P59; FORMAN SJ, 1982, TRANSPLANTATION, V34, P96; FUJII Y, 1992, EUR J IMMUNOL, V22, P1843, DOI 10.1002/eji.1830220725; ISRAEL O, 1993, J NUCL MED, V34, P1330; JOHNSTON MI, 1993, SCIENCE, V260, P1286, DOI 10.1126/science.7684163; MACKALL CL, 1994, BLOOD, V84, P2221; MACKALL CL, 1993, BLOOD, V82, P2585; MELMS A, 1993, J NEUROL NEUROSUR PS, V56, P46, DOI 10.1136/jnnp.56.1.46; MILLER JF, 1961, LANCET, V2, P748; MOSES RD, 1989, TRANSPLANTATION, V47, P435, DOI 10.1097/00007890-198903000-00007; MUELLER BU, 1994, PEDIATRICS, V94, P724; PAPIERNIK M, 1992, PEDIATRICS, V89, P297; PEYLANRAMU N, 1989, J CLIN ONCOL, V7, P1800, DOI 10.1200/JCO.1989.7.12.1800; PILARSKI LM, 1989, EUR J IMMUNOL, V19, P589, DOI 10.1002/eji.1830190403; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P7727, DOI 10.1073/pnas.87.19.7727; SPRENT J, 1989, FUNDAMENTAL IMMUNOLO, P84; STANLEY SK, 1993, J EXP MED, V178, P1151, DOI 10.1084/jem.178.4.1151; STUTMAN O, 1986, IMMUNOL REV, V91, P159, DOI 10.1111/j.1600-065X.1986.tb01488.x; ZINKERNAGEL RM, 1980, J IMMUNOL, V124, P2356	28	902	920	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 19	1995	332	3					143	149		10.1056/NEJM199501193320303	http://dx.doi.org/10.1056/NEJM199501193320303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB160	7800006				2022-12-24	WOS:A1995QB16000003
J	PERSUTTE, WH; LENKE, RR				PERSUTTE, WH; LENKE, RR			FAILURE OF AMNIOTIC-FLUID CELL-GROWTH - IS IT RELATED TO FETAL ANEUPLOIDY	LANCET			English	Note							AMNIOCENTESIS; DIAGNOSIS	We investigated outcome in patients whose amniotic-fluid-cell samples showed unexplained growth failure in culture, 32 of 7872 amniocentesis samples were classified as unexplained growth failures. 10 women did not have repeat cytogenetic testing, but among their pregnancies there were 4 abnormal outcomes (1 fetal bladder-outlet obstruction, 2 stillbirths, and 1 acardiac twin). Of the 2 2 patients who had repeat karyotypic analysis, 18 had normal fetal karyotypes, However, 4 fetuses were aneuploid (2 trisomy 21, 1 trisomy 13, and 1 Pallister-Killian syndrome).			PERSUTTE, WH (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT OBSTET & GYNAECOL,CAMPUS BOX E-197,4200 E 9TH AVE,DENVER,CO 80262, USA.							ASSEL BG, 1992, OBSTET GYNECOL, V79, P940; BELL JA, 1987, MED J AUSTRALIA, V146, P12, DOI 10.5694/j.1326-5377.1987.tb120118.x; BENACERRAF BR, 1988, RADIOLOGY, V169, P709, DOI 10.1148/radiology.169.3.3055033; BENIRSCHKE K, 1977, TERATOLOGY, V15, P311, DOI 10.1002/tera.1420150313; DEACON JS, 1980, AM J MED GENET, V5, P85, DOI 10.1002/ajmg.1320050112; DONNELFELD AE, 1993, BRIT J OBSTET GYNAEC, V100, pS26; NICOLAIDES KH, 1986, LANCET, V1, P283; REBELLO MT, 1991, PRENATAL DIAG, V11, P35, DOI 10.1002/pd.1970110107	8	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					96	97		10.1016/S0140-6736(95)90064-0	http://dx.doi.org/10.1016/S0140-6736(95)90064-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815890				2022-12-24	WOS:A1995QB80400011
J	LEFEBVRE, S; BURGLEN, L; REBOULLET, S; CLERMONT, O; BURLET, P; VIOLLET, L; BENICHOU, B; CRUAUD, C; MILLASSEAU, P; ZEVIANI, M; LEPASLIER, D; FREZAL, J; COHEN, D; WEISSENBACH, J; MUNNICH, A; MELKI, J				LEFEBVRE, S; BURGLEN, L; REBOULLET, S; CLERMONT, O; BURLET, P; VIOLLET, L; BENICHOU, B; CRUAUD, C; MILLASSEAU, P; ZEVIANI, M; LEPASLIER, D; FREZAL, J; COHEN, D; WEISSENBACH, J; MUNNICH, A; MELKI, J			IDENTIFICATION AND CHARACTERIZATION OF A SPINAL MUSCULAR ATROPHY-DETERMINING GENE	CELL			English	Article							WERDNIG-HOFFMANN DISEASE; LINKAGE MAP; CHROMOSOME-5; LOCUS; FREQUENCY; MARKERS; CONTIG; REGION; 5Q13	Spinal muscular atrophy (SMA) is a common fatal autosomal recessive disorder characterized by degeneration of lower motor neurons, leading to progressive paralysis with muscular atrophy. The gene for SMA has been mapped to chromosome 5q13, where large-scale deletions have been reported. We describe here the inverted duplication of a 500 kb element in normal chromosomes and narrow the critical region to 140 kb within the telomeric region. This interval contains a 20 kb gene encoding a novel protein of 294 amino acids. An highly homologous gene is present in the centromeric element of 95% of controls. The telomeric gene is either lacking or interrupted in 226 of 229 patients, and patients retaining this gene (3 of 229) carry either a point mutation (Y272C) or short deletions in the consensus splice sites of introns 6 and 7. These data suggest that this gene, termed the survival motor neuron (SMN) gene, is an SMA-determining gene.	CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE; GENETHON,F-91002 EVRY,FRANCE		LEFEBVRE, S (corresponding author), HOP NECKER ENFANTS MALAD,INST NECKER,INSERM,U393,UNITE RECH HANDICAPS GENET ENFANT,F-75743 PARIS 15,FRANCE.		Zeviani, Massimo/AAU-2632-2021; Zeviani, Massimo/K-2891-2014; Lefebvre, Suzie/D-5092-2017	Zeviani, Massimo/0000-0002-9067-5508; Cruaud, Corinne/0000-0002-4752-7278; BERNARD, BENICHOU/0000-0002-9331-0926; Le Paslier, Denis/0000-0003-4335-9956				BOTTEMA CDK, 1990, AM J HUM GENET, V47, P835; BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; BURGHES AHM, 1994, GENOMICS, V21, P394, DOI 10.1006/geno.1994.1282; CARLOCK LR, 1985, AM J HUM GENET, V37, P839; CLERMONT O, 1994, AM J HUM GENET, V54, P687; CZEIZEL A, 1989, J MED GENET, V26, P761, DOI 10.1136/jmg.26.12.761; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DIDONATO CJ, 1994, AM J HUM GENET, V55, P1218; FOURNIER B, 1994, J CLIN INVEST, V94, P526, DOI 10.1172/JCI117365; FRANCIS MJ, 1993, HUM MOL GENET, V2, P1161, DOI 10.1093/hmg/2.8.1161; GILLIAM TC, 1990, NATURE, V345, P823, DOI 10.1038/345823a0; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; HAZAN J, 1992, GENOMICS, V12, P183, DOI 10.1016/0888-7543(92)90364-X; HERRMANN BG, 1987, CELL, V48, P813, DOI 10.1016/0092-8674(87)90078-X; HIGASHI Y, 1988, AM J HUM GENET, V42, P17; Hoffmann J., 1900, MUENCHEN MED WSCHR, V47, P1649; KLEYN PW, 1993, P NATL ACAD SCI USA, V90, P6801, DOI 10.1073/pnas.90.14.6801; KUGELBERG E, 1956, ARCH NEURO PSYCHIATR, V75, P500, DOI 10.1001/archneurpsyc.1956.02330230050005; LIEN LL, 1991, P NATL ACAD SCI USA, V88, P7873, DOI 10.1073/pnas.88.17.7873; MCLEAN MD, 1994, HUM MOL GENET, V3, P1951; MELKI J, 1990, LANCET, V336, P271, DOI 10.1016/0140-6736(90)91803-I; MELKI J, 1990, NATURE, V344, P767, DOI 10.1038/344767a0; MELKI J, 1994, SCIENCE, V264, P1474, DOI 10.1126/science.7910982; MELKI J, 1993, GENOMICS, V15, P521, DOI 10.1006/geno.1993.1103; MORRISON KE, 1992, AM J HUM GENET, V50, P520; Munsat TL., 1991, NEUROMUSCUL DISORD, V1, P81, DOI [10.1016/0960-8966(91)90052-t, DOI 10.1016/0960-8966(91)90052-T]; MURRU S, 1991, BLOOD, V77, P1342; Orkin S., 1987, MOL BASIS BLOOD DISE, P106; PEARN J, 1978, J MED GENET, V15, P409, DOI 10.1136/jmg.15.6.409; PEARN JH, 1973, J MED GENET, V10, P260, DOI 10.1136/jmg.10.3.260; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Sambrook J., 1989, MOL CLONING LAB MANU; SHETH P, 1991, AM J HUM GENET, V48, P764; SOARES VM, 1993, GENOMICS, V15, P365, DOI 10.1006/geno.1993.1069; Werdnig G., 1894, ARCH PSYCHIAT, V26, P706	36	2785	2912	10	134	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					155	165		10.1016/0092-8674(95)90460-3	http://dx.doi.org/10.1016/0092-8674(95)90460-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813012	Bronze			2022-12-24	WOS:A1995QB91000019
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TOLL-FREE NUMBER FOR LOCATING CERTIFIED MAMMOGRAPHY FACILITIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1994, JAMA-J AM MED ASSOC, V271, P179	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1897	1897						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783288				2022-12-24	WOS:A1995RE35400006
J	VIRGO, KS; VERNAVA, AM; LONGO, WE; MCKIRGAN, LW; JOHNSON, FE				VIRGO, KS; VERNAVA, AM; LONGO, WE; MCKIRGAN, LW; JOHNSON, FE			COST OF PATIENT FOLLOW-UP AFTER POTENTIALLY CURATIVE COLORECTAL-CANCER TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTOPERATIVE SURVEILLANCE; CARCINOMA; COLON; RESECTION; SURGERY; RECTUM; RECURRENCE; MUTATIONS	Objective.- To estimate the cost of follow-up among colorectal cancer patients treated with curative intent based on the broad spectrum of surveillance strategies suggested in the literature. Design.- Economic analysis of the costs associated with 11 separate surveillance strategies. Charge data were obtained from the Part B Medicare Annual Data file and the Hospital Outpatient Bill file. Setting.- Ambulatory care. Main Outcome Measures.- Medicare-allowed charges and an actual-charge proxy for 5 years of follow-up after treatment for colorectal cancer patients on a nationwide basis. Results.- Medicare-allowed charges varied widely for the 5 years of posttreatment follow-up from a low of $561 to a high of $16 492. When Medicare-allowed charges were converted to a proxy for actual charges using a conversion ratio of 1.62, the range was $910 to $26 717, a 28-fold difference in charges. Conclusions.- Charges vary extensively across follow-up strategies, with no indication that higher-cost strategies increase survival or quality of life.	DEPT VET AFFAIRS MED CTR, SURG SERV, ST LOUIS, MO USA		VIRGO, KS (corresponding author), ST LOUIS UNIV, HLTH SCI CTR, DEPT SURG, 3635 VISTA AVE, POB 15250, ST LOUIS, MO 63110 USA.		Virgo, Katherine S/AAG-3188-2021	Virgo, Katherine S/0000-0002-2069-0585				Adloff M, 1989, Chirurgie, V115, P228; ANDERSON C, 1994, SCIENCE, V263, P1080, DOI 10.1126/science.8108722; BEART RW, 1983, MAYO CLIN PROC, V58, P361; BERNSTAM VA, 1992, HDB GENE LEVEL DIAGN; BRUINVELS DJ, 1994, ANN SURG, V219, P174, DOI 10.1097/00000658-199402000-00009; BUHLER H, 1984, CANCER, V54, P791, DOI 10.1002/1097-0142(19840901)54:5<791::AID-CNCR2820540502>3.0.CO;2-R; BUIE WD, 1993, GASTROINTEST ENDOSC, V3, P691; CALI RL, 1993, DIS COLON RECTUM, V36, P388, DOI 10.1007/BF02053945; DELTURCO MR, 1994, JAMA-J AM MED ASSOC, V271, P1593, DOI 10.1001/jama.1994.03510440053032; DEVENEY KE, 1984, AM J SURG, V148, P717, DOI 10.1016/0002-9610(84)90423-9; FISCHER DS, 1983, FOLLOW UP CANCER HDB, P4; FISCHER DS, 1992, FOLLOW UP CANCER HDB, P34; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; GALANDIUK S, 1992, SURG GYNECOL OBSTET, V174, P27; JUHL G, 1990, WORLD J SURG, V14, P255, DOI 10.1007/BF01664886; KELLY CJ, 1992, CANCER-AM CANCER SOC, V70, P1397, DOI 10.1002/1097-0142(19920901)70:3+<1397::AID-CNCR2820701531>3.0.CO;2-A; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; Makela J, 1992, Surg Oncol, V1, P157, DOI 10.1016/0960-7404(92)90029-K; MOERTEL CG, 1993, JAMA-J AM MED ASSOC, V270, P943, DOI 10.1001/jama.270.8.943; NAVA HR, 1982, CANCER, V49, P1043, DOI 10.1002/1097-0142(19820301)49:5<1043::AID-CNCR2820490533>3.0.CO;2-Y; OVASKA J, 1990, AM J SURG, V159, P593, DOI 10.1016/S0002-9610(06)80074-7; OVASKA J, 1990, GASTROENTEROLOGY, V99, P1849; OVASKA JT, 1989, SCAND J GASTROENTERO, V24, P416, DOI 10.3109/00365528909093068; ROBERTS PJ, 1988, SCAND J GASTROENTERO, V23, P50, DOI 10.3109/00365528809096956; ROCKLIN MS, 1990, AM SURGEON, V56, P22; SAFI F, 1993, CANCER DETECT PREV, V17, P417; SANDLER RS, 1984, CANCER, V53, P193, DOI 10.1002/1097-0142(19840101)53:1<193::AID-CNCR2820530134>3.0.CO;2-V; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; STEELE G, 1991, WORLD J SURG, V15, P583, DOI 10.1007/BF01789202; STEELE G, 1986, COLORECTAL CANCER; SUGARBAKER PH, 1987, SURGERY, V102, P79; TORNQVIST A, 1982, BRIT J SURG, V69, P725, DOI 10.1002/bjs.1800691213; VERNAVA AM, 1994, DIS COLON RECTUM, V37, P573, DOI 10.1007/BF02050993; VIRGO KS, IN PRESS ANN SURG ON; 1992, DIS COLON RECTUM, V35, P389; 1994, JAMA-J AM MED ASSOC, V271, P1587; 1960, CONSUMER PRICE INDEX	37	121	123	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	1995	273	23					1837	1841		10.1001/jama.273.23.1837	http://dx.doi.org/10.1001/jama.273.23.1837			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD116	7776499				2022-12-24	WOS:A1995RD11600025
J	KELLEY, RL; SOLOVYEVA, I; LYMAN, LM; RICHMAN, R; SOLOVYEV, V; KURODA, MI				KELLEY, RL; SOLOVYEVA, I; LYMAN, LM; RICHMAN, R; SOLOVYEV, V; KURODA, MI			EXPRESSION OF MSL-2 CAUSES ASSEMBLY OF DOSAGE COMPENSATION REGULATORS ON THE X-CHROMOSOMES AND FEMALE LETHALITY IN DROSOPHILA	CELL			English	Article							SEX-SPECIFIC LETHALS; GENE-PRODUCT; SPLICE-SITE; SEQUENCE SIMILARITY; MELANOGASTER; PROTEIN; RNA; MUTATIONS; BINDING; TRANSCRIPTION	Male-specific lethal-2 (msl-2) is a RING finger protein that is required for X chromosome dosage compensation in Drosophila males. Consistent with the formation of a dosage compensation protein complex, msl-2 colocalizes with the other MSL proteins on the male X chromosome and coimmunoprecipitates with msl-1 from male larval extracts. Ectopic expression of msl-2 in females results in the appearance of the other MSL dosage compensation regulators on the female X chromosomes and decreased female viability. We suggest that msl-2 RNA is the primary target of Sxl regulation in the dosage compensation pathway and present a speculative model for the regulation of two distinct modes of dosage compensation by Sxl.			KELLEY, RL (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOWARD HUGHES MED INST,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Solovyev, Victor/C-4614-2013	Solovyev, Victor/0000-0001-8885-493X	NIGMS NIH HHS [GM45744] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045744, R37GM045744] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER BS, 1994, ANNU REV GENET, V28, P491, DOI 10.1146/annurev.ge.28.120194.002423; BANG DD, 1992, NUCLEIC ACIDS RES, V20, P3925, DOI 10.1093/nar/20.15.3925; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BELOTE JM, 1980, NATURE, V285, P573, DOI 10.1038/285573a0; BELOTE JM, 1980, GENETICS, V96, P165; BENZ WK, 1988, GENETICS, V118, P461; BERNSTEIN M, 1994, GENETICS, V136, P1051; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; CLINE TW, 1978, GENETICS, V90, P683; CLINE TW, 1984, GENETICS, V107, P231; CLINE TW, 1993, TRENDS GENET, V9, P385, DOI 10.1016/0168-9525(93)90138-8; CLINE TW, 1983, DEV BIOL, V95, P260, DOI 10.1016/0012-1606(83)90027-1; CRONMILLER C, 1994, MOL GENETICS SEX DET, P172; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GERGEN JP, 1987, GENETICS, V117, P477; GORMAN M, 1995, DEVELOPMENT, V121, P463; GORMAN M, 1993, CELL, V72, P39, DOI 10.1016/0092-8674(93)90048-U; HIEBERT JC, 1994, GENETICS, V136, P913; HILFIKER A, 1994, EMBO J, V15, P3542; HORABIN JI, 1993, MOL CELL BIOL, V13, P7734, DOI 10.1128/MCB.13.12.7734; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KARPEN GH, 1988, GENE DEV, V2, P1745, DOI 10.1101/gad.2.12b.1745; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; LUCCHESI JC, 1981, CHROMOSOMA, V82, P217, DOI 10.1007/BF00286106; OKUNO T, 1984, JPN J GENET, V59, P237, DOI 10.1266/jjg.59.237; PALMER MJ, 1993, GENETICS, V134, P545; PALMER MJ, 1994, GENE DEV, V8, P698, DOI 10.1101/gad.8.6.698; Paro R, 1993, CURR OPIN CELL BIOL, V5, P999, DOI 10.1016/0955-0674(93)90084-4; SAKAMOTO H, 1992, NUCLEIC ACIDS RES, V20, P5533, DOI 10.1093/nar/20.21.5533; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; SAMUELS ME, 1991, MOL CELL BIOL, V11, P3584, DOI 10.1128/MCB.11.7.3584; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SKRIPSKY T, 1982, DEV BIOL, V94, P153, DOI 10.1016/0012-1606(82)90078-1; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; SWEDER KS, 1993, SCIENCE, V262, P439, DOI 10.1126/science.8211165; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; UENOYAMA T, 1984, JPN J GENET, V59, P335, DOI 10.1266/jjg.59.335; UENOYAMA T, 1982, GENETICS, V102, P233; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; WANG JW, 1994, GENE DEV, V8, P2072, DOI 10.1101/gad.8.17.2072; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; XIAO H, 1989, MOL CELL BIOL, V9, P1746, DOI 10.1128/MCB.9.4.1746; ZHOU S, 1995, IN PRESS EMBO J	53	253	259	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					867	877		10.1016/0092-8674(95)90007-1	http://dx.doi.org/10.1016/0092-8674(95)90007-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781064	Bronze			2022-12-24	WOS:A1995RD76800008
J	LI, C; ULLRICH, B; ZHANG, JZ; ANDERSON, RGW; BROSE, N; SUDHOF, TC				LI, C; ULLRICH, B; ZHANG, JZ; ANDERSON, RGW; BROSE, N; SUDHOF, TC			CA2+-DEPENDENT AND CA2+-INDEPENDENT ACTIVITIES OF NEURAL AND NONNEURAL SYNAPTOTAGMINS	NATURE			English	Article							NEUROTRANSMITTER RELEASE; PROTEIN; FUSION; SYNTAXIN; BINDING; DOCKING	SYNAPTOTAGMINS (Syts) are brain-specific Ca2+/phospholipid-binding proteins(1-5). In hippocampal synapses, Syt I is essential for fast Ca2+-dependent synaptic vesicle exocytosis but not for Ca2+-independent exocytosis(3). In vertebrates and invertebrates(6-9), Syt may therefore participate in Ca2+-dependent synaptic membrane fusion, either by serving as the Ca2+ sensor in the last step of fast Ca2+-triggered neurotransmitter release, or by collaborating with an additional Ca2+ sensor. While Syt I binds Ca2+ (refs 10, 11), its phospholipid binding is triggered at lower calcium concentrations (EC(50)=3-6 mu M) than those required for exocytosis(12). Furthermore, Syts bind clathrin-AP2 with high affinity, indicating that they may play a general role in endocytosis(4,5) rather than being confined to a specialized function in regulated exocytosis(3). Here me resolve this apparent contradiction by describing four Syts, three of which (Syt VI, VII and VIII) are widely expressed in non-neural tissues. All Syts tested share a common domain structure, with a cytoplasmic region composed of two C-2 domains that interacts with clathrin-AP2 (K-d=0.1-1.0 nM) and with neural and non-neural syntaxins. The first C-2 domains of Syt I, II, III, V and VII, but not of IV, VI or VIII, bind phospholipids with a similar Ca2+-concentration dependence (EC(50)=3-6 mu M). The same C-2 domains also bind syntaxin as a function of Ca2+ but the Ca2+-concentration dependence of Syt I, II, and V (>200 mu M) differs from that of Syt III and VII (<10 mu M), Syts therefore appear to be ubiquitous proteins with a role in exocytosis mediated by syntaxin binding. The Ca2+ levels needed to trigger syntaxin binding by the different Syts suggest that they play distinct roles in membrane fusion; the level required by Syt I approximates those required for synaptic exocytosis.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; DAVLETOV BA, 1994, J BIOL CHEM, V269, P28547; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GODA Y, 1994, P NATL ACAD SCI USA, V91, P12942, DOI 10.1073/pnas.91.26.12942; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HEIDELBERGER R, 1994, NATURE, V371, P51; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PERIN MS, 1994, J BIOL CHEM, V266, P623; Sambrook J., 1989, MOL CLONING LAB MANU; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; ULLRICH U, 1994, NEURON, V13, P1281; YOSHIDA A, 1992, J BIOL CHEM, V267, P25925; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	30	548	563	1	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					594	599		10.1038/375594a0	http://dx.doi.org/10.1038/375594a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791877				2022-12-24	WOS:A1995RD28700053
J	ZUCKERMAN, AJ				ZUCKERMAN, AJ			THE NEW GB HEPATITIS VIRUSES	LANCET			English	Editorial Material											ZUCKERMAN, AJ (corresponding author), ROYAL FREE HOSP,SCH MED,WHO,COLLABORATING CTR REFERENCE & RES VIRAL DIS,LONDON,ENGLAND.							DEINHARDT F, 1967, J EXP MED, V125, P673, DOI 10.1084/jem.125.4.673; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; PARKS WP, 1969, J INFECT DIS, V120, P539, DOI 10.1093/infdis/120.5.539; SCHLAUDER GG, 1995, J MED VIROL, V46, P81, DOI 10.1002/jmv.1890460117; SIMONS JN, IN PRESS P NATL ACAD	5	51	58	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 10	1995	345	8963					1453	1454		10.1016/S0140-6736(95)91032-8	http://dx.doi.org/10.1016/S0140-6736(95)91032-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC189	7769898				2022-12-24	WOS:A1995RC18900004
J	PIETTE, JC; FRANCES, C				PIETTE, JC; FRANCES, C			IMAGES IN CLINICAL MEDICINE - RELAPSING POLYCHONDRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PIETTE, JC (corresponding author), HOP LA PITIE SALPETRIERE,F-75651 PARIS 13,FRANCE.								0	5	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	1995	332	9					580	580		10.1056/NEJM199503023320906	http://dx.doi.org/10.1056/NEJM199503023320906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ090	7838192				2022-12-24	WOS:A1995QJ09000006
J	HOSKINS, KF; STOPFER, JE; CALZONE, KA; MERAJVER, SD; REBBECK, TR; GARBER, JE; WEBER, BL				HOSKINS, KF; STOPFER, JE; CALZONE, KA; MERAJVER, SD; REBBECK, TR; GARBER, JE; WEBER, BL			ASSESSMENT AND COUNSELING FOR WOMEN WITH A FAMILY HISTORY OF BREAST-CANCER - A GUIDE FOR CLINICIAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LINE P53 MUTATIONS; OVARIAN-CANCER; INDIVIDUALIZED PROBABILITIES; RISK; DISEASE; ONSET; PREVENTION; LINKAGE; AGE	More women in all risk categories are seeking information regarding their individual breast cancer risk, and there is a need for their primary care clinicians to be able to assess familial risk factors for breast cancer, provide individualized risk information, and offer surveillance recommendations. Estimates of the number of women with a family history of breast cancer range from approximately 5% to 20%, depending on the population surveyed. Many of these women will not have a family history that suggests the presence of a highly penetrant breast cancer susceptibility gene. However, it small subset of such women will come from families with a striking incidence of breast and other cancers often associated with inherited mutations. The development and refinement of risk prediction models provide an epidemiologic basis for counseling women with a family history that does not appear related to a dominant susceptibility gene. In contrast, the recent isolation of BRCA1, the localization of BRCA2, and the acknowledgment that additional breast cancer susceptibility genes must exist provide a molecular basis for counseling some high-risk women. We present a guide for primary care clinicians that may be helpful in defining families as moderate or high risk, in determining individual risk in women with a family history of breast cancer based on this distinction, and for counseling women in a setting where the data necessary to design surveillance and prevention strategies are lacking. We include criteria for selecting women who may be candidates for detection of inherited mutations in breast cancer susceptibility genes.	UNIV PENN, MED CTR, DEPT INTERNAL MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT EPIDEMIOL & BIOSTAT, PHILADELPHIA, PA USA; UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI USA; DANA FARBER CANC INST, BOSTON, MA USA	University of Pennsylvania; University of Pennsylvania; University of Michigan System; University of Michigan; Harvard University; Dana-Farber Cancer Institute			Rebbeck, Timothy/GLU-8348-2022	Rebbeck, Timothy/0000-0002-4799-1900; Calzone, Kathleen/0000-0002-2354-6810				ANDERSON DE, 1985, CANCER, V56, P383, DOI 10.1002/1097-0142(19850715)56:2<383::AID-CNCR2820560230>3.0.CO;2-0; ANDREWS LB, 1994, ASSESSING GENETIC RI, P1; Becker MH, 1974, HLTH BELIEF MODEL PE; BENICHOU J, 1993, COMPUT BIOMED RES, V26, P373, DOI 10.1006/cbmr.1993.1026; BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; BONDY ML, 1994, J NATL CANCER I, V86, P620, DOI 10.1093/jnci/86.8.620; BOWCOCK AM, 1994, AM J HUM GENET, V55, pR1; BROWNSTEIN MH, 1978, CANCER, V41, P2393, DOI 10.1002/1097-0142(197806)41:6<2393::AID-CNCR2820410644>3.0.CO;2-K; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Champion V L, 1991, Oncol Nurs Forum, V18, P733; CLAUS EB, 1991, AM J HUM GENET, V48, P232; CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; COLLINS FS, 1994, JAMA-J AM MED ASSOC, V271, P785, DOI 10.1001/jama.1994.03510340075038; EASTON DF, 1994, LANCET, V344, P761, DOI 10.1016/S0140-6736(94)92256-X; EASTON DF, 1993, AM J HUM GENET, V52, P678; EVANS DGR, 1993, BRIT J CANCER, V67, P612, DOI 10.1038/bjc.1993.112; FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HALL NR, 1994, EUR J CANCER, V30A, P180, DOI 10.1016/0959-8049(94)90083-3; HARTLEY AL, 1986, BRIT J CANCER, V54, P819, DOI 10.1038/bjc.1986.245; HOLFORD TR, 1991, J CLIN EPIDEMIOL, V44, P29, DOI 10.1016/0895-4356(91)90198-I; HUGGINS M, 1990, AM J HUM GENET, V47, P4; KASH KM, 1992, J NATL CANCER I, V84, P24, DOI 10.1093/jnci/84.1.24; Kelly P T, 1992, Semin Oncol Nurs, V8, P288, DOI 10.1016/0749-2081(92)90042-2; KELSEY JL, 1991, CA-CANCER J CLIN, V41, P146, DOI 10.3322/canjclin.41.3.146; LERMAN C, 1990, PREV MED, V19, P279, DOI 10.1016/0091-7435(90)90028-I; LERMAN C, 1991, HEALTH PSYCHOL, V10, P259, DOI 10.1037/0278-6133.10.4.259; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1992, J NATL CANCER I, V84, P1156, DOI 10.1093/jnci/84.15.1156; LYNCH HT, 1994, P ASCO, V13, P56; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCINTYRE JF, 1994, J CLIN ONCOL, V12, P925, DOI 10.1200/JCO.1994.12.5.925; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MORRELL D, 1986, J NATL CANCER I, V77, P89; MUIR EG, 1967, BRIT J SURG, V54, P191, DOI 10.1002/bjs.1800540309; MULVIHILL JJ, 1989, CLIN GENET, V36, P313; MURRAY TH, 1991, FASEB J, V5, P55, DOI 10.1096/fasebj.5.1.1825074; NAROD SA, 1991, LANCET, V338, P82; OFFIT K, 1994, J CLIN ONCOL, V12, P1724, DOI 10.1200/JCO.1994.12.8.1724; POLEDNAK AP, 1991, CANCER DETECT PREV, V15, P257; SATTIN RW, 1985, JAMA-J AM MED ASSOC, V253, P1908, DOI 10.1001/jama.253.13.1908; SHAPIRO DE, 1992, HEALTH PSYCHOL, V11, P61, DOI 10.1037/0278-6133.11.1.61; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; SKINNER CS, 1994, AM J PUBLIC HEALTH, V84, P43, DOI 10.2105/AJPH.84.1.43; SLATTERY ML, 1993, JAMA-J AM MED ASSOC, V270, P1563, DOI 10.1001/jama.270.13.1563; SPIGELMAN AD, 1989, GUT, V30, P1588, DOI 10.1136/gut.30.11.1588; STARINK TM, 1984, J AM ACAD DERMATOL, V11, P1127, DOI 10.1016/S0190-9622(84)70270-2; STEFANEK ME, 1992, CANCER EPIDEM BIOMAR, V1, P591; STRATTON MR, 1994, NAT GENET, V7, P103, DOI 10.1038/ng0594-103; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TAPLIN S, 1989, AM J PUBLIC HEALTH, V79, P1494, DOI 10.2105/AJPH.79.11.1494; WELLISCH DK, 1992, PSYCHOSOMATICS, V33, P171, DOI 10.1016/S0033-3182(92)71993-8; WENDER RC, 1993, CANCER, V72, P1093, DOI 10.1002/1097-0142(19930801)72:3+<1093::AID-CNCR2820721326>3.0.CO;2-B; Wood DA, 1943, CANCER RES, V3, P509; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	63	263	268	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					577	585		10.1001/jama.273.7.577	http://dx.doi.org/10.1001/jama.273.7.577			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QF686	7837392				2022-12-24	WOS:A1995QF68600029
J	TADDIO, A; GOLDBACH, M; IPP, M; STEVENS, B; KOREN, G				TADDIO, A; GOLDBACH, M; IPP, M; STEVENS, B; KOREN, G			EFFECT OF NEONATAL CIRCUMCISION ON PAIN RESPONSES DURING VACCINATION IN BOYS	LANCET			English	Note							STRESS; SLEEP	Using date from one of our randomised trials, we investigated post-hoc whether male neonatal circumcision is associated with a greater pain response to routine vaccination at 4 or 6 months. Pain response during routine vaccination with diphtheria-pertussis-tetanus (DPT) alone or DPT followed by Haemophilus influenzae type b conjugate (HIB) was scored blind. 42 boys received DPT acid 18 also received HIB. After DPT, median visual analogue scores by an observer were higher in the circumcised group (40 vs 26 mm. p=0.03) After HIB, circumcised infants had higher behavioural pain scores (8 vs 6, p=0.01) and cried longer (53 vs 19 s, p=0.02). Thus neonatal circumcision may affect pain response several months after the event.	UNIV TORONTO,HOSP SICK CHILDREN,DEPT PEDIAT,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Koren, Gideon/AAG-7726-2019	Koren, Gideon/0000-0002-9234-0875				ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; ANDERS TF, 1974, PSYCHOSOM MED, V36, P174, DOI 10.1097/00006842-197403000-00009; BRACKBILL Y, 1975, CHILD DEV, V46, P364; DIXON S, 1984, J DEV BEHAV PEDIATR, V5, P246; EMDE RN, 1971, PSYCHOSOM MED, V33, P491, DOI 10.1097/00006842-197111000-00002; MARSHALL RE, 1980, INFANT BEHAV DEV, V3, P1, DOI 10.1016/S0163-6383(80)80003-8; MARSHALL RE, 1982, EARLY HUM DEV, V7, P367, DOI 10.1016/0378-3782(82)90038-X; TADDIO A, 1994, J PEDIATR-US, V124, P643, DOI 10.1016/S0022-3476(05)83150-6; ZELTZER LK, 1992, PEDIATRICS, V90, P816	9	282	285	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					291	292		10.1016/S0140-6736(95)90278-3	http://dx.doi.org/10.1016/S0140-6736(95)90278-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE731	7837863				2022-12-24	WOS:A1995QE73100012
J	CATANZARO, A				CATANZARO, A			PREVENTING NOSOCOMIAL TRANSMISSION OF TUBERCULOSIS	LANCET			English	Editorial Material									UNIV CALIF SAN DIEGO,MED CTR,DEPT FAMILY & PREVENT MED,SAN DIEGO,CA 92103	University of California System; University of California San Diego	CATANZARO, A (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,DEPT MED,SAN DIEGO,CA 92103, USA.							ADAL KA, 1994, NEW ENGL J MED, V331, P169, DOI 10.1056/NEJM199407213310306; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; NETTLEMAN MD, 1994, ANN INTERN MED, V121, P37, DOI 10.7326/0003-4819-121-1-199407010-00007; 1995, LANCET, V345, P235; 1993, FED REGISTER, V58, P52810	5	10	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					204	205		10.1016/S0140-6736(95)90216-3	http://dx.doi.org/10.1016/S0140-6736(95)90216-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823708	Bronze			2022-12-24	WOS:A1995QD53200002
J	WEIH, F; CARRASCO, D; DURHAM, SK; BARTON, DS; RIZZO, CA; RYSECK, RP; LIRA, SA; BRAVO, R				WEIH, F; CARRASCO, D; DURHAM, SK; BARTON, DS; RIZZO, CA; RYSECK, RP; LIRA, SA; BRAVO, R			MULTIORGAN INFLAMMATION AND HEMATOPOIETIC ABNORMALITIES IN MICE WITH A TARGETED DISRUPTION OF RELB, A MEMBER OF THE NF-KAPPA-B/REL FAMILY	CELL			English	Article							DENDRITIC CELLS; TRANSCRIPTION FACTORS; BONE-MARROW; B PROTEINS; STEM-CELLS; GENE; EXPRESSION; ANTIGEN; TRANSACTIVATION; DISEASE	RelB, a member of the NF-kappa B/Rel family of transcription factors, has been implicated in the constitutive expression of kappa B-regulated genes in lymphoid tissues. We have generated mice carrying a germline mutation of the relB gene, resulting in the absence of RelB protein and a dramatic reduction of constitutive kappa B-binding activity in thymus and spleen. Mice homozygous for the disrupted relB locus had phenotypic abnormalities including multifocal, mixed inflammatory cell infiltration in several organs, myeloid hyperplasia, splenomegaly due to extramedullary hematopoiesis, and a reduced population of thymic dendritic cells. RelB-deficient animals also had an impaired cellular immunity, as observed in contact sensitivity experiments. Thus, RelB plays a decisive role in the hematopoietic system, and its absence cannot be functionally compensated by any other member of the NF-kappa B/Rel family.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT EXPTL PATHOL, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb	WEIH, F (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, POB 4000, PRINCETON, NJ 08543 USA.							AGGER R, 1992, J LEUKOCYTE BIOL, V52, P34, DOI 10.1002/jlb.52.1.34; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BREEL M, 1987, EUR J IMMUNOL, V17, P1555, DOI 10.1002/eji.1830171105; CARRASCO D, 1994, DEVELOPMENT, V120, P2991; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; COLIGAN JE, 1992, CURRENT PROTOCOLS IM; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRUSCHWITZ MS, 1992, J INVEST DERMATOL, V99, P114, DOI 10.1111/1523-1747.ep12611890; HESTDAL K, 1991, J IMMUNOL, V147, P22; INABA K, 1993, P NATL ACAD SCI USA, V90, P3038, DOI 10.1073/pnas.90.7.3038; ISSEKUTZ TB, 1992, CURR OPIN IMMUNOL, V4, P287, DOI 10.1016/0952-7915(92)90078-S; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Muller H K, 1992, Semin Immunol, V4, P205; OGARRA A, 1993, CURR OPIN IMMUNOL, V5, P880, DOI 10.1016/0952-7915(93)90100-7; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sambrook J., 1989, MOL CLONING LAB MANU; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; WEIH F, 1994, ONCOGENE, V9, P3289; Wurst W., 1993, Gene targeting: a practical approach., P33	37	683	695	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	1995	80	2					331	340		10.1016/0092-8674(95)90416-6	http://dx.doi.org/10.1016/0092-8674(95)90416-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834753	Bronze			2022-12-24	WOS:A1995QD92400016
J	SHUSTER, S				SHUSTER, S			CAPSAICIN AND THE CAUSE OF CAUSALGIA	LANCET			English	Note							PAIN	From self-experimentation, I propose that the pain which occurs after application of capsaicin is causalgia and that this ''capsaicin causalgia'' is due to actual or functional depletion of neuropeptides such as substance P. This idea could provide an objective definition of the causalgic syndromes and improve the means of diagnosis. The analogy with capsaicin causalgia could also be extended to the pain of epidermal necrolysis, solar and thermal burns, and leprosy. the concept could lead to a better treatment of these causalgic syndromes by modulation of neuropeptide concentration of responsivity, or by mitigation of the consequences of its depletion.			SHUSTER, S (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT DERMATOL,NEWCASTLE TYNE NE2 4BW,TYNE & WEAR,ENGLAND.							BARBUT D, 1981, BRAIN RES, V205, P289, DOI 10.1016/0006-8993(81)90340-1; BRENEMAN DL, 1992, J AM ACAD DERMATOL, V26, P91, DOI 10.1016/0190-9622(92)70013-6; DOTSON RM, 1993, MUSCLE NERVE, V16, P1049, DOI 10.1002/mus.880161008; LEWIS T, 1927, BLOOD VESSELS HUMAN, P69; LYNN B, 1990, PAIN, V51, P61; PORTER R, 1982, CIBA F S, V91; SCHOTT GD, 1986, BRAIN, V109, P717, DOI 10.1093/brain/109.4.717; SIMONE DA, 1989, PAIN, V38, P99, DOI 10.1016/0304-3959(89)90079-1; WALTON J, 1993, BRAINS DISEASES NERV, P563; 1986, CLASSIFICATION CH S3, V26, pS29	10	8	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					160	161		10.1016/S0140-6736(95)90169-8	http://dx.doi.org/10.1016/S0140-6736(95)90169-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823672				2022-12-24	WOS:A1995QC55000012
J	LIMOUSIN, P; POLLAK, P; BENAZZOUZ, A; HOFFMANN, D; LEBAS, JF; BROUSSOLLE, E; PERRET, JE; BENABID, AL				LIMOUSIN, P; POLLAK, P; BENAZZOUZ, A; HOFFMANN, D; LEBAS, JF; BROUSSOLLE, E; PERRET, JE; BENABID, AL			EFFECT ON PARKINSONIAN SIGNS AND SYMPTOMS OF BILATERAL SUBTHALAMIC NUCLEUS STIMULATION	LANCET			English	Article							INTERMEDIATE THALAMIC NUCLEUS; MOVEMENT-DISORDERS; DISEASE; PRIMATE; TREMOR; DYSKINESIAS; REVERSAL; LESIONS	In monkeys rendered parkinsonian, lesions and electrical stimulation of the subthalamic nucleus reduce all major motor disturbances, The effect of electrical stimulation of the subthalamic nucleus was assessed in three patients with disabling akinetic-rigid Parkinson's disease and severe motor fluctuations. Quadripolar electrodes connected to a pulse generator were implanted in the subthalamic nuclei on both sides, Patients were evaluated with the unified Parkinson's disease rating scale and timed motor tests. 3 months after surgery, activities of daily living scores had improved by 58-88% and motor scores by 42-84%. This improvement was maintained for up to 8 months in the first patient operated upon. One patient was confused for 2 weeks after surgery, and another developed neuropsychological impairment related to a thalamic infarction which improved over 3 months, In one patient, stimulation could induce ballism that was stopped by reduction of stimulation. This is the first demonstration in human beings of the part played by the subthalamic nuclei in the pathophysiology of Parkinson's disease.	UNIV GRENOBLE 1,DEPT CLIN & BIOL NEUROSCI,F-38041 GRENOBLE,FRANCE; HOP NEUROL,LYON,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Lyon			Broussolle, Emmanuel/H-1592-2017; Benazzouz, Abdelhamid/E-5050-2016	Broussolle, Emmanuel/0000-0002-0410-9519; 				ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; AZIZ TZ, 1992, BRIT J NEUROSURG, V6, P575, DOI 10.3109/02688699209002375; AZIZ TZ, 1991, MOVEMENT DISORD, V6, P288, DOI 10.1002/mds.870060404; BENABID AL, 1991, LANCET, V337, P403, DOI 10.1016/0140-6736(91)91175-T; BENAZZOUZ A, 1993, EUR J NEUROSCI, V5, P382, DOI 10.1111/j.1460-9568.1993.tb00505.x; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; BLOND S, 1992, J NEUROSURG, V77, P62, DOI 10.3171/jns.1992.77.1.0062; CAPARROSLEFEBVRE D, 1993, J NEUROL NEUROSUR PS, V56, P268, DOI 10.1136/jnnp.56.3.268; DeLong M. R., 1987, BASAL GANGLIA, P415, DOI 10.1007/978-1-4684-5347-8_29; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; DELONG MR, 1985, J NEUROPHYSIOL, V53, P530, DOI 10.1152/jn.1985.53.2.530; FAHN S, 1992, NEW ENGL J MED, V327, P1589, DOI 10.1056/NEJM199211263272209; Fahn S., 1987, RECENT DEV PARKINSON, VVol. 2, P153; HAMADA I, 1992, J NEUROPHYSIOL, V68, P1850, DOI 10.1152/jn.1992.68.5.1850; HITCHCOCK ER, 1988, LANCET, V1, P1274; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; LINDVALL O, 1992, ANN NEUROL, V31, P155, DOI 10.1002/ana.410310206; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; NGUYEN JP, 1993, ARCH NEUROL-CHICAGO, V50, P498, DOI 10.1001/archneur.1993.00540050050014; PILLON B, 1986, NEUROLOGY, V36, P1179, DOI 10.1212/WNL.36.9.1179; POLLAK P, 1993, ADV NEUROL, V60, P408; Schaltenbrand G., 1977, ATLAS STEREOTAXY HUM; SHANNON KM, 1990, CLIN NEUROPHARMACOL, V13, P413, DOI 10.1097/00002826-199010000-00003; Talairach J., 1957, ATLAS ANATOMIE STERE; 1992, MOV DISORD, V7, P2	25	1059	1102	3	66	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					91	95		10.1016/S0140-6736(95)90062-4	http://dx.doi.org/10.1016/S0140-6736(95)90062-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815888				2022-12-24	WOS:A1995QB80400009
J	CALVERT, R; RANDERSON, J; EVANS, P; CAWKWELL, L; LEWIS, F; DIXON, MF; JACK, A; OWEN, R; SHIACH, C; MORGAN, GJ				CALVERT, R; RANDERSON, J; EVANS, P; CAWKWELL, L; LEWIS, F; DIXON, MF; JACK, A; OWEN, R; SHIACH, C; MORGAN, GJ			GENETIC ABNORMALITIES DURING TRANSITION FROM HELICOBACTER-PYLORI-ASSOCIATED GASTRITIS TO LOW-GRADE MALTOMA	LANCET			English	Note							POLYMERASE CHAIN-REACTION	The helicobacter-associated transition from chronic gastritis to MALToma (lymphoma of mucosa-associated lymphoid tissue) may require genetic change in the host. We have studied gastrectomy specimens from twelve cases of primary B-cell gastric lymphoma showing evidence of chronic gastritis and low-grade or high-grade MALToma to look for allele imbalance at microsatellites for six tumour-suppressor genes. We detected allelic imbalance at two of these loci (DCC in three, APC in two). In two DCC cases allele imbalance was seen in the transition from chronic gastritis to low-grade MALToma and in the third between low-grade and high-grade. Allele imbalance between chronic gastritis and low-grade MALToma is not necessarily causal in the transition. Rather, genetic change has occurred in the process of transformation.	LEEDS GEN INFIRM,DEPT MOLEC HAEMATOL,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary; University of Leeds			Maestro, Roberta/P-9748-2019; Maestro, Roberta/M-1846-2015	Maestro, Roberta/0000-0002-6642-5592; Maestro, Roberta/0000-0002-6642-5592; Randerson-Moor, Juliette/0000-0003-0303-0072; morgan, gareth/0000-0002-4271-6360				CAWKWELL L, 1993, BRIT J CANCER, V67, P1262, DOI 10.1038/bjc.1993.236; CAWKWELL L, 1994, BRIT J CANCER, V70, P813, DOI 10.1038/bjc.1994.404; DEANE M, 1991, LEUKEMIA, V5, P726; ENNO A, 1994, J CLIN PATHOL, V173, pA166; GRIBBEN JG, 1991, BLOOD, V78, P3275; MCCARTHY KP, 1990, J CLIN PATHOL, V43, P429, DOI 10.1136/jcp.43.5.429; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F	7	75	75	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					26	27		10.1016/S0140-6736(95)91154-5	http://dx.doi.org/10.1016/S0140-6736(95)91154-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799702				2022-12-24	WOS:A1995QA29000012
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PUBLIC HEARING ON FINANCIAL DISCLOSURE BY CLINICAL INVESTIGATORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1994, JAMA-J AM MED ASSOC, V272, P1160	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1897	1897						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RE354	7783288				2022-12-24	WOS:A1995RE35400008
J	KATSUYA, T; KOIKE, G; YEE, TW; SHARPE, N; JACKSON, R; NORTON, R; HORIUCHI, M; PRATT, RE; DZAU, VJ; MACMAHON, S				KATSUYA, T; KOIKE, G; YEE, TW; SHARPE, N; JACKSON, R; NORTON, R; HORIUCHI, M; PRATT, RE; DZAU, VJ; MACMAHON, S			ASSOCIATION OF ANGIOTENSINOGEN GENE T235 VARIANT WITH INCREASED RISK OF CORONARY HEART-DISEASE	LANCET			English	Article							CONVERTING ENZYME; MYOCARDIAL-INFARCTION; DELETION POLYMORPHISM; CARDIOMYOPATHY; HYPERTENSION	Several genes, including some encoding components of the renin angiotensin system, are associated with the risk of cardiovascular diseases. There have been reports linking a homozygous deletion allele of the angiotensin converting enzyme (ACE) gene (DD) with an increased myocardial infarction, some variants and angiotensinogen gene with hypertension. In a case-control study of a caucasian population from New Zealand, we examined the associations with coronary heart disease (CHD) of ACE DD and of a mis-sense mutation with methionine to threonine aminoacid substitution at codon 235 in the angiotensinogen gene ( T235). We studied 422 patients (mean age 62 years, 81% male) with documented CHD (50% with myocardial infarction) and 406 controls without known CHD (frequency-matched to cases by age and sex). Risk factors for CHD were assessed by standard questionnaire, physical examination, and blood tests. Genomic DNA from leucocytes was analysed for various ACE and angiotensinogen alleles. Angiotensinogen T235 homozygotes were at significantly increased risk of CHD generally (odds ratio 1 . 7, 2p=0 . 008) and of myocardial infarction specifically (1 . 8, 2p=0 . 009). Adjustment for several risk factors increased the estimate of CHD risk associated with this allele to 2 . 6 (2p<0 . 001) and the estimate for myocardial infarction risk to 3 . 4 (2p<0 . 001). By contrast, there was no evidence of a significant increase in the risk of CHD or myocardial infarction among individuals with ACE DD. We conclude that the T235 polymorphism of the angiotensinogen gene is an independent risk factor, which carries an approximately two-fold increased risk of CHD. In this study, however, ACE DD was not associated with any detectable increase in CHD risk.	UNIV AUCKLAND,SCH MED,DEPT MED,CLIN TRIALS RES UNIT,AUCKLAND,NEW ZEALAND; UNIV AUCKLAND,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND; STANFORD UNIV,FALK CARDIOVASC RES CTR,DEPT MED,DIV CARDIOVASC MED,STANFORD,CA	University of Auckland; University of Auckland; Stanford University				Yee, Thomas/0000-0002-9970-3907; Jackson, Rod/0000-0001-5914-6934	NHLBI NIH HHS [HL35252, HL35610, HL46631] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035252, R01HL046631, R01HL035610, R37HL035610] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOHN M, 1993, CLIN GENET, V44, P292; BONNARDEAUX A, 1994, HYPERTENSION, V24, P63, DOI 10.1161/01.HYP.24.1.63; CAMBIEN F, 1994, CIRCULATION, V90, P669, DOI 10.1161/01.CIR.90.2.669; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CAULFIELD M, 1994, NEW ENGL J MED, V330, P1629, DOI 10.1056/NEJM199406093302301; DZAU VJ, 1993, J HYPERTENS, V11, pS13; EVANS AE, 1994, Q J MED, V87, P211; HARRAP SB, 1994, LANCET, V344, P901, DOI 10.1016/S0140-6736(94)92262-4; HATA A, 1994, J CLIN INVEST, V93, P1285, DOI 10.1172/JCI117083; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; LINDPAINTNER K, 1995, NEW ENGL J MED, V332, P706, DOI 10.1056/NEJM199503163321103; LINDPAINTNER K, 1993, CLIN RES, V41, P216; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MARIAN AJ, 1993, LANCET, V342, P1085, DOI 10.1016/0140-6736(93)92064-Z; MIETTINEN HE, 1994, HUM GENET, V94, P189; OHISHI M, 1993, NAT GENET, V5, P324, DOI 10.1038/ng1293-324; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RAYNOLDS MV, 1993, LANCET, V342, P1073, DOI 10.1016/0140-6736(93)92061-W; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RUSS AP, 1993, HUM MOL GENET, V2, P609, DOI 10.1093/hmg/2.5.609; SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056/NEJM199406093302302; TIRET L, 1994, LANCET, V344, P910, DOI 10.1016/S0140-6736(94)92268-3; TIRET L, 1992, AM J HUM GENET, V51, P197; YUSUF S, 1992, LANCET, V340, P1173, DOI 10.1016/0140-6736(92)92889-N; Zhao Y, 1994, HYPERTENS RES, V17, P55	25	282	309	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1600	1603		10.1016/S0140-6736(95)90115-9	http://dx.doi.org/10.1016/S0140-6736(95)90115-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783537	Bronze			2022-12-24	WOS:A1995RE67000008
J	GALLARD, C				GALLARD, C			FEMALE GENITAL MUTILATION IN FRANCE	BRITISH MEDICAL JOURNAL			English	Article											GALLARD, C (corresponding author), FRENCH FAMILY PLANNING ASSOC,4 IRENEE SQ,F-75011 PARIS,FRANCE.							HOSKEN F, 1994, LIVRE IMAGES UNIVERS; 1993, MUTILATIONS SEXUELLE; EXCISION SA PRESENCE	3	25	25	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1592	1593		10.1136/bmj.310.6994.1592	http://dx.doi.org/10.1136/bmj.310.6994.1592			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787655	Green Published			2022-12-24	WOS:A1995RE35300030
J	VINGERLING, JR; DIELEMANS, I; WITTEMAN, JCM; HOFMAN, A; GROBBEE, DE; DEJONG, PTVM				VINGERLING, JR; DIELEMANS, I; WITTEMAN, JCM; HOFMAN, A; GROBBEE, DE; DEJONG, PTVM			MACULAR DEGENERATION AND EARLY MENOPAUSE - A CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							RISK; DISEASE; WOMEN		ERASMUS UNIV ROTTERDAM,SCH MED,DEPT OPHTHALMOL,3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,SCH MED,DEPT BIOSTAT & EPIDEMIOL,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam			Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; PALMER JR, 1992, AM J EPIDEMIOL, V136, P408, DOI 10.1093/oxfordjournals.aje.a116513; WITTEMAN JCM, 1989, BRIT MED J, V298, P642, DOI 10.1136/bmj.298.6674.642; 1992, ARCH OPHTHALMOL-CHIC, V110, P1701	5	61	65	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1570	1571		10.1136/bmj.310.6994.1570	http://dx.doi.org/10.1136/bmj.310.6994.1570			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787646	Green Published, Green Submitted			2022-12-24	WOS:A1995RE35300020
J	MORSE, D; SALOIS, P; MARKOVIC, P; HASTINGS, JW				MORSE, D; SALOIS, P; MARKOVIC, P; HASTINGS, JW			A NUCLEAR-ENCODED FORM-II RUBISCO IN DINOFLAGELLATES	SCIENCE			English	Article							CHLOROPHYLL-B; EVOLUTION; CARBOXYLASE; ORIGINS; PLASTIDS; PROTEINS; PHYLOGENIES; GENE	The chloroplasts of most dinoflagellates are unusual in that they are surrounded by three membranes and contain the carotenoid peridinin. The ribulose-1,5-bisphosphate carboxylase-oxygenase (RuBisCO) in dinoflagellate chloroplasts was found here to also be unusual. Unlike other eukaryotes, dinoflagellates containing peridinin use a form of RuBisCO (form II) previously found only in some species of proteobacteria. Furthermore, this RuBisCO is not encoded in the chloroplast DNA, as is the case in other organisms, but is encoded by the nuclear DNA. The unusual nature of this enzyme and location of its gene support the idea that dinoflagellate chloroplasts may have had a distinctive evolutionary origin.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University	MORSE, D (corresponding author), UNIV MONTREAL,INST RECH BIOL VEGETALE,MONTREAL,PQ H1X 2B2,CANADA.			Morse, David/0000-0003-4131-4367	NIGMS NIH HHS [2R01-GM-19536] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019536] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; ASSALI NE, 1991, PLANT MOL BIOL, V17, P853, DOI 10.1007/BF00037066; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CAVALIERSMITH T, 1982, BIOL J LINN SOC, V17, P289, DOI 10.1111/j.1095-8312.1982.tb02023.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORUZZI G, 1983, J BIOL CHEM, V258, P1399; GIBSON JL, 1977, J BIOL CHEM, V252, P943; GRAY MW, 1989, ANNU REV CELL BIOL, V5, P25, DOI 10.1146/annurev.cb.05.110189.000325; GRAY MW, 1989, TRENDS GENET, V5, P294, DOI 10.1016/0168-9525(89)90111-X; INNI SM, 1990, PCR PROTOCOLS; KANEVSKI I, 1994, P NATL ACAD SCI USA, V91, P1969, DOI 10.1073/pnas.91.5.1969; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAEMMLI UK, 1974, NATURE, V227, P680; LOEBLICH AR, 1976, J PROTOZOOL, V23, P13, DOI 10.1111/j.1550-7408.1976.tb05241.x; MACHABEE S, 1994, PLANT MOL BIOL, V25, P23, DOI 10.1007/BF00024195; MARTIN W, 1992, J MOL EVOL, V35, P385, DOI 10.1007/BF00171817; MILOS P, 1990, NATURWISSENSCHAFTEN, V77, P87, DOI 10.1007/BF01131782; MORDEN CW, 1992, BIOSYSTEMS, V28, P75, DOI 10.1016/0303-2647(92)90010-V; MORDEN CW, 1991, J MOL EVOL, V32, P379, DOI 10.1007/BF02101278; MORSE DC, UNPUB; NARANG F, 1984, MOL GEN GENET, V193, P220; RAVEN PH, 1970, SCIENCE, V169, P641, DOI 10.1126/science.169.3946.641; RITLAND K, 1987, American Naturalist, V130, pS74, DOI 10.1086/284693; SCHULER M, METHODS PLANT MOL BI; TANGEN K, 1981, Journal of Plankton Research, V3, P389, DOI 10.1093/plankt/3.3.389; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATANABE MM, 1987, J PHYCOL, V23, P382, DOI 10.1111/j.1529-8817.1987.tb04148.x; WILCOX LW, 1985, SCIENCE, V227, P192, DOI 10.1126/science.227.4683.192; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443	30	208	220	0	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 16	1995	268	5217					1622	1624		10.1126/science.7777861	http://dx.doi.org/10.1126/science.7777861			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7777861				2022-12-24	WOS:A1995RD45900039
J	TANENHAUS, MK; SPIVEYKNOWLTON, MJ; EBERHARD, KM; SEDIVY, JC				TANENHAUS, MK; SPIVEYKNOWLTON, MJ; EBERHARD, KM; SEDIVY, JC			INTEGRATION OF VISUAL AND LINGUISTIC INFORMATION IN SPOKEN LANGUAGE COMPREHENSION	SCIENCE			English	Article							PERCEPTION	Psycholinguists have commonly assumed that as a spoken linguistic message unfolds over time, it is initially structured by a syntactic processing module that is encapsulated from information provided by other perceptual and cognitive systems. To test the effects of relevant visual context on the rapid mental processes that accompany spoken language comprehension, eye movements were recorded with a head-mounted eye-tracking system while subjects followed instructions to manipulate real objects. Visual context influenced spoken word recognition and mediated syntactic processing, even during the earliest moments of language processing.	UNIV ROCHESTER, DEPT LINGUIST, ROCHESTER, NY 14627 USA	University of Rochester	TANENHAUS, MK (corresponding author), UNIV ROCHESTER, DEPT BRAIN & COGNIT SCI, 601 ELMWOOD AVE, ROCHESTER, NY 14627 USA.		Eberhard, Kathleen M/A-2542-2014; Galantucci, Bruno/E-5770-2010; Eberhard, Kathleen/B-4346-2008	Eberhard, Kathleen/0000-0002-0764-4541	NCRR NIH HHS [1-P41-RR09283] Funding Source: Medline; NICHD NIH HHS [HD27206] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD027206] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR009283] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTMANN G, 1988, COGNITION, V30, P191, DOI 10.1016/0010-0277(88)90020-0; BALLARD DH, 1995, J COGNITIVE NEUROSCI, V7, P66, DOI 10.1162/jocn.1995.7.1.66; BRITT MA, 1994, J MEM LANG, V33, P251, DOI 10.1006/jmla.1994.1013; Chomsky Noam., 1965, ASPECTS THEORY SYNTA; CLARK H, 1994, ARENAS LANGUAGE USE; CRAIN S, 1985, NATURAL LANGUAGE PAR, P320, DOI DOI 10.1017/CBO9780511597855.011; FERREIRA F, 1986, J MEM LANG, V25, P348, DOI 10.1016/0749-596X(86)90006-9; Fodor J. A, 1983, MODULARITY MIND; FRAZIER L, 1987, ATTENTION PERFORM, P559; Jackendoff R., 1992, LANGUAGES MIND; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; MACDONALD MC, 1994, PSYCHOL REV, V101, P676, DOI 10.1037/0033-295X.101.4.676; MARSLENWILSON WD, 1975, SCIENCE, V189, P226, DOI 10.1126/science.189.4198.226; MATIN E, 1993, PERCEPT PSYCHOPHYS, V53, P372, DOI 10.3758/BF03206780; MCCLELLAND JL, 1987, ATTENTION PERFORM, P3; PINKER S, 1991, SCIENCE, V253, P530, DOI 10.1126/science.1857983; Pinker S., 1994, LANGUAGE INSTINCT MI; Pollard C., 1993, HEAD DRIVEN PHRASE S; SPIVEYKNOWLTON M, IN PRESS COGNITION; TANENHAUS M, IN PRESS HDB COGNITI; WILSON WM, 1973, NATURE, V244, P522, DOI 10.1038/244522a0	21	1490	1518	6	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 16	1995	268	5217					1632	1634		10.1126/science.7777863	http://dx.doi.org/10.1126/science.7777863			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RD459	7777863				2022-12-24	WOS:A1995RD45900042
J	KOHN, MA; FARLEY, TA; ANDO, T; CURTIS, M; WILSON, SA; JIN, Q; MONROE, SS; BARON, RC; MCFARLAND, LM; GLASS, RI				KOHN, MA; FARLEY, TA; ANDO, T; CURTIS, M; WILSON, SA; JIN, Q; MONROE, SS; BARON, RC; MCFARLAND, LM; GLASS, RI			AN OUTBREAK OF NORWALK VIRUS GASTROENTERITIS ASSOCIATED WITH EATING RAW OYSTERS - IMPLICATIONS FOR MAINTAINING SAFE OYSTER BEDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFECTIOUS NONBACTERIAL GASTROENTERITIS; POLYMERASE CHAIN-REACTION; TO-PERSON TRANSMISSION; VIRAL GASTROENTERITIS; WATER-SYSTEM; CRUISE SHIP; CONSUMPTION; COMMUNITY; SPECIMENS; ILLNESS	Objective.-To determine the characteristics and the cause of an outbreak of gastroenteritis associated with eating raw oysters. Design.-Survey of groups of persons reporting illness to the health department after eating oysters; survey of convenience sample of oyster harvesters; and tracing of implicated oysters. Setting.-General community. Main Outcome Measures.-Relative risk for illness after oyster consumption, source bed of contaminated oysters, presence of antibodies to Norwalk virus in serum, presence of a Norwalk virus in stool by direct electron microscopy and reverse transcription-polymerase chain reaction (RT-PCR), and DNA sequences of RT-PCR products. Results.-Seventy (83%) of 84 persons who ate raw oysters became ill vs three (7%) of 43 people who did not eat raw oysters (relative risk, 11.9; 95% confidence interval, 4.0 to 34.2). Eleven (79%) of 14 serum pairs had at least a fourfold increase in antibody to Norwalk virus. All 12 stool samples tested were positive by electron microscopy and/or RT-PCR for Norwalk virus. The RT-PCR products from all seven stool samples tested had identical DNA sequences. Implicated oysters were harvested November 9 through 13, 1993, from a remote oyster bed. Crews from 22 (85%) of 26 oyster harvesting boats working in this area reported routine overboard disposal of sewage. One harvester with a high level of antibodies to Norwalk virus reported having gastroenteritis November 7 through 10 and overboard disposal of feces into the oyster bed. Conclusions.-This outbreak was caused by contamination of oysters in the oyster bed, probably by stool from one or more ill harvesters. Education of oyster harvesters and enforcement of regulations governing waste disposal by oyster harvesting boats might prevent similar outbreaks.	CTR DIS CONTROL & PREVENT, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA USA; CTR DIS CONTROL & PREVENT, DIV FIELD EPIDEMIOL, EPIDEM INTELLIGENCE SERV, ATLANTA, GA USA; CTR DIS CONTROL & PREVENT, MED STUDENT ELECT PROGRAM, EPIDEMIOL PROGRAM OFF, ATLANTA, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	KOHN, MA (corresponding author), LOUISIANA DEPT HLTH & HOSP, OFF PUBL HLTH, EPIDEMIOL SECT, POB 60630, NEW ORLEANS, LA 70160 USA.			Monroe, Stephan/0000-0002-5424-716X				ADLER JL, 1969, J INFECT DIS, V119, P668, DOI 10.1093/infdis/119.6.668; ANDO T, 1994, ARCH VIROL, V135, P217, DOI 10.1007/BF01309781; ANDO T, 1995, J CLIN MICROBIOL, V33, P64, DOI 10.1128/JCM.33.1.64-71.1995; APPLETON H, 1977, LANCET, V1, P409; ATMAR RL, 1993, APPL ENVIRON MICROB, V59, P631, DOI 10.1128/AEM.59.2.631-635.1993; BARON RC, 1982, AM J EPIDEMIOL, V115, P163, DOI 10.1093/oxfordjournals.aje.a113287; BLACKLOW NR, 1991, NEW ENGL J MED, V325, P252, DOI 10.1056/NEJM199107253250406; Burkhardt W, 1992, J SHELLFISH RES, V11, P105; CANNON RO, 1991, J INFECT DIS, V164, P860, DOI 10.1093/infdis/164.5.860; DELEON R, 1992, J CLIN MICROBIOL, V30, P3151, DOI 10.1128/JCM.30.12.3151-3157.1992; DOANE FW, 1987, ELECTRON MICROS, P15; DOLIN R, 1972, P SOC EXP BIOL MED, V140, P578, DOI 10.3181/00379727-140-36508; ERDMAN DD, 1989, J CLIN MICROBIOL, V27, P1417, DOI 10.1128/JCM.27.6.1417-1418.1989; GILL ON, 1983, BRIT MED J, V287, P1532, DOI 10.1136/bmj.287.6404.1532; GOODMAN RA, 1982, ARCH ENVIRON HEALTH, V37, P358, DOI 10.1080/00039896.1982.10667591; GOYAL SM, 1979, APPL ENVIRON MICROB, V37, P572, DOI 10.1128/AEM.37.3.572-581.1979; GREENBERG HB, 1979, J INFECT DIS, V139, P564, DOI 10.1093/infdis/139.5.564; GRIFFIN MR, 1982, AM J EPIDEMIOL, V115, P178, DOI 10.1093/oxfordjournals.aje.a113289; GUNN RA, 1982, AM J EPIDEMIOL, V115, P348, DOI 10.1093/oxfordjournals.aje.a113311; GUNN RA, 1980, AM J EPIDEMIOL, V112, P820, DOI 10.1093/oxfordjournals.aje.a113054; HERWALDT BL, 1994, J CLIN MICROBIOL, V32, P861, DOI 10.1128/JCM.32.4.861-866.1994; HO MS, 1989, LANCET, V2, P961; JIANG X, 1990, Science (Washington D C), V250, P1580; KAPIKIAN AZ, 1972, J VIROL, V10, P1075, DOI 10.1128/JVI.10.5.1075-1081.1972; Kapikian AZ, 1990, VIROLOGY, P671; KAPLAN JE, 1982, AM J EPIDEMIOL, V116, P940, DOI 10.1093/oxfordjournals.aje.a113496; KAPLAN JE, 1982, J INFECT DIS, V146, P190, DOI 10.1093/infdis/146.2.190; KAPLAN JE, 1982, AM J PUBLIC HEALTH, V72, P1329, DOI 10.2105/AJPH.72.12.1329; KAPLAN JE, 1982, ANN INTERN MED, V96, P756, DOI 10.7326/0003-4819-96-6-756; KHAN AS, 1994, J CLIN MICROBIOL, V32, P318, DOI 10.1128/JCM.32.2.318-322.1994; KOOPMAN JS, 1982, AM J EPIDEMIOL, V115, P173, DOI 10.1093/oxfordjournals.aje.a113288; KURITSKY JN, 1984, ANN INTERN MED, V100, P519, DOI 10.7326/0003-4819-100-4-519; LAWSON HW, 1991, LANCET, V337, P1200, DOI 10.1016/0140-6736(91)92868-3; LIU OC, 1966, P SOC EXP BIOL MED, V123, P481, DOI 10.3181/00379727-123-31520; LOWRY PW, 1989, J INFECT DIS, V160, P978, DOI 10.1093/infdis/160.6.978; MATSUI SM, 1991, J CLIN INVEST, V87, P1456, DOI 10.1172/JCI115152; MOE CL, 1994, J CLIN MICROBIOL, V32, P642, DOI 10.1128/JCM.32.3.642-648.1994; MONROE SS, 1993, J CLIN MICROBIOL, V31, P2866, DOI 10.1128/JCM.31.11.2866-2872.1993; MORSE DL, 1986, NEW ENGL J MED, V314, P678, DOI 10.1056/NEJM198603133141103; MURPHY AM, 1979, MED J AUSTRALIA, V2, P329, DOI 10.5694/j.1326-5377.1979.tb104133.x; NELSON M, 1986, J ENVIRON HEALTH, V49, P7; REEVE G, 1989, NEW ENGL J MED, V321, P224, DOI 10.1056/NEJM198907273210404; SAWYER LA, 1988, AM J EPIDEMIOL, V127, P1261, DOI 10.1093/oxfordjournals.aje.a114918; WILSON R, 1982, AM J PUBLIC HEALTH, V72, P72, DOI 10.2105/AJPH.72.1.72; XI J, 1992, J CLIN MICROBIOL, V30, P2529, DOI 10.1128/JCM.30.10.2529-2534.1992	45	125	130	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	1995	273	6					466	471		10.1001/jama.273.6.466	http://dx.doi.org/10.1001/jama.273.6.466			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE498	7837364				2022-12-24	WOS:A1995QE49800029
J	JOHN, SWM; KREGE, JH; OLIVER, PM; HAGAMAN, JR; HODGIN, JB; PANG, SC; FLYNN, TG; SMITHIES, O				JOHN, SWM; KREGE, JH; OLIVER, PM; HAGAMAN, JR; HODGIN, JB; PANG, SC; FLYNN, TG; SMITHIES, O			GENETIC DECREASES IN ATRIAL-NATRIURETIC-PEPTIDE AND SALT-SENSITIVE HYPERTENSION	SCIENCE			English	Article							SODIUM-EXCRETION; LOCUS; RATS; POLYMORPHISM; ATRIOPEPTIN; DISRUPTION; RENIN; CELLS; HPND; SITE	To determine if defects in the atrial natriuretic peptide (ANP) system can cause hypertension, mice were generated with a disruption of the proANP gene. Homozygous mutants had no circulating or atrial ANP, and their blood pressures were elevated by 8 to 23 millimeters of mercury when they were fed standard (0.5 percent sodium chloride) and intermediate (2 percent sodium chloride) salt diets. On standard salt diets, heterozygotes had normal amounts of circulating ANP and normal blood pressures. However, on high (8 percent sodium chloride) salt diets they were hypertensive, with blood pressures elevated by 27 millimeters of mercury. These results demonstrate that genetically reduced production of ANP can lead to salt-sensitive hypertension.	UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT INTERNAL MED,CHAPEL HILL,NC 27599; QUEENS UNIV,DEPT ANAT & CELL BIOL,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Queens University - Canada; Queens University - Canada					NHLBI NIH HHS [HL49277] Funding Source: Medline; NIGMS NIH HHS [GM20069] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020069, R01GM020069] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLERMANN BJ, 1991, KIDNEY, pCH14; BARLEY J, 1991, J HYPERTENS, V9, P993, DOI 10.1097/00004872-199111000-00003; BLAINE EH, 1990, HYPERTENSION, V15, P2036; FERRARI P, 1990, J CLIN ENDOCR METAB, V71, P944, DOI 10.1210/jcem-71-4-944; GARCIA R, 1982, EXPERIENTIA, V38, P1071, DOI 10.1007/BF01955373; GOETZ KL, 1990, HYPERTENSION, V15, P9, DOI 10.1161/01.HYP.15.1.9; GRANGER JP, 1986, HYPERTENSION, V8, P112; GREENWALD JE, 1988, J CLIN INVEST, V81, P1036, DOI 10.1172/JCI113414; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JOHN S., COMMUNICATION; KREGE JH, IN PRESS HYPERTENSIO; LARAGH JH, 1990, HYPERTENSION PATHOPH, V1; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MORRIS BJ, 1993, CLIN SCI, V85, P189, DOI 10.1042/cs0850189; NARUSE M, 1985, BIOCHEM BIOPH RES CO, V132, P954, DOI 10.1016/0006-291X(85)91900-X; NEMER M, 1986, NUCLEIC ACIDS RES, V14, P8696, DOI 10.1093/nar/14.21.8696; NEMER M, 1986, NUCLEIC ACIDS RES, V14, P8697, DOI 10.1093/nar/14.21.8697; PANG SC, 1986, J HYPERTENS, V4, pS119; RAMASAWMY R, 1993, HUM GENET, V91, P509; RAMASAWMY R, 1994, HUM GENET, V93, P355, DOI 10.1007/BF00212041; RAMASAWMY R, 1992, HUM GENET, V90, P323; RICHARDS AM, 1988, J CLIN ENDOCR METAB, V66, P465, DOI 10.1210/jcem-66-3-465; SARDA IR, 1989, CLIN BIOCHEM, V22, P11, DOI 10.1016/S0009-9120(89)80063-3; SHEHEE WR, 1993, P NATL ACAD SCI USA, V90, P3177, DOI 10.1073/pnas.90.8.3177; VENANCE SL, 1989, HISTOL HISTOPATHOL, V4, P325; WEIDMANN P, 1991, CAN J PHYSIOL PHARM, V69, P1582, DOI 10.1139/y91-235; 1988, BRIT MED J, V297, P319	27	507	524	0	16	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					679	681		10.1126/science.7839143	http://dx.doi.org/10.1126/science.7839143			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839143				2022-12-24	WOS:A1995QE73300038
J	SHIVDASANI, RA; MAYER, EL; ORKIN, SH				SHIVDASANI, RA; MAYER, EL; ORKIN, SH			ABSENCE OF BLOOD FORMATION IN MICE LACKING THE T-CELL LEUKEMIA ONCOPROTEIN TAL-1/SCL	NATURE			English	Article							DNA-BINDING MOTIF; CHROMOSOMAL TRANSLOCATION; ERYTHROID-DIFFERENTIATION; TARGETED MUTATION; GENE SCL; EXPRESSION; LEUKEMIA; PROTEIN; HEMATOPOIESIS; RECOMBINATION	CHROMOSOMAL translocations associated with malignancies often result in deregulated expression of genes encoding transcription factors(1). In human T-cell leukaemias such regulators belong to diverse protein families and may normally be expressed widely (for example, Ttg-1/rbtn1, Ttg-2/rbtn2)(2'3), exclusively outside the haematopoietic system (for example, Hox11)(4), or specifically in haematopoietic cells and other selected sites (for example, tal-1/ SCL, lyl-1)(5,6). Aberrant expression within T cells is thought to interfere with programmes of normal maturation. The most frequently activated gene in acute T-cell leukaemias, tal-1 (also called SCL)(7,8), encodes a candidate regulator of haematopoietic development(9), a basic-helix-loop-helix protein(5), related to critical myogenic(10) and neurogenic(11) factors. Here we show by targeted gene disruption in mice(12) that tal-1 is essential for embryonic blood formation in vivo. With respect to embryonic erythropoiesis, tal-1 deficiency resembles loss of the erythroid transcription factor GATA-(13,14) or the LIM protein rbtn2(15). Profound reduction in myeloid cells cultured in vivo from tal-1 null yolk sacs suggests a broader defect manifest at the myelo-erythroid or multipotential progenitor cell level.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute	SHIVDASANI, RA (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02115, USA.							APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; AUSUBEL FM, 1987, CURR PROT MOL BIOL; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HWANG LY, 1993, ONCOGENE, V8, P3043; KALLIANPUR AR, 1994, BLOOD, V83, P1200; KELLER G, 1993, MOL CELL BIOL, V13, P472; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VISVADER J, 1991, ONCOGENE, V6, P187; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851	30	747	774	1	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					432	434		10.1038/373432a0	http://dx.doi.org/10.1038/373432a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830794				2022-12-24	WOS:A1995QE67000057
J	TAKAYAMA, S; SATO, T; KRAJEWSKI, S; KOCHEL, K; IRIE, S; MILLAN, JA; REED, JC				TAKAYAMA, S; SATO, T; KRAJEWSKI, S; KOCHEL, K; IRIE, S; MILLAN, JA; REED, JC			CLONING AND FUNCTIONAL-ANALYSIS OF BAG-1 - A NOVEL BCL-2-BINDING PROTEIN WITH ANTI-CELL DEATH ACTIVITY	CELL			English	Article							GENE CED-3; BCL-2; APOPTOSIS; UBIQUITIN; ELEGANS; PATHWAY; ENCODES; ENZYME; LINES; DNA	Using a protein interaction cloning technique, we identified cDNAs that encode a novel Bcl-2-binding protein, termed BAG-1. The BAG-1 protein shares no significant homology with Bcl-2 or other Bcl-2 family proteins, which can form homo- and heterodimers. In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of BAG-1 and Bcl-2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either BAG-1 or Bcl-2 protein alone. BAG-transfected 3T3 fibroblasts also exhibited prolonged cell survival in response to an apoptotic stimulus, The findings indicate that bag-1 represents a new type of anti-cell death gene and suggest that some routes of apoptosis induction previously ascribed to Bcl-5-independent pathways may instead reflect a need for the combination of Bcl-2 and BAG-1.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA-60181] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060181] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DELIC J, 1993, MOL CELL BIOL, V13, P4875, DOI 10.1128/MCB.13.8.4875; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; ITOH N, 1993, J IMMUNOL, V151, P621; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KITADA S, 1994, ANTISENSE RES DEV, V4, P71, DOI 10.1089/ard.1994.4.71; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1992, CANCER RES, V52, P5407; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; OITVAI ZN, 1993, CELL, V74, P609; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; PALAZZOLO MJ, 1990, GENE, V66, P25; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; REED JC, 1992, ANAL BIOCHEM, V205, P70, DOI 10.1016/0003-2697(92)90580-Z; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SARIN A, 1994, J IMMUNOL, V153, P862; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TAKAHASHI S, 1993, EUR J IMMUNOL, V23, P1935, DOI 10.1002/eji.1830230831; TONIOLO D, 1988, P NATL ACAD SCI USA, V85, P851, DOI 10.1073/pnas.85.3.851; TORIGOE T, 1994, CANCER RES, V54, P4851; TORIGOE T, 1994, J EXP MED, V180, P1115, DOI 10.1084/jem.180.3.1115; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VAUX DL, 1992, INT IMMUNOL, V4, P821, DOI 10.1093/intimm/4.7.821; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	29	785	837	2	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 27	1995	80	2					279	284		10.1016/0092-8674(95)90410-7	http://dx.doi.org/10.1016/0092-8674(95)90410-7			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834747	Bronze			2022-12-24	WOS:A1995QD92400010
J	BOWYER, P; CLARKE, BR; LUNNESS, P; DANIELS, MJ; OSBOURN, AE				BOWYER, P; CLARKE, BR; LUNNESS, P; DANIELS, MJ; OSBOURN, AE			HOST-RANGE OF A PLANT-PATHOGENIC FUNGUS DETERMINED BY A SAPONIN DETOXIFYING ENZYME	SCIENCE			English	Article							GAEUMANNOMYCES-GRAMINIS; NEUROSPORA-CRASSA; ESCHERICHIA-COLI; TRANSFORMATION; RESISTANCE; CLONING; ACID; GENE	Antifungal saponins occur in many plant species and may provide a preformed chemical barrier to attack by phytopathogenic fungi. Some fungal pathogens can enzymatically detoxify host plant saponins, which suggests that saponin detoxification may determine the host range of these fungi. A gene encoding a saponin detoxifying enzyme was cloned from the cereal-infecting fungus Gaeumannomyces graminis. Fungal mutants generated by targeted gene disruption were no longer able to infect the saponin-containing host oats but retained full pathogenicity to wheat (which does not contain saponins). Thus, the ability of a phytopathogenic fungus to detoxify a plant saponin can determine its host range.	JOHN INNES INST,JOHN INNES CTR PLANT SCI RES,SAINSBURY LAB,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center				bowyer, paul/0000-0002-1083-9286				ARNESON PA, 1968, PHYTOPATHOLOGY, V58, P536; AUSTIN B, 1990, EXP MYCOL, V14, P9, DOI 10.1016/0147-5975(90)90082-5; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALLANCE DJ, 1986, MOL GEN GENET, V202, P271, DOI 10.1007/BF00331649; BANGHAM AD, 1962, NATURE, V196, P952, DOI 10.1038/196952a0; BOWYER PK, UNPUB; BUXTON FP, 1983, MOL GEN GENET, V190, P403, DOI 10.1007/BF00331067; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROMBIE WML, 1986, PHYTOCHEMISTRY, V25, P2075, DOI 10.1016/0031-9422(86)80069-3; DOURMASHKIN RR, 1962, NATURE, V194, P1116, DOI 10.1038/1941116a0; DURBIN RD, 1969, BIOCHIM BIOPHYS ACTA, V191, P176, DOI 10.1016/0005-2744(69)90331-3; FORD JE, 1977, PHYTOCHEMISTRY, V16, P545, DOI 10.1016/0031-9422(77)80011-3; FRITIG B, 1993, MECHANISMS PLANT DEF, V2; HENSON JM, 1988, CURR GENET, V14, P113, DOI 10.1007/BF00569334; MAHATO SB, 1991, PHYTOCHEMISTRY, V30, P1357, DOI 10.1016/0031-9422(91)84170-W; MAHATO SB, 1988, PHYTOCHEMISTRY, V28, P3037; OSBOURN AE, 1991, PHYSIOL MOL PLANT P, V38, P301, DOI 10.1016/S0885-5765(05)80121-3; OSBOURN AE, 1994, PHYSIOL MOL PLANT P, V45, P457, DOI 10.1016/S0885-5765(05)80042-6; PEGG GF, 1986, PHYSIOL MOL PLANT P, V28, P187, DOI 10.1016/S0048-4059(86)80063-7; PRICE KR, 1991, CRC CRIT REV FOOD SC, V26, P27; PUNT PJ, 1987, GENE, V56, P117, DOI 10.1016/0378-1119(87)90164-8; RAEDER U, 1985, LETT APPL MICROBIOL, V1, P17, DOI 10.1111/j.1472-765X.1985.tb01479.x; SCHONBECK F, 1976, PHYSL PLANT PATHOLOG, P653; TURNER EM, 1961, J EXP BOT, V12, P169, DOI 10.1093/jxb/12.1.169; VERHOEFF K, 1975, PHYTOPATHOL Z, V82, P333; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	26	191	201	0	42	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 20	1995	267	5196					371	374		10.1126/science.7824933	http://dx.doi.org/10.1126/science.7824933			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7824933				2022-12-24	WOS:A1995QC27300033
J	BALFOUR, HH				BALFOUR, HH			NO REASON NOT TO TREAT	BRITISH MEDICAL JOURNAL			English	Article							VARICELLA-ZOSTER VIRUS; ACYCLOVIR TREATMENT; HEALTHY-CHILDREN; CONTROLLED TRIAL; CHICKENPOX; RESISTANT; RESPONSES				BALFOUR, HH (corresponding author), UNIV MINNESOTA,SCH MED,BOX 437,UMHC,15-144 PWB HARVARD ST & E RIVER PKWY,MINNEAPOLIS,MN 55455, USA.							ABZUG MJ, 1993, J PEDIATR-US, V123, P577, DOI 10.1016/S0022-3476(05)80954-0; BALFOUR HH, 1990, J PEDIATR-US, V116, P633, DOI 10.1016/S0022-3476(05)81618-X; BALFOUR HH, 1992, J PEDIATR-US, V120, P627, DOI 10.1016/S0022-3476(05)82495-3; COLE NL, 1986, J INFECT DIS, V153, P605, DOI 10.1093/infdis/153.3.605; DUNKLE LM, 1991, NEW ENGL J MED, V325, P1539, DOI 10.1056/NEJM199111283252203; ENGLUND JA, 1990, J CLIN MICROBIOL, V28, P2327, DOI 10.1128/JCM.28.10.2327-2330.1990; ENGLUND JA, 1990, ANN INTERN MED, V112, P416, DOI 10.7326/0003-4819-76-3-112-6-416; ROTBART HA, 1993, J INFECT DIS, V167, P195, DOI 10.1093/infdis/167.1.195; WALLACE MR, 1992, ANN INTERN MED, V117, P358, DOI 10.7326/0003-4819-117-5-358	9	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					109	110		10.1136/bmj.310.6972.109	http://dx.doi.org/10.1136/bmj.310.6972.109			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC223	7833701	Green Published			2022-12-24	WOS:A1995QC22300028
J	NAISH, J; STURDY, P; TOON, P				NAISH, J; STURDY, P; TOON, P			APPROPRIATE PRESCRIBING IN ASTHMA AND ITS RELATED COST IN EAST LONDON	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; MANAGEMENT	Objectives-To determine the patterns of preventive to reactive prescribing for asthma among general practices in the City and East London Family Health Services Authority area and their relation to prescribing cost. Design-Descriptive study of asthma prescribing during April 1992 to March 1993. Prescribing data were linked with general practice and population data on one database. Setting-City and East London Family Health Services Authority area, including all general practices in contract with the authority, which covers the inner city London Boroughs of Hackney, Tower Hamlets, and Newham and the Corporation of the City of London. Subjects-All 163 general practices as at 1 June 1993. Main outcome measures-Ratios of prescribed inhaled corticosteroids plus cromoglycates (prophylactic treatment) to bronchodilators; distribution of the cost of asthma prescribing; distribution of overall generic prescribing; proportion of asthma generic prescribing; distribution of cost of overall drugs prescribed per prescribing unit. Results-Practices approved for band 3 health promotion or asthma surveillance and those with a general practitioner trainer had on average higher ratios of prophylactic to bronchodilator treatment and significantly higher asthma drug costs than other practices. Those practices with high levels of overall generic prescribing had significantly higher prophylactic to bronchodilator ratios than those with lower levels of generic prescribing. Practices with higher levels of asthma drug generic prescribing also had significantly higher prophylactic prescribing. However, the proportion of generically prescribed asthma drugs was lower than overall generic prescribing. There was no correlation between the ratio of prophylactic to bronchodilator asthma prescribing and the proportion of overall drugs expenditure, but high spending practices spent significantly more on asthma drugs. Conclusions-Pressure to reduce the cost of asthma prescribing may lead to a lowering of the ratio of prophylactic to bronchodilator treatments. However, reducing prophylactic prescribing would run contrary to the British Thoracic Society guidelines and might worsen the quality of asthma care.	UNIV LONDON QUEEN MARY & WESTFIELD COLL,LONDON E1 4NS,ENGLAND	University of London; Queen Mary University London	NAISH, J (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT GEN PRACTICE & PRIMARY CARE,LONDON E1 4NS,ENGLAND.							BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; BOGLE SM, 1994, BRIT MED J, V308, P637, DOI 10.1136/bmj.308.6929.637; GELLERT AR, 1990, BRIT J GEN PRACT, V40, P197; HARRIS CM, 1990, ANAL PRESCRIBING GEN; HAY IFC, 1987, LANCET, V2, P609; HORN CR, 1989, RESP MED, V83, P67, DOI 10.1016/S0954-6111(89)80062-9; Jones K, 1992, Qual Health Care, V1, P110, DOI 10.1136/qshc.1.2.110; MCGAVOCK H, 1988, BRIT MED J, V296, P90; NEVILLE RG, 1993, BRIT MED J, V306, P559, DOI 10.1136/bmj.306.6877.559; PANTON R, 1993, BRIT MED J, V306, P310, DOI 10.1136/bmj.306.6873.310; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; TURNERWARWICK M, 1989, J ROY COLL GEN PRACT, V39, P239; 1994, PRESCRIPTION IMPROVE; 1993, BRIT MED J, V306, P776; 1992, BRIT NATIONAL FORMUL, V23; 1994, HLTH E END ANN PUBLI; 1993, HLTH SERVICE INDICAT	17	45	46	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					97	100		10.1136/bmj.310.6972.97	http://dx.doi.org/10.1136/bmj.310.6972.97			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC223	7833736	Green Published			2022-12-24	WOS:A1995QC22300023
J	FELDMAN, B; POUEYMIROU, W; PAPAIOANNOU, VE; DECHIARA, TM; GOLDFARB, M				FELDMAN, B; POUEYMIROU, W; PAPAIOANNOU, VE; DECHIARA, TM; GOLDFARB, M			REQUIREMENT OF FGF-4 FOR POSTIMPLANTATION MOUSE DEVELOPMENT	SCIENCE			English	Article							GROWTH-FACTOR FAMILY; EMBRYONAL CARCINOMA-CELLS; EXPRESSION; PROTOONCOGENE; LIMB; GENE; GASTRULATION; ONCOGENE; INT-2; DIFFERENTIATION	Fibroblast growth factors (FGFs) are thought to influence many processes in vertebrate development because of their diverse sites of expression and wide range of biological activities in in vitro culture systems. As a means of elucidating embryonic functions of FGF-4, gene targeting was used to generate mice harboring a disrupted Fgf4 gene. Embryos homozygous for the null allele underwent uterine implantation and induced uterine decidualization but did not develop substantially thereafter. As was consistent with their behavior in vivo, Fgf4 null embryos cultured in vitro displayed severely impaired proliferation of the inner cell mass, whereas growth and differentiation of the inner cell mass were rescued when null embryos were cultured in the presence of FGF-4 protein.	REGENERON PHARMACEUT INC, TARRYTOWN, NY 10591 USA; COLUMBIA UNIV, COLL PHYS & SURG, INTEGRATED PROGRAM CELLULAR MOLEC & BIOPHYS STUDI, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT GENET & DEV, NEW YORK, NY 10032 USA	Regeneron; Columbia University; Columbia University				Feldman, Benjamin/0000-0003-4838-8641; Papaioannou, Virginia/0000-0001-7558-8601	NICHD NIH HHS [HD21988, HD27198] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027198, U01HD021988] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BROOKES S, 1989, NUCLEIC ACIDS RES, V17, P4037, DOI 10.1093/nar/17.11.4037; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DRUCKER BJ, 1993, MECH DEVELOP, V40, P155, DOI 10.1016/0925-4773(93)90073-7; FELDMAN B, UNPUB; GAO G, UNPUB; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; HALABAN R, 1988, ONCOGENE RES, V3, P177; HAUB O, 1991, DEVELOPMENT, V112, P397; HEATH JK, 1989, DEVELOPMENT, V107, P113; Heath JK, 1991, CURR OPIN CELL BIOL, V3, P935, DOI 10.1016/0955-0674(91)90110-K; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; HEBERT JM, 1991, DEVELOPMENT, V112, P407; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MIYAGAWA K, 1988, ONCOGENE, V3, P383; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; NISWANDER L, 1993, DEVELOPMENT, V119, P287; PATERNO GD, 1989, DEVELOPMENT, V106, P79; RAPPOLEE DA, 1994, DEVELOPMENT, V120, P2259; Robertson E. J., 1987, TERATOCARCINOMAS EMB; Schultz G A, 1993, Oxf Rev Reprod Biol, V15, P43; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TIESMAN J, 1989, IN VITRO CELL DEV B, V25, P1193; VELCICH A, 1989, ONCOGENE RES, V5, P31; VOGEL A, 1993, DEVELOPMENT, V119, P199; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x	36	608	626	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 13	1995	267	5195					246	249		10.1126/science.7809630	http://dx.doi.org/10.1126/science.7809630			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809630				2022-12-24	WOS:A1995QB15300038
J	DOUGLAS, KA; REDMAN, CWG				DOUGLAS, KA; REDMAN, CWG			ECLAMPSIA IN THE UNITED-KINGDOM	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREECLAMPSIA; HYPERTENSION; MANAGEMENT; PREGNANCY	Objectives--To measure the incidence eclampsia, establish how often it is preceded by signs of pre-eclampsia, document the morbidity associated with eclampsia, and determine the maternal case fatality rates. Design-A prospective, descriptive study of every case of eclampsia in the United Kingdom in 1992. Information was collected from reviews of hospital case notes and questionnaires to general practitioners. Setting-All 279 hospitals in the United Kingdom with a consultant obstetric unit. Results-Obstetricians and midwives notified 582 possible cases, and 383 were confirmed as eclampsia. The national incidence of eclampsia was 4.9/10 000 maternities (95% confidence interval 4.5 to 5.4). Most convulsions occurred despite antenatal care (70%) and within one week of the woman's last visit to a doctor or midwife (85%). Three quarters of first seizures occurred in hospital, of which 38% developed before both proteinuria and hypertension had been documented. Forty four per cent of cases occurred postpartum, more than a third (38%) antepartum, and the remainder (18%) intrapartum. Nearly one in 50 women (1.8%) died, and 35% of all women had at least one major complication. The rate of stillbirths and neonatal deaths was 22.2/1000 and 34.1/1000, respectively. Preterm eclampsia occurred more commonly antepartum and was associated with more maternal complications and fetuses that were small for gestational age, as well as with higher rates of stillbirth and neonatal mortality. Antepartum eclampsia, which was more likely to occur preterm, was associated with a higher rate of maternal complications and a higher neonatal mortality. Both factors (gestational prematurity and antepartum occurrence) contributed independently to the severity of the outcome. Conclusion-Eclampsia occurs in nearly one in 2000 maternities in the United Kingdom and is associated with high maternal morbidity and fatality in cases. It may present unheralded by warning signs. Preterm and antenatal eclampsia seem to be particularly severe.	UNIV OXFORD, JOHN RADCLIFFE HOSP, NUFFIELD DEPT OBSTET & GYNAECOL, OXFORD OX3 9DU, ENGLAND	University of Oxford			Douglas, Kirsty/E-3083-2017	Douglas, Kirsty/0000-0003-0174-782X				CAMPBELL DM, 1980, PREGNANCY HYPERTENS, P483; CORKILL TF, 1961, PATHOL MICROBIOL, V24, P428, DOI 10.1159/000161149; DOUGLAS KA, 1992, BRIT J OBSTET GYNAEC, V99, P355, DOI 10.1111/j.1471-0528.1992.tb13745.x; DULEY I, 1992, OXFORD DATABASE PERI; EDEN TW, 1922, J OBSTET GYN BR COMM, V29, P386; Hall M, 1992, Int J Technol Assess Health Care, V8 Suppl 1, P75; LLERA ML, 1992, AM J OBSTET GYNECOL, V166, P4; MOLLER B, 1986, ACTA OBSTET GYN SCAN, V65, P307; MOODLEY J, 1983, S AFR MED J, V63, P530; MOORE PJ, 1985, S AFR MED J, V67, P597; PORAPAKKHAM S, 1979, OBSTET GYNECOL, V54, P26, DOI 10.1097/00006250-197907000-00007; REDMAN CWG, 1993, LANCET, V341, P1451, DOI 10.1016/0140-6736(93)90890-S; REDMAN CWG, 1988, LANCET, V1, P809; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; SAFTLAS AF, 1990, AM J OBSTET GYNECOL, V163, P460, DOI 10.1016/0002-9378(90)91176-D; SIBAI BM, 1986, AM J OBSTET GYNECOL, V154, P581, DOI 10.1016/0002-9378(86)90605-8; WEINSTEIN L, 1982, AM J OBSTET GYNECOL, V142, P159, DOI 10.1016/S0002-9378(16)32330-4; WIGHTMAN H, 1978, BRIT MED J, V2, P235, DOI 10.1136/bmj.2.6132.235; YUDKIN PL, 1987, EARLY HUM DEV, V15, P45, DOI 10.1016/0378-3782(87)90099-5; 1991, REPORT CONFIDENTIAL; 1994, REPORT CONFIDENTIAL	21	526	548	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 26	1994	309	6966					1395	1400		10.1136/bmj.309.6966.1395	http://dx.doi.org/10.1136/bmj.309.6966.1395			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819845	Green Submitted, Green Published			2022-12-24	WOS:A1994PU76400017
J	RIDKER, PM; VAUGHAN, DE; STAMPFER, MJ; GLYNN, RJ; HENNEKENS, CH				RIDKER, PM; VAUGHAN, DE; STAMPFER, MJ; GLYNN, RJ; HENNEKENS, CH			ASSOCIATION OF MODERATE ALCOHOL-CONSUMPTION AND PLASMA-CONCENTRATION OF ENDOGENOUS TISSUE-TYPE PLASMINOGEN-ACTIVATOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; CARDIOVASCULAR MORTALITY; FIBRINOLYTIC-ACTIVITY; PLATELET-AGGREGATION; CIRCADIAN VARIATION; HDL CHOLESTEROL; ARTERY DISEASE; BLOOD-LIPIDS	Objective.-To assess whether an association exists between moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator (t-PA), a serine protease that plays a central role in the regulation of intravascular fibrinolysis. Design.-Survey of self-reported alcohol consumption and plasma fibrinolytic capacity, controlled for lipid and nonlipid cardiac risk factors. Setting.-Participants in the Physicians' Health Study. Participants.-A total of 631 apparently healthy male physicians aged 40 to 84 years with no history of myocardial infarction, stroke, or transient cerebral ischemia. Main Outcome Measure.-Plasma concentration of t-PA antigen. Results.-A direct association was found between alcohol consumption and plasma level of t-PA antigen, such that mean plasma levels of t-PA antigen for daily, weekly, monthly, and rare or never drinkers were 10.9, 9.7, 9.1, and 8.1 ng/mL, respectively (P trend=.0002). The relation between alcohol consumption and t-PA antigen level was not materially changed in analyses that adjusted for total cholesterol and high-density lipoprotein cholesterol or nonlipid cardiovascular risk factors including age, body mass index, parental history of coronary heart disease, exercise frequency, and systolic and diastolic blood pressure. Conclusions.-These data indicate a positive association between moderate alcohol intake and plasma level of endogenous t-PA antigen that is independent of high-density lipoprotein cholesterol. This finding supports the hypothesis that changes in fibrinolytic potential may be an important mechanism whereby moderate alcohol consumption decreases risk of heart disease.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOL,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CHANNING LAB,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	RIDKER, PM (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV PREVENT MED,900 COMMONWEALTH AVE E,BOSTON,MA 02215, USA.				NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-34595, HL-26490] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALKANO T, 1984, RES ADV ALCOHOL DRUG, V8, P209; ANDREOTTI F, 1991, CHRONOBIOL INT, V8, P336, DOI 10.3109/07420529109059170; ANGLETON P, 1989, CIRCULATION, V79, P101, DOI 10.1161/01.CIR.79.1.101; [Anonymous], 1989, NEW ENGL J MED, V321, P129; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; BRIDGES AB, 1993, BRIT HEART J, V69, P121; BURING JE, 1992, CIRCULATION, V85, P22, DOI 10.1161/01.CIR.85.1.22; BURR ML, 1986, BRIT J NUTR, V56, P81, DOI 10.1079/BJN19860087; CASTELLI WP, 1977, LANCET, V2, P153; COLDITZ GA, 1985, AM HEART J, V109, P886, DOI 10.1016/0002-8703(85)90654-4; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; DEYKIN D, 1982, NEW ENGL J MED, V306, P852, DOI 10.1056/NEJM198204083061406; DIEHL AK, 1988, ATHEROSCLEROSIS, V69, P145, DOI 10.1016/0021-9150(88)90008-1; ELIASSON M, 1993, FIBRINOLYSIS, V7, P316, DOI 10.1016/0268-9499(93)90147-N; ELMER O, 1984, HAEMOSTASIS, V14, P223; ERNST N, 1980, CIRCULATION, V62, P41; FRIEDMAN GD, 1993, NEW ENGL J MED, V329, P1882, DOI 10.1056/NEJM199312163292510; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; HARTUNG GH, 1983, JAMA-J AM MED ASSOC, V249, P747, DOI 10.1001/jama.249.6.747; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; HENNEKENS CH, 1978, AM J EPIDEMIOL, V107, P196, DOI 10.1093/oxfordjournals.aje.a112525; ISO H, 1993, THROMB HAEMOSTASIS, V70, P475; JACKSON R, 1992, AM J EPIDEMIOL, V136, P819, DOI 10.1093/aje/136.7.819; KLATSKY AL, 1974, ANN INTERN MED, V81, P294, DOI 10.7326/0003-4819-81-3-294; KLATSKY AL, 1986, AM J CARDIOL, V58, P710, DOI 10.1016/0002-9149(86)90342-5; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; KLATSKY AL, 1990, ALCOHOL HEALTH RES W, V14, P289; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; LAUG WE, 1983, JAMA-J AM MED ASSOC, V250, P772, DOI 10.1001/jama.250.6.772; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MIKHAILIDIS DP, 1983, BRIT MED J, V287, P1495, DOI 10.1136/bmj.287.6404.1495; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; PIKAAR NA, 1987, METABOLISM, V36, P538, DOI 10.1016/0026-0495(87)90163-6; RANBY M, 1986, CLIN CHEM, V32, P2160; RIDKER PM, 1992, CIRCULATION, V85, P1822, DOI 10.1161/01.CIR.85.5.1822; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; RIDKER PM, 1993, ARTERIOSCLER THROMB, V13, P1587, DOI 10.1161/01.ATV.13.11.1587; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; SMOKOVITIS A, 1988, HAEMOSTASIS, V18, P146; SMOKOVITIS A, 1991, ALCOHOL, V8, P17, DOI 10.1016/0741-8329(91)91152-R; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; SUMI H, 1988, ALCOHOL ALCOHOLISM, V23, P33; THORNTON J, 1983, LANCET, V2, P819; UNDERWOOD MJ, 1993, CARDIOVASC RES, V27, P882, DOI 10.1093/cvr/27.5.882; VEENSTRA J, 1990, THROMB HAEMOSTASIS, V63, P345; VEENSTRA J, 1990, FIBRINOLYSIS, V2, P64; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; [No title captured]	53	262	265	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	1994	272	12					929	933		10.1001/jama.272.12.929	http://dx.doi.org/10.1001/jama.272.12.929			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG737	7794308				2022-12-24	WOS:A1994PG73700019
J	LANGEN, R; CHANG, IJ; GERMANAS, JP; RICHARDS, JH; WINKLER, JR; GRAY, HB				LANGEN, R; CHANG, IJ; GERMANAS, JP; RICHARDS, JH; WINKLER, JR; GRAY, HB			ELECTRON-TUNNELING IN PROTEINS - COUPLING THROUGH A BETA-STRAND	SCIENCE			English	Article							BLUE COPPER PROTEINS; BIOLOGICAL MOLECULES; CRYSTAL-STRUCTURE; MATRIX-ELEMENTS; CYTOCHROME-C; AZURIN; PATHWAYS; RESOLUTION; SYSTEMS; MODEL	Electron coupling through a beta strand has been investigated by measurement of the intramolecular electron-transfer (ET) rates in ruthenium-modified derivatives of the beta barrel blue copper protein Pseudomonas aeruginosa azurin. Surface histidines, introduced on the methionine-121 beta strand by mutagenesis, were modified with a Ru(2,2'-bipyridine)(2)(imidazole)(2+) complex. The Cu+ to Ru3+ rate constants yielded a distance-decay constant of 1.1 per angstrom, a value close to the distance-decay constant of 1.0 per angstrom predicted for electron tunneling through an idealized beta strand. Activationless ET rate constants in combination with a tunneling-pathway analysis of the structures of azurin and cytochrome c confirm that there is a generally efficient network for coupling the internal (native) redox center to the surface of both proteins.	CALTECH,BECKMAN INST,PASADENA,CA 91125	California Institute of Technology			Winkler, Jay R/B-7372-2009	Germanas, Juris/0000-0002-1207-802X				ADMAN ET, 1981, ISRAEL J CHEM, V21, P8, DOI 10.1002/ijch.198100003; Bertini I., 1994, BIOINORGANIC CHEM; BROO A, 1991, J PHYS CHEM-US, V95, P4925, DOI 10.1021/j100166a002; CASIMIRO DR, 1993, J PHYS CHEM-US, V97, P13073, DOI 10.1021/j100152a007; CASIMIRO DR, 1993, J AM CHEM SOC, V115, P1485, DOI 10.1021/ja00057a037; CHANG IJ, 1991, J AM CHEM SOC, V113, P7056, DOI 10.1021/ja00018a064; CHANG TK, 1991, P NATL ACAD SCI USA, V88, P1325, DOI 10.1073/pnas.88.4.1325; CHRISTENSEN HEM, 1992, J PHYS CHEM-US, V96, P4451, DOI 10.1021/j100190a060; EVENSON JW, 1993, SCIENCE, V262, P1247, DOI 10.1126/science.8235654; FARID RS, 1993, CURR OPIN STRUC BIOL, V3, P225, DOI 10.1016/S0959-440X(05)80157-5; FARVER O, 1992, J AM CHEM SOC, V114, P5764, DOI 10.1021/ja00040a043; FRIESNER RA, 1994, STRUCTURE, V2, P339, DOI 10.1016/S0969-2126(00)00035-6; GRUSCHUS JM, 1993, J PHYS CHEM-US, V97, P5581, DOI 10.1021/j100123a021; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P3640, DOI 10.1073/pnas.71.9.3640; JORTNER J, 1976, J CHEM PHYS, V64, P4860, DOI 10.1063/1.432142; KARPISHIN TB, 1994, STRUCTURE, V2, P415, DOI 10.1016/S0969-2126(00)00043-5; LEE FS, 1993, J COMPUT CHEM, V14, P161, DOI 10.1002/jcc.540140205; LOWERY MD, 1992, INORG CHIM ACTA, V200, P233; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NAR H, 1992, FEBS LETT, V306, P119, DOI 10.1016/0014-5793(92)80981-L; NAR H, 1991, J MOL BIOL, V221, P765, DOI 10.1016/0022-2836(91)80173-R; ONUCHIC JN, 1991, J CHEM PHYS, V95, P1131, DOI 10.1063/1.461142; ONUCHIC JN, 1990, J CHEM PHYS, V92, P722, DOI 10.1063/1.458426; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P349, DOI 10.1146/annurev.biophys.21.1.349; SIDDARTH P, 1993, J PHYS CHEM-US, V97, P13078, DOI 10.1021/j100152a008; SIDDARTH P, 1993, J PHYS CHEM-US, V97, P2400, DOI 10.1021/j100112a047; SIDDARTH P, 1990, J PHYS CHEM-US, V94, P8430, DOI 10.1021/j100385a015; SIDDARTH P, 1992, J PHYS CHEM-US, V96, P3213, DOI 10.1021/j100187a008; SIDDARTH PB, 1990, J PHYS CHEM-US, V94, P3213; Sigel H., 1991, METAL IONS BIOL SYST, V27; SKOURTIS SS, 1994, J PHYS CHEM-US, V98, P3379, DOI 10.1021/j100064a019; STUCHEBRUKHOV AA, 1995, J PHYS CHEM-US, V99, P7581, DOI 10.1021/j100019a044; STUDIER FW, 1990, METHODS ENZYMOLOGY; WUTTKE DS, 1992, SCIENCE, V256, P1007, DOI 10.1126/science.256.5059.1007; [No title captured]	37	324	333	0	88	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1733	1735		10.1126/science.7792598	http://dx.doi.org/10.1126/science.7792598			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792598				2022-12-24	WOS:A1995RE66800036
J	SCOFIELD, RH; KURIEN, B; GROSS, T; WARREN, WL; HARLEY, JB				SCOFIELD, RH; KURIEN, B; GROSS, T; WARREN, WL; HARLEY, JB			HLA-B27 BINDING OF PEPTIDE FROM ITS OWN SEQUENCE AND SIMILAR PEPTIDES FROM BACTERIA - IMPLICATIONS FOR SPONDYLOARTHROPATHIES	LANCET			English	Note							ANKYLOSING-SPONDYLITIS; REACTIVE ARTHRITIS; MOLECULAR MIMICRY; B27	The spondyloarthropathies are associated by an unknown mechanism with HLA-B27 and certain bacteria. HLA-B27 shares sequence with proteins from enteric bacteria. The B*2705 sequence contains a nonapeptide, LRRYLENGK, predicted to bind in the binding cleft of B27. Some nonapeptides from enteric organisms that share sequence with this nonapeptide of B27 also bind B27. These observations suggest an unappreciated mechanism for autoimmunity that may operate in the B27-associated spondyloarthropathies involving peptides bound to and derived from histocompatibility alleles.	UNIV OKLAHOMA,HLTH SCI CTR,COLL MED,DEPT MED,OKLAHOMA CITY,OK; USA,DEPT VET AFFAIRS MED CTR,OKLAHOMA CITY,OK	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	SCOFIELD, RH (corresponding author), OKLAHOMA MED RES FDN,ARTHRITIS & IMMUNOL PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104, USA.		Scofield, Robert Hal/AEJ-8314-2022; Kurien, Biji T/C-2392-2008	Kurien, Biji T/0000-0002-7877-6859				BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; CALIN A, 1989, TXB RHEUMATOLOGY, P1023; HAMMER M, 1990, ARTHRITIS RHEUM, V33, P1795, DOI 10.1002/art.1780331206; HERMANN E, 1993, LANCET, V342, P646, DOI 10.1016/0140-6736(93)91760-J; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; PARKER KC, 1992, J BIOL CHEM, V267, P5451; SCHWIMMBECK PL, 1987, J EXP MED, V166, P173, DOI 10.1084/jem.166.1.173; SCOFIELD RH, 1993, P NATL ACAD SCI USA, V90, P9330, DOI 10.1073/pnas.90.20.9330; TERASAKI PI, 1981, ARTHRITIS RHEUM, V30, P353; WILLIAMS RC, 1992, SCAND J RHEUMATOL, V21, P105, DOI 10.3109/03009749209095079	10	90	92	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1542	1544		10.1016/S0140-6736(95)91089-1	http://dx.doi.org/10.1016/S0140-6736(95)91089-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791441				2022-12-24	WOS:A1995RD79000011
J	WALDER, R				WALDER, R			WHY THE PROBLEM CONTINUES IN BRITAIN	BRITISH MEDICAL JOURNAL			English	Article											WALDER, R (corresponding author), REGENTS COLL,INT PLANNED PARENTHOOD FEDERAT,REGENTS PK,LONDON NW1 4NS,ENGLAND.								0	9	9	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1593	1594		10.1136/bmj.310.6994.1593	http://dx.doi.org/10.1136/bmj.310.6994.1593			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787656	Green Published			2022-12-24	WOS:A1995RE35300031
J	LOCKSHON, D; ZWEIFEL, SG; FREEMANCOOK, LL; LORIMER, HE; BREWER, BJ; FANGMAN, WL				LOCKSHON, D; ZWEIFEL, SG; FREEMANCOOK, LL; LORIMER, HE; BREWER, BJ; FANGMAN, WL			A ROLE FOR RECOMBINATION JUNCTIONS IN THE SEGREGATION OF MITOCHONDRIAL-DNA IN YEAST	CELL			English	Article							CRUCIFORM CUTTING ENDONUCLEASE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; REPLICATION; GENOME; LOCALIZATION; PLASMIDS; MUTANTS; ORIGINS; GENE	In S. cerevisiae, mitochondrial DNA (mtDNA) molecules, in spite of their high copy number, segregate as if there were a small number of heritable units. The rapid segregation of mitochondrial genomes can be analyzed using mtDNA deletion variants. These small, amplified genomes segregate preferentially from mixed zygotes relative to wild-type mtDNA. This segregation advantage is abolished by mutations in a gene, MGT1, that encodes a recombination junction-resolving enzyme. We show here that resolvase deficiency causes a larger proportion of molecules to be linked together by recombination junctions, resulting in the aggregation of mtDNA into a small number of cytological structures. This change in mtDNA structure can account far the increased mitotic loss of mtDNA and the altered pattern of mtDNA segregation from zygotes. We propose that the level of unresolved recombination junctions influences the number of heritable units of mtDNA.	UNIV WASHINGTON, DEPT GENET SK50, SEATTLE, WA 98195 USA; CARLETON COLL, DEPT BIOL, NORTHFIELD, MN 55057 USA	University of Washington; University of Washington Seattle; Carleton College	LOCKSHON, D (corresponding author), UNIV WASHINGTON, DEPT PATHOL SM30, SEATTLE, WA 98195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R15AG011435] Funding Source: NIH RePORTER; NIA NIH HHS [AG11435] Funding Source: Medline; NIGMS NIH HHS [GM43847] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLIN V, 1991, METHOD ENZYMOL, V194, P774; BIRKY CW, 1994, J HERED, V85, P355, DOI 10.1093/oxfordjournals.jhered.a111480; BIRKY CW, 1982, MITOCHONDRIAL GENES, P279; BLANC H, 1984, GENE, V30, P47, DOI 10.1016/0378-1119(84)90104-5; BLANC H, 1980, P NATL ACAD SCI-BIOL, V77, P3942, DOI 10.1073/pnas.77.7.3942; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CANCER CELL, V6, P229; BROWN MD, 1994, J BIOENERG BIOMEMBR, V26, P273, DOI 10.1007/BF00763099; DEZAMAROCZY M, 1981, NATURE, V292, P75, DOI 10.1038/292075a0; Dujon B., 1981, MOL BIOL YEAST SACCH, P505; EVANS DH, 1988, J MOL BIOL, V201, P69, DOI 10.1016/0022-2836(88)90439-1; EZEKIEL UR, 1993, MOL GEN GENET, V240, P414, DOI 10.1007/BF00280395; FANGMAN WL, 1989, MOL CELL BIOL, V9, P1917, DOI 10.1128/MCB.9.5.1917; FANGMAN WL, 1978, NUCLEIC ACIDS RES, V5, P653, DOI 10.1093/nar/5.3.653; FRIEDMAN KL, 1995, IN PRESS METH ENZYMO, V262; GINGOLD EB, 1988, DIVISION SEGREGATION, P149; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; KLEFF S, 1992, EMBO J, V11, P699, DOI 10.1002/j.1460-2075.1992.tb05102.x; MARINI JC, 1980, J BIOL CHEM, V255, P4976; NORDSTROM K, 1989, ANNU REV GENET, V23, P37, DOI 10.1146/annurev.genet.23.1.37; OOI BG, 1986, CURR GENET, V10, P713, DOI 10.1007/BF00405093; PISKUR J, 1994, PLASMID, V31, P229, DOI 10.1006/plas.1994.1025; SENA EP, 1986, MOL GEN GENET, V202, P421, DOI 10.1007/BF00333272; SIMONETTI S, 1992, BIOCHIM BIOPHYS ACTA, V1180, P113, DOI 10.1016/0925-4439(92)90059-V; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; Williamson D H, 1979, Methods Enzymol, V56, P728; WILLIAMSON D H, 1977, P1; WILLIAMSON DH, 1974, MOL GEN GENET, V131, P193, DOI 10.1007/BF00267959; WILLIAMSON DH, 1976, GENETICS BIOGENESIS, P117; ZWEIFEL SG, 1991, GENETICS, V128, P214	30	148	149	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 16	1995	81	6					947	955		10.1016/0092-8674(95)90014-4	http://dx.doi.org/10.1016/0092-8674(95)90014-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781070	Bronze			2022-12-24	WOS:A1995RD76800015
J	SOSIN, DM; SNIEZEK, JE; WAXWELLER, RJ				SOSIN, DM; SNIEZEK, JE; WAXWELLER, RJ			TRENDS IN DEATH ASSOCIATED WITH TRAUMATIC BRAIN INJURY, 1979 THROUGH 1992 - SUCCESS AND FAILURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							UNITED-STATES; HEAD-INJURY	Objective.-To report updated national trends in traumatic brain injury deaths from 1979 through 1992. Design.-Retrospective analysis of Multiple Cause-of-Death Public Use Data Tapes from the National Center for Health Statistics. All deaths associated with traumatic brain injury were identified, the underlying causes of death were categorized, and the annual rates were calculated per 100 000 US residents. Patients.-Residents of the United States who died with traumatic brain injury from 1979 through 1992. Results.-An average of 52 000 US residents die each year with traumatic brain injuries. The brain injury-associated death rate declined 22% from 24.6 per 100 000 US residents in 1979 to 19.3 per 100 000 US residents in 1992. Firearm-related rates increased 13% from 1984 through 1992, undermining a 25% decline in motor vehicle-related rates for the same period. Firearms surpassed motor vehicles as the largest single cause of death associated with traumatic brain injury in 1990. Conclusions.-These data highlight the success of efforts to prevent traumatic brain injury due to motor vehicles and failure to prevent such injuries due to firearms. The increasing importance of penetrating injury has important implications for research, treatment, and prevention of traumatic brain injury in the United States.			SOSIN, DM (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,ATLANTA,GA 30341, USA.							FINGERHUT LA, 1992, JAMA-J AM MED ASSOC, V267, P3048, DOI 10.1001/jama.267.22.3048; FINGERHUT LA, 1994, FIREARM MOTOR VEHICL; GRAHAM J, 1992, POSITION PAPERS 3RD; IRWIN R, 1970, INTERCENSAL POPULATI; Kraus JF, 1993, HEAD INJURY, P1; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76, DOI DOI 10.1097/00001199-199106000-00010; Mercy J. A., 1993, HLTH AFFAIRS     WIN, P7; Nelson David E., 1993, Morbidity and Mortality Weekly Report, V42, P29; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1992, JAMA-J AM MED ASSOC, V268, P791, DOI 10.1001/jama.1992.03490060127048; 1994, MMWR-MORBID MORTAL W, V43, P37; 1993, CURRENT POPULATI P25, V1095; 1994, DOT HS808022 US DEP; 1977, MANUAL INT CLASSIFIC	14	273	279	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	1995	273	22					1778	1780		10.1001/jama.273.22.1778	http://dx.doi.org/10.1001/jama.273.22.1778			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB800	7769773				2022-12-24	WOS:A1995RB80000032
J	PHILP, I; MCKEE, KJ; MELDRUM, P; BALLINGER, BR; GILHOOLY, MLM; GORDON, DS; MUTCH, WJ; WHITTICK, JE				PHILP, I; MCKEE, KJ; MELDRUM, P; BALLINGER, BR; GILHOOLY, MLM; GORDON, DS; MUTCH, WJ; WHITTICK, JE			COMMUNITY CARE FOR DEMENTED AND NONDEMENTED ELDERLY PEOPLE - A COMPARISON STUDY OF FINANCIAL BURDEN, SERVICE USE, AND UNMET NEEDS IN FAMILY SUPPORTERS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To measure and compare perceived financial burden, use of services, and perceived unmet service needs of supporters of demented and non-demented elderly people. Design-Comparison study of age and sex matched demented and non-demented elderly people and their supporters. Setting-25 primary health care teams in Dundee. Subjects-114 community resident elderly (age over 65) people with dementia, 114 age and sex matched comparators, and the main informal supporter of each elderly person. Main outcome measures-Carers' perceptions of financial impact of looking after an old person, service use (from a list of locally available services), unmet service needs, and needs for three types of generic service (help with supervision, housework, or personal care). Results-Financial impact was low, except for extra household expense in the dementia group. There was significantly greater use of mainstream domiciliary and day care services in the dementia group. Dementia was nevertheless associated with a high level of unmet need, mainly for more mainstream support and help with supervision of the elderly person. Conclusion-Supervisory care for demented elderly people should be further developed within an expanded domiciliary service to meet supporters needs.	ROYAL VICTORIA HOSP,DEPT GERIATR MED,DUNDEE,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT MED,AGING & HLTH SECT,DUNDEE DD1 9SY,SCOTLAND; UNIV ABERDEEN,DEPT PUBL HLTH,HLTH ECON RES UNIT,ABERDEEN,SCOTLAND; ROYAL DUNDEE LIFF HOSP,DUNDEE,SCOTLAND; UNIV GLASGOW,BEHAV SCI GRP,GLASGOW G61 1BD,LANARK,SCOTLAND; BANGOR DIST GEN HOSP,LOTHIAN,SCOTLAND	University of Dundee; University of Aberdeen; University of Glasgow			Gilhooly, Mary/A-6330-2014	Gilhooly, Mary/0000-0003-0504-3619; philp, ian/0000-0002-3972-6496				[Anonymous], 1981, GROWING OLDER; ARIE T, 1986, BRIT MED BULL, V42, P91, DOI 10.1093/oxfordjournals.bmb.a072105; BOND J, 1980, BRIT J PSYCHIAT, V157, P221; BRANCH LG, 1982, AM J PUBLIC HEALTH, V72, P1373, DOI 10.2105/AJPH.72.12.1373; GILHOOLY MLM, 1984, BRIT J MED PSYCHOL, V57, P35, DOI 10.1111/j.2044-8341.1984.tb01578.x; GRAD J, 1986, BRIT J PSYCHIAT, V114, P265; HAY JW, 1987, AM J PUBLIC HEALTH, V77, P1169, DOI 10.2105/AJPH.77.9.1169; HOWELLS J, 1990, Medical Science Research, V18, P843; HUANG LF, 1985, PUBLIC HLTH REP, V130, P3; LEVIN E, 1989, FAMILIES SERVICES CO; MACLENNAN WJ, 1984, BRIT MED J, V288, P701, DOI 10.1136/bmj.288.6418.701; PATTIE AH, 1979, CLIFTOTT ASSESSMENT; PHILP I, 1992, Health Bulletin (Edinburgh), V50, P296; PHILP I, 1988, J ROY COLL GEN PRACT, V38, P153; POULSHOCK SW, 1984, J GERONTOL, V39, P230, DOI 10.1093/geronj/39.2.230; Sheldon F, 1982, Age Ageing, V11, P184, DOI 10.1093/ageing/11.3.184; TONER H, 1985, DEMENTIA RES INNOVAT, P28; WEST P, 1984, SOC SCI MED, V18, P287, DOI 10.1016/0277-9536(84)90117-5; WHITTICK JE, 1988, BRIT J CLIN PSYCHOL, V27, P167, DOI 10.1111/j.2044-8260.1988.tb00765.x; WHITTICK JE, 1993, THESIS U GLASGOW GLA; WILSON L A, 1973, Age and Ageing, V2, P92, DOI 10.1093/ageing/2.2.92; 1987, REPORT MRC ALZHEIMER; 1980, SCOTTISH HLTH AUTHOR	23	63	64	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1503	1506		10.1136/bmj.310.6993.1503	http://dx.doi.org/10.1136/bmj.310.6993.1503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RD285	7787599	Green Published			2022-12-24	WOS:A1995RD28500024
J	NASIR, J; FLORESCO, SB; OKUSKY, JR; DIEWERT, VM; RICHMAN, JM; ZEISLER, J; BOROWSKI, A; MARTH, JD; PHILLIPS, AG; HAYDEN, MR				NASIR, J; FLORESCO, SB; OKUSKY, JR; DIEWERT, VM; RICHMAN, JM; ZEISLER, J; BOROWSKI, A; MARTH, JD; PHILLIPS, AG; HAYDEN, MR			TARGETED DISRUPTION OF THE HUNTINGTONS-DISEASE GENE RESULTS IN EMBRYONIC LETHALITY AND BEHAVIORAL AND MORPHOLOGICAL-CHANGES IN HETEROZYGOTES	CELL			English	Article							BULBAR MUSCULAR-ATROPHY; EXPRESSION; TISSUES	Huntington's disease (HD) is an incurable neuropsychiatric disease associated with CAG repeat expansion within a widely expressed gene that causes selective neuronal death. To understand its normal function, we have created a targeted disruption in exon 5 of Hdh (Hdh(ex5)), the murine homolog of the HD gene. Homozygotes die before embryonic day 8.5, initiate gastrulation, but do not proceed to the formation of somites or to organogenesis, Mice heterozygous for the Hdh(ex5) mutation display increased motor activity and cognitive deficits. Neuropathological assessment of two heterozygous mice shows significant neuronal loss in the subthalamic nucleus. These studies show that the HD gene is essential for postimplantation development and that it may play an important role in normal functioning of the basal ganglia.	UNIV BRITISH COLUMBIA, DEPT MED GENET, VANCOUVER, BC V6T 1Z4, CANADA; UNIV BRITISH COLUMBIA, DEPT PSYCHOL, VANCOUVER, BC V6T 1Z4, CANADA; UNIV BRITISH COLUMBIA, DEPT PATHOL & LAB MED, VANCOUVER, BC V6T 1Z4, CANADA; UNIV BRITISH COLUMBIA, DEPT CLIN DENT SCI, VANCOUVER, BC V6T 1Z4, CANADA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER, BC V6T 1Z4, CANADA; UNIV BRITISH COLUMBIA, CTR MOLEC MED & THERAPEUT, VANCOUVER, BC V6T 1Z4, CANADA	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia			Richman, Joy M./C-3111-2018; Richman, Joy/AAD-9445-2020; Floresco, Stan B/F-8160-2012; Hayden, Michael R/D-8581-2011	Richman, Joy M./0000-0002-1409-8163; Richman, Joy/0000-0002-1409-8163; Floresco, Stan B/0000-0002-5633-243X; Hayden, Michael R/0000-0001-5159-1419; Nasir, Jamal/0000-0001-6378-5616				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; AMBROSE CM, 1994, SOMAT CELL MOLEC GEN, V20, P27, DOI 10.1007/BF02257483; ARBIZU T, 1983, J NEUROL SCI, V59, P371, DOI 10.1016/0022-510X(83)90022-9; CARPENTER MB, 1950, J COMP NEUROL, V92, P293, DOI 10.1002/cne.900920303; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPP AJ, 1995, TRENDS GENET, V11, P87, DOI 10.1016/S0168-9525(00)89008-3; DUNNETT SB, 1981, BEHAV BRAIN RES, V2, P189, DOI 10.1016/0166-4328(81)90055-3; FOLSTEIN SE, 1989, HUNTINGTONS DISEASE; GRAVELAND GA, 1985, SCIENCE, V227, P770, DOI 10.1126/science.3155875; Harper PS, 1991, HUNTINGTONS DISEASE; Hayden MR., 1981, HUNTINGTONS CHOREA, P45; Hogan B., 1986, MANIPULATING MOUSE E; JOU YS, 1995, HUM MOL GENET, V4, P465, DOI 10.1093/hmg/4.3.465; KREMER B, 1994, NEW ENGL J MED, V330, P1401, DOI 10.1056/NEJM199405193302001; LANGE H, 1976, J NEUROL SCI, V28, P401, DOI 10.1016/0022-510X(76)90114-3; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LI SH, 1993, NEURON, V11, P985, DOI 10.1016/0896-6273(93)90127-D; LIN BY, 1995, GENOMICS, V25, P707, DOI 10.1016/0888-7543(95)80014-D; LIN BY, 1994, HUM MOL GENET, V3, P85, DOI 10.1093/hmg/3.1.85; LIN BY, 1993, HUM MOL GENET, V2, P1541, DOI 10.1093/hmg/2.10.1541; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MCDONALD RJ, 1994, BEHAV NEURAL BIOL, V61, P260, DOI 10.1016/S0163-1047(05)80009-3; MHATRE AN, 1993, NAT GENET, V5, P184, DOI 10.1038/ng1093-184; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MYERS RH, 1989, AM J HUM GENET, V45, P615; NASIR J, 1994, GENOMICS, V22, P198, DOI 10.1006/geno.1994.1361; PARENT A, 1995, BRAIN RES REV, V20, P128, DOI 10.1016/0165-0173(94)00008-D; ROBBINS TW, 1992, SEMIN NEUROSCI, V4, P119; Sambrook J., 1989, MOL CLONING LAB MANU; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STRONG TV, 1993, NAT GENET, V5, P259, DOI 10.1038/ng1193-259; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; WHITTIER JR, 1947, ARCH NEURO PSYCHIATR, V58, P672, DOI 10.1001/archneurpsyc.1947.02300350022002; WILLEMS PJ, 1994, NAT GENET, V8, P213, DOI 10.1038/ng1194-213	37	626	644	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					811	823		10.1016/0092-8674(95)90542-1	http://dx.doi.org/10.1016/0092-8674(95)90542-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774020	Bronze			2022-12-24	WOS:A1995RB96100019
J	BOEHMELT, G; MADRUGA, J; DORFLER, P; BRIEGEL, K; SCHWARZ, H; ENRIETTO, PJ; ZENKE, M				BOEHMELT, G; MADRUGA, J; DORFLER, P; BRIEGEL, K; SCHWARZ, H; ENRIETTO, PJ; ZENKE, M			DENDRITIC CELL PROGENITOR IS TRANSFORMED BY A CONDITIONAL V-REL ESTROGEN-RECEPTOR FUSION PROTEIN V-REIER	CELL			English	Article							AVIAN RETICULOENDOTHELIOSIS VIRUS; ANTIVIMENTIN MONOCLONAL-ANTIBODY; MOUSE BONE-MARROW; RETROVIRAL TRANSFORMATION; LYMPHOID-CELLS; EXPRESSION; ONCOGENE; GENE; DIFFERENTIATION; INVITRO	A conditional v-Rel estrogen receptor fusion protein, v-RelER, causes estrogen-dependent but otherwise unaltered v-rel-specific transformation of chicken bone marrow cells. Here, we demonstrate that such v-relER-transformed cells exhibit B lymphoid determinants in line with earlier studies on v-rel-transformed cells. However, following inactivation of v-RelER oncoprotein activity by administration of an estrogen antagonist, cells differentiate into antigen-presenting dendritic cells as judged by several morphological and functional criteria. Additionally, under yet different culture conditions, v-relER cells differentiate into cells resembling polymorphonuclear neutrophils. Our studies therefore suggest that the conditional v-RelER, and probably also the authentic v-Rel, transform a common progenitor for neutrophils and dendritic cells.	INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA; MAX PLANCK INST ENTWICKLUNGSBIOL, D-72076 TUBINGEN, GERMANY; SUNY STONY BROOK, DEPT MICROBIOL, STONY BROOK, NY 11794 USA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Max Planck Society; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL CANCER INSTITUTE [R01CA051792] Funding Source: NIH RePORTER; NCI NIH HHS [CA 51792] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; BARKA T, 1962, J HISTOCHEM CYTOCHEM, V10, P741, DOI 10.1177/10.6.741; BARTH CF, 1988, MOL CELL BIOL, V8, P5358, DOI 10.1128/MCB.8.12.5358; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; BENATAR T, 1991, EUR J IMMUNOL, V21, P2529, DOI 10.1002/eji.1830211033; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1982, J CELL PHYSIOL, P195; BEUG H, 1989, EUR J CLIN INVEST, V19, P491, DOI 10.1111/j.1365-2362.1989.tb00265.x; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOEHMELT G, 1994, IN PRESS P AVIAN IMM; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; CHEN CLH, 1982, J IMMUNOL, V129, P2580; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; INABA K, 1993, P NATL ACAD SCI USA, V90, P3038, DOI 10.1073/pnas.90.7.3038; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JEURISSEN SHM, 1992, IMMUNOLOGY, V77, P75; KAUFMAN J, 1990, J IMMUNOL, V144, P2258; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; Lucas AM, 1961, AGR MONOGRAPH, V25; MARMOR MD, 1993, J EXP MED, V177, P647, DOI 10.1084/jem.177.3.647; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P677; MORRISON LE, 1992, ONCOGENE, V7, P1137; MUSSMAN HC, 1971, AVIAN DIS, V15, P483, DOI 10.2307/1588725; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OLAH I, 1992, ANAT RECORD, V232, P121, DOI 10.1002/ar.1092320113; OLAH I, 1992, ANAT RECORD, V233, P111, DOI 10.1002/ar.1092330115; OLAH I, 1992, ANAT RECORD, V233, P577, DOI 10.1002/ar.1092330412; OLSON LD, 1967, AM J VET RES, V28, P1501; PAGLIA P, 1993, J EXP MED, V178, P1893, DOI 10.1084/jem.178.6.1893; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAPPERSBERGER K, 1990, J INVEST DERMATOL, V94, P700, DOI 10.1111/1523-1747.ep12876275; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHAT KA, 1992, AVIAN DIS, V36, P432, DOI 10.2307/1591524; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SEVOIAN M, 1964, AVIAN DIS, V8, P336, DOI 10.2307/1587964; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; THEILEN GH, 1966, J NATL CANCER I, V37, P731; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; ZHANG J, 1991, VIROLOGY, V183, P457, DOI 10.1016/0042-6822(91)90975-H; ZOOROB R, 1990, IMMUNOGENETICS, V31, P179, DOI 10.1007/BF00211553; ZUCKERFRANKLIN D, 1988, ATLAS BLOOD CELLS FU, V1, P157	53	52	54	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	1995	80	2					341	352		10.1016/0092-8674(95)90417-4	http://dx.doi.org/10.1016/0092-8674(95)90417-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834754	Bronze			2022-12-24	WOS:A1995QD92400017
J	GSTAIGER, M; KNOEPFEL, L; GEORGIEV, O; SCHAFFNER, W; HOVENS, CM				GSTAIGER, M; KNOEPFEL, L; GEORGIEV, O; SCHAFFNER, W; HOVENS, CM			A B-CELL COACTIVATOR OF OCTAMER-BINDING TRANSCRIPTION FACTORS	NATURE			English	Article							IMMUNOGLOBULIN PROMOTERS; REMOTE ENHANCER; DNA MOTIF; ACTIVATION; EXPRESSION; DOMAINS; SEQUENCES; CLONING; OTF-2; OCT-2	THE octamer motif (ATGCAAAT) paradoxically plays a central role in mediating the activity of both B-cell specific and ubiquitous promoters. It has been widely assumed that the predominantly lymphoid-restricted octamer-binding factor Oct-2 mediates tissue-specific promoter activity, whereas the ubiquitously expressed Oct-1 mediates general promoter activity, but this view has been challenged(1-6). Here we use a modified yeast one-hybrid assay to isolate a B-cell factor, Bob1, which associates with either Oct-2 or Oct-1. In transfection experiments, this factor boosts Oct-1-mediated promoter activity and to a lesser extent, that of Oct-2. This coactivation is strictly dependent on the specific interaction with Oct-1 or Oct-2 because deletion of the octamer motif abolishes coactivation. We conclude that Bob1 could represent a new tissue-specific transcriptional coactivator which may convert a ubiquitously expressed transcription factor to a cell-type-specific activator.	UNIV ZURICH,INST MOLEK BIOL 2,CH-8057 ZURICH,SWITZERLAND	University of Zurich				Hovens, Christopher/0000-0002-0610-1289				ARNOSTI DN, 1993, NUCLEIC ACIDS RES, V21, P5570, DOI 10.1093/nar/21.24.5570; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FELDHAUS AL, 1993, EMBO J, V12, P2763, DOI 10.1002/j.1460-2075.1993.tb05937.x; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HERR W, 1992, TRANSCRIPTIONAL REGU, P1103; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; KEMLER I, 1991, NUCLEIC ACIDS RES, V19, P237, DOI 10.1093/nar/19.2.237; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MULLERIMMERGLUC.MM, 1990, EMBO J, V9, P1625; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; ROSE M, 1983, J MOL BIOL, V170, P883, DOI 10.1016/S0022-2836(83)80193-4; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; STRUBIN M, IN PRESS CELL; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0	21	286	289	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					360	362		10.1038/373360a0	http://dx.doi.org/10.1038/373360a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7779176				2022-12-24	WOS:A1995QD40400065
J	YAN, Q; MATHESON, C; LOPEZ, OT				YAN, Q; MATHESON, C; LOPEZ, OT			IN-VIVO NEUROTROPHIC EFFECTS OF GDNF ON NEONATAL AND ADULT FACIAL MOTOR-NEURONS	NATURE			English	Article							OCCURRING MOTONEURON DEATH; FACTOR PREVENTS; CELL-DEATH; IN-VIVO; AXOTOMY; DEGENERATION; SURVIVAL; RATS	MOTOR neurons require neurotrophic factor(s) for their survival during development and for maintenance of function in adulthood(1-3). In vivo studies have shown that motor neurons respond to a variety of molecules, including ciliary neurotrophic factor, members of the neurotrophin family, and the insulin growth factor IGF-1 (refs 3-13). Here we investigate the potential motor neuron neurotrophic effects of glial-cell-line-derived neurotrophic factor (GDNF), initially identified as a neurotrophic factor for substantia nigra dopaminergic neurons(14). We find that GDNF is retrogradely transported, in a receptor-mediated fashion, by spinal cord motor neurons in neonatal rats. Local application of GDNF to the transected nerve prevents the massive motor neuron cell death and atrophy that normally follows axotomy in the neonatal period. In adult rats, GDNF administered locally or systemically can markedly attenuate the lesion-induced decrease of choline acetyltransferase immunoreactivity in the facial nucleus. Our data indicate that GDNF has very profound neurotrophic effects in vivo on developing as well as on adult motor neurons, and is the most potent motor neuron trophic factor found so far.			YAN, Q (corresponding author), AMGEN INC,AMGEN CTR,DEPT NEUROBIOL,1840 DEHAVILLAND DR,THOUSAND OAKS,CA 91320, USA.							HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; LAMS BE, 1988, BRAIN RES, V475, P401, DOI 10.1016/0006-8993(88)90635-X; LI L, 1994, J NEUROBIOL, V35, P759; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P229; NEFF NT, 1993, J NEUROBIOL, V24, P1578, DOI 10.1002/neu.480241203; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; OPPENHEIM RW, 1993, J NEUROBIOL, V24, P1065, DOI 10.1002/neu.480240806; OPPENHEIM RW, 1989, TRENDS NEUROSCI, V12, P252, DOI 10.1016/0166-2236(89)90021-0; SCHAAR DG, 1993, EXP NEUROL, V124, P368, DOI 10.1006/exnr.1993.1207; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; THOENEN H, 1993, EXP NEUROL, V124, P47, DOI 10.1006/exnr.1993.1173; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YAN Q, 1993, J NEUROBIOL, V24, P1555, DOI 10.1002/neu.480241202; YAN Q, 1994, J NEUROSCI, V14, P5281; YAN Q, 1988, J NEUROSCI, V8, P3481	21	548	616	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					341	344		10.1038/373341a0	http://dx.doi.org/10.1038/373341a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830768				2022-12-24	WOS:A1995QD40400059
J	OVERDUIN, M; HARVEY, TS; BAGBY, S; TONG, KI; YAU, P; TAKEICHI, M; IKURA, M				OVERDUIN, M; HARVEY, TS; BAGBY, S; TONG, KI; YAU, P; TAKEICHI, M; IKURA, M			SOLUTION STRUCTURE OF THE EPITHELIAL CADHERIN DOMAIN RESPONSIBLE FOR SELECTIVE CELL-ADHESION	SCIENCE			English	Article							BINDING-SITE; MOLECULE UVOMORULIN; CYTOPLASMIC DOMAIN; HUMAN CD2; PROTEINS; FACE	Cadherins are calcium-dependent cell adhesion molecules containing extracellular repeats of approximately 110 amino acids. The three-dimensional structure of the amino-terminal repeat of mouse epithelial cadherin was determined by multidimensional heteronuclear magnetic resonance spectroscopy. The calcium ion was bound by a short alpha helix and by loops at one end of the seven-stranded beta-barrel structure. An exposed concave face is in a position to provide homophilic binding specificity and was also sensitive to calcium ligation. Unexpected structural similarities with the immunoglobulin fold suggest an evolutionary relation between calcium-dependent and calcium-independent cell adhesion molecules.	UNIV TORONTO,ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Kyoto University			Harvey, Timothy S/F-9863-2013; Overduin, Michael/AAG-3632-2020	Harvey, Timothy S/0000-0001-6270-1943; Overduin, Michael/0000-0002-3114-6585; Bagby, Stefan/0000-0003-2302-9511; Ikura, Mitsuhiko/0000-0002-9524-1303				AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; BAGBY S, 1994, STRUCTURE, V2, P107, DOI 10.1016/S0969-2126(00)00013-7; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Brunger A.T., 1993, X PLOR VERSION 3 1 S; EDELMAN M, 1991, ANNU REV BIOCHEM, V60, P155; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; JONES EY, 1993, CURR OPIN STRUC BIOL, V3, P846, DOI 10.1016/0959-440X(93)90147-D; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; MOINGEON P, 1989, IMMUNOL REV, V111, P111, DOI 10.1111/j.1600-065X.1989.tb00544.x; MUHANDIRAM DR, 1993, J MAGN RESON SER B, V102, P317, DOI 10.1006/jmrb.1993.1102; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; OVERDUIN M, UNPUB; OZAWA M, 1990, MECH DEVELOP, V33, P49, DOI 10.1016/0925-4773(90)90134-8; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; PASCAL S, 1994, J MAGN RESON, V101, P197; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; POLJAK RJ, 1974, P NATL ACAD SCI USA, V71, P3440, DOI 10.1073/pnas.71.9.3440; SOMOZA C, 1993, J EXP MED, V178, P549, DOI 10.1084/jem.178.2.549; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TONG KI, 1994, FEBS LETT, V352, P318; WISHART DS, 1993, J BIOMOL NMR, V4, P171; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	30	364	381	1	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 20	1995	267	5196					386	389		10.1126/science.7824937	http://dx.doi.org/10.1126/science.7824937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7824937				2022-12-24	WOS:A1995QC27300038
J	SERRANO, M; GOMEZLAHOZ, E; DEPINHO, RA; BEACH, D; BARSAGI, D				SERRANO, M; GOMEZLAHOZ, E; DEPINHO, RA; BEACH, D; BARSAGI, D			INHIBITION OF RAS-INDUCED PROLIFERATION AND CELLULAR-TRANSFORMATION BY P16(INK4)	SCIENCE			English	Article							RETINOBLASTOMA GENE-PRODUCT; CYCLIN-DEPENDENT KINASES; C-MYC; ADENOVIRUS E1A; PROTEIN; BINDING; G(1); P21; PHOSPHORYLATION; FIBROBLASTS	The cyclin-dependent kinase 4 (CDK4) regulates progression through the G(1) phase of the cell cycle. The activity of CDK4 is controlled by the opposing effects of the D-type cyclin, an activating subunit, and p16(INK4), inhibitory subunit. Ectopic expression of p16(INK4) blocked entry into S phase of the cell cycle induced by oncogenic Ha-Ras, and this block was relieved by coexpression of a catalytically inactive CDK4 mutant. Expression of p16(INK4) suppressed cellular transformation of primary rat embryo fibroblasts by oncogenic Ha-Ras and Myc, but not by Ha-Ras and E1a. Together, these observations provide direct evidence that p16(INK4) inhibit cell growth.	COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724; ALBERT EINSTEIN COLL MED,DEPT IMMUNOL & MICROBIOL,NEW YORK,NY 10461; ALBERT EINSTEIN COLL MED,DEPT MED,NEW YORK,NY 10461	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Yeshiva University; Yeshiva University			Serrano, Manuel/H-2634-2015	Serrano, Manuel/0000-0001-7177-9312; DePinho, Ronald/0000-0002-5625-577X; Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA55360] Funding Source: Medline; NEI NIH HHS [EY09300-01] Funding Source: Medline; NICHD NIH HHS [HD28317-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R37CA055360, R01CA055360] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009300] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BATES S, 1994, ONCOGENE, V9, P1633; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZLAHOZ E, UNPUB; GOMEZLAHOZ E, 1994, P NATL ACAD SCI USA, V91, P5503; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HARLOW E, 1992, NATURE, V359, P270, DOI 10.1038/359270a0; HARPER JW, 1993, CELL, V75, P805; Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955-0674(93)90102-V; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LUKAS J, 1994, ONCOGENE, V9, P707; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORI T, 1994, CANCER RES, V54, P3396; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2456, DOI 10.1128/MCB.13.4.2456; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TAM SW, 1994, CANCER RES, V54, P5816; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	44	418	440	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 13	1995	267	5195					249	252		10.1126/science.7809631	http://dx.doi.org/10.1126/science.7809631			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809631				2022-12-24	WOS:A1995QB15300039
J	FALL, CHD; VIJAYAKUMAR, M; BARKER, DJP; OSMOND, C; DUGGLEBY, S				FALL, CHD; VIJAYAKUMAR, M; BARKER, DJP; OSMOND, C; DUGGLEBY, S			WEIGHT IN INFANCY AND PREVALENCE OF CORONARY HEART-DISEASE IN ADULT LIFE	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; GROWTH; DEATH; FETAL	Objective-To determine whether low birth weight and low weight at 1 year are followed by an increased prevalence of coronary heart disease in adult life. Design-A follow up study of men horn during 1920-30 whose birth weights and weights at 1 year were recorded. Setting-Hertfordshire, England. Subjects-290 men born and still living in East Hertfordshire, Main outcome measure-The prevalence of coronary heart disease, defined by the Rose/WHO chest pain questionnaire, standard electrocardiographic criteria, or history of coronary artery angioplasty or graft surgery. Results-42 (14%) men had coronary heart disease, Their mean birth weight, 7.9 lb (3600 g), was the same as that of the other men, Their mean weight at 1 year, 21.8 lb (9.9 kg), was 1 lb (454 g) lower (95% confidence interval 0.1 to 1.8, P=0.02). Percentages of men with coronary heart disease fell from 27% in those who weighed 18 lb (8.2 kg) or less at 1 year to 9% in those who weighed more than 26 lb (11.8 kg) (P value for trend=0.03). This trend occurred in both smokers and non-smokers and within each social class. Conclusion-These findings add to the evidence that coronary heart disease is ''programmed'' during early growth.			FALL, CHD (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.			Osmond, Clive/0000-0002-9054-4655				[Anonymous], 1980, CLASSIFICATION OCCUP; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; ELFORD J, 1991, INT J EPIDEMIOL, V20, P833, DOI 10.1093/ije/20.4.833; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LUCAS A, 1991, CIBA F S, V156; LYNCH JW, 1994, LANCET, V343, P524, DOI 10.1016/S0140-6736(94)91468-0; MARMOT MG, 1986, LANCET, V2, P274; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; Prineas R., 1982, MINNESOTA CODE MANUA; REID DD, 1974, LANCET, V1, P469; ROSE GA, 1968, WHO MONOGRAPH SERIES, V56; SHAPER AG, 1984, BRIT HEART J, V51, P595, DOI 10.1136/hrt.51.6.595; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157	19	166	170	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					17	19		10.1136/bmj.310.6971.17	http://dx.doi.org/10.1136/bmj.310.6971.17			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827546	Green Published			2022-12-24	WOS:A1995QB06000020
J	MANGINO, JE; MOSER, SA; WAITES, KB				MANGINO, JE; MOSER, SA; WAITES, KB			WHEN TO USE FLUCONAZOLE	LANCET			English	Editorial Material							CRYPTOCOCCAL MENINGITIS; CONTROLLED TRIAL; AMPHOTERICIN-B; PREVENT		UNIV ALABAMA,DEPT PATHOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham	MANGINO, JE (corresponding author), UNIV ALABAMA,DIV INFECT DIS,BIRMINGHAM,AL, USA.		Moser, Stephen A/A-1168-2008					BODEY GP, 1992, CLIN INFECT DIS, V14, pS161, DOI 10.1093/clinids/14.Supplement_1.S161; COMO JA, 1994, NEW ENGL J MED, V330, P263, DOI 10.1056/NEJM199401273300407; DENNING DW, 1994, AM J MED, V97, P135, DOI 10.1016/0002-9343(94)90023-X; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; GRASELA TH, 1994, ANN PHARMACOTHER, V28, P261, DOI 10.1177/106002809402800220; GRASELA TH, 1994, ANN PHARMACOTHER, V28, P252, DOI 10.1177/106002809402800219; HEALD A, 1994, 34TH INT C ANT AG CH; LAINE L, 1992, ANN INTERN MED, V177, P655; PERFECT JR, 1993, AM J MED, V94, P233, DOI 10.1016/0002-9343(93)90053-R; POWDERLY WG, 1992, NEW ENGL J MED, V326, P793, DOI 10.1056/NEJM199203193261203; REX JH, 1994, NEW ENGL J MED, V331, P1325, DOI 10.1056/NEJM199411173312001; SAAG MS, 1992, NEW ENGL J MED, V326, P83, DOI 10.1056/NEJM199201093260202; WINSTON DJ, 1993, ANN INTERN MED, V181, P495	13	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					6	7		10.1016/S0140-6736(95)91147-2	http://dx.doi.org/10.1016/S0140-6736(95)91147-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799720				2022-12-24	WOS:A1995QA29000006
J	VANDAMME, P; CRAMM, M; VANDERAUWERA, JC; VRANCKX, R; MEHEUS, A				VANDAMME, P; CRAMM, M; VANDERAUWERA, JC; VRANCKX, R; MEHEUS, A			HORIZONTAL TRANSMISSION OF HEPATITIS-B VIRUS	LANCET			English	Note							TRANSMISSION; CHILDREN; INFECTION; FAMILIES	In 1991-92, a cross-sectional survey in Flanders (Belgium) for hepatitis B virus (HBV) markers among 277 relatives of institutionalised mentally handicapped persons to evaluate the prevalence of hepatitis B and the risk of infection showed that relatives of an HBV positive resident were 7.6 times more likely to be infected than relatives of an HBV seronegative mentally handicapped person. HBV infection among the family members could be attributed in 83% to exposure to an HBV positive resident. This study demonstrated the importance of horizontal transmission among relatives of institutionalised mentally handicapped people, even if family contact is reduced to weekend and holiday activities. We recommend that HBV vaccination policy should be expanded to include relatives of institutionalised mentally retarded people.	INST HYG & EPIDEMIOL,B-1050 BRUSSELS,BELGIUM		VANDAMME, P (corresponding author), UNIV ANTWERP,DEPT EPIDEMIOL & COMMUNITY MED,B-2610 ANTWERP,BELGIUM.		van damme, pierre/I-4846-2013					BERNIER RH, 1982, AM J EPIDEMIOL, V116, P199, DOI 10.1093/oxfordjournals.aje.a113406; CANCIOBELLO TP, 1982, J INFECT DIS, V146, P652, DOI 10.1093/infdis/146.5.652; DAVIS LG, 1989, LANCET, V1, P889; FRANKS AL, 1989, NEW ENGL J MED, V321, P1301, DOI 10.1056/NEJM198911093211905; FRIEDE A, 1988, AM J PUBLIC HEALTH, V78, P26, DOI 10.2105/AJPH.78.1.26; HAYASHI J, 1987, AM J EPIDEMIOL, V125, P492, DOI 10.1093/oxfordjournals.aje.a114555; JENISON SA, 1987, J INFECT DIS, V156, P299, DOI 10.1093/infdis/156.2.299; MCPHILLIPS JC, 1984, J PEDIATR GASTR NUTR, V3, P69, DOI 10.1097/00005176-198401000-00015; VANDAMME P, 1989, LANCET, V1, P840; VANDITZHUIJSEN TJM, 1988, AM J EPIDEMIOL, V128, P629, DOI 10.1093/oxfordjournals.aje.a115010	10	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					27	29		10.1016/S0140-6736(95)91155-3	http://dx.doi.org/10.1016/S0140-6736(95)91155-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799703				2022-12-24	WOS:A1995QA29000013
J	KRUMHOLZ, HM; SEEMAN, TE; MERRILL, SS; DELEON, CFM; VACCARINO, V; SILVERMAN, DI; TSUKAHARA, R; OSTFELD, AM; BERKMAN, LF				KRUMHOLZ, HM; SEEMAN, TE; MERRILL, SS; DELEON, CFM; VACCARINO, V; SILVERMAN, DI; TSUKAHARA, R; OSTFELD, AM; BERKMAN, LF			LACK OF ASSOCIATION BETWEEN CHOLESTEROL AND CORONARY HEART-DISEASE MORTALITY AND MORBIDITY AND ALL-CAUSE MORTALITY IN PERSONS OLDER THAN 70 YEARS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH BLOOD CHOLESTEROL; UNITED-STATES ADULTS; SERUM-CHOLESTEROL; CARDIOVASCULAR-HEALTH; PLASMA-LIPIDS; RISK-FACTORS; MEN; HYPERCHOLESTEROLEMIA; LIPOPROTEINS; DESIGN	Objectives.-To determine whether elevated serum cholesterol level is associated with all-cause mortality, mortality from coronary heart disease, or hospitalization for acute myocardial infarction and unstable angina in persons older than 70 years. Also, to evaluate the association between low levels of high-density lipoprotein cholesterol (HDL-C) and elevated ratio of serum cholesterol to HDL-C with these outcomes. Design.-Prospective, community-based cohort study with yearly interviews. Participants.-A total of 997 subjects who were interviewed in 1988 as part of the New Haven, Conn, cohort of the Established Population for the Epidemiologic Study of the Elderly (EPESE) and consented to have blood drawn. Main Outcome Measures.-The risk factor-adjusted odds ratios of the 4-year incidence of all-cause mortality, mortality from coronary heart disease, and hospitalization for myocardial infarction or unstable angina were calculated for the following: subjects with total serum cholesterol levels greater than or equal to 6.20 mmol/L (greater than or equal to 240 mg/dL) compared with subjects with cholesterol levels less than 5.20 mmol/L (<200 mg/dL); subjects in the lowest tertile of HDL-C level compared with those in the highest tertile; and subjects in the highest tertile of the ratio of total serum cholesterol to HDL-C level compared with those in the lowest tertile. Results.-Elevated total serum cholesterol level, low HDL-C, and high total serum cholesterol to HDL-C ratio were not associated with a significantly higher rate of all-cause mortality, coronary heart disease mortality, or hospitalization for myocardial infarction or unstable angina after adjustment for cardiovascular risk factors. The risk factor-adjusted odds ratio for all-cause mortality was 0.99 (95% confidence interval [Cl], 0.56 to 2.69) for the group who had cholesterol levels greater than or equal to 6.20 mmol/L (greater than or equal to 240 mg/dl) compared with the group that had levels less than 5.20 mmol/L (<200 mg/dL); 1.00 (95% Cl, 0.59 to 1.70) for the group in the lowest tertile of HDL-C compared with those in the highest tertile; and 1.03 (95% Cl, 0.62 to 1.71) for subjects in the highest tertile of the ratio of total serum cholesterol to HDL-C compared with those in the lowest tertile. Conclusions.-Our findings do not support the hypothesis that hypercholesterolemia or low HDL-C are important risk factors for all-cause mortality, coronary heart disease mortality, or hospitalization for myocardial infarction or unstable angina in this cohort of persons older than 70 years.	YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, CHRON DIS EPIDEMIOL SECT, NEW HAVEN, CT 06520 USA; UNIV CONNECTICUT, SCH MED, DIV CARDIOL, FARMINGTON, CT USA	Yale University; University of Connecticut	KRUMHOLZ, HM (corresponding author), YALE UNIV, SCH MED,DEPT INTERNAL MED,CARDIOVASC MED SECT, 333 CEDAR ST, POB 208017, NEW HAVEN, CT 06520 USA.		, Harlan/AAI-2875-2020		NATIONAL INSTITUTE ON AGING [T32AG000153, R01AG011042] Funding Source: NIH RePORTER; NIA NIH HHS [1T-32-AG-0-0153, R01-AG-1-1042] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARONOW WS, 1989, J AM GERIATR SOC, V37, P501, DOI 10.1111/j.1532-5415.1989.tb05679.x; BARRETTCONNOR E, 1984, J CHRON DIS, V37, P903, DOI 10.1016/0021-9681(84)90066-3; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; CASTELLI WP, 1984, AM J MED, V76, P4, DOI 10.1016/0002-9343(84)90952-5; CASTELLI WP, 1989, AM J CARDIOL, V63, pH12; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; CURB JD, 1986, J AM GERIATR SOC, V34, P773, DOI 10.1111/j.1532-5415.1986.tb03980.x; DENKE MA, 1990, ANN INTERN MED, V112, P780, DOI 10.7326/0003-4819-112-10-780; ETTINGER WH, 1992, CIRCULATION, V86, P858, DOI 10.1161/01.CIR.86.3.858; Freeman Daniel H. Jr., 1992, P46; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HULLEY SB, 1992, CIRCULATION, V86, P1026, DOI 10.1161/01.CIR.86.3.1026; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KAFONEK SD, 1990, ANN INTERN MED, V112, P723, DOI 10.7326/0003-4819-112-10-723; KRONMAL RA, 1993, ARCH INTERN MED, V153, P1065, DOI 10.1001/archinte.153.9.1065; LACROIX AZ, 1990, CIRCULATION, V81, P437, DOI 10.1161/01.CIR.81.2.437; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; MANOLIO TA, 1992, ANN INTERN MED, V116, P641, DOI 10.7326/0003-4819-116-8-641; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RIFKIND BM, 1979, CIRCULATION, V60, P427; RUBIN SM, 1990, ANN INTERN MED, V113, P916, DOI 10.7326/0003-4819-113-12-916; SEEMAN T, 1993, AM J EPIDEMIOL, V138, P1037, DOI 10.1093/oxfordjournals.aje.a116822; SEMPOS CT, 1993, JAMA-J AM MED ASSOC, V269, P3009, DOI 10.1001/jama.269.23.3009; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; WONG ND, 1991, ANN INTERN MED, V115, P687, DOI 10.7326/0003-4819-115-9-687; ZIMETBAUM P, 1992, ARTERIOSCLER THROMB, V12, P416, DOI 10.1161/01.ATV.12.4.416; 1971, 5TH WORK GROUP ISCH; 1991, AGING AM, P273; 1988, INT CLASSIFICATON DI; 1977, JAMA-J AM MED ASSOC, V237, P2385	31	365	370	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	1994	272	17					1335	1340		10.1001/jama.272.17.1335	http://dx.doi.org/10.1001/jama.272.17.1335			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP020	7772105				2022-12-24	WOS:A1994PP02000027
J	WHEELER, DB; RANDALL, A; TSIEN, RW				WHEELER, DB; RANDALL, A; TSIEN, RW			ROLES OF N-TYPE AND Q-TYPE CA2+ CHANNELS IN SUPPORTING HIPPOCAMPAL SYNAPTIC TRANSMISSION	SCIENCE			English	Article							LONG-TERM POTENTIATION; OMEGA-CONOTOXIN GVIA; CALCIUM CHANNELS; TRANSMITTER RELEASE; PERIPHERAL NEURONS; SENSORY NEURONS; P-TYPE; CURRENTS; INVITRO; DEPRESSION	Several types of calcium channels found in the central nervous system are possible participants in triggering neurotransmitter release. Synaptic transmission between hippocampal CA3 and CA1 neurons was mediated by N-type calcium channels, together with calcium channels whose pharmacology differs from that of L- and P-type channels but resembles that of the Q-type channel encoded by the alpha1A subunit gene. Blockade of either population of channels strongly increased enhancement of synaptic transmission with repetitive stimuli. Even after complete blockade of N-type channels, transmission was strongly modulated by stimulation of neurotransmitter receptors or protein kinase C. These findings suggest a role for alpha1A subunits in synaptic transmission and support the idea that neurotransmitter release may depend on multiple types of calcium channels under physiological conditions.	STANFORD UNIV, MED CTR,SCH MED,BECKMAN CTR MOLEC & GENET MED, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA	Stanford University				Randall, Andrew/0000-0001-8852-3671	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048108] Funding Source: NIH RePORTER; NIMH NIH HHS [MH48108-02] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alger B.E., 1984, BRAIN SLICES, P381; ANWYL R, 1991, BRAIN RES REV, V16, P265, DOI 10.1016/0165-0173(91)90010-6; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CREAGER R, 1980, J PHYSL, V299, P400; DEISZ RA, 1985, NEUROSCI LETT, V56, P205, DOI 10.1016/0304-3940(85)90130-2; DINGLEDINE R, 1981, BRAIN RES, V207, P218, DOI 10.1016/0006-8993(81)90697-1; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; DUTAR P, 1989, EUR J PHARMACOL, V174, P261, DOI 10.1016/0014-2999(89)90318-X; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; GAHWILER BH, 1987, NEUROSCI LETT, V76, P301, DOI 10.1016/0304-3940(87)90419-8; GROSS RA, 1989, J PHYSIOL-LONDON, V411, P585, DOI 10.1113/jphysiol.1989.sp017592; HORNE AL, 1991, BRIT J PHARMACOL, V103, P1733, DOI 10.1111/j.1476-5381.1991.tb09855.x; KAMIYA H, 1988, NEUROSCI LETT, V91, P84, DOI 10.1016/0304-3940(88)90253-4; KASAI H, 1987, Neuroscience Research, V4, P228, DOI 10.1016/0168-0102(87)90014-9; LEMOS JR, 1989, NEURON, V2, P1419, DOI 10.1016/0896-6273(89)90187-6; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MCKECHNIE K, 1989, BRIT J PHARMACOL, V98, pP673; MILLER RJ, 1993, CURR BIOL, V3, P481, DOI 10.1016/0960-9822(93)90364-T; MILLER RJ, 1990, INTRACELLULAR CALCIU, P97; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1993, NEUROPHARMACOLOGY, V32, P1161, DOI 10.1016/0028-3908(93)90010-Z; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; MULKEEN D, 1988, BRAIN RES, V447, P234, DOI 10.1016/0006-8993(88)91124-9; MULLER D, 1989, BRAIN RES, V479, P290, DOI 10.1016/0006-8993(89)91631-4; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; PARFITT KD, 1993, J PHYSIOL-LONDON, V471, P245, DOI 10.1113/jphysiol.1993.sp019900; Randall A. D., 1993, Society for Neuroscience Abstracts, V19, P1478; RANDALL AD, 1993, FUNCT NEUROL S, V8, P44; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SCHOLZ KP, 1992, NEURON, V8, P1139, DOI 10.1016/0896-6273(92)90134-Y; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; Swartz K. J., 1993, Society for Neuroscience Abstracts, V19, P1478; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; SWARTZ KJ, 1993, NEURON, V11, P305, DOI 10.1016/0896-6273(93)90186-U; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; TURNER TJ, 1993, P NATL ACAD SCI USA, V90, P9518, DOI 10.1073/pnas.90.20.9518; TURNER TJ, 1992, SCIENCE, V258, P310, DOI 10.1126/science.1357749; WHEELER D, UNPUB; Wu L. G., 1993, Society for Neuroscience Abstracts, V19, P1518; WU LG, 1994, J NEUROSCI, V14, P645; YANG J, 1993, NEURON, V10, P127, DOI 10.1016/0896-6273(93)90305-B; ZHANG J, UNPUB; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	57	863	873	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 1	1994	264	5155					107	111		10.1126/science.7832825	http://dx.doi.org/10.1126/science.7832825			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	7832825				2022-12-24	WOS:A1994ND53600042
J	PHILLIPS, S; DONALDSON, L; GEISLER, K; PERA, A; KOCHAR, R				PHILLIPS, S; DONALDSON, L; GEISLER, K; PERA, A; KOCHAR, R			STOOL COMPOSITION IN FACTITIAL DIARRHEA - A 6-YEAR EXPERIENCE WITH STOOL ANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Article						FACTITIOUS DISORDERS; DIARRHEA; FECES; BODY WATER; CATHARTICS	LAXATIVE ABUSE; OSMOTIC GAP; MALABSORPTION; PREVALENCE	Objective: To evaluate the utility of stool water analysis in the management of patients with chronic diarrhea. Design: Retrospective analysis of 6 years of experience. Setting: A specialized laboratory in a major referral center, Patients: 325 patients with diarrhea who were referred for stool chemistry analysis. Fecal analysis was requested by many internists and gastroenterologists. Patient records were reviewed to establish the final and most likely cause of diarrhea. Results: One third of patients provided samples that were inappropriate for analysis, but data from 202 persons were available, The usefulness of the general separation of cases of chronic diarrhea into those in which patients had predominantly osmotic pathophysiologies and those in which patients had predominantly secretory pathophysiologies was confirmed, but overlap and intra-individual variability limited the usefulness of this approach in individual patients. Thirty-five patients (17%) had a diagnosis of factitial diarrhea (30 because of laxative use and 5 because of fluid added to stools). Conclusions: Among selected subpopulations, the chemical analysis of fresh stools has a role in the evaluation of obscure examples of chronic diarrhea. It is especially useful in identifying factitial diarrhea.			PHILLIPS, S (corresponding author), MAYO CLIN & MAYO FDN, GASTROENTEROL RES UNIT, 200 1ST ST SW, ROCHESTER, MN 55905 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032121] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32121] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BINDER HJ, 1992, GASTROENTEROLOGY, V103, P702, DOI 10.1016/0016-5085(92)90870-5; BYTZER P, 1990, SCAND J GASTROENTERO, V25, P572, DOI 10.3109/00365529009095532; BYTZER P, 1989, GUT, V30, P1379, DOI 10.1136/gut.30.10.1379; DALY JA, 1972, CLIN CHEM, V18, P263; DEWOLFF FA, 1983, HUM TOXICOL, V2, P385, DOI 10.1177/096032718300200235; EARNEST DL, 1993, GASTROINTESTINAL DIS, P1563; EHERER AJ, 1992, GASTROENTEROLOGY, V103, P545, DOI 10.1016/0016-5085(92)90845-P; FINE KD, 1992, GASTROENTEROLOGY, V102, P1936, DOI 10.1016/0016-5085(92)90316-Q; FINE KD, 1991, NEW ENGL J MED, V324, P1012, DOI 10.1056/NEJM199104113241502; FINE KD, 1993, GASTROINTESTINAL DIS, P1043; GALATOLA G, 1992, EUR J GASTROEN HEPAT, V4, P533; Grindler E., 1971, CLIN CHEM, V17, P662; HAMMER HF, 1990, J CLIN INVEST, V86, P1936, DOI 10.1172/JCI114927; HAMMER HF, 1989, J CLIN INVEST, V84, P1056, DOI 10.1172/JCI114267; HARVEY RF, 1983, LANCET, V1, P632; KACERE RD, 1993, MAYO CLIN PROC, V68, P355, DOI 10.1016/S0025-6196(12)60130-X; KASPI T, 1978, LANCET, V1, P1162; LADEFOGED K, 1987, SCAND J GASTROENTERO, V22, P813, DOI 10.3109/00365528708991920; MORRISON G, 1987, CLIN DISORDERS FLUID; PHILLIPS SF, 1972, GASTROENTEROLOGY, V63, P495; TALLEY NJ, 1989, ANN INTERN MED, V111, P671, DOI 10.7326/0003-4819-111-8-671; VALENTZAS CG, 1971, JAMA-J AM MED ASSOC, V217, P966	22	29	30	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1995	123	2					97	100		10.7326/0003-4819-123-2-199507150-00003	http://dx.doi.org/10.7326/0003-4819-123-2-199507150-00003			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM435	7778841				2022-12-24	WOS:A1995RM43500003
J	BAYERDORFFER, E; NEUBAUER, A; RUDOLPH, B; THIEDE, C; LEHN, N; EIDT, S; STOLTE, M				BAYERDORFFER, E; NEUBAUER, A; RUDOLPH, B; THIEDE, C; LEHN, N; EIDT, S; STOLTE, M			REGRESSION OF PRIMARY GASTRIC LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID-TISSUE TYPE AFTER CURE OF HELICOBACTER-PYLORI INFECTION	LANCET			English	Article							POLYMERASE CHAIN-REACTION; CAMPYLOBACTER-PYLORI; STAGING CLASSIFICATION; IMMUNE-RESPONSE; MONOCLONALITY; ERADICATION; DNA	Lymphoma of gastric-mucosa-associated lymphatic tissue (MALT) type has been linked to infection with Helicobacter pylori. We investigated the effect on MALT lymphoma of eradicating H pylori infection. 33 patients with primary gastric low-grade MALT lymphoma associated with H pylori gastritis were treated with omeprazole (120 mg daily) and amoxycillin (2 . 25 g daily) for 14 days to eradicate H pylori. In addition to histology, PCR was used to examine proliferation of monoclonal B cells before treatment and during follow-up. All patients had at least two post-treatment examinations, and all became negative for H pylori, 2 after a second treatment course. On histology, 23 (70%) patients showed complete regression and 4 (12%) partial regression of lymphoma. 6 (18%) patients had no change after cure of H pylori infection. 1 was treated with chemotherapy. Of 5 treated surgically, 4 were found to have high-grade B-cell lymphoma on histology of the resected stomach and 1 a high-grade T-cell lymphoma. PCR showed complete disappearance of monoclonal B cells after cure of H pylori infection in 13 of 16 patients investigated. During median follow-up of 1 year no relapse of MALT lymphoma occurred. Low-grade primary gastric MALT lymphoma can completely regress after eradication of H pylori infection. However, longer follow-up is needed to clarify whether the remission is lasting.	FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,DEPT INTERNAL MED & HEMATOL,BERLIN,GERMANY; TECH UNIV MUNICH,INST MICROBIOL,MUNICH,GERMANY; UNIV COLOGNE,INST PATHOL,COLOGNE,GERMANY; INST PATHOL,BAYREUTH,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Technical University of Munich; University of Cologne	BAYERDORFFER, E (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT MED 2,D-81377 MUNICH,GERMANY.		Thiede, Christian/A-1417-2008; Thiede, Christian/AAS-7595-2020	Thiede, Christian/0000-0003-1241-2048				BAYERDORFFER E, 1992, GASTROENTEROLOGY, V102, P1575, DOI 10.1016/0016-5085(92)91716-H; BAYERDORFFER E, 1995, GASTROENTEROLOGY, V108, P1412, DOI 10.1016/0016-5085(95)90689-4; CAMMAROTA G, 1995, LANCET, V345, P192, DOI 10.1016/S0140-6736(95)90195-7; CARBONE PP, 1971, CANCER RES, V31, P1860; COGLIATTI SB, 1991, GASTROENTEROLOGY, V101, P1159, DOI 10.1016/0016-5085(91)90063-Q; DISS TC, 1993, J PATHOL, V169, P291, DOI 10.1002/path.1711690303; EIDT S, 1994, PATHOL RES PRACT, V190, P1077, DOI 10.1016/S0344-0338(11)80904-0; HARRIS AW, 1994, LANCET, V343, P1503; HEILMANN KL, 1991, GUT, V32, P137, DOI 10.1136/gut.32.2.137; HORSTMANN M, LANCET, V3438, P94; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; ISAACSON PG, 1994, NEW ENGL J MED, V330, P1310, DOI 10.1056/NEJM199405053301812; MARSHALL BJ, 1988, LANCET, V2, P1437; MUSSHOFF K, 1977, STRAHLENTHER ONKOL, V153, P218; NEUBAUER A, 1990, NUCLEIC ACIDS RES, V18, P993, DOI 10.1093/nar/18.4.993; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; RADASZKIEWICZ T, 1992, GASTROENTEROLOGY, V102, P1628, DOI 10.1016/0016-5085(92)91723-H; SAMBROOK J, 1989, MOL CLONING LANBORAT; STOLTE M, 1992, LANCET, V339, P745, DOI 10.1016/0140-6736(92)90645-J; STOLTE M, 1989, J CLIN PATHOL, V42, P1269, DOI 10.1136/jcp.42.12.1269; STOLTE M, 1993, LANCET, V342, P568, DOI 10.1016/0140-6736(93)91404-A; STOLTE M, 1992, Z GASTROENTEROL, V29, P6; TRAINOR KJ, 1990, BLOOD, V75, P2220; WAN JH, 1990, J CLIN PATHOL, V43, P880; WEBER DM, 1994, GASTROENTEROLOGY, V107, P1835, DOI 10.1016/0016-5085(94)90828-1; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; WOTHERSPOON AC, LANCET, V3433, P94; WYATT JI, 1988, SCAND J GASTROENTERO, V23, P44, DOI 10.3109/00365528809091712	29	816	833	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1591	1594		10.1016/S0140-6736(95)90113-2	http://dx.doi.org/10.1016/S0140-6736(95)90113-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783535				2022-12-24	WOS:A1995RE67000006
J	FRIEDMAN, AM; FISCHMANN, TO; STEITZ, TA				FRIEDMAN, AM; FISCHMANN, TO; STEITZ, TA			CRYSTAL-STRUCTURE OF LAC REPRESSOR CORE TETRAMER AND ITS IMPLICATIONS FOR DNA LOOPING	SCIENCE			English	Article							LACTOSE REPRESSOR; BINDING-PROTEIN; 3-DIMENSIONAL STRUCTURE; ESCHERICHIA-COLI; OPERATOR; SEQUENCE; OPERON; GENE; ASSOCIATION; PROMOTER	The crystal structure of the tryptic core fragment of the lac repressor of Escherichia coli (LacR) complexed with the inducer isopropyl-beta-D-thiogalactoside was determined at 2.6 Angstrom resolution. The quaternary structure consists of two dyad-symmetric dimers that are nearly parallel to each other. This structure places all four DNA binding domains of intact LacR on the same side of the tetramer, and results in a deep, V-shaped cleft between the two dimers. Each monomer contributes a carboxyl-terminal helix to an antiparallel four-helix bundle that functions as a tetramerization domain. Some of the side chains whose mutation reduce DNA binding form clusters on a surface near the amino terminus. Placing the structure of the DNA binding domain complexed with operator previously determined by nuclear magnetic resonance onto this surface results in two operators being adjacent and nearly parallel to each other. Structural considerations suggest that the two dimers of LacR may flexibly alter their relative orientation in order to bind to the known varied spacings between two operators.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06520; YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06520	Yale University; Howard Hughes Medical Institute; Yale University; Yale University			Friedman, Alan M/J-2696-2012; Steitz, Thomas A./C-6559-2009		NIGMS NIH HHS [GM22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTI S, 1991, NEW BIOL, V3, P57; BARKLEY MD, 1975, BIOCHEMISTRY-US, V14, P1700, DOI 10.1021/bi00679a024; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CARRA JH, EMBO J, V12, P35; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHANG WI, 1993, J BIOL CHEM, V268, P17613; CHARLIER M, 1980, NATURE, V286, P423, DOI 10.1038/286423a0; CHEN B, 1971, NATURE-NEW BIOL, V233, P67, DOI 10.1038/newbio233067a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUPRINA VP, 1993, J MOL BIOL, V234, P446, DOI 10.1006/jmbi.1993.1598; CROMER DT, 1970, J CHEM PHYS, V53, P1891, DOI 10.1063/1.1674266; DANDANELL G, 1987, NATURE, V325, P823, DOI 10.1038/325823a0; DUNN TM, 1984, P NATL ACAD SCI-BIOL, V81, P5017, DOI 10.1073/pnas.81.16.5017; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Friedman A. J., UNPUB; GEISLER N, 1977, BIOCHEMISTRY-US, V16, P938, DOI 10.1021/bi00624a020; GILBERT W, 1973, P NATL ACAD SCI USA, V70, P3581, DOI 10.1073/pnas.70.12.3581; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; GORDON AJE, 1988, J MOL BIOL, V200, P239, DOI 10.1016/0022-2836(88)90237-9; GRIFFITH J, 1986, NATURE, V322, P750, DOI 10.1038/322750a0; HARRIS LJ, 1992, NATURE, V360, P369, DOI 10.1038/360369a0; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOPE H, 1989, ACTA CRYSTALLOGR B, V45, P190, DOI 10.1107/S0108768188013710; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; KANIA J, 1976, P NATL ACAD SCI USA, V73, P3529, DOI 10.1073/pnas.73.10.3529; KAPTEIN R, 1985, J MOL BIOL, V182, P179, DOI 10.1016/0022-2836(85)90036-1; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; KRAMER H, 1987, EMBO J, V6, P1481, DOI 10.1002/j.1460-2075.1987.tb02390.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE W, 1994, NAT STRUCT BIOL, V265, P386; MAJORS J, 1975, P NATL ACAD SCI USA, V72, P4394, DOI 10.1073/pnas.72.11.4394; MAJUMDAR A, 1984, P NATL ACAD SCI-BIOL, V81, P6100, DOI 10.1073/pnas.81.19.6100; MANDAL N, 1990, GENE DEV, V4, P410, DOI 10.1101/gad.4.3.410; MCKAY DB, 1982, J MOL BIOL, V156, P175, DOI 10.1016/0022-2836(82)90465-X; MONOD J, 1985, J MOL BIOL, V12, P88; MOWBRAY SL, 1993, J MOL BIOL, V225, P155; MULLERHILL B, 1983, NATURE, V302, P163, DOI 10.1038/302163a0; NICHOLS JC, 1993, J BIOL CHEM, V268, P17602; NICK H, 1985, NATURE, V313, P795, DOI 10.1038/313795a0; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; OGATA RT, 1979, J MOL BIOL, V132, P709, DOI 10.1016/0022-2836(79)90384-X; OH BH, 1993, J BIOL CHEM, V268, P11348; OHSHIMA Y, 1975, J MOL BIOL, V91, P515, DOI 10.1016/0022-2836(75)90277-6; PARDEE AB, 1959, J MOL BIOL, V1, P165, DOI 10.1016/S0022-2836(59)80045-0; PLATT T, 1973, J BIOL CHEM, V248, P110; PORSCHKE D, 1987, BIOPHYS CHEM, V28, P137, DOI 10.1016/0301-4622(87)80083-2; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; ROSENBERG JM, 1977, NUCLEIC ACIDS RES, V4, P567, DOI 10.1093/nar/4.3.567; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SCHMITZ A, 1976, J BIOL CHEM, V251, P3359; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; THEVENY B, 1987, NATURE, V329, P79, DOI 10.1038/329079a0; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WHITSON PA, 1987, J BIOL CHEM, V262, P14592; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	71	269	271	0	23	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1721	1727		10.1126/science.7792597	http://dx.doi.org/10.1126/science.7792597			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792597				2022-12-24	WOS:A1995RE66800033
J	LAWRENCE, CM; RODWELL, VW; STAUFFACHER, CV				LAWRENCE, CM; RODWELL, VW; STAUFFACHER, CV			CRYSTAL-STRUCTURE OF PSEUDOMONAS-MEVALONII HMG-COA REDUCTASE AT 3.0 ANGSTROM RESOLUTION	SCIENCE			English	Article							COENZYME-A REDUCTASE; ACTIVATED PROTEIN-KINASE; AREA DETECTOR DIFFRACTOMETER; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; RAT-LIVER; CHEMICAL MODIFICATION; MEMBRANE DOMAIN; CATALYTIC SITE; CRYSTALLOGRAPHY; IDENTIFICATION	The rate-limiting step in cholesterol biosynthesis in mammals is catalyzed by 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a four-electron oxidoreductase that converts HMG-CoA to mevalonate. The crystal structure of HMG-CoA reductase from Pseudomonas mevalonii was determined at 3.0 angstrom resolution by multiple isomorphous replacement. The structure reveals a tightly bound dimer that brings together at the subunit interface the conserved residues implicated in substrate binding and catalysis. These dimers are packed about a threefold crystallographic axis, forming a hexamer with 23 point group symmetry. Difference Fourier studies reveal the binding sites for the substrates HMG-CoA and reduced or oxidized nicotinamide adenine dinucleotide [NAD(H)] and demonstrate that the active sites are at the dimer interfaces. The HMG-CoA is bound by a domain with an unusual fold, consisting of a central alpha helix surrounded by a triangular set of walls of beta sheets and alpha helices. The NAD(H) is bound by a domain characterized by an antiparallel beta structure that defines a class of dinucleotide-binding domains.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907; PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus			Lawrence, C. Martin/AAH-3420-2020	Lawrence, C. Martin/0000-0002-5398-466X	NHLBI NIH HHS [HL 47113] Funding Source: Medline; NIAID NIH HHS [AI 127713] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047113] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEACH MJ, 1989, J BACTERIOL, V171, P2994, DOI 10.1128/jb.171.6.2994-3001.1989; BOLLN JT, 1993, 1993 AM CRYST ASS 2; BROWN MS, 1986, SCIENCE, V232, P32; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHUN KT, 1992, J BIOL CHEM, V267, P4236; CLARKE CF, 1985, J BIOL CHEM, V260, P4363; CLARKE PR, 1990, FEBS LETT, V269, P213, DOI 10.1016/0014-5793(90)81157-J; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; DARNAY BG, 1993, J BIOL CHEM, V268, P8429; DARNAY BG, 1992, J BIOL CHEM, V267, P15064; DUGAN RE, 1986, BIOCHEM BIOPH RES CO, V141, P278, DOI 10.1016/S0006-291X(86)80365-5; EDWARDS PA, 1985, J BIOL CHEM, V260, P278; ENDO A, 1992, J LIPID RES, V33, P1569; GILL JF, 1985, J BIOL CHEM, V260, P9393; GILL JF, 1984, J BACTERIOL, V160, P294, DOI 10.1128/JB.160.1.294-298.1984; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORDANSTARCK TC, 1989, J BIOL CHEM, V264, P17919; JORDANSTARCK TC, 1989, J BIOL CHEM, V264, P17913; KIRTLEY ME, 1967, BIOCHEMISTRY-US, V6, P230, DOI 10.1021/bi00853a036; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE CM, 1995, ACTA CRYSTALLOGR D, V51, P386, DOI 10.1107/S0907444994009819; LESLIE GW, 1987, ASPECTS PROTEIN CRYS, P35; LOUISFLAMBERG P, 1990, BIOCHEMISTRY-US, V29, P4115, DOI 10.1021/bi00469a014; MAYER RJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P110, DOI 10.1016/0003-9861(88)90014-8; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; OMKUMAR RV, 1994, J BIOL CHEM, V269, P16862; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; Pflugrath J. W., 1984, Methods and Applications in Crystallographic Computing. International Summer School on Crystallographic Computing, P404; ROITELMAN J, 1989, J LIPID RES, V30, P97; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; SCALNICK DG, 1988, J BIOL CHEM, V263, P6836; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG Y, 1989, J BACTERIOL, V171, P5567, DOI 10.1128/jb.171.10.5567-5571.1989; WANG YL, 1990, J BIOL CHEM, V265, P21634; XUONG NH, 1985, ACTA CRYSTALLOGR B, V41, P267, DOI 10.1107/S0108768185002105; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433	46	73	78	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1758	1762		10.1126/science.7792601	http://dx.doi.org/10.1126/science.7792601			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792601				2022-12-24	WOS:A1995RE66800044
J	GONZALEZREYES, A; ELLIOTT, H; STJOHNSTON, D				GONZALEZREYES, A; ELLIOTT, H; STJOHNSTON, D			POLARIZATION OF BOTH MAJOR BODY AXES IN DROSOPHILA BY GURKEN-TORPEDO SIGNALING	NATURE			English	Article							EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; BICOID RNA; OOGENESIS; GENE; MELANOGASTER; OOCYTE; AXIS; LOCALIZATION; ENCODES	Anterior-posterior polarity in Drosophila arises from the movement of the oocyte to the posterior of the egg chamber, and the subsequent acquisition of posterior fate by the adjacent somatic follicle cells. We demonstrate that gurken is necessary in the oocyte and torpedo/DER in the follicle cells for the induction of posterior fate. As the gurken-torpedo/DER pathway also establishes dorsoventral polarity later in oogenesis, Drosophila uses the same germline to soma signalling pathway to determine both embryonic axes.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 1QR,ENGLAND	University of Cambridge	GONZALEZREYES, A (corresponding author), UNIV CAMBRIDGE,CRC INST,CAMBRIDGE CB2 1QR,ENGLAND.		St Johnston, Daniel/C-9568-2009; Gonzalez-Reyes, Acaimo/L-1993-2014	Gonzalez-Reyes, Acaimo/0000-0003-3048-0968; St Johnston, Daniel/0000-0001-5582-3301	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHBURNER M, 1990, GENETICS, V126, P679; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Chasan Rebecca, 1993, P387; CHEUNG HK, 1992, DEVELOPMENT, V114, P653; CHRISTERSON LB, 1994, GENE DEV, V8, P614, DOI 10.1101/gad.8.5.614; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; Driever Wolfgang, 1993, P301; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FASANO L, 1988, DEVELOPMENT, V104, P245; FROHNHOFER H, 1982, THESIS U TUBINGEN; FUJISUE M, 1993, DEVELOPMENT, V118, P163; GINIGER E, 1993, ROUX ARCH DEV BIOL, V202, P112, DOI 10.1007/BF00636536; GONZALEZREYES A, 1994, SCIENCE, V266, P639, DOI 10.1126/science.7939717; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; KAMMERMEYER KL, 1987, DEVELOPMENT, V100, P201; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KLYMKOWSKY MW, 1994, DEV BIOL, V165, P372, DOI 10.1006/dbio.1994.1260; KOCH EA, 1983, CELL TISSUE RES, V228, P21; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LANTZ V, 1994, GENE DEV, V8, P598, DOI 10.1101/gad.8.5.598; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; NEUMANSILBERBER.FS, 1993, CELL, V75, P165; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; ROTH S, 1994, DEVELOPMENT, V120, P2245; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPACH T, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P163; SCHUPBACH T, 1991, GENETICS, V129, P1119; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SHILO BZ, 1991, TRENDS GENET, V7, P388, DOI 10.1016/0168-9525(91)90261-N; Spradling Allan C., 1993, P1; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; TOLIAS PP, 1990, EMBO J, V9, P1457, DOI 10.1002/j.1460-2075.1990.tb08262.x; WIESCHAUS E, 1978, ROUX ARCH DEV BIOL, V184, P75, DOI 10.1007/BF00848670; YUGE M, 1990, DEVELOPMENT, V110, P1051	43	417	423	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					654	658		10.1038/375654a0	http://dx.doi.org/10.1038/375654a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791898				2022-12-24	WOS:A1995RE57600051
J	BLACK, JA; DEBELLE, GD				BLACK, JA; DEBELLE, GD			FEMALE GENITAL MUTILATION IN BRITAIN	BRITISH MEDICAL JOURNAL			English	Article							CIRCUMCISION	Much has been written about female genital mutilation in Africa, but little attention has been paid to its existence in Britain. Though it has been illegal in this country since 1985, it is practised secretly or children are sent abroad to have the operation. From the social worker's point of view it is technically a form of child abuse which poses special problems. Black and Debelle review the historical background of female genital mutilation and describe its medical complications. Gallard discusses the problem in France, and Walder considers why such mutilation still continues in Britain.	S BIRMINGHAM HLTH AUTHOR,CHILDRENS SERV UNIT,BIRMINGHAM,W MIDLANDS,ENGLAND		BLACK, JA (corresponding author), VICTORIA MILL HOUSE,WOODBRIDGE IP13 9EG,SUFFOLK,ENGLAND.							[Anonymous], 1991, CHILDREN ACT 1989; DIRIE MA, 1991, TROP DOCT, V21, P146, DOI 10.1177/004947559102100404; Dorkeno E., 1992, FEMALE GENITAL MUTIL; FAYYAD S, 1993, VOICES, P102; HEDLEY R., 1992, CHILD PROTECTION FEM; KORBIN JE, 1991, CHILD ABUSE NEGLECT, V15, P67, DOI 10.1016/0145-2134(91)90010-B; LADJALI M, 1993, BRIT MED J, V307, P460, DOI 10.1136/bmj.307.6902.460; RICHARDS T, 1993, BRIT MED J, V307, P957; SAMI IR, 1986, ANN TROP PAEDIATR, V6, P99, DOI 10.1080/02724936.1986.11748419; WEBB E, 1994, ARCH DIS CHILD, V70, P441, DOI 10.1136/adc.70.5.441; 1986, WHO CHRON, V40, P31	11	62	62	0	26	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1590	1592		10.1136/bmj.310.6994.1590	http://dx.doi.org/10.1136/bmj.310.6994.1590			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787654	Green Published			2022-12-24	WOS:A1995RE35300029
J	KIZER, KW; VASSAR, MJ; HARRY, RL; LAYTON, KD				KIZER, KW; VASSAR, MJ; HARRY, RL; LAYTON, KD			HOSPITALIZATION CHARGES, COSTS AND INCOME FOR FIREARM-RELATED INJURIES AT A UNIVERSITY TRAUMA CENTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To quantify the actual cost of inpatient medical care for firearm-related injuries at a university trauma center. Design.-Retrospective Case Series of all hospital admissions for firearm-related injuries for the 3 years 1990 through 1992. Total inpatient financial data Were examined by means of a recently instituted cost-accounting methodology. Setting.-Level trauma Center at a university hospital that provides trauma care and tertiary care to 3.7 million residents of 23 Counties. Patients.-A total of 787 consecutive patients were admitted to the hospital with firearm-related injuries information from the trauma registry and hospital finance records were linked for 750 (95%) of these patients. Main Outcome Measures.-Total inpatient hospital charges, costs, revenues, and net income according to payer source. Results.-Men aged 15 to 44 years accounted for 77% of patients with firearm-related injuries. The overall mean and median hospital charges per admission were $52 271 and $28 033, respectively, whereas the overall mean and median hospital costs per admission were $13 794 and $7964, respectively. The net income per patient ranged from an average loss of $6980 for each patient having no insurance to an average profit of $28 557 for each patient with a health maintenance organization contract the losses sustained on nonsponsored and Medicaid patients were more than offset by net income from patients having private health insurance, Medicare or other insurance coverage such that there was an average profit of $5809 per admission for a firearm-related injury. Concluslons.-Treatment of firearm-related injuries produces net income for this University trauma center by virtue of the cost shifting built into its pricing structure. if data from this institution ate extrapolated to the nation, then the actual cost of providing medical care for firearm-related injuries in the United States in 1995 is projected to be $4.0 billion. The majority of this cost will be paid indirectly by private health insurance.	UNIV CALIF DAVIS,SCH MED,DEPT COMMUNITY & INT HLTH,DAVIS,CA 95616; UNIV CALIF DAVIS,SCH MED,DEPT INTERNAL MED,DIV EMERGENCY MED & CLIN TOXICOL,DAVIS,CA 95616; UNIV CALIF DAVIS,MED CTR,FINANCIAL SERV ADM,SACRAMENTO,CA 95817; UNIV CALIF DAVIS,MED CTR,TRAUMA PROGRAM,SACRAMENTO,CA 95817	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis			Vassar, Matt/AAD-5385-2020					[Anonymous], 1988, INT CLASSIFICATION D; FINE PR, 1994, J FORENSIC SCI, V39, P674; FINGERHUT LA, 1991, MONTHLY VITAL STAT R, V39, P1; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; MARTIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P3048, DOI 10.1001/jama.260.20.3048; MAX W, 1993, HEALTH AFFAIR, V12, P171, DOI 10.1377/hlthaff.12.4.171; MCGONIGAL MD, 1993, J TRAUMA, V35, P532, DOI 10.1097/00005373-199310000-00006; MOCK C, 1994, J TRAUMA, V36, P516, DOI 10.1097/00005373-199404000-00010; PAYNE JE, 1993, J TRAUMA, V34, P276, DOI 10.1097/00005373-199302000-00018; Rice DP, 1989, COST INJURY US REPOR; ROPP L, 1992, JAMA-J AM MED ASSOC, V267, P2905, DOI 10.1001/jama.267.21.2905; SMITH SM, 1989, AM J PREV MED, V5, P296, DOI 10.1016/S0749-3797(18)31070-5; TARDIFF K, 1994, JAMA-J AM MED ASSOC, V272, P43, DOI 10.1001/jama.272.1.43; WINTEMUTE GJ, 1992, J TRAUMA, V33, P556, DOI 10.1097/00005373-199210000-00011; 1989, DETERMINING INJURY S; 1990, TRANSITION 1 SOFTWAR; 1994, MMWR-MORBID MORTAL W, V43, P37; 1991, TRAUMA CARE LIFESAVI	18	51	51	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	1995	273	22					1768	1773		10.1001/jama.273.22.1768	http://dx.doi.org/10.1001/jama.273.22.1768			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB800	7769771				2022-12-24	WOS:A1995RB80000030
J	CHEN, JQ; DEVIVO, M; DINGUS, J; HARRY, A; LI, JR; SUI, JL; CARTY, DJ; BLANK, JL; EXTON, JH; STOFFEL, RH; INGLESE, J; LEFKOWITZ, RJ; LOGOTHETIS, DE; HILDEBRANDT, JD; IYENGAR, R				CHEN, JQ; DEVIVO, M; DINGUS, J; HARRY, A; LI, JR; SUI, JL; CARTY, DJ; BLANK, JL; EXTON, JH; STOFFEL, RH; INGLESE, J; LEFKOWITZ, RJ; LOGOTHETIS, DE; HILDEBRANDT, JD; IYENGAR, R			A REGION OF ADENYLYL-CYCLASE-2 CRITICAL FOR REGULATION BY G-PROTEIN BETA-GAMMA-SUBUNITS	SCIENCE			English	Article							MUSCARINIC K+-CHANNEL; ALPHA-SUBUNIT; BINDING; SITE; STIMULATION; ACTIVATION; CLONING; BRAIN	Receptor-mediated activation of heterotrimeric guanine nucleotide-binding proteins (G proteins) results in the dissociation of alpha from beta gamma subunits, thereby allowing both to regulate effecters. Little is known about the regions of effecters required for recognition of G beta gamma. A peptide encoding residues 956 to 982 of adenylyl cyclase 2 specifically blocked G beta gamma stimulation of adenylyl cyclase 2, phospholipase C-beta 3, potassium channels, and beta-adrenergic receptor kinase as well as inhibition of calmodulin-stimulated adenylyl cyclases, but had no effect on interactions between G beta gamma and G alpha(o). Substitutions in this peptide identified a functionally important motif, Gln-X-X-G lu-Arg, that is also conserved in regions of potassium channels and beta-adrenergic receptor kinases that participate in G beta gamma interactions, Thus, the region defined by residues 956 to 982 of adenylyl cyclase 2 may contain determinants important for receiving signals from G beta gamma.	CUNY,MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029; MED UNIV S CAROLINA,DEPT CELL & MOLEC PHARMACOL,CHARLESTON,SC 29425; CUNY,MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029; VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHYSIOL,NASHVILLE,TN 37232; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Medical University of South Carolina; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University; Duke University; Howard Hughes Medical Institute; Duke University			Lefkowitz, Robert/AAW-2649-2021		NCI NIH HHS [CA-44998] Funding Source: Medline; NIDDK NIH HHS [DK-38761, DK-37219] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761, R01DK037219] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENOVIC J, 1991, J BIOL CHEM, V261, P14939; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BLANK JL, 1994, METHOD ENZYMOL, V238, P237; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DEVIVO M, 1994, METHOD ENZYMOL, V238, P131; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DINGUS J, 1994, METHOD ENZYMOL, V237, P457; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; PADRELL E, 1991, J BIOL CHEM, V266, P9771; PREMONT RT, 1993, ENDOCRINOLOGY, V131, P2774; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9808; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; TAKAO K, 1994, NEURON, V13, P747, DOI 10.1016/0896-6273(94)90041-8; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; UEDA N, 1994, J BIOL CHEM, V269, P4388; WATSON PA, 1994, J BIOL CHEM, V269, P28893	33	221	228	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1166	1169		10.1126/science.7761832	http://dx.doi.org/10.1126/science.7761832			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761832				2022-12-24	WOS:A1995RA60400034
J	MANTZOROS, CS; GEORGIADIS, EI; TRICHOPOULOS, D				MANTZOROS, CS; GEORGIADIS, EI; TRICHOPOULOS, D			CONTRIBUTION OF DIHYDROTESTOSTERONE TO MALE SEXUAL-BEHAVIOR	BRITISH MEDICAL JOURNAL			English	Article							TESTOSTERONE; MEN	Objective-To document the relative importance of endogenous sex steroids in modulating the frequency of orgasms, the dominant aspect of sexual behaviour in healthy eugonadal men. Design-Measurement of adrenal and testicular sex steroids in a sample of army recruits and study of their relation to frequency of orgasms ascertained by questionnaire after potential confounding variables were controlled for. Setting-Military campus and military hospital laboratories in Athens, Greece. Subjects-92 consecutively enrolled healthy male recruits aged 18-22 years. Main outcome measures-Weekly number of orgasms. Serum concentrations of testosterone, dehydroepiandrosterone sulphate, dihydrotestosterone, oestradiol, oestrone, Delta-4-androstenedione, and sex hormone binding globulin. Results-Serum dihydrotestosterone concentration was the only independent hormonal predictor of the frequency of orgasms; an increase in concentration of 1.36 nmol/l (about 2 SD) corresponded to an average increase of one orgasm a week. Conclusions-Differences in concentrations of circulating dihydrotestosterone within the normal range may represent a major predictor of sexual activity in healthy young men.	MIL HOSP 401,ENDOCRINE UNIT,ATHENS,GREECE; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02215	Harvard University; Harvard T.H. Chan School of Public Health			Mantzoros, Christos/Y-2902-2019					ANDERSON RA, 1992, J CLIN ENDOCR METAB, V75, P1503, DOI 10.1210/jc.75.6.1503; BAGATELL CJ, 1994, J CLIN ENDOCR METAB, V78, P711, DOI 10.1210/jc.78.3.711; BANCROFT J, 1980, CLIN OBSTET GYNAECOL, V7, P253; DAVIDSON JM, 1983, J CLIN ENDOCR METAB, V57, P71, DOI 10.1210/jcem-57-1-71; KNUSSMANN R, 1986, ARCH SEX BEHAV, V15, P429, DOI 10.1007/BF01543113; KRAEMER HC, 1976, ARCH SEX BEHAV, V5, P125, DOI 10.1007/BF01541869; MOORADIAN AD, 1987, ENDOCR REV, V8, P1, DOI 10.1210/edrv-8-1-1; TSITOURAS PD, 1987, ENDOCRIN METAB CLIN, V16, P1045, DOI 10.1016/S0889-8529(18)30458-4; WEINBAUER GF, 1990, ACTA ENDOCRINOL-COP, V122, P432, DOI 10.1530/acta.0.1220432	9	69	73	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	1995	310	6990					1289	1291		10.1136/bmj.310.6990.1289	http://dx.doi.org/10.1136/bmj.310.6990.1289			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773040	Green Published			2022-12-24	WOS:A1995QZ86000018
J	KANTARJIAN, HM; SMITH, TL; OBRIEN, S; BERAN, M; PIERCE, S; TALPAZ, M; ROBERTSON, L; KOLLER, C; ESTEY, E; KEATING, MJ				KANTARJIAN, HM; SMITH, TL; OBRIEN, S; BERAN, M; PIERCE, S; TALPAZ, M; ROBERTSON, L; KOLLER, C; ESTEY, E; KEATING, MJ			PROLONGED SURVIVAL IN CHRONIC MYELOGENOUS LEUKEMIA AFTER CYTOGENETIC RESPONSE TO INTERFERON-ALPHA THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						LEUKEMIA, MYELOID, CHRONIC; INTERFERON-ALPHA; CYTOGENETICS; BASOPHILS; SPLENOMEGALY	PHILADELPHIA-CHROMOSOME; CHRONIC-PHASE; REMISSION	Objective: To determine whether a cytogenetic response after interferon-alpha therapy in patients with chronic myelogenous leukemia is independently associated with improved survival. Design: Retrospective analysis. Patients: 274 patients with a diagnosis of Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase who were treated with interferon-alpha-based programs between 1982 and 1990. Intervention: Therapy with daily subcutaneous interferon-alpha given at 5 x 10(6) U/m(2) body surface area (highest dose schedule allowed on studies) or the maximally tolerated lower-dose schedule. Results: Overall, 219 (80%) patients achieved a complete hematologic response and 104 (38%) achieved a major cytogenetic response (<35% Philadelphia chromosome-positive cells). Estimated median survival was 89 months. Several pretreatment factors were associated with failure to achieve a major cytogenetic response and with worse survival. The existing prognostic models were generally predictive of which patients were likely to achieve a major cytogenetic response (P less than or equal to 0.01) and of survival outcomes (P less than or equal to 0.01). Multivariate analysis identified bone marrow basophilia (P < 0.01) and splenomegaly (P < 0.01) as independent poor prognostic factors for survival. Achievement of a major cytogenetic response, entered as a time-dependent variable while accounting for the other independent factors, was associated with improved survival (P < 0.001). Comparison of survival (dated from 12 months into therapy) with cytogenetic response at 12 months showed that a cytogenetic response was associated with longer survival (P < 0.001). Conclusion: Achieving a cytogenetic response with interferon-alpha therapy in patients with chronic myelogenous leukemia was independently associated with improved survival when tested as a time-dependent variable in a multivariate analysis, and this association was confirmed by landmark analysis at 12 months.			KANTARJIAN, HM (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT HEMATOL, BOX 61, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.			Talpaz, Moshe/0000-0003-3361-3981	NCI NIH HHS [CA19639] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIMENA G, 1988, BLOOD, V72, P642; ANDERSON JR, 1983, J CLIN ONCOL, V1, P710, DOI 10.1200/JCO.1983.1.11.710; COX DR, 1972, J R STAT SOC B, V34, P187; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; GOLDMAN JM, 1993, BLOOD, V82, P2235; GOLDMAN JM, 1990, LEUKEMIA, V4, P163; HEHLMANN R, 1993, BLOOD, V82, P398, DOI 10.1182/blood.V82.2.398.bloodjournal822398; KANTARJIAN HM, 1993, BLOOD, V82, P691; KANTARJIAN HM, 1990, AM J MED, V88, P1, DOI 10.1016/0002-9343(90)90119-X; KANTARJIAN HM, 1985, BLOOD, V66, P1326; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; OZER H, 1993, BLOOD, V82, P2975; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SOKAL JE, 1984, BLOOD, V63, P789, DOI 10.1182/blood.V63.4.789.789; TALPAZ M, 1987, BLOOD, V69, P1280; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; TURA S, 1994, NEW ENGL J MED, V330, P820; TURA S, 1994, NEW ENGL J MED, V331, P402; 1988, GUIDELINES REPORTING	21	422	428	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					254	261		10.7326/0003-4819-122-4-199502150-00003	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825760				2022-12-24	WOS:A1995QF76900003
J	LIFSON, AR; ALLEN, S; WOLF, W; SERUFILIRA, A; KANTARAMA, G; LINDAN, CP; HUDES, ES; NSENGUMUREMYI, F; TAELMAN, H; BATUNGWANAYO, J				LIFSON, AR; ALLEN, S; WOLF, W; SERUFILIRA, A; KANTARAMA, G; LINDAN, CP; HUDES, ES; NSENGUMUREMYI, F; TAELMAN, H; BATUNGWANAYO, J			CLASSIFICATION OF HIV-INFECTION AND DISEASE IN WOMEN FROM RWANDA - EVALUATION OF THE WORLD-HEALTH-ORGANIZATION HIV STAGING SYSTEM AND RECOMMENDED MODIFICATIONS	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REPRESENTATIVE SAMPLE; CHILDBEARING WOMEN; SEDIMENTATION-RATE; ORAL CANDIDIASIS; LYMPHOCYTE COUNT; HOMOSEXUAL MEN; AIDS; TUBERCULOSIS; PROGRESSION	Objective: To develop a human immunodeficiency virus (HIV) staging system for sub-Saharan Africa on the basis of an evaluation of the World Health Organization (WHO) system and predictors of mortality. Design: Prospective cohort study with 4 years of follow-up. Setting: Kigali, Rwanda. Patients: 412 HIV-infected women recruited from prenatal and pediatric clinics. Measurements: Clinical signs and symptoms of HIV disease, laboratory assays (including complete blood count and erythrocyte sedimentation rate), and cumulative mortality. Results: The WHO staging system includes a clinical and a laboratory axis. The clinical axis was revised by inclusion of oral candidiasis, chronic oral or genital ulcers, and pulmonary tuberculosis as ''severe'' disease (clinical stage IV); in addition, body mass index was substituted for weight loss in the definition for the wasting syndrome. The 36-month cumulative mortality was 7% for women in modified clinical stage I (''asymptomatic''), 15% for those in stage II, 19% for those in stage III, and 36% for those in stage IV (P < 0.001). The laboratory axis was revised by replacing lymphocyte count with hematocrit and erythrocyte sedimentation rate. The 36-month mortality was 10% for women in modified stage A (''normal'' laboratory results) and 33% for those in stage B (erythrocyte sedimentation rate >65 mm/h or hematocrit <0.38) (P < 0.001). A single staging system combining clinical and laboratory criteria is proposed, with a 36-month mortality of 7% for women in combined stage I, 10% for those in stage II, 29% for those in stage III, and 62% for those in stage IV (P < 0.001). Conclusions: On the basis of this analysis, a staging system relevant for sub-Saharan Africa is proposed that reflects the range of HIV-related outcomes, has strong prognostic significance, includes inexpensive and available laboratory tests, and can be used by both clinicians and researchers.	UNIV CALIF SAN FRANCISCO, CTR AIDS PREVENT STUDIES, SAN FRANCISCO, CA 94105 USA; CENT HOSP, KIGALI, RWANDA; MINIST HLTH, KIGALI, RWANDA	University of California System; University of California San Francisco					NIAID NIH HHS [AI23980] Funding Source: Medline; NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439, DOI 10.1164/ajrccm/146.6.1439; ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; ALLEN S, 1991, J INFECT DIS, V164, P67, DOI 10.1093/infdis/164.1.67; [Anonymous], 1993, MMWR Recomm Rep, V42, P1; [Anonymous], 1994, Wkly Epidemiol Rec, V69, P273; [Anonymous], 1990, Wkly Epidemiol Rec, V65, P221; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; AYLWARD RB, 1994, AIDS, V8, P1129, DOI 10.1097/00002030-199408000-00015; BATUNGWANAYO J, 1993, AIDS, V7, P73, DOI 10.1097/00002030-199301000-00011; BATUNGWANAYO J, 1994, AM J RESP CRIT CARE, V149, P1591, DOI 10.1164/ajrccm.149.6.8004318; BLATT SP, 1993, JAMA-J AM MED ASSOC, V269, P622, DOI 10.1001/jama.269.5.622; CAHN P, 1993, AIDS, V7, P711; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS, P186; FERROLUZZI A, 1992, EUR J CLIN NUTR, V46, P173; HAVERKOS HW, 1985, J INFECT DIS, V152, P1095, DOI 10.1093/infdis/152.5.1095; HOOVER DR, 1993, J ACQ IMMUN DEF SYND, V6, P537; KATZ MH, 1992, AIDS, V6, P95, DOI 10.1097/00002030-199201000-00013; KERLIKOWSKE KM, 1994, AIDS, V8, P963, DOI 10.1097/00002030-199407000-00014; LEDERMAN MM, 1994, J ACQ IMMUN DEF SYND, V7, P727; LEFRERE JJ, 1988, AIDS, V2, P63, DOI 10.1097/00002030-198802000-00013; LIMA LAA, 1993, AIDS, V7, P295, DOI 10.1097/00002030-199302000-00031; LIN RY, 1993, AM J MED SCI, V305, P345, DOI 10.1097/00000441-199306000-00001; LINDAN CP, 1992, ANN INTERN MED, V116, P320, DOI 10.7326/0003-4819-116-4-320; Mann J, 1992, AIDS WORLD, P11; MONTANER JSG, 1992, AIDS, V6, P719, DOI 10.1097/00002030-199207000-00016; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; MUKADI Y, 1993, LANCET, V342, P143, DOI 10.1016/0140-6736(93)91346-N; MUNOZ A, 1988, J ACQ IMMUN DEF SYND, V1, P396; OKWERA A, 1994, LANCET, V344, P1323, DOI 10.1016/S0140-6736(94)90693-9; RABENECK L, 1993, J GEN INTERN MED, V8, P5, DOI 10.1007/BF02600284; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; REVICKI DA, 1986, AM J PUBLIC HEALTH, V76, P992, DOI 10.2105/AJPH.76.8.992; ROYCE RA, 1991, AIDS, V5, P355, DOI 10.1097/00002030-199104000-00001; SCHECHTER M, 1994, J ACQ IMMUN DEF SYND, V7, P163; SCHWARTLANDER B, 1993, AIDS, V7, P813, DOI 10.1097/00002030-199306000-00009; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; VANDENBRUAENE M, 1993, AIDS, V7, P1613, DOI 10.1097/00002030-199312000-00011; VANDEPERRE P, 1988, SCAND J INFECT DIS, V20, P277, DOI 10.3109/00365548809032451; WALLIS RS, 1993, J INFECT DIS, V167, P43, DOI 10.1093/infdis/167.1.43; WENIGER BG, 1992, J ACQ IMMUN DEF SYND, V5, P1212; 1986, MMWR-MORBID MORTAL W, V35, P334	42	58	59	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					262	270		10.7326/0003-4819-122-4-199502150-00004	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825761				2022-12-24	WOS:A1995QF76900004
J	DERIJARD, B; RAINGEAUD, J; BARRETT, T; WU, IH; HAN, JH; ULEVITCH, RJ; DAVIS, RJ				DERIJARD, B; RAINGEAUD, J; BARRETT, T; WU, IH; HAN, JH; ULEVITCH, RJ; DAVIS, RJ			INDEPENDENT HUMAN MAP KINASE SIGNAL-TRANSDUCTION PATHWAYS DEFINED BY MEK AND MKK ISOFORMS	SCIENCE			English	Article							PROTEIN-KINASE; CLONING; YEAST	Mammalian mitogen-activated protein (MAP) kinases include extracellular signal-regulated protein kinase (ERK), c-Jun amino-terminal kinase (JNK), and p38 subgroups. These MAP kinase isoforms are activated by dual phosphorylation on threonine and tyrosine. Two human MAP kinase kinases (MKK3 and MKK4) were cloned that phosphorylate and activate p38 MAP kinase. These MKK isoforms did not activate the ERK subgroup of MAP kinases, but MKK4 did activate JNK. These data demonstrate that the activators of p38 (MKK3 and MKK4), JNK (MKK4), and ERK (MEK1 and MEK2) define independent MAP kinase signal transduction pathways.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA; HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; Scripps Research Institute			Ulevitch, Richard J/Q-3393-2017; Han, J/G-4671-2010		NCI NIH HHS [CA58396] Funding Source: Medline; NIAID NIH HHS [AI15136] Funding Source: Medline; NIGMS NIH HHS [GM37696] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, UNPUB; DRESSLER H, 1992, BIOTECHNIQUES, V13, P866; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GUPTA S, 1995, SCIENCE, V389; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; RAINGEAUD J, UNPUB; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; YAN MH, 1994, NATURE, V372, P798; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	31	1398	1442	0	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					682	685		10.1126/science.7839144	http://dx.doi.org/10.1126/science.7839144			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839144				2022-12-24	WOS:A1995QE73300039
J	LYONS, JR				LYONS, JR			METAL-IONS IN THE ATMOSPHERE OF NEPTUNE	SCIENCE			English	Article							PLANETARY-ATMOSPHERES; INTERSTELLAR CLOUDS; POSITIVE-IONS; VOYAGER-2; LAYERS; IONOSPHERE; MESOSPHERE; CATIONS	Microwave propagation experiments performed with Voyager 2 at Neptune revealed sharp layers of electrons in Neptune's lower ionosphere with densities of similar to 10(4) per cubic centimeter. These layers are reminiscent of the sporadic-E layers in the Earth's ionosphere, and when taken together with data from the other giant planets, these data confirm the importance of the magnetic field in layer formation, A photochemical model that incorporates species produced by meteoroid ablation predicts that singly ionized magnesium is the most likely metal to be found in the layers, although laboratory data on the kinetics of metallic atoms and ions in a reducing environment are lacking. The metal chemistry discussed here is directly relevant to the abundant metals observed at the impact site of the G fragment of comet Shoemaker Levy 9 on Jupiter.			LYONS, JR (corresponding author), CALTECH, DIV GEOL & PLANETARY SCI, PASADENA, CA 91125 USA.							ALLEN M, 1981, J GEOPHYS RES-SPACE, V86, P3617, DOI 10.1029/JA086iA05p03617; ANICICH VG, 1993, J PHYS CHEM REF DATA, V22, P1469, DOI 10.1063/1.555940; ATREYE SK, 1986, ATMOSPHERES IONOSPHE; BARTH CA, 1992, MARS, P1054; BAUSCHLICHER CW, 1990, INT REV PHYS CHEM, V9, P149, DOI 10.1080/01442359009353245; BRACE LH, 1991, SPACE SCI REV, V55, P81, DOI 10.1007/BF00177136; BRISTOW WA, 1991, GEOPHYS RES LETT, V18, P404, DOI 10.1029/90GL02588; CANOSA A, 1992, J CHEM PHYS, V97, P1028, DOI 10.1063/1.463282; CHEN RH, 1981, J GEOPHYS RES-SPACE, V86, P7792, DOI 10.1029/JA086iA09p07792; CONNERNEY JEP, 1984, NATURE, V312, P136, DOI 10.1038/312136a0; CONNERNEY JEP, 1991, J GEOPHYS RES-PLANET, V96, P19023, DOI 10.1029/91JA01165; FERGUSON EE, 1968, J GEOPHYS RES, V73, P6215, DOI 10.1029/JA073i019p06215; FJELDBO G, 1965, J GEOPHYS RES, V70, P3701, DOI 10.1029/JZ070i015p03701; HAIL GA, IN PRESS INT J IMAGI; HUNTEN DM, 1980, J ATMOS SCI, V37, P1342, DOI 10.1175/1520-0469(1980)037<1342:SADPOM>2.0.CO;2; HUNTRESS WT, 1977, ASTROPHYS J SUPPL S, V33, P495, DOI 10.1086/190439; JESSBERGER EK, 1991, ASTROPHYS SPACE SC L, V167, P1075, DOI 10.1017/S0252921100012823; Kelley M. C., 1989, EARTHS IONOSPHERE, V43; KIM YH, 1991, GEOPHYS RES LETT, V18, P123, DOI 10.1029/90GL02587; KIRKWOOD S, 1989, J ATMOS TERR PHYS, V51, P259, DOI 10.1016/0021-9169(89)90077-9; LINDAL GF, 1992, ASTRON J, V103, P967, DOI 10.1086/116119; LINDAL GF, 1987, J GEOPHYS RES, V92, P14987, DOI 10.1029/JA092iA13p14987; Lyons J. L., UNPUB; MAJEED T, 1991, PLANET SPACE SCI, V39, P1715, DOI 10.1016/0032-0633(91)90031-5; MOSES JI, 1992, ICARUS, V99, P368, DOI 10.1016/0019-1035(92)90153-X; NOLL K, 1994, 6038 INT ASTR UN CIR; OHANESSIAN G, 1990, ACCOUNTS CHEM RES, V23, P386, DOI 10.1021/ar00179a007; ROMANL PN, 1994, ICARUS, V106, P442; ROQUES F, 1994, ASTRON ASTROPHYS, V288, P985; SICARDY B, 1992, B AM ASTRON SOC, V24, P963; STONE EC, 1989, SCIENCE, V246, P1417, DOI 10.1126/science.246.4936.1417; STROBEL DF, 1991, URANUS, P65; TYLER GL, 1989, SCIENCE, V246, P1466, DOI 10.1126/science.246.4936.1466; WEAST RC, 1986, CRC HDB CHEM PHYSICS, pF167; WHITEHEAD J, 1961, J ATMOS TERR PHYS, V20, P49, DOI 10.1016/0021-9169(61)90097-6	35	46	46	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					648	651						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839139				2022-12-24	WOS:A1995QE73300029
J	SELHUB, J; JACQUES, PF; BOSTOM, AG; DAGOSTINO, RB; WILSON, PWF; BELANGER, AJ; OLEARY, DH; WOLF, PA; SCHAEFER, EJ; ROSENBERG, IH				SELHUB, J; JACQUES, PF; BOSTOM, AG; DAGOSTINO, RB; WILSON, PWF; BELANGER, AJ; OLEARY, DH; WOLF, PA; SCHAEFER, EJ; ROSENBERG, IH			ASSOCIATION BETWEEN PLASMA HOMOCYSTEINE CONCENTRATIONS AND EXTRACRANIAL CAROTID-ARTERY STENOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; ATHEROTHROMBOTIC BRAIN INFARCTION; RISK-FACTORS; CARDIOVASCULAR HEALTH; ATHEROSCLEROSIS RISK; VASCULAR-DISEASE; ELDERLY PATIENTS; FOLLOW-UP; ULTRASOUND; FOLATE	Background. Epidemiologic studies have identified hyperhomocysteinemia as a possible risk factor for atherosclerosis. We determined the risk of carotid-artery atherosclerosis in relation to both plasma homocysteine concentrations and nutritional determinants of hyperhomocysteinemia. Methods. We performed a cross-sectional study of 1041 elderly subjects (418 men and 623 women; age range, 67 to 96 years) from the Framingham Heart Study. We examined the relation between the maximal degree of stenosis of the extracranial carotid arteries (as assessed by ultrasonography) and plasma homocysteine concentrations, as well as plasma concentrations and intakes of vitamins involved in homocysteine metabolism, including folate, vitamin B-12, and vitamin B-6. The subjects were classified into two categories according to the findings in the more diseased of the two carotid vessels: stenosis of 0 to 24 percent and stenosis of 25 to 100 percent. Results. The prevalence of carotid stenosis of less than or equal to 25 percent was 43 percent in the men and 34 percent in the women. The odds ratio for stenosis of greater than or equal to 25 percent was 2.0 (95 percent confidence interval, 1.4 to 2.9) for subjects with the highest plasma homocysteine concentrations (greater than or equal to 14.4 mu mol per liter) as compared with those with the lowest concentrations (less than or equal to 9.1 mu mol per liter), after adjustment for sex, age, plasma high-density lipoprotein cholesterol concentration, systolic blood pressure, and smoking status (P<0.001 for trend). Plasma concentrations of folate and pyridoxal-5'-phosphate (the coenzyme form of vitamin B-6) and the level of folate intake were inversely associated with carotid-artery stenosis after adjustment for age, sex, and other risk factors. Conclusions. High plasma homocysteine concentrations and low concentrations of folate and vitamin B,, through their role in homocysteine metabolism, are associated with an increased risk of extracranial carotid-artery stenosis in the elderly.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY, FRAMINGHAM, MA USA; BOSTON UNIV, DEPT MATH, STAT & CONSULTING UNIT, BOSTON, MA 02215 USA; GEISINGER MED CTR, DEPT RADIOL, DANVILLE, PA 17822 USA; BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA; UNIV BOSTON HOSP, EVANS MEM DEPT CLIN RES, PREVENT MED & EPIDEMIOL SECT, BOSTON, MA 02118 USA; UNIV BOSTON HOSP, DEPT MED, BOSTON, MA 02118 USA	Framingham Heart Study; Boston University; Geisinger Medical Center; Boston University	SELHUB, J (corresponding author), TUFTS UNIV, USDA, HUMAN NUTR RES CTR AGING, 711 WASHINGTON ST, BOSTON, MA 02111 USA.		Wilson, Peter W.F./J-2455-2016	Wolf, Philip/0000-0002-3628-301X	NHLBI NIH HHS [R01-HL-40423-05, N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [2-R01-NS-17950-12] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; ARONOW WS, 1992, NEW YORK STATE J MED, V92, P424; ARONOW WS, 1993, AM J CARDIOL, V71, P999, DOI 10.1016/0002-9149(93)90923-Z; ARONOW WS, 1993, AM J CARDIOL, V71, P1479, DOI 10.1016/0002-9149(93)90622-J; ARONOW WS, 1992, CORONARY ARTERY DIS, V3, P249, DOI 10.1097/00019501-199203000-00012; BLANKENHORN DH, 1993, CIRCULATION, V88, P20, DOI 10.1161/01.CIR.88.1.20; BOND MG, 1989, AM J MED, V86, P33; BOTS ML, 1992, HYPERTENSION, V19, P717, DOI 10.1161/01.HYP.19.6.717; BRATTSTROM L, 1990, ATHEROSCLEROSIS, V81, P51, DOI 10.1016/0021-9150(90)90058-Q; CAMP VM, 1983, CLIN CHEM, V29, P642; CHAMBLESS LE, 1993, AM J EPIDEMIOL, V138, P660; CLARKE R, 1992, IRISH J MED SCI, V161, P61, DOI 10.1007/BF02983714; CROUSE JR, 1987, STROKE, V18, P990, DOI 10.1161/01.STR.18.6.990; DAWBER T. R., 1957, AMER JOUR PUBL HEALTH, V47, P4, DOI 10.2105/AJPH.47.4_Pt_2.4; FALKE P, 1989, INT ANGIOL, V8, P175; FINEEDELSTEIN JS, 1994, NEUROLOGY, V44, P1046, DOI 10.1212/WNL.44.6.1046; FURBERG CD, 1993, CIRCULATION S1, V88, P1; HEISS G, 1991, AM J EPIDEMIOL, V134, P250, DOI 10.1093/oxfordjournals.aje.a116078; JACQUES PF, 1993, AM J CLIN NUTR, V57, P182, DOI 10.1093/ajcn/57.2.182; JOOSTEN E, 1993, AM J CLIN NUTR, V58, P468, DOI 10.1093/ajcn/58.4.468; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; MCCULLY KS, 1969, AM J PATHOL, V56, P111; MCNAMARA JR, 1987, CLIN CHIM ACTA, V166, P1, DOI 10.1016/0009-8981(87)90188-4; NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837; O'Leary D H, 1992, Ann Epidemiol, V2, P147, DOI 10.1016/1047-2797(92)90049-V; OLEARY DH, 1992, STROKE, V23, P1752, DOI 10.1161/01.STR.23.12.1752; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RUBBA P, 1990, METABOLISM, V39, P1191, DOI 10.1016/0026-0495(90)90093-R; RUSSELL RM, 1992, AM J CLIN NUTR, V55, P1203; SALONEN JT, 1991, ARTERIOSCLER THROMB, V11, P1245, DOI 10.1161/01.ATV.11.5.1245; SALONEN R, 1988, ARTERIOSCLEROSIS, V8, P788, DOI 10.1161/01.ATV.8.6.788; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; TAMURA T, 1990, CLIN CHEM, V36, P1993; UBBINK JB, 1993, AM J CLIN NUTR, V57, P47, DOI 10.1093/ajcn/57.1.47; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; WARNICK GR, 1982, CLIN CHEM, V28, P1379; 1990, SAS PROCEDURES GUIDE; 1990, MONOGRAPHS EPIDEMIOL, V15, P92	40	1006	1052	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 2	1995	332	5					286	291		10.1056/NEJM199502023320502	http://dx.doi.org/10.1056/NEJM199502023320502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD396	7816063	Bronze			2022-12-24	WOS:A1995QD39600002
J	PAWLOTSKY, JM; ROUDOTTHORAVAL, F; SIMMONDS, P; MELLOR, J; BENYAHIA, M; ANDRE, C; VOISIN, MC; INTRATOR, L; ZAFRANI, ES; DUVAL, J; DHUMEAUX, D				PAWLOTSKY, JM; ROUDOTTHORAVAL, F; SIMMONDS, P; MELLOR, J; BENYAHIA, M; ANDRE, C; VOISIN, MC; INTRATOR, L; ZAFRANI, ES; DUVAL, J; DHUMEAUX, D			EXTRAHEPATIC IMMUNOLOGICAL MANIFESTATIONS IN CHRONIC HEPATITIS-C AND HEPATITIS-C VIRUS SEROTYPES	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS C; HEPATITIS C VIRUSES; HEPATITIS, CHRONIC ACTIVE; SEROTYPING; CRYOGLOBULINEMIA	ESSENTIAL MIXED CRYOGLOBULINEMIA; POLYMERASE CHAIN-REACTION; INTERFERON-ALPHA THERAPY; INFECTION; GENOTYPES; SEQUENCE; HCV; AUTOANTIBODIES; REGION; TYPE-1	Objective: To determine, using a serotyping assay, whether the occurrence of extrahepatic immunologic disorders in patients with chronic hepatitis C is dependent on hepatitis C virus serotype. II Design: Prospective study. Setting: Liver unit and virology laboratory of a university hospital. Patients: 59 consecutive patients with chronic hepatitis C. Measurements: Hepatitis C virus serotype was determined using a recently developed immunoenzymatic assay that detects antibodies directed to serotype-specific immunodominant epitopes. Cryoglobulin, rheumatoid factor, and numerous antitissue antibodies were sought. Biopsies of labial salivary glands were done in 49 of the 59 patients. Results: Prevalence was 59% for serotype 1, 10% for serotype 2, 12% for serotype 3, and 3% for mixed infection. Fifteen percent of patients could not be serotyped. Cryoglobulinemia was found in 36% of patients and rheumatoid factor was found in the serum of 71%. At least one antitissue antibody was found in the serum of 41% of patients; salivary gland biopsy showed lymphocytic capillaritis in 49% of patients. These immunologic abnormalities were seen in patients infected with any of the three serotypes, and prevalences of the abnormalities did not differ significantly among patients infected with different serotypes. Conclusions: We confirm that the prevalence of extrahepatic immunologic abnormalities is high in patients with chronic hepatitis C. These abnormalities may occur in patients infected with any of the three major hepatitis C virus serotypes now present in developed countries.	UNIV PARIS 12, CRETEIL, FRANCE; UNIV EDINBURGH, DEPT MED MICROBIOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND	Universite Paris-Est-Creteil-Val-de-Marne (UPEC); University of Edinburgh			Pawlotsky, Jean-Michel/R-8159-2018	Simmonds, Peter/0000-0002-7964-4700; Pawlotsky, Jean-Michel/0000-0003-0745-7559				ABUAF N, 1993, J HEPATOL, V18, P359, DOI 10.1016/S0168-8278(05)80281-8; AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; ALONSO C, 1994, J CLIN MICROBIOL, V32, P211, DOI 10.1128/JCM.32.1.211-212.1994; AUTHIER FJ, 1993, ANN NEUROL, V34, P749, DOI 10.1002/ana.410340524; BRECHOT C, 1993, J HEPATOL, V17, P265, DOI 10.1016/S0168-8278(05)80203-X; BUKH J, 1993, P NATL ACAD SCI USA, V90, P8234, DOI 10.1073/pnas.90.17.8234; CHA TA, 1992, P NATL ACAD SCI USA, V89, P7144, DOI 10.1073/pnas.89.15.7144; CHAN SW, 1992, J GEN VIROL, V73, P1131, DOI 10.1099/0022-1317-73-5-1131; CHEMELLO L, 1994, NEW ENGL J MED, V330, P143, DOI 10.1056/NEJM199401133300215; CHISHOLM DM, 1968, J CLIN PATHOL, V21, P656, DOI 10.1136/jcp.21.5.656; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CZAJA AJ, 1992, GASTROENTEROLOGY, V103, P1290, DOI 10.1016/0016-5085(92)91518-9; DAMMACCO F, 1992, CLIN EXP IMMUNOL, V87, P352, DOI 10.1111/j.1365-2249.1992.tb03001.x; ENOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021, DOI 10.1016/0006-291X(90)90494-8; FERAY C, 1993, HEPATOLOGY, V18, pA59, DOI 10.1016/0270-9139(93)91763-I; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P621; GEROLAMI V, 1993, J INFECT DIS, V168, P1328, DOI 10.1093/infdis/168.5.1328; HIJIKATA M, 1993, J VIROL, V67, P1953, DOI 10.1128/JVI.67.4.1953-1958.1993; JOHNSON RJ, 1993, NEW ENGL J MED, V328, P465, DOI 10.1056/NEJM199302183280703; JUBERT C, 1994, ARCH DERMATOL, V130, P73, DOI 10.1001/archderm.130.1.73; LENZI M, 1990, LANCET, V335, P258, DOI 10.1016/0140-6736(90)90070-L; LI JS, 1991, GENE, V105, P167; LUNEL F, 1994, GASTROENTEROLOGY, V106, P1291, DOI 10.1016/0016-5085(94)90022-1; LUNEL F, 1992, HEPATOLOGY, V16, P630, DOI 10.1002/hep.1840160304; MAGRIN S, 1991, J HEPATOL, V13, P364, DOI 10.1016/0168-8278(91)90082-M; MANNS MP, 1991, J CLIN INVEST, V88, P1370, DOI 10.1172/JCI115443; MARCELLIN P, 1993, GASTROENTEROLOGY, V104, P272, DOI 10.1016/0016-5085(93)90862-7; MCOMISH F, 1993, TRANSFUSION, V33, P7, DOI 10.1046/j.1537-2995.1993.33193142314.x; MCOMISH F, 1994, J CLIN MICROBIOL, V32, P884, DOI 10.1128/JCM.32.4.884-892.1994; MICHEL G, 1992, LANCET, V339, P267, DOI 10.1016/0140-6736(92)91332-3; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; NOUSBAUM JB, 1993, HEPATOLOGY, V18, pA88; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1993, J GEN VIROL, V74, P2385, DOI 10.1099/0022-1317-74-11-2385; PAWLOTSKY JM, 1994, HEPATOLOGY, V19, P841, DOI 10.1016/0270-9139(94)90281-X; PAWLOTSKY JM, 1993, GUT, V34, pS66, DOI 10.1136/gut.34.2_Suppl.S66; PISTELLO M, 1994, J CLIN MICROBIOL, V32, P232, DOI 10.1128/JCM.32.1.232-234.1994; ROITT IM, 1972, WHO BOOKLET IMMUNOLO, P1; SIMMONDS P, 1993, J GEN VIROL, V74, P661, DOI 10.1099/0022-1317-74-4-661; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; SIMMONDS P, 1993, J CLIN MICROBIOL, V31, P1493, DOI 10.1128/JCM.31.6.1493-1503.1993; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TAKADA N, 1993, J HEPATOL, V17, P277, DOI 10.1016/S0168-8278(05)80205-3; TRAN A, 1993, HEPATOLOGY, V18, P253, DOI 10.1002/hep.1840180205; YAMAMOTO AM, 1993, GASTROENTEROLOGY, V104, P1762, DOI 10.1016/0016-5085(93)90657-X; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203	48	317	324	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1995	122	3					169	173		10.7326/0003-4819-122-3-199502010-00002	http://dx.doi.org/10.7326/0003-4819-122-3-199502010-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD733	7810933				2022-12-24	WOS:A1995QD73300002
J	SOYSETH, V; KONGERUD, J; HAARR, D; STRAND, O; BOLLE, R; BOE, J				SOYSETH, V; KONGERUD, J; HAARR, D; STRAND, O; BOLLE, R; BOE, J			RELATION OF EXPOSURE TO AIRWAY IRRITANTS IN INFANCY TO PREVALENCE OF BRONCHIAL HYPERRESPONSIVENESS IN SCHOOLCHILDREN	LANCET			English	Article							INHALED HISTAMINE; ASTHMA; CHILDREN; SYMPTOMS	To find out whether exposure to sulphur dioxide during infancy is related to the prevalence of bronchial hyperresponsiveness (BHR), we studied schoolchildren (aged 7-13 years) from two areas of Norway-a Valley containing a sulphur-dioxide-emitting aluminium smelter and a similar but non-industrialised valley. Bronchial responsiveness was assessed in 529 of the 620 participants. The median exposures to sulphur dioxide and fluoride were 37.1 mu g/m(3) and 4.4 mu g/m(3) at ages 0-12 months and 37.9 mu g/m(3) and 4.4 mu g/m(3) at 13-36 months. The risk of BHR increased with exposure to sulphur dioxide and fluoride at these ages; the odds ratio for a 10 mu g/m(3) increase in sulphur dioxide exposure at 0-12 months was 1.62 (95% CI 1.11-2.35) and that for a 1 mu g/m(3) increase in fluoride exposure was 1.35 (1.07-1.70) at 0-12 months and 1.38 (1.05-1.82) at 13-36 months. Exposure to these low concentrations of airway irritants during early childhood is associated with an increased prevalence of BHR in schoolchildren.	UNIV OSLO, RIKSHOSP, DEPT THORAC MED, N-0027 OSLO, NORWAY; ARDAL MUNICIPAL, PRIMARY HLTH CARE UNIT, ARDALSTANGEN, NORWAY; REG HOSP, DEPT PAEDIAT, TROMSO, NORWAY	University of Oslo; National Hospital Norway	SOYSETH, V (corresponding author), HYDRO ALUMINIUM ARDAL, N-5870 OVRE ARDAL, NORWAY.							ANDERSON HR, 1989, ARCH DIS CHILD, V64, P172, DOI 10.1136/adc.64.1.172; ANDRAE S, 1988, ARCH DIS CHILD, V63, P473, DOI 10.1136/adc.63.5.473; [Anonymous], 1985, THEORETICAL EPIDEMIO; BELIN L, 1985, ALLERGY S4, V40, P60; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COTES JE, 1979, LUNG FUNCTION, P340; DAVIES RJ, 1993, AGENT ACTION SUPPL, V43, P87; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; DODGE R, 1985, AM J EPIDEMIOL, V121, P720, DOI 10.1093/aje/121.5.720; ERNST P, 1986, AM REV RESPIR DIS, V133, P307; FERRIS BG, 1988, EPIDEMIOLOGY HLTH RI, P120; Hosmer D., 1989, APPL LOGISTIC REGRES, P82; KONGERUD J, 1991, EUR RESPIR J, V4, P159; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; LESOUEF PN, 1989, AM REV RESPIR DIS, V139, P62, DOI 10.1164/ajrccm/139.1.62; MANTEL N, 1959, J NATL CANCER I, V22, P719; PEAT JK, 1987, CLIN ALLERGY, V17, P283, DOI 10.1111/j.1365-2222.1987.tb02016.x; ROBINS JM, 1986, BIOMETRICS, V68, P525; RONNEBERG A, 1994, INT J EPIDEMIOL, V23, P267, DOI 10.1093/ije/23.2.267; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P84; SHEPPARD D, 1988, J ALLERGY CLIN IMMUN, V82, P961, DOI 10.1016/0091-6749(88)90131-5; SOYSETH V, IN PRESS CHEST; STEENJOHNSEN J, 1993, NOR J EPIDEMIOL, V3, P44; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; WEINBERG CR, 1993, AM J EPIDEMIOL, V137, P1	25	40	40	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	1995	345	8944					217	220		10.1016/S0140-6736(95)90222-8	http://dx.doi.org/10.1016/S0140-6736(95)90222-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823714				2022-12-24	WOS:A1995QD53200008
J	BECK, KD; VALVERDE, J; ALEXI, T; POULSEN, K; MOFFAT, B; VANDLEN, RA; ROSENTHAL, A; HEFTI, F				BECK, KD; VALVERDE, J; ALEXI, T; POULSEN, K; MOFFAT, B; VANDLEN, RA; ROSENTHAL, A; HEFTI, F			MESENCEPHALIC DOPAMINERGIC-NEURONS PROTECTED BY GDNF FROM AXOTOMY-INDUCED DEGENERATION IN THE ADULT BRAIN	NATURE			English	Article							NEUROTROPHIC FACTOR PREVENTS; FIBROBLAST GROWTH-FACTOR; MOTOR NEURONS; IN-VIVO; FIMBRIAL TRANSECTIONS; MOTONEURONS; SURVIVAL; SYSTEM; DEATH; PROMOTES	GLIAL-CELL-LINE-DERIVED neurotrophic factor (GDNF) promotes survival of embryonic dopaminergic neurons in culture(1), and its expression pattern suggests a role as a transient target-derived trophic factor for dopaminergic neurons of the substantia nigra(2-4). These neurons participate in the control of motor activity, emotional status and cognition(5), and they degenerate in Parkinson's disease for unknown reasons. To test whether GDNF has a trophic effect on dopaminergic neurons in the adult brain, we used a rat model in which these neurons are induced to degenerate by transecting their axons within the medial forebrain bundle(6). We report here that axotomy resulted in loss of half the tyrosine hydroxylase-expressing neurons in the substantia nigra. This loss was largely prevented by repeated injections of GDNF adjacent to the substantia nigra. Our findings suggest that GDNF or related molecules may be useful for the treatment of Parkinson's disease.	GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; UNIV SO CALIF,ETHEL PERCY ANDRUS GERONTOL CTR,LOS ANGELES,CA 90089	Roche Holding; Genentech; Roche Holding; Genentech; University of Southern California	BECK, KD (corresponding author), GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080, USA.							ALEXI T, 1993, NEUROSCIENCE, V55, P903, DOI 10.1016/0306-4522(93)90307-2; ARAUJO DM, 1993, J NEUROCHEM, V61, P899, DOI 10.1111/j.1471-4159.1993.tb03601.x; Bjorklund A, 1984, HDB CHEM NEUROANATOM, P55; CLATTERBUCK RE, 1993, P NATL ACAD SCI USA, V90, P2222, DOI 10.1073/pnas.90.6.2222; CUMMINGS BJ, 1992, BRAIN RES, V591, P271, DOI 10.1016/0006-8993(92)91707-L; GROTHE C, 1992, J NEUROSCI RES, V32, P317, DOI 10.1002/jnr.490320304; HAGG T, 1993, P NATL ACAD SCI USA, V90, P6315, DOI 10.1073/pnas.90.13.6315; HAGG T, 1994, SOC NEUR ABS, V20; HEFTI F, 1986, J NEUROSCI, V6, P2155; HUGHES RA, 1993, J NEUROSCI RES, V36, P663, DOI 10.1002/jnr.490360607; HYNES MA, 1994, J NEUROSCI RES, V37, P144, DOI 10.1002/jnr.490370118; KNUSEL B, 1990, J NEUROSCI, V10, P558; KNUSEL B, 1992, J NEUROSCI, V12, P4391; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; OTTO D, 1990, J NEUROSCI, V10, P1912; POULSEN KT, 1994, NEURON, V13, P1245, DOI 10.1016/0896-6273(94)90062-0; SCHAAR DG, 1993, EXP NEUROL, V124, P368, DOI 10.1006/exnr.1993.1207; SCHMIDTKASTNER R, 1994, MOL BRAIN RES, V26, P325, DOI 10.1016/0169-328X(94)90106-6; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; STROMBERG I, 1993, EXP NEUROL, V124, P401, DOI 10.1006/exnr.1993.1214; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YAN Q, 1993, J NEUROBIOL, V24, P1555, DOI 10.1002/neu.480241202	24	612	654	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					339	341		10.1038/373339a0	http://dx.doi.org/10.1038/373339a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830767				2022-12-24	WOS:A1995QD40400058
J	NADEAU, JH; GRANT, PL; MANKALA, S; REINER, AH; RICHARDSON, JE; EPPIG, JT				NADEAU, JH; GRANT, PL; MANKALA, S; REINER, AH; RICHARDSON, JE; EPPIG, JT			A ROSETTA-STONE OF MAMMALIAN GENETICS	NATURE			English	Article							MAP	Mammalian Comparative Database provides genetic maps of mammalian species. Comparative maps are valuable aids for predicting linkages, developing animal models and studying genome organization and evolution.	LINNEAN TECHNOL,ENFIELD,NH 03748		NADEAU, JH (corresponding author), JACKSON LAB,BAR HARBOR,ME 04609, USA.							[Anonymous], 1994, MOUSE GENOME DATABAS; ARCHIBALD AL, 1994, CURR OPIN GENET DEV, V4, P395, DOI 10.1016/0959-437X(94)90027-2; BROAD TE, 1994, BRIT VET J, V150, P237, DOI 10.1016/S0007-1935(05)80004-1; Castle WE, 1924, GENETICS, V9, P1; CHAPMAN VM, 1993, MAMM GENOME, V4, pS1; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; EPPIG JT, IN PRESS MAMMAL GENO; HETZEL J, 1993, NAT GENET, V4, P327, DOI 10.1038/ng0893-327; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; NADEAU JH, 1992, MAMM GENOME, V3, P480, DOI 10.1007/BF00778825; OBRIEN SJ, 1993, GENETIC MAPS	11	25	25	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					363	365		10.1038/373363a0	http://dx.doi.org/10.1038/373363a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830773				2022-12-24	WOS:A1995QD40400066
J	WACHTER, RM; LUCE, JM; SAFRIN, S; BERRIOS, DC; CHARLEBOIS, E; SCITOVSKY, AA				WACHTER, RM; LUCE, JM; SAFRIN, S; BERRIOS, DC; CHARLEBOIS, E; SCITOVSKY, AA			COST AND OUTCOME OF INTENSIVE-CARE FOR PATIENTS WITH AIDS, PNEUMOCYSTIS-CARINII PNEUMONIA, AND SEVERE RESPIRATORY-FAILURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; MECHANICAL VENTILATION; VIRUS INFECTION; CONTROLLED TRIAL; TERM SURVIVAL; MEDICAL-CARE; HIV; CORTICOSTEROIDS; PATTERNS; THERAPY	Objective.-To determine the costs and outcomes associated with intensive care unit (ICU) admission for patients with acquired immunodeficiency syndrome (AIDS)-related Pneumocystis carinii pneumonia (PCP), and severe respiratory failure. Design.-Survival and cost-effectiveness analysis. Setting.-A large municipal teaching hospital serving an indigent population. Patients.-Consecutive patients intubated and mechanically ventilated for AIDS, PCP, and respiratory failure from 1981 through 1991 (n=113). The cohort was separated into three groups for analysis: patients admitted to the ICU in 1981 through 1985 (era I, n=43), those admitted in 1986 through 1988 (era II, n=33), and those admitted in 1989 through 1991 (era III, n=37). Main Outcome Measures.-Hospital charges and survival time; cost per year of life saved, using a zero-cost, zero-life assumption. Results.-Twenty-eight (25%) of the 113 patients mechanically ventilated for PCP and respiratory failure survived to hospital discharge: six (14%) of 43 in era I, 13 (39%) of 33 in era II, and nine (24%) of 37 in era III (P=.04). Post-ICU admission charges averaged $57 874 for the entire cohort, remaining relatively stable across the three eras. Cost of care for survivors was significantly more expensive than for those dying before discharge. The cost of ICU admission and subsequent hospitalization averaged $174 781 per year of life saved; $305 795 in era 1, $94 528 in era II, and $215 233 in era III. Improved survival rates and shorter lengths of ICU stay led to the improved cost-effectiveness in era II, while the opposite trends resulted in worsening cost-effectiveness in recent years. The strongest predictors of hospital mortality in era III were low CD4 cell counts on hospital admission and the development of pneumothorax during mechanical ventilation. Conclusions.-The cost-effectiveness of intensive care for patients with PCP and severe respiratory failure improved during the first 8 years of the AIDS epidemic but fell in recent years such that it is now below that of many accepted medical interventions.	UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOSTAT & EPIDEMIOL,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,MED CTR,MED SERV,SAN FRANCISCO,CA 94110; PALO ALTO MED FDN,DIV HLTH ECON,PALO ALTO,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; Palo Alto Medical Foundation Research Institute	WACHTER, RM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,BOX 0862,SAN FRANCISCO,CA 94143, USA.							ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; BAGGOTT LA, 1987, CHEST S, V92; BENNETT CL, 1991, J ACQ IMMUN DEF SYND, V4, P197; BENNETT CL, 1990, ARCH INTERN MED, V150, P1447, DOI 10.1001/archinte.150.7.1447; BENNETT RL, 1993, J ACQ IMMUN DEF SYND, V6, P1319; BONE RC, 1991, ARCH INTERN MED, V151, P1061, DOI 10.1001/archinte.151.6.1061; BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; BOZZETTE SA, 1992, CHEST, V101, P1404, DOI 10.1378/chest.101.5.1404; CALLAHAN D, 1991, J AM GERIATR SOC, V39, P622, DOI 10.1111/j.1532-5415.1991.tb03605.x; CLEMENT M, 1989, American Review of Respiratory Disease, V139, pA250; CURTIS JR, 1994, AM J RESP CRIT CARE, V150, P1305, DOI 10.1164/ajrccm.150.5.7952557; DANIELS N, 1991, JAMA-J AM MED ASSOC, V265, P2232, DOI 10.1001/jama.265.17.2232; DOHN MN, 1992, ARCH INTERN MED, V152, P2465, DOI 10.1001/archinte.152.12.2465; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2493, DOI 10.1001/jama.263.18.2493; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; EFFEREN LS, 1989, AM J MED, V87, P401, DOI 10.1016/S0002-9343(89)80821-6; ELSADR W, 1988, AM REV RESPIR DIS, V137, P1264, DOI 10.1164/ajrccm/137.6.1264; ENGELHARDT HT, 1986, JAMA-J AM MED ASSOC, V255, P1159, DOI 10.1001/jama.255.9.1159; FREEDBERG KA, 1991, J ACQ IMMUN DEF SYND, V4, P521; FRIEDMAN Y, 1989, CHEST, V96, P862, DOI 10.1378/chest.96.4.862; FRIEDMAN Y, 1991, JAMA-J AM MED ASSOC, V266, P89, DOI 10.1001/jama.266.1.89; GACHOT B, 1992, INTENS CARE MED, V18, P155, DOI 10.1007/BF01709239; GAGNON S, 1990, NEW ENGL J MED, V323, P1444, DOI 10.1056/NEJM199011223232103; GARAY S, 1986, AM REV RESPIR DIS, V133, pA344; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HARDY AM, 1986, JAMA-J AM MED ASSOC, V255, P209, DOI 10.1001/jama.255.2.209; HARRIS JE, 1990, JAMA-J AM MED ASSOC, V263, P397, DOI 10.1001/jama.263.3.397; HAWLEY PH, 1994, CHEST, V106, P1456, DOI 10.1378/chest.106.5.1456; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HOPEWELL PC, 1988, J INFECT DIS, V157, P1115, DOI 10.1093/infdis/157.6.1115; JACOBSON LP, 1993, AM J EPIDEMIOL, V138, P952, DOI 10.1093/oxfordjournals.aje.a116815; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Levine M E, 1989, Crit Care Nurs Q, V12, P82; LEVINSKY NG, 1984, NEW ENGL J MED, V311, P1573, DOI 10.1056/NEJM198412133112412; LEVINSKY NG, 1993, NEW ENGL J MED, V329, P1395, DOI 10.1056/NEJM199311043291907; MANDELBLATT JS, 1988, JAMA-J AM MED ASSOC, V259, P2409, DOI 10.1001/jama.259.16.2409; MONTANER JSG, 1990, ANN INTERN MED, V113, P14, DOI 10.7326/0003-4819-113-1-14; MONTANER JSG, 1989, CHEST, V95, P881, DOI 10.1378/chest.95.4.881; MONTANER JSG, 1992, CHEST, V102, P1823, DOI 10.1378/chest.102.6.1823; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; OSMOND D, 1994, JAMA-J AM MED ASSOC, V271, P1083, DOI 10.1001/jama.271.14.1083; OYE RK, 1991, CHEST, V99, P685, DOI 10.1378/chest.99.3.685; PEAR R, 1993, NY TIMES        0320, P11; PERUZZI WT, 1991, CRIT CARE MED, V19, P892, DOI 10.1097/00003246-199107000-00012; PETERS BS, 1991, BRIT MED J, V302, P203, DOI 10.1136/bmj.302.6770.203; RELMAN AS, 1990, NEW ENGL J MED, V323, P911, DOI 10.1056/NEJM199009273231310; ROGERS PL, 1989, CRIT CARE MED, V17, P113, DOI 10.1097/00003246-198902000-00001; ROSEN MJ, 1986, J INTENSIVE CARE MED, V1, P55; SCHAPIRA DV, 1993, JAMA-J AM MED ASSOC, V269, P783, DOI 10.1001/jama.269.6.783; SCHEIN RMH, 1986, CRIT CARE MED, V14, P1026, DOI 10.1097/00003246-198612000-00006; SCHULMAN KA, 1991, ANN INTERN MED, V114, P798, DOI 10.7326/0003-4819-114-9-798; SCITOVSKY AA, 1986, JAMA-J AM MED ASSOC, V256, P3103, DOI 10.1001/jama.256.22.3103; SCITOVSKY AA, 1989, MILBANK Q, V67, P318, DOI 10.2307/3350143; SMITH RL, 1989, CHEST, V96, P857, DOI 10.1378/chest.96.4.857; Sonnefeld S T, 1991, Health Care Financ Rev, V13, P1; STAIKOWSKY F, 1993, CHEST, V104, P756, DOI 10.1378/chest.104.3.756; STEIN M, 1992, AM J MED, V93, P387, DOI 10.1016/0002-9343(92)90167-A; STEINBROOK R, 1986, NEW ENGL J MED, V314, P457, DOI 10.1056/NEJM198602133140730; STOVER DE, 1985, AM J MED, V78, P429, DOI 10.1016/0002-9343(85)90334-1; STRAUSS MJ, 1986, JAMA-J AM MED ASSOC, V255, P1143, DOI 10.1001/jama.255.9.1143; TOBIN MJ, 1994, NEW ENGL J MED, V330, P1056, DOI 10.1056/NEJM199404143301507; TUCKER KJ, 1992, WESTERN J MED, V157, P637; UDVARHELYI IS, 1992, ANN INTERN MED, V116, P238, DOI 10.7326/0003-4819-116-3-238; WACHTER RM, 1988, ARCH INTERN MED, V148, P149, DOI 10.1001/archinte.148.1.149; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; WACHTER RM, 1991, AM REV RESPIR DIS, V143, P251, DOI 10.1164/ajrccm/143.2.251; WACHTER RM, 1986, AM REV RESPIR DIS, V134, P891, DOI 10.1164/arrd.1986.134.5.891; WACHTER RM, 1992, JAMA-J AM MED ASSOC, V267, P541, DOI 10.1001/jama.267.4.541; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184; 1991, PRIORITIZATION HLTH	73	81	82	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					230	235		10.1001/jama.273.3.230	http://dx.doi.org/10.1001/jama.273.3.230			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807663				2022-12-24	WOS:A1995QB23400028
J	GOSDEN, CM				GOSDEN, CM			WHEN AMNIOTIC-FLUID CELLS DO NOT GROW	LANCET			English	Editorial Material							FETAL				GOSDEN, CM (corresponding author), UNIV LIVERPOOL,DEPT OBSTET & GYNAECOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							GOSDEN C, 1978, J MED GENET, V15, P262, DOI 10.1136/jmg.15.4.262; MARTEAU TM, 1992, PRENATAL DIAG, V12, P205, DOI 10.1002/pd.1970120309; NICOLAIDES KH, 1992, LANCET, V340, P704, DOI 10.1016/0140-6736(92)92240-G	3	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					78	78		10.1016/S0140-6736(95)90058-6	http://dx.doi.org/10.1016/S0140-6736(95)90058-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815884				2022-12-24	WOS:A1995QB80400005
J	CHEN, JH; RAUCH, CA; WHITE, JH; ENGLUND, PT; COZZARELLI, NR				CHEN, JH; RAUCH, CA; WHITE, JH; ENGLUND, PT; COZZARELLI, NR			THE TOPOLOGY OF THE KINETOPLAST DNA NETWORK	CELL			English	Article							LEISHMANIA-TARENTOLAE; TRYPANOSOMA-BRUCEI; REPLICATION; MINICIRCLES; HYBRIDIZATION; CATENANES; PROTEIN; GYRASE	Kinetoplast DNA (kDNA) of trypanosomatid parasites is a network of similar to 5000 catenated DNA minicircles and similar to 25 maxicircles. We developed the following strategy to deduce the topological linkage of the minicircles of the Crithidia fasciculata network. First, we used graph theory to provide precise models of possible network structures. Second, on the basis of these models, we predicted the frequencies of minicircle oligomers expected from random network breakage. Third, we determined the fragmentation pattern of kDNA networks as a function of the extent of digestion. Fourth, by comparison of the results with the predictions, we identified the model that best represents the network. We conclude that each minicircle is linked on average to three other minicircles. A honeycomb arrangement probably results, with each minicircle typically at the vertex of a hexagonal cell. This topology has implications for the assembly, structure, and function of kDNA networks.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; UNIV CALIF LOS ANGELES, DEPT MATH, LOS ANGELES, CA 90024 USA	Johns Hopkins University; University of California System; University of California Los Angeles	CHEN, JH (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, 229 STANLEY HALL, BERKELEY, CA 94720 USA.		Chen, Junghuei/B-5217-2011		NIEHS NIH HHS [ES01896-15] Funding Source: Medline; NIGMS NIH HHS [GM31657, GM27608] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027608, R01GM027608, R37GM031657, R01GM031657] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORST P, 1980, BIOCHIM BIOPHYS ACTA, V610, P197, DOI 10.1016/0005-2787(80)90001-5; BORST P, 1979, PLASMID, V2, P20, DOI 10.1016/0147-619X(79)90003-9; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; FERGUSON ML, 1994, J CELL BIOL, V126, P631, DOI 10.1083/jcb.126.3.631; GIBSON W, 1990, MOL BIOCHEM PARASIT, V42, P45, DOI 10.1016/0166-6851(90)90111-X; HAJDUK SL, 1984, CELL, V36, P483, DOI 10.1016/0092-8674(84)90241-1; HAJDUK SL, 1986, MOL CELL BIOL, V6, P4372, DOI 10.1128/MCB.6.12.4372; HOEIJMAKERS JHJ, 1980, PLASMID, V4, P97, DOI 10.1016/0147-619X(80)90086-4; KRASNOW MA, 1983, NATURE, V304, P559, DOI 10.1038/304559a0; KREUZER KN, 1980, CELL, V20, P245, DOI 10.1016/0092-8674(80)90252-4; MARINI JC, 1980, J BIOL CHEM, V255, P4976; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; MOREL C, 1980, P NATL ACAD SCI-BIOL, V77, P6810, DOI 10.1073/pnas.77.11.6810; PEREZMORGA D, 1993, J CELL BIOL, V123, P1069, DOI 10.1083/jcb.123.5.1069; RAUCH CA, 1991, THESIS JOHNS HOPKINS; RAUCH GA, 1991, EMBO J, V12, P403; RAY DS, 1987, PLASMID, V17, P177, DOI 10.1016/0147-619X(87)90026-6; RENGER HC, 1972, J CELL BIOL, V54, P346, DOI 10.1083/jcb.54.2.346; RYAN KA, 1988, ANNU REV MICROBIOL, V42, P339, DOI 10.1146/annurev.mi.42.100188.002011; SIMPSON L, 1974, J PROTOZOOL, V21, P382, DOI 10.1111/j.1550-7408.1974.tb03675.x; SIMPSON L, 1971, J MOL BIOL, V56, P443, DOI 10.1016/0022-2836(71)90394-9; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; STUART K, 1992, INT REV CYTOL, V141, P65, DOI 10.1016/S0074-7696(08)62063-X; SUGISAKI H, 1987, MOL BIOCHEM PARASIT, V23, P253, DOI 10.1016/0166-6851(87)90032-6; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; THRESHER RJ, 1990, P NATL ACAD SCI USA, V87, P5056, DOI 10.1073/pnas.87.13.5056; WILLIAMS RC, 1977, P NATL ACAD SCI USA, V74, P2311, DOI 10.1073/pnas.74.6.2311; WIRTH DF, 1982, P NATL ACAD SCI-BIOL, V79, P6999, DOI 10.1073/pnas.79.22.6999	29	119	119	1	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 13	1995	80	1					61	69		10.1016/0092-8674(95)90451-4	http://dx.doi.org/10.1016/0092-8674(95)90451-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813018	hybrid			2022-12-24	WOS:A1995QB91000010
J	DAI, XC; DEMESMAEKER, A; JOYCE, GF				DAI, XC; DEMESMAEKER, A; JOYCE, GF			CLEAVAGE OF AN AMIDE BOND BY A RIBOZYME	SCIENCE			English	Article							TETRAHYMENA RIBOZYME; RNA WORLD; CATALYSIS; BINDING; EVOLUTION; SUBSTRATE; SEQUENCE; ANTIBODY; ENZYME; ORIGIN	A variant form of a group I ribozyme, optimized by in vitro evolution for its ability to catalyze magnesium-dependent phosphoester transfer reactions involving DNA substrates, also catalyzes the cleavage of an unactivated alkyl amide when that linkage is presented in the context of an oligodeoxynucleotide analog. Substrates containing an amide bond that joins either two DNA oligos, or a DNA oligo and a short peptide, are cleaved in a magnesium-dependent fashion to generate the expected products. The first-order rate constant, k(cat), is 0.1 x 10(-5) min(-1) to 1 x 10(-5) min(-1) for the DNA-flanked substrates, which corresponds to a rate acceleration of more than 10(3) as compared with the uncatalyzed reaction.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA; CIBA GEIGY LTD, CENT RES LABS, BASEL, SWITZERLAND	Scripps Research Institute; Scripps Research Institute; Novartis								BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; BENKOVIC SJ, 1990, SCIENCE, V250, P1135, DOI 10.1126/science.2251500; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; BREAKER RR, 1994, TRENDS BIOTECHNOL, V12, P268, DOI 10.1016/0167-7799(94)90138-4; CECH TR, 1992, J BIOL CHEM, V267, P17479; CHAPMAN KB, 1994, CURR OPIN STRUC BIOL, V4, P618, DOI 10.1016/S0959-440X(94)90227-5; EHLER KW, 1976, BIOCHIM BIOPHYS ACTA, V434, P233, DOI 10.1016/0005-2795(76)90055-6; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8299, DOI 10.1021/bi00083a034; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; IVERSON BL, 1989, SCIENCE, V243, P1184, DOI 10.1126/science.2922606; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; JOYCE GF, 1994, CURR OPIN STRUC BIOL, V4, P331, DOI 10.1016/S0959-440X(94)90100-7; KAHNE D, 1988, J AM CHEM SOC, V110, P7529, DOI 10.1021/ja00230a041; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LEBRETON J, 1993, TETRAHEDRON LETT, V34, P6383, DOI 10.1016/0040-4039(93)85051-W; MARTIN MT, 1994, J AM CHEM SOC, V116, P6508, DOI 10.1021/ja00094a003; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, NATURE, V353, P302, DOI 10.1038/353302a0; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PRUDENT JR, 1994, SCIENCE, V264, P1924; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; RAILLARD SA, UNPUB; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; TSANG J, 1994, BIOCHEMISTRY-US, V33, P5966, DOI 10.1021/bi00185a038; TSANG JC, UNPUB; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; YAMANA T, 1972, CHEM PHARM BULL, V20, P881; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZIEBOLL G, 1994, J MOL EVOL, V38, P561	35	91	108	0	15	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 13	1995	267	5195					237	240		10.1126/science.7809628	http://dx.doi.org/10.1126/science.7809628			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809628				2022-12-24	WOS:A1995QB15300035
J	MATSUFUJI, S; MATSUFUJI, T; MIYAZAKI, Y; MURAKAMI, Y; ATKINS, JF; GESTELAND, RF; HAYASHI, S				MATSUFUJI, S; MATSUFUJI, T; MIYAZAKI, Y; MURAKAMI, Y; ATKINS, JF; GESTELAND, RF; HAYASHI, S			AUTOREGULATORY FRAMESHIFTING IN DECODING MAMMALIAN ORNITHINE DECARBOXYLASE ANTIZYME	CELL			English	Article							RELEASE FACTOR-II; MESSENGER-RNA; INHIBITORY PROTEIN; GENE-EXPRESSION; RAT-LIVER; POLYAMINES; DEGRADATION; CELLS; PSEUDOKNOT; SEQUENCE	Rat antizyme gene expression requires programmed, ribosomal frameshifting. A novel autoregulatory mechanism enables modulation of frameshifting according to the cellular concentration of polyamines. Antizyme binds to, and destabilizes, ornithine decarboxylase, a key enzyme in polyamine synthesis, Rapid degradation ensues, thus completing a regulatory circuit. In vitro experiments with a fusion construct using reticulocyte lysates demonstrate polyamine-dependent expression with a frameshift efficiency of 19% at the optimal concentration of spermidine. The frameshift is +1 and occurs at the codon just preceding the terminator of the initiating frame. Both the termination codon of the initiating frame and a pseudoknot downstream in the mRNA have a stimulatory effect. The shift site sequence, UCC-UGA-U, is not similar to other known frameshift sites. The mechanism does not seem to involve re-pairing of peptidyl-tRNA in the new frame but rather reading or occlusion of a fourth base.	UNIV UTAH, DEPT HUMAN GENET, SALT LAKE CITY, UT 84112 USA; JIKEI UNIV, SCH MED, DEPT NUTR, MINATO KU, TOKYO 105, JAPAN	Utah System of Higher Education; University of Utah; Jikei University	MATSUFUJI, S (corresponding author), UNIV UTAH, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84112 USA.			Atkins, John/0000-0001-7933-0165	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048152] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM48152] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLQUIST P, 1981, J MOL BIOL, V153, P23, DOI 10.1016/0022-2836(81)90524-6; Atkins J. F., 1995, P471; ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; ATKINS JF, 1975, J BIOL CHEM, V250, P5688; BALASUNDARAM D, 1994, P NATL ACAD SCI USA, V91, P172, DOI 10.1073/pnas.91.1.172; BRAULT V, 1992, P NATL ACAD SCI USA, V89, P2262, DOI 10.1073/pnas.89.6.2262; BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4; CHAMORRO M, 1992, P NATL ACAD SCI USA, V89, P713, DOI 10.1073/pnas.89.2.713; CRAIGEN WJ, 1986, NATURE, V322, P273, DOI 10.1038/322273a0; CURRAN JF, 1988, J MOL BIOL, V203, P75, DOI 10.1016/0022-2836(88)90092-7; FARABAUGH PJ, 1993, CELL, V74, P93, DOI 10.1016/0092-8674(93)90297-4; FONG WF, 1976, BIOCHIM BIOPHYS ACTA, V428, P456, DOI 10.1016/0304-4165(76)90054-4; GESTELAND RF, 1992, ANNU REV BIOCHEM, V45, P747; GORLACH M, 1989, EUR J BIOCHEM, V184, P589, DOI 10.1111/j.1432-1033.1989.tb15054.x; Hayashi S., 1989, ORNITHINE DECARBOXYL, P35; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; HEIDER J, 1992, EMBO J, V11, P3759, DOI 10.1002/j.1460-2075.1992.tb05461.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; ICHIBA T, 1994, BIOCHEM BIOPH RES CO, V200, P1721, DOI 10.1006/bbrc.1994.1651; JANDA M, 1987, VIROLOGY, V158, P259, DOI 10.1016/0042-6822(87)90265-0; KAMEJI T, 1987, J BIOL CHEM, V262, P2427; KITANI T, 1984, J BIOL CHEM, V259, P36; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; MATSUFUJI S, 1990, J BIOCHEM, V107, P87, DOI 10.1093/oxfordjournals.jbchem.a123018; MATSUFUJI S, 1990, J BIOCHEM-TOKYO, V108, P365, DOI 10.1093/oxfordjournals.jbchem.a123207; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MIYAZAKI Y, 1992, GENE, V113, P191, DOI 10.1016/0378-1119(92)90395-6; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1985, BIOCHEM J, V225, P689, DOI 10.1042/bj2250689; MURAKAMI Y, 1985, BIOCHEM J, V226, P893, DOI 10.1042/bj2260893; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PLEIJ CWA, 1985, NUCLEIC ACIDS RES, V13, P1717, DOI 10.1093/nar/13.5.1717; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; ROM E, 1994, P NATL ACAD SCI USA, V91, P9195; RUSSELL DH, 1969, MOL PHARMACOL, V5, P253; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; ten Dam E B, 1990, Virus Genes, V4, P121, DOI 10.1007/BF00678404; TOKUNAGA F, 1994, J BIOL CHEM, V269, P17382; Weiss R B, 1990, Prog Nucleic Acid Res Mol Biol, V39, P159, DOI 10.1016/S0079-6603(08)60626-1; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078	46	421	435	2	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 13	1995	80	1					51	60		10.1016/0092-8674(95)90450-6	http://dx.doi.org/10.1016/0092-8674(95)90450-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813017	Green Published, Bronze			2022-12-24	WOS:A1995QB91000009
J	GRIMES, J; BASAK, AK; ROY, P; STUART, D				GRIMES, J; BASAK, AK; ROY, P; STUART, D			THE CRYSTAL-STRUCTURE OF BLUETONGUE VIRUS VP7	NATURE			English	Article							CORE-LIKE PARTICLES; RESOLUTION; PROTEIN; SURFACE	BLUETONGUE virus (BTV), a representative of the orbivirus genus of the Reoviridae, is considerably larger (at 80 nm across), and structurally more complex, than any virus for which we have comprehensive structural information. Orbiviruses infect mammalian hosts through insect vectors and cause economically important diseases of domesticated animals(1). They possess a segmented double-stranded RNA genome within a capsid composed of four major types of polypeptide chains(1). An outer layer of VP2 and VP5 is removed as the virus enters the target cell, to leave an intact core within the cell. This fore is 70 nm across and composed of 78O copies of VP7 (M(r) 38K) that, as trimers, form 260 'bristly' capsomeres clothing an inner scaffold constructed from VP3 (M(r)103K)(2). We report here the crystal structure of VP7 from BTV serotype 10, which reveals a molecular architecture not seen previously in viral structural proteins. Each subunit consists of two domains, one a beta-sandwich, the other a bundle of alpha-helices, and a short carboxy-terminal arm which might tie trimers together during capsid formation. A concentration of methionine residues at the core of the molecule could provide plasticity, relieving structural mismatches during assembly.	OXFORD CTR MOLEC SCI,OXFORD OX1 3QT,ENGLAND; NERC,INST VIROL & ENVIRONM MICROBIOL,OXFORD OX1 3SR,ENGLAND; UNIV ALABAMA,SCH PUBL HLTH,BIRMINGHAM,AL 35294	University of Oxford; UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); University of Alabama System; University of Alabama Birmingham	GRIMES, J (corresponding author), UNIV OXFORD,MOLEC BIOPHYS LAB,REX RICHARDS BLDG,S PARKS RD,OXFORD OX1 3QU,ENGLAND.			Grimes, Jonathan Mark/0000-0001-9698-0389; Roy, Polly/0000-0001-6535-6911; Stuart, David/0000-0002-3426-4210				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNGER AT, 1992, XPLOR VERSION 3 0; Creighton T.E., 1993, PROTEINS; EATON BT, 1991, VIROLOGY, V180, P687, DOI 10.1016/0042-6822(91)90082-M; FISHER AJ, 1993, NATURE, V361, P176, DOI 10.1038/361176a0; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HEWAT EA, 1992, VIROLOGY, V189, P10, DOI 10.1016/0042-6822(92)90676-G; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES EY, 1991, ISOMORPHOUS REPLACEM, P39; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KNUDSON EL, 1990, VIROLOGY, P1405; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEBLOIS H, 1993, J VIROL, V67, P353, DOI 10.1128/JVI.67.1.353-359.1993; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; McPherson A, 1982, PREPARATION ANAL PRO; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MERTENS PPC, 1993, INFECTION CULICOIDES; OLIVEIRA MA, 1993, STRUCTURE, V1, P51, DOI 10.1016/0969-2126(93)90008-5; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PRASAD BVV, 1992, J VIROL, V66, P2135, DOI 10.1128/JVI.66.4.2135-2142.1992; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROSSMANN MG, 1983, J MOL BIOL, V165, P711, DOI 10.1016/S0022-2836(83)80276-9; ROY R, 1990, BLUETONGUE VIRUS, P43; STUART D, 1993, CURR OPIN STRUC BIOL, V3, P167, DOI 10.1016/S0959-440X(05)80148-4; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WISTOW G, 1983, J MOL BIOL, V170, P175, DOI 10.1016/S0022-2836(83)80232-0	30	137	147	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					167	170		10.1038/373167a0	http://dx.doi.org/10.1038/373167a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816101				2022-12-24	WOS:A1995QB06300064
J	WALKER, P				WALKER, P			CONTROVERSIES IN MANAGEMENT - SHOULD OBSTETRICIANS SEE WOMEN WITH NORMAL PREGNANCIES - OBSTETRICIANS SHOULD BE INCLUDED IN INTEGRATED TEAM CARE .15.	BRITISH MEDICAL JOURNAL			English	Article											WALKER, P (corresponding author), ROYAL FREE HOSP,POND ST,LONDON NW3 2QG,ENGLAND.							STEER PJ, 1992, BRIT J OBSTET GYNAEC, V99, P415; STREET P, 1991, BRIT MED J, V302, P698, DOI 10.1136/bmj.302.6778.698; 1993, CHANGING CHILDBIRTH; 1992, CHANGING CHILDBIRTH	4	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					36	37		10.1136/bmj.310.6971.36	http://dx.doi.org/10.1136/bmj.310.6971.36			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827554	Green Published			2022-12-24	WOS:A1995QB06000031
J	AGGLETON, JP; BLAND, JM; KENTRIDGE, RW; NEAVE, NJ				AGGLETON, JP; BLAND, JM; KENTRIDGE, RW; NEAVE, NJ			HANDEDNESS AND LONGEVITY - ARCHIVAL STUDY OF CRICKETERS	BRITISH MEDICAL JOURNAL			English	Article							LEFT-HANDERS; AGE; PREFERENCE	Objective-To test whether handedness is associated with a change in longevity. Design-Archival survey. Setting-British Isles. Subjects-All first class cricketers born before 1961 whose bowling hand was specified (right, n = 5041; left, n = 1132) in a comprehensive encyclopaedia. Main outcome measures-Bowling hand and life span. Results-Regression analysis of the 5960 players born between 1840 and 1960 (3387 dead, 2573 alive) showed no significant relation between mortality and handedness (P = 0.3). Left handedness was, however, associated with an increased likelihood of death from unnatural causes (P = 0.03, log hazard 0.37, 95% confidence interval 0.04 to 0.70). This effect was especially related to deaths during warfare (P = 0.009, log hazard 0.53, 0.13 to 0.92). Conclusion-Left handedness is not, in general, associated with an increase in mortality.	UNIV DURHAM,DEPT PSYCHOL,DURHAM DH1 3LE,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND	Durham University; St Georges University London			Kentridge, Robert W/A-5430-2008	Kentridge, Robert W/0000-0003-3688-3899; Neave, Nick/0000-0002-5380-4614; Aggleton, John/0000-0002-5573-1308				AGGLETON JP, 1993, J EPIDEMIOL COMMUN H, V47, P206, DOI 10.1136/jech.47.3.206; ANDERSON MG, 1989, NATURE, V341, P112, DOI 10.1038/341112a0; ANNETT M, 1993, PERCEPT MOTOR SKILL, V76, P295, DOI 10.2466/pms.1993.76.1.295; Bailey Philip, 1993, WHOS WHO CRICKETERS; BRYDEN MP, 1977, NEUROPSYCHOLOGIA, V15, P617, DOI 10.1016/0028-3932(77)90067-7; COREN S, 1991, PSYCHOL BULL, V109, P90, DOI 10.1037/0033-2909.109.1.90; COREN S, 1989, AM J PUBLIC HEALTH, V79, P1; COX DR, 1972, J R STAT SOC B, V34, P187; GILBERT AN, 1992, NEUROPSYCHOLOGIA, V30, P601, DOI 10.1016/0028-3932(92)90065-T; HALPERN DF, 1988, NATURE, V333, P213, DOI 10.1038/333213b0; HARRIS LJ, 1993, PSYCHOL BULL, V114, P203, DOI 10.1037/0033-2909.114.2.203; HUGDAHL K, 1993, NEUROPSYCHOLOGIA, V31, P325, DOI 10.1016/0028-3932(93)90156-T; KUHLEMEIER KV, 1991, AM J PUBLIC HEALTH, V81, P513, DOI 10.2105/AJPH.81.4.513; MARKS JS, 1991, NEW ENGL J MED, V325, P1042; PETERS M, 1991, NEUROPSYCHOLOGIA, V29, P1257, DOI 10.1016/0028-3932(91)90039-B; PETO R, 1994, BRIT MED J, V308, P408, DOI 10.1136/bmj.308.6925.408; ROTHMAN KJ, 1991, NEW ENGL J MED, V325, P1041; THORN P, 1982, CRICKET STATISTICIAN, V37, P30; THORN P, 1984, CRICKET STATISTICIAN, V45, P27; TURNER BS, 1993, BRIT MED J, V307, P1577, DOI 10.1136/bmj.307.6919.1577; WOLF PA, 1991, NEW ENGL J MED, V325, P1042; WOOD CJ, 1989, BRIT J PSYCHOL, V80, P227, DOI 10.1111/j.2044-8295.1989.tb02316.x; WOOD EK, 1988, NATURE, V335, P212, DOI 10.1038/335212a0	23	28	28	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1681	1684		10.1136/bmj.309.6970.1681	http://dx.doi.org/10.1136/bmj.309.6970.1681			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PY717	7819983	Green Published			2022-12-24	WOS:A1994PY71700007
J	MARSHALL, J; SHARP, E; BARRISON, IG				MARSHALL, J; SHARP, E; BARRISON, IG			ONCE BITTEN, TWICE SHY	BRITISH MEDICAL JOURNAL			English	Article									HEMEL HEMPSTEAD GEN HOSP,DEPT MED,HEMEL HEMPSTEAD HP2 4AD,HERTS,ENGLAND; HEMEL HEMPSTEAD GEN HOSP,DEPT SURG,HEMEL HEMPSTEAD HP2 4AD,HERTS,ENGLAND									AZIMI P, 1990, PEDIATR INFECT DIS J, V9, P670; MOLINA JM, 1991, SCAND J INFECT DIS, V23, P659, DOI 10.3109/00365549109024289; RUMLEY RL, 1987, ANN RHEUM DIS, V46, P793, DOI 10.1136/ard.46.10.793	3	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1694	1695		10.1136/bmj.309.6970.1694a	http://dx.doi.org/10.1136/bmj.309.6970.1694a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819993	Green Published			2022-12-24	WOS:A1994PY71700019
J	WILLIAMS, R				WILLIAMS, R			DE INERTIA URBANORUM	BRITISH MEDICAL JOURNAL			English	Article																		ANDERSON D, 1991, ENERGY ENV; ANGRIST SW, 1967, ORDER CHAOS LAWS ENE; ARCHER MD, 1974, FUTURES          JUN, P261; ARCHER MD, 1991, PHOTOCHEMSITRY PHOTO; Bryant C., 1993, Biologist (London), V40, P58; CAIRNCROSS F, 1991, COSTING EARTH, P133; Cooper KH, 1970, NEW AEROBICS; FOWLER D, 1990, GREENHOUSE EFFECT TE, P10; HARRISS RC, 1989, OZONE DEPLETION GREE, P79; HOLMAN C, 1991, ROAD TRANSPORT AIR P, P11; JOUZEL J, 1993, NATURE, V364, P407, DOI 10.1038/364407a0; KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547; LAMB HH, 1972, CLIMATE PRESENT PAST, V1, P45; NEFTEL A, 1985, NATURE, V315, P45, DOI 10.1038/315045a0; Orwell G., 1946, COLLECTED ESSAYS JOU, V4, P127; RICE RA, 1972, TECHNOL REV, V74, P31; RILEY F, 1923, SETTLE DISTRICT N W, P29; SHINE KP, 1989, OZONE DEPLETION HLTH, P72; SMITH R, 1993, BRIT MED J, V306, P1285, DOI 10.1136/bmj.306.6888.1285; WALKER JCG, 1992, GLOBAL PLANET CHANGE, V97, P151, DOI 10.1016/0921-8181(92)90009-Y; Wilkie, 1968, MUSCLE; WILLIAMS RE, 1975, BRIT MED J, V4, P25, DOI 10.1136/bmj.4.5987.25; 1974, NEW ENCY BRITANNICA, V17, P1018; 1993, DESIGN MANUAL ROADS, V11; 1992, CLIMATE CHANGE DISCU; 1993, TRANSPORT STATISTICS, P10	26	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1741	1745		10.1136/bmj.309.6970.1741	http://dx.doi.org/10.1136/bmj.309.6970.1741			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7820010	Green Published			2022-12-24	WOS:A1994PY71700042
J	BARTLEY, M; POWER, C; BLANE, D; SMITH, GD; SHIPLEY, M				BARTLEY, M; POWER, C; BLANE, D; SMITH, GD; SHIPLEY, M			BIRTH-WEIGHT AND LATER SOCIOECONOMIC DISADVANTAGE - EVIDENCE FROM THE 1958 BRITISH COHORT STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADULT LIFE; MORTALITY RISK; DISEASE; HEALTH; MIGRATION; INFANCY; SMOKING; GROWTH; DEATH; FETAL	Objective-To investigate the relation between birth weight and socioeconomic disadvantage during childhood and adolescence in a birth cohort study. Design-Longitudinal analysis of birth weight in relation to social class, household amenities and overcrowding, and financial difficulties as reported by parents at interview when participants were aged 7, 11, and 16 years; and receipt of unemployment or supplementary benefits as reported by participants at age 23. Subjects-Male participants in the 1958 birth cohort (national child development study) born to parents resident in Great Britain during the week of 3-9 March 1958. Data on birth weight and financial difficulties between birth and 23 years were available for 4321; data on housing conditions and social class at ages 7, 11 and 16 years were available for 3370. Main outcome measures-Socioeconomic disadvantage at later ages in men weighing 6 lb (2721g) or under at birth compared with those weighing over 6 lb and between fifths of the distribution of birth weight. Results-Cohort members who weighed 6 lb or under at birth were more likely to experience socioeconomic disadvantage subsequently. Those in lower fifths of the distribution were more likely to experience socioeconomic disadvantage. Conclusion-Low birth weight is associated with socioeconomic disadvantage in childhood and adolescence. Studies of the association of indicators of early development and adult disease need to take into account experiences right through from birth to adulthood if they are to elucidate the combination of risks attributable to developmental problems and socioeconomic disadvantage.	INST CHILD HLTH, DIV PUBL HLTH, LONDON WC1N 1EH, ENGLAND; CHARING CROSS & WESTMINSTER MED SCH, ACAD DEPT PSYCHIAT, LONDON W6 8RP, ENGLAND; UNIV GLASGOW, DEPT PUBL HLTH, GLASGOW G12 8RZ, LANARK, SCOTLAND; UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6EA, ENGLAND	University of London; University College London; Imperial College London; University of Glasgow; University of London; University College London; UCL Medical School	BARTLEY, M (corresponding author), CITY UNIV LONDON, SOCIAL STAT RES UNIT, LONDON EC1R 0BN, ENGLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Barker DJP, 1992, FETAL INFANT ORIGINS; BARTLEY M, 1992, SOCIOL HEALTH ILL, V14, P313; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; BENTHAM G, 1988, SOC SCI MED, V26, P49, DOI 10.1016/0277-9536(88)90044-5; Brown M., 1982, DESPITE WELFARE STAT; Butler N.R., 1963, PERINATAL MORTALITY; COLLEY JRT, 1973, BRIT MED J, V3, P195, DOI 10.1136/bmj.3.5873.195; ESSEN J, 1978, CHILD CARE HLTH DEV, V4, P357, DOI 10.1111/j.1365-2214.1978.tb00095.x; ESSEN J, 1982, CONTINUITIES CHILDHO; ESSEX J, 1978, CHILD CARE HLTH DEV, V3, P41; FOGELMAN KR, 1988, BRIT MED J, V297, P1233, DOI 10.1136/bmj.297.6658.1233; FORSDAHL A, 1978, J EPIDEMIOL COMMUN H, V32, P34, DOI 10.1136/jech.32.1.34; GOLDBLATT P, 1990, LONGITUDINAL STUDY M, P163; GOLDSTEIN H, 1983, GROWING UP GB; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; KUH D, 1989, INT J EPIDEMIOL, V18, P663, DOI 10.1093/ije/18.3.663; KUH D, 1993, SOC HIST MED, V6, P101; KUH DJL, 1993, SOC SCI MED, V37, P905, DOI 10.1016/0277-9536(93)90145-T; MANN SL, 1992, J EPIDEMIOL COMMUN H, V46, P286, DOI 10.1136/jech.46.3.286; MARTYN CN, 1993, J EPIDEMIOL COMMUN H, V47, P76, DOI 10.1136/jech.47.1.76; NIE NH, 1983, STATISTICAL PACKAGE; PARKER DJP, 1992, J EPIDEMIOL COMMUN H, V46, P8, DOI 10.1136/jech.46.1.8; PILLING D, 1990, ESCAPE DISADVANTAGE; Power C., 1991, HLTH CLASS EARLY YEA; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SMITH GD, 1992, BRIT MED J, V304, P638, DOI 10.1136/bmj.304.6827.638-b; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; SMITH GD, 1992, LANCET, V340, P709; VERNON HM, 1939, HLTH RELATION OCCUPA; Wadsworth M. E. J., 1991, IMPRINT TIME CHILDHO; Wilkinson RG, 1986, CLASS HLTH RES LONGI; WILLIAMS DRR, 1979, J EPIDEMIOL COMMUN H, V33, P199, DOI 10.1136/jech.33.3.199	36	98	99	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 3	1994	309	6967					1475	1478		10.1136/bmj.309.6967.1475	http://dx.doi.org/10.1136/bmj.309.6967.1475			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804048	Green Published			2022-12-24	WOS:A1994PW05300020
J	MICHAELS, JA; RUTTER, P; COLLIN, J; LEGG, FM; GALLAND, RB				MICHAELS, JA; RUTTER, P; COLLIN, J; LEGG, FM; GALLAND, RB			RELATION BETWEEN RATES OF LEG AMPUTATION AND DISTAL ARTERIAL RECONSTRUCTIVE SURGERY	BRITISH MEDICAL JOURNAL			English	Article									UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT SURG,OXFORD OX3 9DU,ENGLAND	University of Oxford								CHESHIRE NJW, 1992, J VASC SURG, V15, P167, DOI 10.1016/0741-5214(92)70025-G; LINDHOLT JS, 1994, EUR J VASCULAR SURG, V8, P31, DOI 10.1016/S0950-821X(05)80116-1; MICHAELS JA, 1994, BRIT MED J, V309, P387, DOI 10.1136/bmj.309.6951.387; MICHAELS JA, 1994, BRIT J SURG, V81, P377, DOI 10.1002/bjs.1800810318	4	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1479	1480		10.1136/bmj.309.6967.1479a	http://dx.doi.org/10.1136/bmj.309.6967.1479a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804051	Green Published			2022-12-24	WOS:A1994PW05300022
J	GUERINA, NG; HSU, HW; MEISSNER, HC; MAGUIRE, JH; LYNFIELD, R; STECHENBERG, B; ABROMS, I; PASTERNACK, MS; HOFF, R; EATON, RB; GRADY, GF; CHEESEMAN, SH; MCINTOSH, K; MEDEARIS, DN; ROBB, R; WEIBLEN, BJ				GUERINA, NG; HSU, HW; MEISSNER, HC; MAGUIRE, JH; LYNFIELD, R; STECHENBERG, B; ABROMS, I; PASTERNACK, MS; HOFF, R; EATON, RB; GRADY, GF; CHEESEMAN, SH; MCINTOSH, K; MEDEARIS, DN; ROBB, R; WEIBLEN, BJ			NEONATAL SEROLOGIC SCREENING AND EARLY TREATMENT FOR CONGENITAL TOXOPLASMA-GONDII INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TISSUE-CULTURE; PREGNANCIES; MANAGEMENT	Background. Most infants with congenital Toxoplasma gondii infection have no symptoms at birth, but many will have retinal disease or neurologic abnormalities later in life. Early detection and treatment of congenital toxoplasmosis may reduce these sequelae. Methods. In Massachusetts since January 1986, and in New Hampshire since July 1988, newborns have been screened for intrauterine infection with T. gondii by means of an IgM capture immunoassay of blood specimens routinely collected for screening for metabolic disorders. Congenital infection is confirmed by assays for specific IgG and IgM antibodies in serum from infants and their mothers. For this study, infants with serologic evidence of infection underwent extensive clinical evaluation and received one year of treatment. Results. Through June 1992, 100 of 635,000 infants tested had positive screening tests. Congenital infection was confirmed in 52 infants, 50 of whom were identified only through neonatal screening and not through initial clinical examination. However, after the serologic results became available, more detailed examinations revealed abnormalities of either the central nervous system or the retina in 19 of 48 infants evaluated (40 percent). After treatment, only 1 of 46 children had a neurologic deficit (hemiplegia attributable to a cerebral lesion present at birth). Thirty-nine treated children had follow-up ophthalmologic examinations when one to six years old; four (10 percent) had eye lesions that may have developed postnatally (a macular lesion in one child and minor retinal scars in three). Conclusions. Routine neonatal screening for toxoplasmosis identifies congenital infections that are subclinical, and early treatment may reduce the severe long-term sequelae.	CHILDRENS HOSP, DIV INFECT DIS, BOSTON, MA 02115 USA; CHILDRENS HOSP, DIV NEWBORN MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; NEWTON WELLESLEY HOSP, DIV NEONATOL, NEWTON, MA USA; MASSACHUSETTS STATE LAB INST, NEW ENGLAND REG NEWBORN SCREENING PROGRAM, BOSTON, MA USA; TUFTS UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02111 USA; BRIGHAM & WOMENS HOSP, DEPT INFECT DIS, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; MASSACHUSETTS GEN HOSP, PEDIAT INFECT DIS UNIT, BOSTON, MA 02114 USA; BAYSTATE MED CTR, DIV PEDIAT INFECT DIS, SPRINGFIELD, MA 01107 USA; UNIV MASSACHUSETTS, MED CTR, DEPT NEUROL, WORCESTER, MA 01655 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Newton Wellesley Hospital; Tufts University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Baystate Medical Center; University of Massachusetts System; University of Massachusetts Worcester	GUERINA, NG (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DEPT PEDIAT INFECT DIS, DIV NEWBORN MED, NEMC 44, 750 WASHINGTON ST, BOSTON, MA 02111 USA.							BONADIO WA, 1992, PEDIATR INFECT DIS J, V11, P589, DOI 10.1097/00006454-199207000-00015; CHANG CH, 1972, J PEDIATR-US, V81, P790, DOI 10.1016/S0022-3476(72)80106-9; COUVREUR J, 1984, ANN PEDIATR-PARIS, V31, P855; COUVREUR J, 1984, ANN PEDIATR-PARIS, V31, P815; DAFFOS F, 1988, NEW ENGL J MED, V318, P271, DOI 10.1056/NEJM198802043180502; DEROUIN F, 1987, J CLIN MICROBIOL, V25, P1597, DOI 10.1128/JCM.25.9.1597-1600.1987; DEVROEDE M, 1979, ACTA PAEDIATR SCAND, V68, P761, DOI 10.1111/j.1651-2227.1979.tb18453.x; HOFF R, 1990, ALB BIR DEF, P169; HSU HW, 1992, SCAND J INFECT DIS, P59; KOPPE JG, 1974, EUR J OBSTET GYN R B, V4, P101, DOI 10.1016/0028-2243(74)90029-X; KOPPE JG, 1986, LANCET, V1, P254; MCCABE R, 1988, NEW ENGL J MED, V318, P313, DOI 10.1056/NEJM198802043180509; NAOT Y, 1981, J PEDIATR-US, V98, P32, DOI 10.1016/S0022-3476(81)80528-8; Remington JS., 1990, INFECT DIS FETUS NEW, V3, P89; ROBERTS T, 1990, J AM VET MED ASSOC, V196, P249; SEVER JL, 1988, PEDIATRICS, V82, P181; THORP JM, 1988, NEW ENGL J MED, V319, P372, DOI 10.1056/NEJM198808113190615; WEIBLEN BJ, 1993, LABORATORY METHODS N, P191; WILSON CB, 1980, PEDIATRICS, V66, P767	19	290	312	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 30	1994	330	26					1858	1863		10.1056/NEJM199406303302604	http://dx.doi.org/10.1056/NEJM199406303302604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT530	7818637				2022-12-24	WOS:A1994NT53000004
J	SAVITSKY, K; BARSHIRA, A; GILAD, S; ROTMAN, G; ZIV, Y; VANAGAITE, L; TAGLE, DA; SMITH, S; UZIEL, T; SFEZ, S; ASHKENAZI, M; PECKER, I; FRYDMAN, M; HARNIK, R; PATANJALI, SR; SIMMONS, A; CLINES, GA; SARTIEL, A; GATTI, RA; CHESSA, L; SANAL, O; LAVIN, MF; JASPERS, NGJ; MALCOLM, A; TAYLOR, R; ARLETT, CF; MIKI, T; WEISSMAN, SM; LOVETT, M; COLLINS, FS; SHILOH, Y				SAVITSKY, K; BARSHIRA, A; GILAD, S; ROTMAN, G; ZIV, Y; VANAGAITE, L; TAGLE, DA; SMITH, S; UZIEL, T; SFEZ, S; ASHKENAZI, M; PECKER, I; FRYDMAN, M; HARNIK, R; PATANJALI, SR; SIMMONS, A; CLINES, GA; SARTIEL, A; GATTI, RA; CHESSA, L; SANAL, O; LAVIN, MF; JASPERS, NGJ; MALCOLM, A; TAYLOR, R; ARLETT, CF; MIKI, T; WEISSMAN, SM; LOVETT, M; COLLINS, FS; SHILOH, Y			A SINGLE ATAXIA-TELANGIECTASIA GENE WITH A PRODUCT SIMILAR TO PI-3 KINASE	SCIENCE			English	Article							SCHIZOSACCHAROMYCES-POMBE; IONIZING-RADIATION; DNA-SYNTHESIS; COMPLEMENTATION ANALYSIS; CDNA SELECTION; FAMILIES; PROTEIN; CELLS; PATHWAYS; CANCERS	A gene, ATM, that is mutated in the autosomal recessive disorder ataxia telangiectasia (AT) was identified by positional cloning on chromosome 11q22-23. AT is characterized by cerebellar degeneration, immunodeficiency, chromosomal instability, cancer predisposition, radiation sensitivity, and cell cycle abnormalities. The disease is genetically heterogeneous, with four complementation groups that have been suspected to represent different genes. ATM, which has a transcript of 12 kilobases, was found to be mutated in AT patients from all complementation groups, indicating that it is probably the sole gene responsible for this disorder. A partial ATM complementary DNA clone of 5.9 kilobases encoded a putative protein that is similar to several yeast and mammalian phosphatidylinositol-3' kinases that are involved in mitogenic signal transduction, meiotic recombination, and cell cycle control. The discovery of ATM should enhance understanding of AT and related syndromes and may allow the identification of AT heterozygotes, who are at increased risk of cancer.	TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,IL-69978 TEL AVIV,ISRAEL; NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; CHAIM SHEBA MED CTR,INST HUMAN GENET,IL-52621 TEL HASHOMER,ISRAEL; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,NEW HAVEN,CT 06536; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,MCDERMOTT CTR,DALLAS,TX 75235; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90095; UNIV ROMA LA SAPIENZA,DIPARTIMENTO MED SPERIMENTALE,I-00161 ROME,ITALY; HACETTEPE UNIV,FAC MED,DEPT PEDIAT,ANKARA 06100,TURKEY; QUEENSLAND INST MED RES,HERSTON,QLD 4006,AUSTRALIA; ERASMUS UNIV ROTTERDAM,DEPT CELL BIOL & GENET,3000 DR ROTTERDAM,NETHERLANDS; UNIV BIRMINGHAM,CRC,INST CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Chaim Sheba Medical Center; Yale University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Sapienza University Rome; Hacettepe University; QIMR Berghofer Medical Research Institute; Erasmus University Rotterdam; University of Birmingham; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00882] Funding Source: Medline; NINDS NIH HHS [NS31763] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ARLETT CF, 1985, ATAXIA TELANGIECTASI, P101; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; BORRESEN AL, 1990, GENE CHROMOSOME CANC, V2, P339, DOI 10.1002/gcc.2870020412; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CARR AG, UNPUB; CHEN P, 1984, MUTAT RES, V129, P165, DOI 10.1016/0027-5107(84)90149-0; Chen P., UNPUB; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; DIECHA N, 1995, CELL, V80, P269; FORD MD, 1984, MUTAT RES, V125, P115, DOI 10.1016/0027-5107(84)90038-1; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; GREEN MHL, 1987, J CELL SCI S, V6, P127; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUNZ J, 1993, CELL, V73, P586; LANGE E, IN PRESS AM J HUM GE; LAVIN M, UNPUB; LAVIN MF, 1993, NATO ASI SERIES H, V77, P235; LEHMANN AR, 1982, ATAXIA TELANGIECTASI, P83; LIU Q, 1995, BIOTECHNIQUES, V18, P470; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MCCONVILLE CM, 1994, INT J RADIAT BIOL, V66, pS45, DOI 10.1080/09553009414551851; Meyn M. S., 1994, American Journal of Human Genetics, V55, pA3; MEYN MS, 1993, AM J HUM GENET, V53, P1206; MONFAR M, 1995, MOL CELL BIOL, V15, P325; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; MURNANE JP, 1982, P NATL ACAD SCI-BIOL, V79, P1960, DOI 10.1073/pnas.79.6.1960; OSKATO R, 1993, AM J HUM GENET, V53, P1055; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PARIMOO S, 1993, NUCLEIC ACIDS RES, V21, P4422, DOI 10.1093/nar/21.18.4422; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RICHARD CW, 1993, GENOMICS, V17, P1, DOI 10.1006/geno.1993.1275; ROTMAN G, 1994, INT J RADIAT BIOL, V66, pS63, DOI 10.1080/09553009414551871; ROTMAN G, 1994, GENOMICS, V24, P234, DOI 10.1006/geno.1994.1611; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Shiloh Y., 1994, American Journal of Human Genetics, V55, pA49; SHILOH Y, IN PRESS EUR J HUM G; SHILOH Y, 1985, ATAXIA TELANGIECTASI, P111; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TAGLE DA, 1993, NATURE, V361, P751, DOI 10.1038/361751a0; UHRHAMMER N, IN PRESS AM J HUM GE; VANAGAITE L, 1995, HUM GENET, V95, P451; VANAGAITE L, UNPUB; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WEINERT TA, UNPUB; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZAMPETTIBOSSELE.F, 1981, INT J RADIAT BIOL, V39, P547; ZIV Y, 1991, GENOMICS, V9, P373, DOI 10.1016/0888-7543(91)90268-J; ZIV Y, UNPUB; ZIV Y, 1992, HUM GENET, V88, P6219; ZIV Y, IN PRESS SOMATIC CEL	68	2231	2307	0	75	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1749	1753		10.1126/science.7792600	http://dx.doi.org/10.1126/science.7792600			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792600				2022-12-24	WOS:A1995RE66800042
J	GALE, CR; MARTYN, CN; WINTER, PD; COOPER, C				GALE, CR; MARTYN, CN; WINTER, PD; COOPER, C			VITAMIN-C AND RISK OF DEATH FROM STROKE AND CORONARY HEART-DISEASE IN COHORT OF ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article							PLASMA-CHOLESTEROL CONCENTRATION; FOLLOW-UP; MORTALITY; CONSUMPTION; ATHEROSCLEROSIS; WHITEHALL; FRUIT; MEN	Objectives-To determine whether vitamin C status, as measured by dietary intake and plasma ascorbic acid concentration, is related to mortality from stroke and coronary heart disease in people aged 65 and over. Design-A 20 year follow up study of a cohort of randomly selected elderly people living in the community who had taken part in the 1973-4 Department of Health and Social Security nutritional survey and for whom dietary and other data had been recorded. Setting-Eight areas in Britain (five in England, two in Scotland, and one in Wales). Subjects-730 men and women who had completed a seven day dietary record and who had no history or symptoms of stroke, cerebral arteriosclerosis, or coronary heart disease when examined by a geriatrician in 1973-4. Results-Mortality from stroke was highest in those with the lowest vitamin C status. Those in the highest third of the distribution of vitamin C intake had a relative risk of 0.5 (95% confidence interval 0.3 to 0.8) compared with those in the lowest third, after adjustment for age, sex, and established cardiovascular risk factors. The relation between Vitamin C intake and stroke was independent of social class and other dietary variables. A similar gradient in risk was present for plasma ascorbic acid concentrations. No association was found between vitamin C status and risk of death from coronary heart disease. Conclusion-In elderly people vitamin C concentration, whether measured by dietary intake or plasma concentration of ascorbic acid, is strongly related to subsequent risk of death from stroke but not from coronary heart disease.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND	University of Southampton			Gale, Catharine R/B-1653-2012					ACHESON RM, 1983, LANCET, V1, P1191; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; ARMSTRONG BK, 1975, J CHRON DIS, V28, P455, DOI 10.1016/0021-9681(75)90056-9; BONITA R, 1993, LANCET, V341, P1510, DOI 10.1016/0140-6736(93)90640-3; CASTELLI WP, 1989, AM J CARDIOL, V63, pH12; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; JAJICH CL, 1984, JAMA-J AM MED ASSOC, V252, P2831, DOI 10.1001/jama.252.20.2831; KHAW KT, 1984, STROKE, V15, P244, DOI 10.1161/01.STR.15.2.244; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; MANSON JE, 1992, CIRCULATION, V85, P865; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Roe JH, 1943, J BIOL CHEM, V147, P399; ROSE G, 1980, LANCET, V1, P523; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHIPLEY MJ, 1991, BRIT MED J, V303, P89, DOI 10.1136/bmj.303.6794.89; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; STRINGER MD, 1989, BRIT MED J, V298, P281, DOI 10.1136/bmj.298.6669.281; VERLANGIERI AJ, 1985, MED HYPOTHESES, V16, P7, DOI 10.1016/0306-9877(85)90035-0; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WINAWER SJ, 1990, JAMA-J AM MED ASSOC, V263, P2083, DOI 10.1001/jama.263.15.2083; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9	22	231	238	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1563	1566		10.1136/bmj.310.6994.1563	http://dx.doi.org/10.1136/bmj.310.6994.1563			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787644	Green Published, Green Submitted			2022-12-24	WOS:A1995RE35300018
J	GOLDBERG, S; SAVAGE, MP; FISCHMAN, DL				GOLDBERG, S; SAVAGE, MP; FISCHMAN, DL			CORONARY-ARTERY STENTS	LANCET			English	Editorial Material							ANGIOPLASTY; OCCLUSION				GOLDBERG, S (corresponding author), JEFFERSON MED COLL,PHILADELPHIA,PA 19107, USA.							COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; DEFEYTER PJ, 1992, AM HEART J, V123, P1633, DOI 10.1016/0002-8703(92)90818-G; DETRE KM, 1990, CIRCULATION, V82, P739, DOI 10.1161/01.CIR.82.3.739; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; HERRMANN HC, 1992, CIRCULATION, V86, P812, DOI 10.1161/01.CIR.86.3.812; HIRSHFELD JW, 1991, J AM COLL CARDIOL, V18, P647, DOI 10.1016/0735-1097(91)90783-6; ROUBIN GS, 1992, CIRCULATION, V85, P916, DOI 10.1161/01.CIR.85.3.916; SAVAGE MP, 1994, J AM COLL CARDIOL, V24, P1207, DOI 10.1016/0735-1097(94)90099-X; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SRIDHAR K, 1994, CIRCULATION, V90, P1; SUTTON JM, 1994, CIRCULATION, V89, P1126, DOI 10.1161/01.CIR.89.3.1126; WALLER BF, 1989, J AM COLL CARDIOL, V13, P969, DOI 10.1016/0735-1097(89)90248-9	12	7	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1523	1524		10.1016/S0140-6736(95)91083-2	http://dx.doi.org/10.1016/S0140-6736(95)91083-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791436	Bronze			2022-12-24	WOS:A1995RD79000005
J	RISCH, N; ZHANG, HP				RISCH, N; ZHANG, HP			EXTREME DISCORDANT SIB PAIRS FOR MAPPING QUANTITATIVE TRAIT LOCI IN HUMANS	SCIENCE			English	Article							LINKAGE	Analysis of differences between siblings (sib pair analysis) is a standard method of genetic linkage analysis for mapping quantitative trait loci, such as those contributing to hypertension and obesity, in humans. In traditional designs, pairs are selected at random or with one sib having an extreme trait value. The majority of such pairs provide little power to detect linkage; only pairs that are concordant for high values, low values, or extremely discordant pairs (for example, one in the top 10 percent and the other in the bottom 10 percent of the distribution) provide substantial power. Focus on discordant pairs can reduce the amount of genotyping necessary over conventional designs by 10- to 40-fold.	YALE UNIV,SCH MED,DEPT GENET,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06520	Yale University					NHGRI NIH HHS [HG00348] Funding Source: Medline; NICHD NIH HHS [HD30712] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD030712] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000348] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AMOS CI, 1989, GENET EPIDEMIOL, V6, P349, DOI 10.1002/gepi.1370060205; BLACKWELDER WC, 1982, COMMUN STAT A-THEOR, V11, P449, DOI 10.1080/03610928208828250; CARDON LR, 1994, SCIENCE, V266, P276, DOI 10.1126/science.7939663; CARDON LR, 1994, AM J HUM GENET, V55, P825; CAREY G, 1991, AM J HUM GENET, V49, P786; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DAVIES JL, 1994, NATURE, V371, P161; Falconer D. S., 1989, Introduction to quantitative genetics.; FULKER DW, 1991, READ WRIT, V3, P299, DOI 10.1007/BF00354964; FULKER DW, 1994, AM J HUM GENET, V54, P1092; GHOSH S, 1993, NAT GENET, V4, P404, DOI 10.1038/ng0893-404; GOLDGAR DE, 1990, AM J HUM GENET, V47, P957; HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731; LANDER ES, 1989, GENETICS, V121, P185; OLSON JM, 1993, GENET EPIDEMIOL, V10, P87, DOI 10.1002/gepi.1370100202; RISCH N, 1993, AM J HUM GENET, V53, P702; RISCH N, UNPUB	17	456	464	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 16	1995	268	5217					1584	1589		10.1126/science.7777857	http://dx.doi.org/10.1126/science.7777857			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RD459	7777857				2022-12-24	WOS:A1995RD45900027
J	NOWAK, MA; MAY, RM; PHILLIPS, RE; ROWLANDJONES, S; LALLOO, DG; MCADAM, S; KLENERMAN, P; KOPPE, B; SIGMUND, K; BANGHAM, CRM; MCMICHAEL, AJ				NOWAK, MA; MAY, RM; PHILLIPS, RE; ROWLANDJONES, S; LALLOO, DG; MCADAM, S; KLENERMAN, P; KOPPE, B; SIGMUND, K; BANGHAM, CRM; MCMICHAEL, AJ			ANTIGENIC OSCILLATIONS AND SHIFTING IMMUNODOMINANCE IN HIV-1 INFECTIONS	NATURE			English	Article							T-CELL DETERMINANTS; LYMPHOCYTES-T; SELECTION; VIRUS; RECOGNITION; RESPONSES; DOMINANCE; PEPTIDES; GENES	A TYPICAL protein antigen contains several epitopes that can be recognized by cytotoxic T lymphocytes (CTL), but in a characteristic antiviral immune response in vivo, CTL recognize only a small number of these potential epitopes, sometimes only one(1,2), this phenomenon is known as immunodominance(1-10). Antigenic variation within CTL epitopes has been demonstrated for the human immunodeficiency virus HIV-1 (ref. 11) and other viruses(12-17) and such 'antigenic escape' may be responsible for viral persistence. Here we develop a new mathematical model that deals with the interaction between CTL and multiple epitopes of a genetically variable pathogen, acid show that the nonlinear competition among CTL responses against different epitopes can explain immunodominance. This model suggests that an antigenically homogeneous pathogen population tends to induce a dominant response against a single epitope, whereas a heterogeneous pathogen population can stimulate complicated fluctuating responses against multiple epitopes. Antigenic variation in the immunodominant epitope can shift responses to weaker epitopes and thereby reduce immunological control of the pathogen population. These ideas are consistent with detailed longitudinal studies of CTL responses in HIV-1 infected patients. For vaccine design, the model suggests that the major response should be directed against conserved epitopes even if they are subdominant.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND; UNIV VIENNA,INST MATH,A-1090 VIENNA,AUSTRIA	University of Oxford; University of Vienna	NOWAK, MA (corresponding author), UNIV OXFORD,DEPT ZOOL,S PARKS RD,OXFORD OX1 3PS,ENGLAND.		Nowak, Martin A/A-6977-2008	Lalloo, David/0000-0001-7680-2200; klenerman, paul/0000-0003-4307-9161; Bangham, Charles/0000-0003-2624-3599	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADORINI L, 1988, J EXP MED, V168, P2091, DOI 10.1084/jem.168.6.2091; AEBISCHER T, 1991, P NATL ACAD SCI USA, V88, P11047, DOI 10.1073/pnas.88.24.11047; BANGHAM CRM, 1989, T CELLS, P281; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; CAMPOSLIMA P, 1993, SCIENCE, V260, P98; Carpenter S., 1990, Applied Virology Research, V2, P99; Gegin Cem, 1992, Journal of Immunology, V149, P3331; HILL AB, 1993, IMMUNOL REV, V133, P75, DOI 10.1111/j.1600-065X.1993.tb01510.x; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LIU ZR, 1993, J IMMUNOL, V151, P1852; MCMICHAEL AJ, 1994, AIDS S1, V8, pS155; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; NIEWIESK S, 1995, J VIROL, V69, P2649, DOI 10.1128/JVI.69.4.2649-2653.1995; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; NOWAK M, 1993, AIDS, V7, pS3, DOI 10.1097/00002030-199301001-00002; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; NOWAK MA, IN PRESS J THEOR BIO; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; SAFRIT JT, 1994, J EXP MED, V179, P463, DOI 10.1084/jem.179.2.463; SCHAEFFER EB, 1989, P NATL ACAD SCI USA, V86, P4649, DOI 10.1073/pnas.86.12.4649; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.iy.11.040193.003501; TAKAHASHI H, 1989, SCIENCE, V246, P118, DOI 10.1126/science.2789433; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WALKER BD, 1988, SCIENCE, V240, P64, DOI 10.1126/science.2451288; ZINKERNAGEL RM, 1978, J EXP MED, V148, P592, DOI 10.1084/jem.148.2.592	28	306	311	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					606	611		10.1038/375606a0	http://dx.doi.org/10.1038/375606a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791879				2022-12-24	WOS:A1995RD28700056
J	POWERS, NL; SALVI, RJ; WANG, J; SPONGR, V; QIU, CX				POWERS, NL; SALVI, RJ; WANG, J; SPONGR, V; QIU, CX			ELEVATION OF AUDITORY-THRESHOLDS BY SPONTANEOUS COCHLEAR OSCILLATIONS	NATURE			English	Article							SPONTANEOUS OTOACOUSTIC EMISSIONS; OUTER HAIR-CELLS; ACOUSTIC EMISSIONS; EAR CANALS; NERVE; RESPONSES; FREQUENCY; PATTERNS	THE inner ear sometimes acts as a robust sound generator, continuously broadcasting sounds (spontaneous otoacoustic emissions) which can be intense enough to be heard by other individuals standing nearby(1-4). Paradoxically, most individuals are unaware of the sounds generated within their ears, Two hypotheses could explain this paradox: (1) the spontaneous emissions may not be transmitted to the central nervous system; or (2) the spontaneous emission produces a continuous, high rate of neural activity, which, like the natural pattern of spontaneous activity, is ignored by the central nervous system. Here we demonstrate that high-intensity spontaneous otoacoustic emissions can vigorously activate auditory nerve fibres in mammals (Chinchilla laniger). This 'internal biological noise' creates a 'line busy' signal that significantly degrades a neuron's ability to respond to sound and results in a hearing loss completely different from that caused by damage to sensory cells(1,4).	SUNY BUFFALO,DEPT COMMUNICAT DISORDERS & SCI,HEARING RES LAB,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo				Wang, Jian/0000-0003-3633-6799				ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; CLARK WW, 1984, HEARING RES, V16, P299, DOI 10.1016/0378-5955(84)90119-9; DALLOS P, 1976, J ACOUST SOC AM, V60, P510, DOI 10.1121/1.381086; DIELER R, 1991, J NEUROCYTOL, V20, P637, DOI 10.1007/BF01187066; ELDREDGE DH, 1981, J ACOUST SOC AM, V69, P1091, DOI 10.1121/1.385688; EVANS EF, 1981, TINNITUS, P108; FROYMOVICH O, 1995, J ACOUST SOC AM, V97, P3021, DOI 10.1121/1.411867; KEMP DT, 1978, J ACOUST SOC AM, V64, P1386, DOI 10.1121/1.382104; Kiang NY, 1970, SENSORINEURAL HEARIN, P241, DOI DOI 10.1002/9780470719756.CH15; Kiang NYS, 1965, DISCHARGE PATTERNS S; Liberman M. C., 1986, BASIC APPL ASPECTS N, P163; LIBERMAN MC, 1982, SCIENCE, V217, P1239; LONSBURYMARTIN BL, 1990, ANN OTO RHINOL LARYN, V99, P15, DOI 10.1177/00034894900990S502; MCFADDEN D, 1984, J ACOUST SOC AM, V76, P443, DOI 10.1121/1.391585; NEDZELNITSKY V, 1980, J ACOUST SOC AM, V68, P1676, DOI 10.1121/1.385200; POWERS NL, 1991, THESIS SUNY BUFFALO; RUGGERO MA, 1984, HEARING RES, V13, P293, DOI 10.1016/0378-5955(84)90083-2; SACHS MB, 1968, J ACOUST SOC AM, V43, P1120, DOI 10.1121/1.1910947; SALVI R, 1982, NEW PERSPECTIVES NOI, P165; SCHMIEDT RA, 1980, J NEUROPHYSIOL, V43, P1367, DOI 10.1152/jn.1980.43.5.1367; SINEX DG, 1984, HEARING RES, V13, P285, DOI 10.1016/0378-5955(84)90082-0; SINEX DG, 1986, J NEUROPHYSIOL, V56, P1763, DOI 10.1152/jn.1986.56.6.1763; SPOENDLIN H, 1972, ACTA OTO-LARYNGOL, V73, P235, DOI 10.3109/00016487209138937; SUBRAMANIAM M, 1994, HEARING RES, V74, P204, DOI 10.1016/0378-5955(94)90188-0; WILSON JP, 1980, HEARING RES, V2, P233, DOI 10.1016/0378-5955(80)90060-X; WILSON JP, 1981, TINNITUS, P82; ZUREK PM, 1982, J ACOUST SOC AM, V72, P774, DOI 10.1121/1.388258; ZUREK PM, 1981, J ACOUST SOC AM, V70, P446, DOI 10.1121/1.386787; ZUREK PM, 1981, J ACOUST SOC AM, V69, P514, DOI 10.1121/1.385481	30	33	33	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					585	587		10.1038/375585a0	http://dx.doi.org/10.1038/375585a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791874				2022-12-24	WOS:A1995RD28700050
J	JUST, I; SELZER, J; WILM, M; VONEICHELSTREIBER, C; MANN, M; AKTORIES, K				JUST, I; SELZER, J; WILM, M; VONEICHELSTREIBER, C; MANN, M; AKTORIES, K			GLUCOSYLATION OF RHO-PROTEINS BY CLOSTRIDIUM-DIFFICILE TOXIN-B	NATURE			English	Article							TRIPHOSPHATE CONFORMATION; MECHANISM; P21	TOXIN A and B, the major virulence factors of Clostridium difficile, are the causative agents of antibiotic-associated pseudomembranous colitis. In cultured cell lines their potent cytotoxicity results from their ability to induce disaggregation of the microfilament cytoskeleton(1,2). Toxin B acts on the low-molecular-mass GTPase RhoA(3,4), which is involved in the regulation of the actin cytoskeleton. We report here that toxin B catalyses the incorporation of up to one mole of glucose per mole of RhoA at the amino acid threonine at position 37. The modification was identified and localized by tandem electrospray mass spectrometry. UDP-glucose selectively serves as cosubstrate for the monoglucosylation reaction catalysed by toxin B. Microinjection of RhoA previously glucosylated by toxin B into monolayer cells caused disaggregation of actin filaments, indicating a dominant-negative activity of glucosylated RhoA.	EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY; UNIV MAINZ,INST MED MIKROBIOL,D-55101 MAINZ,GERMANY	European Molecular Biology Laboratory (EMBL); Johannes Gutenberg University of Mainz; University of Hamburg; University Medical Center Hamburg-Eppendorf	JUST, I (corresponding author), UNIV SAARLAND,INST PHARMAKOL & TOXIKOL,D-66421 HOMBURG,GERMANY.		Aktories, Klaus/CAJ-5682-2022; Mann, Matthias/A-3454-2013	Aktories, Klaus/0000-0002-5397-0436; Mann, Matthias/0000-0003-1292-4799; Wilm, Matthias/0000-0002-5461-6834				BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1994, J CELL SCI, V107, P1653; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; LYERLY D M, 1988, Clinical Microbiology Reviews, V1, P1; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SELF AJ, 1993, ONCOGENE, V8, P655; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9	12	856	880	1	36	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					500	503		10.1038/375500a0	http://dx.doi.org/10.1038/375500a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777059				2022-12-24	WOS:A1995RC18800051
J	PHILLIPS, DM				PHILLIPS, DM			HUMAN-IMMUNODEFICIENCY-VIRUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PHILLIPS, DM (corresponding author), POPULAT COUNCIL,1230 YORK AVE,NEW YORK,NY 10021, USA.								0	2	2	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	1995	332	4					233	233		10.1056/NEJM199501263320406	http://dx.doi.org/10.1056/NEJM199501263320406			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC270	7808490				2022-12-24	WOS:A1995QC27000006
J	LONGSTRETH, GF; FEITELBERG, SP				LONGSTRETH, GF; FEITELBERG, SP			OUTPATIENT CARE OF SELECTED PATIENTS WITH ACUTE NONVARICEAL UPPER GASTROINTESTINAL HEMORRHAGE	LANCET			English	Article								Patients with upper gastrointestinal haemorrhage (UGIH) are usually cared for in hospital. To evaluate the efficacy and safety of outpatient care of selected patients with acute non-variceal UGIH who had endoscopy, we retrospectively analysed 4.5 years' experience of patients treated without hospital admission. We developed practice guidelines for outpatient care, and prospectively studied patients treated during the first 6 months of their use. 78 (8.4%) of 933 patients in the retrospective series and 34 (24.1%) of 141 in the prospective series received outpatient care. The guidelines comprised early notification of a gastroenterologist, urgent endoscopy, clinical, laboratory, and endoscopic criteria for outpatient care, and details of care. In the prospective study patients treated as outpatients were younger than those admitted (52.8 [SE 3.6] vs 63.0 [1.5] years) and had a slightly longer time from onset of bleeding to endoscopy (2.4 [0.2] vs 2.1 [0.2] days). Outpatients were less likely to have alcoholism, other major concomitant disease, syncope or presyncope, or supine tachycardia. Outpatients had higher haemoglobin concentrations than inpatients (125 [4] vs 106 [3] g/L). Most patients in both groups had peptic ulcers. There were no complications in the retrospective series; 1 of the 34 prospective outpatients was admitted with rebleeding. All outpatients survived. The estimated hospital cost saved per outpatient was about $990. A substantial proportion of carefully selected patients with acute non-variceal UGIH can be effectively cared for without admission to hospital.			LONGSTRETH, GF (corresponding author), KAISER PERMANENTE MED CTR,DEPT MED,SAN DIEGO,CA 92120, USA.							CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CUTLER JA, 1981, DIG DIS SCI S, V26, P90; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; FREEMAN ML, 1993, GASTROINTEST ENDOSC, V39, P359, DOI 10.1016/S0016-5107(93)70106-6; GILBERT DA, 1990, DIG DIS SCI S, V36, P8; GOSTOUT CJ, 1992, SEMIN GASTROINTEST D, V33, P53; GUPTA PK, 1993, MED CLIN N AM, V77, P973, DOI 10.1016/S0025-7125(16)30206-1; HARLAND R, 1992, J ROY SOC MED, V85, P26; JOHNSTON JH, 1990, GASTROINTEST ENDOS S, V36, P16; KURATA JH, 1988, J CLIN GASTROENTEROL, V10, P259, DOI 10.1097/00004836-198806000-00007; LAINE L, 1992, GASTROENTEROLOGY, V102, P314, DOI 10.1016/0016-5085(92)91816-M; LAINE L, 1989, ANN INTERN MED, V110, P510, DOI 10.7326/0003-4819-110-7-510; LICHTENSTEIN DR, 1992, GASTROINTESTINAL EME, P92; LONGSTRETH GF, 1994, J CLIN GASTROENTEROL, V19, P189, DOI 10.1097/00004836-199410000-00003; LONGSTRETH GF, 1986, J CLIN GASTROENTEROL, V8, P23, DOI 10.1097/00004836-198602000-00006; LONGSTRETH GF, IN PRESS AM J GASTRO; TERBLANCHE J, 1992, ANNU REV MED, V43, P69, DOI 10.1146/annurev.med.43.1.69; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; 1989, JAMA-J AM MED ASSOC, V262, P1369	19	109	111	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					108	111		10.1016/S0140-6736(95)90068-3	http://dx.doi.org/10.1016/S0140-6736(95)90068-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815854				2022-12-24	WOS:A1995QB80400015
J	ORSCHESCHEK, K; MERZ, H; HELL, J; BINDER, T; BARTELS, H; FELLER, AC				ORSCHESCHEK, K; MERZ, H; HELL, J; BINDER, T; BARTELS, H; FELLER, AC			LARGE-CELL ANAPLASTIC LYMPHOMA-SPECIFIC TRANSLOCATION (T[2-5] [P23-Q35]) IN HODGKINS-DISEASE - INDICATION OF A COMMON PATHOGENESIS	LANCET			English	Article							KI-1 LYMPHOMA; RECEPTOR; EXPRESSION; 5Q35	Chromosomal aberrations are characteristic and specific events; the detection of chromosomal abnormalities often provides information on diagnosis and prognosis of disease. Some patients with large-cell anaplastic lymphoma (Ki 1 lymphoma) have the translocation t(2;5) (p23; q35), involving a possible growth-regulating tyrosine kinase. We found this translocation in 11 patients with Hodgkin's disease of nodular sclerosis and mixed-cellularity types. This finding has implications for the understanding of the relation between large-cell anaplastic lymphoma and Hodgkin's disease, diseases with morphological and immunophenotypical similarities. Study of this translocation may help understanding of the origins of cancer and cancer growth. It also allows a more precise definition of Hodgkin's disease and may be used as an indicator for clonality-which has long been sought.	UNIV LUBECK,DEPT PATHOL,D-23538 LUBECK,GERMANY; UNIV ULM,DEPT INTERNAL MED 3,W-7900 ULM,GERMANY; STADT KRANKENHAUS SUD,DEPT HEMATOL ONCOL,LUBECK,GERMANY	University of Lubeck; Ulm University			Feller, Alfred/E-3853-2010					ANAGNOSTOPOULOS I, 1989, BLOOD, V74, P810; BOEHM T, 1989, EUR J BIOCHEM, V185, P1, DOI 10.1111/j.1432-1033.1989.tb15074.x; FISCHER P, 1988, BLOOD, V72, P234; FONATSCH C, 1986, CANCER GENET CYTOGEN, V20, P39, DOI 10.1016/0165-4608(86)90106-8; JUCKER M, 1991, BLOOD, V77, P2413; KADIN ME, 1985, LANCET, V123, P864; LADANYI M, 1991, GENE CHROMOSOME CANC, V3, P294, DOI 10.1002/gcc.2870030408; Lennert K, 1992, HISTOPATHOLOGY NONHO; MACLENNAN KA, 1992, INT REV EXP PATHOL, V33, P27; MASON DY, 1990, BRIT J HAEMATOL, V74, P161; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MERZ H, 1991, BLOOD, V78, P1311; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; ORSCHESCHEK K, 1994, EUR J IMMUNOL, V24, P2682, DOI 10.1002/eji.1830241117; PEBUSQUE MJ, 1993, GENE CHROMOSOME CANC, V8, P119, DOI 10.1002/gcc.2870080209; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	17	100	100	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					87	90		10.1016/S0140-6736(95)90061-6	http://dx.doi.org/10.1016/S0140-6736(95)90061-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815887				2022-12-24	WOS:A1995QB80400008
J	KOVACSOVICSBANKOWSKI, M; ROCK, KL				KOVACSOVICSBANKOWSKI, M; ROCK, KL			A PHAGOSOME-TO-CYTOSOL PATHWAY FOR EXOGENOUS ANTIGENS PRESENTED ON MHC CLASS-I MOLECULES	SCIENCE			English	Article							TOXIC LYMPHOCYTES-T; CELLS; PROTEIN; EXPRESSION; GELONIN	Peptides from endogenous proteins are presented by major histocompatibility complex class I molecules, but antigens (Ags) in the extracellular fluids are generally not. However, pathogens or particulate Ags that are internalized into phagosomes of macrophages (MOs) stimulate CD8 T cells. The presentation of these Ags is resistant to chloroquine but is blocked by inhibitors of the proteasome, a mutation in the TAP1-TAP2 transporter, and brefeldin A. Moreover, phagocytosis of a ribosomal-inactivating protein inhibited MM protein synthesis. These results demonstrate that MOs transfer Ags from phagosomes into the cytosol and that endogenous and exogenous Ags use a final common pathway for class I presentation.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV LYMPHOCYTE BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NIAID NIH HHS [AI31337, AI20248] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020248, R01AI020248, R01AI031337] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACIK I, 1994, J IMMUNOL, V152, P381; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; CARTER VC, 1981, J IMMUNOL, V126, P1655; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; FURUNO K, 1986, BIOCHEM J, V237, P859, DOI 10.1042/bj2370859; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; KAUFMANN SHE, 1988, IMMUNOL TODAY, V9, P168, DOI 10.1016/0167-5699(88)91292-3; KNOP K, 1993, CURR OPIN CELL BIOL, V5, P990; KOVACSOVICSBANK.M, 1994, EUR J IMMUNOL, V24, P2421; KOVACSOVICSBANK.M, UNPUB; KOVACSOVICSBANKOWS, 1993, P NATL ACAD SCI USA, V90, P4942; LAMBERT JM, 1985, J BIOL CHEM, V260, P2035; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; ROCK KL, 1990, J IMMUNOL, V145, P804; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; STAERZ UD, 1987, NATURE, V329, P449, DOI 10.1038/329449a0; STIRPE F, 1980, J BIOL CHEM, V255, P6947; SZALAY G, 1994, EUR J IMMUNOL, V24, P1471, DOI 10.1002/eji.1830240703; Townsend A, 1993, Semin Cell Biol, V4, P53, DOI 10.1006/scel.1993.1007; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; WATSON J, 1979, J EXP MED, V150, P1510, DOI 10.1084/jem.150.6.1510; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175	27	714	728	0	25	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 13	1995	267	5195					243	246		10.1126/science.7809629	http://dx.doi.org/10.1126/science.7809629			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809629				2022-12-24	WOS:A1995QB15300037
J	ISACSSON, G; REDFORS, I; WASSERMAN, D; BERGMAN, U				ISACSSON, G; REDFORS, I; WASSERMAN, D; BERGMAN, U			CHOICE OF ANTIDEPRESSANTS - QUESTIONNAIRE SURVEY OF PSYCHIATRISTS AND GENERAL-PRACTITIONERS IN 2 AREAS OF SWEDEN	BRITISH MEDICAL JOURNAL			English	Article							SUICIDE	Objective-To identify factors that affect physicians' choice of specific antidepressant drugs in order to evaluate the validity of epidemiological studies of the risks (particularly suicide) and benefits of different compounds. Design-Questionnaire survey of 264 psychiatrists and general practitioners in an urban area and a rural area of Sweden with validation of data by independent prescription surveys. Setting-Urban area of greater Stockholm and rural county of Jamtland, Sweden. Subjects-228 physicians (86%) who answered the questionnaire. Main outcome measures-The drugs used as first line drugs of choice, as drugs of choice in particularly severe depression, and as drugs of choice for disorders other than depression. Results-Amitriptyline was the most common first line drug of choice among both psychiatrists and general practitioners. The patterns of choice of antidepressants in the two areas accorded with prescribing patterns in two independent prescription surveys. Amitriptyline was chosen even more frequently for severe depression and depression with severe insomnia. Clomipramine was chosen comparatively more often for depression with severe anxiety. Low toxicity compounds (mainly lofepramine, mianserin, and moclobemide) were more often the drug of choice in depression associated with overt risk of suicide. Amitriptyline and clomipramine were used extensively for disorders other than depression (40% and 54% of prescriptions, compared with 13-19% for some other major antidepressants). Conclusion-Patient groups treated with different antidepressant compounds may not be comparable with respect to diagnoses and severity of disease. In particular, lofepramine, mianserin, and moclobemide, and possibly amitriptyline, seem to be chosen more often for patients prone to suicide.	ORSA PRIMARY HLTH CARE CTR,ORSA,SWEDEN; KAROLINSKA HOSP,CTR SUICIDE RES & PREVENT,STOCKHOLM,SWEDEN; HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT MED LAB SCI & TECHNOL,DIV CLIN PHARMACOL,HUDDINGE,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	ISACSSON, G (corresponding author), HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT CLIN NEUROSCI & FAMILY MED,PSYCHIAT SECT,S-14186 HUDDINGE,SWEDEN.							AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; BARRACLOUGH BM, 1975, PSYCHOL MED, V5, P55, DOI 10.1017/S0033291700007212; GOODE H, 1994, BRIT MED J, V308, P915; Henry J A, 1992, Eur J Med, V1, P343; ISACSSON G, 1994, BRIT MED J, V308, P506, DOI 10.1136/bmj.308.6927.506; ISACSSON G, 1992, ACTA PSYCHIAT SCAND, V85, P444, DOI 10.1111/j.1600-0447.1992.tb03209.x; ISACSSON G, 1994, BRIT MED J, V308, P916; ISOMETSA E, 1994, BRIT MED J, V308, P915, DOI 10.1136/bmj.308.6933.915; ISOMETSA ET, 1994, AM J PSYCHIAT, V151, P530; KAPUR S, 1992, JAMA-J AM MED ASSOC, V268, P3441, DOI 10.1001/jama.268.24.3441; OHARE T, 1994, BRIT MED J, V308, P915; OWEN A, 1994, BRIT MED J, V308, P915; Siegel S., 2009, NONPARAMETRIC STAT B, V2nd; Tomson G, 1990, Lakartidningen, V87, P1483; WESSLING A, 1991, EUR J CLIN PHARMACOL, V40, P495, DOI 10.1007/BF00315229	15	37	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1546	1549		10.1136/bmj.309.6968.1546	http://dx.doi.org/10.1136/bmj.309.6968.1546			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PX564	7819894	Green Published			2022-12-24	WOS:A1994PX56400020
J	KEENEY, RL				KEENEY, RL			DECISIONS ABOUT LIFE-THREATENING RISKS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MORTALITY				KEENEY, RL (corresponding author), UNIV SO CALIF,LOS ANGELES,CA 90089, USA.							BEAUCHAMP TS, 1982, PHILOS ETHICS; GRAHAM JD, 1992, RISK ANAL, V12, P333, DOI 10.1111/j.1539-6924.1992.tb00684.x; GRAHAM JD, 1986, RISK EVALUATION MANA, P503; KEENEY RL, 1984, RISK ANAL, V4, P117, DOI 10.1111/j.1539-6924.1984.tb00941.x; KEENEY RL, 1990, RISK ANAL, V10, P147, DOI 10.1111/j.1539-6924.1990.tb01029.x; Kitagawa EM, 1973, DIFFERENTIAL MORTALI; MACRAE J, 1992, COMMUNICATION   0310; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; WILDAVSKY A, 1980, PUBLIC INTEREST, V60, P23; Wildavsky AaronB., 1988, SEARCHING SAFETY	11	30	30	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 21	1994	331	3					193	196		10.1056/NEJM199407213310311	http://dx.doi.org/10.1056/NEJM199407213310311			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NW797	7794298				2022-12-24	WOS:A1994NW79700011
J	GUEST, TM; RAMANATHAN, AV; TUTEUR, PG; SCHECHTMAN, KB; LADENSON, JH; JAFFE, AS				GUEST, TM; RAMANATHAN, AV; TUTEUR, PG; SCHECHTMAN, KB; LADENSON, JH; JAFFE, AS			MYOCARDIAL INJURY IN CRITICALLY ILL PATIENTS - A FREQUENTLY UNRECOGNIZED COMPLICATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CREATINE-KINASE ISOENZYMES; CARDIAC TROPONIN-I; SKELETAL-MUSCLES; INTENSIVE-CARE; MB ISOENZYME; INFARCTION; SERUM; SURVIVAL; DISEASE; ASSAY	Objective.-To determine the incidence and effect of unrecognized cardiac injury in critically ill patients, Design.-Prospective, blinded, single-center study. Setting.-The medical and respiratory intensive care unit of an academic health center, Patients.-Two hundred nine patients (224 admissions), Main Outcome Measures.-Daily measurement of levels of cardiac troponin I, a sensitive, highly specific, and long-lived marker of myocardial injury, Concurrently, signs and symptoms potentially related to myocardial ischemia were tabulated by blinded investigators, All clinical evaluation and management decisions were made by the physicians responsible for the care of the patient, Results.-Thirty-two (15%) of the 209 patients had evidence of myocardial damage based on elevated levels of cardiac troponin !, Only 12 (37%) of these 32 patients were diagnosed as having acute myocardial infarction by the intensive care unit staff, Cardiac damage was unrecognized in the other 20 (63%), Unrecognized cardiac injury was more common in young patients and in blacks, Mortality in patients with myocardial injury that was recognized (42%) or unrecognized (40%) was higher than in those without myocardial injury (15%) (P<.001), Patients with cardiac injury were more frequently hypotensive (75% vs 50%; P=.007) and in need of mechanical ventilation (66% vs 27%; P<.001) and had longer intensive care unit stays (5.3 vs 3.1 days; P<.007) than patients without cardiac injury. Conclusion.-The incidence of myocardial injury defined by elevated levels of cardiac troponin I was unexpectedly high and associated with increased morbidity and mortality, Clinically it was often unrecognized.	WASHINGTON UNIV,SCH MED,DIV PULM & CRIT CARE,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOSTAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV CARDIOVASC,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017646, P60HL017646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 17646] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JE, 1994, CLIN CHEM, V40, P1291; ADAMS JE, 1994, NEW ENGL J MED, V330, P670, DOI 10.1056/NEJM199403103301003; ADAMS JE, 1993, CIRCULATION, V88, P101, DOI 10.1161/01.CIR.88.1.101; ADAMS JE, 1993, CIRCULATION, V88, P750, DOI 10.1161/01.CIR.88.2.750; BODOR GS, 1992, CLIN CHEM, V38, P2203; CAMPION EW, 1981, JAMA-J AM MED ASSOC, V246, P2052, DOI 10.1001/jama.246.18.2052; CHEITLIN MD, 1975, JAMA-J AM MED ASSOC, V231, P951, DOI 10.1001/jama.231.9.951; CUMMINS B, 1987, AM HEART J, V113, P1333, DOI 10.1016/0002-8703(87)90645-4; CUMMINS P, 1987, EUR J CLIN INVEST, V17, P317, DOI 10.1111/j.1365-2362.1987.tb02194.x; DETSKY AS, 1981, NEW ENGL J MED, V305, P667, DOI 10.1056/NEJM198109173051204; DRASNER K, 1992, PRINCIPLES CRITICAL, P959; FEDULLO AJ, 1983, CRIT CARE MED, V11, P155, DOI 10.1097/00003246-198303000-00001; Girard K, 1985, Respir Care, V30, P339; GOSALAKKAL JA, 1991, SCAND J THORAC CARD, V25, P159, DOI 10.3109/14017439109098103; GRAM J, 1990, DAN MED BULL, V37, P210; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; JAFFE AS, 1984, J LAB CLIN MED, V104, P193; JULKUNEN H, 1972, ANN CHIR GYNAECOL FE, V60, P107; KUTOM AH, 1991, CHEST, V100, P571, DOI 10.1378/chest.100.2.571; LARUE C, 1993, CLIN CHEM, V39, P972; LEGALL JR, 1984, CRIT CARE MED, V12, P975; MADIAS JE, 1973, CIRCULATION, V49, P448; NICOD P, 1989, CIRCULATION, V79, P528, DOI 10.1161/01.CIR.79.3.528; PARMLEY WW, 1976, PROG CARDIOL, V5, P19; PARRY G, 1992, CLIN CARDIOL, V15, P305, DOI 10.1002/clc.4960150416; Perry SV, 1979, BIOCHEM SOC T, V7, P593, DOI 10.1042/bst0070593; PINGLETON SK, 1992, PRINCIPLES CRITICAL, P599; ROSALKI SB, 1967, J LAB CLIN MED, V69, P696; SCHEINMAN MM, 1973, AM J MED, V55, P602, DOI 10.1016/0002-9343(73)90181-2; SCHNEIDER DJ, 1992, CORONARY ARTERY DIS, V3, P26, DOI 10.1097/00019501-199201000-00004; TOYOTA N, 1981, J CELL BIOL, V91, P497, DOI 10.1083/jcb.91.2.497; TRASK RV, 1990, BIOCHIM BIOPHYS ACTA, V1049, P182, DOI 10.1016/0167-4781(90)90039-5; Travis K W, 1973, Crit Care Med, V1, P235, DOI 10.1097/00003246-197309000-00001; TSUNG JS, 1986, CLIN CHEM, V32, P1568; TSUNG SH, 1981, AM J CLIN PATHOL, V75, P711, DOI 10.1093/ajcp/75.5.711; URETSKY BF, 1977, AM J CARDIOL, V40, P498, DOI 10.1016/0002-9149(77)90062-5; VAIDYA HC, 1986, CLIN CHEM, V32, P657; WILHELM A H, 1976, IRCS (International Research Communications System) Medical Science Library Compendium, V4, P418; YOUNG RKB, 1974, BRIT MED J, V1, P307, DOI 10.1136/bmj.1.5903.307	40	269	286	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1945	1949		10.1001/jama.273.24.1945	http://dx.doi.org/10.1001/jama.273.24.1945			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783306				2022-12-24	WOS:A1995RE35400032
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FAMOTIDINE APPROVED FOR OVER-THE-COUNTER USE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1897	1897						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783288				2022-12-24	WOS:A1995RE35400005
J	YOUNG, ID				YOUNG, ID			DIAGNOSING PRADER-WILLI-SYNDROME	LANCET			English	Editorial Material							ANGELMAN				YOUNG, ID (corresponding author), CITY HOSP,CLIN GENET SERV,NOTTINGHAM,ENGLAND.							DITTRICH B, 1992, HUM GENET, V90, P313; DONALDSON MDC, 1994, ARCH DIS CHILD, V70, P58, DOI 10.1136/adc.70.1.58; GILLESSENKAESBA.G, 1995, J MED GENET, V32, P88; HOLM VA, 1993, PEDIATRICS, V91, P398; LERER I, 1994, AM J MED GENET, V52, P79, DOI 10.1002/ajmg.1320520116; NICHOLLS RD, 1993, AM J MED GENET, V46, P16, DOI 10.1002/ajmg.1320460106; OZCELIK T, 1992, NAT GENET, V2, P265, DOI 10.1038/ng1292-265; Prader A, 1956, SCHWEIZERISCHE MEDIZ, V86, P1260, DOI DOI 10.1007/978-3-642-47669-3_24; REIS A, 1994, AM J HUM GENET, V54, P741; Smith, 1982, RECOGNIZABLE PATTERN; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52	11	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1590	1590		10.1016/S0140-6736(95)90112-4	http://dx.doi.org/10.1016/S0140-6736(95)90112-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783534				2022-12-24	WOS:A1995RE67000005
J	LANYI, JK				LANYI, JK			BACTERIORHODOPSIN AS A MODEL FOR PROTON PUMPS	NATURE			English	Article							CYTOCHROME-C-OXIDASE; X-RAY-DIFFRACTION; STRUCTURAL-CHANGES; MECHANISM; PHOTOCYCLE; TRANSPORT; ENERGY; INTERMEDIATE; ACTIVATION; PROTEINS	According to a long-standing hypothesis, membrane pumps function by flip-flopping between two protein conformations that allow alternative access of the ion binding site to the two membrane surfaces. Site-specific mutagenesis, time-resolved spectroscopy and X-ray diffraction confirm this mechanism for bacteriorhodopsin, and implicate change of electrostatic interaction at the active site as the trigger for the global protein conformation change during the proton transport cycle.			LANYI, JK (corresponding author), UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717, USA.		Lanyi, Janos/C-3808-2011; Ueno, Hiroshi/C-3301-2009					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AMES JB, 1990, BIOCHEMISTRY-US, V29, P7181, DOI 10.1021/bi00483a005; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BIRGE RR, 1990, BIOCHIM BIOPHYS ACTA, V1016, P293, DOI 10.1016/0005-2728(90)90163-X; BOEKEMA EJ, 1986, BIOCHIM BIOPHYS ACTA, V851, P353, DOI 10.1016/0005-2728(86)90071-X; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BROWN LS, 1994, J MOL BIOL, V239, P401, DOI 10.1006/jmbi.1994.1381; BRZEZINSKI P, 1986, P NATL ACAD SCI USA, V83, P4282, DOI 10.1073/pnas.83.12.4282; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COPELAND RA, 1989, ANNU REV PHYS CHEM, V40, P671; FILLINGAME RH, 1994, BACTERIA, V12, P345; FODOR SPA, 1988, BIOCHEMISTRY-US, V27, P7097, DOI 10.1021/bi00418a064; FRAUENFELDER H, 1988, ANNU REV BIOPHYS BIO, V17, P451; FUTAI M, 1994, BBA-BIOENERGETICS, V1187, P165, DOI 10.1016/0005-2728(94)90104-X; GRABER P, 1994, BBA-BIOENERGETICS, V1187, P171, DOI 10.1016/0005-2728(94)90105-8; GROTH G, 1993, BIOCHEMISTRY-US, V32, P8103, DOI 10.1021/bi00083a008; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; Jencks W P, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P75; KATAOKA M, 1994, J MOL BIOL, V243, P621, DOI 10.1016/0022-2836(94)90037-X; KOCH MHJ, 1991, EMBO J, V10, P521, DOI 10.1002/j.1460-2075.1991.tb07978.x; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; LAUBINGER W, 1989, BIOCHEMISTRY-US, V28, P7194, DOI 10.1021/bi00444a010; LAUBINGER W, 1994, BIOCHEMISTRY-US, V29, P5458; MALMSTROM BG, 1993, ACCOUNTS CHEM RES, V26, P332, DOI 10.1021/ar00030a006; MALMSTROM BG, 1990, ARCH BIOCHEM BIOPHYS, V280, P233, DOI 10.1016/0003-9861(90)90325-S; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; Mitchell P, 1966, CHEMIOSMOTIC COUPLIN; NAGLE JF, 1978, P NATL ACAD SCI USA, V75, P298, DOI 10.1073/pnas.75.1.298; NAKASAKO M, 1991, FEBS LETT, V292, P73, DOI 10.1016/0014-5793(91)80837-S; OPRIAN DD, 1993, J BIOENERG BIOMEMBR, V24, P211; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SPUDICH JL, 1994, CELL, V79, P747, DOI 10.1016/0092-8674(94)90064-7; STRADER CD, 1994, DEV BIOCHEM, V63, P101; SUBRAMANIAM S, 1993, EMBO J, V12, P1; TANFORD C, 1983, ANNU REV BIOCHEM, V52, P379, DOI 10.1146/annurev.bi.52.070183.002115; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P10923, DOI 10.1021/bi00091a048; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; VALPUESTA JM, 1990, J MOL BIOL, V214, P237, DOI 10.1016/0022-2836(90)90158-I; VARO G, 1992, BIOCHEMISTRY-US, V30, P5016; WIKSTROM M, 1994, BBA-BIOENERGETICS, V1187, P106, DOI 10.1016/0005-2728(94)90093-0; WIKSTROM M, 1979, BIOCHIM BIOPHYS ACTA, V549, P177, DOI 10.1016/0304-4173(79)90014-4; ZIMANYI L, 1993, BIOCHEMISTRY-US, V32, P7669, DOI 10.1021/bi00081a010; ZIMANYI L, 1992, BIOCHEMISTRY-US, V3, P8535; ZVYAGA TA, 1994, BIOCHEMISTRY-US, V33, P9753, DOI 10.1021/bi00198a046	50	133	137	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					461	463		10.1038/375461a0	http://dx.doi.org/10.1038/375461a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777054				2022-12-24	WOS:A1995RC18800039
J	SHIVDASANI, RA; ROSENBLATT, MF; ZUCKERFRANKLIN, D; JACKSON, CW; HUNT, P; SARIS, CJM; ORKIN, SH				SHIVDASANI, RA; ROSENBLATT, MF; ZUCKERFRANKLIN, D; JACKSON, CW; HUNT, P; SARIS, CJM; ORKIN, SH			TRANSCRIPTION FACTOR NF-E2 IS REQUIRED FOR PLATELET FORMATION INDEPENDENT OF THE ACTIONS OF THROMBOPOIETIN/MGDF IN MEGAKARYOCYTE DEVELOPMENT	CELL			English	Article							DOMINANT CONTROL REGION; TARGETED MUTATION; BINDING PROTEINS; GENE; EXPRESSION; CELLS; MOUSE; LINEAGES; MARROW; GROWTH	Despite the importance of blood platelets in health and disease, the mechanisms regulating their formation within megakaryocytes are unknown. We generated mice lacking the hematopoietic subunit (p45) of the heterodimeric erythroid transcription factor NF-E2. Unexpectedly, NF-E2(-/-) mice lack circulating platelets and die of hemorrhage; their megakaryocytes show no cytoplasmic platelet formation. Though platelets are absent, serum levels of the growth factor thrombopoietin/MGDF are not elevated above controls. Nonetheless, NF-E2(-/-) megakaryocytes proliferate in vivo in response to thrombopoietin administration. Thus, as an essential factor for megakaryocyte maturation and platelet production, NF-ES must regulate critical target genes independent of the action of thrombopoietin. These findings provide insight into the genetic analysis of megakaryocyte maturation and thrombopoiesis.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA USA; CHILDRENS HOSP, DIV HEMATOL ONCOL, BOSTON, MA USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; NYU, MED CTR, DEPT MED, NEW YORK, NY 10016 USA; ST JUDE CHILDRENS RES HOSP, DIV EXPTL HEMATOL, MEMPHIS, TN 38105 USA; AMGEN INC, AMGEN CTR, THOUSAND OAKS, CA 91320 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; New York University; St Jude Children's Research Hospital; Amgen	SHIVDASANI, RA (corresponding author), DANA FARBER CANC INST, DIV MED ONCOL, BOSTON, MA 02115 USA.				NHLBI NIH HHS [HL42103, HL51290] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042103, U01HL142103, R01HL051290] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; BECKSTEAD JH, 1986, BLOOD, V67, P285; BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; BLOCK KL, 1994, BLOOD, V84, P3385; BRETONGORIUS J, 1981, BRIT J HAEMATOL, V47, P635, DOI 10.1111/j.1365-2141.1981.tb02693.x; BURSTEIN SA, 1992, EXP HEMATOL, V20, P1170; BURSTEIN SA, 1995, WILLIAMS HEMATOLOGY, P1149; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CHOI ES, 1995, BLOOD, V85, P402; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DEUEL TF, 1977, P NATL ACAD SCI USA, V74, P2256, DOI 10.1073/pnas.74.6.2256; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JACKSON CW, 1984, BLOOD, V63, P768; JACKSON CW, 1973, BLOOD, V42, P413, DOI 10.1182/blood.V42.3.413.413; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KUTER DJ, 1994, BLOOD, V84, P1464; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LEVINE RF, 1976, J CELL BIOL, V69, P159, DOI 10.1083/jcb.69.1.159; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lind S.E., 1995, BLOOD PRINCIPLES PRA, P949; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MAZUR EM, 1981, J CLIN INVEST, V68, P733, DOI 10.1172/JCI110309; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIURA M, 1988, EXP HEMATOL, V16, P139; MOUTHON MA, 1993, BLOOD, V81, P647; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ODELL TT, 1968, BLOOD, V32, P102, DOI 10.1182/blood.V32.1.102.102; OGAWA M, 1989, HEMATOL ONCOL CLIN N, V3, P453, DOI 10.1016/S0889-8588(18)30541-0; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PAULUS JM, 1970, BLOOD-J HEMATOL, V35, P298, DOI 10.1182/blood.V35.3.298.298; PETERS LL, 1990, BLOOD, V76, P745; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; ROBERTSON EJ, 1987, TERATOCARCIOMAS EMBR; ROBINSON MO, 1994, P NATL ACAD SCI USA, V91, P12798, DOI 10.1073/pnas.91.26.12798; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; SUDA T, 1983, P NATL ACAD SCI-BIOL, V80, P6689, DOI 10.1073/pnas.80.21.6689; SWANK RT, 1993, BLOOD, V81, P2626; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZUCKERFRANKLIN D, 1984, J CELL BIOL, V99, P390, DOI 10.1083/jcb.99.2.390; ZUCKERFRANKLIN D, 1989, ATLAS BLOOD CELLS FU, P621	65	602	617	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 2	1995	81	5					695	704		10.1016/0092-8674(95)90531-6	http://dx.doi.org/10.1016/0092-8674(95)90531-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774011	hybrid			2022-12-24	WOS:A1995RB96100008
J	WERNER, MH; RUTH, JR; GRONENBORN, AM; CLORE, GM				WERNER, MH; RUTH, JR; GRONENBORN, AM; CLORE, GM			MOLECULAR-BASIS OF HUMAN 46X,Y SEX REVERSAL REVEALED FROM THE 3-DIMENSIONAL SOLUTION STRUCTURE OF THE HUMAN SRY-DNA COMPLEX	CELL			English	Article							HMG BOX; BINDING DOMAIN; MINOR-GROOVE; XY FEMALES; NUCLEOPROTEIN STRUCTURES; DETERMINING REGION; DETERMINING LOCUS; CRYSTAL-STRUCTURE; NUCLEIC-ACIDS; PROTEINS	The solution structure of the specific complex between the high mobility group (HMG) domain of SRY (hSRY-HMG), the protein encoded by the human testis-determining gene, and its DNA target site in the promoter of the Mullerian inhibitory substance gene has been determined by multidimensional NMR spectroscopy. hSRY-HMG has a twisted L shape that presents a concave surface (made up of three helices and the N- and C-terminal strands) to the DNA for sequence-specific recognition. Binding of hSRY-HMG to its specific target site occurs exclusively in the minor groove and induces a large conformational change in the DNA. The DNA in the complex has an overall 70 degrees-80 degrees bend and is helically unwound relative to classical A- and B-DNA. The structure of the complex reveals the origin of sequence-specific binding within the HMG-1/HMG-2 family and provides a framework for understanding the effects of point mutations that cause 46X, Y sex reversal at the atomic level.	NIDDKD, CHEM PHYS LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525				AFFARA NA, 1993, HUM MOL GENET, V2, P785, DOI 10.1093/hmg/2.6.785; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1994, METHOD ENZYMOL, V239, P79; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; BRAUN A, 1993, AM J HUM GENET, V52, P578; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger A. T, 1993, XPLOR MANUAL VERSION; BRUNGER AT, 1993, AVS XPLOR USERS MANU; CLORE GM, 1994, PROTEIN SCI, V3, P372; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; DECASTRO E, 1992, VISP ONE ZERO USERS; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GARRETT DS, 1994, J MAGN RESON SER B, V104, P99, DOI 10.1006/jmrb.1994.1061; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; GUSTAFSON ML, 1994, ANNU REV MED, V45, P505, DOI 10.1146/annurev.med.45.1.505; HAQQ CM, 1993, P NATL ACAD SCI USA, V90, P1097, DOI 10.1073/pnas.90.3.1097; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HAWKINS JR, 1992, HUM GENET, V88, P471, DOI 10.1007/BF00215684; HAWKINS JR, 1992, AM J HUM GENET, V51, P979; JONES DNM, 1994, STRUCTURE, V2, P609, DOI 10.1016/S0969-2126(00)00063-0; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; KUSZEWSKI J, 1995, J MAGN RESON SER B, V106, P92, DOI 10.1006/jmrb.1995.1017; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; MCELREAVY K, 1992, P NATL ACAD SCI USA, V89, P11016, DOI 10.1073/pnas.89.22.11016; Nicholls A.J., 1993, GRASP MANUAL; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; NILGES M, 1993, PROTEIN-STRUCT FUNCT, V17, P295; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; READ CM, 1994, EMBO J, V13, P5639, DOI 10.1002/j.1460-2075.1994.tb06902.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; TAJIMA T, 1994, HUM MOL GENET, V3, P1187, DOI 10.1093/hmg/3.7.1187; THIAN R, 1994, CELL, V77, P5; TUCKER PK, 1993, NATURE, V364, P715, DOI 10.1038/364715a0; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0	49	407	413	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					705	714		10.1016/0092-8674(95)90532-4	http://dx.doi.org/10.1016/0092-8674(95)90532-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774012	Bronze			2022-12-24	WOS:A1995RB96100009
J	HOPTON, JL; DLUGOLECKA, M				HOPTON, JL; DLUGOLECKA, M			NEED AND DEMAND FOR PRIMARY HEALTH-CARE - A COMPARATIVE SURVEY APPROACH	BRITISH MEDICAL JOURNAL			English	Article							ORIENTED PRIMARY CARE; RESOURCE-ALLOCATION; PUBLIC-HEALTH; RAWP; NHS	Objective-To develop general practice profiles of needs and demand for primary health care. Design-Postal survey of a stratified random sample of 3478 people registered with five general practices. Data from a single practice were compared with data from the remaining four to identify areas of comparative need. Setting-Five general practices in Lothian. Main outcome measures-Differences between the single practice and the comparison practices in terms of social and economic circumstances, limiting long term illness, specific ongoing conditions, minor illness or symptoms, psychosocial problems, discussion of lifestyle, associated use of services. Results-Respondents from the single practice reported higher rates than those in the four comparison practices of ongoing mental health and respiratory problems and use of antidepressants, tranquillisers, or sleeping tablets. Although rates of limiting long term illness and other specific ongoing conditions were comparable, the rates of minor illness or symptoms and psychosocial difficulties were higher in the single practice. Respondents from the single practice were more likely to consult frequently, to have contacted the practice out of normal working hours, and to have discussed psychosocial difficulties with a general practitioner. For any specific ongoing condition or ''minor'' illness, respondents from the single practice were no more likely to consult. Conclusions-A comparative survey approach is a useful method of developing an understanding of patterns of need and demand among general practice populations. It has the potential to inform planning within individual general practices and the process of commissioning among general practices within a given area.	LOTHIAN HLTH,EDINBURGH,MIDLOTHIAN,SCOTLAND		HOPTON, JL (corresponding author), UNIV EDINBURGH,DEPT GEN PRACTICE,EDINBURGH EH8 9DX,MIDLOTHIAN,SCOTLAND.							ABRAMSON J H, 1988, Public Health Reviews, V16, P35; ASHTON J, 1990, PUBLIC HEALTH, V104, P387, DOI 10.1016/S0033-3506(05)80082-4; BLAXTER M, 1985, Q J SOC AFF, V1, P131; Bradshaw J, 1972, PROBLEMS PROGR MED C, P71; CARRHILL RA, 1991, BRIT MED J, V302, P393, DOI 10.1136/bmj.302.6773.393; DONABEDIAN A, 1973, ASPECTS MED CARE ADM; GAFFY JP, 1994, BRIT MED J, V308, P391; HAM C, 1992, 30 U BIRM HLTH SERV; HANNAY DR, 1993, BRIT MED J, V307, P516, DOI 10.1136/bmj.307.6903.516; HOPTON JL, 1992, BRIT J GEN PRACT, V42, P236; Howie J G, 1972, J R Coll Gen Pract, V22, P310; HOWIE JGR, IN PRESS BR J GEN PR; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; KEVELL PT, 1990, SOC SCI MED, V30, P701; KNOX EG, 1978, J EPIDEMIOL COMMUN H, V32, P3, DOI 10.1136/jech.32.1.3; MAGI M, 1981, SOCIOLOGY HLTH ILLNE, V25, P49; MAYS N, 1989, COMMUNITY MED, V11, P173; MAYS N, 1987, BRIT MED J, V295, P703, DOI 10.1136/bmj.295.6600.703; MCDOWELL I, 1976, INT J EPIDEMIOL, V6, P247; MORLEY V, 1993, BMJ-BRIT MED J, V306, P112, DOI 10.1136/bmj.306.6870.112; REDELMEIER DA, 1990, NEW ENGL J MED, V322, P1162, DOI 10.1056/NEJM199004193221620; SHELDON TA, 1994, BRIT MED J, V309, P1059, DOI 10.1136/bmj.309.6961.1059; SHELDON TA, 1993, BRIT MED J, V306, P835, DOI 10.1136/bmj.306.6881.835; STONE DH, 1987, J ROY COLL GEN PRACT, V37, P218; TOLLMAN S, 1991, SOC SCI MED, V32, P633, DOI 10.1016/0277-9536(91)90142-Y; TUDORHART J, 1984, BRIT MED J, V288, P1670; 1992, LOCAL VOICES; 1989, 1990 CONTRACT GENERA	28	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1369	1373		10.1136/bmj.310.6991.1369	http://dx.doi.org/10.1136/bmj.310.6991.1369			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB005	7787542	Green Published			2022-12-24	WOS:A1995RB00500025
J	BRABIN, L; KEMP, J; OBUNGE, OK; IKIMALO, J; DOLLIMORE, N; ODU, NN; HART, CA; BRIGGS, ND				BRABIN, L; KEMP, J; OBUNGE, OK; IKIMALO, J; DOLLIMORE, N; ODU, NN; HART, CA; BRIGGS, ND			REPRODUCTIVE-TRACT INFECTIONS AND ABORTION AMONG ADOLESCENT GIRLS IN RURAL NIGERIA	LANCET			English	Article							FEMALE ADOLESCENTS; SEXUAL-BEHAVIOR; PREVALENCE; POPULATION; COMMUNITY; DISEASES; HEALTH; WOMEN	Few studies from developing countries have investigated reproductive tract infections or other indicators of sexual health among unmarried adolescent girls in rural areas. We have obtained baseline demographic, clinical, and microbiological data on reproductive tract infections and induced abortion in girls in a rural area of southeast Nigeria, in order to assess the need for health care for adolescents. 868 females attended for interview and examination: 458 aged 20 and above and 410 aged 12-19, the latter representing 93.4% of the adolescent population. 43.6% of those <17 and 80.1% aged 17-19 years were sexually active and at least 24.1% had undergone an induced abortion; only 5.3% had ever used in modern contraceptive. Vaginal discharge was reported by 82.4%, though few sought treatment. 94.1% of sexually active adolescents and 97.6% of sexually active women 20 years old or older were gynaecologically examined and screened for reproductive tract infections. Of those aged less than 17, 19.8% had symptomatic candida and 11.1% trichomonas infections. Among those aged 17-19 years, chlamydia was detected in 10.5%, and symptomatic candidosis in 25.6%; this was the group most likely to have any infection (43.8%). 42.1% of sexually active adolescents had experienced either an abortion or a sexually transmitted disease. Syphilis was the only infection for which the incidence clearly increased with age. Health-care services for adolescents in this community are needed and should include sex education, contraceptive provision (especially barrier methods), and access to treatment for reproductive tract infections. Investments in health for this age group will have an effect on subsequent reproductive health.	UNIV PORT HARCOURT,PORT HARCOURT,NIGERIA; COMMISS WOMEN,PORT HARCOURT,NIGERIA; UNIV LIVERPOOL,DEPT MED MICROBIOL & GENITOURINARY MED,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Port Harcourt; University of Liverpool	BRABIN, L (corresponding author), UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,PEMBROKE PL,LIVERPOOL L3 5QA,MERSEYSIDE,ENGLAND.		Harry, Tubonye/A-2107-2012	Harry, Tubonye/0000-0003-3773-5230; Brabin, Loretta/0000-0003-4478-6503				ADETORO O O, 1991, African Journal of Medicine and Medical Sciences, V20, P149; [Anonymous], 1993, WORLD DEV REPORT; Anosike J. C., 1993, Applied Parasitology, V34, P19; ARNO JN, 1994, SEX TRANSM DIS, V21, P47, DOI 10.1097/00007435-199401000-00010; ARYA OP, 1973, B WORLD HEALTH ORGAN, V49, P587; BANG RA, 1989, LANCET, V1, P85; BARKER GK, 1992, STUD FAMILY PLANN, V23, P199, DOI 10.2307/1966728; BLACKWELL AL, 1993, LANCET, V342, P206, DOI 10.1016/0140-6736(93)92299-9; BLYTHE MJ, 1988, J PEDIATR-US, V112, P1000, DOI 10.1016/S0022-3476(88)80236-1; BLYTHE MJ, 1992, J PEDIATR-US, V121, P487, DOI 10.1016/S0022-3476(05)81812-8; CATES W, 1993, SEX TRANSM DIS, V20, P174, DOI 10.1097/00007435-199305000-00011; Feachem RGA, 1992, HLTH ADULTS DEV WORL; KINSMAN OS, 1986, INFECT IMMUN, V53, P498, DOI 10.1128/IAI.53.3.498-504.1986; LAGA M, 1994, SEX TRANSM DIS, V21, pS45; LAGA M, 1993, AIDS, V3, P95; MOSHA F, 1993, GENITOURIN MED, V69, P415; NICHOLS D, 1986, STUD FAMILY PLANN, V17, P100, DOI 10.2307/1967070; OGBONNA C I C, 1991, Angewandte Parasitologie, V32, P198; OH MK, 1993, SEX TRANSM DIS, V20, P45, DOI 10.1097/00007435-199301000-00009; OLALEYE OD, 1993, J INFECT DIS, V167, P710, DOI 10.1093/infdis/167.3.710; OSOBU AO, 1973, W AFR MED J, V22, P23; ROSENBERG MJ, 1993, SEX TRANSM DIS, V20, P41, DOI 10.1097/00007435-199301000-00008; Singh B, 1977, ADV PLANNED PARENTHO, V12, P45; SINGLETON AF, 1980, CLIN PEDIATR, V19, P799, DOI 10.1177/000992288001901204; SOBEL J, 1990, SEXUALLY TRANSMITTED; VUYLSTEKE B, 1993, CLIN INFECT DIS, V17, P82, DOI 10.1093/clinids/17.1.82; WASSERHEIT JN, 1989, STUD FAMILY PLANN, V20, P69, DOI 10.2307/1966461; YOUNIS N, 1993, STUD FAMILY PLANN, V24, P175, DOI 10.2307/2939232; WHOADH931 DIV FAM HL; 1987, BARRIER CONTRACEPTIV; 1991, PREVENTION ORBIDITY; 1990, GUIDELINES TRAINING; 1992, 1990 NIG DEM HLTH SU	33	91	93	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					300	304		10.1016/S0140-6736(95)90281-3	http://dx.doi.org/10.1016/S0140-6736(95)90281-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE731	7837866				2022-12-24	WOS:A1995QE73100015
J	MULHOLLAND, K				MULHOLLAND, K			MEASLES AND PERTUSSIS IN DEVELOPING-COUNTRIES WITH GOOD VACCINE COVERAGE	LANCET			English	Editorial Material							EPIDEMIC; IMMUNITY; CHILDREN; IMMUNIZATION; POLICY; AGE				MULHOLLAND, K (corresponding author), MRC LABS,POB 273,BANJUL,GAMBIA.							ADCOCK LM, 1992, INFECT DIS CLIN N AM, V6, P133; BAKER CJ, 1988, NEW ENGL J MED, V319, P1180, DOI 10.1056/NEJM198811033191802; BASS JW, 1994, PEDIATR INFECT DIS J, V13, P343, DOI 10.1097/00006454-199405000-00002; BLACK FL, 1984, B WORLD HEALTH ORGAN, V62, P315; BLACK FL, 1986, AM J EPIDEMIOL, V124, P442, DOI 10.1093/oxfordjournals.aje.a114415; BOTTIGER M, 1993, SCAND J INFECT DIS, V25, P239, DOI 10.3109/00365549309008490; CARTER H, 1992, BRIT MED J, V304, P637, DOI 10.1136/bmj.304.6827.637; Clements C. John, 1992, World Health Statistics Quarterly, V45, P285; COHEN P, 1946, J PEDIATR-US, V29, P609, DOI 10.1016/S0022-3476(46)80128-8; ENGLUND JA, IN PRESS J INFECT DI; KAMBARAMI RA, 1991, B WORLD HEALTH ORGAN, V69, P213; LAMB WH, 1988, REV INFECT DIS, V10, P457; LINNEMANN CC, 1982, PEDIATRICS, V69, P332; MCLEAN AR, 1995, LANCET, V345, P272, DOI 10.1016/S0140-6736(95)90272-4; PABST HF, 1992, PEDIATR INFECT DIS J, V11, P525, DOI 10.1097/00006454-199207000-00004; PRESTON NW, 1994, LANCET, V344, P491, DOI 10.1016/S0140-6736(94)91894-5; PROVENZANO RW, 1965, NEW ENGL J MED, V273, P959, DOI 10.1056/NEJM196510282731804; REYNOLDS DW, 1972, AM J DIS CHILD, V124, P848, DOI 10.1001/archpedi.1972.02110180050006; SCHOUB BD, 1993, S AFR MED J, V83, P82; TULCHINSKY TH, 1993, B WORLD HEALTH ORGAN, V71, P93; 1994, CVI FORUM, V7, P2; 1992, LANCET, V340, P232	22	37	38	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					305	307		10.1016/S0140-6736(95)90282-1	http://dx.doi.org/10.1016/S0140-6736(95)90282-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7837867				2022-12-24	WOS:A1995QE73100016
J	BULLITT, E; MAKOWSKI, L				BULLITT, E; MAKOWSKI, L			STRUCTURAL POLYMORPHISM OF BACTERIAL ADHESION PILI	NATURE			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; SUBUNIT; IMAGES; PROTEINS; FLAGELLA; TIP	BACTERIAL adhesion pill are designed to bind specifically and maintain attachment of bacteria to target cells. Uropathogenic P-pili are sufficiently mechanically resilient to resist the cleansing action of urine flow that removes most other bacteria(1). P-pili are 68 Angstrom in diameter and similar to 1 mu m long(2), and are composed of similar to 1,000 copies of the principal structural protein, PapA(3). They are attached to the outer membrane by a minor structural protein, PapH(4) and are terminated by an similar to 20 Angstrom diameter fibrillus composed of PapK, PapE and PapF, which presents the host-binding adhesin PapG(5-7). The amino-acid sequences of PapA(3,8), PapE(9), and PapF(9) are similar, with highly conserved C-termini being responsible for binding to PapD(10-12), the periplasmic chaperone. Our three-dimensional reconstruction indicates that pill are formed by the tight winding of a much thinner structure. A structural transition allows the pilus to unravel without depolymerizing, producing a thin, extended structure five times the length of the original pilus.	FLORIDA STATE UNIV, INST MOLEC BIOPHYS, TALLAHASSEE, FL 32306 USA	State University System of Florida; Florida State University	BULLITT, E (corresponding author), BOSTON UNIV, SCH MED, DEPT BIOPHYS, BOSTON, MA 02118 USA.							AMOS LA, 1975, J MOL BIOL, V99, P51, DOI 10.1016/S0022-2836(75)80158-6; BAGA M, 1987, CELL, V49, P241, DOI 10.1016/0092-8674(87)90565-4; BAGA M, 1984, J BACTERIOL, V157, P330; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; CALLADINE CR, 1978, J MOL BIOL, V118, P457, DOI 10.1016/0022-2836(78)90285-1; DENICH K, 1991, INFECT IMMUN, V59, P3849, DOI 10.1128/IAI.59.11.3849-3858.1991; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; EGELMAN EH, 1986, ULTRAMICROSCOPY, V19, P367, DOI 10.1016/0304-3991(86)90096-3; GONG MF, 1992, J MOL BIOL, V228, P735, DOI 10.1016/0022-2836(92)90860-M; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; HULTGREN SJ, 1993, ADV PROTEIN CHEM, V44, P99, DOI 10.1016/S0065-3233(08)60565-3; JACOBDUBUISSON F, 1993, EMBO J, V12, P837, DOI 10.1002/j.1460-2075.1993.tb05724.x; KAMIYA R, 1976, J MOL BIOL, V106, P167, DOI 10.1016/0022-2836(76)90306-5; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; LINDBERG F, 1987, NATURE, V328, P84, DOI 10.1038/328084a0; LINDBERG F, 1986, P NATL ACAD SCI USA, V83, P1891, DOI 10.1073/pnas.83.6.1891; MACNAB RM, 1977, J MOL BIOL, V112, P1, DOI 10.1016/S0022-2836(77)80153-8; MAKOWSKI L, 1992, J MOL BIOL, V228, P885, DOI 10.1016/0022-2836(92)90872-H; MARKLUND BI, 1992, J BACTERIOL, V157, P330; MORGAN DG, 1992, ULTRAMICROSCOPY, V46, P263, DOI 10.1016/0304-3991(92)90019-G; ORSKOV I, 1980, INFECT IMMUN, V27, P657, DOI 10.1128/IAI.27.2.657-666.1980; OWEN C, 1993, J CELL BIOL, V123, P337, DOI 10.1083/jcb.123.2.337; SLONIM LN, 1992, EMBO J, V11, P4747, DOI 10.1002/j.1460-2075.1992.tb05580.x	24	180	195	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 12	1995	373	6510					164	167		10.1038/373164a0	http://dx.doi.org/10.1038/373164a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816100				2022-12-24	WOS:A1995QB06300063
J	BAERHEIM, A; SANDVIK, H				BAERHEIM, A; SANDVIK, H			EFFECT OF ALE, GARLIC, AND SOURED CREAM ON THE APPETITE OF LEECHES	BRITISH MEDICAL JOURNAL			English	Article											BAERHEIM, A (corresponding author), UNIV BERGEN,DIV GEN PRACTICE,ULRIKSDAL 8C,N-5009 BERGEN,NORWAY.							JOSEPH PK, 1989, INDIAN J EXP BIOL, V27, P997; Laerum O D, 1991, Tidsskr Nor Laegeforen, V111, P924; LENT CM, 1988, SCI AM, V258, P98, DOI 10.1038/scientificamerican0688-98; SANDVIK H, IN PRESS TIDSSKR NOR; 1828, EYR, V3, P57	5	8	8	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1689	1689		10.1136/bmj.309.6970.1689	http://dx.doi.org/10.1136/bmj.309.6970.1689			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819987	Green Published			2022-12-24	WOS:A1994PY71700012
J	CURRIE, PF; JACOB, AJ; FOREMAN, AR; ELTON, RA; BRETTLE, RP; BOON, NA				CURRIE, PF; JACOB, AJ; FOREMAN, AR; ELTON, RA; BRETTLE, RP; BOON, NA			HEART-MUSCLE DISEASE-RELATED TO HIV-INFECTION - PROGNOSTIC IMPLICATIONS	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HOMOSEXUAL MEN; AIDS; RISK; DYSFUNCTION	Objectives-To determine the natural course of heart muscle disease in patients infected with HIV. Design-Prospective echocardiographic survey and observational study over four years. Setting-Edinburgh. Subjects-296 adults infected with HIV (mean age 32.7 years (range 21.5 to 67.6) drawn from all the major groups at risk of HIV infection in Britain. Main outcome measures-Detection of myocardial dysfunction and time to death from index echocardiogram in serial echocardiography. Results-Cardiac dysfunction was identified in 44 subjects (dilated cardiomyopathy, 13; isolated right ventricular dysfunction, 12; borderline left ventricular dysfunction, 19). Dilated cardiomyopathy was strongly associated with a CD4 cell count of < 100x10(6)/1, in contrast with the other forms of cardiac dysfunction. During the study 12/13 (92%) subjects with dilated cardiomyopathy, 5/12 (42%) with right ventricular dysfunction, and 8/19 (42%) with borderline left ventricular function died of conditions related to AIDS. Survival was significantly reduced in the subjects with dilated cardiomyopathy compared with those with normal hearts (P < 0.001). The median survival from the index echocardiogram was 101 days (95% confidence interval 42 to 146) for the subjects with cardiomyopathy compared with 472 days (383 to 560) for those with normal hearts and a CD4 cell count of < 20x10(6)/1. No significant difference existed in survival for subjects with borderline left or isolated right ventricular dysfunction. Conclusion-Even after adjustment for the significantly reduced CD4 cell count with which dilated cardiomyopathy is associated, the outlook for patients with HIV infection and dilated cardiomyopathy is poor. Isolated right and borderline left ventricular dysfunction are not associated with reduced CD4 cells counts and do not carry adverse prognostic implications.	CITY HOSP EDINBURGH,REG INFECT DIS UNIT,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,MED STAT UNIT,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh	CURRIE, PF (corresponding author), ROYAL INFIRM,DEPT CARDIOL,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.							ACIERNO LJ, 1989, J AM COLL CARDIOL, V13, P1144, DOI 10.1016/0735-1097(89)90277-5; ANDERSON DW, 1992, PATHOLOGY AIDS OTHER; CURRIE PF, 1993, Q J MED, V86, P751; DEWOLF F, 1988, J INFECT DIS, V158, P615, DOI 10.1093/infdis/158.3.615; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; GREENSPAN D, 1987, J INFECT DIS, V155, P475, DOI 10.1093/infdis/155.3.475; HERSKOWITZ A, 1994, J AM COLL CARDIOL, V24, P1025, DOI 10.1016/0735-1097(94)90865-6; HIMELMAN RB, 1989, J AM COLL CARDIOL, V13, P1030, DOI 10.1016/0735-1097(89)90256-8; HIMELMAN RB, 1989, AM J CARDIOL, V64, P1396, DOI 10.1016/0002-9149(89)90594-8; JACOB AJ, 1992, BRIT HEART J, V68, P549, DOI 10.1136/hrt.68.12.549; KINNEY EL, 1989, ANGIOLOGY, V40, P970, DOI 10.1177/000331978904001106; KLEIN RS, 1984, NEW ENGL J MED, V311, P354, DOI 10.1056/NEJM198408093110602; MELBYE M, 1987, LANCET, V1, P728; MONSUEZ JJ, 1988, AM J CARDIOL, V62, P1311, DOI 10.1016/0002-9149(88)90286-X; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PETERS BS, 1991, BRIT MED J, V302, P203, DOI 10.1136/bmj.302.6770.203; PHILLIPS AN, 1991, LANCET, V337, P389; WILLOUGHBY SB, 1993, AM J CARDIOL, V71, P446, DOI 10.1016/0002-9149(93)90451-H; 1994, LANCET, V343, P871; 1986, MMWR-MORBID MORTAL W, V35, P334	20	100	102	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1605	1607		10.1136/bmj.309.6969.1605	http://dx.doi.org/10.1136/bmj.309.6969.1605			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819934	Green Published			2022-12-24	WOS:A1994PY22000014
J	MARTEAU, T				MARTEAU, T			SCREENING FOR CARRIERS OF CYSTIC-FIBROSIS - PSYCHOLOGICAL CONSEQUENCES ARE UNCLEAR	BRITISH MEDICAL JOURNAL			English	Article							EARLY-PREGNANCY				MARTEAU, T (corresponding author), UNITED MED & DENT SCH,PSYCHOL & GENET RES GRP,LONDON SE1 9RT,ENGLAND.			Marteau, Theresa/0000-0003-3025-1129	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; BRITTON J, 1991, LANCET, V338, P1524, DOI 10.1016/0140-6736(91)92341-X; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; HARRIS H, 1993, BRIT MED J, V306, P1580, DOI 10.1136/bmj.306.6892.1580; Holland WW, 1990, SCREENING HLTH CARE; ILES S, 1989, BAILLIERE CLIN OB GY, V3, P769, DOI 10.1016/S0950-3552(89)80064-1; SUTCLIFFE M, 1993, LANCET, V342, P1174, DOI 10.1016/0140-6736(93)92158-P; WALTERS S, 1993, BRIT MED J, V306, P549, DOI 10.1136/bmj.306.6877.549; WEST R, 1993, SMOKING PREGNANCY GU, P9; 1991, LANCET, V338, P131; 1992, SMOKING YOUNG REPORT	11	6	6	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1429	1430		10.1136/bmj.309.6966.1429	http://dx.doi.org/10.1136/bmj.309.6966.1429			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PU764	7819858	Green Published			2022-12-24	WOS:A1994PU76400033
J	MURPHY, CJ; ARKIN, MR; JENKINS, Y; GHATLIA, ND; BOSSMANN, SH; TURRO, NJ; BARTON, JK				MURPHY, CJ; ARKIN, MR; JENKINS, Y; GHATLIA, ND; BOSSMANN, SH; TURRO, NJ; BARTON, JK			LONG-RANGE PHOTOINDUCED ELECTRON-TRANSFER THROUGH A DNA HELIX	SCIENCE			English	Article							MARCUS INVERTED REGION; MOLECULAR LIGHT SWITCH; METAL-COMPLEXES; EXCITED-STATE; DIIMINE COMPLEXES; RUTHENIUM(II); DISTANCE; RHODIUM(III); RECOGNITION; SEQUENCE	Rapid photoinduced electron transfer is demonstrated over a distance of greater than 40 angstroms between metallointercalators that are tethered to the 5' termini of a 15-base pair DNA duplex. An oligomeric assembly was synthesized in which the donor is Ru(phen)2dppz2+ (phen, phenanthroline, and dppz, dipyridophenazine) and the acceptor is Rh(phi)2phen3+ (phi, phenanthrenequinone diimine). These metal complexes are intercalated either one or two base steps in from the helix termini. Although the ruthenium-modified oligonucleotide hybridized to an unmodified complement luminesces intensely, the ruthenium-modified oligomer hybridized to the rhodium-modified oligomer shows no detectable luminescence. Time-resolved studies point to a lower limit of 10(9) per second for the quenching rate. No quenching was observed upon metallation of two complementary octamers by Ru(phen)3(2+) and Rh(phen)3(3+) under conditions where the phen complexes do not intercalate. The stacked aromatic heterocycles of the DNA duplex therefore serve as an efficient medium for coupling electron donors and acceptors over very long distances.	CALTECH, BECKMAN INST, PASADENA, CA 91125 USA; COLUMBIA UNIV, DEPT CHEM, NEW YORK, NY 10027 USA	California Institute of Technology; Columbia University			Bossmann, Stefan/AAG-9881-2020	Murphy, Catherine/0000-0001-7066-5575	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049216] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49216] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOUYAL E, 1990, J CHEM SOC DALTON, P1841, DOI 10.1039/dt9900001841; BANNWARTH W, 1988, HELV CHIM ACTA, V71, P2085, DOI 10.1002/hlca.19880710826; BARTON JK, 1986, J AM CHEM SOC, V108, P6391, DOI 10.1021/ja00280a047; BARTON JK, 1986, J AM CHEM SOC, V108, P2081, DOI 10.1021/ja00268a057; BERATAN DN, 1991, ADV CHEM SER, P71; BOWLER BE, 1990, PROG INORG CHEM, V38, P259; BRUN AM, 1992, J AM CHEM SOC, V114, P3656, DOI 10.1021/ja00036a013; CHAMBRON JC, 1985, NOUV J CHIM, V9, P527; CHEN CHB, 1986, P NATL ACAD SCI USA, V83, P7147, DOI 10.1073/pnas.83.19.7147; CHOW CS, 1990, J AM CHEM SOC, V112, P2839, DOI 10.1021/ja00163a076; CHOW CS, 1992, BIOCHEMISTRY-US, V31, P972, DOI 10.1021/bi00119a005; CLEMENTI E, 1982, INT J QUANTUM CHEM, P213; CLOSS GL, 1988, SCIENCE, V240, P440, DOI 10.1126/science.240.4851.440; CLOSS GL, 1986, J PHYS CHEM-US, V90, P3673, DOI 10.1021/j100407a039; DAVID SS, 1993, J AM CHEM SOC, V115, P2984, DOI 10.1021/ja00060a060; FRIEDMAN AE, 1990, J AM CHEM SOC, V112, P4960, DOI 10.1021/ja00168a052; FROMHERZ P, 1986, J AM CHEM SOC, V108, P5361, DOI 10.1021/ja00277a060; FURUE M, 1990, CHEM LETT, P2065, DOI 10.1246/cl.1990.2065; GUPTA N, 1992, ANGEW CHEM INT EDIT, V31, P1048, DOI 10.1002/anie.199210481; HARTSHORN RM, 1992, J AM CHEM SOC, V114, P5919, DOI 10.1021/ja00041a002; HOFFMAN BM, 1991, STRUCT BOND, V75, P85; HOFFMANN TA, 1964, ADV CHEM PHYS, V7, P84; JENKINS Y, 1992, BIOCHEMISTRY-US, V31, P10809, DOI 10.1021/bi00159a023; JENKINS Y, 1992, J AM CHEM SOC, V114, P8736, DOI 10.1021/ja00048a077; JORAN AD, 1987, NATURE, V327, P508, DOI 10.1038/327508a0; JORAN AD, 1984, J AM CHEM SOC, V106, P6090, DOI 10.1021/ja00332a062; KALYANASUNDARAM K, 1992, J PHYS CHEM-US, V96, P5865, DOI 10.1021/j100193a041; KROTZ AH, 1993, J AM CHEM SOC, V115, P3877, DOI 10.1021/ja00063a004; KROTZ AH, 1990, IN PRESS INORG CHEM, V29; KUMAR CV, 1985, J AM CHEM SOC, V107, P5518, DOI 10.1021/ja00305a032; LARSSON S, 1982, CHEM PHYS LETT, V90, P136, DOI 10.1016/0009-2614(82)83627-0; LINDBERG O, 1954, METHODS BIOCH ANAL, V3; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MARCUS RA, 1964, ANNU REV PHYS CHEM, V15, P155, DOI 10.1146/annurev.pc.15.100164.001103; MARKS TJ, 1985, SCIENCE, V227, P881, DOI 10.1126/science.227.4689.881; MCLENDON G, 1988, ACCOUNTS CHEM RES, V21, P160, DOI 10.1021/ar00148a005; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; MURPHY CF, UNPUB; NALEWAY CA, 1991, J PHYS CHEM-US, V95, P8434, DOI 10.1021/j100175a005; NOZAKI K, 1992, J PHYS CHEM-US, V96, P10880, DOI 10.1021/j100205a051; PURUGGANAN MD, 1988, SCIENCE, V241, P1645, DOI 10.1126/science.3420416; PYLE AM, 1990, J AM CHEM SOC, V112, P9432, DOI 10.1021/ja00181a077; PYLE AM, 1990, INORG CHEM, V29, P4487, DOI 10.1021/ic00347a031; PYLE AM, 1989, J AM CHEM SOC, V111, P4520, DOI 10.1021/ja00194a070; RATNER MA, 1990, J PHYS CHEM-US, V94, P4877, DOI 10.1021/j100375a024; SCHOUTEN PG, 1991, NATURE, V353, P736, DOI 10.1038/353736a0; SITLANI A, 1992, J AM CHEM SOC, V114, P2303, DOI 10.1021/ja00033a003; TANAKA M, 1991, J PHYS CHEM-US, V95, P955, DOI 10.1021/j100155a084; TELSER J, 1989, J AM CHEM SOC, V111, P7221, DOI 10.1021/ja00200a049; Turro N. J., 1978, MODERN MOL PHOTOCHEM; UCHIDA K, 1989, NUCLEIC ACIDS RES, V17, P10259, DOI 10.1093/nar/17.24.10259; WASIELEWSKI MR, 1992, CHEM REV, V92, P435, DOI 10.1021/cr00011a005; WOITELLIER S, 1989, INORG CHEM, V28, P758, DOI 10.1021/ic00303a029	53	894	936	3	172	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1993	262	5136					1025	1029		10.1126/science.7802858	http://dx.doi.org/10.1126/science.7802858			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	7802858				2022-12-24	WOS:A1993MG18700026
J	NIGHTINGALE, SL				NIGHTINGALE, SL			SEAFOOD SAFETY HOT LINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1897	1897						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783288				2022-12-24	WOS:A1995RE35400009
J	BEACH, ME; HAWKINS, RD; OSMAN, M; KANDEL, ER; MAYFORD, M				BEACH, ME; HAWKINS, RD; OSMAN, M; KANDEL, ER; MAYFORD, M			IMPAIRMENT OF SPATIAL BUT NOT CONTEXTUAL MEMORY IN CAMKII MUTANT MICE WITH A SELECTIVE LOSS OF HIPPOCAMPAL LTP IN THE RANGE OF THE THETA-FREQUENCY	CELL			English	Article							LONG-TERM POTENTIATION; RADIAL MAZE; PLACE NAVIGATION; RATS; BEHAVIOR; NEURONS; RHYTHM; AREA; CA1; STIMULATION	We assessed hippocampal-dependent memory in mice with a Ca2+-independent form of CaMKII generated by the introduction of an aspartate at amino acid 286. The CaMKII-Asp-286 mice show normal LTP at high frequency stimulation, but in the 5-10 Hz range, they show a shift in the frequency-response curve favoring LTD. This range of frequencies is similar to the theta rhythm, which is associated with exploration in rodents. Using the Barnes maze to assess spatial memory, we found the transgenic mice could not learn to navigate to a specific location using spatial cues. In contrast, one line of transgenic mice performed normally in contextual fear conditioning, a task that is also hippocampal dependent. This dissociation between spatial and contextual memory suggests that even though both require the hippocampus, they may be mediated by different synaptic mechanisms.			BEACH, ME (corresponding author), COLUMBIA UNIV, COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.			Mayford, Mark/0000-0002-9001-5024	NIMH NIH HHS [MH50733] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ARAI A, 1992, BRAIN RES, V598, P173, DOI 10.1016/0006-8993(92)90181-8; AUER RN, 1989, J NEUROSCI, V9, P1641; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; BEARMF, 1994, CURR OPIN NEUROBIOL, V4, P389; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLANCHARD RJ, 1969, J COMP PHYSIOL PSYCH, V67, P370, DOI 10.1037/h0026779; BLAND BH, 1986, PROG NEUROBIOL, V26, P1, DOI 10.1016/0301-0082(86)90019-5; BLAND BH, 1988, BRAIN RES, V447, P364, DOI 10.1016/0006-8993(88)91141-9; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLLES RC, 1970, PSYCHOL REV, V77, P32, DOI 10.1037/h0028589; CAREW TJ, 1973, SCIENCE, V182, P1158, DOI 10.1126/science.182.4117.1158; COSTALL B, 1989, PHARMACOL BIOCHEM BE, V32, P777, DOI 10.1016/0091-3057(89)90033-6; DALE RHI, 1986, BEHAV BRAIN RES, V19, P17, DOI 10.1016/0166-4328(86)90043-4; DAVIS HP, 1990, SYMP MED H, V23, P477; DAVIS S, 1992, J NEUROSCI, V12, P21; DEVAN BD, 1992, PSYCHOBIOLOGY, V20, P120; DEVENPORT LD, 1988, BEHAV NEUROSCI, V102, P489; DIMATTIA BD, 1988, BEHAV NEUROSCI, V102, P471, DOI 10.1037/0735-7044.102.4.471; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; FANSELOW MS, 1980, PAVLOVIAN J BIOL SCI, V15, P177; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GALLAGHER M, 1993, BEHAV NEUROSCI, V107, P618, DOI 10.1037/0735-7044.107.4.618; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HEBB DO, 1949, ORG BEHAVIOR; HUERTA PT, 1993, NATURE, V364, P723, DOI 10.1038/364723a0; KANDEL ER, 1968, PHYSIOL REV, V48, P65, DOI 10.1152/physrev.1968.48.1.65; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; LEUNG LWS, 1991, BRAIN RES, V553, P261, DOI 10.1016/0006-8993(91)90834-I; MACVICAR BA, 1989, J PHYSIOL-LONDON, V417, P197, DOI 10.1113/jphysiol.1989.sp017797; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MULLER RU, 1991, BRAIN SPACE, P297; O'Keefe J, 1993, Curr Opin Neurobiol, V3, P917, DOI 10.1016/0959-4388(93)90163-S; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; Olton D., 1978, COGNITIVE PROCESS, P341; OLTON DS, 1978, PHYSIOL BEHAV, V20, P597, DOI 10.1016/0031-9384(78)90252-4; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; SCHACTER DL, 1994, MEMORY SYYSTEMS; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SEJNOWSKI TJ, 1977, J MATH BIOL, V4, P303, DOI 10.1007/BF00275079; SHAPIRO ML, 1992, BEHAV NEUROSCI, V106, P604, DOI 10.1037/0735-7044.106.4.604; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SMYTHE JW, 1992, NEUROSCI BIOBEHAV R, V16, P289, DOI 10.1016/S0149-7634(05)80203-9; SPARKS PD, 1995, BEHAV NEUROSCI, V109, P184; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; STADDON JER, 1983, ADAPTIVE BEHAVIOR LE, P378; STEVENS CF, 1994, CURR BIOL, V4, P687, DOI 10.1016/S0960-9822(00)00153-6; SUTHERLAND RJ, 1984, CAN J PSYCHOL, V38, P322, DOI 10.1037/h0080832; SUZUKI S, 1980, LEARN MOTIV, V11, P1, DOI 10.1016/0023-9690(80)90018-1; TOLMAN EC, 1948, PSYCHOL REV, V55, P189, DOI 10.1037/h0061626; WATTS J, 1981, PHYSIOL BEHAV, V26, P845, DOI 10.1016/0031-9384(81)90108-6; WINSON J, 1978, SCIENCE, V201, P160, DOI 10.1126/science.663646; YOERG SI, 1982, ANIM LEARN BEHAV, V10, P530, DOI 10.3758/BF03212295; ZOLADEK L, 1978, ANIM LEARN BEHAV, V6, P77, DOI 10.3758/BF03212006; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	61	355	367	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 16	1995	81	6					905	915		10.1016/0092-8674(95)90010-1	http://dx.doi.org/10.1016/0092-8674(95)90010-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781067	Bronze			2022-12-24	WOS:A1995RD76800011
J	JEANLOZ, R; MITCHELL, DL; SPRAGUE, AL; DEPATER, I				JEANLOZ, R; MITCHELL, DL; SPRAGUE, AL; DEPATER, I			EVIDENCE FOR A BASALT-FREE SURFACE ON MERCURY AND IMPLICATIONS FOR INTERNAL HEAT	SCIENCE			English	Article							THERMAL EVOLUTION; ATMOSPHERE; POTASSIUM; MANTLE; PLANETS; SODIUM	Microwave and mid-infrared observations reveal that Mercury's surface contains less FeO + TiO2 and at least as much feldspar as the lunar highlands. The results are compatible with the high albedo (brightness) of Mercury's surface at visible wavelengths in suggesting a rock and soil composition that is devoid of basalt, the primary differentiate of terrestrial mantles. The occurrence of a basalt-free, highly differentiated crust is in accord with recent models of the planet's thermal evolution and suggests that Mercury has retained a hot interior as a result of a combination of inefficient mantle convection and minimal volcanic heat loss.	CALTECH,JET PROP LAB,PASADENA,CA 91109; UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721; UNIV CALIF BERKELEY,DEPT ASTRON,BERKELEY,CA 94720	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Arizona; University of California System; University of California Berkeley	JEANLOZ, R (corresponding author), UNIV CALIF BERKELEY,DEPT GEOL & GEOPHYS,BERKELEY,CA 94720, USA.							BENZ W, 1988, ICARUS, V74, P516, DOI 10.1016/0019-1035(88)90118-2; Cameron A. G. W., 1988, MERCURY, P692; CAMPBELL MJ, 1969, J GEOPHYS RES, V74, P5867, DOI 10.1029/JB074i025p05867; Chapman C., 1988, MERCURY, P670; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; GRIEVE RA, 1993, METEORITICS, V28, P602; GRIEVE RAF, 1992, METEORITICS, V27, P526, DOI 10.1111/j.1945-5100.1992.tb01074.x; Heiken GH., 1991, LUNAR SOURCEBOOK; Hunten D.M., 1988, MERCURY, P562; HYNDMAN DW, 1982, PETROLOGY IGNEOUS ME; JEANLOZ R, 1986, ANNU REV EARTH PL SC, V14, P377, DOI 10.1146/annurev.ea.14.050186.002113; KILLEN RM, 1991, SCIENCE, V252, P974, DOI 10.1126/science.252.5008.974; LEDLOW MJ, 1992, ASTROPHYS J, V384, P640, DOI 10.1086/170906; Lewis J.S., 1988, MERCURY, P651; Lissauer J.J., 1993, PROTOSTARS PLANETS, P1061; Melosh H.J., 1988, TECTONICS MERCURY, P374; MITCHELL DL, 1994, ICARUS, V110, P2, DOI 10.1006/icar.1994.1105; NESS NF, 1979, PHYS EARTH PLANET IN, V20, P209, DOI 10.1016/0031-9201(79)90044-X; NESS NF, 1975, J GEOPHYS RES-SPACE, V80, P2708, DOI 10.1029/JA080i019p02708; NESS NF, 1978, SPACE SCI REV, V21, P527, DOI 10.1007/BF00240907; POTTER A, 1985, SCIENCE, V229, P651, DOI 10.1126/science.229.4714.651; POTTER AE, 1990, SCIENCE, V248, P835, DOI 10.1126/science.248.4957.835; POTTER AE, 1986, ICARUS, V67, P336, DOI 10.1016/0019-1035(86)90113-2; Ringwood A.E, 1975, COMPOSITION PETROLOG; ROEDER PL, 1970, CONTRIB MINERAL PETR, V29, P275, DOI 10.1007/BF00371276; Schubert G., 1988, MERCURY, P429; SHOEMAKER EM, 1994, SCIENCE, V266, P1851, DOI 10.1126/science.266.5192.1851; SOLOMON SC, 1978, GEOPHYS RES LETT, V5, P461, DOI 10.1029/GL005i006p00461; SPOHN T, 1991, ICARUS, V90, P222, DOI 10.1016/0019-1035(91)90103-Z; SPRAGUE AL, 1994, ICARUS, V109, P156, DOI 10.1006/icar.1994.1083; SPRAGUE AL, 1990, SCIENCE, V249, P1140, DOI 10.1126/science.249.4973.1140; STEVENSON DJ, 1983, ICARUS, V54, P466, DOI 10.1016/0019-1035(83)90241-5; STOLPER E, 1981, J GEOPHYS RES, V86, P6261, DOI 10.1029/JB086iB07p06261; STROM RG, 1989, MERCURY ELUSIVE PLAN; STROM RG, 1984, NASA, P13; Taylor SR, 1992, SOLAR SYSTEM EVOLUTI; TONKS WB, 1992, ICARUS, V109, P326; TYLER AL, 1988, GEOPHYS RES LETT, V15, P808, DOI 10.1029/GL015i008p00808; Veverka J., 1988, MERCURY, P37; Vilas F., 1988, MERCURY; VILAS F, 1988, MERCURY, P59; VONHIPPEL AR, 1952, DIELECTRIC MATERIALS; Wasson J.T., 1988, MERCURY, P622; Yoder H. S. J., 1976, GENERATION BASALTIC; 1981, BASALTIC VOLCANISM T	45	68	68	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1455	1457		10.1126/science.7770770	http://dx.doi.org/10.1126/science.7770770			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770770				2022-12-24	WOS:A1995RC19000027
J	SUZUKI, H; KUNDIG, TM; FURLONGER, C; WAKEHAM, A; TIMMS, E; MATSUYAMA, T; SCHMITS, R; SIMARD, JJL; OHASHI, PS; GRIESSER, H; TANIGUCHI, T; PAIGE, CJ; MAK, TW				SUZUKI, H; KUNDIG, TM; FURLONGER, C; WAKEHAM, A; TIMMS, E; MATSUYAMA, T; SCHMITS, R; SIMARD, JJL; OHASHI, PS; GRIESSER, H; TANIGUCHI, T; PAIGE, CJ; MAK, TW			DEREGULATED T-CELL ACTIVATION AND AUTOIMMUNITY IN MICE LACKING INTERLEUKIN-2 RECEPTOR-BETA	SCIENCE			English	Article							IL-2 RECEPTOR; MOLECULAR-CLONING; HUMAN NEUTROPHILS; LYMPHOCYTE-T; GAMMA-CHAIN; EXPRESSION; GENE; P75; SUBSETS; CDNAS	In mice lacking the interleukin-2 receptor beta chain (lL-2R beta), T cells were shown to be spontaneously activated, resulting in exhaustive differentiation of B cells into plasma cells and the appearance of high serum concentrations of immunoglobulins G1 and E as well as autoantibodies that cause hemolytic anemia. Marked infiltrative granulocytopoiesis was also apparent, and the animals died after about 12 weeks. Depletion of CD4(+) T cells in mutant mice rescued B cells without reversion of granulocyte abnormalities. T cells did not proliferate in response to polyclonal activators, nor could antigen-specific immune responses be elicited. Thus, IL-2R beta is required to keep the activation programs of T cells under control, to maintain homeostasis, and to prevent autoimmunity.	UNIV TORONTO,ONTARIO CANC INST,AMGEN INST,DEPT IMMUNOL,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,ONTARIO CANC INST,AMGEN INST,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,WELLESLEY HOSP,RES INST,TORONTO,ON M4Y 1J3,CANADA; UNIV TORONTO,DEPT PATHOL,TORONTO,ON M4X 1K9,CANADA; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Osaka University				Ohashi, Pamela S./0000-0003-2915-9317				ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BEGLEY CG, 1990, LEUKEMIA RES, V14, P263, DOI 10.1016/0145-2126(90)90134-U; CHARAN S, 1986, J VIROL, V57, P1139, DOI 10.1128/JVI.57.3.1139-1144.1986; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; DJEU JY, 1993, J IMMUNOL, V150, P960; ESPINOZADELGADO I, 1990, J EXP MED, V171, P1821, DOI 10.1084/jem.171.5.1821; FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; JENKINSON EJ, 1994, CURR OPIN IMMUNOL, V6, P293, DOI 10.1016/0952-7915(94)90104-X; KONO T, 1990, P NATL ACAD SCI USA, V87, P1806, DOI 10.1073/pnas.87.5.1806; LEIST TP, 1987, J IMMUNOL, V138, P2278; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEUNG WP, 1994, J EXP MED, V180, P959; MATSUYAMA T, 1992, CELL, V75, P1; MOSKOPHIDIS D, 1989, P NATL ACAD SCI USA, V86, P3291, DOI 10.1073/pnas.86.9.3291; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NISHIKAWA K, 1990, INT IMMUNOL, V2, P481, DOI 10.1093/intimm/2.6.481; RAULET DH, 1985, NATURE, V314, P101, DOI 10.1038/314101a0; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; STARKEY PM, 1991, IMMUNOLOGY, V73, P64; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAKEUCHI Y, 1992, EUR J IMMUNOL, V22, P2929, DOI 10.1002/eji.1830221126; TANAKA K, 1993, J IMMUNOL, V151, P748; TANAKA K, 1994, CELL IMMUNOL, V153, P401; TANAKA T, 1992, INT IMMUNOL, V4, P487, DOI 10.1093/intimm/4.4.487; TORIBIO ML, 1989, NATURE, V342, P82, DOI 10.1038/342082a0; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X; WEI S, 1993, J IMMUNOL, V150, P1979; YOKOYAMA WM, 1988, J IMMUNOL, V141, P369; ZOLA H, 1991, IMMUNOLOGY, V72, P167	35	729	743	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1472	1476		10.1126/science.7770771	http://dx.doi.org/10.1126/science.7770771			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770771				2022-12-24	WOS:A1995RC19000033
J	HUNG, J; KISHIMOTO, Y; SUGIO, K; VIRMANI, A; MCINTIRE, DD; MINNA, JD; GAZDAR, AF				HUNG, J; KISHIMOTO, Y; SUGIO, K; VIRMANI, A; MCINTIRE, DD; MINNA, JD; GAZDAR, AF			ALLELE-SPECIFIC CHROMOSOME 3P DELETIONS OCCUR AT AN EARLY-STAGE IN THE PATHOGENESIS OF LUNG-CARCINOMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SMALL-CELL; BRONCHIAL EPITHELIUM; SHORT ARM; CANCER; DNA; ABNORMALITIES; AMPLIFICATION; HYPERPLASIA; TUMORS; GENE	Background.-Deletions in the short arm of chromosome 3 (3p) are present in most lung carcinomas. Objective.-To investigate the role of these chromosome 3p deletions in the pathogenesis of non-small cell lung carcinomas. Design.-Seven archival, paraffin-embedded, surgically resected lung cancer specimens were studied. Fifty precisely identified malignant and preneoplastic lesions present in bronchi, bronchioles, and alveoli were microdissected from stained slides and analyzed for allele loss using polymerase chain reaction-based assays for dinucleotide repeat polymorphisms at three chromosome 3p loci (3p14, 3p21.3, and 3p25). Setting.-University-based medical center and affiliated hospitals. Subjects.-Samples were analyzed from seven patients who underwent surgical resection with curative intent for non-small cell lung cancer and whose specimens included extensive multifocal areas of preneoplastic lesions (hyperplasia, metaplasia, dysplasia, or noninvasive cancer). Results.-Lymphocytes from all seven cases were heterozygous (ie, informative) for all three microsatellites analyzed. Six (86%) of seven invasive cancers had loss of heterozygosity at one or more chromosome 3p sites. In the accompanying preneoplastic lesions, loss of heterozygosity was detected in none of two normal bronchioles, 13 (76%) of 17 hyperplasias, six (86%) of seven dysplasias, and four (100%) of four noninvasive cancers. Loss of heterozygosity was detected throughout the respiratory tract, in bronchi, bronchioles, and alveoli. In 18 (78%) of 23 preneoplastic lesions, the specific alleles lost were identical to those lost in the corresponding carcinomas. The probability of this happening by chance is 5.3x10(-3). Conclusions.-Deletions in the short arm of chromosome 3 occur at the earliest stage (hyperplasia) in the pathogenesis of lung cancer and involve all regions of the respiratory tract. Allele loss is highly specific, but its mechanism remains unknown. Our findings may be of considerable biologic, prognostic, and clinical significance.	UNIV TEXAS,SW MED CTR,SIMMONS CANC CTR,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX; UNIV TEXAS,SW MED CTR,ACAD COMP SERV,DALLAS,TX	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NCI NIH HHS [P20 CA58220-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P20CA058220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUERBACH O, 1979, NEW ENGL J MED, V300, P381, DOI 10.1056/NEJM197902223000801; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; CHEN B, 1994, CARCINOGENESIS, V15, P2031, DOI 10.1093/carcin/15.9.2031; CHENG JM, 1993, NAT GENET, V4, P191, DOI 10.1038/ng0693-191; DALY MC, 1993, ONCOGENE, V8, P1271; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FERGUSONSMITH AC, 1990, CANCER SURV, V9, P487; GAZDAR AF, 1994, BIOL GENETICS LUNG C; GREENBERG SD, 1987, LUNG CARCINOMAS, P287; HALL JG, 1992, NEW ENGL J MED, V326, P827, DOI 10.1056/NEJM199203193261210; HEGI ME, 1994, CANCER RES, V54, P6257; HIBI K, 1992, ONCOGENE, V7, P445; Jones Michael H., 1992, Human Molecular Genetics, V1, P131, DOI 10.1093/hmg/1.2.131; KNUDSON AG, 1989, BRIT J CANCER, V59, P661, DOI 10.1038/bjc.1989.137; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LITT M, 1993, BIOTECHNIQUES, V15, P280; MINNA JD, 1993, CHEST, V103, pS449, DOI 10.1378/chest.103.4_Supplement.449S; NAKANISHI K, 1990, ARCH PATHOL LAB MED, V114, P363; OCONNELL P, 1994, BREAST CANCER RES TR, V32, P5, DOI 10.1007/BF00666201; PAABO S, 1989, P NATL ACAD SCI USA, V86, P1939, DOI 10.1073/pnas.86.6.1939; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; SACCOMANNO G, 1976, ANN NY ACAD SCI, V271, P377, DOI 10.1111/j.1749-6632.1976.tb23134.x; SARKAR G, 1990, NUCLEIC ACIDS RES, V18, P7465, DOI 10.1093/nar/18.24.7465; SATO S, 1994, CANCER RES, V54, P5652; SEKIDO Y, 1994, ONCOGENE, V9, P853; SIEGEL S, 1956, NONPARAMETRIC STAT, P36; SLAUGHTER DP, 1954, CANCER, V6, P963; SOZZI G, 1991, CANCER RES, V51, P400; STRONG MS, 1984, J OTOLARYNGOL, V13, P1; SUGIO K, 1994, CANCER RES, V54, P5811; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; WENG S, 1990, HISTOPATHOLOGY, V16, P101, DOI 10.1111/j.1365-2559.1990.tb01073.x; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WHETSELL L, 1992, ONCOGENE, V7, P2355; YAMAKAWA K, 1993, ONCOGENE, V8, P327; [No title captured]	38	288	307	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					558	563		10.1001/jama.273.7.558	http://dx.doi.org/10.1001/jama.273.7.558			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF686	7837389				2022-12-24	WOS:A1995QF68600026
J	LILLY, B; ZHAO, B; RANGANAYAKULU, G; PATERSON, BM; SCHULZ, RA; OLSON, EN				LILLY, B; ZHAO, B; RANGANAYAKULU, G; PATERSON, BM; SCHULZ, RA; OLSON, EN			REQUIREMENT OF MADS DOMAIN TRANSCRIPTION FACTOR D-MEF2 FOR MUSCLE FORMATION IN DROSOPHILA	SCIENCE			English	Article							ENHANCER-BINDING-FACTOR; FACTOR MEF-2; GENE; EXPRESSION; PROTEINS; ENCODES; MEMBER; FAMILY; EMBRYOGENESIS; TRANSPOSITION	Members of the myocyte enhancer binding factor-2 (MEF2) family of MADS (MCM1, agamous, deficiens, and serum response factor) box transcription factors are expressed in the skeletal, cardiac, and smooth muscle lineages of vertebrate and Drosophila embryos. These factors bind an adenine-thymidine-rich DNA sequence associated with muscle-specific genes. The function of MEF2 was determined by generating a loss-of-function of the single mef2 gene in Drosophila (D-mef2). In loss-of-function embryos, somatic, cardiac, and visceral muscle cells did not differentiate, but myoblasts were normally specified and positioned. These results demonstrate that different muscle cell types share a common myogenic differentiation program controlled by MEF2.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030; NCI,BIOCHEM LAB,BETHESDA,MD 20892	University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			LILLY, BRENDA/N-6867-2015	LILLY, BRENDA/0000-0002-3125-7496				AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BATE M, 1993, DEV DROSOPHILA MELAN, V3, P1013; BODMER R, 1993, DEVELOPMENT, V118, P719; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAVIS R, COMMUNICATION; DOHRMANN C, 1990, GENE DEV, V4, P2098, DOI 10.1101/gad.4.12a.2098; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; KAISER K, 1990, P NATL ACAD SCI USA, V87, P1686, DOI 10.1073/pnas.87.5.1686; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KIEHART DP, 1986, J CELL BIOL, V103, P1517, DOI 10.1083/jcb.103.4.1517; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, THESIS U TEXAS HOUST; Martin J., UNPUB; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; OBRIEN MA, 1994, GENETICS, V137, P121; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RANGANAYAKULU G, UNPUB; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING LAB MANU; SHISHIDO E, 1993, DEVELOPMENT, V117, P751; TOWER J, 1993, GENETICS, V133, P347; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WRIGHT WE, 1993, CURR OPIN GENET DEV, V2, P243; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHANG P, 1993, GENETICS, V133, P361	46	412	426	0	21	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					688	693		10.1126/science.7839146	http://dx.doi.org/10.1126/science.7839146			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839146				2022-12-24	WOS:A1995QE73300041
J	MENINI, A; PICCO, C; FIRESTEIN, S				MENINI, A; PICCO, C; FIRESTEIN, S			QUANTAL-LIKE CURRENT FLUCTUATIONS INDUCED BY ODORANTS IN OLFACTORY RECEPTOR-CELLS	NATURE			English	Article							MONKEY MACACA-FASCICULARIS; VISUAL TRANSDUCTION; TIGER SALAMANDER; RETINAL RODS; CONDUCTANCE; CHANNELS; CILIA	MANY sensory systems have evolved signal detection capabilities that are limited only by the physical attributes of the stimulus(1). For example, 'hair' cells of the inner ear can detect displacements of atomic dimensions(2). Likewise, both in vertebrates and in invertebrates photoreceptors can detect a single photon(3,4). The olfactory stimulus also has a quantal unit, the single odorant molecule, Insects are reportedly able to detect a single pheromone molecule(5), whereas quantal responses in vertebrate olfactory receptor cells have not been reported yet. Psychophysical measurements indicate that a minimum of 50 odorant molecules are necessary for human olfactory detection, suggesting that an individual receptor may be activated ba a single odorant molecule(6). We report here measurements of current fluctuations induced by odorants that suggest a quantal event of about 03-1 pA, presumably triggered by the binding of a single odorant molecule.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University	MENINI, A (corresponding author), CNR, IST CIBERNET & BIOFIS, I-16146 GENOA, ITALY.			Picco, Cristiana/0000-0002-6512-1802; Menini, Anna/0000-0001-9304-0412				BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BLOCK SM, 1992, SOC GEN PHY, V47, P1; CRAWFORD AC, 1985, J PHYSIOL-LONDON, V364, P359, DOI 10.1113/jphysiol.1985.sp015750; DEVRIES H, 1961, SENS COMMUN, P159; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; FIRESTEIN S, 1987, P NATL ACAD SCI USA, V84, P6292, DOI 10.1073/pnas.84.17.6292; FUORTES MGF, 1964, J GEN PHYSIOL, V47, P443, DOI 10.1085/jgp.47.3.443; KALSSLING KE, 1986, A REV NEUROSCI, V9, P121; KLEENE SJ, 1991, J NEUROSCI, V11, P3624; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; KURAHASHI T, 1993, NATURE, V363, P71, DOI 10.1038/363071a0; LAMB TD, 1992, TRENDS NEUROSCI, V15, P291, DOI 10.1016/0166-2236(92)90079-N; LYNCH JW, 1989, BIOPHYS J, V55, P755, DOI 10.1016/S0006-3495(89)82874-7; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NUNN BJ, 1982, NATURE, V299, P726, DOI 10.1038/299726a0; SCHNAPF JL, 1990, J PHYSIOL-LONDON, V427, P681, DOI 10.1113/jphysiol.1990.sp018193; TROTIER D, 1986, PFLUG ARCH EUR J PHY, V407, P589, DOI 10.1007/BF00582636; ZUFALL F, 1991, J NEUROSCI, V11, P3573	19	69	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					435	437		10.1038/373435a0	http://dx.doi.org/10.1038/373435a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830795				2022-12-24	WOS:A1995QE67000058
J	COWEY, A; STOERIG, P				COWEY, A; STOERIG, P			BLINDSIGHT IN MONKEYS	NATURE			English	Article							RESIDUAL VISION	BLINDSIGHT, the visually evoked voluntary responses of patients with striate cortical destruction that are demonstrated despite a phenomenal blindness, has attracted attention from neuroscientists and philosophers interested in problems of perceptual consciousness and its neuronal basis(1-3). It is assumed to be mediated by the numerous extra-geniculostriate cortical retinofugal pathways whose properties are studied primarily in monkeys(4). Like patients with blindsight(4-7), monkeys with lesions of the primary visual cortex can learn to detect, localize and distinguish between visual stimuli presented within their visual field defects(4,8-11). Although the patients deny seeing the stimuli they can nevertheless respond to (by forced-choice guessing) in their phenomenally blind fields, it is not known whether the monkeys experience the same absence of phenomenal vision. To determine whether they too have blindsight, or whether they actuary see the stimuli in their held defects, monkeys who showed excellent detection in tasks where a visual stimulus was presented on every trial, albeit at different positions, were tested in a signal-detection task(12) in which half the trials were blank trials, with no visual stimulus. They classified the visual stimuli presented in the field defect as blank trials, demonstrating, like patients, blindsight rather than degraded real vision.	UNIV MUNICH,INST MED PSYCHOL,D-80336 MUNICH,GERMANY	University of Munich	COWEY, A (corresponding author), UNIV OXFORD,DEPT EXPTL PSYCHOL,S PARKS RD,OXFORD OX1 3UD,ENGLAND.							BARBUR JL, 1980, BRAIN, V103, P905, DOI 10.1093/brain/103.4.905; BARBUR JL, 1993, BRAIN, V116, P1293, DOI 10.1093/brain/116.6.1293; BLYTHE IM, 1987, BRAIN, V110, P887, DOI 10.1093/brain/110.4.887; COWEY A, 1963, Q J EXP PSYCHOL, V15, P91, DOI 10.1080/17470216308416561; COWEY A, 1991, TRENDS NEUROSCI, V14, P140, DOI 10.1016/0166-2236(91)90085-9; Crick F., 1990, Seminars in the Neurosciences, V2, P263; FENDRICH R, 1992, SCIENCE, V258, P1489, DOI 10.1126/science.1439839; Kluver H, 1941, J PSYCHOL, V11, P23; MOHLER CW, 1977, J NEUROPHYSIOL, V40, P74, DOI 10.1152/jn.1977.40.1.74; NELKIN N, 1993, PHILOS SCI, V60, P419, DOI 10.1086/289744; PASIK P, 1982, CONTRIBUTIONS SENSOR, V7, P147; STOERIG P, 1993, THEOR MED, V14, P117, DOI 10.1007/BF00997271; STOERIG P, 1991, BRAIN, V114, P1489; Swets J., 1982, EVALUATION DIAGNOSTI; WEISKRANTZ L, 1990, PROC R SOC SER B-BIO, V239, P247, DOI 10.1098/rspb.1990.0016; Weiskrantz L., 1986, BLINDSIGHT CASE STUD	16	213	215	0	46	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					247	249		10.1038/373247a0	http://dx.doi.org/10.1038/373247a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QC278	7816139				2022-12-24	WOS:A1995QC27800064
J	GODDARD, N; COULL, D				GODDARD, N; COULL, D			COLOR-BLIND CRICKETERS AND SNOWBALLS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether colour blindness affects batting in professional cricketers. Design-Comparison of batting averages of colour blind cricketers and those with normal vision. Setting-Players on 18 first class county cricket teams. Subjects-280 of 306 players were tested. Main outcome measures-Results of Isihara colour blindness tests. Results-Batting average for the colour blind group (12 players) was slightly lower than for players with normal vision (20.88 v 26.31). There was no difference in the number of batsmen and bowlers affected. Batting averages before and after the introduction of the white ball into Sunday League cricket did not differ significantly. Conclusions-That batting performance is not significantly impaired by colour blindness suggests that to some extent these players are self selected. Routine testing of cricketers for colour blindness is not recommended.			GODDARD, N (corresponding author), ROYAL FREE HOSP,SCH MED,LONDON NW3 2QG,ENGLAND.							FRINDALL B, 1994, PLAYFAIR CRICKET ANN; TREVORROPER PD, 1976, LECTURE NOTES OPHTHA	2	5	5	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1684	1685		10.1136/bmj.309.6970.1684	http://dx.doi.org/10.1136/bmj.309.6970.1684			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819984	Green Published			2022-12-24	WOS:A1994PY71700008
J	SAGGARMALIK, AK; MISSOURIS, CG; GILL, JS; SINGER, DRJ; MARKANDU, ND; MACGREGOR, GA				SAGGARMALIK, AK; MISSOURIS, CG; GILL, JS; SINGER, DRJ; MARKANDU, ND; MACGREGOR, GA			LEFT-VENTRICULAR MASS IN NORMOTENSIVE SUBJECTS WITH AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE		ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON SW17 0RE,ENGLAND	St Georges University London	SAGGARMALIK, AK (corresponding author), ST GEORGE HOSP,SCH MED,BLOOD PRESSURE UNIT,LONDON SW17 0RE,ENGLAND.							ABISAMRA F, 1983, AM J MED, V75, P26, DOI 10.1016/0002-9343(83)90114-6; IGLESIAS CG, 1983, AM J KIDNEY DIS, V2, P630; JOHNSTON DW, 1993, BMJ-BRIT MED J, V306, P963, DOI 10.1136/bmj.306.6883.963; TIMIO M, 1992, CLIN NEPHROL, V37, P245; ZEIER M, 1993, J AM SOC NEPHROL, V3, P1451	5	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1617	1618		10.1136/bmj.309.6969.1617	http://dx.doi.org/10.1136/bmj.309.6969.1617			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819937	Green Published			2022-12-24	WOS:A1994PY22000018
J	PANDEY, M; GAUTAM, A; SHUKLA, VK				PANDEY, M; GAUTAM, A; SHUKLA, VK			ABO AND RH BLOOD-GROUPS IN PATIENTS WITH CHOLELITHIASIS AND CARCINOMA OF THE GALLBLADDER	BRITISH MEDICAL JOURNAL			English	Article							CANCER		BANARAS HINDU UNIV,INST MED SCI,DEPT SURG,VARANASI 221005,UTTAR PRADESH,INDIA	Banaras Hindu University (BHU)			Pandey, Manoj/AAS-2315-2020; Gautam, Amitabh/A-5636-2013	Pandey, Manoj/0000-0002-1496-9846; Gautam, Amitabh/0000-0002-0969-7866				AIRD I, 1953, BRIT MED J, V1, P799, DOI 10.1136/bmj.1.4814.799; HENDERSON J, 1993, J EPIDEMIOL COMMUN H, V47, P287, DOI 10.1136/jech.47.4.287; JUVONEN T, 1992, BRIT MED J, V305, P26, DOI 10.1136/bmj.305.6844.26; SHUKLA VK, 1985, J SURG ONCOL, V28, P32, DOI 10.1002/jso.2930280109; SLATER G, 1993, DIS COLON RECTUM, V36, P5, DOI 10.1007/BF02050293	5	27	28	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1639	1639		10.1136/bmj.310.6995.1639	http://dx.doi.org/10.1136/bmj.310.6995.1639			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF698	7795450	Green Published			2022-12-24	WOS:A1995RF69800021
J	SANES, JN; DONOGHUE, JP; THANGARAJ, V; EDELMAN, RR; WARACH, S				SANES, JN; DONOGHUE, JP; THANGARAJ, V; EDELMAN, RR; WARACH, S			SHARED NEURAL SUBSTRATES CONTROLLING HAND MOVEMENTS IN HUMAN MOTOR CORTEX	SCIENCE			English	Article							CEREBRAL BLOOD-FLOW; POSITRON EMISSION TOMOGRAPHY; SUPPLEMENTARY MOTOR; VOLUNTARY MOVEMENTS; CORTICAL AREAS; ORGANIZATION; CONNECTIONS; STIMULATION; MONKEYS; ARM	Voluntary hand movements in humans involve the primary motor cortex (M1). A functional magnetic resonance imaging method that measures relative cerebral blood flow was used to identify a distributed, overlapping pattern of hand movement representation within the posterior precentral gyrus, which contains M1. The observed pattern resembles those reported in nonhuman primates and differs from a somatotopically organized plan typically used to portray human motor cortex organization. Finger and wrist movements activated a wide expanse of the posterior precentral gyrus, and representations for different finger movements overlapped each other and the wrist representation. Multiple sites of activation occurred in the precentral gyrus for all movements. The overlapping representations may mediate motor and cognitive functions requiring coordinated neural processing for finger and wrist actions rather than discrete control implied by somatotopic maps.	HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT RADIOL, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	SANES, JN (corresponding author), BROWN UNIV, DIV BIOL & MED, DEPT NEUROSCI, PROVIDENCE, RI 02912 USA.		Warach, Steven/R-5074-2019		NIA NIH HHS [AG 10634] Funding Source: Medline; NINDS NIH HHS [NS 25074, NS 01634] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS025074, K08NS001634, R01NS025074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG010634] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENNETT KMB, 1994, J PHYSIOL-LONDON, V477, P291, DOI 10.1113/jphysiol.1994.sp020191; BOECKER H, 1994, BRAIN, V117, P1231, DOI 10.1093/brain/117.6.1231; COLEBATCH JG, 1991, J NEUROPHYSIOL, V65, P1392, DOI 10.1152/jn.1991.65.6.1392; CONSTABLE RT, 1993, MAGN RESON IMAGING, V11, P451, DOI 10.1016/0730-725X(93)90463-N; DELBER MP, 1991, EXP BRAIN RES, V84, P393; DONOGHUE JP, 1992, EXP BRAIN RES, V89, P1; EDELMAN RR, 1994, RADIOLOGY, V192, P513, DOI 10.1148/radiology.192.2.8029425; GOULD HJ, 1986, J COMP NEUROL, V247, P297, DOI 10.1002/cne.902470303; GRAFTON ST, 1991, J NEUROPHYSIOL, V66, P735, DOI 10.1152/jn.1991.66.3.735; GRAFTON ST, 1993, EXP BRAIN RES, V95, P172; HESS G, 1994, J NEUROPHYSIOL, V71, P2543, DOI 10.1152/jn.1994.71.6.2543; HUNTLEY GW, 1991, J NEUROPHYSIOL, V66, P390, DOI 10.1152/jn.1991.66.2.390; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; KIM SG, 1993, J NEUROPHYSIOL, V69, P297, DOI 10.1152/jn.1993.69.1.297; KIM SG, 1993, SCIENCE, V261, P615, DOI 10.1126/science.8342027; KWAN HC, 1978, J NEUROPHYSIOL, V41, P1120, DOI 10.1152/jn.1978.41.5.1120; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LUKASHIN AV, 1994, P NATL ACAD SCI USA, V91, P8651, DOI 10.1073/pnas.91.18.8651; MCKIERNAN BJ, 1994, ROC NEUR ABS, V20, P983; NUDO RJ, 1992, J NEUROSCI, V12, P2918, DOI 10.1523/JNEUROSCI.12-08-02918.1992; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; RAO SM, 1995, NEUROLOGY, V45, P919, DOI 10.1212/WNL.45.5.919; RAO SM, 1993, NEUROLOGY, V43, P2311, DOI 10.1212/WNL.43.11.2311; ROLAND PE, 1980, J NEUROPHYSIOL, V43, P137, DOI 10.1152/jn.1980.43.1.137; ROLAND PE, 1980, J NEUROPHYSIOL, V43, P118, DOI 10.1152/jn.1980.43.1.118; SANES JN, 1994, BEHAV BRAIN SCI, V17, P221, DOI 10.1017/S0140525X00034270; SCHAD LR, 1993, MAGN RESON IMAGING, V11, P461, DOI 10.1016/0730-725X(93)90464-O; SCHIEBER MH, 1993, SCIENCE, V261, P489, DOI 10.1126/science.8332915; WOOLSEY CN, 1950, RES PUBL ASSOC RES N, V30, P238	29	367	376	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 23	1995	268	5218					1775	1777		10.1126/science.7792606	http://dx.doi.org/10.1126/science.7792606			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792606				2022-12-24	WOS:A1995RE66800049
J	ARMSTRONG, DS; GRIMWOOD, K; CARZINO, R; CARLIN, JB; OLINSKY, A; PHELAN, PD				ARMSTRONG, DS; GRIMWOOD, K; CARZINO, R; CARLIN, JB; OLINSKY, A; PHELAN, PD			LOWER RESPIRATORY-INFECTION AND INFLAMMATION IN INFANTS WITH NEWLY-DIAGNOSED CYSTIC-FIBROSIS	BRITISH MEDICAL JOURNAL			English	Article									UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT THORAC MED,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT PAEDIAT,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,ROYAL CHILDRENS HOSP,CLIN EPIDEMIOL & BIOSTAT UNIT,PARKVILLE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne			Carlin, John/AAG-4332-2020; Grimwood, Keith/F-9334-2011; Carlin, John B/B-3492-2012	Carlin, John/0000-0002-2694-9463; Carlin, John B/0000-0002-2694-9463; Grimwood, Keith/0000-0003-3174-9834				ABMAN SH, 1991, J PEDIATR-US, V119, P211, DOI 10.1016/S0022-3476(05)80729-2; BIRRER P, 1994, AM J RESP CRIT CARE, V150, P207, DOI 10.1164/ajrccm.150.1.7912987; KAHN FW, 1987, J INFECT DIS, V155, P862, DOI 10.1093/infdis/155.5.862; KONSTAN MW, 1994, AM J RESP CRIT CARE, V150, P448, DOI 10.1164/ajrccm.150.2.8049828; RAMSEY BW, 1991, AM REV RESPIR DIS, V144, P331, DOI 10.1164/ajrccm/144.2.331	5	269	273	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1571	1572		10.1136/bmj.310.6994.1571	http://dx.doi.org/10.1136/bmj.310.6994.1571			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787647	Green Published			2022-12-24	WOS:A1995RE35300021
J	SPENCER, I; UNWIN, N; PLEDGER, G				SPENCER, I; UNWIN, N; PLEDGER, G			HOSPITAL INVESTIGATION OF MEN AND WOMEN TREATED FOR ANGINA	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,DEPT MED,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; NEWCASTLE & N TYNESIDE HLTH AUTHOR,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK				Unwin, Nigel/0000-0002-1368-1648				CAMPEAU L, 1975, CIRCULATION, V54, P522; CLARKE KW, 1994, BMJ-BRIT MED J, V309, P563, DOI 10.1136/bmj.309.6954.563; JACKSON G, 1994, BRIT MED J, V309, P555, DOI 10.1136/bmj.309.6954.555; PETTICREW M, 1994, BRIT MED J, V306, P1164; Rose G, 1982, CARDIOVASCULAR SURVE	5	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1576	1576		10.1136/bmj.310.6994.1576	http://dx.doi.org/10.1136/bmj.310.6994.1576			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787649	Green Published			2022-12-24	WOS:A1995RE35300024
J	CARRINGTON, WA; LYNCH, RM; MOORE, EDW; ISENBERG, G; FOGARTY, KE; FREDRIC, FS				CARRINGTON, WA; LYNCH, RM; MOORE, EDW; ISENBERG, G; FOGARTY, KE; FREDRIC, FS			SUPERRESOLUTION 3-DIMENSIONAL IMAGES OF FLUORESCENCE IN CELLS WITH MINIMAL LIGHT EXPOSURE	SCIENCE			English	Article							SMOOTH-MUSCLE; MICROSCOPY; NUCLEUS	Fluorescent probes offer insight into the highly localized and rapid molecular events that underlie cell function. However, methods are required that can efficiently transform the limited signals from such probes into high-resolution images. An algorithm has now been developed that produces highly accurate images of fluorescent probe distribution inside cells with minimal light exposure and a conventional light microscope. This method provides resolution nearly four times greater than that currently available from any fluorescence microscope and was used to study several biological problems.	UNIV ARIZONA, DEPT PHYSIOL, TUCSON, AZ 85724 USA; UNIV BRITISH COLUMBIA, DEPT PHYSIOL, VANCOUVER, BC V6T 1Z3, CANADA; UNIV HALLE WITTENBERG, FAK MED, JULIUS BERNSTEIN INST PHYSIOL, DEPT PHYSIOL, D-06097 HALLE, GERMANY	University of Arizona; University of British Columbia; Martin Luther University Halle Wittenberg	CARRINGTON, WA (corresponding author), UNIV MASSACHUSETTS, SCH MED, PROGRAM MOLEC MED, BIOMED IMAGING GRP, WORCESTER, MA 01605 USA.			Moore, Edwin DW/0000-0001-7519-5592				AGARD DA, 1989, METHOD CELL BIOL, V30, P353; AGARD DA, 1983, NATURE, V302, P676, DOI 10.1038/302676a0; BOYDE A, 1985, SCIENCE, V230, P1270, DOI 10.1126/science.4071051; BRAKENHOFF GJ, 1985, NATURE, V317, P748, DOI 10.1038/317748a0; BRENNER M, 1994, AM LAB, V26, P14; BUTLER JP, 1981, SIAM J NUMER ANAL, V18, P381, DOI 10.1137/0718025; CARRINGTON W, 1987, 13TH P ANN NE BIOENG, P108; CARRINGTON WA, 1990, P SOC PHOTO-OPT INS, V1205, P72, DOI 10.1117/12.17785; CARRINGTON WA, 1989, HANDBOOK OF BIOLOGICAL CONFOCAL MICROSCOPY, REVISED EDITION, P151; CARRINGTON WA, 1990, NONINVASIVE TECHNIQU, P53; CARRINGTON WA, 1992, THESIS WASHINGTON U; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; COLEMAN R, 1987, J MICROSC-OXFORD, V153, P233; CONCHELLO JA, 1994, SPIE P, V2302, P369; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; ELLIOTT DJ, 1992, EMBO J, V11, P3731, DOI 10.1002/j.1460-2075.1992.tb05458.x; FAY FS, 1989, J MICROSC-OXFORD, V153, P133, DOI 10.1111/j.1365-2818.1989.tb00554.x; FAY FS, 1986, OPTICAL METHODS CELL, P51; FRISKENGIBSON S, 1989, J OPT SOC AM A, V6, P9; GASBJERG PK, 1994, BIOPHYS J, V66, pA274; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GROETSCH CW, 1984, RES NOTES MATH, V107; GUERRERO A, 1993, BIOPHYS J, V64, pA153; GULL SF, 1978, NATURE, V272, P686, DOI 10.1038/272686a0; Hanson K. M., 1987, IMAGE RECOVERY THEOR, P79; HELL S, 1993, J MICROSC-OXFORD, V169, P391, DOI 10.1111/j.1365-2818.1993.tb03315.x; HIRAOKA Y, 1987, SCIENCE, V238, P36, DOI 10.1126/science.3116667; IINO M, 1987, BIOCHEM BIOPH RES CO, V142, P47, DOI 10.1016/0006-291X(87)90449-9; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KOSHY M, 1990, SOC PHOTO OPT INSTRU, V1205, P64; KRISHNAMURTHY V, 1992, SPIE, V1660, P95; Lanni F., 1993, Bioimaging, V1, P187, DOI 10.1002/1361-6374(199312)1:4<187::AID-BIO1>3.3.CO;2-G; LOEW LM, 1993, BIOPHYS J, V65, P2396, DOI 10.1016/S0006-3495(93)81318-3; LOEW LM, 1994, P NATL ACAD SCI USA, V91, P12579, DOI 10.1073/pnas.91.26.12579; LYNCH R M, 1991, Biophysical Journal, V59, p157A; MOORE EDW, 1993, NATURE, V365, P657, DOI 10.1038/365657a0; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; TELLA LL, 1985, THESIS WORCESTER POL; Tikhonov A. N., 1977, SOLUTION ILL POSED P; TUFT R A, 1992, Biophysical Journal, V61, pA34; Wilson J E, 1980, Curr Top Cell Regul, V16, P1; WILSON JE, 1988, MICROCOMPARTMENTATIO, P172	42	285	298	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 9	1995	268	5216					1483	1487		10.1126/science.7770772	http://dx.doi.org/10.1126/science.7770772			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770772				2022-12-24	WOS:A1995RC19000036
J	FUNAKOSHI, H; BELLUARDO, N; ARENAS, E; YAMAMOTO, Y; CASABONA, A; PERSSON, H; IBANEZ, CF				FUNAKOSHI, H; BELLUARDO, N; ARENAS, E; YAMAMOTO, Y; CASABONA, A; PERSSON, H; IBANEZ, CF			MUSCLE-DERIVED NEUROTROPHIN-4 AS AN ACTIVITY-DEPENDENT TROPHIC SIGNAL FOR ADULT MOTOR-NEURONS	SCIENCE			English	Article							NEUROMUSCULAR-JUNCTIONS; POSTNATAL-DEVELOPMENT; MESSENGER-RNA; CELL-DEATH; NERVE; BRAIN; EXPRESSION; RECEPTORS; SURVIVAL; INVIVO	The production of neurotrophin-4 (NT-4) in rat skeletal muscle was found to depend on muscle activity. The amounts of NT-4 messenger RNA present decreased after blockade of neuromuscular transmission with alpha-bungarotoxin and increased during postnatal development and after electrical stimulation in a dose-dependent manner. NT-4 immunoreactivity was detected in slow, type I muscle fibers. Intramuscular administration of NT-4 induced sprouting of intact adult motor nerves. Thus, muscle-derived NT-4 acted as an activity-dependent neurotrophic signal for growth and remodeling of about motor-neuron innervation. NT-4 may thus be partly responsible for the effects of exercise and electrical stimulation on neuromuscular performance.	KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,MOLEC NEUROBIOL LAB,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,NOBEL INST NEUROPHYSIOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,INST WOMAN & CHILD HLTH,S-17177 STOCKHOLM,SWEDEN; UNIV CATANIA,INST FISIOL HUMANA,CATANIA,ITALY	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Catania			Arenas, Ernest/AAO-5231-2020	Arenas, Ernest/0000-0003-0197-6577; Casabona, Antonino/0000-0003-0180-4695				BALICEGORDON RJ, 1990, J NEUROSCI, V10, P894; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BRADLEY WG, 1983, ANN NEUROL, V14, P267, DOI 10.1002/ana.410140304; BROWN MC, 1981, ANNU REV NEUROSCI, V4, P17, DOI 10.1146/annurev.ne.04.030181.000313; CARONI P, 1994, J CELL BIOL, V125, P893, DOI 10.1083/jcb.125.4.893; CONNOLD AL, 1986, DEV BRAIN RES, V28, P99, DOI 10.1016/0165-3806(86)90069-6; CONNOLD AL, 1994, NEUROSCIENCE, V63, P327, DOI 10.1016/0306-4522(94)90027-2; CONNOR EA, 1994, J NEUROBIOL, V25, P722, DOI 10.1002/neu.480250611; CZEH G, 1978, J PHYSIOL-LONDON, V281, P239, DOI 10.1113/jphysiol.1978.sp012419; DENNIS MJ, 1981, ANNU REV NEUROSCI, V4, P43, DOI 10.1146/annurev.ne.04.030181.000355; DESCHENES MR, 1993, J NEUROCYTOL, V22, P603, DOI 10.1007/BF01181487; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; FUNAKOSHI H, 1993, J CELL BIOL, V123, P455, DOI 10.1083/jcb.123.2.455; Funakoshi H., UNPUB; GURNEY ME, 1992, J NEUROSCI, V12, P3241, DOI 10.1523/JNEUROSCI.12-08-03241.1992; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HENDERSON CE, 1983, NATURE, V302, P609, DOI 10.1038/302609a0; HOPKINS WG, 1981, J NEUROCYTOL, V10, P537, DOI 10.1007/BF01262589; IBANEZ CF, 1993, DEVELOPMENT, V117, P1345; KAPLAN DB, COMMUNICATION; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; LANDMESSER L, 1992, J NEUROBIOL, V23, P1131, DOI 10.1002/neu.480230906; LIND A, 1991, J HISTOCHEM CYTOCHEM, V39, P589, DOI 10.1177/39.5.1826695; MUNSAT TL, 1976, ARCH NEUROL-CHICAGO, V33, P608, DOI 10.1001/archneur.1976.00500090014004; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; PERSSON H, 1993, CURR OPIN NEUROL NEU, V6, P11; PIEHL F, 1994, NEUROREPORT, V5, P697, DOI 10.1097/00001756-199402000-00009; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; WAERHAUG O, 1992, ANAT EMBRYOL, V185, P115; WERNIG A, 1991, J NEUROCYTOL, V20, P903, DOI 10.1007/BF01190468; WERNIG A, 1986, PROG NEUROBIOL, V27, P251, DOI 10.1016/0301-0082(86)90023-7; WIGSTON DJ, 1989, J NEUROSCI, V9, P639; WONG V, 1993, EUR J NEUROSCI, V5, P466, DOI 10.1111/j.1460-9568.1993.tb00513.x; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0	38	305	324	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1495	1499		10.1126/science.7770776	http://dx.doi.org/10.1126/science.7770776			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770776				2022-12-24	WOS:A1995RC19000040
J	KATZ, JD; BENOIST, C; MATHIS, D				KATZ, JD; BENOIST, C; MATHIS, D			T-HELPER CELL SUBSETS IN INSULIN-DEPENDENT DIABETES	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; NOD MICE; INTERFERON-GAMMA; LEISHMANIA-MAJOR; TRANSGENIC MICE; CD4+; ANTIBODY; RECEPTOR; INTERLEUKIN-4; DESTRUCTION	It has been proposed that the development of insulin-dependent diabetes is controlled by the T helper 1 (T(H)1) versus T(H)2 phenotype of autoreactive T-H cells: T(H)1 cells would promote diabetes, whereas, T(H)2 cells would actually protect from disease. This proposition was tested by establishing cultures of T(H)1 and T(H)2 cells that express and identical diabetogenic T cell receptor and comparing their ability to initiate disease in neonatal nonobese diabetic mice. T(H)1-like cells actively promoted diabetes; T(H)2-like cells invaded the islets but did not provoke disease-neither did they provide substantial protection.	UNIV STRASBOURG 1, INST GENET & BIOL MOLEC & CELLULAIRE, CNRS, INSERM, F-67404 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Katz, Jonathan/0000-0002-9864-2268				AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; ALZONA M, 1994, J IMMUNOL, V153, P2861; ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428; BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; BENDELAC A, 1987, J EXP MED, V166, P823, DOI 10.1084/jem.166.4.823; BENDTZEN K, 1986, SCIENCE, V232, P1545, DOI 10.1126/science.3086977; BRADLEY BJ, 1992, DIABETES, V41, P1603, DOI 10.2337/diabetes.41.12.1603; CAMPBELL IL, 1991, J CLIN INVEST, V87, P739, DOI 10.1172/JCI115055; CHRISTIANSON SW, 1993, DIABETES, V42, P44, DOI 10.2337/diabetes.42.1.44; CROFT M, 1992, J EXP MED, V176, P1431, DOI 10.1084/jem.176.5.1431; DARDENNE M, 1989, EUR J IMMUNOL, V19, P889, DOI 10.1002/eji.1830190516; DEBRAYSACHS M, 1991, J AUTOIMMUN, V4, P237, DOI 10.1016/0896-8411(91)90021-4; DUNCAN DD, 1994, EUR J IMMUNOL, V24, P2506, DOI 10.1002/eji.1830241037; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; HARADA M, 1986, EXP ANIM TOKYO, V35, P501, DOI 10.1538/expanim1978.35.4_501; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HASKINS K, 1990, SCIENCE, V249, P1433, DOI 10.1126/science.2205920; HATTORI M, 1986, SCIENCE, V231, P733, DOI 10.1126/science.3003909; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HSIEH CS, 1993, INT IMMUNOL, V5, P371; KATZ JD, 1993, CELL, V74, P1089, DOI 10.1016/0092-8674(93)90730-E; KATZ JE, UNPUB; KOIKE T, 1987, DIABETES, V36, P539, DOI 10.2337/diabetes.36.4.539; LAGOO AS, 1994, EUR J IMMUNOL, V24, P3087, DOI 10.1002/eji.1830241226; LEAL LMCC, 1993, EUR J IMMUNOL, V23, P566, DOI 10.1002/eji.1830230241; LEE MS, 1994, J CLIN INVEST, V93, P1332, DOI 10.1172/JCI117092; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; MAKINO S, 1986, EXP ANIM TOKYO, V35, P495, DOI 10.1538/expanim1978.35.4_495; MILLER BJ, 1988, J IMMUNOL, V140, P52; MIYAZAKI A, 1985, CLIN EXP IMMUNOL, V60, P622; MORI Y, 1986, DIABETOLOGIA, V29, P244, DOI 10.1007/BF00454884; MORITANI M, 1994, INT IMMUNOL, V6, P1927, DOI 10.1093/intimm/6.12.1927; NAKANO N, 1991, J EXP MED, V173, P1091, DOI 10.1084/jem.173.5.1091; NANDA NK, 1994, INT IMMUNOL, V6, P731, DOI 10.1093/intimm/6.5.731; OGAWA M, 1985, BIOMED RES-TOKYO, V6, P103; OREILLY LA, 1991, EUR J IMMUNOL, V21, P1171, DOI 10.1002/eji.1830210512; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PENNLINE KJ, 1994, CLIN IMMUNOL IMMUNOP, V71, P169, DOI 10.1006/clin.1994.1068; PFEIFFER C, 1995, J EXP MED, V181, P1569, DOI 10.1084/jem.181.4.1569; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; PUKEL C, 1988, DIABETES, V37, P133, DOI 10.2337/diabetes.37.1.133; RAPOPORT MJ, 1993, J EXP MED, V178, P87, DOI 10.1084/jem.178.1.87; REICH EP, 1989, NATURE, V341, P326, DOI 10.1038/341326a0; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; SCHMITT E, 1994, EUR J IMMUNOL, V24, P343, DOI 10.1002/eji.1830240211; SCOTT B, 1994, IMMUNITY, V1, P73, DOI 10.1016/1074-7613(94)90011-6; SCOTT P, 1993, CURR OPIN IMMUNOL, V5, P391, DOI 10.1016/0952-7915(93)90058-Z; SEDER RA, 1995, J EXP MED, V181, P5, DOI 10.1084/jem.181.1.5; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SEMPEP, 1991, EUR J IMMUNOL, V21, P1663; SHEHADEH NN, 1993, J AUTOIMMUN, V6, P291, DOI 10.1006/jaut.1993.1025; SHIZURU JA, 1988, SCIENCE, V240, P659, DOI 10.1126/science.2966437; SWAIN SL, 1994, IMMUNITY, V1, P543, DOI 10.1016/1074-7613(94)90044-2; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; TREMBLEAU S, 1995, J EXP MED, V181, P817, DOI 10.1084/jem.181.2.817; VOLLMER S, 1994, EUR J IMMUNOL, V24, P2377, DOI 10.1002/eji.1830241018; WANG Y, 1991, P NATL ACAD SCI USA, V88, P527, DOI 10.1073/pnas.88.2.527; WOGENSEN L, 1994, J EXP MED, V179, P1379, DOI 10.1084/jem.179.4.1379	60	523	544	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	1995	268	5214					1185	1188		10.1126/science.7761837	http://dx.doi.org/10.1126/science.7761837			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761837				2022-12-24	WOS:A1995RA60400040
J	SINGH, R; VALCARCEL, J; GREEN, MR				SINGH, R; VALCARCEL, J; GREEN, MR			DISTINCT BINDING SPECIFICITIES AND FUNCTIONS OF HIGHER EUKARYOTIC POLYPYRIMIDINE TRACT-BINDING PROTEINS	SCIENCE			English	Article							PRE-MESSENGER-RNA; SPLICING FACTOR U2AF; CIS-ACTING ELEMENTS; SEX-LETHAL; PREMESSENGER RNA; TRANSFORMER GENE; DROSOPHILA; SITE; EXON; CLONING	In higher eukaryotes, the polypyrimidine-tract (Py-tract) adjacent to the 3' splice site is recognized by several proteins, including the essential splicing factor U2AF(65), the splicing regulator Sex-lethal (Sxl), and polypyrimidine tract-binding protein (PTB), whose function is unknown. Iterative in vitro genetic selection was used to show that these proteins have distinct sequence preferences. The uridine-rich degenerate sequences selected by U2AF(65) are similar to those present in the diverse array of natural metazoan Py-tracts. In contrast, the Sxl-consensus is a highly specific sequence, which can help explain the ability of Sxl to regulate splicing of transformer pre-mRNA and autoregulate splicing of its own pre-mRNA. The PTB-consensus is not a typical Py-tract; it can be found in certain alternatively spliced pre-mRNAs that undergo negative regulation. Here it is shown that PTB can regulate alternative splicing by selectively repressing 3' splice sites that contain a PTB-binding site.			SINGH, R (corresponding author), UNIV MASSACHUSETTS, MED CTR, HOWARD HUGHES MED INST, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA.		Valcarcel, Juan/O-9814-2014	Valcarcel, Juan/0000-0001-5398-3571				BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; GOODING C, 1994, EMBO J, V13, P3861, DOI 10.1002/j.1460-2075.1994.tb06697.x; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; HORABIN JI, 1993, MOL CELL BIOL, V13, P7734, DOI 10.1128/MCB.13.12.7734; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; IRVINE D, 1991, J MOL BIOL, V222, P739, DOI 10.1016/0022-2836(91)90509-5; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; JIN W, 1990, NUCLEIC ACIDS RES, V18, P5995, DOI 10.1093/nar/18.20.5995; KANAAR R, 1993, SCIENCE, V262, P569, DOI 10.1126/science.7692602; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; MAYEDA A, 1994, SCIENCE, V265, P1706; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOOREMJ, 1993, RNA WORLD, P1; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; NADALGINARD B, 1991, ADV ENZYME REGUL, V31, P261, DOI 10.1016/0065-2571(91)90017-G; NORTON PA, 1994, NUCLEIC ACIDS RES, V22, P3854, DOI 10.1093/nar/22.19.3854; ONEIL MT, 1992, GENETICS, V131, P113; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; POTASHKIN J, 1993, SCIENCE, V262, P573, DOI 10.1126/science.8211184; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; SAIKI R. K., 1990, PCR PROTOCOLS GUIDE, P13; SAKAMOTO H, 1992, NUCLEIC ACIDS RES, V20, P5533, DOI 10.1093/nar/20.21.5533; SAKASHITA E, 1994, NUCLEIC ACIDS RES, V22, P4082, DOI 10.1093/nar/22.20.4082; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SOSNOWSKI BA, 1994, DEV BIOL, V161, P302, DOI 10.1006/dbio.1994.1030; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SZOSTAK JW, 1992, TRENDS BIOCHEM SCI, V17, P89, DOI 10.1016/0968-0004(92)90242-2; TIAN M, 1994, GENE DEV, V8, P1703, DOI 10.1101/gad.8.14.1703; TSUKAHARA T, 1994, NUCLEIC ACIDS RES, V22, P2318, DOI 10.1093/nar/22.12.2318; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; WANG JW, 1994, GENE DEV, V8, P2072, DOI 10.1101/gad.8.17.2072; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAPP ML, 1989, NUCLEIC ACIDS RES, V17, P2655, DOI 10.1093/nar/17.7.2655	50	467	474	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	1995	268	5214					1173	1176		10.1126/science.7761834	http://dx.doi.org/10.1126/science.7761834			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761834				2022-12-24	WOS:A1995RA60400036
J	KOOPMANS, PP				KOOPMANS, PP			REGISTRATION OF DRUGS FOR TREATING CANCER AND HIV-INFECTION - A PLEA TO CARRY OUT PHASE-3 TRIALS BEFORE ADMISSION TO THE MARKET	BRITISH MEDICAL JOURNAL			English	Article							CHEMOTHERAPY; THERAPY; QUALITY; AIDS; LIFE	Drugs for cancer and HIV infection tend to be admitted to the market on the basis of results from phase 2 trials. Assessing the benefit-risk balance with phase 2 trials often is difficult-the effect of the drug is usually temporary; the correlation between response or improvement of clinical measurements and the patient's wellbeing is often poor; and the side effects of drugs for these fatal diseases are serious. Therefore, although sometimes difficult to conduct, comparative trials that use standard treatment, placebos, or best supportive care remain the corner-stone for reliably assessing the benefit-risk balance.	UNIV NIJMEGEN ST RADBOUD HOSP,DEPT CLIN PHARMACOL,6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen	KOOPMANS, PP (corresponding author), UNIV NIJMEGEN ST RADBOUD HOSP,DEPT MED,DIV GEN INTERNAL MED,POB 9101,6500 HB NIJMEGEN,NETHERLANDS.		Koopmans, Peter/O-9276-2015					ATZPODIEN J, 1990, LANCET, V335, P1509, DOI 10.1016/0140-6736(90)93039-R; BEUTLER E, 1992, LANCET, V340, P952, DOI 10.1016/0140-6736(92)92826-2; BOYD KM, 1992, BRIT MED J, V305, P699; BYRNE M, 1992, BRIT MED J, V304, P1523, DOI 10.1136/bmj.304.6841.1523; COATES A, 1987, NEW ENGL J MED, V317, P1490, DOI 10.1056/NEJM198712103172402; GROOPMAN JE, 1989, ANN INTERN MED, V110, P335, DOI 10.7326/0003-4819-110-5-335; HIRSCH MS, 1993, NEW ENGL J MED, V328, P1686, DOI 10.1056/NEJM199306103282307; LAGAKOS SW, 1992, ANN INTERN MED, V116, P599, DOI 10.7326/0003-4819-116-7-599; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P54; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; SCHEITHAUER W, 1993, BRIT MED J, V306, P752, DOI 10.1136/bmj.306.6880.752; SILVERMAN WA, 1994, LANCET, V343, P1585; SOUQUET PJ, 1993, LANCET, V342, P19; TOBIAS JS, 1994, BRIT MED J, V308, P961, DOI 10.1136/bmj.308.6934.961; TRIMBLE EL, 1993, J CLIN ONCOL, V11, P2405, DOI 10.1200/JCO.1993.11.12.2405; TWYCROSS R, 1992, BRIT MED J, V305, P969, DOI 10.1136/bmj.305.6860.969; WALSH TD, 1988, BRIT MED J, V296, P477, DOI 10.1136/bmj.296.6620.477; 1994, LANCET, V343, P871	19	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	1995	310	6990					1305	1306		10.1136/bmj.310.6990.1305	http://dx.doi.org/10.1136/bmj.310.6990.1305			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773046	Green Published, Green Submitted			2022-12-24	WOS:A1995QZ86000026
J	ROLFE, S; HARPER, NJN				ROLFE, S; HARPER, NJN			ABILITY OF HOSPITAL DOCTORS TO CALCULATE DRUG DOSES	BRITISH MEDICAL JOURNAL			English	Article											ROLFE, S (corresponding author), MANCHESTER ROYAL INFIRM,DEPT ANAESTHESIA,OXFORD RD,MANCHESTER M13 9WL,LANCS,ENGLAND.							MULLER NF, 1992, EUROPEAN DRUG INDEX; SCRIMSHIRE JA, 1989, BRIT MED J, V298, P1497; 1994, AMPOULE LABELS NHS S; 1993, BRIT MED J, V306, P1589	4	66	68	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1173	1174		10.1136/bmj.310.6988.1173	http://dx.doi.org/10.1136/bmj.310.6988.1173			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX566	7767153	Green Published			2022-12-24	WOS:A1995QX56600023
J	STREBEL, PM; IONNEDELCU, N; BAUGHMAN, AL; SUTTER, RW; COCHI, SL				STREBEL, PM; IONNEDELCU, N; BAUGHMAN, AL; SUTTER, RW; COCHI, SL			INTRAMUSCULAR INJECTIONS WITHIN 30 DAYS OF IMMUNIZATION WITH ORAL POLIOVIRUS VACCINE - A RISK FACTOR FOR VACCINE-ASSOCIATED PARALYTIC POLIOMYELITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENGLAND; SYSTEM; WALES	Background. In Romania the rate of vaccine-associated paralytic poliomyelitis is for unexplained reasons 5 to 17 times higher than in other countries. Long ago it was noted that intramuscular injections administered during the incubation period of wild-type poliovirus infection increased the risk of paralytic disease (a phenomenon known as ''provocation'' poliomyelitis). We conducted a case-control study to explore the association between intramuscular injections and vaccine-associated poliomyelitis in Romania. Methods. The patients were 31 young children in whom vaccine-associated paralytic poliomyelitis developed from 1988 through 1992. Eighteen were vaccine recipients, and 13 had acquired the disease by contact with vaccine recipients. Each of these children was matched with up to five controls according to health center, age, and in the case of vaccine recipients, history of receipt of the live attenuated oral poliovirus vaccine. Data were abstracted from medical records that documented the injections administered in the 30 days before the onset of paralysis. Results. Of the 31 children with vaccine-associated disease, 27 (87 percent) had received one or more intramuscular injections within 30 days before the onset of paralysis, as compared with 77 of the 151 controls (51 percent) (matched odds ratio, 31.2; 95 percent confidence interval, 4.0 to 244.2). Nearly all the intramuscular injections were of antibiotics, and the association was strongest for the patients who received 10 or more injections (matched odds ratio for greater than or equal to 10 injections as compared with no injections, 182.1; 95 percent confidence interval, 15.2 to 2186.4). The risk of paralytic disease was strongly associated with injections given after the oral poliovirus vaccine, but not with injections given before or at the same time as the vaccine (matched odds ratio, 56.7; 95 percent confidence interval, 8.9 to infinity). The attributable risk in the population for intramuscular injections given in the 30 days before the onset of paralysis was 86 percent (95 percent confidence interval, 66 to 95 percent); that is, we estimate that 86 percent of the cases of vaccine-associated paralytic poliomyelitis in this population might have been prevented by the elimination of intramuscular injections within 30 days after exposure to Oral poliovirus vaccine. Conclusions. Provocation paralysis, previously described only for wild-type poliovirus infection, may rarely occur in a child who receives multiple intramuscular injections shortly after exposure to oral poliovirus vaccine, either as a vaccine recipient or through contact with a recent recipient. This phenomenon may explain the high rate of vaccine-associated paralytic poliomyelitis in Romania, where the use of intramuscular injections of antibiotics in infants with febrile illness is common.	CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,DIV DATA MANAGEMENT,ATLANTA,GA 30333; MINIST HLTH,EXPANDED PROGRAMME IMMUNIZAT,BUCHAREST,ROMANIA	Centers for Disease Control & Prevention - USA	STREBEL, PM (corresponding author), CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,DIV EPIDEMIOL & SURVEILLANCE,MAILSTOP E-61,ATLANTA,GA 30333, USA.							ANDERSON GW, 1951, PEDIATRICS, V7, P741; ANDRUS JK, IN PRESS B WHO; BANKS HS, 1950, BRIT MED J, V2, P251, DOI 10.1136/bmj.2.4673.251; BODIAN D, 1954, AM J HYG, V60, P358, DOI 10.1093/oxfordjournals.aje.a119727; BRESLOW NE, 1980, IARC SCI PUBL, V32, P247; COCKBURN WC, 1988, B WORLD HEALTH ORGAN, V66, P143; COLLINGHAM KE, 1978, LANCET, V1, P976; CRAINIC R, 1983, INFECT IMMUN, V41, P1217, DOI 10.1128/IAI.41.3.1217-1225.1983; Deivanayagam N, 1993, Indian Pediatr, V30, P335; ESTEVES K, 1988, B WORLD HEALTH ORGAN, V66, P739; FLEISS JL, 1991, STATISTICAL METHODS; GREENBERG M, 1952, AM J PUBLIC HEALTH, V42, P142; GREENLAND S, 1987, STAT MED, V6, P701, DOI 10.1002/sim.4780060607; GUYER B, 1980, B WORLD HEALTH ORGAN, V58, P285; HERSH BS, 1993, AIDS, V7, P1617, DOI 10.1097/00002030-199312000-00012; HILL AB, 1950, BMJ-BRIT MED J, V2, P1; HIRJI KF, 1989, AM STAT, V43, P7, DOI 10.2307/2685158; HIRJI KF, 1988, BIOMETRICS, V44, P803, DOI 10.2307/2531592; Hollander M., 1973, NONPARAMETRIC STAT, P68; JOCE R, 1992, BRIT MED J, V305, P79, DOI 10.1136/bmj.305.6845.79; MCCLOSKEY BP, 1950, LANCET, V1, P659; NATHANSON N, 1961, B JOHNS HOPKINS HOSP, V108, P308; REN R, 1993, J INFECT DIS, V166, P747; ROSEN L, 1953, AM J HYG, V57, P237, DOI 10.1093/oxfordjournals.aje.a119571; SIMOES EAF, 1994, 34TH INT C ANT AG CH, P66; STREBEL PM, 1994, AM J EPIDEMIOL, V140, P1111, DOI 10.1093/oxfordjournals.aje.a117211; SUTTER RW, 1989, AM J PUBLIC HEALTH, V79, P495, DOI 10.2105/AJPH.79.4.495; SUTTER RW, 1992, J INFECT DIS, V165, P444, DOI 10.1093/infdis/165.3.444; TOWNSENDCOLES WF, 1953, T ROY SOC TROP MED H, V47, P77, DOI 10.1016/0035-9203(53)90027-3; Wyatt H V, 1986, Dev Biol Stand, V65, P123; WYATT HV, 1990, REV INFECT DIS, V12, P547; WYATT HV, 1984, SOC SCI MED, V19, P911, DOI 10.1016/0277-9536(84)90320-4; WYATT HV, 1985, T ROY SOC TROP MED H, V79, P355, DOI 10.1016/0035-9203(85)90379-7; YANG CF, 1991, VIRUS RES, V20, P159; 1981, INFECT DIS, P35; 1982, B WORLD HEALTH ORGAN, V60, P231; 1956, LANCET, V2, P1223; 1976, B WORLD HEALTH ORGAN, V53, P319; 1993, LOGXACT TURBO USER M; 1989, EXPANDED PROGRAMME I, P35	40	61	61	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 23	1995	332	8					500	506		10.1056/NEJM199502233320804	http://dx.doi.org/10.1056/NEJM199502233320804			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH288	7830731				2022-12-24	WOS:A1995QH28800004
J	GUPTA, S; CAMPBELL, D; DERIJARD, B; DAVIS, RJ				GUPTA, S; CAMPBELL, D; DERIJARD, B; DAVIS, RJ			TRANSCRIPTION FACTOR ATF2 REGULATION BY THE JNK SIGNAL-TRANSDUCTION PATHWAY	SCIENCE			English	Article							RETINOBLASTOMA GENE-PRODUCT; DNA-BINDING SPECIFICITY; LEUCINE ZIPPER PROTEINS; C-JUN; HETERODIMER FORMATION; TAX PROTEIN; CREB; FAMILY; E1A; PHOSPHORYLATION	Treatment of cells with pro-inflammatory cytokines or ultraviolet radiation causes activation of the c-Jun NH2-terminal protein kinase (JNK). Activating transcription factor-2 (ATF2) was found to be a target of the JNK signal transduction pathway. ATF2 was phosphorylated by JNK on two closely spaced threonine residues within the NH2-terminal activation domain. The replacement of these phosphorylation sites with alanine inhibited the transcriptional activity of ATF2. These mutations also inhibited ATF2-stimulated gene expression mediated by the retinoblastoma (Rb) tumor suppressor and the adenovirus early region 1A (E1A) oncoprotein. Furthermore, expression of dominant-negative JNK inhibited ATF2 transcriptional activity. Together, these data demonstrate a role for the JNK signal transduction pathway in transcriptional responses mediated by ATF2.	UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester								ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BENBROOK DM, 1990, ONCOGENE, V5, P295; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FLINT KJ, 1991, ONCOGENE, V6, P2019; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Gupta SK, UNPUB; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOEFFLER JP, 1992, J INVEST DERMATOL, V98, pS21, DOI 10.1111/1523-1747.ep12462126; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KALLUNKI T, IN PRESS GENES DEV; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SETH A, 1992, J BIOL CHEM, V267, P24796; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DH, 1985, MOL CELL BIOL, V5, P2684, DOI 10.1128/MCB.5.10.2684; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	40	1342	1360	1	39	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 20	1995	267	5196					389	393		10.1126/science.7824938	http://dx.doi.org/10.1126/science.7824938			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7824938				2022-12-24	WOS:A1995QC27300039
J	SANTORO, M; CARLOMAGNO, F; ROMANO, A; BOTTARO, DP; DATHAN, NA; GRIECO, M; FUSCO, A; VECCHIO, G; MATOSKOVA, B; KRAUS, MH; DIFIORE, PP				SANTORO, M; CARLOMAGNO, F; ROMANO, A; BOTTARO, DP; DATHAN, NA; GRIECO, M; FUSCO, A; VECCHIO, G; MATOSKOVA, B; KRAUS, MH; DIFIORE, PP			ACTIVATION OF RET AS A DOMINANT TRANSFORMING GENE BY GERMLINE MUTATIONS OF MEN2A AND MEN2B	SCIENCE			English	Article							CELLS; PROTOONCOGENE; RECEPTOR; ONCOGENE; KINASE	Multiple endocrine neoplasia types 2A and 2B (MEN2A and MEN2B) and familial medullary thyroid carcinoma are dominantly inherited cancer syndromes. All three syndromes are associated with mutations in RET, which encodes a receptor-like tyrosine kinase. The altered RET alleles were shown to be transforming genes in NIH 3T3 cells as a consequence of constitutive activation of the RET kinase. The MEN2A mutation resulted in RET dimerization at steady state, whereas the MEN2B mutation altered RET catalytic properties both quantitatively and qualitatively. Oncogenic conversion RET in these neoplastic syndromes establishes germline transmission of dominant transforming genes in human cancer.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; UNIV NAPLES,CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,NAPLES,ITALY; UNIV NAPLES,DEPT BIOL & PATOL CELLULARE & MOLEC L CALIFANO,NAPLES,ITALY; NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892; FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,CATANZARO,ITALY; NCI,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Naples Federico II; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Magna Graecia University of Catanzaro; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Di Fiore, Pier Paolo/K-2130-2012; Bottaro, Donald P/F-8550-2010; Bottaro, Donald P/AAF-3853-2020	Di Fiore, Pier Paolo/0000-0002-2252-0950; Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334; Grieco, Michele/0000-0002-4212-7814; Fusco, Alfredo/0000-0003-3332-5197				CARLOMAGNO F, UNPUB; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; COCHET C, 1988, J BIOL CHEM, V263, P3290; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; ROMANO A, 1994, ONCOGENE, V9, P2923; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, UNPUB; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TAKAHASHI M, 1988, ONCOGENE, V4, P805; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	20	716	729	0	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 20	1995	267	5196					381	383		10.1126/science.7824936	http://dx.doi.org/10.1126/science.7824936			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7824936	Green Submitted			2022-12-24	WOS:A1995QC27300036
J	THORN, SN; DANIELS, RG; AUDITOR, MTM; HILVERT, D				THORN, SN; DANIELS, RG; AUDITOR, MTM; HILVERT, D			LARGE RATE ACCELERATIONS IN ANTIBODY CATALYSIS BY STRATEGIC USE OF HAPTENIC CHARGE	NATURE			English	Article							PHYSICAL ORGANIC-CHEMISTRY; BENZISOXAZOLES; ENERGY	GENERAL acid-base catalysis contributes substantially to the efficacy of many enzymes, enabling an impressive array of eliminations, isomerizations, racemizations, hydrolyses and carbon-carbon bond-forming reactions to be carried out with high rates and selectivities(1). The fundamental challenge of exploiting similar effects in designed catalysts such as catalytic antibodies(2,3) is that of correctly positioning the catalytic groups in an appropriate active-site microenvironment, Charge complementarity between antibody and hapten (the template used to induce an antibody) has been used successfully in a number of instances to elicit acids and bases within immunoglobulin combining sites(4-9), but the activities of the catalysts obtained by this strategy are generally considerably lower than those of natural enzymes, Here we report that by optimizing hapten design and efficiently screening the immune response, antibodies can be obtained that act effectively as general base catalysts. Thus a cationic hapten correctly mimicking the transition-state geometry of all reacting bonds and bearing little resemblance to the reaction product has yielded carboxylate-containing antibodies that catalyse an E2 elimination with more than 10(3) turnovers per active site and rate accelerations of greater than 10(8). These results demonstrate that very large effects can be achieved by strategic use of haptenic charge.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute								AHRLOW E, 1988, ANTIBODIES LABORATOR; CASEY ML, 1973, J ORG CHEM, V38, P2295; CRAVATT BF, 1994, J AM CHEM SOC, V116, P6013, DOI 10.1021/ja00092a080; GERIT JA, 1991, J AM CHEM SOC, V113, P9667; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; HILVERT D, 1994, CURR OPIN STRUC BIOL, V4, P612, DOI 10.1016/S0959-440X(94)90226-7; JACKSON DY, 1991, J AM CHEM SOC, V113, P2319, DOI 10.1021/ja00006a070; JANDA KD, 1990, J AM CHEM SOC, V112, P1274, DOI 10.1021/ja00159a074; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KEMP DS, 1975, J AM CHEM SOC, V97, P7312, DOI 10.1021/ja00858a018; KEMP DS, 1973, J AM CHEM SOC, V95, P6670, DOI 10.1021/ja00801a024; Kirby A.J., 1980, ADV PHYS ORG CHEM, V17, P183; KULIOPULOS A, 1990, BIOCHEMISTRY-US, V29, P10271, DOI 10.1021/bi00496a017; LAUER RC, 1974, EXPERIENTIA, V30, P560, DOI 10.1007/BF01926352; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LUNDBLAD RL, 1991, CHEM REAGENTS PROTEI, P267; PARKER AJ, 1969, CHEM REV, V69, P1, DOI 10.1021/cr60257a001; REYMOND JL, 1993, J AM CHEM SOC, V115, P3909, DOI 10.1021/ja00063a009; SHOKAT K, 1994, J AM CHEM SOC, V116, P2261, DOI 10.1021/ja00085a004; SHOKAT KM, 1989, NATURE, V338, P269, DOI 10.1038/338269a0; UNO T, 1992, J AM CHEM SOC, V114, P6573, DOI 10.1021/ja00042a055; WALSH CT, 1979, ENZYMATIC REACTION M; WARSHELL A, 1991, COMPUTER MODELING CH, P153	24	133	138	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					228	230		10.1038/373228a0	http://dx.doi.org/10.1038/373228a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	QC278	7816136				2022-12-24	WOS:A1995QC27800057
J	WU, L; NIEMEYER, B; COLLEY, N; SOCOLICH, M; ZUKER, CS				WU, L; NIEMEYER, B; COLLEY, N; SOCOLICH, M; ZUKER, CS			REGULATION OF PLC-MEDIATED SIGNALING IN-VIVO BY CDP-DIACYLGLYCEROL SYNTHASE	NATURE			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; PHOTORECEPTOR DEACTIVATION; DROSOPHILA PHOTORECEPTORS; DIGLYCERIDE SYNTHETASE; VISUAL TRANSDUCTION; MOLECULAR-CLONING; PHOSPHATIDIC-ACID; ESCHERICHIA-COLI; GENE	CDP-diacylglycerol synthase (CDS) is an enzyme required for the regeneration of the signalling molecule phosphatidylinositol-4,5-bisphosphate (PtdlnsP(2)) from phosphatidic acid. A photoreceptor cell-specific isoform of CDS from Drosophila is a key regulator of phototransduction, a G-protein-coupled signalling cascade mediated by phospholipase C, cds mutants cannot sustain a light-activated current as a result of depletion of PtdlnsP(2). Overexpression of CDS increases the amplitude of the light response, demonstrating that availability of PtdlnsP(2) is a determinant in the gain of this pathway. cds mutants undergo light-dependent retinal degeneration which can be suppressed by a mutation in phospholipase C. Thus, enzymes involved in PtdlnsP(2) metabolism regulate phosphoinositide-mediated signalling cascades in vivo.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego			Niemeyer, Barbara A./AAL-8972-2021	Socolich, Michael/0000-0002-0702-1061; Wu, Louisa/0000-0001-8609-3081	NATIONAL EYE INSTITUTE [R01EY008768] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY008768] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ASHBRUNER M, 1989, DROSOPHILA LABORATOR; BAUMANN O, 1989, CELL TISSUE RES, V255, P511, DOI 10.1007/BF00218786; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1994, MOL CELL ENDOCRINOL, V98, P119, DOI 10.1016/0303-7207(94)90129-5; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; Breer H, 1992, Curr Opin Neurobiol, V2, P439, DOI 10.1016/0959-4388(92)90177-M; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; ELDRED WD, 1983, J HISTOCHEM CYTOCHEM, V31, P285, DOI 10.1177/31.2.6339606; EXTON JH, 1994, ANNU REV PHYSIOL, V56, P349; FEILER R, 1992, J NEUROSCI, V12, P3862; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; ICHO T, 1985, J BIOL CHEM, V260, P2078; INOUE H, 1989, J BIOL CHEM, V264, P5996; JONES GA, 1993, J BIOL CHEM, V268, P20845; KENT C, 1991, FASEB J, V5, P2258, DOI 10.1096/fasebj.5.9.1860617; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; MARGOLSKEE RF, 1993, BIOESSAYS, V15, P645, DOI 10.1002/bies.950151003; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MASAI I, 1992, P NATL ACAD SCI USA, V89, P6030, DOI 10.1073/pnas.89.13.6030; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; MCCABE MJ, 1992, ANN NY ACAD SCI, V663, P269, DOI 10.1111/j.1749-6632.1992.tb38670.x; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MOOLENAAR WH, 1991, CELL GROWTH DIFFER, V2, P359; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PAK WL, 1970, NATURE, V227, P518, DOI 10.1038/227518b0; PETERS KG, 1992, COLD SPRING HARB SYM, V57, P63, DOI 10.1101/SQB.1992.057.01.008; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; SPARROW CP, 1985, J BIOL CHEM, V260, P2084; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VIHTELIC TS, 1993, J CELL BIOL, V122, P1013, DOI 10.1083/jcb.122.5.1013; YOSHIOKA T, 1985, J BIOCHEM-TOKYO, V97, P1251, DOI 10.1093/oxfordjournals.jbchem.a135171; Zuker Charles S., 1992, Current Opinion in Neurobiology, V2, P622, DOI 10.1016/0959-4388(92)90029-K	50	146	151	1	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 19	1995	373	6511					216	222		10.1038/373216a0	http://dx.doi.org/10.1038/373216a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816135				2022-12-24	WOS:A1995QC27800054
J	ROBERTS, I; NORTON, R; JACKSON, R; DUNN, R; HASSALL, I				ROBERTS, I; NORTON, R; JACKSON, R; DUNN, R; HASSALL, I			EFFECT OF ENVIRONMENTAL-FACTORS ON RISK OF INJURY OF CHILD PEDESTRIANS BY MOTOR-VEHICLES - A CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							ACCIDENTS; MORTALITY	Objective-To identify and assess contribution of environmental risk factors for injury of child pedestrians by motor vehicles. Design-Community based case-control study. Environmental characteristics of sites of child pedestrian injury were compared with the environmental characteristics of selected comparison sites. Each comparison site was the same distance and direction from home of control child as was the injury site from home of relevant case child. Two control sites were selected for each injury site. Setting-Auckland region of New Zealand. Subjects-Cases were 190child pedestrians aged < 15 who were killed or hospitalised after collision with a motor vehicle on a public road during two years and two months. Controls were 380 children randomly sampled from population and frequency matched for age and sex. Main outcome measures-Traffic volume and speed and level of parking on curbs at injury sites and comparison sites. Results-Risk of injury of child pedestrians was strongly associated with traffic volume: risk of injury at sites with highest traffic volumes was 14 times greater than that at least busy sites (odds ratio 14.30; 95% confidence interval 6.98 to 29.20), and risk increased with increasing traffic volume. High density of curb parking was also associated with increased risk (odds ratio 8.12; 3.32 to 19.90). Risk was increased at sites with mean speeds over 40 km/h (odds ratio 2.68; 1.26 to 5.69), although risk did not increase further with increasing speed. Conclusion-Reducing traffic volume in urban areas could significantly reduce rates of child pedestrian injury. Restricting curb parking may also be effective.	DEPT COMMUNITY HLTH,INJURY PREVENT RES CTR,AUCKLAND,NEW ZEALAND; UNIV AUCKLAND,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND; UNIV AUCKLAND,DEPT CIVIL & RESOURCE ENGN,AUCKLAND,NEW ZEALAND; OFF COMMISSIONER CHILDREN,WELLINGTON,NEW ZEALAND	University of Auckland; University of Auckland				Jackson, Rod/0000-0001-5914-6934				ELLEY WB, 1985, NEW ZEAL J EDUC STUD, V20, P115; ENGEL U, 1992, ACCIDENT ANAL PREV, V24, P17, DOI 10.1016/0001-4575(92)90068-T; KENDRICK D, 1993, ARCH DIS CHILD, V68, P669, DOI 10.1136/adc.68.5.669; Lawson S., 1990, ACCIDENTS YOUNG PEDE; MUELLER BA, 1990, AM J EPIDEMIOL, V132, P550, DOI 10.1093/oxfordjournals.aje.a115691; PLESS IB, 1987, AM J PUBLIC HEALTH, V77, P358, DOI 10.2105/AJPH.77.3.358; Preston B., 1992, CUTTING PEDESTRIAN C; RIVARA FP, 1985, PEDIATRICS, V76, P375; RIVARA FP, 1990, AM J DIS CHILD, V144, P692, DOI 10.1001/archpedi.1990.02150300090023; ROBERTS I, 1992, BRIT MED J, V305, P283, DOI 10.1136/bmj.305.6848.283; ROBERTS I, 1993, J PAEDIATR CHILD H, V29, P233, DOI 10.1111/j.1440-1754.1993.tb00494.x; ROBERTS I, 1992, NEW ZEAL MED J, V105, P51; ROBERTS I, 1993, BRIT MED J, V306, P1737, DOI 10.1136/bmj.306.6894.1737; ROBERTS I, 1991, NEW ZEAL MED J, V104, P247; ROBERTS I, 1994, SOC SCI MED, V38, P749, DOI 10.1016/0277-9536(94)90465-0; ROBERTS I, 1993, EPIDEMIOLOGY, V4, P477, DOI 10.1097/00001648-199309000-00015; ROBERTS I, 1994, AUST J PUBLIC HEALTH, V18, P43; ROBERTS I, IN PRESS PEDIATRICS; ROBERTS IG, 1993, ARCH DIS CHILD, V68, P190, DOI 10.1136/adc.68.2.190; 1991, CENSUS POPULATION DW; 1983, ROAD TRANSPORT RES T	21	161	164	1	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					91	94		10.1136/bmj.310.6972.91	http://dx.doi.org/10.1136/bmj.310.6972.91			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QC223	7833733	Green Published			2022-12-24	WOS:A1995QC22300019
J	JAMES, DK				JAMES, DK			CONTROVERSIES IN MANAGEMENT - SHOULD OBSTETRICIANS SEE WOMEN WITH NORMAL PREGNANCIES - OBSTETRICIANS SHOULD FOCUS ON PROBLEMS	BRITISH MEDICAL JOURNAL			English	Article							DELIVERY				JAMES, DK (corresponding author), QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND.							HAVERCAMP A, 1982, PERINATOLOGY NEONATO, V6, P75; INCH S, 1985, J ROY SOC MED, V78, P683, DOI 10.1177/014107688507800821; JAMES D, 1991, HOSPITAL UPDATE, V18, P885; KLEIN M, 1983, BRIT J OBSTET GYNAEC, V90, P118, DOI 10.1111/j.1471-0528.1983.tb08894.x; MACVICAR J, 1993, BRIT J OBSTET GYNAEC, V100, P316, DOI 10.1111/j.1471-0528.1993.tb12972.x; PARSBOOSINGH J, 1990, EFFECTIVE CARE PREGN, V1, P192; REID M, 1990, EFFECTIVE CARE PREGN, V1, P131; REID M, 1986, PERINATAL CARE DELIV, P486; 1993, CHANGING CHILDBIRTH; 1992, 2ND HOUS COMM SEL CO	10	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					37	38		10.1136/bmj.310.6971.37	http://dx.doi.org/10.1136/bmj.310.6971.37			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827555	Green Published			2022-12-24	WOS:A1995QB06000032
J	DAVIES, G; PYKE, S; KINMONTH, AL; WOOD, DA; COLES, C; CRAMB, R; DURRINGTON, P; KOK, Y; LEGUEN, C; MARTEAU, T; ODWYER, A; PYKE, SMD; STEELE, DW; THOMPSON, SG; YARWOOD, J				DAVIES, G; PYKE, S; KINMONTH, AL; WOOD, DA; COLES, C; CRAMB, R; DURRINGTON, P; KOK, Y; LEGUEN, C; MARTEAU, T; ODWYER, A; PYKE, SMD; STEELE, DW; THOMPSON, SG; YARWOOD, J			EFFECT OF NONATTENDERS ON THE POTENTIAL OF A PRIMARY-CARE PROGRAM TO REDUCE CARDIOVASCULAR RISK IN THE POPULATION	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; GENERAL-PRACTICE	Objectives-To determine the feasibility of enrolling non-attenders of a population based cardiovascular risk reduction programme (the British family heart study) into a further, similar programme and to assess the effect of non-attendance on the effectiveness of the programme. Design-Follow up of non-attenders by practice nurses, including home visits if necessary, to administer questionnaires and obtain physiological measurements. Setting-Eight general practices across England, Scotland, and Wales. Subjects-Non-attenders in a cardiovascular risk factor screening and intervention programme compared with attenders. Main outcome measures-Number of nonattenders enrolled; sociodemographic characteristics; personal and family history of coronary heart disease; cardiovascular risk factors; and total coronary risk score. Results-Data were collected from 106 (17%) of the 608 non-attending families (99 men and 42 women). Of the 543 non-attending families from five practices that attempted complete follow up, 256 had moved away or died. Only 76 were eventually enrolled into the study. The prevalence of coronary heart disease and a family history of coronary heart disease were similar among non-attenders and attenders as were the individual coronary risk factors studied except smoking. Women non-attenders were more likely to be current cigarette smokers than attenders (15/42 v 202/948, P = 0.02). Conclusions-The intensive follow up of nonattenders resulted in real intervention opportunities in only a small number. Since the effect of any intervention in a population is reduced by nonattendance audit of preventive medical programmes aimed at the population should allow for the effect of non-attenders on the overall results.	UNIV SOUTHAMPTON,FAC MED,SOUTHAMPTON,HANTS,ENGLAND; UNIV LONDON,LONDON SCH HYG & TROP MED,MED STAT UNIT,LONDON,ENGLAND	University of Southampton; University of London; London School of Hygiene & Tropical Medicine								CRIQUI MH, 1978, AM J EPIDEMIOL, V108, P367, DOI 10.1093/oxfordjournals.aje.a112633; DIFFORD F, 1987, BRIT MED J, V294, P1130, DOI 10.1136/bmj.294.6580.1130; KINMONTH AL, 1991, BRIT MED J, V303, P1060, DOI 10.1136/bmj.303.6809.1060-a; PILL R, 1988, J ROY COLL GEN PRACT, V38, P53; Rose G., 1992, STRATEGY PREVENTIVE; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; WRENCH JG, 1984, J ROY COLL GEN PRACT, V34, P477; 1992, HLTH NATION STRATEGY; 1994, BRIT MED J, V308, P313; 1991, BRIT MED J, V302, P1057	10	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1553	1556		10.1136/bmj.309.6968.1553	http://dx.doi.org/10.1136/bmj.309.6968.1553			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819899	Green Published			2022-12-24	WOS:A1994PX56400025
J	KAPLAN, NM				KAPLAN, NM			ALCOHOL AND HYPERTENSION	LANCET			English	Editorial Material							BLOOD-PRESSURE; CONSUMPTION				KAPLAN, NM (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235, USA.							ABE H, 1994, CIRCULATION, V89, P2626, DOI 10.1161/01.CIR.89.6.2626; ALTURA BM, 1994, ALCOHOL CLIN EXP RES, V18, P1057, DOI 10.1111/j.1530-0277.1994.tb00082.x; CUSHMAN WC, 1994, AM J HYPERTENS, V7, P814, DOI 10.1093/ajh/7.9.814; GOLDBERG RJ, 1994, CIRCULATION, V89, P651, DOI 10.1161/01.CIR.89.2.651; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; Keil U, 1993, CARDIOVASC RISK FACT, V3, P189; KLAG MJ, 1993, HYPERTENSION, V22, P365, DOI 10.1161/01.HYP.22.3.365; KUPARI M, 1983, BRIT HEART J, V49, P174, DOI 10.1136/hrt.49.2.174; Lian C, 1915, B ACAD MED PARIS, V74, P525; MACMAHON S, 1987, HYPERTENSION, V9, P111, DOI 10.1161/01.HYP.9.2.111; MAHESWARAN R, 1992, HYPERTENSION, V19, P79, DOI 10.1161/01.HYP.19.1.79; VANDONGEN R, 1994, TXB HYPERTENSION, P567; WANNAMETHEE G, 1991, J HUM HYPERTENS, V5, P59	13	35	37	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1588	1589		10.1016/S0140-6736(95)90110-8	http://dx.doi.org/10.1016/S0140-6736(95)90110-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783532				2022-12-24	WOS:A1995RE67000003
J	SORDINO, P; VANDERHOEVEN, F; DUBOULE, D				SORDINO, P; VANDERHOEVEN, F; DUBOULE, D			HOX GENE-EXPRESSION IN TELEOST FINS AND THE ORIGIN OF VERTEBRATE DIGITS	NATURE			English	Article							PATTERN-FORMATION; LIMB; MICE	Hox genes are essential for growth and patterning of the tetrapod limb skeleton(1-5). Mice mutant for the Hoxd-13 gene have an important delay in morphogenesis owing to reduced proliferation(2). Based on the appearance of atavisms in such mice, we suggested that modifications of Hox gene regulation may have been a source of morphological variation during the evolution of tetrapod limbs(2,6). Pectoral and pelvic fins are homologous to fore- and hindlimbs, respectively. To compare the relative importance of Hox genes during fin versus limb morphogenesis, we cloned zebrafish (Danio rerio) HoxD and HoxA complex genes and analysed their expression during fin development. The results suggest a scheme for the fin-limb transition in which the distal autopods (digits) are neomorphic structures produced by unequal proliferation of the posterior part of an ancestral appendix.	UNIV GENEVA, DEPT ZOOL & ANIM BIOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva				duboule, denis/0000-0001-9961-2960				AHLBERG PE, 1994, NATURE, V368, P507, DOI 10.1038/368507a0; COATES M, 1991, DEV PATTERNING VERTE, P328; COATES MI, 1994, DEVELOPMENT, P169; DANE PJ, 1985, J EMBRYOL EXP MORPH, V87, P145; DAVIS AP, 1994, DEVELOPMENT, V120, P2187; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DUBOULE D, 1994, SCIENCE, V266, P575, DOI 10.1126/science.7939709; DUBOULE D, 1994, DEVELOPMENT, P135; FAVIER B, 1995, P NATL ACAD SCI USA, V92, P310, DOI 10.1073/pnas.92.1.310; GERAUDIE J, ACTA ZOOL-STOCKHOLM, V59, P85; HAACK H, 1993, DEV BIOL, V157, P410, DOI 10.1006/dbio.1993.1145; Hinchliffe J. R., 1980, DEV VERTEBRATE LIMB; HOLMGREN NILS, 1952, ACTA ZOOL [STOCKHOLM], V33, P1; IZPISUABELMONTE JC, 1992, DEV BIOL, V152, P26, DOI 10.1016/0012-1606(92)90153-8; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; POTTHOFF T, 1993, B MAR SCI, V52, P669; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SHUBIN N, 1995, EVOL BIOL, V28, P39; SHUBIN NH, 1986, EVOL BIOL, V20, P319; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; STRAHLE U, 1993, ZEBRAFISH SCI MONITO, V2, P5; STREISINGER G, 1986, GENETICS, V112, P311; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THOROGOOD P, 1991, NATO ADV SCI I A-LIF, V205, P347; TICKLE C, 1991, DEVELOPMENT, P113; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0	30	277	281	2	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 22	1995	375	6533					678	681		10.1038/375678a0	http://dx.doi.org/10.1038/375678a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791900				2022-12-24	WOS:A1995RE57600059
J	VANGENT, DC; MCBLANE, JF; RAMSDEN, DA; SADOFSKY, MJ; HESSE, JE; GELLERT, M				VANGENT, DC; MCBLANE, JF; RAMSDEN, DA; SADOFSKY, MJ; HESSE, JE; GELLERT, M			INITIATION OF V(D)J RECOMBINATION IN A CELL-FREE SYSTEM	CELL			English	Article							RAG-1; GENES; MICE; DNA	Cells performing V(D)J recombination make specific cuts in DNA at recombination signal sequences. Here, we show that nuclear extracts of pre-a cell lines carry out this specific cleavage. The products of cleavage are the same as found previously in thymocytes: full-length, blunt, 5'-phosphorylated signal ends, and covalently sealed (hairpin) coding ends. A complete signal sequence is required. Recombinant RAG1 protein greatly increases activity and complements an inactive extract from a RAG1 (-/-) pre-a cell line. When the extracts are fractionated, cleavage activity correlates with the presence of RAG2 protein. These results suggest that RAG1 and RAG2 are components of the V(D)J recombinase.			VANGENT, DC (corresponding author), NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.			Ramsden, Dale/0000-0003-1575-4748; Sadofsky, Moshe/0000-0002-6893-629X				BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GELLERT M, 1992, ANNU REV GENET, V22, P425; HARLOW E, 1988, ANTIBODIES LABORATOR; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCKEARN JP, 1985, EUR J IMMUNOL, V15, P295, DOI 10.1002/eji.1830150316; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Sambrook J., 1989, MOL CLONING LAB MANU; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHATZ DG, 1988, CELL, V53, P107, DOI 10.1016/0092-8674(88)90492-8; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	27	253	256	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					925	934		10.1016/0092-8674(95)90012-8	http://dx.doi.org/10.1016/0092-8674(95)90012-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781069	Green Published, Bronze			2022-12-24	WOS:A1995RD76800013
J	WYATT, J; BEARD, D; GRAY, A; BUSUTTIL, A; ROBERTSON, C				WYATT, J; BEARD, D; GRAY, A; BUSUTTIL, A; ROBERTSON, C			THE TIME OF DEATH AFTER TRAUMA	BRITISH MEDICAL JOURNAL			English	Article									ROYAL EDINBURGH & ASSOCIATED HOSP,DIRECTORATE ACCID & EMERGENCY MED,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,FORENS MED UNIT,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh								ANDERSON ID, 1988, BRIT MED J, V296, P1305, DOI 10.1136/bmj.296.6632.1305; TRUNKEY DD, 1983, SCI AM, V249, P20; 1988, REPORT WORKING PARTY; 1994, EMERGENCY HEALTHCARE; 1992, HLTH NATION, P102	5	39	40	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1502	1502		10.1136/bmj.310.6993.1502	http://dx.doi.org/10.1136/bmj.310.6993.1502			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787598	Green Published			2022-12-24	WOS:A1995RD28500023
J	NOGALES, E; WOLF, SG; KHAN, IA; LUDUENA, RF; DOWNING, KH				NOGALES, E; WOLF, SG; KHAN, IA; LUDUENA, RF; DOWNING, KH			STRUCTURE OF TUBULIN AT 6.5 ANGSTROM AND LOCATION OF THE TAXOL-BINDING SITE	NATURE			English	Article							MICROTUBULE ASSEMBLY INVITRO; ZINC-INDUCED SHEETS; 3-DIMENSIONAL STRUCTURE; ELECTRON-MICROSCOPY; BETA-TUBULIN; GUANOSINE 5'-TRIPHOSPHATE; PURPLE MEMBRANE; LOW RESOLUTION; CROSS-LINKING; COLCHICINE	TUBULIN, the major component of microtubules, is a heterodimer of two chains, alpha and beta(1), both of relative molecular mass 50,000 (M(r) 50K) and sith 40-50% identity. The isotypic variety(2) and conformational flexibility of tubulin have so far made it impossible to obtain crystals for X-ray work(3). Structural knowledge of tubulin has been limited to about 20 Angstrom from X-ray diffraction of oriented microtubules(4), and from electron microscopy of microtubules and zinc-induced crystalline sheets in negative stain(5,6). The sheets consist of protofilaments similar to those in microtubules but associated in an antiparallel arrangement(7) and their two-dimensional character is ideal for high-resolution electron microscopy(8,9). Here we present a three-dimensional reconstruction of tubulin to 6.5 Angstrom resolution, obtained by electron crystallography of zinc-induced two-dimensional crystals of the protein, The alpha- and beta-subunits appear topologically similar, in agreement with their sequence homology(10). Several features can be defined in terms of secondary structure. An apparent alpha-helical portion, adjacent to both interdimer and inter-protofilament contacts, is tentatively attributed to a segment near the carboxy terminus of the protein. We can assign the alpha- and beta-subunits on the basis of projection studies of the binding of taxol*, which show one taxol site per tubulin heterodimer, in agreement with the known stoichiometry of taxol in microtubules(11). These studies indicate that taxol affects the interaction between protofilaments; to our knowledge, this is the first time that a ligand-binding site has been visualized in the tubulin molecule.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio	NOGALES, E (corresponding author), LAWRENCE BERKELEY LAB,DIV LIFE SCI,BERKELEY,CA 94720, USA.		WOLF, SHARON G/K-1768-2012	WOLF, SHARON G/0000-0002-5337-5063				AMOS LA, 1979, NATURE, V279, P607, DOI 10.1038/279607a0; AMOS LA, 1974, MICROTUBULES, P1; ANDREU JM, 1992, J MOL BIOL, V226, P169, DOI 10.1016/0022-2836(92)90132-4; BANERJEE A, 1992, J BIOL CHEM, V267, P5625; BEESE L, 1987, J MOL BIOL, V194, P257, DOI 10.1016/0022-2836(87)90373-1; BURNS RG, 1993, MICROTUBULES, P3; CARLIER MF, 1983, BIOCHEMISTRY-US, V22, P4814, DOI 10.1021/bi00289a031; COMBEAU C, 1994, BIOCHEMISTRY-US, V33, P6676, DOI 10.1021/bi00187a038; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P10067, DOI 10.1021/bi00089a023; DOWNING KH, 1991, SCIENCE, V251, P53, DOI 10.1126/science.1846047; DOWNING KH, 1992, J STRUCT BIOL, V109, P152, DOI 10.1016/1047-8477(92)90046-D; DOWNING KH, 1992, ULTRAMICROSCOPY, V46, P199, DOI 10.1016/0304-3991(92)90015-C; DYE RB, 1993, J BIOL CHEM, V288, P6847; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; HEUSER JE, 1986, J CELL BIOL, V103, P2209, DOI 10.1083/jcb.103.6.2209; HOWARD WD, 1988, J BIOL CHEM, V263, P1342; KIRCHNER K, 1985, EMBO J, V4, P2397, DOI 10.1002/j.1460-2075.1985.tb03945.x; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; KUMAR N, 1981, J BIOL CHEM, V250, P10435; LOBERT S, 1991, ARCH BIOCHEM BIOPHYS, V290, P93, DOI 10.1016/0003-9861(91)90595-A; LUDUENA RF, 1977, J BIOL CHEM, V252, P7006; LUDUENA RF, 1993, MOL BIOL CELL, V44, P445; MANDELKOW E, 1977, P NATL ACAD SCI USA, V74, P3370, DOI 10.1073/pnas.74.8.3370; MANFREDI JJ, 1982, J CELL BIOL, V94, P688, DOI 10.1083/jcb.94.3.688; MARGOLIS RL, 1980, BIOCHEMISTRY-US, V19, P5550, DOI 10.1021/bi00565a014; NOGALES E, IN PRESS J STRUCT BI; PALANIVELU P, 1982, J BIOL CHEM, V257, P6311; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1992, J NATL CANCER I, V84, P785, DOI 10.1093/jnci/84.10.785; ROWINSKY EK, 1993, CANCER SURV, V17, P283; SACKETT DL, 1993, BIOCHEMISTRY-US, V32, P13560, DOI 10.1021/bi00212a023; SCHIFF PB, 1981, BIOCHEMISTRY-US, V20, P3247, DOI 10.1021/bi00514a041; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; TAMM LK, 1979, J MOL BIOL, V130, P473, DOI 10.1016/0022-2836(79)90435-2; TRACHTENBERG S, 1987, J MOL BIOL, V195, P581, DOI 10.1016/0022-2836(87)90184-7; WANG DN, 1991, J MOL BIOL, V217, P691, DOI 10.1016/0022-2836(91)90526-C; WOLF SG, 1994, J STRUCT BIOL, V111, P190	45	320	325	2	46	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					424	427		10.1038/375424a0	http://dx.doi.org/10.1038/375424a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760939				2022-12-24	WOS:A1995RB10100059
J	ELLRODT, AG; CONNER, L; RIEDINGER, M; WEINGARTEN, S				ELLRODT, AG; CONNER, L; RIEDINGER, M; WEINGARTEN, S			MEASURING AND IMPROVING PHYSICIAN COMPLIANCE WITH CLINICAL-PRACTICE GUIDELINES - A CONTROLLED INTERVENTIONAL TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							CARE; APPROPRIATENESS; DELAYS; TOOL	Objective: To determine factors that may lead physicians not to comply with clinical practice guidelines. Design: Retrospective analysis of patients whose physicians were not compliant with discharge recommendations from a prospective, controlled interventional trial of a guideline to reduce hospital length of stay for patients admitted for chest pain. Setting: A large community teaching hospital. Participants: Patients admitted with chest pain who were not discharged according to a practice guideline. Results: 79 (34%) of 230 patients with chest pain classified as being at low risk by concurrent or retrospective review were not discharged by day 3 (the guideline recommendation). Of these 79 patients, 33 (42%) were misclassified at concurrent review (10 were falsely classified as being at high risk and 23 were falsely classified as being at low risk). Of 46 correctly classified patients, 11 (14%) were classified as having noncompliant physicians because of health care system inefficiencies. The status of 7 (9%) patients was changed to high risk between initial classification and potential discharge. For 15 patients (19%), no obvious reason for delayed discharge was found, but they had a higher severity of illness than did low-risk patients discharged according to the guideline as measured by mean time-insensitive predictive instrument scores (41.3% +/- [SD] 14.1% compared with 31.5% +/- 14.3%; P = 0.017). In 13 patients (16%), physicians refused to follow the guideline recommendations. Conclusions: In measuring and attempting to improve physician compliance with a length-of-stay guideline, physician refusal accounts for a small percentage (16%) of noncompliance. Implementation issues, health care system inefficiency, and severity of illness were the predominant reasons why physicians did not comply with guidelines. Our study further supports the principle that clinical practice guidelines should complement rather than be a substitute for physician judgment.			ELLRODT, AG (corresponding author), CEDARS SINAI MED CTR, DEPT MED, 8700 BEVERLY BLVD, BECKER 113, LOS ANGELES, CA 90048 USA.							CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Ellrodt A G, 1992, QRB Qual Rev Bull, V18, P456; FRIEDMAN P, 1991, GB STAT VERSION 3 0; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; LAFFEL G, 1993, TXB TOTAL QUALITY HE, P40; PHELPS CE, 1993, NEW ENGL J MED, V329, P1241, DOI 10.1056/NEJM199310213291707; RELMAN AS, 1991, NEW ENGL J MED, V324, P922; SALEMSCHATZ S, 1994, JAMA-J AM MED ASSOC, V272, P871, DOI 10.1001/jama.272.11.871; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; SELKER HP, 1989, MED CARE, V27, P112, DOI 10.1097/00005650-198902000-00003; SHENG A, 1993, J GEN INTERN MED, V8, P573, DOI 10.1007/BF02599642; TANENBAUM SJ, 1993, NEW ENGL J MED, V329, P1268, DOI 10.1056/NEJM199310213291713; WEINGARTEN S, 1993, AM J CARDIOL, V71, P259, DOI 10.1016/0002-9149(93)90787-D; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; WILSON MC, 1991, MED DECIS MAKING, V11, P334; 1992, TRUE EPISTAT STATIST	17	137	138	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					277	282		10.7326/0003-4819-122-4-199502150-00007	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825764				2022-12-24	WOS:A1995QF76900007
J	FLETCHER, JC; SPENCER, EM				FLETCHER, JC; SPENCER, EM			INCOMPETENT PATIENT ON THE SLIPPERY SLOPE	LANCET			English	Editorial Material							ADVANCE DIRECTIVES				FLETCHER, JC (corresponding author), UNIV VIRGINIA,SCH MED,CTR BIOMED ETH,CHARLOTTESVILLE,VA 22908, USA.							Beauchamp T. L., 1994, PRINCIPLES BIOMEDICA, P178; BROCK DW, 1994, J CLIN ETHIC, V5, P57; DRESSER R, 1994, HASTINGS CENT REP, V24, P6, DOI 10.2307/3562836; EMANUEL L, 1993, J CLIN ETHIC, V4, P8; FAGAN J, 1992, J CLIN EXP NEUROPSYC, V14, P36; MENIKOFF JA, 1992, NEW ENGL J MED, V327, P1165, DOI 10.1056/NEJM199210153271612; NIEMIRA D, 1993, HASTINGS CENT REP, V23, P14, DOI 10.2307/3563361; TENO JM, 1994, J CLIN ETHIC, V5, P23	8	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					271	272		10.1016/S0140-6736(95)90271-6	http://dx.doi.org/10.1016/S0140-6736(95)90271-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE731	7837859				2022-12-24	WOS:A1995QE73100005
J	HUBER, M; RETTLER, I; BERNASCONI, K; FRENK, E; LAVRIJSEN, SPM; PONEC, M; BON, A; LAUTENSCHLAGER, S; SCHORDERET, DF; HOHL, D				HUBER, M; RETTLER, I; BERNASCONI, K; FRENK, E; LAVRIJSEN, SPM; PONEC, M; BON, A; LAUTENSCHLAGER, S; SCHORDERET, DF; HOHL, D			MUTATIONS OF KERATINOCYTE TRANSGLUTAMINASE IN LAMELLAR ICHTHYOSIS	SCIENCE			English	Article							AMINO-ACID-SEQUENCE; MEMBRANE ANCHORAGE; EPIDERMAL-CELLS; DIFFERENTIATION; ENVELOPE; CLONING; EXPRESSION; GENE	Lamellar ichthyosis Is a severe congenital skin disorder characterized by generalized large scales and variable redness. Affected individuals in three families exhibited drastically reduced keratinocyte transglutaminase (TGK) activity. In two of these families, expression of TGK transcripts was diminished or abnormal and no TGK protein was detected. Homozygous or compound heterozygous mutations of the TGK gene were identified in all families. These data suggest that defects in TGK cause lamellar ichthyosis and that intact cross-linkage of cornified cell envelopes is required for epidermal tissue homeostasis.	CHU VAUDOIS, HOP BEAUMONT, DEPT DERMATOL, CUTANEOUS BIOL LAB, CH-1011 LAUSANNE, SWITZERLAND; LEIDEN UNIV HOSP, DEPT DERMATOL, 2333 AA LEIDEN, NETHERLANDS; MUNICIPAL DERMATOL CLIN, CH-8000 ZURICH, SWITZERLAND; CHU VAUDOIS, DEPT MED GENET, CH-1011 LAUSANNE, SWITZERLAND; CHU VAUDOIS, MOLEC GENET UNIT, CH-1011 LAUSANNE, SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Leiden University; Leiden University Medical Center (LUMC); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)			Huber, Marcel/M-8822-2016; Hohl, Daniel M/N-7554-2016	Huber, Marcel/0000-0003-3821-2378; 				CHAKRAVARTY R, 1990, BIOCHEM J, V271, P25, DOI 10.1042/bj2710025; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; CLADARAS C, 1987, J BIOL CHEM, V262, P2310; COOPER DN, 1993, ANN MED, V25, P11, DOI 10.3109/07853899309147851; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; FROST P, 1966, ARCH DERMATOL, V94, P113, DOI 10.1001/archderm.94.2.113; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HO KC, 1992, J BIOL CHEM, V267, P12660; HOHL D, 1993, ARCH DERMATOL, V129, P618, DOI 10.1001/archderm.129.5.618; HOHL D, 1991, J BIOL CHEM, V266, P6626; HOHL D, 1993, MOL BIOL SKIN, pCH5; HUBER ME, UNPUB; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1992, J BIOL CHEM, V267, P7710; LAVRIJSEN APM, 1993, IN PRESS ARCH DERMAT; LICHTI U, 1985, J BIOL CHEM, V260, P1422; MA ASP, 1986, J CELL BIOL, V103, P41, DOI 10.1083/jcb.103.1.41; MIKKOLA H, 1994, BLOOD, V84, P517; PHILLIPS MA, 1993, BIOCHEMISTRY-US, V32, P11057, DOI 10.1021/bi00092a015; PHILLIPS MA, 1992, J BIOL CHEM, V267, P2282; PHILLIPS SB, 1993, DERMATOLOGY GENERAL, pCH42; REICHERT U, 1993, MOL BIOL SKIN, pCH4; Sambrook J., 1989, MOL CLONING LAB MANU; THACHER SM, 1989, J INVEST DERMATOL, V92, P578; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; TOKUNAGA F, 1993, J BIOL CHEM, V268, P262; TRAUPE H, 1989, ICHTHYOSES, P111; WERAARCHAKULBOONMARK N, 1992, P NATL ACAD SCI USA, V89, P9804, DOI 10.1073/pnas.89.20.9804	28	377	394	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	1995	267	5197					525	528		10.1126/science.7824952	http://dx.doi.org/10.1126/science.7824952			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824952				2022-12-24	WOS:A1995QD40300042
J	VILLE, Y; HYETT, J; HECHER, K; NICOLAIDES, K				VILLE, Y; HYETT, J; HECHER, K; NICOLAIDES, K			PRELIMINARY EXPERIENCE WITH ENDOSCOPIC LASER-SURGERY FOR SEVERE TWIN-TWIN TRANSFUSION SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THERAPEUTIC AMNIOCENTESIS; NEUROLOGIC DAMAGE; ANTENATAL ORIGIN; NEWBORN-INFANTS; STUCK TWIN; PREGNANCY; VOLUME	Background. In monozygotic twin pregnancies, there are placental vascular communications between the two fetuses. In 15 percent of such pregnancies there is an imbalance in net blood flow between the twins, resulting in the twin-twin transfusion syndrome. The recipient twin may have severe hydramnios during the second trimester of pregnancy, and there is a high risk of perinatal death and cerebral palsy in survivors. This condition can now be treated by endoscopic coagulation of the vascular anastomoses responsible for fetofetal transfusion with a neodymium:yttrium-aluminum-garnet (Nd:YAG) laser. Methods. We performed intrauterine surgery in 45 pregnant women carrying twins at 15 to 28 weeks of gestation (median, 21); in each case there was severe hydramnios in one fetus due to the twin-twin transfusion syndrome. With the use of local anesthesia and continuous ultrasound visualization, a rigid fetoscope 2 mm in diameter, housed in a 2.7-mm cannula, was introduced transabdominally into the amniotic cavity of the recipient twin. A systematic search was made for all vessels approaching or crossing the membrane between the twins, and these were coagulated with an Nd:YAG laser by means of a fiber in the side arm of the cannula. Results. Coagulation of the communicating vessels was successful in all cases. The total number of fetuses who survived to delivery was 48 (53 percent), and the number of pregnancies with at least 1 survivor was 32 (71 percent). Among the live-born infants, the median gestational age at delivery was 35 weeks (range, 25 to 40), and the median birth weight was 2098 g (range, 550 to 4252). The median interval between the endoscopic laser procedure and delivery was 14 weeks (range, 0 to 21). All the survivors were developing normally at a median age of 12 months (range, 2 to 24). Conclusions. Our preliminary experience suggests that the twin-twin transfusion syndrome can be treated effectively by endoscopic laser coagulation of the communicating placental vessels.	UNIV LONDON KINGS COLL,SCH MED,HARRIS BIRTHRIGHT RES CTR FETAL MED,LONDON SE5 8RX,ENGLAND	University of London; King's College London				Nicolaides, Kypros/0000-0003-1266-0711				BEJAR R, 1988, AM J OBSTET GYNECOL, V159, P357, DOI 10.1016/S0002-9378(88)80084-X; BEJAR R, 1990, AM J OBSTET GYNECOL, V162, P1230, DOI 10.1016/0002-9378(90)90024-2; BENDON R W, 1989, Pediatric Pathology, V9, P591; BENIRSCHKE K, 1973, NEW ENGL J MED, V288, P1276, DOI 10.1056/NEJM197306142882406; DELIA JE, 1990, OBSTET GYNECOL, V75, P1046; ELLIOTT JP, 1991, OBSTET GYNECOL, V77, P537; FUSI L, 1991, OBSTET GYNECOL, V78, P517; GOLDBERG RN, 1980, J PEDIATR-US, V96, P1060, DOI 10.1016/S0022-3476(80)80642-1; HADLOCK FP, 1985, AM J OBSTET GYNECOL, V151, P333, DOI 10.1016/0002-9378(85)90298-4; HRUBEC Z, 1984, NEW ENGL J MED, V310, P435, DOI 10.1056/NEJM198402163100706; LARROCHE JC, 1990, BIOL NEONATE, V57, P261; PATTEN RM, 1989, RADIOLOGY, V172, P153, DOI 10.1148/radiology.172.1.2662249; PINETTE MG, 1993, OBSTET GYNECOL, V82, P841; REISNER DP, 1993, AM J OBSTET GYNECOL, V169, P991, DOI 10.1016/0002-9378(93)90041-G; SAUDNERS NJ, 1991, FETAL DIAGN THER, V6, P34; SAUNDERS NJ, 1992, AM J OBSTET GYNECOL, V166, P820, DOI 10.1016/0002-9378(92)91340-G; VILLE Y, 1992, ULTRASOUND OBST GYN, V2, P429, DOI 10.1046/j.1469-0705.1992.02060429.x; WEIR PE, 1979, BRIT J OBSTET GYNAEC, V86, P849, DOI 10.1111/j.1471-0528.1979.tb10710.x	18	263	267	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	1995	332	4					224	227		10.1056/NEJM199501263320404	http://dx.doi.org/10.1056/NEJM199501263320404			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC270	7808488	Bronze			2022-12-24	WOS:A1995QC27000004
J	DUGGLEBY, HJ; TOLLEY, SP; HILL, CP; DODSON, EJ; DODSON, G; MOODY, PCE				DUGGLEBY, HJ; TOLLEY, SP; HILL, CP; DODSON, EJ; DODSON, G; MOODY, PCE			PENICILLIN ACYLASE HAS A SINGLE-AMINO-ACID CATALYTIC CENTER	NATURE			English	Article							ESCHERICHIA-COLI ATCC-11105; HYDROLYSIS; MECHANISM; SUBUNITS; SERINE	PENICILLIN acylase (penicillin amidohydrolase, EC3.5.1.11) is widely distributed among microorganisms, including bacteria, yeast and filamentous fungi. It is used on an industrial scale for the production of 6-aminopenicillanic acid, the starting material for the synthesis of semi-synthetic penicillins. Its in vivo role remains unclear, however, and the observation that expression of the Escherichia coli enzyme in vivo is regulated by both temperature and phenylacetic acid has prompted speculation that the enzyme could be involved in the assimilation of aromatic compounds as carbon sources in the organism's free-living mode(1). The mature E. coli enzyme is a periplasmic 80K heterodimer of A and B chains (209 and 566 amino acids, respectively(2,3)) synthesized as a single cytoplasmic precursor containing a 26-amino-acid signal sequence to direct export to the cytoplasm and a 54-amino-acid spacer between the A and B chains which may influence the final folding of the chains(5). The N-terminal serine of the B chain reacts with phenylmethylsulphonyl fluoride, which is consistent with a catalytic role for the serine hydrouyl group. Modifying this serine to a cysteine(6,7) inactivates the enzyme, whereas threonine, arginine or glycine substitution prevents in vivo processing of the enzyme indicating that this must be an important recognition site for cleavage. Here we report the crystal structure of penicillin acylase at 1.9 Angstrom resolution. Our analysis shows that the environment of the catalytically active N-terminal serine of the B chain contains no adjacent histidine equivalent to that found in the serine proteases. The nearest base to the hydroxyl of this serine is its own alpha-amino group, which may act by a new mechanism to endow the enzyme with its catalytic properties.	UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK			Moody, Peter/A-6832-2008	Moody, Peter/0000-0003-1762-9238				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; BOCK A, 1983, FEMS MICROBIOL LETT, V20, P135, DOI 10.1016/0378-1097(83)90182-9; BOCK A, 1983, FEMS MICROBIOL LETT, V20, P140; BRUNGER AT, 1987, SCIENCE, V23, P458; BURLINGAME R, 1983, J BACTERIOL, V155, P113, DOI 10.1128/JB.155.1.113-121.1983; CHOI KS, 1992, J BACTERIOL, V174, P6270, DOI 10.1128/JB.174.19.6270-6276.1992; COLE M, 1969, BIOCHEM J, V155, P733; DAUMY GO, 1985, J BACTERIOL, V163, P1279, DOI 10.1128/JB.163.3.1279-1281.1985; HUANG HT, 1963, APPL MICROBIOL, V11, P1; HUNT PD, 1990, PROTEIN ENG, V3, P635, DOI 10.1093/protein/3.7.635; KONECNY J, 1981, BIOTECHNOL LETT, V3, P112; KRAULIS PJ, 1990, J APPL CRYSTALLOGR, V24, P946; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KUTZBACH C, 1974, HOPPESEYLERS Z PHYSL, V354, P45; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; MARTIN J, 1990, BIOCHIM BIOPHYS ACTA, V1037, P133, DOI 10.1016/0167-4838(90)90158-C; MILLER M, 1993, FEBS LETT, V328, P275, DOI 10.1016/0014-5793(93)80943-O; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; Savidge T A, 1975, Methods Enzymol, V43, P705; SCHUMACHER G, 1986, NUCLEIC ACIDS RES, V14, P5713, DOI 10.1093/nar/14.14.5713; SLADE A, 1991, EUR J BIOCHEM, V197, P75, DOI 10.1111/j.1432-1033.1991.tb15884.x; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; TANFORD C, 1962, ADV PROTEIN CHEM, V17, P69; Virden R, 1990, BIOTECHNOL GENET, V8, P189, DOI [10.1080/02648725.1990.10647869, DOI 10.1080/02648725.1990.10647869]	25	419	434	3	69	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					264	268		10.1038/373264a0	http://dx.doi.org/10.1038/373264a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816145				2022-12-24	WOS:A1995QC27800070
J	NAVAS, TA; ZHOU, Z; ELLEDGE, SJ				NAVAS, TA; ZHOU, Z; ELLEDGE, SJ			DNA-POLYMERASE-EPSILON LINKS THE DNA-REPLICATION MACHINERY TO THE S-PHASE CHECKPOINT	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; RIBONUCLEOTIDE REDUCTASE; ATAXIA-TELANGIECTASIA; REPAIR SYNTHESIS; YEAST; GENE; DAMAGE; MITOSIS; P53	Inhibition of DNA synthesis induces transcription of DNA damage-inducible genes and prevents mitotic entry through the action of the S phase checkpoint. We have isolated a mutant, dun2, defective for both of these responses. DUN2 is identical to POL2, encoding DNA polymerase epsilon (pol epsilon). Unlike sad1 mutants defective for multiple cell cycle checkpoints, pol2 mutants are defective only for the S phase checkpoint and the activation of DUN1 kinase necessary for the transcriptional response to damage. Interallelic complementation and mutation analysis indicate that pol epsilon contains two separable essential domains, an N-terminal polymerase domain and a C-terminal checkpoint domain unique to epsilon polymerases. We propose that DNA pol epsilon acts as a sensor of DNA replication that coordinates the transcriptional and cell cycle responses to replication blocks.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine					NIGMS NIH HHS [GM44664] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044664, R37GM044664] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ALLEN JB, 1994, YEAST, V10, P1267, DOI 10.1002/yea.320101003; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDIERY WS, 1993, CELL, V75, P817; ELLEDGE SJ, 1989, MOL CELL BIOL, V9, P4932, DOI 10.1128/MCB.9.11.4932; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; HARPER JW, 1993, CELL, V75, P805; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KESTI T, 1993, J BIOL CHEM, V268, P10238; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE SH, 1991, J BIOL CHEM, V266, P22707; LI JJ, 1993, CELL, V74, P223, DOI 10.1016/0092-8674(93)90413-K; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MORRISON AL, 1990, CELL, V62, P1142; NAGASAWA H, 1985, MUTAT RES, V148, P71, DOI 10.1016/0027-5107(85)90209-X; NISHIDA C, 1988, J BIOL CHEM, V263, P501; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT, P265; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; ROBERGE M, 1992, Trends in Cell Biology, V2, P277, DOI 10.1016/0962-8924(92)90201-W; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SIEDE W, 1993, P NATL ACAD SCI USA, V90, P7985, DOI 10.1073/pnas.90.17.7985; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1993, GENETICS, V134, P63; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHENG P, 1993, MOL CELL BIOL, V13, P5829, DOI 10.1128/MCB.13.9.5829; ZHOU Z, 1992, GENETICS, V131, P851; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	43	371	375	1	11	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					29	39		10.1016/0092-8674(95)90448-4	http://dx.doi.org/10.1016/0092-8674(95)90448-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813016	Bronze			2022-12-24	WOS:A1995QB91000007
J	REYNAUD, CA; GARCIA, C; HEIN, WR; WEILL, JC				REYNAUD, CA; GARCIA, C; HEIN, WR; WEILL, JC			HYPERMUTATION GENERATING THE SHEEP IMMUNOGLOBULIN REPERTOIRE IS AN ANTIGEN-INDEPENDENT PROCESS	CELL			English	Article							PEYERS-PATCHES; LYMPHOCYTE-B; GENES; EXPRESSION; MICE; CELLS; ILEAL; SEQUENCES; TOLERANCE; DIVERSITY	Somatic hypermutation of light chain V genes during development of B cells in sheep ileal Peyer's patches was studied in three experimental conditions: in sterile fragments of the ileum surgically isolated from the gut during fetal life, in germ-free sheep, and in animals thymectomized during early fetal life. The somatic mutation pattern was found identical to control tissues in all three experiments. The same age-dependent amount of mutations, a higher than theoretical R/S ratio in complementarity-determining regions (CDRs), and a similar clustering of mutations in CDRs were observed. The mechanism, as estimated from the silent mutation pattern, appears to target mutations to CDRs; moreover, the major V lambda genes have a specific codon usage with a high purine content at the first two bases of the codons and a low content at the third position, which, together with a specific targeting of mutations to purines, favors replacement mutations in CDRs.	BASEL INST IMMUNOL,CH-4002 BASEL,SWITZERLAND		REYNAUD, CA (corresponding author), UNIV PARIS 05,FAC MED NECKER ENFANTS MALAD,INST NECKER,INSERM,U373,F-75730 PARIS 15,FRANCE.		Cordier, Corinne/F-9966-2018; Hein, Wayne/E-9090-2013	Cordier, Corinne/0000-0003-4799-6143; Hein, Wayne/0000-0003-0769-6525				BECKER RS, 1990, CELL, V63, P987, DOI 10.1016/0092-8674(90)90502-6; BETZ AG, 1993, IMMUNOL TODAY, V14, P405, DOI 10.1016/0167-5699(93)90144-A; BETZ AG, 1993, P NATL ACAD SCI USA, V90, P2385, DOI 10.1073/pnas.90.6.2385; BOS NA, 1989, EUR J IMMUNOL, V19, P1811, DOI 10.1002/eji.1830191008; BRENNER S, 1966, NATURE, V211, P242, DOI 10.1038/211242a0; DEENEN GJ, 1993, INT IMMUNOL, V5, P735, DOI 10.1093/intimm/5.7.735; EKINO S, 1993, EUR J IMMUNOL, V23, P772, DOI 10.1002/eji.1830230331; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; HEIN WR, 1989, IMMUNOLOGY, V68, P365; HEIN WR, 1990, EUR J IMMUNOL, V20, P1805, DOI 10.1002/eji.1830200827; HUETZ F, 1993, EMBO J, V12, P1819, DOI 10.1002/j.1460-2075.1993.tb05830.x; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LANDSVERK T, 1987, IMMUNOL CELL BIOL, V65, P251, DOI 10.1038/icb.1987.28; Lawton A R 3rd, 1974, Contemp Top Immunobiol, V3, P193; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; MA A, 1992, EMBO J, V11, P2727, DOI 10.1002/j.1460-2075.1992.tb05338.x; METCALF ES, 1976, J EXP MED, V143, P1327, DOI 10.1084/jem.143.6.1327; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1975, J EXP MED, V141, P904; REYNAUD CA, 1991, CELL, V64, P995, DOI 10.1016/0092-8674(91)90323-Q; REYNOLDS JD, 1983, EUR J IMMUNOL, V13, P627, DOI 10.1002/eji.1830130805; REYNOLDS JD, 1983, IMMUNOLOGY, V49, P501; REYNOLDS JD, 1986, J IMMUNOL, V136, P2005; REYNOLDS JD, 1976, THESIS AUSTR NATIONA; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; VIALE AC, 1992, J EXP MED, V175, P1449, DOI 10.1084/jem.175.6.1449	28	265	270	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					115	125		10.1016/0092-8674(95)90456-5	http://dx.doi.org/10.1016/0092-8674(95)90456-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813007	Bronze			2022-12-24	WOS:A1995QB91000015
J	PEARCE, N; BEASLEY, R; CRANE, J; BURGESS, C; JACKSON, R				PEARCE, N; BEASLEY, R; CRANE, J; BURGESS, C; JACKSON, R			END OF THE NEW-ZEALAND ASTHMA MORTALITY EPIDEMIC	LANCET			English	Article							BETA-AGONISTS; PRESCRIBED FENOTEROL; DEATHS	In 1989, a case-control study reported that inhaled fenoterol was associated with the epidemic of asthma deaths that had affected New Zealand since 1976. The New Zealand Department of Health issued warnings about the safety of fenoterol and restricted its availability. The associated time trends are consistent with the hypothesis that fenoterol was the main factor in the New Zealand asthma mortality epidemic. The epidemic commenced when fenoterol was introduced in 1976, and the New Zealand death rate remained the highest in the world for more than a decade. After publication of the case-control study, the death rate fell by half and has now remained low for a further 3 years (1990-92). Time-trend data do not suggest a class effect of inhaled beta-agonists in the epidemic: there was no association between beta-agonist sales and the start of the epidemic, and total sales of inhaled beta-agonists actually increased slightly during 1989-90 when the epidemic came to an end. Time-trend data are also inconsistent with the hypothesis that the epidemic may have occurred because of underprescribing of inhaled corticosteroids. Similarly, time-trend data is inconsistent with hypotheses postulating a major role of social factors such as unemployment. Data on time trends should be assessed with caution, because time trends in asthma deaths can be affected by many factors. Nevertheless, the New Zealand time trends are consistent with fenoterol being the main cause of the New Zealand asthma mortality epidemic and are inconsistent with a significant role for other suggested causes.			PEARCE, N (corresponding author), WELLINGTON SCH MED,DEPT MED,WELLINGTON ASTHMA RES GRP,POB 7343,WELLINGTON,NEW ZEALAND.			Jackson, Rod/0000-0001-5914-6934; Pearce, Neil/0000-0002-9938-7852; Beasley, Richard/0000-0003-0337-406X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEASLEY R, 1989, NEW ZEAL MED J, V102, P294; BEASLEY R, 1991, AUST NZ J MED, V21, P753, DOI 10.1111/j.1445-5994.1991.tb01385.x; BERNSTEIN DS, 1990, OPTIM CONTR APPL MET, V11, P1, DOI 10.1002/oca.4660110102; CRANE J, 1989, LANCET, V1, P917; CRANE J, 1992, BRIT MED J, V304, P1307, DOI 10.1136/bmj.304.6837.1307; Cried CP, 1993, EUR RESPIR J, V6, p426S; DAVIS P, 1994, HEALTH POLICY, V29, P113, DOI 10.1016/0168-8510(94)90010-8; GARRETT J, 1992, POSITIVE DIRECTIONS; GRAINGER J, 1991, THORAX, V46, P105, DOI 10.1136/thx.46.2.105; HAAS JF, 1992, BRIT MED J, V304, P1634, DOI 10.1136/bmj.304.6842.1634; HENSLEY MJ, 1992, MED J AUSTRALIA, V157, P568; HENSLEY MJ, 1992, MED J AUSTRALIA, V156, P882, DOI 10.5694/j.1326-5377.1992.tb137010.x; HORWITZ RI, 1991, CHEST, V100, P1586, DOI 10.1378/chest.100.6.1586; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; JACKSON RT, 1983, NZ MED J, V96, P727; KEATING G, 1984, BRIT MED J, V289, P348, DOI 10.1136/bmj.289.6441.348; MULLEN M, 1993, JAMA-J AM MED ASSOC, V270, P1842, DOI 10.1001/jama.270.15.1842; PEARCE N, 1990, THORAX, V45, P170, DOI 10.1136/thx.45.3.170; PEARCE N, 1991, CLIN EXP ALLERGY, V21, P401, DOI 10.1111/j.1365-2222.1991.tb01679.x; PEARCE N, 1992, NEW ENGL J MED, V327, P355; PEARCE N, 1994, JAMA-J AM MED ASSOC, V271, P822, DOI 10.1001/jama.271.11.822; Prime Ministerial Task Force on Employment, 1994, EMPLOYMENT ISSUES; SEARS MR, 1986, AM J EPIDEMIOL, V124, P1004, DOI 10.1093/oxfordjournals.aje.a114470; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STOLLEY PD, 1972, AM REV RESPIR DIS, V105, P883; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; SUISSA S, 1992, BRIT MED J, V305, P889, DOI 10.1136/bmj.305.6858.889; WILSON JD, 1981, LANCET, V1, P1235; WOODMAN K, 1992, CLIN PHARMACOL THER, V51, P566, DOI 10.1038/clpt.1992.64	30	137	141	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					41	44		10.1016/S0140-6736(95)91159-6	http://dx.doi.org/10.1016/S0140-6736(95)91159-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799709				2022-12-24	WOS:A1995QA29000017
J	WIESENFELD, K; MOSS, F				WIESENFELD, K; MOSS, F			STOCHASTIC RESONANCE AND THE BENEFITS OF NOISE - FROM ICE AGES TO CRAYFISH AND SQUIDS	NATURE			English	Article							CLIMATIC TRANSITIONS; BISTABLE SYSTEMS; DEVILS-HOLE; FIELDS; INFORMATION; ESCAPE	Noise in dynamical systems is usually considered a nuisance. But in certain nonlinear systems, including electronic circuits and biological sensory apparatus, the presence of noise can in fact enhance the detection of weak signals. This phenomenon, called stochastic resonance, may find useful application in physical, technological and biomedical contexts.	UNIV MISSOURI, DEPT PHYS & ASTRON, ST LOUIS, MO 63121 USA	University of Missouri System; University of Missouri Saint Louis	WIESENFELD, K (corresponding author), GEORGIA INST TECHNOL, SCH PHYS, ATLANTA, GA 30332 USA.							ADAIR RK, 1991, PHYS REV A, V43, P1039, DOI 10.1103/PhysRevA.43.1039; Anishchenko V. S., 1992, International Journal of Bifurcation and Chaos in Applied Sciences and Engineering, V2, P397, DOI 10.1142/S0218127492000379; ANISHCHENKO VS, 1994, INT J BIFURCAT CHAOS, V4, P441, DOI 10.1142/S0218127494000290; BENNETT WR, 1994, PHYS TODAY, V47, P23, DOI 10.1063/1.881417; BENZI R, 1982, TELLUS, V34, P10, DOI 10.1111/j.2153-3490.1982.tb01787.x; BENZI R, 1981, J PHYS A-MATH GEN, V14, pL453, DOI 10.1088/0305-4470/14/11/006; BRAUN HA, 1994, NATURE, V367, P270, DOI 10.1038/367270a0; BULSARA A, 1993, J STAT PHYS, V70, P1, DOI 10.1007/BF01053949; BULSARA AR, 1994, PHYS REV E, V49, P4989, DOI 10.1103/PhysRevE.49.4989; CARROLL TL, 1993, PHYS REV LETT, V70, P576, DOI 10.1103/PhysRevLett.70.576; DOUGLASS JK, 1993, NATURE, V365, P337, DOI 10.1038/365337a0; DYKAMAN MI, 1990, PHYS REV LETT, V65, P2606; FAUVE S, 1983, PHYS LETT A, V97, P5, DOI 10.1016/0375-9601(83)90086-5; GAMMAITONI L, 1989, PHYS REV LETT, V62, P349, DOI 10.1103/PhysRevLett.62.349; GAMMAITONI L, 1993, PHYS REV LETT, V71, P3625, DOI 10.1103/PhysRevLett.71.3625; GHIL M, 1987, TOPICS GEOPHYSICAL 4; GINGL Z, IN PRESS EUROPHYS LE; HIBBS A, IN PRESS J APPL PHYS; HIBBS A, 1993, AIP C P, V295, P720; IMBRIE J, 1993, NATURE, V363, P531, DOI 10.1038/363531a0; JUNG P, 1989, EUROPHYS LETT, V8, P505, DOI 10.1209/0295-5075/8/6/003; JUNG P, 1993, PHYS REP, V234, P175, DOI 10.1016/0370-1573(93)90022-6; JUNG P, 1991, PHYS REV A, V44, P8032, DOI 10.1103/PhysRevA.44.8032; KELSO JAS, IN PRESS MULTISTABIL; KRUGLIKOV IL, IN PRESS BIOELECTROM; LOFSTEDT R, 1994, PHYS REV LETT, V72, P1947, DOI 10.1103/PhysRevLett.72.1947; LONGTIN A, 1991, PHYS REV LETT, V67, P656, DOI 10.1103/PhysRevLett.67.656; LONGTIN A, 1993, J STAT PHYS, V70, P309, DOI 10.1007/BF01053970; Makeyev V. M., 1993, Biophysics (English Translation of Biofizika), V38, P189; MATTEUCCI G, 1991, CLIM DYNAM, V6, P67; MCNAMARA B, 1988, PHYS REV LETT, V60, P2626, DOI 10.1103/PhysRevLett.60.2626; MCNAMARA B, 1989, PHYS REV A, V39, P4854, DOI 10.1103/PhysRevA.39.4854; MOSS F, 1993, ANN NY ACAD SCI, V706, P26, DOI 10.1111/j.1749-6632.1993.tb24679.x; Necker LA., 1832, LONDON EDINBURGH, V1, P329, DOI [10.1080/14786443208647909, DOI 10.1080/14786443208647909]; NEIMAN A, 1994, PHYS REV LETT, V72, P2988, DOI 10.1103/PhysRevLett.72.2988; NICOLIS C, 1993, J STAT PHYS, V70, P3, DOI 10.1007/BF01053950; NICOLIS C, 1982, TELLUS, V34, P1, DOI 10.1111/j.2153-3490.1982.tb01786.x; PANTAZELOU E, IN PRESS INT J BIFUR; POLK C, IN PRESS 13TH P A M; RIANI M, 1994, PHYS REV LETT, V72, P3120, DOI 10.1103/PhysRevLett.72.3120; SIMON A, 1992, PHYS REV LETT, V68, P3375, DOI 10.1103/PhysRevLett.68.3375; STOCKS NG, 1993, J PHYS A-MATH GEN, V26, pL385, DOI 10.1088/0305-4470/26/7/007; TENFORDE TS, 1992, ANNU REV PUBL HEALTH, V13, P173, DOI 10.1146/annurev.publhealth.13.1.173; WEAVER JC, 1990, SCIENCE, V247, P459, DOI 10.1126/science.2300806; WIESENFELD K, 1994, PHYS REV LETT, V72, P2125, DOI 10.1103/PhysRevLett.72.2125; WIESENFELD K, IN PRESS NUOVO CIM S; WINOGRAD IJ, 1992, SCIENCE, V258, P255, DOI 10.1126/science.258.5080.255; ZHOU T, 1990, PHYS REV A, V42, P3161, DOI 10.1103/PhysRevA.42.3161	48	1521	1540	7	138	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					33	36		10.1038/373033a0	http://dx.doi.org/10.1038/373033a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800036				2022-12-24	WOS:A1995QA23900046
J	URWIN, G; YUAN, MF; FELDMAN, RA				URWIN, G; YUAN, MF; FELDMAN, RA			PROSPECTIVE-STUDY OF BACTERIAL-MENINGITIS IN NORTH-EAST THAMES REGION, 1991-3, DURING INTRODUCTION OF HAEMOPHILUS-INFLUENZAE VACCINE	BRITISH MEDICAL JOURNAL			English	Article							B INVASIVE DISEASE; UNITED-STATES; SURVEILLANCE; EPIDEMIOLOGY	Objective-To describe the epidemiology of primary bacterial meningitis in the North East Thames region over a three year period before and during the introduction of the vaccine for Haemophilus influenzae type b. Design-Analysis of information on cases of primary bacterial meningitis identified by microbiology laboratories in the region, with collection of case data by questionnaire. Main outcome measures-Annual incidence rates for types of meningitis according to age and ethnic group. Results-The annual incidence rates for the three major causes of bacterial meningitis in the general population were 1.9/100 000 for Neisseria meningitidis, 1.6/100 000 for Haemophilus influenzae before vaccination, and 1.0/100 000 for Streptococcus pneumoniae. Higher rates of H influenzae meningitis were found in Asians compared with white people (3.6/100 000 v 1.5/100 000, P=0.01). As a result of the vaccine programme introduced in October 1992 the number of cases of H influenzae meningitis in children under 5 years has fallen by 87%. Conclusions-Bacterial meningitis is a serious problem especially in preschool children. There are differences in the incidence of some causes of bacterial meningitis in different ethnic groups; with H influenzae type b being significantly more common among black and Asian people than among white people. The immunisation programme for H influenzae type b in the North East Thames region has been successful in reducing the incidence of this type of meningitis in Asian and white populations. The numbers were too small to evaluate in the black population.	UNIV LONDON QUEEN MARY & WESTFIELD COLL,LONDON HOSP,COLL MED,DEPT EPIDEMIOL & MED STAT,LONDON E1 4NS,ENGLAND; UNIV LONDON LONDON HOSP,COLL MED,DEPT MED MICROBIOL,LONDON E1 2AD,ENGLAND	University of London; Queen Mary University London; University of London; University College London								ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; BREWSTER D, 1993, HLTH B EDINB, V56, P385; CARTWRIGHT KAV, 1986, LANCET, V2, P558; FALLON RJ, 1991, BRIT MED J, V303, P1203, DOI 10.1136/bmj.303.6811.1203-b; GILLAM S, 1990, POSTGRAD MED J, V66, P989, DOI 10.1136/pgmj.66.782.989; HOWARD AJ, 1991, BRIT MED J, V303, P441, DOI 10.1136/bmj.303.6800.441; Jackson Lisa A., 1993, Morbidity and Mortality Weekly Report, V42, P21; Jones D M, 1991, CDR (Lond Engl Rev), V1, pR76; MACLEOD C, 1994, CDR REV, V2, pR13; NAZARETH B, 1992, COMM DIS REP REV, V2, P13; OBRIEN H, 1994, COM DIS REP CDR REV, V2, pR17; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; RALEIGH VS, 1994, BRIT MED J, V309, P287, DOI 10.1136/bmj.309.6950.287; SCHLECH WF, 1985, JAMA-J AM MED ASSOC, V253, P1749, DOI 10.1001/jama.253.12.1749; TUDORWILLIAMS G, 1989, ARCH DIS CHILD, V64, P517, DOI 10.1136/adc.64.4.517; WARD JI, 1986, J INFECT DIS, V153, P17, DOI 10.1093/infdis/153.1.17; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316	17	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1412	1414		10.1136/bmj.309.6966.1412	http://dx.doi.org/10.1136/bmj.309.6966.1412			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819853	Green Published			2022-12-24	WOS:A1994PU76400027
J	KESSLER, DA				KESSLER, DA			NICOTINE ADDICTION IN YOUNG-PEOPLE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											KESSLER, DA (corresponding author), US FDA,ROCKVILLE,MD 20857, USA.							BANTLE LF, 1968, JAN MIN SNUFF CHEW T, P3; CUMMINGS KM, 1994, AM J PUBLIC HEALTH, V84, P300, DOI 10.2105/AJPH.84.2.300; FISCHER PM, 1991, JAMA-J AM MED ASSOC, V266, P3145, DOI 10.1001/jama.266.22.3145; FREEDMAN AM, 1994, WALL ST J       0603, pA1; GIOVINO GA, 1994, AUG FOOD DRUG ADM DR; HILTS PJ, 1994, NY TIMES        1127, P1; LYNCH BS, 1994, GROWING TOBACCO FREE, P8; LYNCH BS, 1994, GROWING UP TOBACCO F; LYNCH BS, 1994, GROWING TOBACCO FREE, P3; MCMAHON JP, 1990, COMMUNICATION   0110; MOSS AJ, 1992, ADV DATA VITAL HLTH, V221; PIERCE JP, 1994, JAMA-J AM MED ASSOC, V271, P608, DOI 10.1001/jama.271.8.608; SHAPIRO E, 1994, WALL STREET J   1006; TEINOWITZ I, 1993, ADVERTISING AGE 0426, P3; WARLICK RG, 1990, COMMUNICATION   0405; 1992, 1992 GALLUP SURVEY, P59; 1991, J NATL CANCER I, V83, P1620; 1994, REPORT C PURSUANT FE, P3; 1995, NATIONS 1ST SURVEY R; 1988, OVERALL MARKET CONDI, P6; 1994, MONITORING FUTURE ST; 1988, HLTH CONSEQUENCES SM, P7; 1995, FINDINGS SURVEY APPR, P4; 1993, MMWR-MORBID MORTAL W, V42, P645; 1994, MMWR-MORBID MORTAL W, V43, P580; 1994, PREVENTING TOBACCO U, P124; 1994, PREVENTING TOBACCO U, V5, P58; 1994, MMWR-MORBID MORTAL W, V43, P577; 1982, PROJECT PLUS MINUS 3, P1; 1988, HLTH CONSEQUENCES SM, P9; 1994, PREVENTING TOBACCO U, P249; 1989, REDUCING HLTH CONSEQ, P131; 1994, PREVENTING TOBACCO U, P192; 1977, 16 KWECH MARK RES PR, pR6; 1992, TEENAGE ATTITUDES BE, P54; 1994, PREVENTING TOBACCO U, P70; 1986, NIH 862874 DEP HLTH, pR7	37	91	92	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 20	1995	333	3					186	189		10.1056/NEJM199507203330311	http://dx.doi.org/10.1056/NEJM199507203330311			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RK917	7791824				2022-12-24	WOS:A1995RK91700011
J	VLADECK, BC				VLADECK, BC			END-STAGE RENAL-DISEASE CORE INDICATORS PROJECT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											VLADECK, BC (corresponding author), US HLTH CARE FINANCING ADM,DIV HLTH STAND & QUAL,REG OFF X,SEATTLE,WA, USA.							1994, JAMA-J AM MED ASSOC, V271, P1896	1	19	19	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1896	1896		10.1001/jama.273.24.1896	http://dx.doi.org/10.1001/jama.273.24.1896			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783287				2022-12-24	WOS:A1995RE35400004
J	IRVING, M; ALLEN, TS; SABIDODAVID, C; CRAIK, JS; BRANDMEIER, B; KENDRICKJONES, J; CORRIE, JET; TRENTHAM, DR; GOLDMAN, YE				IRVING, M; ALLEN, TS; SABIDODAVID, C; CRAIK, JS; BRANDMEIER, B; KENDRICKJONES, J; CORRIE, JET; TRENTHAM, DR; GOLDMAN, YE			TILTING OF THE LIGHT-CHAIN REGION OF MYOSIN DURING STEP LENGTH CHANGES AND ACTIVE FORCE GENERATION IN SKELETAL-MUSCLE	NATURE			English	Article							CONTRACTING MUSCLE; MECHANICAL TRANSIENTS; FROG-MUSCLE; FIBERS; ORIENTATION; STIFFNESS; HEAD	FORCE generation and relative sliding between the myosin and actin filaments in muscle are thought to be caused by tilting of the head region of the myosin crossbridges between the filaments(1-3). Structural and spectroscopic experiments have demonstrated segmental flexibility of myosin in muscle(4-6), but have not shown a direct linkage between tilting of the myosin heads and either force generation or filament sliding. Here we use fluorescence polarization to detect changes in the orientation of the light-chain region of the head, the part most likely to tilt(5,7,8), and synchronized head movements by imposing rapid length steps(9-11). We found that the light-chain region of the myosin head tilts both during the imposed filament sliding and during the subsequent quick force recovery that is thought to signal the elementary force-generating event.	UNIV PENN,DEPT DEV & CELL BIOL,PHILADELPHIA,PA 19104; NATL INST MED RES,LONDON NW7 1AA,ENGLAND; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; UNIV PENN,PENN MUSCLE INST,PHILADELPHIA,PA 19104	University of Pennsylvania; MRC National Institute for Medical Research; MRC Laboratory Molecular Biology; University of Pennsylvania	IRVING, M (corresponding author), UNIV LONDON KINGS COLL,RANDALL INST,26-29 DRURY LANE,LONDON WC2B 5RL,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERGER CL, 1994, BIOPHYS J, V66, pA189; CHASE PB, 1988, BIOPHYS J, V53, P935, DOI 10.1016/S0006-3495(88)83174-6; COOKE R, 1982, NATURE, V300, P776, DOI 10.1038/300776a0; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; CORRIE JET, 1994, J CHEM SOC PERK T 1, P2967, DOI 10.1039/p19940002967; DANTZIG JA, 1985, J GEN PHYSIOL, V86, P305, DOI 10.1085/jgp.86.3.305; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V350, P497, DOI 10.1113/jphysiol.1984.sp015215; GOLDMAN YE, 1977, J PHYSIOL-LONDON, V269, pP55; GOLDMAN YE, 1987, BIOPHYS J, V52, P57, DOI 10.1016/S0006-3495(87)83188-0; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; HUXLEY AF, 1974, J PHYSIOL-LONDON, V243, P1; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; HUXLEY HE, 1983, J MOL BIOL, V169, P469, DOI 10.1016/S0022-2836(83)80062-X; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; IRVING M, 1989, J PHYSIOL-LONDON, V418, pP57; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; LOMBARDI V, 1990, J PHYSIOL-LONDON, V431, P141, DOI 10.1113/jphysiol.1990.sp018324; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; LOMBARDI V, 1995, NATURE, V374, P553, DOI 10.1038/374553a0; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MARTYN DA, 1992, J GEN PHYSIOL, V99, P795, DOI 10.1085/jgp.99.5.795; MOSS RL, 1982, J BIOL CHEM, V257, P8588; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; ROWE T, 1992, EMBO J, V11, P4715, DOI 10.1002/j.1460-2075.1992.tb05576.x; SABIDODAVID C, 1994, BIOPHYS J, V66, P234; TANNER JW, 1992, J MOL BIOL, V223, P185, DOI 10.1016/0022-2836(92)90725-Y; THOMAS DD, 1987, ANNU REV PHYSIOL, V49, P691, DOI 10.1146/annurev.ph.49.030187.003355; TREGEAR RT, 1975, BIOPHYS J, V15, P455, DOI 10.1016/S0006-3495(75)85830-9; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	35	180	180	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					688	691		10.1038/375688a0	http://dx.doi.org/10.1038/375688a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791902				2022-12-24	WOS:A1995RE57600062
J	JUNG, M; ZHANG, Y; LEE, S; DRITSCHILO, A				JUNG, M; ZHANG, Y; LEE, S; DRITSCHILO, A			CORRECTION OF RADIATION SENSITIVITY IN ATAXIA-TELANGIECTASIA CELLS BY A TRUNCATED I-KAPPA-B-ALPHA	SCIENCE			English	Article							INHIBITOR; GENE; RADIOSENSITIVITY; LOCALIZATION; FIBROBLASTS; EXPRESSION; PLASMIDS; SURVIVAL	Cells from patients with ataxia telangiectasia (AT) are hypersensitive to ionizing radiation and are defective in the regulation of DNA synthesis. A complementary DNA that corrects the radiation sensitivity and DNA synthesis defects in fibroblasts from an AT group D patient was isolated by expression cloning and shown to encode a truncated form of I kappa B-alpha, an inhibitor of the nuclear factor kappa B (NF-kappa B) transcriptional activator. The parental AT fibroblasts expressed large amounts of the I kappa B-alpha transcript and showed constitutive activation of NF-kappa B. The AT fibroblasts transfected with the truncated I kappa B-alpha expressed normal amounts of the I kappa B-alpha transcript and showed regulated activation of NF-kappa B. These results suggest that aberrant regulation of NF-kappa B and I kappa B-alpha contribute to the cellular defect in AT.	GEORGETOWN UNIV, SCH MED, DEPT RADIAT MED, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, SCH MED, DEPT IMMUNOL & MICROBIOL, WASHINGTON, DC 20007 USA	Georgetown University; Georgetown University					NATIONAL CANCER INSTITUTE [R01CA045408, R29CA063023] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA63023, CA45408] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADCOCK IM, 1994, BIOCHEM BIOPH RES CO, V199, P1518, DOI 10.1006/bbrc.1994.1403; ALBRIGHT N, 1987, RADIAT RES, V112, P331, DOI 10.2307/3577260; ARLETT CF, 1988, INT J RADIAT BIOL, V54, P911, DOI 10.1080/09553008814552321; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BODER E, 1985, ATAXIA TELANGIECTASI, P1; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HIRT B, 1967, J MOL BIOL, V26, P265; HOPGOOD R, 1992, BIOTECHNIQUES, V13, P82; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; Jung M, 1992, PCR Methods Appl, V1, P171; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; LEA DE, 1962, ACTIONS RAD LIVING C, P74; LEBEAU MM, 1992, GENOMICS, V14, P529, DOI 10.1016/S0888-7543(05)80261-7; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MEYN MS, 1993, AM J HUM GENET, V53, P1206; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; SALEHI Z, 1991, EXP BIOL M, P377; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; WEICHSELBAUM RR, 1988, INT J RADIAT ONCOL, V15, P575, DOI 10.1016/0360-3016(88)90297-0; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806	31	171	177	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 16	1995	268	5217					1619	1621		10.1126/science.7777860	http://dx.doi.org/10.1126/science.7777860			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7777860				2022-12-24	WOS:A1995RD45900038
J	DOWELL, SF; TOKO, A; SITA, C; PIARROUX, R; DUERR, A; WOODRUFF, BA				DOWELL, SF; TOKO, A; SITA, C; PIARROUX, R; DUERR, A; WOODRUFF, BA			HEALTH AND NUTRITION IN CENTERS FOR UNACCOMPANIED REFUGEE CHILDREN - EXPERIENCE FROM THE 1994 RWANDAN REFUGEE CRISIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORTALITY		MED MONDE, MARSEILLE, FRANCE; UN, CHILDRENS FUND, KINSHASA, DEM REP CONGO		DOWELL, SF (corresponding author), CTR DIS CONTROL & PREVENT, RESP & ENTER VIRUSES BRANCH, 1600 CLIFTON RD NE, ATLANTA, GA 30333 USA.			piarroux, renaud/0000-0002-4151-4134				[Anonymous], 1986, B WORLD HEALTH ORGAN, V64, P929; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BARRERE B, 1994, ENQUETE DEMOGRAPHIQU; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; PAQUET C, 1994, LANCET, V344, P823, DOI 10.1016/S0140-6736(94)92381-7; SIDDIQUE AK, 1995, LANCET, V345, P359, DOI 10.1016/S0140-6736(95)90344-5; TOOLE MJ, 1992, LANCET, V339, P1214, DOI 10.1016/0140-6736(92)91143-V; Williamson J, 1988, UNACCOMPANIED CHILDR; YIP R, 1993, JAMA-J AM MED ASSOC, V270, P587, DOI 10.1001/jama.270.5.587; 1992, GUIDELINES CHOLERA C; 1995, LANCET, V348, P339; 1994, MMWR-MORBID MORTAL W, V43, P701; 1992, MMWR MORB MORTAL WKL, V41; 1994, STANDARDS PROTECTION; 1983, MEASURING CHANGE NUT	15	19	19	2	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	1995	273	22					1802	1806		10.1001/jama.273.22.1802	http://dx.doi.org/10.1001/jama.273.22.1802			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB800	7769778				2022-12-24	WOS:A1995RB80000037
J	KOH, J; ENDERS, GH; DYNLACHT, BD; HARLOW, E				KOH, J; ENDERS, GH; DYNLACHT, BD; HARLOW, E			TUMOR-DERIVED P16 ALLELES ENCODING PROTEINS DEFECTIVE IN CELL-CYCLE INHIBITION	NATURE			English	Article							RETINOBLASTOMA PROTEIN	THE cyclin-dependent kinase inhibitor p16 is a candidate tumour-suppressor protein that maps to a genomic locus strongly associated with familial melanoma and other tumour types(1-3). Screening of primary tumours and linkage analysis of familial melanoma pedigrees have identified many potential mutations in p16, but the functional significance of these sequence variants has remained unclear(1,3-9). We report here that p16 can act as a potent and specific inhibitor of progression through the G1 phase of the cell cycle, and we demonstrate that several tumour-derived alleles of p16 encode functionally compromised proteins. The ability of p16 to arrest cell-cycle progression generally correlates with inhibition of cyclin D1/Cdk4 kinase activity irt vitro, with two exceptions among the alleles tested. In vivo, the presence of functional retinoblastoma protein appears to be necessary but may not be sufficient to confer full sensitivity to p16-mediated growth arrest. Our results provide support for the notion that p16 is an important cell-cycle regulator whose inactivation contributes to the outgrowth of human tumours.	MASSACHUSETTS GEN HOSP, GASTROINTESTINAL UNIT, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital	KOH, J (corresponding author), MASSACHUSETTS GEN HOSP, CTR CANC, BLDG 149, 13TH ST, BOSTON, MA 02129 USA.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; DEUSCHLE U, 1990, SCIENCE, V248, P480, DOI 10.1126/science.2158670; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORI T, 1994, CANCER RES, V54, P3396; OTTERSON GA, 1994, ONCOGENE, V9, P3375; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WAINWRIGHT B, 1994, NAT GENET, V8, P3, DOI 10.1038/ng0994-3; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	27	530	548	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 8	1995	375	6531					506	510		10.1038/375506a0	http://dx.doi.org/10.1038/375506a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777061				2022-12-24	WOS:A1995RC18800053
J	MADINE, MA; KHOO, CY; MILLS, AD; LASKEY, RA				MADINE, MA; KHOO, CY; MILLS, AD; LASKEY, RA			MCM3 COMPLEX REQUIRED FOR CELL-CYCLE REGULATION OF DNA-REPLICATION IN VERTEBRATE CELLS	NATURE			English	Article							LICENSING FACTOR; XENOPUS EGGS; YEAST; INITIATION; PROTEINS; NUCLEI; LOCALIZATION; EXTRACT; GENES	AN intact nuclear membrane restricts DNA replication to only one round in each cell cycle, apparently by excluding an essential replication-licensing factor throughout interphase(1-5). A family of related yeast replication proteins, MCM2, 3 and 5 (also called, after cell-division cycle, CDC46), resemble licensing factor, entering the nucleus only during mitosis(6-8). We have cloned a Xenopus homologue of MCM3 (XMCM3) and raised antibodies against expressed protein, Immunodepletion of Xenopus egg extracts removes a complex of MCM2, 3 and 5 homologues and inhibits replication of Xenopus sperm nuclei or permeable G2 HeLa nuclei. However, G1 HeLa nuclei still replicate efficiently. Mock-depleted extracts replicate all three templates. XMCM3 accumulates in nuclei before replication but anti-XMCM3 staining decreases during replication. These results can explain why replicated nuclei are unable to reinitiate replication in a single cell cycle.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND	University of Cambridge	MADINE, MA (corresponding author), WELLCOME CRC INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BUCCI S, 1993, INT J DEV BIOL, V37, P509; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; COVERLEY D, 1993, J CELL BIOL, V122, P985, DOI 10.1083/jcb.122.5.985; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; HARLOW E, 1988, ANTIBODIES LABORATOR; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KUBOTA Y, 1993, J CELL BIOL, V123, P1321, DOI 10.1083/jcb.123.6.1321; KUBOTA Y, 1995, IN PRSS CELL; LEMAIRE P, 1993, CR ACAD SCI III-VIE, V316, P938; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; MANIATIS T, 1991, MOL CLONING; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; TODOROV IT, 1994, J CELL SCI, V107, P253; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	28	241	243	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					421	424		10.1038/375421a0	http://dx.doi.org/10.1038/375421a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760938				2022-12-24	WOS:A1995RB10100058
J	JACKSON, LA; SCHUCHAT, A; REEVES, MW; WENGER, JD				JACKSON, LA; SCHUCHAT, A; REEVES, MW; WENGER, JD			SEROGROUP-C MENINGOCOCCAL OUTBREAKS IN THE UNITED-STATES - AN EMERGING THREAT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEISSERIA-MENINGITIDIS; POLYSACCHARIDE VACCINE; DISEASE; EPIDEMIC; INFLUENZA; AGE; MYCOPLASMA; INFECTIONS; CARRIAGE; CANADA	Objective.-Multiple outbreaks of serogroup C Neisseria meningitidis have recently been reported from diverse areas of the United States. To better define the characteristics of this increasingly important problem, we reviewed data on all known serogroup C outbreaks in the United States from January 1980 through June 1993. Data Sources.-MEDLINE searches, Centers for Disease Control and Prevention records, state health department officials, infectious disease experts, and the meningococcal vaccine manufacturer. Definition of an Outbreak.-Three or more cases of serogroup C meningococcal disease within a 3-month period, either among members of a community or persons attending a single school or other institution, for which those cases represented an attack rate of at least five per 100 000 population. Results.-Twenty-one outbreaks of serogroup C meningococcal disease were identified; eight occurred since 1991. In 1992 and the first half of 1993, approximately 180 000 doses of vaccine were administered for outbreak control, compared with approximately 34 000 doses from 1980 to 1991. Approximately 50% of community-outbreak cases were between the ages of 5 and 24 years, compared with only 19% of sporadic serogroup C cases (P<.001). Subtyping of patient isolates indicates that outbreaks are clonal; however, at least five distinct but closely related strains have caused recent outbreaks. Conclusions.-Serogroup C outbreaks are occurring more frequently in the United States. The effectiveness of preventive measures depends on early recognition; therefore, physicians should promptly report all cases of suspected meningococcal disease, and the causative serogroup should be established for every case.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA								ARTENSTEIN MS, 1970, NEW ENGL J MED, V282, P417, DOI 10.1056/NEJM197002192820803; ASHTON FE, 1991, J CLIN MICROBIOL, V29, P2489, DOI 10.1128/JCM.29.11.2489-2493.1991; BROOME CV, 1983, B WORLD HEALTH ORGAN, V61, P325; CARTWRIGHT KAV, 1991, LANCET, V338, P554, DOI 10.1016/0140-6736(91)91112-8; Dean A. G., 1990, EPI INFO VERSION 5 W; DEMORAIS JS, 1974, J INFECT DIS, V129, P568; EDMOND MB, 1993, 33RD INT C ANT AG CH; FEIGIN RD, 1982, NEW ENGL J MED, V307, P1255, DOI 10.1056/NEJM198211113072007; GILMORE A, 1992, CAN MED ASSOC J, V147, P729; GOLD R, 1992, CAN J PUBLIC HEALTH, V83, P5; GUILMETTE P, 1993, CAN DIS WKLY REP, V17, P295; HARRISON LH, 1991, ARCH INTERN MED, V151, P1005, DOI 10.1001/archinte.151.5.1005; HOUCK P, IN PRESS PUBLIC HLTH; HUDSON PJ, 1986, PEDIATR INFECT DIS J, V5, P213, DOI 10.1097/00006454-198603000-00011; IMREY PB, 1993, 3RD ANN M SOC HOSP E; JACOBS D, 1990, 15TH P ANN SAS US GR, P1413; JACOBSON JA, 1977, J INFECT DIS, V136, P104, DOI 10.1093/infdis/136.1.104; JAFARI H, 1993, 33RD INT C ANT AG CH; KRASINSKI K, 1987, AM J EPIDEMIOL, V125, P499, DOI 10.1093/oxfordjournals.aje.a114556; MASTERTON RG, 1988, J INFECTION, V17, P177, DOI 10.1016/S0163-4453(88)91907-X; MOORE PS, 1990, JAMA-J AM MED ASSOC, V264, P1271, DOI 10.1001/jama.264.10.1271; MOORE PS, 1989, LANCET, V2, P260; MORROW HW, 1991, MISS MORB REP, V9, P1; PELTOLA H, 1977, NEW ENGL J MED, V297, P686, DOI 10.1056/NEJM197709292971302; PELTOLA H, 1982, LANCET, V2, P595; PINNER RW, 1991, J INFECT DIS, V164, P368, DOI 10.1093/infdis/164.2.368; REINGOLD AL, 1985, LANCET, V2, P114; RONNE T, 1993, SCAND J INFECT DIS, V25, P331, DOI 10.3109/00365549309008507; SACCHI CT, 1992, J CLIN MICROBIOL, V30, P1734, DOI 10.1128/JCM.30.7.1734-1738.1992; SAEZNIETO JA, 1984, J INFECTION, V8, P49, DOI 10.1016/S0163-4453(84)93327-9; SCHOLTEN RJPM, 1994, J INFECT DIS, V169, P673, DOI 10.1093/infdis/169.3.673; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; TAPPERO JW, 1994, 34TH INT C ANT AG CH; THOMAS JC, 1991, AM J EPIDEMIOL, V133, P286, DOI 10.1093/oxfordjournals.aje.a115873; WAHDAN MH, 1977, B WORLD HEALTH ORGAN, V55, P645; WENGER JD, 1994, INFECT DIS CLIN PRAC, V3, P136, DOI 10.1097/00019048-199403000-00022; YOUNG LS, 1972, NEW ENGL J MED, V287, P5, DOI 10.1056/NEJM197207062870102; ZEIT, 1993, 33RD INT C ANT AG CH; 1993, MMWR-MORBID MORTAL W, V42, P21; 1985, MMWR-MORBID MORTAL W, V34, P255	40	201	206	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	1995	273	5					383	389		10.1001/jama.273.5.383	http://dx.doi.org/10.1001/jama.273.5.383			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD203	7823383				2022-12-24	WOS:A1995QD20300022
J	SCOTT, G				SCOTT, G			NONINVASIVE TESTS FOR CHLAMYDIA-TRACHOMATIS	LANCET			English	Editorial Material							URINE SPECIMENS				SCOTT, G (corresponding author), ROYAL INFIRM,DEPT GENITOURINARY MED,EDINBURGH,MIDLOTHIAN,SCOTLAND.							CHERNESKY MA, 1994, J INFECT DIS, V170, P1308, DOI 10.1093/infdis/170.5.1308; JASCHEK G, 1993, J CLIN MICROBIOL, V31, P1209, DOI 10.1128/JCM.31.5.1209-1212.1993; JONES RB, 1986, J CLIN MICROBIOL, V24, P1029, DOI 10.1128/JCM.24.6.1029-1033.1986; LEONARDI GP, 1992, J CLIN MICROBIOL, V30, P2793, DOI 10.1128/JCM.30.11.2793-2796.1992; MOSS TR, 1993, SEX TRANSM DIS, V20, P61, DOI 10.1097/00007435-199303000-00001; SCHACHTER J, 1992, SEX TRANSM DIS, V19, P243, DOI 10.1097/00007435-199209000-00001; SVENSSON LO, 1991, GENITOURIN MED, V67, P117; 1995, LANCET, V345, P213	8	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					207	207		10.1016/S0140-6736(95)90218-X	http://dx.doi.org/10.1016/S0140-6736(95)90218-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823710				2022-12-24	WOS:A1995QD53200004
J	MULLER, CW; REY, FA; SODEOKA, M; VERDINE, GL; HARRISON, SC				MULLER, CW; REY, FA; SODEOKA, M; VERDINE, GL; HARRISON, SC			STRUCTURE OF THE NF-KAPPA-B P50 HOMODIMER BOUND TO DNA	NATURE			English	Article							CRYSTAL-STRUCTURE; BINDING SUBUNIT; TRANSCRIPTIONAL ACTIVATION; 3-DIMENSIONAL STRUCTURE; CYTOPLASMIC RETENTION; NUCLEIC-ACIDS; P65 SUBUNIT; PROTEIN; REL; GENE	The structure of a large fragment of the p50 subunit of the human transcription factor NF-kappa B, bound as a homodimer to DNA, reveals that the Rel-homology region has two beta-barrel domains that grip DNA in the major groove. Both domains contact the DNA backbone. The amino-terminal specificity domain contains a recognition loop that interacts with DNA bases; the carboxy-terminal dimerization domain bears the site of I-kappa B interaction. The folds of these domains are related to immunoglobulin-like modules. The amino-terminal domain also resembles the core domain of p53.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	Harvard University; Harvard University; University of Tokyo	MULLER, CW (corresponding author), HOWARD HUGHES MED INST,7 DIVINITY AVE,CAMBRIDGE,MA 02138, USA.		Müller, Christoph W/I-7420-2012; Sodeoka, Mikiko/A-9952-2008; Rey, Felix/B-6497-2012	Müller, Christoph W/0000-0003-2176-8337; Sodeoka, Mikiko/0000-0002-1344-364X; 				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR VERSION 3 1; BURKE PA, 1989, J EXP MED, V169, P1309, DOI 10.1084/jem.169.4.1309; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KIDD S, 1992, CELL, V1, P623; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LEHMING N, UNPUB EMBO J; LIU J, 1994, P NATL ACAD SCI USA, V91, P908, DOI 10.1073/pnas.91.3.908; Liu J, 1994, CHEM BIOL, V1, P47, DOI 10.1016/1074-5521(94)90040-X; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; NEKLUDOVA L, 1994, P NATL ACAD SCI USA, V91, P6948, DOI 10.1073/pnas.91.15.6948; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SODEOKA M, 1993, BIOORG MED CHEM LETT, V3, P1095, DOI 10.1016/S0960-894X(00)80294-2; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x	48	470	494	1	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					311	317		10.1038/373311a0	http://dx.doi.org/10.1038/373311a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830764				2022-12-24	WOS:A1995QD40400049
J	CALVIN, JE; KLEIN, LW; VANDENBERG, BJ; MEYER, P; CONDON, JV; SNELL, RJ; RAMIREZMORGEN, LM; PARRILLO, JE				CALVIN, JE; KLEIN, LW; VANDENBERG, BJ; MEYER, P; CONDON, JV; SNELL, RJ; RAMIREZMORGEN, LM; PARRILLO, JE			RISK STRATIFICATION IN UNSTABLE ANGINA - PROSPECTIVE VALIDATION OF THE BRAUNWALD CLASSIFICATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYOCARDIAL-INFARCTION; INTRAVENOUS NITROGLYCERIN; PECTORIS; PROPRANOLOL; THERAPY; MODELS	Objectives.-To validate the Braunwald classification of unstable angina as a predictor of in-hospital cardiac complications; to determine which factors of the Braunwald classification contributed significantly to this prediction; and to devise a method of combining these predictive factors into an overall odds ratio for complications. Design.-A validation cohort of consecutive patients followed prospectively for in-hospital cardiac complications including myocardial infarction and death. Setting.-A community-based academic medical center. Patients.-A total of 393 patients admitted consecutively to the coronary care and intermediate care units with unstable angina. Main Outcome Measures.-Major cardiac complications including death, myocardial infarction, congestive heart failure, cardiogenic shock, and severe ventricular dysrhythmias. Results.-Multiple logistic regression analysis identified four clinical factors used in the Braunwald classification that predicted the in-hospital occurrence of major cardiac complications: (1) myocardial infarction within less than 14 days (odds ratio [OR], 5.72; 95% confidence interval [CI], 1.92 to 16.97); (2) need for intravenous nitroglycerin (OR, 2.33; 95% CI, 1.31 to 4.17); (3) lack of beta-blocker or calcium channel blocker prior to admission (OR, 3.83; 95% CI, 1.55 to 9.42); and (4) baseline ST depression (OR, 2.81; 95% CI, 1.45 to 5.47). Two other clinical factors, diabetes and age, were also significant predictors. Validation of this model using parametric and nonparametric bootstrap techniques revealed excellent agreement between the CIs for adjusted ORs derived from the multiple logistic regression and those derived from the bootstrap. Conclusions.-The classification of unstable angina proposed by Braunwald includes four factors that predict risk of major in-hospital cardiac complications. Specific factors used in this classification can be combined with diabetes and age to better stratify risk of major cardiac complications in this disorder using a simpler model.			CALVIN, JE (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,CARDIOL SECT,1653 W CONGRESS PKWY,CHICAGO,IL 60612, USA.							BERTOLASI CA, 1976, CHEST, V70, P596, DOI 10.1378/chest.70.5.596; BERTOLET BD, 1993, CLIN CARDIOL, V16, P116, DOI 10.1002/clc.4960160207; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; BRAUNWALD E, 1994, 940602 US DEP HLTH H; CALIFF RM, 1988, J AM COLL CARDIOL, V11, P20, DOI 10.1016/0735-1097(88)90160-X; CALVIN JE, 1994, CLIN RES, V42, pA248; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COHEN M, 1991, AM J CARDIOL, V67, P1368, DOI 10.1016/0002-9149(91)90467-Y; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; CURFMAN GD, 1983, CIRCULATION, V67, P276, DOI 10.1161/01.CIR.67.2.276; Efron Bradley., 1994, INTRO BOOTSTRAP; FINEBERG HV, 1984, NEW ENGL J MED, V310, P1301, DOI 10.1056/NEJM198405173102006; FREEMAN MR, 1989, AM HEART J, V117, P306, DOI 10.1016/0002-8703(89)90773-4; FUCHS J, 1990, EUR HEART J, V11, P1029, DOI 10.1093/oxfordjournals.eurheartj.a059630; GAZES PC, 1973, CIRCULATION, V48, P331, DOI 10.1161/01.CIR.48.2.331; GERWITZ H, 1979, CIRCULATION, V59, P707; GLANTZ SA, 1990, PRIMER APPLIED REGRE, P512; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; KAPLAN K, 1983, AM J CARDIOL, V51, P694, DOI 10.1016/S0002-9149(83)80117-9; MURPHY JJ, 1992, BRIT HEART J, V67, P395; NEUMANN FJ, 1989, BRIT HEART J, V62, P421; NORRIS RM, 1978, LANCET, V2, P907; THEROUX P, 1985, J AM COLL CARDIOL, V5, P717, DOI 10.1016/S0735-1097(85)80400-9; UDVARHELYI IS, 1992, J GEN INTERN MED, V7, P1, DOI 10.1007/BF02599092; WACKERS FJT, 1978, CIRCULATION, V57, P738, DOI 10.1161/01.CIR.57.4.738; 1986, BRIT HEART J, V56, P400	28	125	128	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 11	1995	273	2					136	141						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ687	7799494				2022-12-24	WOS:A1995PZ68700027
J	LITWIN, MS; HAYS, RD; FINK, A; GANZ, PA; LEAKE, B; LEACH, GE; BROOK, RH				LITWIN, MS; HAYS, RD; FINK, A; GANZ, PA; LEAKE, B; LEACH, GE; BROOK, RH			QUALITY-OF-LIFE OUTCOMES IN MEN FOR LOCALIZED PROSTATE-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADICAL PROSTATECTOMY; RADIATION-THERAPY; CARCINOMA; STAGE; ADENOCARCINOMA; PAIN	Objective.-To assess health-related quality of life (HRQOL) in men treated for clinically localized prostate cancer. Design.-A cross-sectional analysis of HRQOL after treatment with radical prostatectomy, pelvic irradiation, or observation alone for clinically localized prostatic adenocarcinoma, and in age-matched comparison patients. Setting.-A large managed care population in California. Subjects.-A total of 528 men, including 214 treated for clinically localized prostate cancer (41 with evidence of metastatic disease were excluded from this analysis) and 273 age-matched, ZIP code-matched comparison patients without prostate cancer. Cancer patients were analyzed in three treatment groups: radical prostatectomy (n=98), primary pelvic irradiation (n=56), and observation alone (n=60). Main Outcome Measures.-General HRQOL was measured with the RAND 36-item Health Survey 1.0. Cancer-specific HRQOL was measured with the CAncer Rehabilitation Evaluation System-Short Form and the Functional Assessment of Cancer Therapy-General form, Disease-targeted quality of life was measured with a new instrument assessing function and bother in three organ systems: sexual, urinary, and bowel. Resuls.-No differences among treatment groups were seen in comparisons of general HRQOL. Significant differences among treatment groups were seen in both function and bother in the prostate-targeted measures of sexual, urinary, and bowel domains, When cancer patients were compared with men of similar age without prostate cancer, differences were seen in the sexual, urinary, and bowel function and bother but not in general HRQOL measures. Although cancer-free men were found not to have full potency or continence, prostate cancer patients treated with surgery or radiation reported significantly worse sexual, urinary, and bower function than men without cancer. Men who had undergone nerve-sparing prostatectomy did not differ from those who had undergone standard prostatectomy, but the power to detect a difference was low. Conclusions.-Although no differences were seen in general HRQOL, three disease-targeted domains were found to differ significantly among the treatment groups and comparison patients. Even after controlling for the sexual and urinary dysfunction experienced by older men without cancer, those receiving therapeutic interventions for their prostate cancer were found to have poorer disease-targeted HRQOL. We conclude that in addition to general HRQOL, disease-targeted measures must be used to assess outcomes of care in men treated for localized prostate cancer.	UNIV CALIF LOS ANGELES, SCH MED, DIV GEN INTERNAL MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DIV GERIATR, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT HLTH SERV, LOS ANGELES, CA 90024 USA; RAND CORP, HLTH SCI PROGRAM, SANTA MONICA, CA USA; SO CALIF PERMANENTE MED GRP, LOS ANGELES, CA 90027 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; RAND Corporation; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups	LITWIN, MS (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DIV UROL, 10833 LE CONTE AVE, LOS ANGELES, CA 90024 USA.		Hays, Ronald/D-5629-2013	Hays, Ronald/0000-0001-6697-907X; Litwin, Mark/0000-0002-2318-344X				BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; Cassileth B R, 1992, Qual Life Res, V1, P323, DOI 10.1007/BF00434946; CASSILETH BR, 1989, UROLOGY, V33, P57, DOI 10.1016/0090-4295(89)90108-8; CELLA D F, 1988, Comprehensive Therapy, V14, P69; Cella D F, 1990, Oncology (Williston Park), V4, P29; CELLA DF, 1987, CANCER-AM CANCER SOC, V60, P1661, DOI 10.1002/1097-0142(19871001)60:7<1661::AID-CNCR2820600740>3.0.CO;2-4; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; DASILVA FC, 1993, EUR UROL, V24, P113; DASILVA FC, 1993, CANCER, V71, P1138, DOI 10.1002/1097-0142(19930201)71:3+<1138::AID-CNCR2820711436>3.0.CO;2-7; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; FOSSA SD, 1992, PROSTATE, P145; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; FOWLER FJ, 1988, JAMA-J AM MED ASSOC, V259, P3018, DOI 10.1001/jama.259.20.3018; FOWLER FJ, 1991, EUR UROL, V20, P44; Ganz P A, 1992, Qual Life Res, V1, P19, DOI 10.1007/BF00435432; GBUREK B, 1992, Journal of Urology, V147, p466A; GIBBONS RP, 1989, J UROLOGY, V141, P564, DOI 10.1016/S0022-5347(17)40895-0; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; GREENFIELD S, 1993, MED CARE, V31, P141, DOI 10.1097/00005650-199302000-00005; Hays R D, 1993, Health Econ, V2, P217, DOI 10.1002/hec.4730020305; HERR HW, 1993, CANCER, V71, P1143, DOI 10.1002/1097-0142(19930201)71:3+<1143::AID-CNCR2820711437>3.0.CO;2-I; JACOBSEN SJ, 1993, UROLOGY, V42, P663, DOI 10.1016/0090-4295(93)90530-N; LEIBEL SA, 1980, UROL CLIN N AM, V7, P593; LIANG MH, 1985, ARTHRITIS RHEUM, V28, P542, DOI 10.1002/art.1780280513; LITWIN MS, 1993, J UROLOGY, V149, P84, DOI 10.1016/S0022-5347(17)36005-6; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; MAUSNER JS, 1974, EPIDEMIOLOGY INTRO T, P146; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; PATRICK DL, 1989, MED CARE, V27, pS217, DOI 10.1097/00005650-198903001-00018; PAULSON DF, 1990, J UROLOGY, V144, P1180, DOI 10.1016/S0022-5347(17)39686-6; PAULSON DF, 1988, J UROLOGY, V140, P535, DOI 10.1016/S0022-5347(17)41712-5; PEDERSEN KV, 1993, EUR UROL, V24, P7; RAY GR, 1973, RADIOLOGY, V106, P407, DOI 10.1148/106.2.407; RIEKER P, 1993, P AN M AM SOC CLIN, V12, P452; Schag C A, 1990, Oncology (Williston Park), V4, P135; SCHAG CAC, 1991, CANCER, V68, P1406, DOI 10.1002/1097-0142(19910915)68:6<1406::AID-CNCR2820680638>3.0.CO;2-2; SCHAG CAC, 1988, CANCER REHABILITATIO; SHARP JW, 1993, CANCER, V71, P1078, DOI 10.1002/1097-0142(19930201)71:3+<1078::AID-CNCR2820711429>3.0.CO;2-Z; Steward A., 1992, MEASURING FUNCTIONIN, P345; TANNOCK I, 1989, J CLIN ONCOL, V7, P590, DOI 10.1200/JCO.1989.7.5.590; Tannock I F, 1990, Oncology (Williston Park), V4, P149; TCHEKMEDYIAN NS, 1991, QUALITY LIFE CURRENT; TULSKY DS, 1990, P SOC BEHAV MED, V11, P45; VILLAVICENCIO H, 1993, EUR UROL, V24, P118; WALSH PC, 1982, J UROLOGY, V128, P492, DOI 10.1016/S0022-5347(17)53012-8; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	46	822	832	0	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 11	1995	273	2					129	135		10.1001/jama.273.2.129	http://dx.doi.org/10.1001/jama.273.2.129			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PZ687	7799493				2022-12-24	WOS:A1995PZ68700026
J	JAKEMAN, P				JAKEMAN, P			RISK OF RELAPSE IN MULTIBACILLARY LEPROSY	LANCET			English	Editorial Material											JAKEMAN, P (corresponding author), LEPROSY MISSION EVALUAT UNIT,SINGAPORE,SINGAPORE.							CARTEL JL, 1991, LEPROSY REV, V62, P186; 1994, WHO TECH REP SER, V847, P6; WHOCTDLEP941; 1993, LEPROSY REV, V64, P377; 1994, WHO WEEKLY EPIDEMIOL, V69, P301	5	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					4	5		10.1016/S0140-6736(95)91145-6	http://dx.doi.org/10.1016/S0140-6736(95)91145-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799708				2022-12-24	WOS:A1995QA29000004
J	TRAVISANO, M; MONGOLD, JA; BENNETT, AF; LENSKI, RE				TRAVISANO, M; MONGOLD, JA; BENNETT, AF; LENSKI, RE			EXPERIMENTAL TESTS OF THE ROLES OF ADAPTATION, CHANCE, AND HISTORY IN EVOLUTION	SCIENCE			English	Article							ESCHERICHIA-COLI; PROGRAM	The contributions of adaptation, chance, and history to the evolution of fitness and cell size were measured in two separate experiments using bacteria. In both experiments, populations propagated in identical environments achieved similar fitnesses, regardless of prior history or subsequent chance events. In contrast, the evolution of cell size, a trait weakly correlated with fitness, was more strongly influenced by history and chance.	MICHIGAN STATE UNIV, CTR MICROBIAL ECOL, E LANSING, MI 48824 USA; UNIV CALIF IRVINE, DEPT ECOL & EVOLUTIONARY BIOL, IRVINE, CA 92717 USA	Michigan State University; University of California System; University of California Irvine			Travisano, Michael/AAI-4809-2020	Lenski, Richard/0000-0002-1064-8375				BENNETT AF, 1992, EVOLUTION, V46, P16, DOI 10.1111/j.1558-5646.1992.tb01981.x; Calder WA., 1984, SIZE FUNCTION LIFE H; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; DYKHUIZEN DE, 1983, MICROBIOL REV, V47, P150, DOI 10.1128/MMBR.47.2.150-168.1983; Fisher R. A., 1930, GENETICAL THEORY NAT, DOI 10.5962/bhl.title.27468; Gould S.J, 1989, WONDERFUL LIFE BURGE; GOULD SJ, 1979, PROC R SOC SER B-BIO, V205, P581, DOI 10.1098/rspb.1979.0086; KIMURA M, 1968, NATURE, V217, P624, DOI 10.1038/217624a0; Kimura M, 1985, NEUTRAL THEORY MOL E; KING JL, 1969, SCIENCE, V164, P788, DOI 10.1126/science.164.3881.788; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LENSKI RE, ENCY MICROBIOL, V2, P125; MAYR E, 1983, AM NAT, V121, P324, DOI 10.1086/284064; OSTER G, 1982, EVOLUTION, V36, P444, DOI 10.1111/j.1558-5646.1982.tb05066.x; PARKER GA, 1990, NATURE, V348, P27, DOI 10.1038/348027a0; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; SMITH JM, 1985, Q REV BIOL, V60, P265, DOI 10.1086/414425; SOKAL RR, 1981, BIOMETRY, P217; Stephens D.W., 1986, pi; TRAVISANO M, IN PRESS EVOLUTION; VASI F, 1994, AM NAT, V144, P432, DOI 10.1086/285685; Williams G.C, 1992, NATURAL SELECTION DO; Wright S., 1969, THEORY GENE FREQUENC, V2, P520	23	357	359	3	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 6	1995	267	5194					87	90		10.1126/science.7809610	http://dx.doi.org/10.1126/science.7809610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7809610				2022-12-24	WOS:A1995QA23500035
J	COUNSELL, CE; CLARKE, MJ; SLATTERY, J; SANDERCOCK, PAG				COUNSELL, CE; CLARKE, MJ; SLATTERY, J; SANDERCOCK, PAG			THE MIRACLE OF DICE THERAPY FOR ACUTE STROKE - FACT OR FICTIONAL PRODUCT OF SUBGROUP ANALYSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PUBLICATION BIAS; MYOCARDIAL-INFARCTION; RANDOMIZED TRIALS; CLINICAL-TRIALS; NEED	Objective-To determine whether inappropriate subgroup analysis together with chance could change the conclusion of a systematic review of several randomised trials of an ineffective treatment. Design-44 randomised controlled trials of DICE therapy for stroke were performed (simulated by rolling different coloured dice; two trials per investigator). Each roll of the dice yielded the outcome (death or survival) for that ''patient.'' Publication bias was also simulated. The results were combined in a systematic review. Setting-Edinburgh. Main outcome measure-Mortality. Results-The ''hypothesis generating'' trial suggested that DICE therapy provided complete protection against death from acute stroke. However, analysis of all the trials suggested a reduction of only 11% (SD 11) in the odds of death. A predefined subgroup analysis by colour of dice suggested that red dice therapy increased the odds by 9% (22). If the analysis excluded red dice trials and those of poor methodological quality the odds decreased by 22% (13, 2P = 0.09). Analysis of ''published'' trials showed a decrease of 23% (13, 2P = 0.07) while analysis of only those in which the trialist had become familiar with the intervention showed a decrease of 39% (17, 2P = 0 .02). Conclusion-The early benefits of DICE therapy were not confirmed by subsequent trials. A plausible (but inappropriate) subset analysis of the effects of treatment led to the qualitatively different conclusion that DICE therapy reduced mortality, whereas in truth it was ineffective. Chance influences the outcome of clinical trials and systematic reviews of trials much more than many investigators realise, and its effects may lead to incorrect conclusions about the benefits of treatment.	WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; RADCLIFFE INFIRM, CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND; RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, CANC STUDIES UNIT, OXFORD OX2 6HE, ENGLAND	University of Edinburgh; Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford			sandercock, peter/GQI-3167-2022	sandercock, peter/0000-0001-8484-0135	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1992, Lancet, V339, P1; [Anonymous], 1986, Lancet, V1, P397; BERLIN JA, 1989, J AM STAT ASSOC, V84, P381; BEROYZ G, 1994, LANCET, V343, P619; CHAN SS, 1982, CLIN RES, V30, pA234; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; HINE LK, 1989, JAMA-J AM MED ASSOC, V262, P3037, DOI 10.1001/jama.262.21.3037; IMPERIALE T F, 1991, Journal of the American Medical Association, V266, P260, DOI 10.1001/jama.266.2.260; KOUDSTAAL PJ, 1988, BRIT MED J, V297, P1571, DOI 10.1136/bmj.297.6663.1571; MOHR JP, 1994, CEREBROVASC DIS, V4, P197, DOI 10.1159/000108482; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; PETO R, 1993, ANN NY ACAD SCI, V703, P314, DOI 10.1111/j.1749-6632.1993.tb26369.x; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; 1994, PREPARING MAINTAININ	20	84	88	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 24	1994	309	6970					1677	1681		10.1136/bmj.309.6970.1677	http://dx.doi.org/10.1136/bmj.309.6970.1677			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819982	Green Published			2022-12-24	WOS:A1994PY71700006
J	KALPANA, GV; MARMON, S; WANG, WD; CRABTREE, GR; GOFF, SP				KALPANA, GV; MARMON, S; WANG, WD; CRABTREE, GR; GOFF, SP			BINDING AND STIMULATION OF HIV-1 INTEGRASE BY A HUMAN HOMOLOG OF YEAST TRANSCRIPTION FACTOR SNF5	SCIENCE			English	Article							I-HYPERSENSITIVE SITES; SACCHAROMYCES-CEREVISIAE; RETROVIRUS INTEGRATION; PROTEIN INVITRO; CHROMATIN STRUCTURE; PREFERRED TARGETS; GENES; DNA; EXPRESSION; SNF2/SWI2	Upon entry into a host cell, retroviruses direct the reverse transcription of the viral RNA genome and the establishment of an integrated proviral DNA. The retroviral integrase protein (IN) is responsible for the insertion of the viral DNA into host chromosomal targets. The two-hybrid system was used to identify a human gene product that binds tightly to the human immunodeficiency virus-type 1 (HIV-1) integrase in vitro and stimulates its DNA-joining activity. The sequence of the gene suggests that the protein is a human homolog of yeast SNF5, a transcriptional activator required for high-level expression of many genes. The gene, termed INI1 (for integrase interactor 1), may encode a nuclear factor that promotes integration and targets incoming viral DNA to active genes.	COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; STANFORD UNIV,HOWARD HUGHES MED INST,DEPT DEV BIOL,BECKMAN CTR B207,STANFORD,CA 94305	Columbia University; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Stanford University			Wang, Weidong/AAV-2446-2021	Wang, Weidong/0000-0002-0658-7928; Kalpana, Ganjam/0000-0003-4111-0604	NIAID NIH HHS [U01 AI 24845] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI024845] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMS E, 1986, MOL CELL BIOL, V6, P3643, DOI 10.1128/MCB.6.11.3643; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; CRAIGIE R, 1992, TRENDS GENET, V8, P187, DOI 10.1016/0168-9525(92)90223-Q; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KALPANA GV, 1993, P NATL ACAD SCI USA, V90, P10593, DOI 10.1073/pnas.90.22.10593; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LEE MS, 1994, P NATL ACAD SCI USA, V91, P9823, DOI 10.1073/pnas.91.21.9823; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NEIGEBORN L, 1984, GENETICS, V108, P845; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; SCHERDIN U, 1990, J VIROL, V64, P907, DOI 10.1128/JVI.64.2.907-912.1990; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VIJAYA S, 1986, J VIROL, V60, P683, DOI 10.1128/JVI.60.2.683-692.1986; WEISS R, 1984, RNA TUMOR VIRUSES; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	40	433	459	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					2002	2006		10.1126/science.7801128	http://dx.doi.org/10.1126/science.7801128			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801128				2022-12-24	WOS:A1994PZ26700033
J	POWRIE, JK; WATTS, GF; INGHAM, JN; TAUB, NA; TALMUD, PJ; SHAW, KM				POWRIE, JK; WATTS, GF; INGHAM, JN; TAUB, NA; TALMUD, PJ; SHAW, KM			ROLE OF GLYCEMIC CONTROL IN DEVELOPMENT OF MICROALBUMINURIA IN PATIENTS WITH INSULIN-DEPENDENT DIABETES	BRITISH MEDICAL JOURNAL			English	Article							URINARY ALBUMIN EXCRETION; DELETION POLYMORPHISM; CONVERTING ENZYME; NEPHROPATHY; MELLITUS; PREVENTION; PRESSURE; GENE	Objective-To ascertain which factors determine the progression from very low rates of albumin excretion to persistent microalbuminuria in patients with insulin dependent diabetes mellitus. Design-A 10 year prospective study of a cohort of diabetic patients. Setting-Outpatient department of the Portsmouth District Hospitals. Subjects-97 patients with insulin dependent diabetes mellitus who were initially free of microalbuminuria and hypertension. Main outcome measure-Urinary albumin: creatinine ratio. Results-Eight of the 97 patients had developed microalbuminuria (urinary albumin:creatinine ratio >3 mg/mmol in three consecutive early morning samples) by the 10 year follow up. The group who developed microalbuminuria had higher baseline log(10) plasma glucose concentrations (mean (SD), 1.210 (0.122) v 0.984 (0.196) mmol/l, P < 0.001) and glycated haemoglobin concentrations (1.112% (0.069%) v 0.997% (0.076%), P < 0.001) and a younger age at onset of diabetes (10.0 (5.5) v 15.6 (7.8) years, P < 0.05). There was no difference in baseline duration of diabetes, smoking, sex, insulin dose, body mass index, serum creatinine concentration, or systolic, diastolic, or mean arterial blood pressure between the two groups. Multiple linear regression analysis showed that urinary albumin:creatinine ratio at 10 years was influenced by initial albumin: creatinine ratio (P = 0.006), initial glycated haemoglobin concentration (P = 0.002), and duration of diabetes (P = 0.045). Genotype for angiotensin converting enzyme was not related to the development of microalbuminuria nor, in a larger group of patients, the presence of any degree of diabetic nephropathy. Conclusion-In patients with insulin dependent diabetes mellitus the progression of minimal albuminuria and the development of microalbuminuria is determined primarily by poor long term glycaemic control. There is a weaker relation with longer duration of disease and younger age at onset of diabetes, but blood pressure does not seem to be implicated. Gene polymorphism for angiotensin converting enzyme is not linked to the development of microalbuminuria or established diabetic nephropathy.	UNIV WESTERN AUSTRALIA, ROYAL PERTH HOSP, PERTH, WA 6001, AUSTRALIA; QUEEN ALEXANDRA HOSP, DEPT ENDOCRINOL & DIABET, PORTSMOUTH PO6 3LY, HANTS, ENGLAND; UNITED MED & DENT SCH, ST THOMAS HOSP, DEPT PUBL HLTH MED, LONDON SE1 7EH, ENGLAND; UCL, SCH MED, DIV CARDIOVASC GENET, LONDON WC1E 6JJ, ENGLAND	Royal Perth Hospital; University of Western Australia; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; University College London; UCL Medical School	POWRIE, JK (corresponding author), UNITED MED & DENT SCH, ST THOMAS HOSP, DIV MED, LONDON SE1 7EH, ENGLAND.		Talmud, Philippa J/C-4402-2008	Watts, Gerald/0000-0003-2276-1524; Talmud, Philippa/0000-0002-5560-1933				CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; EARLE K, 1992, NEW ENGL J MED, V326, P673, DOI 10.1056/NEJM199203053261005; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MARRE M, 1994, DIABETES, V43, P384, DOI 10.2337/diabetes.43.3.384; MATHIESEN ER, 1990, DIABETES, V39, P245, DOI 10.2337/diabetes.39.2.245; MATHIESEN ER, 1984, DIABETOLOGIA, V26, P406; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; PARVING HH, 1982, ACTA ENDOCRINOL-COP, V100, P500; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; RUDBERG S, 1993, DIABETOLOGIA, V36, P1309, DOI 10.1007/BF00400811; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; VIBERTI G, 1984, DIABETES, V33, P686, DOI 10.2337/diab.33.7.686; VIBERTI GC, 1982, LANCET, V1, P1430; VIBERTI GC, 1987, BRIT MED J, V295, P515, DOI 10.1136/bmj.295.6597.515; WATTS GF, 1990, DIABETES RES CLIN PR, V9, P169, DOI 10.1016/0168-8227(90)90109-7; WATTS GF, 1986, CLIN CHEM, V32, P1544; WATTS GF, 1991, Q J MED, V79, P365; WATTS GF, 1988, CLIN CHIM ACTA, V172, P191, DOI 10.1016/0009-8981(88)90323-3; WATTS GF, 1989, DIABETIC MED, V6, P25, DOI 10.1111/j.1464-5491.1989.tb01134.x; WISEMAN MJ, 1984, DIABETOLOGIA, V26, P402; YIP J, 1993, BRIT MED J, V306, P1235	24	69	70	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1608	1612		10.1136/bmj.309.6969.1608	http://dx.doi.org/10.1136/bmj.309.6969.1608			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819935	Green Published			2022-12-24	WOS:A1994PY22000015
J	MACKENZIE, WR; HOXIE, NJ; PROCTOR, ME; GRADUS, MS; BLAIR, KA; PETERSON, DE; KAZMIERCZAK, JJ; ADDISS, DG; FOX, KR; ROSE, JB; DAVIS, JP				MACKENZIE, WR; HOXIE, NJ; PROCTOR, ME; GRADUS, MS; BLAIR, KA; PETERSON, DE; KAZMIERCZAK, JJ; ADDISS, DG; FOX, KR; ROSE, JB; DAVIS, JP			A MASSIVE OUTBREAK IN MILWAUKEE OF CRYPTOSPORIDIUM INFECTION TRANSMITTED THROUGH THE PUBLIC WATER-SUPPLY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DRINKING-WATER; SURFACE-WATER; GIARDIA; IMMUNOCOMPETENT; TRANSMISSION; DIARRHEA	Background. Early in the spring of 1993 there was a widespread outbreak of acute watery diarrhea among the residents of Milwaukee. Methods. We investigated the two Milwaukee water-treatment plants, gathered data from clinical laboratories on the results of tests for enteric pathogens, and examined ice made during the time of the outbreak for cryptosporidium oocysts. We surveyed residents with confirmed cryptosporidium infection and a sample of those with acute watery diarrhea consistent with cryptosporidium infection. To estimate the magnitude of the outbreak, we also conducted a survey using randomly selected telephone numbers in Milwaukee and four surrounding counties. Results. There were marked increases in the turbidity of treated water at the city's southern water-treatment plant from March 23 until April 9, when the plant was shut down. Cryptosporidium oocysts were identified in water from ice made in southern Milwaukee during these weeks. The rates of isolation of other enteric pathogens remained stable, but there was more than a 100-fold increase in the rate of isolation of cryptosporidium. The median duration of illness was 9 days (range, 1 to 55). The median maximal number of stools per day was 12 (range, 1 to 90). Among 285 people surveyed who had laboratory-confirmed cryptosporidiosis, the clinical manifestations included watery diarrhea (in 93 percent), abdominal cramps (in 84 percent), fever (in 57 percent), and vomiting (in 48 percent). We estimate that 403,000 people had watery diarrhea attributable to this outbreak. Conclusions. This massive outbreak of watery diarrhea was caused by cryptosporidium oocysts that passed through the filtration system of one of the city's water-treatment plants. Water-quality standards and the testing of patients for cryptosporidium were not adequate to detect this outbreak.	WISCONSIN DEPT HLTH & SOCIAL SERV, BUR PUBL HLTH, MADISON, WI 53703 USA; CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV PARASIT DIS, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, DIV FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, EPIDEM INTELLIGENCE SERV, ATLANTA, GA 30341 USA; MILWAUKEE DEPT HLTH, MILWAUKEE, WI USA; BUR LABS, MILWAUKEE, WI USA; UNIV S FLORIDA, TAMPA, FL USA; US EPA, CINCINNATI, OH 45268 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; State University System of Florida; University of South Florida; United States Environmental Protection Agency			Kenzie, William R Mac/F-1528-2013	Kenzie, William R Mac/0000-0001-7723-0339				ALPERT G, 1986, PEDIATRICS, V77, P152; ARROWOOD MJ, 1989, J CLIN MICROBIOL, V27, P1490, DOI 10.1128/JCM.27.7.1490-1495.1989; BADENOCH J, 1990, CRYPTOSPORIDIUM WATE; COLBOURNE JS, 1989, 1989 P AM WAT WORKS, P275; CURRENT WL, 1983, NEW ENGL J MED, V308, P1252, DOI 10.1056/NEJM198305263082102; CURRENT WL, 1991, CLIN MICROBIOL REV, V4, P325, DOI 10.1128/CMR.4.3.325-358.1991; DANTONIO RG, 1985, ANN INTERN MED, V103, P886, DOI 10.7326/0003-4819-103-6-886; FAYER R, 1986, MICROBIOL REV, V50, P458, DOI 10.1128/MMBR.50.4.458-483.1986; GALLAGHER MM, 1989, AM J PUBLIC HEALTH, V79, P39, DOI 10.2105/AJPH.79.1.39; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; JOKIPII L, 1985, GASTROENTEROLOGY, V89, P838, DOI 10.1016/0016-5085(85)90581-5; JOKIPII L, 1986, NEW ENGL J MED, V315, P1643, DOI 10.1056/NEJM198612253152604; JOSEPH C, 1991, EPIDEMIOL INFECT, V107, P509, DOI 10.1017/S0950268800049207; KOCH KL, 1985, ANN INTERN MED, V102, P593, DOI 10.7326/0003-4819-102-5-593; LECHEVALLIER MW, 1991, APPL ENVIRON MICROB, V57, P2617, DOI 10.1128/AEM.57.9.2617-2621.1991; LECHEVALLIER MW, 1992, APPL ENVIRON MICROB, V58, P780; LECHEVALLIER MW, 1991, APPL ENVIRON MICROB, V57, P2610, DOI 10.1128/AEM.57.9.2610-2616.1991; LELAND D, 1993, J AM WATER WORKS ASS, V85, P34; MA P, 1983, J INFECT DIS, V147, P824, DOI 10.1093/infdis/147.5.824; MEISEL JL, 1976, GASTROENTEROLOGY, V70, P1156; NAVIN TR, 1984, REV INFECT DIS, V6, P313; NIME FA, 1976, GASTROENTEROLOGY, V70, P592; PALIT C, 1983, SOCIOL METHOD RES, V12, P169, DOI 10.1177/0049124183012002005; PALIT D, 1988, CASS CATI VERSION 3; PALMER SR, 1990, BRIT MED J, V300, P774, DOI 10.1136/bmj.300.6727.774; RICHARDSON AJ, 1991, EPIDEMIOL INFECT, V107, P485, DOI 10.1017/S0950268800049189; ROSE JB, 1989, APPL ENVIRON MICROB, V55, P3189, DOI 10.1128/AEM.55.12.3189-3196.1989; ROSE JB, 1991, ENVIRON SCI TECHNOL, V25, P1393, DOI 10.1021/es00020a005; ROSE JB, 1990, METHODS INVESTIGATIO, P223; SKEELS MR, 1990, AM J PUBLIC HEALTH, V80, P305, DOI 10.2105/AJPH.80.3.305; WOLFSON JS, 1985, NEW ENGL J MED, V312, P1278, DOI 10.1056/NEJM198505163122002; XI JA, 1992, J VIROL, V66, P6527, DOI 10.1128/JVI.66.11.6527-6532.1992	32	1386	1439	5	175	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 21	1994	331	3					161	167		10.1056/NEJM199407213310304	http://dx.doi.org/10.1056/NEJM199407213310304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW797	7818640				2022-12-24	WOS:A1994NW79700004
J	KANNUS, P; HAAPASALO, H; SANKELO, M; SIEVANEN, H; PASANEN, M; HEINONEN, A; OJA, P; VUORI, I				KANNUS, P; HAAPASALO, H; SANKELO, M; SIEVANEN, H; PASANEN, M; HEINONEN, A; OJA, P; VUORI, I			EFFECT OF STARTING AGE OF PHYSICAL-ACTIVITY ON BONE MASS IN THE DOMINANT ARM OF TENNIS AND SQUASH PLAYERS	ANNALS OF INTERNAL MEDICINE			English	Article						EXERCISE; BONE DENSITY; AGE FACTORS; MENARCHE; TENNIS	X-RAY ABSORPTIOMETRY; MINERAL DENSITY; WOMEN; ADOLESCENTS; PRECISION; CHILDREN; SITES	Objective: To determine in female tennis and squash players the effect of biological age (that is, the starting age of playing relative to the age at menarche) at which tennis or squash playing was started on the difference in bone mineral content between the playing and nonplaying arms. Design: Cross-sectional study. Setting: Finnish tennis and squash federations. Participants: 105 female Finnish national-level players and 50 healthy female controls. Main Outcome Measures: Differences in bone mineral content in playing and nonplaying (dominant to nondominant) arms (proximal humerus, humeral shaft, radial shaft, and distal radius) were compared in the players and controls and among six groups of players. Players were divided into groups according to the biological age (years before or after menarche) at which their playing careers began: more than 5 years before; 3 to 5 years before; 2 to 0 years before; 1 to 5 years after; 6 to 15 years after; and more than 15 years after. Results: Compared with controls (whose mean +/- SD differences in bone mineral content were 4.6% +/- 4.6%, 3.2% +/- 2.3%, 3.2% +/- 3.8%, and 3.9% +/- 4.3% at the previously noted anatomical sites), the players had a significantly (P < 0.001) larger side-to-side difference in every measured site (15.5% +/- 8.4%, 16.2% +/- 9.8%, 8.5% +/- 6.6, and 12.5% +/- 7.1%). Among players, the group differences in bone mineral content were significant (P < 0.001 to P = 0.005), with the group means clearly decreasing with increasing starting biological age of playing. The difference was two to four times greater in the players who had started their playing careers before or at menarche (lowest mean difference in bone mineral content, 10.5% +/- 7.2%; highest difference, 23.5% +/- 7.2%) than in those who started more than 15 years after menarche (lowest difference, 2.4% +/- 4.8%; highest difference, 9.6% +/- 4.9%). Adjustment for potential confounding factors (age and height) did not change these trends. Conclusions: Bones of the playing extremity clearly benefit from active tennis and squash training, which increases their mineral mass. The benefit of playing is about two times greater if females start playing at or before menarche rather than after it. The minimal level and minimum number of years of activity necessary to produce these results, the extent to which this benefit is sustained after cessation of intensive training, and the degree to which these results can be extended to other forms of physical activity and other bone sites should be studied further.	TAMPERE RES CTR SPORTS MED, TAMPERE, FINLAND		KANNUS, P (corresponding author), UKK INST HLTH PROMOT RES, KAUPINPUISTONKATU 1, SF-33500 TAMPERE, FINLAND.		Heinonen, Ari/A-9199-2014; Heinonen, Ari/I-5292-2019	Heinonen, Ari/0000-0002-3681-9953; Heinonen, Ari/0000-0002-3681-9953				CONROY BP, 1993, MED SCI SPORT EXER, V25, P1103; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DALSKY GP, 1988, ANN INTERN MED, V108, P824, DOI 10.7326/0003-4819-108-6-824; GRIMSTON SK, 1993, MED SCI SPORT EXER, V25, P1203; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; JOHNSTON CC, 1993, OSTEOPOROSIS INT, V3, pS54, DOI 10.1007/BF01621864; KANNUS P, 1994, BONE, V15, P279, DOI 10.1016/8756-3282(94)90289-5; KATZMAN DK, 1991, J CLIN ENDOCR METAB, V73, P1332, DOI 10.1210/jcem-73-6-1332; KROGER H, 1993, BONE MINER, V23, P171, DOI 10.1016/S0169-6009(08)80094-3; LU PW, 1994, J BONE MINER RES, V9, P1451; MATKOVIC V, 1994, J CLIN INVEST, V93, P799, DOI 10.1172/JCI117034; MCCULLOCH RG, 1990, CAN MED ASSOC J, V142, P221; OTT SM, 1991, NEW ENGL J MED, V325, P1646, DOI 10.1056/NEJM199112053252310; SIEVANEN H, 1993, BONE MINER, V20, P235, DOI 10.1016/S0169-6009(08)80004-9; SIEVANEN H, 1992, J NUCL MED, V33, P1137; SLEMENDA CW, 1991, J BONE MINER RES, V6, P1227; TANNER JM, 1981, NUTR REV, V39, P43, DOI 10.1111/j.1753-4887.1981.tb06734.x; THEINTZ G, 1992, J CLIN ENDOCR METAB, V75, P1060, DOI 10.1210/jc.75.4.1060	18	544	549	0	39	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1995	123	1					27	31		10.7326/0003-4819-123-1-199507010-00003	http://dx.doi.org/10.7326/0003-4819-123-1-199507010-00003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE665	7762910				2022-12-24	WOS:A1995RE66500004
J	JACOBER, SJ				JACOBER, SJ			EXERCISE AND HYPERTENSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											JACOBER, SJ (corresponding author), WAYNE STATE UNIV, SCH MED, DETROIT, MI 48202 USA.							GRASSI G, 1992, CHEST, V101, pS312, DOI 10.1378/chest.101.5.312S; STEWART KJ, 1992, PROG CARDIOVASC DIS, V35, P159, DOI 10.1016/0033-0620(92)90004-J; Tipton C M, 1991, Exerc Sport Sci Rev, V19, P447; 1993, NIH931088 NAT HEART; [No title captured]	5	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1965	1965		10.1001/jama.273.24.1965	http://dx.doi.org/10.1001/jama.273.24.1965			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783310				2022-12-24	WOS:A1995RE35400037
J	FINLAY, BL; DARLINGTON, RB				FINLAY, BL; DARLINGTON, RB			LINKED REGULARITIES IN THE DEVELOPMENT AND EVOLUTION OF MAMMALIAN BRAINS	SCIENCE			English	Article							POSSUM TRICHOSURUS-VULPECULA; ANTERIOR OLFACTORY NUCLEUS; LATERAL GENICULATE-NUCLEUS; GANGLION-CELL LAYER; REELER MUTANT MICE; RHESUS-MONKEY; AUTORADIOGRAPHIC ANALYSIS; VISUAL-CORTEX; NEURON ORIGIN; THYMIDINE-H-3 AUTORADIOGRAPHY	Analysis of data collected on 131 species of primates, bats, and insectivores showed that the sizes of brain components, from medulla to forebrain, are highly predictable from absolute brain size by a nonlinear function. The order of neurogenesis was found to be highly conserved across a wide range of mammals and to correlate with the relative enlargement of structures as brain size increases, with disproportionately large growth occurring in late-generated structures. Because the order of neurogenesis is conserved, the most likely brain alteration resulting from selection for any behavioral ability may be a coordinated enlargement of the entire nonolfactory brain.			FINLAY, BL (corresponding author), CORNELL UNIV,DEPT PSYCHOL,URIS HALL,ITHACA,NY 14853, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019245] Funding Source: NIH RePORTER; NINDS NIH HHS [NS19245] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1981, EXP BRAIN RES, V42, P411; ALTMAN J, 1981, EXP BRAIN RES, V42, P424; ALTMAN J, 1978, J COMP NEUROL, V182, P945, DOI 10.1002/cne.901820511; ALTMAN J, 1980, J COMP NEUROL, V194, P877, DOI 10.1002/cne.901940410; ALTMAN J, 1980, J COMP NEUROL, V194, P1, DOI 10.1002/cne.901940102; ALTMAN J, 1980, J COMP NEUROL, V194, P905, DOI 10.1002/cne.901940411; ALTMAN J, 1978, J COMP NEUROL, V179, P23, DOI 10.1002/cne.901790104; ALTMAN J, 1978, J COMP NEUROL, V179, P49, DOI 10.1002/cne.901790105; ALTMAN J, 1978, J COMP NEUROL, V188, P455; ALTMAN J, 1980, J COMP NEUROL, V198, P677; ANGEVINE JAY B., 1965, EXP NEUROL SUPPL, V2, P1; ANGEVINE JB, 1974, ANAT REC, V178, P300; ANGEVINE JB, 1964, ANAT REC, V148, P255; BARON G, 1988, J HIRNFORSCH, V29, P509; Bayer S.A., 1991, NEOCORTICAL DEV; BAYER SA, 1979, J COMP NEUROL, V183, P89, DOI 10.1002/cne.901830108; BAYER SA, 1983, EXP BRAIN RES, V50, P329; BAYER SA, 1986, INT J DEV NEUROSCI, V4, P225, DOI 10.1016/0736-5748(86)90062-6; BAYER SA, 1980, J COMP NEUROL, V194, P845, DOI 10.1002/cne.901940409; BAYER SA, 1980, J COMP NEUROL, V190, P87, DOI 10.1002/cne.901900107; BAYER SA, 1987, PROG NEUROBIOL, V29, P57, DOI 10.1016/0301-0082(87)90015-3; BAYER SA, 1990, EXP NEUROL, V107, P48, DOI 10.1016/0014-4886(90)90062-W; BRAND S, 1980, NEUROSCIENCE, V5, P2125, DOI 10.1016/0306-4522(80)90128-1; BRAND S, 1979, NEUROSCIENCE, V4, P767, DOI 10.1016/0306-4522(79)90005-8; BRANDSTATTER R, 1990, BRAIN BEHAV EVOLUT, V35, P195, DOI 10.1159/000115867; BRUNJES PC, 1989, NEUROSCI LETT, V107, P114, DOI 10.1016/0304-3940(89)90801-X; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205; CAVINESS VS, 1982, DEV BRAIN RES, V4, P293, DOI 10.1016/0165-3806(82)90141-9; CAVINESS VS, 1973, J COMP NEUROL, V151, P113, DOI 10.1002/cne.901510203; CAVINESS VS, 1973, J COMP NEUROL, V148, P141, DOI 10.1002/cne.901480202; COOPER ML, 1981, J COMP NEUROL, V202, P309; CREPS ES, 1974, J COMP NEUROL, V157, P139, DOI 10.1002/cne.901570204; CREPS ES, 1974, J COMP NEUROL, V157, P161, DOI 10.1002/cne.901570205; CROSSLAND WJ, 1982, DEV BRAIN RES, V5, P99, DOI 10.1016/0165-3806(82)90117-1; DAVIS FC, 1990, BRAIN RES, V519, P192, DOI 10.1016/0006-8993(90)90077-O; DEHAY C, 1993, NATURE, V366, P464, DOI 10.1038/366464a0; DELONG GR, 1962, J COMP NEUROL, V118, P205, DOI 10.1002/cne.901180207; DEVOOGD TJ, 1993, P ROY SOC B-BIOL SCI, V254, P75, DOI 10.1098/rspb.1993.0129; DRAGER UC, 1985, PROC R SOC SER B-BIO, V224, P57, DOI 10.1098/rspb.1985.0021; Erwin, 1988, COMP PRIMATE BIOL, V4, P1; FRAHM HD, 1982, J HIRNFORSCH, V23, P375; GALABURDA AM, 1987, NEUROPSYCHOLOGIA, V25, P853, DOI 10.1016/0028-3932(87)90091-1; GESCHWIND N, 1968, SCIENCE, V161, P186, DOI 10.1126/science.161.3837.186; GOULD BB, 1981, EXP BRAIN RES, V44, P195; Gould S. J., 1977, ONTOGENY PHYLOGENY; HICKEY TL, 1984, J COMP NEUROL, V228, P186, DOI 10.1002/cne.902280205; HINDS JW, 1968, J COMP NEUROL, V134, P287, DOI 10.1002/cne.901340304; HOFMAN MA, 1985, BRAIN BEHAV EVOLUT, V27, P28, DOI 10.1159/000118718; HOFMAN MA, 1989, PROG NEUROBIOL, V32, P137, DOI 10.1016/0301-0082(89)90013-0; JERISON HJ, 1991, NATO ADV SCI I A-LIF, V200, P5; Jerison HJ., 1973, EVOLUTION BRAIN INTE; JOHNSTON AM, 1966, ANAT REC, V154, P163; KIMBLE J, 1994, SCIENCE, V266, P577, DOI 10.1126/science.7939710; KORDOWER JH, 1992, DEV BRAIN RES, V68, P9, DOI 10.1016/0165-3806(92)90242-O; KORDOWER JH, 1990, J COMP NEUROL, V291, P637, DOI 10.1002/cne.902910410; KOSTOVIC I, 1980, J NEUROCYTOL, V9, P219, DOI 10.1007/BF01205159; KREBS JR, 1990, PHILOS T R SOC LON B, V329, P161; LAVAIL MM, 1991, J COMP NEUROL, V309, P86, DOI 10.1002/cne.903090107; LEVITT P, 1984, SCIENCE, V223, P299, DOI 10.1126/science.6199842; LEVITT P, 1979, SOC NEUR ABSTR, V5, P341; LEVITT P, 1986, NEUROBIOLOGY DOWN SY, P195; LUSKIN MB, 1985, J COMP NEUROL, V242, P611, DOI 10.1002/cne.902420409; LUSKIN MB, 1985, J NEUROSCI, V5, P1062; MARCHAND R, 1986, NEUROSCIENCE, V17, P573, DOI 10.1016/0306-4522(86)90031-X; MCCONNELL JA, 1975, ANAT REC, V181, P418; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; NOTTEBOHM F, 1981, BRAIN RES, V213, P99, DOI 10.1016/0006-8993(81)91250-6; NUDO RJ, 1990, J COMP NEUROL, V296, P584, DOI 10.1002/cne.902960406; NUSSLEINVOLHARD C, 1994, SCIENCE, V266, P572, DOI 10.1126/science.7939708; PATEL NH, 1994, SCIENCE, V266, P581, DOI 10.1126/science.7939712; PATON JA, 1984, SCIENCE, V225, P1046, DOI 10.1126/science.6474166; PIERCE ET, 1970, ANAT REC, V166, P388; PIERCE ET, 1970, J COMP NEUROL, V131, P27; PIERCE ET, 1967, J COMP NEUROL, V126, P219; Polley E.H., 1989, P3; PURVES D, 1994, P NATL ACAD SCI USA, V91, P5030, DOI 10.1073/pnas.91.11.5030; RAKIC P, 1981, J COMP NEUROL, V196, P99, DOI 10.1002/cne.901960109; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; RAKIC P, 1977, J COMP NEUROL, V176, P23, DOI 10.1002/cne.901760103; REEP RL, 1990, BRAIN BEHAV EVOLUT, V35, P185, DOI 10.1159/000115866; REESE BE, 1992, NEUROSCIENCE, V46, P419, DOI 10.1016/0306-4522(92)90062-7; REHKAMPER G, 1991, BRAIN BEHAV EVOLUT, V37, P125, DOI 10.1159/000114353; SANDERSON KJ, 1990, BRAIN BEHAV EVOLUT, V35, P339, DOI 10.1159/000115879; SANDERSON KJ, 1990, BRAIN BEHAV EVOLUT, V35, P325, DOI 10.1159/000115878; SCHWERDTFEGER WK, 1984, ANAT EMBRYOL, V170, P11, DOI 10.1007/BF00319453; Sengelaub D.R., 1989, Advances in Comparative and Environmental Physiology, V3, P239; SENGELAUB DR, 1986, J COMP NEUROL, V246, P527, DOI 10.1002/cne.902460409; SHERRY DF, 1992, TRENDS NEUROSCI, V15, P298, DOI 10.1016/0166-2236(92)90080-R; SIDMAN RL, 1962, ANAT REC, V142, P327; Sidman RL, 1961, STRUCTURE EYE, P487; STANFIELD BB, 1979, J COMP NEUROL, V185, P423, DOI 10.1002/cne.901850303; STEPHAN H, 1981, FOLIA PRIMATOL, V35, P1, DOI 10.1159/000155963; TABER E, 1963, ANAT REC, V145, P291; UZMAN LL, 1960, J COMP NEUROL, V114, P137; WOO TU, 1990, CEREB CORTEX, V1, P433; WYSS JM, 1985, DEV BRAIN RES, V21, P89, DOI 10.1016/0165-3806(85)90026-4	96	865	873	4	143	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 16	1995	268	5217					1578	1584		10.1126/science.7777856	http://dx.doi.org/10.1126/science.7777856			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7777856				2022-12-24	WOS:A1995RD45900026
J	ZHANG, GG; KAZANIETZ, MG; BLUMBERG, PM; HURLEY, JH				ZHANG, GG; KAZANIETZ, MG; BLUMBERG, PM; HURLEY, JH			CRYSTAL-STRUCTURE OF THE CYS2 ACTIVATOR-BINDING DOMAIN OF PROTEIN-KINASE C-DELTA IN COMPLEX WITH PHORBOL ESTER	CELL			English	Article							PROGRAM; REFINEMENT; ZINC	Protein kinase Cs (PKCs) are a ubiquitous family of regulatory enzymes that associate with membranes and are activated by diacylglycerol or tumor-promoting agonists such as phorbol esters. The structure of the second activator-binding domain of PKC delta has been determined in complex with phorbol 13-acetate, which binds in a groove between two pulled-apart beta strands at the tip of the domain. The C3, C4, and C20 phorbol oxygens form hydrogen bonds with mai n-chain groups whose orientation is controlled by a set of highly conserved residues. Phorbol binding caps the groove and forms a contiguous hydrophobic surface covering one-third of the domain, explaining how the activator promotes insertion of PKC into membranes.	NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NCI, CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB, MOLEC MECHANISMS TUMOR PROMOT SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; BELL RM, 1991, J BIOL CHEM, V266, P4661; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; FINERMOORE JS, 1992, PROTEINS, V12, P203, DOI 10.1002/prot.340120302; HAUSER H, 1981, BIOCHIM BIOPHYS ACTA, V650, P21, DOI 10.1016/0304-4157(81)90007-1; Hecker E., 1978, CARCINOGENESIS, P11; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; HUBBARD SR, 1991, SCIENCE, V254, P1776; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; Rando RR, 1992, PROTEIN KINASE C CUR, P41; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P11, DOI 10.1107/S0907444993008224; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P17, DOI 10.1107/S0907444993008236; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WANG BC, 1985, METHOD ENZYMOL, V115, P90	23	593	601	2	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					917	924		10.1016/0092-8674(95)90011-X	http://dx.doi.org/10.1016/0092-8674(95)90011-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781068	Bronze			2022-12-24	WOS:A1995RD76800012
J	HOUSMAN, D				HOUSMAN, D			HUMAN DNA POLYMORPHISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											HOUSMAN, D (corresponding author), MIT,CTR CANC RES,BLDG E17,RM 543,40 AMES ST,CAMBRIDGE,MA 02139, USA.							GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; WEBER JL, 1989, AM J HUM GENET, V44, P388	3	32	32	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	1995	332	5					318	320		10.1056/NEJM199502023320508	http://dx.doi.org/10.1056/NEJM199502023320508			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD396	7816069				2022-12-24	WOS:A1995QD39600007
J	THOMAS, BA				THOMAS, BA			POPULATION BREAST-CANCER SCREENING - THEORY, PRACTICE, AND SERVICE IMPLICATIONS	LANCET			English	Editorial Material											THOMAS, BA (corresponding author), JARVIS BREAST SCREENING TRAINING & DIAGNOST CTR, GUILDFORD, SURREY, ENGLAND.							HAKAMA M, 1995, LANCET, V345, P221; Moss S M, 1994, J Med Screen, V1, P193; SHAPIRO S, 1971, J AMER MED ASSOC, V215, P1777; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TABAR L, 1992, LANCET, V339, P412, DOI 10.1016/0140-6736(92)90090-P; THOMAS BA, 1989, INT CONGR SER, V865, P11; Wald NJ, 1993, BREAST, V2, P209; YOUNG KC, 1994, CLIN RADIOL, V49, P461, DOI 10.1016/S0009-9260(05)81741-6; 1993, STANDARDS NHS BREAST; 1991, CMO91, P15	10	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 28	1995	345	8944					205	207		10.1016/S0140-6736(95)90217-1	http://dx.doi.org/10.1016/S0140-6736(95)90217-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823709	Bronze			2022-12-24	WOS:A1995QD53200003
J	CAO, YZ; QIN, LM; ZHANG, LQ; SAFRIT, J; HO, DD				CAO, YZ; QIN, LM; ZHANG, LQ; SAFRIT, J; HO, DD			VIROLOGICAL AND IMMUNOLOGICAL CHARACTERIZATION OF LONG-TERM SURVIVORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MONONUCLEAR-CELLS; HIV-1 INFECTION; HOMOSEXUAL MEN; MESSENGER-RNA; T-LYMPHOCYTES; BISEXUAL MEN; REPLICATION; AIDS; INDIVIDUALS; CORRELATE	Background. In most subjects infected with human immunodeficiency virus type 1 (HIV-1), clinical or laboratory evidence of immunodeficiency develops within 10 years of seroconversion, but a few infected people remain healthy and immunologically normal for more than a decade. Studies of these subjects, termed long-term survivors, may yield important clues for the development of prophylactic and therapeutic interventions against the acquired immunodeficiency syndrome. Methods and Results. We studied 10 seropositive subjects who remained asymptomatic with normal and stable CD4+ lymphocyte counts despite 12 to 15 years of HIV-1 infection. Plasma cultures were uniformly negative for infectious virus. However, particle-associated HIV-1 RNA was detected in four subjects with a sensitive branched-DNA signal-amplification assay, whereas in five others the levels of HIV-1 RNA were too low to detect. Infectious HIV-1 was detected in peripheral-blood mononuclear cells (PBMC) of three subjects by standard limiting-dilution cultures, and infectious virus was recovered from another subject with use of a CD8-depleted culture. The other six subjects had no detectable infectious virus in their PBMC. A quantitative polymerase-chain-reaction assay revealed that all subjects had detectable but low titers of viral DNA in PBMC. Overall, the viral burden in the plasma and PBMC of long-term survivors was orders of magnitude lower than that typically found in subjects with progressive disease. There was no in vitro evidence of resistance by host CD4+ lymphocytes to HIV-1 infection. However, longterm survivors had a vigorous, virus-inhibitory CD8+ lymphocyte response and a strong neutralizing-antibody response. In two subjects the kinetics of viral replication was consistent with the presence of a substantially attenuated strain of HIV-1. Conclusions. Subjects who remain asymptomatic for many years despite HIV-1 infection have low levels of HIV-1 and a combination of strong virus-specific immune responses with some degree of attenuation of the virus.	NYU,SCH MED,AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016	New York University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032427, R01AI024030, R01AI025541] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32427, AI25541, AI24030] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAGASRA O, 1992, NEW ENGL J MED, V326, P1385, DOI 10.1056/NEJM199205213262103; BUCHBINDER SP, 1994, AIDS, V8, P1123, DOI 10.1097/00002030-199408000-00014; CAO Y, IN PRESS AIDS RES HU; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FULTZ T, 1995, 2ND NAT C HUM RETR R; GREENOUGH TC, 1994, AIDS RES HUM RETROV, V10, P395, DOI 10.1089/aid.1994.10.395; HO DD, 1991, J VIROL, V65, P489, DOI 10.1128/JVI.65.1.489-493.1991; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HUANG YX, 1995, J VIROL, V69, P93, DOI 10.1128/JVI.69.1.93-100.1995; JASON J, 1989, JAMA-J AM MED ASSOC, V261, P725, DOI 10.1001/jama.261.5.725; JASSOY C, 1993, J VIROL, V67, P2844, DOI 10.1128/JVI.67.5.2844-2852.1993; KANNAGI M, 1988, J IMMUNOL, V140, P2237; KEET IPM, 1994, J INFECT DIS, V169, P1236, DOI 10.1093/infdis/169.6.1236; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; LIFSON AR, 1991, J INFECT DIS, V163, P959, DOI 10.1093/infdis/163.5.959; LIFSON AR, 1988, J INFECT DIS, V158, P1360, DOI 10.1093/infdis/158.6.1360; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; MOORE J, IN PRESS J VIROL; MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367; PACHL C, IN PRESS J ACQUIR IM; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SCHRAGER LK, 1994, AIDS S, V1, pS95; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SPIRA AI, 1995, J VIROL, V69, P422, DOI 10.1128/JVI.69.1.422-429.1995; WALKER CM, 1991, CELL IMMUNOL, V137, P420, DOI 10.1016/0008-8749(91)90090-X; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WALKER CM, 1991, J VIROL, V65, P5921, DOI 10.1128/JVI.65.11.5921-5927.1991; WILLIAMS LM, 1991, VIROLOGY, V184, P723, DOI 10.1016/0042-6822(91)90442-E	39	922	950	1	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	1995	332	4					201	208		10.1056/NEJM199501263320401	http://dx.doi.org/10.1056/NEJM199501263320401			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC270	7808485				2022-12-24	WOS:A1995QC27000001
J	MILBERG, JA; DAVIS, DR; STEINBERG, KP; HUDSON, LD				MILBERG, JA; DAVIS, DR; STEINBERG, KP; HUDSON, LD			IMPROVED SURVIVAL OF PATIENTS WITH ACUTE RESPIRATORY-DISTRESS-SYNDROME (ARDS) - 1983-1993	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VENTILATION; SEVERITY	Objective.-To analyze temporal trends in acute respiratory distress syndrome (ARDS) fatality rates since 1983 at one institution. Design.-Cohort. Setting.-Intensive care units of a large county hospital. Patients.-Consecutive adult patients (greater than or equal to 18 years of age) meeting ARDS criteria were identified through daily surveillance of intensive care units (N=918 from 1983 through 1993). The major causes were sepsis syndrome in 37% and major trauma in 25%; 37% had other risks. Sixty-five percent were male. The median age was 45 years (range, 18 to 92 years); 70% were younger than 60 years. Main Outcome Measure.-Hospital mortality. Results.-Overall fatality rates showed no trend from 1983 to 1987, declined slightly in 1988 and 1989, and decreased to a low of 36% in 1993 (95% confidence interval, 25% to 46%). The crude rates were largely unchanged after adjustment for age, ARDS risk, and gender distribution. While patients both younger than 60 years and 60 years or older experienced declines in fatality rate, the larger decrease occurred in the younger cohort. In sepsis patients, ARDS fatality rates declined steadily, from 67% in 1990 to 40% in 1993 (95% confidence interval, 23% to 57%). The decline in sepsis-related ARDS fatality was confined largely to patients less than 60 years of age. Trauma patients and all other patients also experienced declines in fatality rates after 1987, although these trends were not as strong and consistent as in the sepsis population. Conclusions.-In this large series, we observed a significant decrease in fatality rates occurring largely in patients younger than 60 years and in those with sepsis syndrome as their risk for ARDS. We are unable to determine the extent to which experimental therapies or other changes in treatment have contributed to the observed decline in the ARDS fatality rate, institution-specific rates and temporal trends in ARDS fatality rates should be considered in clinical trials designed to prevent ARDS and the high mortality associated with this syndrome.			MILBERG, JA (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT MED,DIV PULM & CRIT CARE MED,ZA-62,325 9TH AVE,SEATTLE,WA 98104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL030542] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30542] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATO MBP, 1993, AM REV RESPIR DIS, V147, pA890; ARMITAGE P, 1987, STATISTICAL METHODS; ARTIGAS A, 1990, ACUTE RESPIRATORY FA, P37; ASHBAUGH DG, 1967, LANCET, V2, P319; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BIDANI A, 1994, JAMA-J AM MED ASSOC, V272, P957, DOI 10.1001/jama.272.12.957; GATTINONI L, 1986, JAMA-J AM MED ASSOC, V256, P881, DOI 10.1001/jama.256.7.881; Hosmer DW, 1989, APPL LOGISTIC REGRES, P140; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEE PC, 1990, CHEST, V97, P430, DOI 10.1378/chest.97.2.430; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; SELVIN S, 1991, STATISTICAL ANAL EPI; SUCHYTA MR, 1991, CHEST, V99, P951, DOI 10.1378/chest.99.4.951; SUCHYTA MR, 1992, CHEST, V101, P1074, DOI 10.1378/chest.101.4.1074; TUXEN DV, 1994, AM J RESP CRIT CARE, V150, P870, DOI 10.1164/ajrccm.150.3.8087364; ZAPOL WM, 1990, ACUTE RESPIRATORY FA, P367	17	502	532	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					306	309		10.1001/jama.273.4.306	http://dx.doi.org/10.1001/jama.273.4.306			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC057	7815658				2022-12-24	WOS:A1995QC05700029
J	GRIFFITHS, E; CORTES, A; GILBERT, N; STEVENSON, P; MACDONALD, S; PEPPER, D				GRIFFITHS, E; CORTES, A; GILBERT, N; STEVENSON, P; MACDONALD, S; PEPPER, D			HEMOGLOBIN-BASED BLOOD SUBSTITUTES AND SEPSIS	LANCET			English	Note							HEMOGLOBIN	An important concern that has received little attention is the possible increased susceptibility to bacterial infections of patients infused with cell-free haemoglobin-based blood substitutes. We show that pyridoxalated polymerised human haemoglobin promotes fulminating Escherichia coli septicaemia in mice, which draws attention to the potential danger of such products in the clinic.	NATL INST BIOL STAND & CONTROLS,S MIMMS,HERTS,ENGLAND; SCOTTISH NATL BLOOD TRANSFUS SERV,NATL SCI LAB,EDINBURGH,MIDLOTHIAN,SCOTLAND	National Institute for Biological Standards & Control				Gilbert, Nick/0000-0003-0505-6081				Bullen J.J., 1987, IRON INFECTION MOL P; CROWLEY JP, 1993, CIRC SHOCK, V41, P144; HOYT DB, 1981, J TRAUMA, V21, P938, DOI 10.1097/00005373-198111000-00005; KIM YM, 1994, ARCH BIOCHEM BIOPHYS, V309, P308, DOI 10.1006/abbi.1994.1118; LEE JT, 1979, SURGERY, V86, P41; LOOKER D, 1992, NATURE, V356, P258, DOI 10.1038/356258a0; MACDONALD SL, 1994, METHOD ENZYMOL, V231, P287; OTTO BR, 1992, NATURE, V358, P23, DOI 10.1038/358023b0; ROBSON MC, 1973, J SURG RES, V14, P426, DOI 10.1016/0022-4804(73)90049-8; Vandegriff K D, 1992, Biotechnol Genet Eng Rev, V10, P403	10	50	50	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					158	160		10.1016/S0140-6736(95)90168-X	http://dx.doi.org/10.1016/S0140-6736(95)90168-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823671				2022-12-24	WOS:A1995QC55000011
J	MCCAIG, LF; HUGHES, JM				MCCAIG, LF; HUGHES, JM			TRENDS IN ANTIMICROBIAL DRUG PRESCRIBING AMONG OFFICE-BASED PHYSICIANS IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIBIOTIC USE; RESISTANCE; EPIDEMIOLOGY; GUIDELINES; AGENTS	Objective.-To assess changes in oral antimicrobial drug prescribing by office-based physicians from 1980 through 1992, with emphasis on the treatment of otitis media and sinusitis and on the possible impact of demographic variables on such use. Design.-The National Ambulatory Medical Care Survey is a sample survey of office-based physicians in the United States conducted by the National Center for Health Statistics, Centers for Disease Control and Prevention. Setting.-Physicians' offices. Patients or Other Participants.-Physicians sampled for the 1980, 1985, 1989, and 1992 National Ambulatory Medical Care Surveys, which included groups of 2959, 5032, 2540, and 3000 physicians, respectively. Sample physicians responding in 1980, 1985, 1989, and 1999 reported data for 46 081, 71 594, 38 384, and 34 606 sample office visits, respectively, including information on antimicrobial drug prescribing. Main Outcome Measure.-Trends in the antimicrobial drug prescription rates. Results.-From 1980 through 1992, increasing prescribing measured by the annual drug prescription rate per 1000 population, was found for the more expensive, broad-spectrum antimicrobial drugs, such as the cephalosporins; decreasing rates were observed for less expensive antimicrobial drugs with a narrower spectrum, such as the penicillins. No trend was found for trimethoprim-sulfamethoxazole, the erythromycins, or the tetracyclines. During the decade, an increasing trend in the visit rate to office-based physicians for otitis media was observed, while the visit rate for sinusitis among adults was found to be higher in 1992 than in each of the other study years. Conclusions.-The increased use of broader-spectrum and more expensive antimicrobial drugs have implications for all patients because of the impact on health care costs and the potential for the emergence of antimicrobial resistance. The data suggest that the incidence of otitis media and sinusitis is increasing.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, ATLANTA, GA 30333 USA; CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, DIV HLTH CARE STAT, AMBULATORY CARE STAT BRANCH, HYATTSVILLE, MD 20782 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)								ADAMS PF, 1992, VITAL HLTH STAT 184, V10; BENSON V, 1994, VITAL HLTH STAT 189, V10; BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; BILLUPS NF, 1989, AM DRUG INDEX; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BRYANT E, 1988, VITAL HLTH STAT 108, V2; CHRETIEN JH, 1975, ARCH INTERN MED, V135, P1063, DOI 10.1001/archinte.135.8.1063; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; ENA J, 1993, JAMA-J AM MED ASSOC, V269, P598, DOI 10.1001/jama.269.5.598; FARYNA A, 1987, J GEN INTERN MED, V2, P102, DOI 10.1007/BF02596306; HAHN B, 1992, PHS AHCPR930007 PUBL; HOLMBERG SD, 1987, REV INFECT DIS, V9, P1065; INFANTERIVARD C, 1983, EPIDEMIOL REV, V15, P44; KUNIN CM, 1973, ANN INTERN MED, V79, P555, DOI 10.7326/0003-4819-79-4-555; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; KUNIN CM, 1985, J INFECT DIS, V151, P388, DOI 10.1093/infdis/151.3.388; KUNIN CM, 1990, PRINCIPLES PRACTICE; LEE LA, 1994, J INFECT DIS, V170, P128, DOI 10.1093/infdis/170.1.128; MARR JJ, 1988, J INFECT DIS, V157, P869, DOI 10.1093/infdis/157.5.869; MCAIG LF, 1994, ADV DATA VITAL HLTH, V245; MCEVOY GK, 1988, AM HOSPITAL FORMULAR; MELNICK SL, 1992, ANN PHARMACOTHER, V26, P1292, DOI 10.1177/106002809202601020; MURRAY BE, 1994, NEW ENGL J MED, V330, P1229, DOI 10.1056/NEJM199404283301710; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PHELPS CE, 1989, MED CARE, V27, P194, DOI 10.1097/00005650-198902000-00009; RICHTSMEIER WJ, 1992, ANN OTO RHINOL LARYN, V101, P46, DOI 10.1177/00034894921010S110; SCHABERG DR, 1991, AM J MED, V91, pS72, DOI 10.1016/0002-9343(91)90346-Y; SCHAPPERT S, 1992, ADV DATA VITAL HLTH, V214; SIMBERKOFF MS, 1994, JAMA-J AM MED ASSOC, V271, P1875, DOI 10.1001/jama.271.23.1875; SIRKEN MG, 1990, MANUAL STANDARDS PRO; SOYKA LF, 1975, PEDIATRICS, V55, P552; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725; WILLETT LR, 1994, J GEN INTERN MED, V9, P38, DOI 10.1007/BF02599141; WYATT TD, 1990, BRIT MED J, V300, P441, DOI 10.1136/bmj.300.6722.441; 1990, DRUG EVALUATIONS SUB; 1992, PHYSICIANS DESK REFE; 1992, EMERGING INFECTIONS; 1988, DRUG FACTS COMP; 1994, ADRESSING EMERGING I; 1994, MED LETT, V36, P19; 1985, VITAL HLTH STAT 50, V10; 1988, PHYSICIANS DESK REFE; 1992, NATIONAL AMBULATORY	44	607	618	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					214	219		10.1001/jama.273.3.214	http://dx.doi.org/10.1001/jama.273.3.214			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807660				2022-12-24	WOS:A1995QB23400025
J	RAVIGLIONE, MC; SNIDER, DE; KOCHI, A				RAVIGLIONE, MC; SNIDER, DE; KOCHI, A			GLOBAL EPIDEMIOLOGY OF TUBERCULOSIS - MORBIDITY AND MORTALITY OF A WORLDWIDE EPIDEMIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; IMMUNE-DEFICIENCY-SYNDROME; PULMONARY TUBERCULOSIS; RESISTANT TUBERCULOSIS; ACTIVE TUBERCULOSIS; DRUG-USERS; RISK; EMERGENCE; DEATHS	This article describes the global epidemiology of tuberculosis and reviews recent estimates of tuberculosis incidence and mortality in the world. The highest prevalence of tuberculosis infection and estimated annual risk of tuberculosis infection are in sub-Saharan Africa and Southeast Asia. Overall, almost 3.8 million cases of tuberculosis were reported in the world in 1990, of which 49% were in Southeast Asia. From the period 1984 through 1986 to the period 1989 through 1991, notification rates increased in ail World Health Organization regions, except the American and the European regions. In 1990, there were an estimated 7.5 million cases of tuberculosis and 2.5 million deaths worldwide. The human immunodeficiency virus epidemic is causing increases in the number of tuberculosis cases, particularly in Africa, although increases are also expected in Southeast Asia. In many industrialized countries, tuberculosis has recently failed to decline, and in eastern Europe and the former Soviet Union, cases and deaths are increasing. Drug resistance is a serious problem, especially in the United States. If worldwide control of tuberculosis does not improve, 90 million new cases and 30 million deaths are expected in the decade 1990 through 1999.	CTR DIS CONTROL & PREVENT, ATLANTA, GA 30341 USA	Centers for Disease Control & Prevention - USA	RAVIGLIONE, MC (corresponding author), WHO, TB PROGRAMME, CH-1211 GENEVA 27, SWITZERLAND.			RAVIGLIONE, Mario/0000-0002-9331-2067				AISU T, 1992, 1992 WORLD C TUB BET; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439, DOI 10.1164/ajrccm/146.6.1439; [Anonymous], 1994, MMWR MORB MORTAL WKL; BAMRUNGTRAKUL T, 1993, 17TH E REG C TUB RES; BOUVET E, 1991, B EPIDEMIOLOGIQUE HE, V45, P196; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; CAUTHEN GM, 1988, WHO TB88154 PUBL; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P961; CHUM HL, 1992, NOV WORLD C TUB BETH; CLERMONT HC, 1990, 6TH INT C AIDS SAN F; CULLINAN P, 1991, THORAX, V46, P347, DOI 10.1136/thx.46.5.347; Dalcomo Margareth Pretti, 1993, Revista Argentina del Torax, V54, P29; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DECOCK KM, 1991, BMJ-BRIT MED J, V302, P496, DOI 10.1136/bmj.302.6775.496; DIDILESCU C, 1993, TUBERCULOZA ROMANIA; DIPERRI G, 1989, LANCET, V2, P1502; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; DOLIN PJ, 1993, WHOTB93173 PUBL; DROLET GJ, 1938, AM REV TUBERC, V87, P125; Dubos Rene, 1987, WHITE PLAGUE TUBERCU; ELLIOTT AM, 1990, BRIT MED J, V301, P412, DOI 10.1136/bmj.301.6749.412; Enarson D A, 1991, Bull Int Union Tuberc Lung Dis, V66, P195; ERIKI PP, 1991, AM REV RESPIR DIS, V143, P185, DOI 10.1164/ajrccm/143.1.185; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GIRARDI E, 1993, 9TH INT C AIDS HIV S; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; GUELAR A, 1993, AIDS, V7, P1345, DOI 10.1097/00002030-199310000-00007; HAMBURG MA, 1994, NEW ENGL J MED, V330, P1750, DOI 10.1056/NEJM199406163302410; Hargreaves J., 1994, Communicable Diseases Intelligence, V18, P330; HONG YP, 1993, TUBERCLE LUNG DIS, V74, P323, DOI 10.1016/0962-8479(93)90107-9; HUMPHRIES MJ, 1984, BRIT J DIS CHEST, V78, P149, DOI 10.1016/0007-0971(84)90115-3; HURET B, 1993, B EPIDEMIOL HEBDOMAD, V52, P243; Jain NK, 1992, IND J TUBERC, V92, P145; JESSURUN J, 1990, J ACQ IMMUN DEF SYND, V3, P579; KAUR A, 1992, J ACQ IMMUN DEF SYND, V5, P883; KOCHI A, 1993, RES MICROBIOL, V144, P104, DOI 10.1016/0923-2508(93)90023-U; KRITSKI AL, 1993, J ACQ IMMUN DEF SYND, V6, P1008; LINDHART M, 1939, STATISTICS PULMONARY; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MBAGA JM, 1990, E AFR MED J, V67, P95; MCLEOD DT, 1989, T ROY SOC TROP MED H, V83, P694, DOI 10.1016/0035-9203(89)90400-8; MOHANTY KC, 1993, 17TH E REG C TUB RES; MONNO L, 1991, LANCET, V337, P852, DOI 10.1016/0140-6736(91)92559-K; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; ONORATO I, 1993, 33RD INT C ANT AG CH; PAPE JW, 1985, ANN INTERN MED, V103, P674, DOI 10.7326/0003-4819-103-5-674; PAYANANDANA V, 1993, 1993 MIN PUBL HLTH D; Raviglione M. C., 1993, Morbidity and Mortality Weekly Report, V42, P628; RAVIGLIONE MC, 1994, TUBERCLE LUNG DIS, V75, P400, DOI 10.1016/0962-8479(94)90113-9; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; SCHWOEBEL V, 1993, BEH, V50, P235; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SINGH II, 1993, 17TH E REG C TUB RES; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SNIDER DE, 1993, HEART LUNG, V22, P365; SPRINGETT V H, 1971, Tubercle, V52, P73, DOI 10.1016/0041-3879(71)90015-8; STYBLO K, 1969, Bulletin of the International Union Against Tuberculosis, V42, P5; STYBLO K, 1981, Bulletin of the International Union Against Tuberculosis, V56, P118; Styblo K., 1985, B INT UNION TUBERC, V60, P117; SUDRE P, 1992, B WORLD HEALTH ORGAN, V70, P149; Sutherland I, 1976, Adv Tuberc Res, V19, P1; TANSUPHASWASDIK.S, 1993, 17TH P E REG C TUB R; WURBURTON ARE, 1993, COMMUNICAB DIS REP, V3, pR175; 1992, MMWR-MORBID MORTAL W, V41, P13; 1991, MMWR-MORBID MORTAL W, V40, P485; 1974, B WORLD HEALTH ORGAN, V51, P473; 1991, 44TH WORLD HLTH ASS; 1989, CHILDHOOD TUBERCULOS; 1990, MMWR-MORBID MORTAL W, V39, P7; 1989, MMWR-MORBID MORTAL W, V38, P313; 1994, WHOTB94175 PUBL; 1994, WHOTB94179 PUBL; 1993, 1993 WORLD BANK WORL, P1; 1993, B OFFICE FEDERAL SAN, V41, P739; 1993, TUBERCULOSIS STATIST; 1994, WKLY EPIDEMIOL REC, V69, P189	80	1251	1301	1	58	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					220	226		10.1001/jama.273.3.220	http://dx.doi.org/10.1001/jama.273.3.220			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807661				2022-12-24	WOS:A1995QB23400026
J	OBAYASHI, T; YOSHIDA, M; MORI, T; GOTO, H; YASUOKA, A; IWASAKI, H; TESHIMA, H; KOHNO, S; HORIUCHI, A; ITO, A; YAMAGUCHI, H; SHIMADA, K; KAWAI, T				OBAYASHI, T; YOSHIDA, M; MORI, T; GOTO, H; YASUOKA, A; IWASAKI, H; TESHIMA, H; KOHNO, S; HORIUCHI, A; ITO, A; YAMAGUCHI, H; SHIMADA, K; KAWAI, T			PLASMA (1-]3)-BETA-D-GLUCAN MEASUREMENT IN DIAGNOSIS OF INVASIVE DEEP MYCOSIS AND FUNGAL FEBRILE EPISODES	LANCET			English	Article							PNEUMOCYSTIS-CARINII; HUMAN-BLOOD; LIMULUS; CANDIDIASIS; IMMUNOASSAY; ENDOTOXIN	(1-->3)-beta-D-glucan is a characteristic fungal cell-wall constituent. To assess the clinical usefulness of this glucan in screening for invasive fungal infection or fungal febrile episodes, we measured the plasma concentration at the time of routine blood culture in 202 febrile episodes by means of factor G, a horseshoe-crab coagulation enzyme that is extremely sensitive to this polysaccharide. With a plasma cut-off value of 20 pg/mL, 37 of 41 of definite fungal infections (confirmed at or by microbiology) had positive results of 59 episodes of non-fungal fever, or collagen diseases had concentrations below the cut-off value (specificity 100%). Of 102 episodes of fever of unknown origin, 26 had plasma glucan concentrations of more than 20 pg/mL. With those 102 cases taken as non-fungal infections, the positive predictive Value of the test was estimated as 59% (37/63), the negative predictive value as 97% (135/139), and the efficiency as 85% (172/202). The positive predictive Value should improve if there were a sensitive gold standard that could discriminate fungal from non-fungal infections. Causative fungi included candida, aspergillus, cryptococcus, and trichosporon. Determination of plasma (1-->3)-beta-D-glucan with factor G is a highly sensitive and specific test for invasive deep mycosis and fungal febrile episodes, and will substantially benefit immunocompromised patients.	JICHI MED SCH,DEPT INTERNAL MED,DIV HEMATOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; JUNTENDO UNIV,SCH MED,DEPT INTERNAL MED,TOKYO,JAPAN; TOKYO METROPOLITAN KOMAGOME GEN HOSP,DEPT PULM DIS,TOKYO,JAPAN; UNIV TOKYO,INST MED SCI,DEPT INFECT DIS,TOKYO,JAPAN; FUKUI MED SCH,DEPT INTERNAL MED 1,FUKUI,JAPAN; CTR ADULT DIS,DEPT INTERNAL MED 5,OSAKA 537,JAPAN; NAGASAKI UNIV,SCH MED,DEPT INTERNAL MED 2,NAGASAKI 852,JAPAN; KINKI UNIV,SCH MED,DEPT INTERNAL MED 3,OSAKA,OSAKA 577,JAPAN; YOKOHAMA CITY UNIV,SCH HOSP,DIV CLIN LAB,YOKOHAMA,KANAGAWA,JAPAN; TEIKYO UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,TOKYO,JAPAN	Jichi Medical University; Juntendo University; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; University of Tokyo; University of Fukui; Nagasaki University; Kindai University (Kinki University); Yokohama City University; Teikyo University	OBAYASHI, T (corresponding author), JICHI MED SCH,DEPT CLIN PATHOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.							EDMAN JC, 1988, NATURE, V334, P519, DOI 10.1038/334519a0; HOPWOOD V, 1991, FUNGAL INFECTION COM, P311; IWAMA A, 1993, EUR J HAEMATOL, V51, P156, DOI 10.1111/j.1600-0609.1993.tb00617.x; KAKINUMA A, 1981, BIOCHEM BIOPH RES CO, V101, P434, DOI 10.1016/0006-291X(81)91278-X; KAMMER RB, 1974, AM J MED, V56, P506, DOI 10.1016/0002-9343(74)90483-5; LEVIN J, 1968, THROMB DIATH HAEMOST, V19, P186; LEVIN J, 1970, J LAB CLIN MED, V75, P903; MORITA T, 1981, FEBS LETT, V129, P318, DOI 10.1016/0014-5793(81)80192-5; NAKAMURA A, 1991, J CLIN MICROBIOL, V29, P2363, DOI 10.1128/JCM.29.11.2363-2367.1991; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; OBAYASHI T, 1992, J MED VET MYCOL, V30, P275; OBAYASHI T, 1986, INFECT IMMUN, V53, P294, DOI 10.1128/IAI.53.2.294-297.1986; OBAYASHI T, 1987, DETECTION BACTERIAL, P357; REISS E, 1986, MOL IMMUNOLOGY MYCOT, P11; Soyama K., 1986, Japanese Journal of Medical Mycology, V27, P165; TAMURA T, 1994, CLIN CHIM ACTA, V226, P109; TANAKA S, 1991, CARBOHYD RES, V218, P167, DOI 10.1016/0008-6215(91)84095-V; VANDEVENTER SJH, 1988, LANCET, V1, P605; WALSH TJ, 1991, NEW ENGL J MED, V324, P1026, DOI 10.1056/NEJM199104113241504; YPMAWONG MF, 1992, INFECT IMMUN, V60, P4140, DOI 10.1128/IAI.60.10.4140-4145.1992	20	398	428	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					17	20		10.1016/S0140-6736(95)91152-9	http://dx.doi.org/10.1016/S0140-6736(95)91152-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799700				2022-12-24	WOS:A1995QA29000010
J	EVANS, SA; STONER, J; HARDY, C				EVANS, SA; STONER, J; HARDY, C			ARE GENERAL-PRACTITIONERS EQUIPPED TO MANAGE ACUTE SEVERE ASTHMA	BRITISH MEDICAL JOURNAL			English	Article									MANCHESTER ROYAL INFIRM,DEPT RESP MED,MANCHESTER M13 9WL,LANCS,ENGLAND; PETERLOO MED CTR,MANCHESTER,LANCS,ENGLAND	University of Manchester								KENDRICK AH, 1993, BRIT MED J, V307, P422, DOI 10.1136/bmj.307.6901.422; MORGAN MDL, 1982, BRIT MED J, V285, P849, DOI 10.1136/bmj.285.6345.849; NEVILLE RG, 1993, BRIT MED J, V306, P559, DOI 10.1136/bmj.306.6877.559; 1990, BRIT MED J, V30, P797; 1993, BRIT MED J, V306, P776	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1486	1486		10.1136/bmj.309.6967.1486	http://dx.doi.org/10.1136/bmj.309.6967.1486			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804056	Green Published			2022-12-24	WOS:A1994PW05300028
J	STOKOE, D; MACDONALD, SG; CADWALLADER, K; SYMONS, M; HANCOCK, JF				STOKOE, D; MACDONALD, SG; CADWALLADER, K; SYMONS, M; HANCOCK, JF			ACTIVATION OF RAF AS A RESULT OF RECRUITMENT TO THE PLASMA-MEMBRANE	SCIENCE			English	Article							PROTEIN-KINASE KINASE; SIGNAL-TRANSDUCTION; IN-VITRO; ASSOCIATION; P21(RAS); CELLS; TRANSFORMATION; SUFFICIENT; COMPLEXES; PATHWAY	The small guanine nucleotide binding protein Ras participates in a growth promoting signal transduction pathway. The mechanism by which interaction of Ras with the protein kinase Raf leads to activation of Raf was studied. Raf was targeted to the plasma membrane by addition of the COOH-terminal localization signals of K-ras. This modified form of Raf (RafCAAX) was activated to the same extent as Raf coexpressed with oncogenic mutant Ras. Plasma membrane localization rather than farnesylation or the presence of the additional COOH-terminal sequence accounted for the activation of RafCAAX. The acti vation of RafCAAX was completely independent of Ras; it was neither potentiated by oncogenic mutant Ras nor abrogated by dominant negative Ras. Raf, once recruited to the plasma membrane, was not anchored there by Ras; most activated Raf in cells was associated with plasma membrane cytoskeletal elements, not the lipid bilayer. Thus, Ras functions in the activation of Raf by recruiting Raf to the plasma membrane where a separate, Ras-independent, activation of Raf occurs.	ONXY PHARMACEUT,RICHMOND,CA 94806					Hancock, John/0000-0003-0542-4710				BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CADWALLADER K, IN PRESS MOL CELL BI; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MACDONALD SG, UNPUB; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; TRAVERSE S, 1993, ONCOGENE, V8, P3175; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	29	902	918	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 3	1994	264	5164					1463	1467		10.1126/science.7811320	http://dx.doi.org/10.1126/science.7811320			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP221	7811320				2022-12-24	WOS:A1994NP22100044
J	LEAPE, LL; BATES, DW; CULLEN, DJ; COOPER, J; DEMONACO, HJ; GALLIVAN, T; HALLISEY, R; IVES, J; LAIRD, N; LAFFEL, G; NEMESKAL, R; PETERSEN, LA; PORTER, K; SERVI, D; SHEA, BF; SMALL, SD; SWEITZER, BJ; THOMPSON, BT; VANDERVLIET, M				LEAPE, LL; BATES, DW; CULLEN, DJ; COOPER, J; DEMONACO, HJ; GALLIVAN, T; HALLISEY, R; IVES, J; LAIRD, N; LAFFEL, G; NEMESKAL, R; PETERSEN, LA; PORTER, K; SERVI, D; SHEA, BF; SMALL, SD; SWEITZER, BJ; THOMPSON, BT; VANDERVLIET, M			SYSTEMS-ANALYSIS OF ADVERSE DRUG EVENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREVENTION; FAILURES; COMPUTER; ERRORS	Objective.-To identify and evaluate the systems failures that underlie errors causing adverse drug events (ADEs) and potential ADEs. Design.-Systems analysis of events from a prospective cohort study. Participants.-All admissions to 11 medical and surgical units in two tertiary care hospitals over a 6-month period. Main Outcome Measures.-Errors, proximal causes, and systems failures. Methods.-Errors were detected by interviews of those involved. Errors were classified according to proximal cause and underlying systems failure by multidisciplinary teams of physicians, nurses, pharmacists, and systems analysts. Results.-During this period, 334 errors were detected as the causes of 264 preventable ADEs and potential ADEs. Sixteen major systems failures were identified as the underlying causes of the errors. The most common systems failure was in the dissemination of drug knowledge, particularly to physicians, accounting for 29% of the 334 errors. Inadequate availability of patient information, such as the results of laboratory tests, was associated with 18% of errors. Seven systems failures accounted for 78% of the errors; all could be improved by better information systems. Conclusions.-Hospital personnel willingly participated in the detection and investigation of drug use errors and were able to identify underlying systems failures. The most common defects were in systems to disseminate knowledge about drugs and to make drug and patient information readily accessible at the time it is needed. Systems changes to improve dissemination and display of drug and patient data should make errors in the use of drugs less likely.	HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV GEN MED & PRIMARY CARE, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PHARM, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT ANESTHESIA, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT NURSING, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT PHARM, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; APM INC, NEW YORK, NY USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	LEAPE, LL (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.				AHRQ HHS [R01-HS07107-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Ackoff R.L., 1974, REDESIGNING FUTURE; ALLNUTT MF, 1987, BRIT J ANAESTH, V59, P856, DOI 10.1093/bja/59.7.856; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; Bates D W, 1994, Qual Manag Health Care, V2, P18; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bertalanffy Ludwig, 1968, GEN SYSTEM THEORY; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; Cook RI, 1994, HUMAN ERROR MED; COOPER JB, 1984, ANESTHESIOLOGY, V60, P34, DOI 10.1097/00000542-198401000-00008; Deming E., 1986, OUT CRISIS QUALITY P; FOLLI HL, 1987, PEDIATRICS, V79, P718; Gaba D, 1994, HUMAN ERROR MED; GABA DM, 1987, ANESTHESIOLOGY, V66, P670, DOI 10.1097/00000542-198705000-00013; LANGLEY GJ, 1992, F IMPROVEMENT; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1976, ANN INTERN MED, V84, P162, DOI 10.7326/0003-4819-84-2-162; Moray N, 1994, HUMAN ERROR MED; Norman D., 1988, PSYCHOL EVERYDAY THI; ONEIL AC, 1993, ANN INTERN MED, V119, P370, DOI 10.7326/0003-4819-119-5-199309010-00004; Perrow C., 1984, NORMAL ACCIDENTS LIV; Rasmussen J., 1994, COGNITIVE SYSTEMS EN; REASON J, 1990, PHILOS T ROY SOC B, V327, P475, DOI 10.1098/rstb.1990.0090; Reason J., 1991, HUMAN ERROR, DOI 10.1017/cbo9781139062367; SOUMERAI SB, 1986, MED CARE, V24, P313, DOI 10.1097/00005650-198604000-00003; VANCOTT H, 1994, HUMAN ERROR MED; 1980, MED MALPRACTICE CLOS	31	1354	1409	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					35	43		10.1001/jama.1995.03530010049034	http://dx.doi.org/10.1001/jama.1995.03530010049034			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG233	7791256				2022-12-24	WOS:A1995RG23300028
J	ZHAO, K; HART, CM; LAEMMLI, UK				ZHAO, K; HART, CM; LAEMMLI, UK			VISUALIZATION OF CHROMOSOMAL DOMAINS WITH BOUNDARY ELEMENT-ASSOCIATED FACTOR BEAF-32	CELL			English	Article							SCAFFOLD-ATTACHED REGIONS; PROTEIN-DNA INTERACTIONS; BETA-GLOBIN GENE; DROSOPHILA-MELANOGASTER; RNA-POLYMERASE; HEAT-SHOCK; REGULATORY SEQUENCES; IN-VIVO; EXPRESSION; CELLS	We have purified two proteins from Drosophila that bind to the scs' boundary element of the hsp70 domain at locus 87A7. Their palindromic binding sites (CGATA-TATCG) symmetrically abut the previously mapped hypersensitive site of scs'. We have cloned a cDNA for one of these proteins, BEAF-32 (boundary element-associated factor of 32 kDa). It encodes a novel protein that is bound to scs' but not scs in vivo. Immunostaining localizes BEAF to hundreds of interbands and many puff boundaries on polytene chromosomes, suggesting that a chromosomal domain consists of a band (or puff) and part of the flanking interbands. Enhancer blocking assays implicate the palindromic binding site in boundary function. The lack of enhancer blocking in transiently transfected cells suggests an involvement of chromatin, nuclear structure, or both in boundary function.	UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA,SWITZERLAND	University of Geneva	ZHAO, K (corresponding author), UNIV GENEVA,DEPT BIOCHEM,CH-1211 GENEVA,SWITZERLAND.		Hart, Craig/B-4832-2016	Hart, Craig/0000-0002-9870-991X; Galora De Mora, Raul Pavlov/0000-0001-8342-9782				ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ASHBURNER M, 1989, DROSOPHILA LABORATOR, P51; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; DUBENDORFER A, 1986, INSECT BIOCHEM, V16, P645, DOI 10.1016/0020-1790(86)90007-7; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; FARKAS G, 1992, NUCLEIC ACIDS RES, V20, P2604, DOI 10.1093/nar/20.10.2604; FLEISCHMANN G, 1984, P NATL ACAD SCI-BIOL, V81, P6958, DOI 10.1073/pnas.81.22.6958; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HELLER RA, 1986, J BIOL CHEM, V261, P8063; HOLDRIDGE C, 1991, MOL CELL BIOL, V11, P1894, DOI 10.1128/MCB.11.4.1894; JAMRICH M, 1977, P NATL ACAD SCI USA, V74, P2079, DOI 10.1073/pnas.74.5.2079; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; POLJAK L, 1994, NUCLEIC ACIDS RES, V22, P4386, DOI 10.1093/nar/22.21.4386; RIDDIHOUGH G, 1986, EMBO J, V5, P1653, DOI 10.1002/j.1460-2075.1986.tb04408.x; RIO DC, 1985, MOL CELL BIOL, V5, P1833, DOI 10.1128/MCB.5.8.1833; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; RYKOWSKI MC, 1988, CELL, V54, P461, DOI 10.1016/0092-8674(88)90067-0; Sambrook J., 1989, MOL CLONING LAB MANU; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TTSUKIYAMA T, 1994, NATURE, V367, P525; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; VAZQUEZ J, 1994, EMBO J, V13, P5984, DOI 10.1002/j.1460-2075.1994.tb06944.x; VAZQUEZ J, 1993, COLD SPRING HARB SYM, V58, P45, DOI 10.1101/SQB.1993.058.01.008; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365	44	267	277	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					879	889		10.1016/0092-8674(95)90008-X	http://dx.doi.org/10.1016/0092-8674(95)90008-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781065	Bronze, Green Published			2022-12-24	WOS:A1995RD76800009
J	FAIRMAN, WA; VANDENBERG, RJ; ARRIZA, JL; KAVANAUGH, MP; AMARA, SG				FAIRMAN, WA; VANDENBERG, RJ; ARRIZA, JL; KAVANAUGH, MP; AMARA, SG			AN EXCITATORY AMINO-ACID TRANSPORTER WITH PROPERTIES OF A LIGAND-GATED CHLORIDE CHANNEL	NATURE			English	Article							XENOPUS-LAEVIS OOCYTES; GLUTAMATE TRANSPORTER; RAT-BRAIN; ASPARTATE TRANSPORTER; EXPRESSION; CALCIUM; SALAMANDER; BLOCKERS; RECEPTOR; CLONING	EXCITATORY amino-acid transporters (EAATs) in the central nervous system maintain extracellular glutamate concentrations below excitotoxic levels and may limit the activation of glutamate receptors. Here we report the cloning of a novel human aspartate/glutamate transporter, EAAT4, which is expressed predominantly in the cerebellum. The transport activity encoded by EAAT4 has high apparent affinity for L-aspartate and L-glutamate, and has a pharmacological profile consistent with previously described cerebellar transport activities. In Xenopus oocytes expressing EAAT4, L-aspartate and L-glutamate elicited a current predominantly carried by chloride ions. This chloride conductance was not blocked by components that block endogenous oocyte chloride channels. Thus EAAT4 combines the re-uptake of neurotransmitter with a mechanism for increasing chloride permeability, both of which could regulate excitatory neurotransmission.	OREGON HLTH SCI UNIV,HOWARD HUGHES MED INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201	Howard Hughes Medical Institute; Oregon Health & Science University; Oregon Health & Science University			Vandenberg, Robert John/E-6018-2016	Vandenberg, Robert John/0000-0003-1523-4814; Amara, Susan/0000-0001-8914-1106				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; COYLE JT, 1985, J NEUROSCI RES, V16, P491; CUNNINGHAM SA, 1992, AM J PHYSIOL, V262, P783; ELIASOF S, 1993, J NEUROSCI, V13, P402; FLETCHER EJ, 1991, J NEUROCHEM, V57, P911, DOI 10.1111/j.1471-4159.1991.tb08237.x; GREGER R, 1990, METHOD ENZYMOL, V191, P793; KANAI Y, 1994, J BIOL CHEM, V269, P20599; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KLOCKNER U, 1993, J BIOL CHEM, V268, P14594; KUHAR MJ, 1978, J NEUROCHEM, V31, P251, DOI 10.1111/j.1471-4159.1978.tb12456.x; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; PIN JP, 1984, FEBS LETT, V175, P31, DOI 10.1016/0014-5793(84)80563-3; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; ROBINSON MB, 1993, J NEUROCHEM, V60, P167, DOI 10.1111/j.1471-4159.1993.tb05835.x; SARANTIS M, 1988, NATURE, V332, P451, DOI 10.1038/332451a0; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; WADICHE JI, IN PRESS NEURON; WHITE MM, 1990, MOL PHARMACOL, V37, P720; WI G, 1992, PFLUGERS ARCH, V420, P227; ZACZEK R, 1987, NEUROPHARMACOLOGY, V26, P281, DOI 10.1016/0028-3908(87)90179-1	30	979	997	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					599	603		10.1038/375599a0	http://dx.doi.org/10.1038/375599a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791878				2022-12-24	WOS:A1995RD28700054
J	HAOUARI, N; WOOD, C; GRIFFITHS, G; LEVENE, M				HAOUARI, N; WOOD, C; GRIFFITHS, G; LEVENE, M			THE ANALGESIC EFFECT OF SUCROSE IN FULL-TERM INFANTS - A RANDOMIZED CONTROLLED TRIAL	BRITISH MEDICAL JOURNAL			English	Article							NEWBORN; PAIN	Objective-To evaluate the effects of different sucrose concentrations on measures of neonatal pain, Design-Randomised, double blind, placebo controlled trial of sterile water (control) or one of three solutions of sucrose-namely, 12.5%, 25%, and 50% wt/vol. Setting-Postnatal ward, Patients-60 healthy infants of gestational age 37-42 weeks and postnatal age 1-6 days randomised to receive 2 ml of one of the four solutions on to the tongue two minutes before heel prick sampling for serum bilirubin concentrations. Main outcome measure-Duration of crying over the first three minutes after heel prick. Results-There was a significant reduction in overall crying time and heart rate after three minutes in the babies given 50% sucrose as compared with controls. This was maximal one minute after heel prick in the 50% sucrose group and became statistically significant in the 25% sucrose group at two minutes, There was a significant trend for a reduction in crying time with increasing concentrations of sucrose over the first three minutes. Conclusion-Concentrated sucrose solution seems to reduce crying and the autonomic effects of a painful procedure in healthy normal babies, Sucrose may be a useful and safe analgesic for minor procedures in neonates.	UNIV LEEDS,LEEDS GEN INFIRM,DIV PAEDIAT & CHILD HLTH,LEEDS LS2 9NS,W YORKSHIRE,ENGLAND	Leeds General Infirmary; University of Leeds								ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; BLASS E, 1987, PHARMACOL BIOCHEM BE, V26, P483, DOI 10.1016/0091-3057(87)90153-5; BLASS EM, 1991, PEDIATRICS, V87, P215; BLASS EM, 1989, ANN NY ACAD SCI, V575, P292; CUSIK J, 1985, STAT MED, V4, P87; FITZGERALD M, 1989, ARCH DIS CHILD-FETAL, V64, P441, DOI 10.1136/adc.64.4_Spec_No.441; LIEBLICH I, 1983, SCIENCE, V97, P871; PRECHTL HFR, 1974, BRAIN RES, V76, P185, DOI 10.1016/0006-8993(74)90454-5; RUSHFORTH JA, 1994, ARCH DIS CHILD-FETAL, V70, pF174, DOI 10.1136/fn.70.3.F174; RUSHFORTH JA, 1993, ARCH DIS CHILD, V69, P388, DOI 10.1136/adc.69.3.388	10	114	117	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1498	1500		10.1136/bmj.310.6993.1498	http://dx.doi.org/10.1136/bmj.310.6993.1498			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787595	Green Published			2022-12-24	WOS:A1995RD28500020
J	EVANS, MR				EVANS, MR			CHILDREN WHO MISS IMMUNIZATION - IMPLICATIONS FOR ELIMINATING MEASLES	BRITISH MEDICAL JOURNAL			English	Article											EVANS, MR (corresponding author), S GLAMORGAN HLTH AUTHOR,ABTON HOUSE,CARDIFF CF4 3QX,S GLAM,WALES.		Evans, Meirion/C-2990-2008	Evans, Meirion/0000-0003-3578-1866				ERDMAN DD, 1994, J MED VIROL, V41, P44; MILLER E, 1994, BRIT MED J, V309, P1102, DOI 10.1136/bmj.309.6962.1102; RAMSAY N, 1994, COMMUN DIS REP CDR R, V4, P141; TULCHINSKY TH, 1993, B WORLD HEALTH ORGAN, V71, P93; WHITE JM, 1994, COMMUN DIS REP CDR R, V4, P129	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1367	1368		10.1136/bmj.310.6991.1367	http://dx.doi.org/10.1136/bmj.310.6991.1367			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB005	7787540	Green Published			2022-12-24	WOS:A1995RB00500023
J	FREED, GL; CLARK, SJ; SORENSON, J; LOHR, JA; CEFALO, R; CURTIS, P				FREED, GL; CLARK, SJ; SORENSON, J; LOHR, JA; CEFALO, R; CURTIS, P			NATIONAL ASSESSMENT OF PHYSICIANS BREAST-FEEDING KNOWLEDGE, ATTITUDES, TRAINING, AND EXPERIENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EDUCATION; MANAGEMENT; HEALTH; CARE	Objective.-Previous reports have demonstrated that physician counseling can improve rates of breast-feeding initiation and duration but suggest that physicians are ill-prepared for this role. It is unclear whether residency training for pediatricians, obstetrician/gynecologists, and family physicians provides the knowledge and skills necessary for effective breast-feeding promotion. Design.-Survey. Participants.-A national random sample of 3115 residents and 1920 practicing physicians in pediatrics, obstetrics/gynecology, and family medicine. Outcomes.-Assessment of breast-feeding knowledge, attitudes, training, and experience. Results.-Overall response rate was 68%. All groups demonstrated significant deficits in knowledge of breast-feeding benefits and clinical management; for example, less than 50% of residents chose appropriate clinical management for a breast-fed jaundiced infant or a breast abscess. Practicing physicians performed slightly better, but still more than 30% chose incorrect advice for mothers with low milk supply. Residents reported that their breast-feeding instruction consisted mainly of didactic lecture, not patient experience. Only 55% of senior residents recalled even one instance of precepting related to breast-feeding, and less than 20% had demonstrated breast-feeding techniques at least five times during residency. Regarding preparation for breast-feeding counseling, more than 50% of all practicing physicians rated their residency training as inadequate. Overall, physician involvement in breast-feeding promotion was endorsed by 90% of respondents, yet only half rated themselves as effective in counseling breast-feeding patients. The greatest predictor of physician self-confidence was previous personal or spousal breast-feeding experience. Conclusions.-In this national sample of residents and practicing physicians in three specialties, physicians were ill-prepared to counsel breast-feeding mothers. Deliberate efforts must be made to incorporate clinically based breast-feeding training into residency programs and continuing education workshops to better prepare physicians for their role in breast-feeding promotion.	UNIV N CAROLINA,DEPT HLTH BEHAV & HLTH EDUC,CHAPEL HILL,NC; UNIV N CAROLINA,DEPT OBSTET & GYNECOL,CHAPEL HILL,NC; UNIV N CAROLINA,DEPT FAMILY MED,CHAPEL HILL,NC	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	FREED, GL (corresponding author), UNIV N CAROLINA,CECIL G SHEPS CTR HLTH SERV RES,DIV COMMUNITY PEDIAT,CB 7590,CHAPEL HILL,NC 27599, USA.				NICHD NIH HHS [1-R29-HD-29555-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029555] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson E, 1991, J Obstet Gynecol Neonatal Nurs, V20, P58, DOI 10.1111/j.1552-6909.1991.tb01677.x; APPLEBAUM RM, 1975, REPROD MED, V14, P93; BENTLEY JD, 1989, NEW ENGL J MED, V320, P1531, DOI 10.1056/NEJM198906083202306; CUNNINGHAM AS, 1991, J PEDIATR-US, V118, P659, DOI 10.1016/S0022-3476(05)80023-X; FREED GL, 1993, JAMA-J AM MED ASSOC, V269, P243, DOI 10.1001/jama.269.2.243; FREED GL, 1992, SOUTHERN MED J, V85, P483, DOI 10.1097/00007611-199205000-00006; FREED GL, 1991, AM J DIS CHILD, V145, P917, DOI 10.1001/archpedi.1991.02160080095027; GOLDSTEIN AO, 1993, FAM MED, V25, P254; HAYES B, 1981, J OBSTET GYNECOL NEO, V10, P480; HELLIKER K, 1994, WALL STREET J   0822, pA1; HOLLEN B K, 1976, Journal of Tropical Pediatrics and Environmental Child Health, V22, P288; KISTIN N, 1990, PEDIATRICS, V86, P741; Lawrence R A, 1989, Pediatr Rev, V11, P163, DOI 10.1542/pir.11-6-163; LAWRENCE RA, 1982, PEDIATRICS, V70, P912; LAWRENCE RA, 1989, BREASTFEEDING GUIDE; Lewinski C A, 1992, J Hum Lact, V8, P143, DOI 10.1177/089033449200800319; MITCHELMAN DF, 1990, AM J HEALTH PROMOT, V4, P181; NEIFERT MR, 1986, PEDIATR CLIN N AM, V33, P743; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; Simon J L, 1988, Fam Med, V20, P224; 1978, PEDIATRICS, V62, P591; 1993, GRADUATE MED ED DIRE; 1994, AM FAM PHYSICIAN, V50, P457; 1993, HLTH US 1992; 1990, HLTH PEOPLE 2000; 1992, GUIDELINES PERINATAL	26	200	204	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	1995	273	6					472	476		10.1001/jama.273.6.472	http://dx.doi.org/10.1001/jama.273.6.472			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE498	7837365				2022-12-24	WOS:A1995QE49800030
J	WHALEN, CM; HOCKIN, JC; RYAN, A; ASHTON, F				WHALEN, CM; HOCKIN, JC; RYAN, A; ASHTON, F			THE CHANGING EPIDEMIOLOGY OF INVASIVE MENINGOCOCCAL-DISEASE IN CANADA, 1985 THROUGH 1992 - EMERGENCE OF A VIRULENT CLONE OF NEISSERIA-MENINGITIDIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DECEMBER 1991; FEBRUARY 1992; INFLUENZA-A; INFECTIONS; OUTBREAK; AGE	Objective.-To describe the occurrence of invasive meningococcal disease (IMD) in Canada with respect to demographic variables and characteristics of the isolated strains of Neisseria meningitidis. Design.-National surveillance case series. Setting.-Canada, 1985 through 1992. Outcome Measures.-Morbidity and mortality. Main Results.-The incidence of IMD averaged 1.38 per 100 000 person-years, with considerable regional variation. In 1988, serogroup C organisms became more common, with one strain of the electrophoretic type 37 (ET-37) complex of N meningitidis,termed ET-15, the predominant group C strain identified. With the increase in group C disease, a greater proportion of cases were older than 5 years. By 1991, ET-15 was the most common strain identified in most parts of the country. Electrophoretic type 15 had a case fatality of 17.8% vs 8.1% for all other IMD (P<.001). Among cases 20 years and older the case fatality for ET-15 was 22.4%. Conclusions.-The group C, ET-15 strain of N meningitidis, first identified in Canada, was more virulent than other prevalent strains during this period, Active surveillance, rapid identification, and typing of N meningitidis will assist public health decision making in the control of emerging strains.	HLTH & WELF CANADA,HLTH PROTECT BRANCH,LAB CTR DIS CONTROL,BUR COMMUNICABLE DIS EPIDEMIOL,OTTAWA,ON K1A 0L2,CANADA; HLTH & WELF CANADA,HLTH PROTECT BRANCH,LAB CTR DIS CONTROL,BUR MICROBIOL,NATL LAB BACTERIOL,OTTAWA,ON K1A 0L2,CANADA; UNIV OTTAWA,DEPT EPIDEMIOL & COMMUNITY MED,OTTAWA,ON,CANADA	University of Ottawa								ASHTON FE, 1991, J CLIN MICROBIOL, V29, P2489, DOI 10.1128/JCM.29.11.2489-2493.1991; BAKER CJ, 1983, PEDIATRICS, V71, P923; BOUCHARD F, 1992, CAN J PUBLIC HEALTH, V83, P131; CARTWRIGHT KAV, 1991, LANCET, V338, P554, DOI 10.1016/0140-6736(91)91112-8; CORBETTFEENEY G, 1991, IRISH J MED SCI, V160, P134, DOI 10.1007/BF02965936; EDWARDS EA, 1977, SCAND J INFECT DIS, V9, P105, DOI 10.3109/inf.1977.9.issue-2.09; FALLON RJ, 1988, J MED MICROBIOL, V26, P161; FARLEY JD, 1992, CAN J PUBLIC HEALTH, V83, P138; GEMMILL I, 1992, CAN J PUBLIC HEALTH, V83, P134; GOLD R, 1992, CAN J PUBLIC HEALTH, V83, P5; HOCKIN J, 1993, 3RD NAT M CAN SOC EP; HUBERT B, 1992, J INFECT DIS, V166, P542, DOI 10.1093/infdis/166.3.542; HUME SE, 1992, JAMA-J AM MED ASSOC, V267, P1833, DOI 10.1001/jama.267.13.1833; JAFARI H, 1993, 33RD P INT C ANT AG; Jones D M, 1988, J Med Microbiol, V26, P165; Jones D M, 1994, Commun Dis Rep CDR Rev, V4, pR97; KRANSINSKI K, 1987, AM J EPIDEMIOL, V125, P499; LABIN LL, 1978, STATISTICS MODERN BU, P561; Le Saux N, 1992, Can J Infect Dis, V3, P60; MOORE PS, 1990, JAMA-J AM MED ASSOC, V264, P1271, DOI 10.1001/jama.264.10.1271; PELTOLA H, 1982, LANCET, V2, P595; REILLY S, 1991, LANCET, V338, P1143, DOI 10.1016/0140-6736(91)91999-B; SCHWARTZ B, 1989, CLIN MICROBIOL REV, V2, pS118, DOI 10.1128/CMR.2.Suppl.S118-S124.1989; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P837; STROFFOLINI T, 1989, J INFECTION, V19, P69, DOI 10.1016/S0163-4453(89)94980-3; SWEET L, 1992, CAN J PUBLIC HEALTH, V83, P129; Varughese P V, 1989, Can Dis Wkly Rep, V15, P89; VARUGHESE PV, 1987, EVOLUTION MENINGOCOC, V1, P47; Varughese PV, 1983, CAN DIS WKLY REP, V9, P177; WANG JF, 1993, J INFECT DIS, V167, P1320, DOI 10.1093/infdis/167.6.1320; WHITE K, 1992, CAN J PUBLIC HEALTH, V83, P141; YOUNG LS, 1972, NEW ENGL J MED, V287, P5, DOI 10.1056/NEJM197207062870102; 1985, 84208 DEP SUPPL SERV; 1991, NOTIFIABLE DISEASES; 1994, CAN COMMUNICABLE DIS, V20, P17; 1994, B INFORM MALAD INFEC, V1, P5; 1993, CAN COMMUNICABLE DIS, V19, P184; 1991, CAN DIS WKLY REP, V17, P295; 1991, CAN DIS WKLY REP, V17, P293; 1992, CAN COMMUNICABLE DIS, V18, P137; 1991, CAN DIS WKLY REP S3, V17, P24; 1994, 1993 DEP SUPPL SERV; 1989, CAN MED ASSOC J, V141, P567	43	147	150	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	1995	273	5					390	394		10.1001/jama.273.5.390	http://dx.doi.org/10.1001/jama.273.5.390			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QD203	7823384				2022-12-24	WOS:A1995QD20300023
J	MADRENAS, J; WANGE, RL; WANG, JL; ISAKOV, N; SAMELSON, LE; GERMAIN, RN				MADRENAS, J; WANGE, RL; WANG, JL; ISAKOV, N; SAMELSON, LE; GERMAIN, RN			ZETA-PHOSPHORYLATION WITHOUT ZAP-70 ACTIVATION-INDUCED BY TCR ANTAGONISTS OR PARTIAL AGONISTS	SCIENCE			English	Article							T-CELL-RECEPTOR; ANTIGEN-PRESENTING CELLS; TYROSINE PHOSPHORYLATION; CYTOCHROME-C; COMPLEX; CHAIN; LIGAND; COMPONENTS; ANALOG; KINASE	Small changes in the peptide-major histocompatibility complex (MHC) molecule ligands recognized by antigen-specific T cell receptors (TCRs) can convert fully activating complexes into partially activating or even inhibitory ones, This study examined early TCR-dependent signals induced by such partial agonists or antagonists, In contrast to typical agonist ligands, both an antagonist and several partial agonists stimulated a distinct pattern of zeta chain phosphorylation and failed to activate associated ZAP-70 kinase, These results identify a specific step in the early tyrosine phosphorylation cascade that is altered after TCR engagement with modified peptide-MHC molecule complexes, This finding may explain the different biological responses to TCR occupancy by these variant ligands.	NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	MADRENAS, J (corresponding author), NIAID, IMMUNOL LAB, LYMPHOCYTE BIOL SECT, BLDG 10, BETHESDA, MD 20892 USA.		Madrenas, Quim/P-5008-2019; Germain, Ronald/ABE-7090-2020; Germain, Ronald N./Z-1945-2019	Wange, Ronald/0000-0001-9593-3572; Isakov, Noah/0000-0002-1412-0957				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BERGMAN RN, 1978, J BIOL CHEM, V253, P3238; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHO EA, 1993, J IMMUNOL, V151, P20; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; DING L, 1993, J IMMUNOL, V151, P1224; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; FRANCO A, 1994, EUR J IMMUNOL, V24, P940, DOI 10.1002/eji.1830240424; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GERMAIN RN, 1993, CURR BIOL, V3, P586, DOI 10.1016/0960-9822(93)90004-8; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; HSI ED, 1989, J BIOL CHEM, V264, P10836; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; KUCHROO VK, 1994, J IMMUNOL, V153, P3326; MADRENAS J, UNPUB; MATIS LA, 1983, J IMMUNOL, V130, P1527; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PAGE DM, 1994, P NATL ACAD SCI USA, V91, P4057, DOI 10.1073/pnas.91.9.4057; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PLOEGH H, 1993, NATURE, V364, P16, DOI 10.1038/364016d0; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; RACIOPPI L, 1991, J IMMUNOL, V147, P3718; RONCHESE F, 1987, NATURE, V329, P254, DOI 10.1038/329254a0; RUPPERT J, 1993, P NATL ACAD SCI USA, V90, P2671, DOI 10.1073/pnas.90.7.2671; SAMELSON LE, 1987, J IMMUNOL, V139, P2708; SAMELSON LE, 1992, ADV EXP MED BIOL, V323, P9; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHWARTZ RH, 1985, J IMMUNOL, V135, P2598; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; VIGNALI DAA, 1994, J EXP MED, V179, P1945, DOI 10.1084/jem.179.6.1945; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YOON ST, 1994, IMMUNITY, V1, P563	49	505	511	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	1995	267	5197					515	518		10.1126/science.7824949	http://dx.doi.org/10.1126/science.7824949			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824949				2022-12-24	WOS:A1995QD40300039
J	WETTERVIK, C; CLAES, G; DROTT, C; EMANUELSSON, H; LOMSKY, M; RADBERG, G; TYGESEN, H				WETTERVIK, C; CLAES, G; DROTT, C; EMANUELSSON, H; LOMSKY, M; RADBERG, G; TYGESEN, H			ENDOSCOPIC TRANSTHORACIC SYMPATHICOTOMY FOR SEVERE ANGINA	LANCET			English	Note							SYMPATHETIC CHAIN; PAIN	We evaluated the antianginal effects of endoscopic transthoracic sympathicotomy (ETS) in 24 patients not eligible for coronary bypass surgery or angioplasty. In this procedure, the sympathetic chain is electrocoagulated under general anaesthesia. No major surgical complications occurred. The frequency of anginal attacks was significantly reduced (p=0.001). The mean increase in maximum exercise capacity was 13 (SD 21) W (p=0.009). ST depression at maximum comparable workload was reduced by 0.052 (0.10) mV (p=0.005). Global ejection fraction during exercise and metaiodobenzylguanidine uptake were unchanged. Heart rate variability analysis showed a reduction of the ratio between low and high frequencies at tilt test (-1.00 [0.96]; p<0.001). We conclude that ETS can be done without major complications, alleviates angina, and increases maximum working capacity in patients with advanced coronary disease.	SAHLGRENS UNIV HOSP,DIV CARDIOL,S-41345 GOTHENBURG,SWEDEN; SAHLGRENS UNIV HOSP,DIV CLIN PHYSIOL,S-41345 GOTHENBURG,SWEDEN; SAHLGRENS UNIV HOSP,DIV THORAC SURG,S-41345 GOTHENBURG,SWEDEN; BORAS CTY HOSP,DEPT MED,BORAS,SWEDEN; BORAS CTY HOSP,DEPT SURG,BORAS,SWEDEN	Sahlgrenska University Hospital; Sahlgrenska University Hospital; Sahlgrenska University Hospital								AKSELROD S, 1985, AM J PHYSIOL, V249, pH867, DOI 10.1152/ajpheart.1985.249.4.H867; BLOMBERG S, 1989, ANESTH ANALG, V69, P558; BLOMBERG S, 1990, ANESTHESIOLOGY, V74, P840; CLAES G, 1991, BRIT J SURG, V78, P760, DOI 10.1002/bjs.1800780634; DROTT C, 1993, ARCH SURG-CHICAGO, V128, P237; FAGRET D, 1993, J NUCL MED, V34, P57; KOCK M, 1992, ANESTH ANALG, V71, P625; LINDGREN I, 1950, ACTA MED SCAND, P1; MASERI A, 1992, PROG CARDIOVASC DIS, V35, P1, DOI 10.1016/0033-0620(92)90031-T; TOFT P, 1987, INTENS CARE MED, V13, P388	10	51	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					97	98		10.1016/S0140-6736(95)90065-9	http://dx.doi.org/10.1016/S0140-6736(95)90065-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815891				2022-12-24	WOS:A1995QB80400012
J	EILERS, J; AUGUSTINE, GJ; KONNERTH, A				EILERS, J; AUGUSTINE, GJ; KONNERTH, A			SUBTHRESHOLD SYNAPTIC CA2+ SIGNALING IN FINE DENDRITES AND SPINES OF CEREBELLAR PURKINJE NEURONS	NATURE			English	Article							GLUTAMATE-RECEPTOR CHANNELS; CENTRAL-NERVOUS-SYSTEM; CALCIUM TRANSIENTS; CELLS; CURRENTS; INVITRO; ACTIVATION; SLICES	THE conventional view of synaptic integration is that it results from the simple summation of electrical signals produced by each active synapse innervating a given neuron(1). However, because synaptic action can go beyond the production of postsynaptic electrical signals, to include intracellular biochemical events such as the generation of second messengers, it is possible that synaptic integration could occur at another level(2). We have considered this possibility by examining changes in the dendritic concentration of the second messenger, calcium, resulting from subthreshold excitatory synaptic activity in cerebellar Purkinje neurons. We report here clear evidence that such non-electrical synaptic integration occurs and that it takes place in restricted dendritic compartments consisting of spines and adjacent fine dendrites.	UNIV SAARLAND,INST PHYSIOL 1,D-66421 HOMBURG,GERMANY; DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710	Saarland University; Duke University			Augustine, George James/J-9228-2013; Eilers, Jens/E-6251-2012	Eilers, Jens/0000-0003-0497-5625				ALFORD S, 1993, J PHYSIOL-LONDON, V469, P693, DOI 10.1113/jphysiol.1993.sp019838; BARBOUR B, 1993, NEURON, V11, P759, DOI 10.1016/0896-6273(93)90085-6; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; ECCLES JC, 1964, PHYSL SYNAPSES, V4, P101; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Eilers Jens, 1995, P213; HILLMAN D, 1991, P NATL ACAD SCI USA, V88, P7076, DOI 10.1073/pnas.88.16.7076; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Ito M, 1991, Curr Opin Neurobiol, V1, P616, DOI 10.1016/S0959-4388(05)80038-8; ITO M, 1984, CEREBELLUM NEURAL CO, P36; KANO M, 1992, NATURE, V356, P601, DOI 10.1038/356601a0; KONNERTH A, 1992, P NATL ACAD SCI USA, V89, P7051, DOI 10.1073/pnas.89.15.7051; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; LLINAS R, 1976, P NATL ACAD SCI USA, V73, P2520, DOI 10.1073/pnas.73.7.2520; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; LLINAS RR, 1990, SYNAPTIC ORG BRAIN, P214; MIDTGAARD J, 1993, J NEUROPHYSIOL, V70, P2455, DOI 10.1152/jn.1993.70.6.2455; MIYAKAWA H, 1992, J NEUROPHYSIOL, V68, P1178, DOI 10.1152/jn.1992.68.4.1178; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; MURPHY TH, 1994, SCIENCE, V263, P529, DOI 10.1126/science.7904774; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; PALAY SL, 1974, CEREBELLAR CORTEX, P79; ROSS WN, 1987, J PHYSIOL-LONDON, V389, P319, DOI 10.1113/jphysiol.1987.sp016659; SCHNEGGENBURGER R, 1993, NEURON, V11, P133, DOI 10.1016/0896-6273(93)90277-X; SUGIMORI M, 1990, P NATL ACAD SCI USA, V87, P5084, DOI 10.1073/pnas.87.13.5084; TANK DW, 1988, SCIENCE, V242, P773, DOI 10.1126/science.2847315; USOWICZ MM, 1992, NEURON, V9, P1185, DOI 10.1016/0896-6273(92)90076-P	29	235	239	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					155	158		10.1038/373155a0	http://dx.doi.org/10.1038/373155a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816097				2022-12-24	WOS:A1995QB06300060
J	CHEN, GH; HOFFMAN, AS				CHEN, GH; HOFFMAN, AS			GRAFT-COPOLYMERS THAT EXHIBIT TEMPERATURE-INDUCED PHASE-TRANSITIONS OVER A WIDE-RANGE OF PH	NATURE			English	Article							DRUG DELIVERY; POLYMERS; HYDROGELS; NETWORKS; RELEASE; GELS; ACID	THERE are many potential applications of 'intelligent' aqueous polymer systems(1-8) in medicine, biotechnology, industry and in environmental problems(9-13). Many of these polymer systems undergo reversible phase transitions-for example, abrupt changes in volume-in response to external stimuli such as temperature, pH or the nature of the solvent. Most of the polymers studied previously are responsive to only one kind of stimulus. But for some applications, independent responsiveness to several factors, such as temperature and pH, may be required. Here we describe a polymer that undergoes marked solubility changes in water in response to temperature and/or pH changes, The polymer is prepared by grafting temperature-sensitive side chains onto a pH-sensitive backbone, We also find that block copolymers, in which the temperature- and pH-sensitive units alternate along the chain, show similar behaviour.	UNIV WASHINGTON,CTR BIOENGN,SEATTLE,WA 98195	University of Washington; University of Washington Seattle								BAE YH, 1988, MAKROMOL CHEM-RAPID, V9, P185; CHEN GH, 1993, BIOCONJUGATE CHEM, V4, P509, DOI 10.1021/bc00024a013; DONG LC, 1990, J CONTROL RELEASE, V13, P21, DOI 10.1016/0168-3659(90)90071-Z; DONG LC, 1991, J CONTROL RELEASE, V15, P141, DOI 10.1016/0168-3659(91)90072-L; Dusek K., 1993, RESPONSIVE GELS VOLU, VII; FREITAS RFS, 1987, CHEM ENG SCI, V42, P97, DOI 10.1016/0009-2509(87)80213-0; Heskins M., 1968, J MACROMOL SCI CHEM, V2, P1441, DOI DOI 10.1080/10601326808051910; HOFFMAN A S, 1987, Journal of Controlled Release, V6, P297, DOI 10.1016/0168-3659(87)90083-6; HOFFMAN AS, 1991, MRS BULL, V16, P42, DOI 10.1557/S0883769400056049; KATONO H, 1991, J CONTROL RELEASE, V16, P215, DOI 10.1016/0168-3659(91)90045-F; KISHI R, 1991, POLYMER GELS, P205; KLIER J, 1990, MACROMOLECULES, V23, P4944, DOI 10.1021/ma00225a011; KUNGWATCHAKUN D, 1988, MAKROMOL CHEM-RAPID, V9, P243; MONJI N, 1987, APPL BIOCHEM BIOTECH, V14, P107, DOI 10.1007/BF02798429; OKANO T, 1990, J CONTROL RELEASE, V11, P255, DOI 10.1016/0168-3659(90)90138-J; PARK TG, 1993, MACROMOLECULES, V26, P5045, DOI 10.1021/ma00071a010; PRIEST JH, 1987, ACS SYM SER, V350, P255; SUZUKI M, 1991, POLYMER GELS, P221; TANAKA T, 1979, POLYMER, V20, P1404, DOI 10.1016/0032-3861(79)90281-7; TAYLOR LD, 1970, J POLYM SCI A, V8, P3405	20	1162	1244	8	331	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					49	52		10.1038/373049a0	http://dx.doi.org/10.1038/373049a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800038				2022-12-24	WOS:A1995QA23900050
J	BAGGALEY, R; GODFREYFAUSSETT, P; MSISKA, R; CHILANGWA, D; CHITU, E; PORTER, J; KELLY, M				BAGGALEY, R; GODFREYFAUSSETT, P; MSISKA, R; CHILANGWA, D; CHITU, E; PORTER, J; KELLY, M			IMPACT OF HIV-INFECTION ON ZAMBIAN BUSINESSES	BRITISH MEDICAL JOURNAL			English	Article									MINIST HLTH,NATL AIDS CONTROL PROGRAMME,LUSAKA,ZAMBIA; UNIV LUSAKA,TEACHING HOSP,DEPT MED,ZAMBART PROJECT,LUSAKA,ZAMBIA; LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	BAGGALEY, R (corresponding author), KARA COUNSELLING & TRAINING TRUST,POB 37559,LUSAKA,ZAMBIA.							BUVE A, IN PRESS AIDS; ELLIOTT AM, 1990, BRIT MED J, V301, P412, DOI 10.1136/bmj.301.6749.412; MURRAY CJL, 1992, HLTH ADULTS DEV WORL, P23; NKOWANE BM, 1991, AIDS, V5, pS7; PIOT P, 1992, AIDS AFRICA MANUAL P	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1549	1550		10.1136/bmj.309.6968.1549	http://dx.doi.org/10.1136/bmj.309.6968.1549			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819895	Green Published			2022-12-24	WOS:A1994PX56400021
J	PARTANEN, J; NISKANEN, L; LEHTINEN, J; MERVAALA, E; SIITONEN, O; UUSITUPA, M				PARTANEN, J; NISKANEN, L; LEHTINEN, J; MERVAALA, E; SIITONEN, O; UUSITUPA, M			NATURAL-HISTORY OF PERIPHERAL NEUROPATHY IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEWLY DIAGNOSED NIDDM; 5-YEAR FOLLOW-UP; NONDIABETIC SUBJECTS; PREVALENCE	Background. There is little information on the incidence and natural history of neuropathy in patients with non-insulin-dependent diabetes mellitus (NIDDM). Methods. We studied patients with newly diagnosed NIDDM and control subjects both at base line and 5 and 10 years later. Polyneuropathy was diagnosed on the basis of clinical criteria (pain and paresthesias) and electrodiagnostic studies (nerve conduction velocity and response-amplitude values). We investigated the relation between metabolic variables (results of oral glucose-tolerance tests, serum lipid and insulin concentrations, and glycosylated hemoglobin values) and the development of polyneuropathy. Results. In 10 years, 36 patients with NIDDM and 8 control subjects died; 86 patients and 121 control subjects completed the study. When the study ended, 18 percent of the patients were being treated only with diet, 59 percent with oral hypoglycemic drugs alone, 12 percent with insulin alone, and 11 percent with both insulin and oral hypoglycemic agents. At base line the prevalence of definite or probable polyneuropathy among the patients with NIDDM was 8.3 percent, as compared with 2.1 percent among the control subjects. These values 10 years later were 41.9 percent and 5.8 percent, respectively. The number of patients with NIDDM who had nerve-conduction abnormalities in the legs and feet increased from 8.3 percent at base line to 16.7 percent after 5 years and to 41.9 percent after 10 years. The decrease in sensory and motor amplitudes, indicating axonal destruction, was more pronounced than the slowing of the nerve conduction velocities, which indicates demyelination. Among the patients with NIDDM, those with polyneuropathy had poorer glycemic control than those without. Low serum insulin concentrations before and after the oral administration of glucose were associated with the development of polyneuropathy, regardless of the degree of glycemia. Conclusions. The prevalence of polyneuropathy among patients with NIDDM increases with time, and the increase may be greater in patients with hypoinsulinemia.	KUOPIO UNIV HOSP, DEPT CLIN NUTR, SF-70211 KUOPIO, FINLAND; KUOPIO UNIV HOSP, DEPT INTERNAL MED, SF-70211 KUOPIO, FINLAND; KUOPIO UNIV, KUOPIO, FINLAND	Kuopio University Hospital; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; University of Eastern Finland	PARTANEN, J (corresponding author), KUOPIO UNIV HOSP, DEPT CLIN NEUROPHYSIOL, POB 1777, SF-70211 KUOPIO, FINLAND.		Uusitupa, Matti Ilmari Julius/AAX-4929-2020					CAMERON NE, 1994, DIABETES METAB REV, V10, P189, DOI 10.1002/dmr.5610100302; DYCK PJ, 1986, ANN NEUROL, V19, P440, DOI 10.1002/ana.410190504; HARATI Y, 1992, NEUROL CLIN, V10, P783, DOI 10.1016/S0733-8619(18)30208-1; LANG AH, 1977, J NEUROL SCI, V33, P229, DOI 10.1016/0022-510X(77)90196-4; LEHTINEN J, 1987, THEIS U KUOPIO KUOPI; LEHTINEN JM, 1989, DIABETES, V38, P1307, DOI 10.2337/diabetes.38.10.1307; LEHTINEN JM, 1993, DIABETOLOGIA, V36, P68, DOI 10.1007/BF00399096; LLEWELYN JG, 1991, BRAIN, V114, P867, DOI 10.1093/brain/114.2.867; Mincu I, 1980, Med Interne, V18, P155; NISKANEN L, 1994, J INTERN MED, V236, P263, DOI 10.1111/j.1365-2796.1994.tb00794.x; NISKANEN LK, 1990, DIABETES CARE, V13, P41, DOI 10.2337/diacare.13.1.41; PENTTILA IM, 1981, SCAND J CLIN LAB INV, V41, P353, DOI 10.3109/00365518109092057; Pirart J., 1978, DIABETES CARE, V1, P168, DOI 10.2337/diacare.1.3.168; RATZMANN K P, 1991, Journal of Diabetic Complications, V5, P1, DOI 10.1016/0891-6632(91)90002-7; SCARPINI E, 1993, J NEUROL SCI, V120, P159, DOI 10.1016/0022-510X(93)90268-4; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; UUSITUPA M, 1985, DIABETOLOGIA, V28, P22, DOI 10.1007/BF00276995; UUSITUPA MIJ, 1993, DIABETOLOGIA, V36, P1175, DOI 10.1007/BF00401063; WAHREN J, 1994, DIABETOLOGIA, V37, pS99, DOI 10.1007/BF00400832; 1980, WHO TECH REP SER, V646, P7	20	429	456	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 13	1995	333	2					89	94		10.1056/NEJM199507133330203	http://dx.doi.org/10.1056/NEJM199507133330203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH225	7777034	Bronze			2022-12-24	WOS:A1995RH22500003
J	MASON, JJ; OWENS, DK; HARRIS, RA; COOKE, JP; HLATKY, MA				MASON, JJ; OWENS, DK; HARRIS, RA; COOKE, JP; HLATKY, MA			THE ROLE OF CORONARY ANGIOGRAPHY AND CORONARY REVASCULARIZATION BEFORE NONCARDIAC VASCULAR-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ARTERY BYPASS-SURGERY; CARDIAC RISK; MYOCARDIAL-INFARCTION; GRAFT-SURGERY; CASS REGISTRY; CLINICAL-DIAGNOSIS; DISEASE; MORTALITY; DIPYRIDAMOLE; ANGIOPLASTY	Objective.-To determine whether preoperative coronary angiography and revascularization improve short-term outcomes in patients undergoing noncardiac vascular surgery. Design.-Decision analysis. Patients.-Patients undergoing elective vascular surgery who had either no angina or mild angina and a positive dipyridamole-thallium scan result. Interventions.-Three strategies were compared, The first strategy was to proceed directly to vascular surgery. The second was to perform coronary angiography, followed by selective coronary revascularization, before proceeding to vascular surgery and to cancel vascular surgery in patients with severe inoperable coronary artery disease (CAD), The third was to perform coronary angiography, followed by selective coronary revascularization, before proceeding to vascular surgery and to perform vascular surgery in patients with inoperable CAD. Main Outcome Measures.-Mortality, nonfatal myocardial infarction, stroke, uncorrected vascular disease, and cost. All outcomes were assessed within 3 months. Results.-Proceeding directly to vascular surgery led to lower morbidity and cost in the base case analysis. The coronary angiography strategy led to higher mortality if vascular surgery would proceed in patients with inoperable CAD, but led to slightly lower mortality if vascular surgery were canceled in patients with inoperable CAD. The coronary angiography strategy also led to lower mortality when vascular surgery was particularly risky. Conclusions.-Decision analysis indicates vascular surgery without preoperative coronary angiography generally leads to better outcomes. Preoperative coronary angiography should be reserved for patients whose estimated mortality from vascular surgery is substantially higher than average.	STANFORD UNIV, SCH MED, DEPT MED, DIV CARDIOVASC MED, PALO ALTO, CA 94304 USA; STANFORD UNIV, SCH MED, DEPT HLTH RES & POLICY, DIV HLTH SERV RES, PALO ALTO, CA 94304 USA; DEPT VET AFFAIRS MED CTR, DEPT MED, GEN INTERNAL MED SECT, PALO ALTO, CA USA	Stanford University; Stanford University				Cooke, John/0000-0003-0033-9138; Hlatky, Mark/0000-0003-4686-9441				ABRAHAM SA, 1991, PROG CARDIOVASC DIS, V34, P205, DOI 10.1016/0033-0620(91)90014-D; ALBRO PC, 1978, AM J CARDIOL, V42, P751, DOI 10.1016/0002-9149(78)90094-2; ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; ANDREWS TC, 1994, J VASC MED BIOL, V5, P8; ASHTON CM, 1993, ANN INTERN MED, V118, P504, DOI 10.7326/0003-4819-118-7-199304010-00004; BELL MR, 1992, CIRCULATION, V86, P446, DOI 10.1161/01.CIR.86.2.446; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BROWN KA, 1993, J AM COLL CARDIOL, V21, P325, DOI 10.1016/0735-1097(93)90670-V; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CHAITMAN BR, 1981, CIRCULATION, V64, P360, DOI 10.1161/01.CIR.64.2.360; COHEN HA, 1982, CIRCULATION, V66, P49; DAVIS K, 1979, CIRCULATION, V59, P1105, DOI 10.1161/01.CIR.59.6.1105; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; DETRE KM, 1984, NEW ENGL J MED, V311, P1333; DETSKY AS, 1986, ARCH INTERN MED, V146, P2131, DOI 10.1001/archinte.146.11.2131; DIAMOND GA, 1980, J CLIN INVEST, V65, P1210, DOI 10.1172/JCI109776; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; EAGLE KA, 1994, J AM COLL CARDIOL, V23, P1091, DOI 10.1016/0735-1097(94)90596-7; EAGLE KA, 1987, JAMA-J AM MED ASSOC, V257, P2185, DOI 10.1001/jama.257.16.2185; ELLIS SG, 1988, J AM COLL CARDIOL, V11, P211, DOI 10.1016/0735-1097(88)90082-4; ELMORE JR, 1993, MAYO CLIN PROC, V68, P637, DOI 10.1016/S0025-6196(12)60598-9; FISHER LD, 1981, CIRCULATION, V63, P987, DOI 10.1161/01.CIR.63.5.987; FOSTER ED, 1986, ANN THORAC SURG, V41, P42, DOI 10.1016/S0003-4975(10)64494-3; FRANCISCO DA, 1982, CIRCULATION, V66, P370, DOI 10.1161/01.CIR.66.2.370; GERSH BJ, 1991, J AM COLL CARDIOL, V18, P203, DOI 10.1016/S0735-1097(10)80241-4; GERSH BJ, 1983, CIRCULATION, V67, P483, DOI 10.1161/01.CIR.67.3.483; GOLDEN MA, 1990, ANN SURG, V212, P415, DOI 10.1097/00000658-199010000-00004; GOLDMAN L, 1994, NEW ENGL J MED, V330, P707, DOI 10.1056/NEJM199403103301010; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HAMMERMEISTER KE, 1990, CIRCULATION, V82, P380; HANNAN EL, 1992, JAMA-J AM MED ASSOC, V268, P3092, DOI 10.1001/jama.268.21.3092; HARRIS PJ, 1979, CIRCULATION, V60, P1259, DOI 10.1161/01.CIR.60.6.1259; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; Hertzer N R, 1987, Ann Vasc Surg, V1, P616, DOI 10.1016/S0890-5096(06)61452-0; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; HIGGINS TL, 1992, JAMA-J AM MED ASSOC, V267, P2344, DOI 10.1001/jama.267.17.2344; HLATKY MA, 1990, CIRCULATION, V82, P208; HOLMES DR, 1988, J AM COLL CARDIOL, V12, P1149, DOI 10.1016/0735-1097(88)92593-4; JOSEPHSON MA, 1982, AM HEART J, V103, P1008, DOI 10.1016/0002-8703(82)90564-6; KENNEDY JW, 1980, J THORAC CARDIOV SUR, V80, P876; KENNEDY JW, 1982, CATHETER CARDIO DIAG, V8, P5, DOI 10.1002/ccd.1810080103; KENNEDY JW, 1982, CATHETER CARDIO DIAG, V8, P323, DOI 10.1002/ccd.1810080402; KIRKLIN JW, 1991, J AM COLL CARDIOL, V17, P543; LEPPO J, 1982, CIRCULATION, V66, P649, DOI 10.1161/01.CIR.66.3.649; LEPPO J, 1987, J AM COLL CARDIOL, V9, P269, DOI 10.1016/S0735-1097(87)80374-1; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MARK DB, 1994, CIRCULATION, V89, P2015, DOI 10.1161/01.CIR.89.5.2015; MARWICK TH, 1990, CLIN CARDIOL, V13, P14, DOI 10.1002/clc.4960130105; MASSIE BM, 1993, CIRCULATION, V87, P1752, DOI 10.1161/01.CIR.87.5.1752; MCFALLS EO, 1993, J AM COLL CARDIOL, V21, P1347, DOI 10.1016/0735-1097(93)90307-M; MOCK MB, 1982, CIRCULATION, V66, P562, DOI 10.1161/01.CIR.66.3.562; OCONNOR GT, 1992, CIRCULATION, V85, P2110, DOI 10.1161/01.CIR.85.6.2110; PASTERNACK PF, 1985, CIRCULATION, V72, P13; PEDERSEN TR, 1994, LANCET, V344, P1383; POLDERMANS D, 1993, CIRCULATION, V87, P1506, DOI 10.1161/01.CIR.87.5.1506; PRYOR DB, 1983, AM J MED, V75, P771, DOI 10.1016/0002-9343(83)90406-0; PRYOR DB, 1993, ANN INTERN MED, V118, P81, DOI 10.7326/0003-4819-118-2-199301150-00001; RABY KE, 1992, JAMA-J AM MED ASSOC, V268, P222, DOI 10.1001/jama.268.2.222; RIHAL CS, 1995, CIRCULATION, V91, P46, DOI 10.1161/01.CIR.91.1.46; ROGER VL, 1989, J AM COLL CARDIOL, V14, P1245, DOI 10.1016/0735-1097(89)90423-3; RUDDY TD, 1987, J AM COLL CARDIOL, V10, P142, DOI 10.1016/S0735-1097(87)80172-9; RYAN TJ, 1993, J AM COLL CARDIOL, V22, P2033, DOI 10.1016/0735-1097(93)90794-2; SIMONETTI I, 1991, CIRCULATION, V83, P43; SMITH LR, 1991, CIRCULATION, V84, P245; TALLEY JD, 1990, CIRCULATION, V82, P1203, DOI 10.1161/01.CIR.82.4.1203; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; WONG T, 1992, ANN INTERN MED, V116, P743, DOI 10.7326/0003-4819-116-9-743; ZHU YY, 1991, AM HEART J, V121, P33, DOI 10.1016/0002-8703(91)90952-E; 1994, STAT B METROP IN JAN, P12	73	114	116	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1919	1925		10.1001/jama.273.24.1919	http://dx.doi.org/10.1001/jama.273.24.1919			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783301				2022-12-24	WOS:A1995RE35400027
J	GALLERANI, M; MANFREDINI, R; CARACCIOLO, S; SCAPOLI, C; MOLINARI, S; FERSINI, C				GALLERANI, M; MANFREDINI, R; CARACCIOLO, S; SCAPOLI, C; MOLINARI, S; FERSINI, C			SERUM-CHOLESTEROL CONCENTRATIONS IN PARASUICIDE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PLASMA-CHOLESTEROL; PRIMARY PREVENTION; TERM MORTALITY; LOWERING DRUGS; MEN; TRIGLYCERIDES; POPULATION; AGGRESSION; SEROTONIN; VIOLENCE	Objective-To evaluate whether people who have committed parasuicide have low serum cholesterol concentrations. Design-Results of blood tests in subjects admitted to hospital for parasuicide compared with those of a control group of non-suicidal subjects; comparison in subgroup of parasuicide subjects of two sets of blood test results (one set from admission for parasuicide and the other from admission for some other illness). Setting-General hospital, Ferrara, Italy. Subjects-331 parasuicide subjects aged 44 (SD 21) years (109 with two sets of blood test results) and 331 controls. Main outcome measures-Serum cholesterol concentrations and possible association with parasuicide, considering sex, violence of method of parasuicide, and underlying psychiatric disorder. Results-Lower serum cholesterol concentrations (4.96 (SD 1.16) mmol/l) were found in the parasuicide subjects than in the controls (5.43 (1.30); P<0.001), regardless of sex and degree of violence of parasuicide method. Both men and women with two sets of blood test results had lower cholesterol concentrations after parsuicide. Linear regression analysis showed that the difference in cholesterol concentrations was significantly related to the length of time between the taking of the two sets of blood samples. Conclusion-The study showed low cholesterol concentrations after parasuicide. This finding agrees with previous studies, which suggest an association between low cholesterol concentration and suicide.	UNIV FERRARA, SCH MED, INST INTERNAL MED 1, FERRARA, ITALY; UNIV FERRARA, SCH MED, DEPT PSYCHOL, FERRARA, ITALY; UNIV FERRARA, DEPT BIOL, FERRARA, ITALY	University of Ferrara; University of Ferrara; University of Ferrara	GALLERANI, M (corresponding author), ST ANNA HOSP, DEPT EMERGENCY, CORSO GIOVECCA 203, I-44100 FERRARA, ITALY.		Scapoli, Chiara/E-2268-2015; Scapoli, Chiara/N-3372-2019; Manfredini, Roberto/A-3471-2008; Manfredini, Roberto/N-3859-2019; Manfredini, Roberto/AAJ-5442-2020	Scapoli, Chiara/0000-0003-4058-4787; Scapoli, Chiara/0000-0003-4058-4787; Manfredini, Roberto/0000-0002-8364-2601; Manfredini, Roberto/0000-0002-8364-2601; 				ALLAIN CC, 1974, CLIN CHEM, V20, P470; BOTTIGER LE, 1972, BRIT MED J, V32, P87; Brown G L, 1986, Ann N Y Acad Sci, V487, P175, DOI 10.1111/j.1749-6632.1986.tb27897.x; BROWN SL, 1994, BRIT MED J, V308, P1328, DOI 10.1136/bmj.308.6940.1328; CARLSON LA, 1985, ACTA CHIR SCAND, P87; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; COCCARO EF, 1989, BRIT J PSYCHIAT, V155, P52, DOI 10.1192/S0007125000291769; CUMMINGS P, 1994, ANN INTERN MED, V120, P848, DOI 10.7326/0003-4819-120-10-199405150-00006; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; FOWKES FGR, 1992, LANCET, V340, P995, DOI 10.1016/0140-6736(92)93009-C; HORROBIN DF, 1989, BRIT J PSYCHIAT, V154, P882, DOI 10.1192/bjp.154.6.882b; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; LINDBERG G, 1992, BRIT MED J, V305, P277, DOI 10.1136/bmj.305.6848.277; LINNOILA M, 1983, LIFE SCI, V33, P2609, DOI 10.1016/0024-3205(83)90344-2; MELTZER H, 1989, BRIT J PSYCHIAT, V155, P25, DOI 10.1192/S0007125000291733; MORGAN RE, 1993, LANCET, V341, P75, DOI 10.1016/0140-6736(93)92556-9; MULDOON MF, 1992, ARCH INTERN MED, V152, P775, DOI 10.1001/archinte.152.4.775; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; OLIVER MF, 1988, J AM COLL CARDIOL, V12, P814, DOI 10.1016/0735-1097(88)90327-0; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; PLATT S, 1992, ACTA PSYCHIAT SCAND, V85, P97, DOI 10.1111/j.1600-0447.1992.tb01451.x; ROY A, 1988, ACTA PSYCHIAT SCAND, V78, P529, DOI 10.1111/j.1600-0447.1988.tb06380.x; RYDER REJ, 1984, BRIT MED J, V289, P1651, DOI 10.1136/bmj.289.6459.1651; SAMPSON EJ, 1975, CLIN CHEM, V21, P1983; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; STRANDBERG TE, 1991, JAMA-J AM MED ASSOC, V266, P1225, DOI 10.1001/jama.266.9.1225; VARTIAINEN E, 1994, BRIT MED J, V309, P445, DOI 10.1136/bmj.309.6952.445; VIRKKUNEN M, 1979, NEUROPSYCHOBIOLOGY, V5, P27, DOI 10.1159/000117660; VIRKKUNEN M, 1989, ARCH GEN PSYCHIAT, V46, P604; WYSOWSKI DK, 1990, ARCH INTERN MED, V150, P2169, DOI 10.1001/archinte.150.10.2169	31	67	67	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 24	1995	310	6995					1632	1636		10.1136/bmj.310.6995.1632	http://dx.doi.org/10.1136/bmj.310.6995.1632			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF698	7795448	Green Published			2022-12-24	WOS:A1995RF69800018
J	BIANCHI, G; SWALES, JD				BIANCHI, G; SWALES, JD			DO WE NEED MORE ANTIHYPERTENSIVE DRUGS - LESSONS FROM THE NEW BIOLOGY	LANCET			English	Editorial Material							SODIUM SENSITIVITY; BLOOD-PRESSURE; RESISTANCE		LEICESTER ROYAL INFIRM,DEPT MED,LEICESTER LE2 7LX,LEICS,ENGLAND; UNIV MILAN,OSPED SAN RAFFAELE,CATTEDRA NEFROL,I-20127 MILAN,ITALY	University of Leicester; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele				Bianchi, Giuseppe/0000-0002-8365-3618				CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; HARRAP S, 1994, LANCET, V344, P167; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; KAPLAN NM, 1994, TXB HYPERTENSION, P811; KURTZ TW, 1994, LANCET, V344, P167, DOI 10.1016/S0140-6736(94)92761-8; LINDHOLM L, 1984, ACTA MED SCAND, V21, P251; LUFT FC, 1982, AM J MED, V72, P726, DOI 10.1016/0002-9343(82)90537-X; SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056/NEJM199406093302302; SWALES JD, 1994, LANCET, V344, P380; SWALES JD, 1993, J HYPERTENS       S5, V2, pS59; WEINBERGER MH, 1987, HYPERTENSION, V10, P443, DOI 10.1161/01.HYP.10.4.443; 1984, HYPERTENSION S1, V6, P198; 1991, NEW ENGL J MED, V325, P293; 1994, NAT GENET, V7, P217	14	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1555	1557		10.1016/S0140-6736(95)91094-8	http://dx.doi.org/10.1016/S0140-6736(95)91094-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791444				2022-12-24	WOS:A1995RD79000016
J	RADFORD, CF; BACON, AS; DART, JKG; MINASSIAN, DC				RADFORD, CF; BACON, AS; DART, JKG; MINASSIAN, DC			RISK-FACTORS FOR ACANTHAMOEBA-KERATITIS IN CONTACT-LENS USERS - A CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							MICROBIAL-CONTAMINATION; WEARERS	Objective-To investigate reasons for an increase in cases of Acanthamoeba keratitis related to contact lenses. Design-Case-control study. Cases were contact lens related acanthamoeba keratitis patients treated between 1 September 1989 and 31 August 1992. Controls were lens users without lens related disease who presented as new patients to the casualty department from 1 March 1992 to 31 August 1992. All subjects completed a questionnaire detailing lens use and hygiene practices. Setting-Eye hospital. Subjects-35 cases with acanthamoeba keratitis and 378 controls. Main outcome measures-Relative risks comparing different contact lens types, socioeconomic classification, age, sex, lens use, lens wearing experience, hygiene compliance, and hygiene systems. Results-The crude relative risk for developing acanthamoeba keratitis with the use of daily wear disposable lenses was 49.45 (95% confidence interval 6.53 to 2227; P < 0.001) compared with conventional soft lenses (the referent). Multivariable analysis showed that this increased risk could be largely attributed to lack of disinfection (relative risk 55.86 (10 to 302); P < 0.001) and use of chlorine based disinfection (14.63 (2.8 to 76); P = 0.001) compared with other chemical systems (the referent). None of the other outcome measures showed a significant association. Conclusions-Both failure to disinfect daily wear soft contact lenses and the use of chlorine release lens disinfection systems, which have little protective effect against the organism, are major risk factors for acanthamoeba keratitis. These risks have been particularly common in disposable lens use. Over 80% of acanthamoeba keratitis could be avoided by the use of lens. disinfection systems that are effective against the organism.	MOORFIELDS EYE HOSP,LONDON EC1V 2PD,ENGLAND; INST OPHTHALMOL,DEPT PREVENT OPHTHALMOL,LONDON EC1V 9EL,ENGLAND	University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of London; University College London			Dart, John Kenneth/GZM-7807-2022					BACON AS, 1993, EYE, V7, P719, DOI 10.1038/eye.1993.168; COSTERTON JW, 1987, ANNU REV MICROBIOL, V41, P435, DOI 10.1146/annurev.mi.41.100187.002251; DARK JK, 1991, LANCET, V338, P650; DEVONSHIRE P, 1993, BRIT J OPHTHALMOL, V77, P41, DOI 10.1136/bjo.77.1.41; DONZIS PB, 1989, AM J OPHTHALMOL, V108, P53, DOI 10.1016/S0002-9394(14)73260-X; Efron N, 1992, INT CONTACT LENS CLI, V19, P8; HELTON D O, 1991, CLAO Journal, V17, P59; KILVINGTON S, 1990, J APPL BACTERIOL, V68, P519, DOI 10.1111/j.1365-2672.1990.tb02904.x; LARKIN DFP, 1990, BRIT J OPHTHALMOL, V74, P133, DOI 10.1136/bjo.74.3.133; LOWE R, 1992, CLAO Journal, V18, P34; MATTHEWS TD, 1992, ARCH OPHTHALMOL-CHIC, V110, P1559, DOI 10.1001/archopht.1992.01080230059020; MINARIK L, 1989, CLAO Journal, V15, P185; Radford CF, 1993, J BRIT CONTACT LENS, V16, P105; Rosenthal R. A., 1992, J BRIT CONTACT LENS, V15, P81; SCHEIN OD, 1994, ARCH OPHTHALMOL-CHIC, V112, P186, DOI 10.1001/archopht.1994.01090140062024; SEAL D, 1992, BRIT J OPHTHALMOL, V76, P424, DOI 10.1136/bjo.76.7.424; Seal D. V., 1992, Pharmaceutical Journal, V248, P717; SHARMA S, 1990, ARCH OPHTHALMOL-CHIC, V108, P676, DOI 10.1001/archopht.1990.01070070062035; Stapleton Fiona, 1993, CLAO (Contact Lens Association of Ophthalmologists) Journal, V19, P204; STEHRGREEN JK, 1987, JAMA-J AM MED ASSOC, V258, P57, DOI 10.1001/jama.258.1.57; STEHRGREEN JK, 1989, AM J OPHTHALMOL, V107, P331, DOI 10.1016/0002-9394(89)90654-5; WILSON LA, 1990, AM J OPHTHALMOL, V110, P193, DOI 10.1016/S0002-9394(14)76991-0; 1982, NOTES APPLICATIONS P, P23; 1990, STANDARD OCCUPATIONA	24	104	107	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1567	1570		10.1136/bmj.310.6994.1567	http://dx.doi.org/10.1136/bmj.310.6994.1567			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787645	Green Published			2022-12-24	WOS:A1995RE35300019
J	BOLDUC, JM; DYER, DH; SCOTT, WG; SINGER, P; SWEET, RM; KOSHLAND, DE; STODDARD, BL				BOLDUC, JM; DYER, DH; SCOTT, WG; SINGER, P; SWEET, RM; KOSHLAND, DE; STODDARD, BL			MUTAGENESIS AND LAUE STRUCTURES OF ENZYME INTERMEDIATES - ISOCITRATE DEHYDROGENASE	SCIENCE			English	Article							X-RAY CRYSTALLOGRAPHY; PROTEIN CRYSTALLOGRAPHY; DIFFRACTION; TIME; MECHANISM; PHOTOGRAPHS; HYDROLYSIS; BINDING	Site-directed mutagenesis and Laue diffraction data to 2.5 Angstrom resolution were used to solve the structures of two sequential intermediates formed during the catalytic actions of isocitrate dehydrogenase. Both intermediates are distinct from the enzyme-substrate and enzyme-product complexes. Mutation of key catalytic residues changed the rate determining steps so that protein and substrate intermediates within the overall reaction pathway could be visualized.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; BROOKHAVEN NATL LABS,DEPT BIOL STRUCT,UPTON,NY 11973; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	MRC Laboratory Molecular Biology; United States Department of Energy (DOE); Brookhaven National Laboratory; University of California System; University of California Berkeley	BOLDUC, JM (corresponding author), FRED HUTCHINSON CANC RES CTR,PROGRAM STRUCT BIOL,DIV BASIC SCI,1124 COLUMBIA ST A3-023,SEATTLE,WA 98104, USA.			Scott, William/0000-0002-9273-3564	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049857] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49857] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOW DM, 1992, PHILOS T ROY SOC A, V340, P311, DOI 10.1098/rsta.1992.0069; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAMERON AD, 1993, BIOCHEMISTRY-US, V32, P13061, DOI 10.1021/bi00211a016; DEAN AM, 1992, BIOCHEMISTRY-US, V132, P9302; FULOP V, 1994, STRUCTURE, V2, P201, DOI 10.1016/S0969-2126(00)00021-6; GETZOFF ED, 1993, NUCL INSTRUM METH B, V79, P249, DOI 10.1016/0168-583X(93)95337-5; GRISSOM CB, 1988, BIOCHEMISTRY-US, V27, P2934, DOI 10.1021/bi00408a040; HAJDU J, 1987, NATURE, V329, P178, DOI 10.1038/329178a0; HELLIWELL JR, 1989, J APPL CRYSTALLOGR, V22, P483, DOI 10.1107/S0021889889006564; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; JOHNSON LN, 1992, PROTEIN SCI, V1, P1237, DOI 10.1002/pro.5560011002; LEE ME, 1995, BIOCHEMISTRY-US, V34, P378, DOI 10.1021/bi00001a046; OCHOA S, 1948, J BIOL CHEM, V174, P115; PETSKO GA, 1992, PHILOS T ROY SOC A, V340, P323, DOI 10.1098/rsta.1992.0070; PLAUT G, 1963, ENZYMES, P112; REID MF, 1994, CRIT REV MICROBIOL, V20, P13, DOI 10.3109/10408419409113545; SCHEIDIG AJ, 1994, ACTA CRYSTALLOGR D, V50, P512, DOI 10.1107/S090744499301443X; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SINGER PT, 1993, SCIENCE, V259, P669, DOI 10.1126/science.8430314; STODDARD BL, 1991, P NATL ACAD SCI USA, V88, P5503, DOI 10.1073/pnas.88.13.5503; STODDARD BL, 1992, BIOCHEMISTRY-US, V32, P9310; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; WALSH C, 1979, ENZYMATIC REACTION M, P344	24	113	117	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1312	1318		10.1126/science.7761851	http://dx.doi.org/10.1126/science.7761851			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761851	Green Submitted			2022-12-24	WOS:A1995RB19800028
J	FORMAN, BM; GOODE, E; CHEN, J; ORO, AE; BRADLEY, DJ; PERLMANN, T; NOONAN, DJ; BURKA, LT; MCMORRIS, T; LAMPH, WW; EVANS, RM; WEINBERGER, C				FORMAN, BM; GOODE, E; CHEN, J; ORO, AE; BRADLEY, DJ; PERLMANN, T; NOONAN, DJ; BURKA, LT; MCMORRIS, T; LAMPH, WW; EVANS, RM; WEINBERGER, C			IDENTIFICATION OF A NUCLEAR RECEPTOR THAT IS ACTIVATED BY FARNESOL METABOLITES	CELL			English	Article							RETINOID-X-RECEPTOR; THYROID-HORMONE; ECDYSONE RECEPTOR; RXR-BETA; ACID; MEVALONATE; PROTEIN; HETERODIMERIZATION; ULTRASPIRACLE; SUPERFAMILY	Nuclear hormone receptors comprise a superfamily of ligand-modulated transcription factors that mediate the transcriptional activities of steroids, retinoids, and thyroid hormones. A growing number of related proteins have been identified that possess the structural features of hormone receptors, but that lack known ligands, Known as orphan receptors, these proteins represent targets for novel signaling molecules. We have isolated a mammalian orphan receptor that forms a heterodimeric complex with the retinoid X receptor. A screen of candidate ligands identified farnesol and related metabolites as effective activators of this complex. Farnesol metabolites are generated intracellularly and are required for the synthesis of cholesterol, bile acids, steroids, retinoids, and farnesylated proteins. Intermediary metabolites have been recognized as transcriptional regulators in bacteria and yeast. Our results now suggest that metabolite-controlled intracellular signaling systems are utilized by higher organisms.	SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037; NIEHS,RECEPTOR BIOL GRP,RES TRIANGLE PK,NC 27709; NIEHS,REPROD & DEV TOXICOL LAB,ORGAN CHEM GRP,RES TRIANGLE PK,NC 27709; NIH,CELL BIOL LAB,BETHESDA,MD 20892; UNIV KENTUCKY,DEPT BIOCHEM,LEXINGTON,KY 40506; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093; LIGAND PHARMACEUT INC,SAN DIEGO,CA 92121	Howard Hughes Medical Institute; Salk Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; University of Kentucky; University of California System; University of California San Diego; Ligand Pharmaceuticals	FORMAN, BM (corresponding author), SALK INST BIOL STUDIES,GENE EXPRESS LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				BRADLEY DJ, 1994, P NATL ACAD SCI USA, V91, P439, DOI 10.1073/pnas.91.2.439; BROWN MS, 1980, J LIPID RES, V21, P505; EDMOND J, 1976, SCIENCE, V193, P154, DOI 10.1126/science.935865; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOMEZ R, 1993, BIOCHEM J, V289, P25, DOI 10.1042/bj2890025; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; KIM CM, 1992, J BIOL CHEM, V267, P23113; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KULKARNI YS, 1987, J ORG CHEM, V52, P1568, DOI 10.1021/jo00384a035; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEID M, 1992, CELL, V71; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MOORE D D, 1990, New Biologist, V2, P100; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OMALLEY BW, 1989, ENDOCRINOLOGY, V125, P1119, DOI 10.1210/endo-125-3-1119; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RIGHETTI M, 1976, J BIOL CHEM, V251, P2716; Rilling H. C., 1985, STEROLS BILE ACIDS, P1; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; SUTCLIFFE JG, 1984, SCIENCE, V225, P1308, DOI 10.1126/science.6474179; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; TNTONOZ P, 1994, CELL, V79, P1147; TOMKINS GM, 1975, SCIENCE, V189, P760, DOI 10.1126/science.169570; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WILEY MH, 1977, J BIOL CHEM, V252, P548; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	45	924	1043	1	49	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					687	693		10.1016/0092-8674(95)90530-8	http://dx.doi.org/10.1016/0092-8674(95)90530-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774010	Bronze			2022-12-24	WOS:A1995RB96100007
J	SPATARO, JA; VANHORN, L				SPATARO, JA; VANHORN, L			EXERCISE TO REDUCE POTBELLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							BODY-COMPOSITION				SPATARO, JA (corresponding author), NORTHWESTERN UNIV, SCH MED, CHICAGO, IL USA.							FOSTER WR, 1985, ANN INTERN MED, V103, P981; FRONTERA WR, 1988, J APPL PHYSIOL, V64, P1038, DOI 10.1152/jappl.1988.64.3.1038; MOREY MC, 1989, J AM GERIATR SOC, V37, P348, DOI 10.1111/j.1532-5415.1989.tb05503.x; NIEMAN DC, 1990, ANN SPORTS MED, V3, P2; POLLOCK ML, 1987, J APPL PHYSIOL, V62, P725, DOI 10.1152/jappl.1987.62.2.725; SIDNEY KH, 1977, AM J CLIN NUTR, V30, P326, DOI 10.1093/ajcn/30.3.326; Stamford B A, 1988, Exerc Sport Sci Rev, V16, P341	7	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	1995	273	6					503	503		10.1001/jama.273.6.503	http://dx.doi.org/10.1001/jama.273.6.503			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE498	7837371				2022-12-24	WOS:A1995QE49800037
J	STROBEL, SA; CECH, TR				STROBEL, SA; CECH, TR			MINOR-GROOVE RECOGNITION OF THE CONSERVED G-CENTER-DOT-U PAIR AT THE TETRAHYMENA RIBOZYME REACTION SITE	SCIENCE			English	Article							5' SPLICE-SITE; GROUP-I INTRON; RNA SUBSTRATE; 2'-HYDROXYL GROUPS; ACTIVE-SITE; TERTIARY INTERACTIONS; THERMOPHILA RIBOZYME; KINETIC DESCRIPTION; CHEMICAL SYNTHESIS; CATALYTIC INTRONS	The guanine uracil (G.U) base pair that helps to define the 5'-splice site of group I introns is phylogenetically highly conserved. In such a wobble base pair, G makes two hydrogen bonds with U in a geometry shifted from that of a canonical Watson-Crick pair. The contribution made by individual functional groups of the G.U pair in the context of the Tetrahymena ribozyme was examined by replacement of the G.U pair with synthetic base pairs that maintain a wobble configuration, but that systematically alter functional groups in the major and minor grooves of the duplex. The substitutions demonstrate that the exocyclic amine of G, when presented on the minor groove surface by the wobble base pair conformation, contributes substantially (2 kilocalories.mole(-1)) to binding by making a tertiary interaction with the ribozyme active site. It contributes additionally to transition state stabilization. The ribozyme active site also makes tertiary contacts with a tripod of 2'-hydroxyls on the minor groove surface of the splice site helix. This suggests that the ribozyme binds the duplex primarily in the minor groove. The alanyl aminoacyl transfer RNA (tRNA) synthetase recognizes the exocyclic amine of an invariant G.U pair and contacts a similar array of 2'-hydroxyls when binding the tRNA(Ala) acceptor stem, providing an unanticipated parallel between protein-RNA and RNA-RNA interactions,	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder								BARFOD ET, 1989, MOL CELL BIOL, V9, P3657, DOI 10.1128/MCB.9.9.3657; BEEN MD, 1994, TRENDS BIOCHEM SCI, V19, P251, DOI 10.1016/0968-0004(94)90151-1; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BEVILACQUA PC, 1993, P NATL ACAD SCI USA, V90, P8357, DOI 10.1073/pnas.90.18.8357; BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; CECH TR, 1994, NAT STRUCT BIOL, V1, P273, DOI 10.1038/nsb0594-273; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CECH TR, 1992, J BIOL CHEM, V267, P17479; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; DOUDNA JA, 1989, P NATL ACAD SCI USA, V86, P7402, DOI 10.1073/pnas.86.19.7402; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; FU DJ, 1993, BIOCHEMISTRY-US, V32, P10629, DOI 10.1021/bi00091a013; GREEN R, 1991, NUCLEIC ACIDS RES, V19, P4161, DOI 10.1093/nar/19.15.4161; GUTELL RR, 1994, MICROBIOL REV, V58, P10, DOI 10.1128/MMBR.58.1.10-26.1994; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8299, DOI 10.1021/bi00083a034; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8312, DOI 10.1021/bi00083a035; HICKEY DR, 1985, BIOCHEMISTRY-US, V24, P3987, DOI 10.1021/bi00336a028; HOLBROOK SR, 1978, J MOL BIOL, V123, P631, DOI 10.1016/0022-2836(78)90210-3; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; KNITT S, 1994, BIOCHEMISTRY-US, V33, P13864; MAJERFELD I, 1994, NAT STRUCT BIOL, V1, P287, DOI 10.1038/nsb0594-287; MCCONNELL TS, 1993, P NATL ACAD SCI USA, V90, P8362, DOI 10.1073/pnas.90.18.8362; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOHR G, 1994, NATURE, V370, P147, DOI 10.1038/370147a0; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; MURPHY FL, 1989, P NATL ACAD SCI USA, V86, P9218, DOI 10.1073/pnas.86.23.9218; MUSIERFORSYTH K, 1992, NATURE, V357, P513, DOI 10.1038/357513a0; MUSIERFORSYTH K, 1991, SCIENCE, V253, P784, DOI 10.1126/science.1876835; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P13856, DOI 10.1021/bi00250a040; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; SALVO JL, 1992, J BIOL CHEM, V267, P2845; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; STROBEL SA, 1993, BIOCHEMISTRY-US, V32, P13593, DOI 10.1021/bi00212a027; STROBEL SA, 1994, BIOCHEMISTRY-US, V33, P13824, DOI 10.1021/bi00250a037; STROBEL SM, UNPUB; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	50	154	167	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					675	679		10.1126/science.7839142	http://dx.doi.org/10.1126/science.7839142			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839142				2022-12-24	WOS:A1995QE73300037
J	EBERT, DA; HECKERLING, PS				EBERT, DA; HECKERLING, PS			COMMUNICATION WITH DEAF PATIENTS - KNOWLEDGE, BELIEFS, AND PRACTICES OF PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SERVICES	Objective.-To assess physicians' knowledge and beliefs regarding communication with deaf people and compare their knowledge and beliefs with their methods of communicating with deaf patients in their practices. Design.-Survey. Setting.-University medical center. Subjects.-Attending physicians in an internal medicine department. Interventions.-Physicians were surveyed regarding prior contacts with deaf patients and with deaf people outside the medical setting, and regarding their knowledge and beliefs concerning methods of communicating with deaf people. Physicians were asked to estimate the fraction of encounters in which they communicated with deaf patients by lipreading, writing, translation by a relative or friend, a sign language interpreter, or other methods. Results.-Writing was the method used most frequently in communicating with deaf patients. Although 63% of physicians knew that signing should be the initial method of communicating with deaf patients who sign, only 22% used sign language interpreters more frequently than other methods in their practices. Past contact with deaf people (P=.05), belief that communication by signing was the best means of communication (P=.04), and knowledge of the inefficiency of lipreading (P=.04) were predictors of the use of sign language interpreters for deaf patients. Physicians who used sign language interpreters more frequently than other methods believed that much more time and effort were involved in caring for deaf than for hearing patients compared with those who used interpreters less frequently (P=.08). Conclusion.-Although most physicians believed that use of sign language interpreters was preferable, only a minority used them in their practices. Greater recognition of the advantages of signing over other methods and greater availability of sign language interpreters should read to more effective communication between deaf patients and physicians.			EBERT, DA (corresponding author), UNIV ILLINOIS,DEPT MED,GEN INTERNAL MED SECT,M-C 787,840 S WOOD ST,CHICAGO,IL 60612, USA.							DAVENPORT SLH, 1977, J FAM PRACTICE, V4, P1065; DIPIETRO LJ, 1981, AM ANN DEAF, V126, P106, DOI 10.1353/aad.2012.1505; ENGELMAN L, 1988, BMDP STATISTICAL SOF, P941; GOLDEN P, 1978, HOSPITALS, V52, P86; HAFFNER L, 1992, WESTERN J MED, V157, P255; KLINE F, 1980, AM J PSYCHIAT, V137, P1530; LASS LG, 1978, AM ANN DEAF, V123, P960; MCENTEE MK, 1993, AM ANN DEAF, V138, P26, DOI 10.1353/aad.2012.0569; MCEWEN E, 1988, J FAM PRACTICE, V26, P289; MINDEL ED, 1971, THEY GROW SILENCE, P96; REISMAN G, 1977, JAMA-J AM MED ASSOC, V237, P2397; SCHEIN JD, 1980, DEAF AM, V32, P5; VERNON M, 1970, REHABIL LIT, V31, P258; WARNER HC, 1986, AM ANN DEAF, V131, P365, DOI 10.1353/aad.2012.1033	14	76	76	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					227	229						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QB234	7807662				2022-12-24	WOS:A1995QB23400027
J	COPI, CJ; SCHRAMM, DN; TURNER, MS				COPI, CJ; SCHRAMM, DN; TURNER, MS			BIG-BANG NUCLEOSYNTHESIS AND THE BARYON DENSITY OF THE UNIVERSE	SCIENCE			English	Article							METAL-DEFICIENT DWARFS; PRIMORDIAL NUCLEOSYNTHESIS; DARK-MATTER; GALACTIC HALO; IRAS GALAXIES; STARS; ABUNDANCES; BERYLLIUM; LITHIUM; ORIGIN	For almost 30 years, the predictions of big-bang nucleosynthesis have been used to test the big-bang model to within a fraction of a second of the bang. The agreement between the predicted and observed abundances of deuterium, helium-3, helium-4, and lithium-7 confirms the standard cosmology model and allows accurate determination of the baryon density, between 1.7 x 10(-31) and 4.1 x 10(-31) grams per cubic centimeter (corresponding to about 1 to 15 percent of the critical density). This measurement of the density of ordinary matter is pivotal to the establishment of two dark-matter problems: (i) most of the baryons are dark, and (ii) if the total mass density is greater than about 15 percent of the critical density, as many determinations indicate, the bulk of the dark matter must be ''nonbaryonic,'' composed of elementary particles left from the earliest moments.	FERMILAB NATL ACCELERATOR LAB, NASA, FERMILAB ASTROPHYS CTR, BATAVIA, IL 60510 USA; UNIV CHICAGO, ENRICO FERMI INST, DEPT ASTRON & ASTROPHYS, CHICAGO, IL 60637 USA	National Aeronautics & Space Administration (NASA); United States Department of Energy (DOE); University of Chicago; Fermi National Accelerator Laboratory; University of Chicago	COPI, CJ (corresponding author), UNIV CHICAGO, DEPT PHYS, CHICAGO, IL 60637 USA.							ALCOCK C, 1993, NATURE, V365, P621, DOI 10.1038/365621a0; ALPHER RA, 1949, PHYS REV, V75, P1089, DOI 10.1103/PhysRev.75.1089; ALPHER RA, 1948, PHYS REV, V73, P803, DOI 10.1103/PhysRev.73.803; APPLEGATE JH, 1988, ASTROPHYS J, V329, P572, DOI 10.1086/166404; AUBOURG E, 1993, NATURE, V365, P623, DOI 10.1038/365623a0; BALSER DS, 1994, 1994 P ESO M LIGHT E; BLACK DC, 1972, GEOCHIM COSMOCHIM AC, V36, P347, DOI 10.1016/0016-7037(72)90028-2; BOYD RN, 1989, ASTROPHYS J, V336, pL55, DOI 10.1086/185360; BRUNE CR, 1994, PHYS REV C, V50, P2205, DOI 10.1103/PhysRevC.50.2205; CARSWELL RF, 1994, MON NOT R ASTRON SOC, V268, pL1, DOI 10.1093/mnras/268.1.L1; CARSWELL RF, COMMUNICATION; CHARBONNEL C, 1992, ASTRON ASTROPHYS, V265, P55; DAVIDSON K, 1985, ASTROPHYS J SUPPL S, V58, P321, DOI 10.1086/191044; DEARBORN DSP, 1986, ASTROPHYS J, V302, P35, DOI 10.1086/163969; DEKEL A, 1994, ANNU REV ASTRON ASTR, V32, P371; DODELSON S, 1994, PHYS REV D, V49, P5068, DOI 10.1103/PhysRevD.49.5068; DUNCAN DK, 1992, ASTROPHYS J, V401, P584, DOI 10.1086/172088; EDVARDSSON B, 1989, GEOCHIM COSMOCHIM AC, V53, P197; EPSTEIN RI, 1976, NATURE, V263, P198, DOI 10.1038/263198a0; FABER SM, 1979, ANNU REV ASTRON ASTR, V17, P135, DOI 10.1146/annurev.aa.17.090179.001031; FOWLER WA, 1962, GEOPHYS J ROY ASTR S, V6, P148, DOI 10.1111/j.1365-246X.1962.tb02977.x; GAMOW G, 1946, PHYS REV, V70, P527; GEISS J, 1972, ASTRON ASTROPHYS, V18, P126; Geiss J., 1993, ORIGIN EVOLUTION ELE, V89; GILMORE G, 1992, NATURE, V357, P379, DOI 10.1038/357379a0; GILMORE G, 1991, ASTROPHYS J, V378, P17, DOI 10.1086/170402; HOBBS LM, 1994, ASTROPHYS J, V428, pL25, DOI 10.1086/187384; HOBBS LM, 1988, ASTROPHYS J, V326, pL23, DOI 10.1086/185115; HOYLE F, 1964, NATURE, V203, P1108, DOI 10.1038/2031108a0; IBEN I, 1978, ASTROPHYS J, V220, P980, DOI 10.1086/155986; JAKOBSEN P, 1994, NATURE, V370, P35, DOI 10.1038/370035a0; JEDAMZIK K, 1994, ASTROPHYS J, V422, P423, DOI 10.1086/173738; KAISER N, 1991, MON NOT R ASTRON SOC, V252, P1; KAWASAKI M, 1994, NUCL PHYS B, V419, P105, DOI 10.1016/0550-3213(94)90359-X; KERNAN PJ, 1994, PHYS REV LETT, V72, P3309, DOI 10.1103/PhysRevLett.72.3309; Kurki-Suonio H., 1990, Astrophysical Journal, V353, P406, DOI 10.1086/168626; LIDDLE AR, 1993, PHYS REP, V231, P1, DOI 10.1016/0370-1573(93)90114-S; LINSKY JL, 1993, ASTROPHYS J, V402, P694, DOI 10.1086/172170; MALANEY RA, 1993, PHYS REP, V229, P147; MAMPE W, 1993, JETP LETT+, V57, P82; MATHER JC, 1994, ASTROPHYS J, V420, P439, DOI 10.1086/173574; MONTANET L, 1994, PHYS REV D, V50, P1680; OLIVE KA, IN PRESS ASTROPHYS S; OSTRIKER JP, 1993, ANNU REV ASTRON ASTR, V31, P689; PAGEL BEJ, 1992, MON NOT R ASTRON SOC, V255, P325, DOI 10.1093/mnras/255.2.325; PEEBLES PJE, 1966, ASTROPHYS J, V146, P542, DOI 10.1086/148918; PINSONNEAULT MH, 1992, ASTROPHYS J SUPPL S, V78, P179, DOI 10.1086/191624; PISONNEAULT MH, 1992, ASTROPHYS J SUPL SER, V78, P179; REBOLO R, 1988, ASTRON ASTROPHYS, V193, P193; REBOLO R, 1988, ASTRON ASTROPHYS, V192, P192; REEVES H, 1970, NATURE, V226, P727, DOI 10.1038/226727a0; REEVES H, 1973, ASTROPHYS J, V179, P909, DOI 10.1086/151928; REIMERS D, 1993, ASTRON ASTROPHYS, V276, pL13; ROGERSON JB, 1973, ASTROPHYS J, V186, pL95, DOI 10.1086/181366; RYAN SG, 1990, ASTROPHYS J, V348, pL57, DOI 10.1086/185630; RYAN SG, 1992, ASTROPHYS J, V388, P184, DOI 10.1086/171141; SASSELOV D, IN PRESS ASTROPHYS J; SATO K, 1991, PHYS SCR TOP ISSUES, V136, P60; SKILLMAN ED, 1993, ASTROPHYS J, V411, P655, DOI 10.1086/172868; SKILLMAN ED, 1993, ANN NY ACAD SCI, V688, P739, DOI 10.1111/j.1749-6632.1993.tb43965.x; SKILLMAN ED, IN PRESS ASTROPHYS J; SKILLMAN ED, IN PRESS; SMITH MS, 1993, ASTROPHYS J SUPPL S, V85, P219, DOI 10.1086/191763; SMITH PF, 1990, PHYS REP, V187, P203, DOI 10.1016/0370-1573(90)90081-C; SMITH VV, 1993, ASTROPHYS J, V408, P262, DOI 10.1086/172585; SONGAILA A, 1994, NATURE, V368, P599, DOI 10.1038/368599a0; SPITE F, 1982, ASTRON ASTROPHYS, V115, P357; SPITE M, 1984, ASTRON ASTROPHYS, V141, P56; STEIGMAN G, 1994, MON NOT R ASTRON SOC, V269, pL53, DOI 10.1093/mnras/269.1.L53; STEIGMAN G, 1993, ASTROPHYS J, V415, pL35, DOI 10.1086/187026; STEIGMAN G, 1977, PHYS LETT B, V66, P202, DOI 10.1016/0370-2693(77)90176-9; STRAUSS MA, 1992, ASTROPHYS J, V397, P395, DOI 10.1086/171796; THOMAS D, 1993, ASTROPHYS J, V406, P569, DOI 10.1086/172469; THORBURN JA, 1994, ASTROPHYS J, V421, P318, DOI 10.1086/173650; TURNER MS, 1993, P NATL ACAD SCI USA, V90, P4827, DOI 10.1073/pnas.90.11.4827; TYTLER D, COMMUNICATION; UDALSKI A, 1993, ACTA ASTRONOM, V43, P289; VANGIONIFLAM E, 1994, ASTROPHYS J, V427, P618, DOI 10.1086/174171; WAGONER RV, 1967, ASTROPHYS J, V148, P3, DOI 10.1086/149126; WALKER TP, 1991, ASTROPHYS J, V376, P51, DOI 10.1086/170255; WHITE SDM, 1993, NATURE, V366, P429, DOI 10.1038/366429a0; WILSON TL, 1983, P ESO WORKSHOP PRIMO, P379; WITTEN E, 1984, PHYS REV D, V30, P272, DOI 10.1103/PhysRevD.30.272; YANG J, 1984, ASTROPHYS J, V281, P493, DOI 10.1086/162123	84	347	349	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 13	1995	267	5195					192	199		10.1126/science.7809624	http://dx.doi.org/10.1126/science.7809624			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809624				2022-12-24	WOS:A1995QB15300023
J	MURGUIA, JR; BELLES, JM; SERRANO, R				MURGUIA, JR; BELLES, JM; SERRANO, R			A SALT-SENSITIVE 3'(2'),5'-BISPHOSPHATE NUCLEOTIDASE INVOLVED IN SULFATE ACTIVATION	SCIENCE			English	Article							FUNCTIONAL EXPRESSION; TRANSGENIC TOBACCO; TOLERANCE; LITHIUM; ION; INHIBITION; PROTEINS; GENETICS; YEAST; CROPS	Overexpression of a yeast gene, HAL2, allows the cells to tolerate higher than normal extracellular salt concentrations. HAL2 encodes a 3'(2')5'-bisphosphate nucleotidase that serves to remove the end products of sulfate transfer during cellular metabolism. The enzyme is inhibited by lithium and sodium and is activated by potassium. Metabolic systems that are sensitive to salt, as well as those governing osmolyte synthesis and ion transport, offer routes by which genetic engineering can be used to improve the tolerance of various organisms to salt.	UNIV POLITECN VALENCIA, CSIC, Inst Biol Mol & Celular Plantas, Camino Vera, E-46022 VALENCIA, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP)	SERRANO, R (corresponding author), UNIV POLITECN VALENCIA, CSIC, Inst Biol Mol & Celular Plantas, Camino Vera, E-46022 VALENCIA, SPAIN.		Bellés, José María/H-4734-2015; Murguia, Jose R./H-4419-2015	Bellés, José María/0000-0003-0362-9616; Murguia, Jose R./0000-0001-9364-4603				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BONE R, 1992, P NATL ACAD SCI USA, V89, P10031, DOI 10.1073/pnas.89.21.10031; BRUNNGRABER EG, 1958, J BIOL CHEM, V233, P472; DOWNTON WJS, 1984, CRC CR REV PLANT SCI, V1, P183, DOI 10.1080/07352688409382177; EPSTEIN E, 1980, SCIENCE, V210, P399, DOI 10.1126/science.210.4468.399; GAXIOLA R, 1992, EMBO J, V11, P3157, DOI 10.1002/j.1460-2075.1992.tb05392.x; GLASER HU, 1993, EMBO J, V12, P3105, DOI 10.1002/j.1460-2075.1993.tb05979.x; GREENWAY H, 1980, ANNU REV PLANT PHYS, V31, P149, DOI 10.1146/annurev.pp.31.060180.001053; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; HEDRICH R, 1989, ANNU REV PLANT PHYS, V40, P539, DOI 10.1146/annurev.pp.40.060189.002543; INHORN RC, 1987, J BIOL CHEM, V262, P15946; JONES RGW, 1986, OUTLOOK AGR, V15, P33; JONES RGW, 1983, ENCY PLANT PHYSL, V15, pCH4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; LI F, 1989, J CHROMATOGR, V461, P353, DOI 10.1016/S0021-9673(00)94302-4; MCCUE KF, 1990, TRENDS BIOTECHNOL, V8, P358, DOI 10.1016/0167-7799(90)90225-M; METZLER DE, 1977, BIOCHEMISTRY-US, P636; NAHORSKI SR, 1991, TRENDS PHARMACOL SCI, V12, P297, DOI 10.1016/0165-6147(91)90581-C; NEUWALD AF, 1991, FEBS LETT, V294, P16, DOI 10.1016/0014-5793(91)81332-3; RAMASWAMY SG, 1987, J BIOL CHEM, V262, P10044; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SERRANO R, 1994, CRIT REV PLANT SCI, V13, P121, DOI 10.1080/713608057; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; STAPLES RC, 1984, SALINITY TOLERANCE C; TAL M, 1985, PLANT SOIL, V89, P199, DOI 10.1007/BF02182243; TARCZYNSKI MC, 1992, P NATL ACAD SCI USA, V89, P2600, DOI 10.1073/pnas.89.7.2600; TARCZYNSKI MC, 1993, SCIENCE, V259, P508, DOI 10.1126/science.259.5094.508; THOMAS D, 1992, J GEN MICROBIOL, V138, P2021, DOI 10.1099/00221287-138-10-2021; TSANG MLS, 1976, EUR J BIOCHEM, V65, P113; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; 1992, ENZYME NOMENCLATURE, P318	34	167	178	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 13	1995	267	5195					232	234						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809627				2022-12-24	WOS:A1995QB15300033
J	LOMBILLO, VA; STEWART, RJ; MCINTOSH, JR				LOMBILLO, VA; STEWART, RJ; MCINTOSH, JR			MINUS-END-DIRECTED MOTION OF KINESIN-COATED MICROSPHERES DRIVEN BY MICROTUBULE DEPOLYMERIZATION	NATURE			English	Article							CYTOPLASMIC DYNEIN; MITOTIC SPINDLE; MOVEMENT; IDENTIFICATION; MICROSCOPY; INVITRO; PROTEIN	DYNAMIC changes in microtubule (MT) length have long been thought to contribute to intracellular motility(1). Both the polymerization(2) and depolymerization(3-5) of tubulin have been shown to do work in vitro, but the biochemical complexity of objects moved, such as chromosomes, has complicated the identification of proteins that couple MT dynamics with motility. Work with MTs grown from and tethered to pellicles of lysed Tetrahymena has shown that disassembly-dependent movement of chromosomes in vitro can be inhibited with antibodies against the motor domain of kinesin(6). To study proteins that can function in disassembly-dependent motion, we have refined this motility assay, replacing chromosomes with protein-coated latex microspheres. We report here the ability of several enzymes, including kinesin, to support in vitro motility of latex microspheres on disassembling Mts (Fig. 1a). The polarity of kinesin's motor activity can be reversed by MT disassembly and interactions between a motor and a MT end can either slow or speed the rate of tubulin depolymerization.	UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309; ROWLAND INST SCI INC,CAMBRIDGE,MA 02142	University of Colorado System; University of Colorado Boulder			McIntosh, Richard/GLN-3533-2022					COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; DAVIS A, 1994, SCIENCE, V264, P839, DOI 10.1126/science.8171338; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; INOUE S, 1981, J CELL BIOL, V91, pS131, DOI 10.1083/jcb.91.3.131s; KOONCE MP, 1990, CELL MOTIL CYTOSKEL, V15, P51, DOI 10.1002/cm.970150108; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; LOMBILLO VA, IN PRESS J CELL BIOL; LOMBILLO VA, 1993, METHOD CELL BIOL, V39, P148; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MIYAMOTO H, 1988, P TANAGUICHI INT S, V14, P220; PORTER ME, 1988, J BIOL CHEM, V263, P6759; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1989, CELL, V59, P915, DOI 10.1016/0092-8674(89)90614-4; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437	16	164	166	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					161	164		10.1038/373161a0	http://dx.doi.org/10.1038/373161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816099				2022-12-24	WOS:A1995QB06300062
J	SCHEFFNER, M; NUBER, U; HUIBREGTSE, JM				SCHEFFNER, M; NUBER, U; HUIBREGTSE, JM			PROTEIN UBIQUITINATION INVOLVING AN E1-E2-E3 ENZYME UBIQUITIN THIOESTER CASCADE	NATURE			English	Article							N-END RULE; ACTIVATING ENZYME; CONJUGATING ENZYME; E6 ONCOPROTEIN; P53; E6-AP; DEGRADATION; BINDING; LIGASE; YEAST	UBIQUITINATION Of proteins involves the concerted action of the El ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzymes and E3 ubiquitin-protein ligases(1-3). It has been proposed that E3s function as 'docking proteins', specifically binding substrate proteins and specific E2s, and that ubiquitin is then transferred directly from E2s to substrates(1-5). We show here that formation of a ubiquitin thioester on E6-AP, an E3 involved in the human papillomavirus EB-induced ubiquitination of p53 (refs 6-10), is an intermediate step in E6-AP-dependent ubiquitination. The order of ubiquitin transfer is from E1 to E2, from E2 to E6-AP, and finally from E6-AP to a substrate. This cascade of ubiquitin thioester complexes suggests that E3s have a defined enzymatic activity and do not function simply as docking proteins. The cysteine residue of E6-AP responsible for ubiquitin thioester formation was mapped to a region that is highly conserved among several proteins of unknown function, suggesting that these proteins share the ability to form thioesters with ubiquitin.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	SCHEFFNER, M (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM,NEUENHEIMER FELD 242,D-69120 HEIDELBERG,GERMANY.		Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128				BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BERLETH ES, 1992, J BIOL CHEM, V267, P16403; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; GIROD PA, 1993, PLANT J, V3, P545, DOI 10.1046/j.1365-313X.1993.03040545.x; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HATFIELD PM, 1992, J BIOL CHEM, V267, P14799; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V13, P4129; JENTSCH S, 1992, ANNU REV GENET, V26, P177; MULLER D, 1992, NUCLEIC ACIDS RES, V20, P1471, DOI 10.1093/nar/20.7.1471; PASCOLO S, 1992, YEAST, V8, P987, DOI 10.1002/yea.320081109; PICKART CM, 1985, J BIOL CHEM, V260, P1573; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SUNG P, 1991, J MOL BIOL, V221, P745, DOI 10.1016/0022-2836(91)80169-U; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WATKINS JF, 1993, GENE DEV, V7, P250, DOI 10.1101/gad.7.2.250	22	714	748	4	85	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					81	83		10.1038/373081a0	http://dx.doi.org/10.1038/373081a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800044	Green Submitted			2022-12-24	WOS:A1995QA23900061
J	COMAI, L; ZOMERDIJK, JCBM; BECKMANN, H; ZHOU, S; ADMON, A; TJIAN, R				COMAI, L; ZOMERDIJK, JCBM; BECKMANN, H; ZHOU, S; ADMON, A; TJIAN, R			RECONSTITUTION OF TRANSCRIPTION FACTOR SL1 - EXCLUSIVE BINDING OF TBP BY SL1 OR TFIID SUBUNITS	SCIENCE			English	Article							RNA POLYMERASE-I; RIBOSOMAL-RNA; DNA-BINDING; MOLECULAR-CLONING; III PROMOTERS; TATA-LESS; PROTEIN; EXPRESSION; SPECIFICITY; COMPLEX	RNA polymerase I and II transcription factors SL1 and TFIID, respectively, are composed of the TATA-binding protein (TBP) and a set of TBP-associated factors (TAFs) responsible for promoter recognition. How the universal transcription factor TBP becomes committed to a TFIID or SL1 complex has not been known. Complementary DNAs encoding each of the three TAF(I)s that are integral components of SL1 have now been isolated. Analysis of subunit interactions indicated that the three TAF(I)s can bind individually and specifically to TBP. In addition, these TAF(I)s interact with each other to form a stable TBP-TAF complex. When TBP was bound first by either TAF(I)110, 63, or 48, subunits of TFIID such as TAF(II)250 and 150 did not bind TBP. Conversely, if TBP first formed a complex with TAF(II)250 or 150, the subunits of SL1 did not bind TBP. These results suggest that a mutually exclusive binding specificity for TBP intrinsic to SL1 and TFIID subunits directs the formation of promoter- and RNA polymerase-selective TBP-TAF complexes.	UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley			Comai, Lucio/L-5905-2019; Comai, Lucio/H-9524-2019; Zomerdijk, Joost/A-5142-2008	Comai, Lucio/0000-0003-3109-1841; Admon, Arie/0000-0003-0504-3950; Zomerdijk, Joost/0000-0003-1865-729X				BECKMANN H, UNPUB; BELL SG, UNPUB; BELL SP, 1989, CELL, V59, P489, DOI 10.1016/0092-8674(89)90032-9; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; COMAI L, UNPUB; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EBERHARD D, 1993, NUCLEIC ACIDS RES, V21, P4180, DOI 10.1093/nar/21.18.4180; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JANZEN HM, 1992, GENE DEV, V6, P1950; KEYS DA, 1994, GENE DEV, V8, P2349, DOI 10.1101/gad.8.19.2349; KIM K, 1994, J BIOL CHEM, V269, P4891; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; KOKUBO T, 1993, P NATL ACAD SCI USA, V90, P5896, DOI 10.1073/pnas.90.13.5896; KOKUBO T, 1993, MOL CELL BIOL, V13, P7859, DOI 10.1128/MCB.13.12.7859; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REEDER RH, 1992, REGULATION TRANSCRIP, V1, P315; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUDLOFF U, 1994, EMBO J, V13, P2611, DOI 10.1002/j.1460-2075.1994.tb06551.x; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TANESE N, 1992, GENES DEV, V5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	45	128	134	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 23	1994	266	5193					1966	1972		10.1126/science.7801123	http://dx.doi.org/10.1126/science.7801123			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801123				2022-12-24	WOS:A1994PZ26700023
J	ZERR, I; BODEMER, M; RACKER, S; GROSCHE, S; POSER, S; KRETZSCHMAR, HA; WEBER, T				ZERR, I; BODEMER, M; RACKER, S; GROSCHE, S; POSER, S; KRETZSCHMAR, HA; WEBER, T			CEREBROSPINAL-FLUID CONCENTRATION OF NEURON-SPECIFIC ENOLASE IN DIAGNOSIS OF CREUTZFELDT-JAKOB-DISEASE	LANCET			English	Note								Neuron-specific enolase (NSE) is among the biochemical markers in cerebrospinal fluid reported to be useful in the differential diagnosis of Creutzfeldt-Jakob disease from other dementing illnesses. In a group of 58 patients definite and Creutzfeldt-Jakob disease, with probable NSE concentrations (median 94 . 0, interquartile range 256 ng/mL) were significantly higher (p<0 . 001) than in 26 control patients (9 . 5, 15 . 5 ng/mL). At a cut-off of 35 ng/mL an optimum sensitivity of 80% with a specificity of 92% for the diagnosis of Creutzfeldt-Jakob disease by NSE in cerebrospinal fluid was obtained.	UNIV GOTTINGEN,NEUROL KLIN & POLIKLIN,D-37075 GOTTINGEN,GERMANY; UNIV GOTTINGEN,INST NEUROPATHOL,D-37075 GOTTINGEN,GERMANY	University of Gottingen; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Gottingen				Weber, Thomas/0000-0002-3833-6197				BROWN P, 1994, ANN NEUROL, V35, P13; JACOBI C, 1988, CLIN CHIM ACTA, V177, P49, DOI 10.1016/0009-8981(88)90306-3; JIMI T, 1992, CLIN CHIM ACTA, V11, P37; Kretzschmar H A, 1993, Arch Virol Suppl, V7, P261; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MOKUNO K, 1983, J NEUROL SCI, V60, P443, DOI 10.1016/0022-510X(83)90155-7; TATEISHI J, 1993, BRIT MED BULL, V49, P971, DOI 10.1093/oxfordjournals.bmb.a072656; TIETJEN GE, 1990, ANN NEUROL, V28, P585, DOI 10.1002/ana.410280420; VERMUYTEN K, 1990, CLIN CHIM ACTA, V187, P69, DOI 10.1016/0009-8981(90)90332-M; WAKAYAMA Y, 1987, KLIN WOCHENSCHR, V65, P798, DOI 10.1007/BF01743256	10	150	153	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1609	1610		10.1016/S0140-6736(95)90118-3	http://dx.doi.org/10.1016/S0140-6736(95)90118-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783539				2022-12-24	WOS:A1995RE67000011
J	KUIPERS, EJ; UYTERLINDE, AM; PENA, AS; ROOSENDAAL, R; PALS, G; NELIS, GF; FESTEN, HPM; MEUWISSEN, SGM				KUIPERS, EJ; UYTERLINDE, AM; PENA, AS; ROOSENDAAL, R; PALS, G; NELIS, GF; FESTEN, HPM; MEUWISSEN, SGM			LONG-TERM SEQUELAE OF HELICOBACTER-PYLORI GASTRITIS	LANCET			English	Article							FOLLOW-UP; CANCER-EPIDEMIOLOGY; INFECTION; CARCINOMA; RISK; CAMPYLOBACTER; POPULATION; ATROPHY; AGE	Chronic Helicobacter pylori gastritis has been put forward as a risk factor for development of gastric mucosal atrophy and gastric cancer. The purpose of our study was to investigate the long-term effects of H pylori gastritis on the gastric mucosa. We prospectively studied 49 subjects negative for H pylori and 58 positive subjects for a mean follow-up of 11.5 years (range 10-13 years). Serum samples were obtained at the initial and follow-up visits for determination of H pylori IgG antibodies. Gastroscopies with biopsy sampling were done in all patients at both visits. Biopsy specimens were used for assessment of H pylori infection and histology. Development of atrophic gastritis and intestinal metaplasia occurred in 2 (4%) uninfected and 16 (28%) infected subjects. Regression of atrophy was noted in 4 (7%) infected subjects. Development of atrophic gastritis and intestinal metaplasia was significantly associated with H pylori infection (p=0.0014; odds ratio 9.0, 95% Cl 1.9-41.3). The proportion of atrophic gastritis in the Study population showed an annual increase of 1.15% (0.5-1.8%). We conclude that H pylori infection is a significant risk factor for development of atrophic gastritis and intestinal metaplasia. Our findings support strongly the causative role of this infection in gastric carcinogenesis.	FREE UNIV AMSTERDAM HOSP,DEPT PATHOL,1007 MB AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT CLIN MICROBIOL,1007 MB AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT HUMAN GENET,1007 MB AMSTERDAM,NETHERLANDS; SOPHIA HOSP,DEPT GASTROENTEROL,ZWOLLE,NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	KUIPERS, EJ (corresponding author), FREE UNIV AMSTERDAM HOSP,DEPT GASTROENTEROL,POB 7057,1007 MB AMSTERDAM,NETHERLANDS.		Kuipers, Ernst J/H-3293-2019; Pals, Gerard/A-5198-2011; Beales, Ian/M-5161-2014	Kuipers, Ernst J/0000-0002-0633-3098; Beales, Ian/0000-0003-1923-3237; Pals, Gerard/0000-0003-4091-7115				[Anonymous], 1994, IARC MONOGR EVAL CAR, V61, P1; BANATVALA N, 1993, J INFECT DIS, V168, P219, DOI 10.1093/infdis/168.1.219; CORREA P, 1975, LANCET, V2, P58; CORREA P, 1990, CANCER RES, V50, P4737; CORREA P, 1992, CANCER RES, V52, P6735; DIXON MF, 1991, J GASTROEN HEPATOL, V6, P125, DOI 10.1111/j.1440-1746.1991.tb01451.x; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; FORMAN D, 1994, LANCET, V343, P243, DOI 10.1016/S0140-6736(94)91034-0; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; GENTA RM, 1993, MODERN PATHOL, V6, P288; IHAMAKI T, 1985, SCAND J GASTROENTERO, V20, P485, DOI 10.3109/00365528509089685; KATELARIS PH, 1993, GUT, V34, P1032, DOI 10.1136/gut.34.8.1032; KUIPERS EJ, 1993, LANCET, V342, P328, DOI 10.1016/0140-6736(93)91473-Y; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MORRIS A, 1987, AM J GASTROENTEROL, V82, P192; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PRICE AB, 1991, J GASTROEN HEPATOL, V6, P209, DOI 10.1111/j.1440-1746.1991.tb01468.x; RAUWS EA, 1988, GASTROENTEROLOGY, V94, P33, DOI 10.1016/0016-5085(88)90606-3; SIPPONEN P, 1984, BRIT J CANCER, V49, P521, DOI 10.1038/bjc.1984.80; SOBALA GM, 1991, GUT, V32, P1415, DOI 10.1136/gut.32.11.1415; VILLAKO K, 1991, SCAND J GASTROENTERO, V26, P135, DOI 10.3109/00365529109104000; WARREN JR, 1983, LANCET, V1, P1273	23	665	685	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1525	1528		10.1016/S0140-6736(95)91084-0	http://dx.doi.org/10.1016/S0140-6736(95)91084-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791437				2022-12-24	WOS:A1995RD79000006
J	REBAY, I; RUBIN, GM				REBAY, I; RUBIN, GM			YAN FUNCTIONS AS A GENERAL INHIBITOR OF DIFFERENTIATION AND IS NEGATIVELY REGULATED BY ACTIVATION OF THE RAS1/MAPK PATHWAY	CELL			English	Article							PROTEIN-KINASE; NUCLEAR-LOCALIZATION; SEVENLESS PROTEIN; DROSOPHILA; NOTCH; EXPRESSION; SEQUENCE; RECEPTOR; DOMAIN; EYE	Drosophila yan has been postulated to act as an antagonist of the proneural signal mediated by the sevenless/Ras1/MAPK pathway. We have mutagenized the eight MAPK phosphorylation consensus sites of yan and examined the effects of overexpressing the mutant protein in transgenic flies and transfected S2 cultured cells. Our results suggest that phosphorylation by MAPK affects the stability and subcellular localization of yan, resulting in rapid down-regulation of yan activity. Furthermore, MAPK-mediated down-regulation of yan function appears to be critical for the proper differentiation of both neuronal and nonneuronal tissues throughout development, suggesting that yan is an essential component of a general timing mechanism controlling the competence of a cell to respond to inductive signals.			REBAY, I (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.			Rubin, Gerald/0000-0001-8762-8703				BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; GLAZER L, 1991, GENE DEV, V5, P697, DOI 10.1101/gad.5.4.697; HAY BA, 1994, DEVELOPMENT, V120, P2121; JANCKNECHT R, 1993, EMBO J, V12, P5097; KLAMBT C, 1993, DEVELOPMENT, V117, P163; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; WHITESIDE ST, 1993, J CELL SCI, V104, P949; WOLFF T, 1991, DEVELOPMENT, V113, P825; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	29	285	285	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					857	866		10.1016/0092-8674(95)90006-3	http://dx.doi.org/10.1016/0092-8674(95)90006-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781063	Bronze			2022-12-24	WOS:A1995RD76800007
J	MCDANIEL, R; EBERTKHOSLA, S; HOPWOOD, DA; KHOSLA, C				MCDANIEL, R; EBERTKHOSLA, S; HOPWOOD, DA; KHOSLA, C			RATIONAL DESIGN OF AROMATIC POLYKETIDE NATURAL-PRODUCTS BY RECOMBINANT ASSEMBLY OF ENZYMATIC SUBUNITS	NATURE			English	Article							STREPTOMYCES-COELICOLOR A3(2); NUCLEOTIDE-SEQUENCE; ENGINEERED BIOSYNTHESIS; HYBRID ANTIBIOTICS; DEDUCED FUNCTION; SYNTHASE GENE; ACTINORHODIN; GLAUCESCENS; CLUSTER	Recent advances in understanding of bacterial aromatic polyketide biosynthesis allow the development of a set of design rules for the rational manipulation of chain synthesis, reduction of keto groups and early cyclization steps by genetic engineering. The concept of rational design is illustrated by the preparation of Streptomyces strains that produce two new polyketides by expression of combinations of appropriate enzymatic subunits from naturally occurring polyketide synthases. The potential for generating molecular diversity within this class of molecules by genetic engineering is enormous.	STANFORD UNIV,DEPT CHEM ENGN,STANFORD,CA 94305; JOHN INNES CTR,DEPT GENET,NORWICH NR4 7UH,NORFOLK,ENGLAND	Stanford University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center				Khosla, Chaitan/0000-0001-6529-495X				AOYAMA T, 1992, J ANTIBIOT, V45, P1767, DOI 10.7164/antibiotics.45.1767; BECK J, 1990, EUR J BIOCHEM, V192, P487, DOI 10.1111/j.1432-1033.1990.tb19252.x; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BIBB MJ, 1994, GENE, V142, P31, DOI 10.1016/0378-1119(94)90351-4; CARTER GT, 1989, J ORG CHEM, V54, P4321, DOI 10.1021/jo00279a018; DAVIS NK, 1990, MOL MICROBIOL, V4, P1679, DOI 10.1111/j.1365-2958.1990.tb00545.x; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DONADIO S, 1992, GENE, V115, P97, DOI 10.1016/0378-1119(92)90546-2; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; Fu H, 1994, Chem Biol, V1, P205, DOI 10.1016/1074-5521(94)90012-4; FU H, 1994, J AM CHEM SOC, V116, P4166, DOI 10.1021/ja00089a003; FU H, 1994, BIOCHEMISTRY-US, V33, P9321, DOI 10.1021/bi00197a036; FU H, 1994, J AM CHEM SOC, V116, P6443, DOI 10.1021/ja00093a058; GRIFFIN DA, 1984, J CHEM SOC PERK T 1, P1035, DOI 10.1039/p19840001035; HALLAM SE, 1988, GENE, V74, P305, DOI 10.1016/0378-1119(88)90165-5; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; KAO CM, 1994, J AM CHEM SOC, V116, P11612, DOI 10.1021/ja00104a069; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; KHOSLA C, 1993, J BACTERIOL, V175, P2197, DOI 10.1128/JB.175.8.2197-2204.1993; MALPARTIDA F, 1987, NATURE, V325, P818, DOI 10.1038/325818a0; MCDANIEL R, 1994, P NATL ACAD SCI USA, V91, P11542, DOI 10.1073/pnas.91.24.11542; MCDANIEL R, 1993, J AM CHEM SOC, V115, P11671, DOI 10.1021/ja00078a002; MCDANIEL R, 1994, J AM CHEM SOC, V116, P10855, DOI 10.1021/ja00103a001; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL R, IN PRESS J AM CHEM S; OHagan D., 1991, POLYKETIDE METABOLIT; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; SUMMERS RG, 1992, J BACTERIOL, V174, P1810, DOI 10.1128/jb.174.6.1810-1820.1992; TOKIWA Y, 1992, J AM CHEM SOC, V114, P4107, DOI 10.1021/ja00037a011; YU TW, 1994, J BACTERIOL, V176, P2627, DOI 10.1128/JB.176.9.2627-2634.1994; ZHANG HL, 1990, J ORG CHEM, V55, P1682, DOI 10.1021/jo00292a053	32	238	249	1	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					549	554		10.1038/375549a0	http://dx.doi.org/10.1038/375549a0			6	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791871				2022-12-24	WOS:A1995RD28700041
J	MOLLER, H; MELLEMKJAER, L; MCLAUGHLIN, JK; OLSEN, JH				MOLLER, H; MELLEMKJAER, L; MCLAUGHLIN, JK; OLSEN, JH			OCCURRENCE OF DIFFERENT CANCERS IN PATIENTS WITH PARKINSONS-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							MELANOMA		DANISH CANC SOC,DIV CANC EPIDEMIOL,COPENHAGEN,DENMARK; NCI,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892	Danish Cancer Society; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	MOLLER, H (corresponding author), INT AGCY RES CANC,F-69372 LYON,FRANCE.			Olsen, Jorgen Helge/0000-0001-9633-5662; Moller, Henrik/0000-0001-8200-5929				GRANDINETTI A, 1994, AM J EPIDEMIOL, V139, P1129, DOI 10.1093/oxfordjournals.aje.a116960; GRENHOFF J, 1989, BRIT J ADDICT, V84, P477; JANSSON B, 1985, ANN NEUROL, V17, P505, DOI 10.1002/ana.410170514; KOCHAR AS, 1985, AM J MED, V79, P119, DOI 10.1016/0002-9343(85)90555-8; WICK MM, 1977, CANCER RES, V37, P2123	5	79	81	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1500	1501		10.1136/bmj.310.6993.1500	http://dx.doi.org/10.1136/bmj.310.6993.1500			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787596	Green Published			2022-12-24	WOS:A1995RD28500021
J	LIANG, C; WEINREICH, M; STILLMAN, B				LIANG, C; WEINREICH, M; STILLMAN, B			ORC AND CDC6P INTERACT AND DETERMINE THE FREQUENCY OF INITIATION OF DNA-REPLICATION IN THE GENOME	CELL			English	Article							ORIGIN RECOGNITION COMPLEX; YEAST-CELL CYCLE; SACCHAROMYCES-CEREVISIAE; S-PHASE; PROTEIN; GENE; CHROMOSOMES; NUCLEAR; MUTANTS; LOCALIZATION	The origin recognition complex (ORC) binds replicators in the yeast S. cerevisiae in a manner consistent with it being an initiator protein for DNA replication. Two-dimensional (2D) gel techniques were used to examine directly initiation of chromosomal DNA replication in temperature-sensitive orc mutants. Unlike in wild-type cells, in orc2-1 and orc5-1 mutant cells, only a subset of replicators formed active origins of DNA replication at the permissive temperature. At the restrictive temperature, the number of active replicators was diminished further. Using a genetic screen, CDC6 was identified as a multicopy suppressor of orc5-1. 2D gel and biochemical analyses demonstrated that Cdc6p interacted functionally and physically with ORC. We suggest that ORC and Cdc6p form a prereplication complex at individual replicators and therefore cooperate to determine the frequency of initiation of DNA replication in the genome.			LIANG, C (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.		Weinreich, Michael/D-2310-2014	Stillman, Bruce/0000-0002-9453-4091	NIAID NIH HHS [AI20460] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020460, R01AI020460] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Blumenthal AB, 1974, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/sqb.1974.038.01.024; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CALLAN HG, 1973, COLD SPRING HARB SYM, V38, P195; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALLON S, 1995, P NATL ACAD SCI USA, V92, P2514; DERSHOWITZ A, 1993, MOL CELL BIOL, V13, P391, DOI 10.1128/MCB.13.1.391; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DIFFLEY JFX, 1990, TRENDS GENET, V6, P427, DOI 10.1016/0168-9525(90)90305-P; DOWELL JFX, 1994, SCIENCE, V265, P1243; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GUTHRIE C, 1991, METH ENZYMOL, V194; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HARTWELL LH, 1985, GENETICS, V110, P381; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1993, GENE DEV, V7, P1072, DOI 10.1101/gad.7.6.1072; LOO S, 1995, IN PRESS MOL BIOL CE; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; PALMER RE, 1990, GENETICS, V125, P763; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; Rose MD., 1990, METHODS YEAST GENETI; ROWLEY A, 1994, BBA-GENE STRUCT EXPR, V1217, P239, DOI 10.1016/0167-4781(94)90283-6; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schiestl Robert H., 1993, Methods (Orlando), V5, P79, DOI 10.1006/meth.1993.1011; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SIKORSKI RS, 1989, GENETICS, V12, P19; STILLMAN B, 1993, NATURE, V366, P506, DOI 10.1038/366506a0; STILLMAN B, 1994, J BIOL CHEM, V269, P7074; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; ZHOU C, 1989, J BIOL CHEM, V264, P9022; ZHOU C, 1990, J BIOL CHEM, V265, P19904; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23352	53	307	313	1	11	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					667	676		10.1016/0092-8674(95)90528-6	http://dx.doi.org/10.1016/0092-8674(95)90528-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774008	Bronze			2022-12-24	WOS:A1995RB96100005
J	KOSTER, T; BLANN, AD; BRIET, E; VANDENBROUCKE, JP; ROSENDAAL, FR				KOSTER, T; BLANN, AD; BRIET, E; VANDENBROUCKE, JP; ROSENDAAL, FR			ROLE OF CLOTTING FACTOR-VIII IN EFFECT OF VON-WILLEBRAND-FACTOR ON OCCURRENCE OF DEEP-VEIN THROMBOSIS	LANCET			English	Article							POOR ANTICOAGULANT RESPONSE; ISCHEMIC-HEART-DISEASE; ACTIVATED PROTEIN-C; BLOOD GROUP-A; VONWILLEBRAND-FACTOR; VENOUS THROMBOSIS; RISK-FACTORS; GROUP-B; ATHEROSCLEROSIS; THROMBOPHILIA	To elucidate the roles of the ABO blood group, von Willebrand factor (vWF), and clotting factor VIII in the process of deep-vein thrombosis we undertook a population-based patient-control study in which 301 consecutive patients younger than 70 with a first, objectively diagnosed episode of venous thrombosis and without an underlying malignant disorder were compared with 301 healthy controls matched for age and sex. In univariate analysis, blood group, vWF concentration, and factor VIII concentrations were all related to deep-vein thrombosis. The risk of thrombosis increased with increasing vWF or factor VIII concentration and was higher in subjects of non-O blood groups than in those of group O. In multivariate analysis only factor VIII remained as a risk factor, and the dose-response relation between factor VIII concentration and risk of thrombosis persisted (subjects with factor VIII concentrations above 1500 IU/L had an adjusted odds ratio of 4.8 [95% CI 2.3-10.0]). By contrast, the adjusted odds ratio for each vWF stratum did not differ from 1, and that for blood group was 1.5 (1.0-2.2). Our findings point to an effect on thrombosis risk of vWF and blood group, the former fully and the latter at least partly mediated through factor VIII. The 25% prevalence of factor VIII concentrations above 1500 IU/L among unselected consecutive thrombosis patients and the high adjusted relative risk for thrombosis lead to the conclusion that high factor VIII concentrations are common and represent a clear increase in risk of thrombosis, similar to the risks conferred by deficiencies of the coagulation-inhibiting proteins and activated protein C resistance.	UNIV LEIDEN HOSP,CTR HEMOSTASIS & THROMBOSIS RES,LEIDEN,NETHERLANDS; UNIV S MANCHESTER HOSP,DEPT SURG,MANCHESTER,LANCS,ENGLAND	Leiden University; Leiden University Medical Center (LUMC); Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	KOSTER, T (corresponding author), UNIV LEIDEN HOSP,DEPT CLIN EPIDEMIOL,BLDG 1 CO-P-43,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020; Rosendaal, Frits/Q-3842-2017	Vandenbroucke, Jan/0000-0001-5668-6716; Rosendaal, Frits/0000-0003-2558-7496				ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLANN AD, 1993, INT J OBESITY, V17, P723; BLANN AD, 1994, EUR J VASCULAR SURG, P10; CAEKEBEKEPEERLI.KM, 1989, BRIT J HAEMATOL, V73, P217; CONLAN MG, 1993, THROMB HAEMOSTASIS, V70, P380; CUCUIANU MP, 1983, THROMB RES, V30, P487, DOI 10.1016/0049-3848(83)90183-4; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; GILL JC, 1987, BLOOD, V69, P1691; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HIRSH J, 1986, J AM COLL CARDIOL, V8, pB104, DOI 10.1016/S0735-1097(86)80012-2; KINGSBURY KJ, 1971, LANCET, V1, P199; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LOELIGER EA, 1984, ANTICOAGULANTS MYOCA, P157; MATSUI T, 1992, J BIOL CHEM, V267, P8723; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEDALIE JH, 1981, NEW ENGL J MED, V285, P1348; MILETICH JP, 1993, CELL, V72, P477, DOI 10.1016/0092-8674(93)90063-V; OBRIEN JR, 1990, THROMB RES, V59, P221, DOI 10.1016/0049-3848(90)90288-N; ROSENDAAL FR, 1990, BRIT J HAEMATOL, V75, P525, DOI 10.1111/j.1365-2141.1990.tb07793.x; ROSENDAAL FR, 1989, BRIT J HAEMATOL, V71, P71, DOI 10.1111/j.1365-2141.1989.tb06277.x; SHORT PE, 1982, MED LAB SCI, V32, P351; SODETZ JM, 1979, J BIOL CHEM, V254, P754; TALBOT S, 1970, LANCET, V1, P1257; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788	26	940	957	0	21	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					152	155		10.1016/S0140-6736(95)90166-3	http://dx.doi.org/10.1016/S0140-6736(95)90166-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823669				2022-12-24	WOS:A1995QC55000009
J	HO, DD; NEUMANN, AU; PERELSON, AS; CHEN, W; LEONARD, JM; MARKOWITZ, M				HO, DD; NEUMANN, AU; PERELSON, AS; CHEN, W; LEONARD, JM; MARKOWITZ, M			RAPID TURNOVER OF PLASMA VIRIONS AND CD4 LYMPHOCYTES IN HIV-1 INFECTION	NATURE			English	Article							CELLS; AIDS; INDIVIDUALS; PCR	Treatment of infected patients with ABT-538, an inhibitor of the protease of human immunodeficiency virus type 1 (HIV-1), causes plasma HIV-1 levels to decrease exponentially (mean half-life, 2.1 +/- 0.4 days) and CD4 lymphocyte counts to rise substantially. Minimum estimates of HIV-1 production and clearance and of CD4 lymphocyte turnover indicate that replication of HIV-1 in vivo is continuous and highly productive, driving the rapid turnover of CD4 lymphocytes.	SANTA FE INST,SANTA FE,NM 87501; LOS ALAMOS NATL LAB,DIV THEORET,LOS ALAMOS,NM 87545; ABBOTT LABS,DIV PHARMACEUT PROD,ABBOTT PK,IL 60064	The Santa Fe Institute; United States Department of Energy (DOE); Los Alamos National Laboratory; Abbott Laboratories	HO, DD (corresponding author), NYU,SCH MED,AARON DIAMOND AIDS RES CTR,455 1ST AVE,NEW YORK,NY 10016, USA.		Perelson, Alan S/Z-1959-2019	Perelson, Alan S/0000-0002-2455-0002				AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; CAO Y, IN PRESS AIDS RES HU; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; GRODY WW, 1985, AM J CLIN PATHOL, V84, P85, DOI 10.1093/ajcp/84.1.85; HAASE AT, 1994, ANN NY ACAD SCI, V724, P75, DOI 10.1111/j.1749-6632.1994.tb38897.x; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KEMPF D, IN PRESS P NATN ACAD; MARKOWITZ M, IN PRESS J VIROL; PACHL C, IN PRESS J AIDS; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PAUL WE, 1985, FUNDAMENTAL IMMUNOLO; PERELSON AS, 1993, MATH BIOSCI, V114, P81, DOI 10.1016/0025-5564(93)90043-A; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; WAINHOBSON S, 1993, NATURE, V366, P22, DOI 10.1038/366022b0; WAINHOBSON S, 1993, CURR OPIN GENET DEV, V3, P878, DOI 10.1016/0959-437X(93)90008-D; WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571	20	3708	3790	3	231	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					123	126		10.1038/373123a0	http://dx.doi.org/10.1038/373123a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816094				2022-12-24	WOS:A1995QB06300049
J	RADZICKA, A; WOLFENDEN, R				RADZICKA, A; WOLFENDEN, R			A PROFICIENT ENZYME	SCIENCE			English	Article							TRANSITION-STATE STABILIZATION; STAPHYLOCOCCAL NUCLEASE; DECARBOXYLASE; ACID; CATALYSIS; MECHANISM; RATES; 5'-PHOSPHATE; PURIFICATION; SPECIFICITY	Orotic acid is decarboxylated with a half-time (t(1/2)) of 78 million years in neutral aqueous solution at room temperature, as indicated by reactions in quartz tubes at elevated temperatures. Spontaneous hydrolysis of phosphodiester bonds, such as those present in the backbone of DNA, proceeds even more slowly at high temperatures, but the heat of activation is less positive, so that dimethyl phosphate is hydrolyzed with a t(1/2) of 130,000 years in neutral solution at room temperature. These values extend the known range of spontaneous rate constants for reactions that are also susceptible to catalysis by enzymes to more than 14 orders of magnitude. Values of the second-order rate constant k(cat)/K-m for the corresponding enzyme reactions are confined to a range of only 600-fold, in contrast. Orotidine 5'-phosphate decarboxylase, an extremely proficient enzyme, enhances the rate of reaction by a factor of 10(17) and is estimated to bind the altered substrate in the transition state with a dissociation constant of less than 5 x 10(-24) M.			RADZICKA, A (corresponding author), UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.				NIGMS NIH HHS [GM-18325] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018325, R01GM018325] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHESON SA, 1990, BIOCHEMISTRY-US, V29, P3198, DOI 10.1021/bi00465a007; ALBERTY RA, 1958, J PHYS CHEM-US, V62, P154, DOI 10.1021/j150560a005; ANDREWS PR, 1973, BIOCHEMISTRY-US, V12, P3492, DOI 10.1021/bi00742a022; BEAK P, 1976, J AM CHEM SOC, V98, P3601, DOI 10.1021/ja00428a035; BELL JB, 1991, J BIOL CHEM, V266, P12662; BUNTON CA, 1960, J CHEM SOC, P3293, DOI 10.1039/jr9600003293; BURGNER JW, 1984, BIOCHEMISTRY-US, V23, P3636, DOI 10.1021/bi00311a010; DEWOLF WE, 1979, J BIOL CHEM, V254, P868; DUMAS DP, 1989, J BIOL CHEM, V264, P19659; FOX JJ, 1957, BIOCHIM BIOPHYS ACTA, V23, P295, DOI 10.1016/0006-3002(57)90331-1; FRICK L, 1987, BIOORG CHEM, V15, P100, DOI 10.1016/0045-2068(87)90011-3; GARRETT ER, 1972, J AM CHEM SOC, V94, P8532, DOI 10.1021/ja00779a040; GRATHWOHL C, 1981, BIOPOLYMERS, V20, P2623, DOI 10.1002/bip.1981.360201209; HALL A, 1975, BIOCHEMISTRY-US, V14, P4348, DOI 10.1021/bi00690a032; HAWKINSON DC, 1991, BIOCHEMISTRY-US, V30, P10849, DOI 10.1021/bi00109a007; HUNT SW, 1982, J BIOL CHEM, V257, P14240; JOHNSON FH, 1954, KINETIC BASIS MOLECU, P187; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; LAIDLER KJ, 1965, CHEMICAL KINETICS, P488; LEVINE HL, 1980, BIOCHEMISTRY-US, V19, P4993, DOI 10.1021/bi00563a010; MIHEL I, 1979, J AM CHEM SOC, V101, P4349, DOI 10.1021/ja00509a050; NOBLE WJL, 1967, PROGR PHYS ORG CHEM, V5, P207; POLLACK RM, 1989, J AM CHEM SOC, V111, P6419, DOI 10.1021/ja00198a066; PUTMAN SJ, 1972, BIOCHEM J, V129, P301, DOI 10.1042/bj1290301; Roughton FJW, 1941, J AM CHEM SOC, V63, P2930, DOI 10.1021/ja01856a018; SERPERSU EH, 1986, BIOCHEMISTRY-US, V25, P68, DOI 10.1021/bi00349a011; SMILEY JA, 1991, BIOCHEMISTRY-US, V30, P6216, DOI 10.1021/bi00239a020; SMILEY JA, 1994, P NATL ACAD SCI USA, V91, P8319, DOI 10.1073/pnas.91.18.8319; SMILEY JA, 1992, BIOCHEMISTRY-US, V31, P12162, DOI 10.1021/bi00163a027; STEINER H, 1975, EUR J BIOCHEM, V59, P253, DOI 10.1111/j.1432-1033.1975.tb02449.x; TUCKER PW, 1978, MOL CELL BIOCHEM, V22, P67, DOI 10.1007/BF00496235; WHITAKER JR, 1986, BIOCHEMISTRY-US, V5, P386; WOLFENDEN R, 1976, ANNU REV BIOPHYS BIO, V5, P271, DOI 10.1146/annurev.bb.05.060176.001415	33	697	709	3	175	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 6	1995	267	5194					90	93		10.1126/science.7809611	http://dx.doi.org/10.1126/science.7809611			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7809611				2022-12-24	WOS:A1995QA23500036
J	THUT, CJ; CHEN, JL; KLEMM, R; TJIAN, R				THUT, CJ; CHEN, JL; KLEMM, R; TJIAN, R			P53 TRANSCRIPTIONAL ACTIVATION MEDIATED BY COACTIVATORS TAF(II)40 AND TAF(II)60	SCIENCE			English	Article							WILD-TYPE; BINDING PROTEIN; MDM-2 ONCOGENE; DOMAIN; GENE; EXPRESSION; INVITRO; DNA; SUPPRESSION; MUTATIONS	The tumor suppressor protein p53 is a transcriptional regulator that enhances the expression of proteins that control cellular proliferation. The multisubunit transcription factor IID (TFIID) is thought to be a primary target for site-specific activators of transcription. Here, a direct interaction between the activation domain of p53 and two subunits of the TFIID complex, TAF(II)40 and TAF(II)60, is reported. A double point mutation in the activation domain of p53 impaired the ability of this domain to activate transcription and, simultaneously, its ability to interact with both TAF(II)40 and TAF(II)60. Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAF(II)250, dTAF(II)60, and dTAF(II)40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAF(II)40 and TAF(II)60 did not. Together, these results suggest that TAF(II)40 and TAF(II)60 are important targets for transmitting activation signals between p53 and the initiation complex.			THUT, CJ (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,401 BARKER HALL,BERKELEY,CA 94720, USA.							BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DYNALECHT BD, 1991, CELL, V66, P563; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CURR OPIN CELL BIOL, V6, P403; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HOEY T, 1993, CELL, V72, P274; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLEMM RA, UNPUB; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MILLER C W, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P386; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THUT CJ, UNPUB; TONG X, IN PRESS J VIROL; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	41	419	422	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 6	1995	267	5194					100	104		10.1126/science.7809597	http://dx.doi.org/10.1126/science.7809597			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7809597				2022-12-24	WOS:A1995QA23500039
J	UNWIN, N				UNWIN, N			ACETYLCHOLINE-RECEPTOR CHANNEL IMAGED IN THE OPEN STATE	NATURE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; DELTA-SUBUNIT; LIGAND-BINDING; ION CHANNELS; AMINO-ACIDS; H-3 CHLORPROMAZINE; CRYSTAL-STRUCTURE; TUBULAR CRYSTALS; GAMMA-SUBUNIT; AGONIST	The structure of the open-channel form of the acetylcholine receptor has been determined from electron images of Torpedo ray postsynaptic membranes activated by brief (<5 ms) mixing with droplets containing acetylcholine. Comparison with the closed-channel form shows that acetylcholine Initiates small rotations of the subunits in the extracellular domain, which trigger a change in configuration of a-helices lining the membrane-spanning pore. The open pore tapers towards the intracellular membrane face, where it is shaped by a 'barrel' of a-helices having a pronounced right-handed twist.			UNWIN, N (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.							AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BERRIMAN J, 1994, ULTRAMICROSCOPY, V56, P241, DOI 10.1016/0304-3991(94)90012-4; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BRISSON A, 1984, J CELL BIOL, V99, P1202, DOI 10.1083/jcb.99.4.1202; CHANGEUX JP, 1992, Q REV BIOPHYS, V25, P395, DOI 10.1017/S0033583500004352; CHARNET P, 1990, NEURON, V2, P497; COHEN BN, 1992, J GEN PHYSIOL, V100, P373, DOI 10.1085/jgp.100.3.373; COLQUHOUN D, 1988, J PHYSIOL-LONDON, V395, P131, DOI 10.1113/jphysiol.1988.sp016912; COLQUHOUN D, 1985, J PHYSIOL-LONDON, V369, P501, DOI 10.1113/jphysiol.1985.sp015912; CZAJKOWSKI C, 1991, J BIOL CHEM, V266, P22603; DANI JA, 1989, J NEUROSCI, V9, P844; DEROSIER DJ, 1968, NATURE, V217, P130, DOI 10.1038/217130a0; DILGER JP, 1990, BIOPHYS J, V57, P723, DOI 10.1016/S0006-3495(90)82593-5; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GORNETSCHELNOKOW U, 1994, EMBO J, V13, P338, DOI 10.1002/j.1460-2075.1994.tb06266.x; HERZ JM, 1989, J BIOL CHEM, V264, P12439; Hille B., 1992, IONIC CHANNELS EXCIT; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1991, FEBS LETT, V289, P193, DOI 10.1016/0014-5793(91)81068-J; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JACKSON MB, 1989, P NATL ACAD SCI USA, V86, P2219; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KUBALEK E, 1987, J CELL BIOL, V105, P9, DOI 10.1083/jcb.105.1.9; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LEE YH, 1994, BIOPHYS J, V66, P646, DOI 10.1016/S0006-3495(94)80838-0; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; MATSUBARA N, 1992, BIOCHEMISTRY-US, V31, P5507, DOI 10.1021/bi00139a012; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; POPOT JL, 1984, PHYSIOL REV, V64, P1162, DOI 10.1152/physrev.1984.64.4.1162; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1984, BIOPHYS J, V46, P277, DOI 10.1016/S0006-3495(84)84022-9; SINE SM, 1990, J GEN PHYSIOL, V96, P395, DOI 10.1085/jgp.96.2.395; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; STEIN PE, 1994, STRUCTURE, V2, P45, DOI 10.1016/S0969-2126(00)00007-1; TOYOSHIMA C, 1990, J CELL BIOL, V111, P2623, DOI 10.1083/jcb.111.6.2623; TOYOSHIMA C, 1988, NATURE, V336, P247, DOI 10.1038/336247a0; TOYOSHIMA C, 1988, ULTRAMICROSCOPY, V25, P279, DOI 10.1016/0304-3991(88)90003-4; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; UNWIN PNT, 1975, J MOL BIOL, V94, P425, DOI 10.1016/0022-2836(75)90212-0; VALENZUELA CF, 1994, BIOPHYS J, V66, P674, DOI 10.1016/S0006-3495(94)80841-0; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; WHITE BH, 1992, J BIOL CHEM, V267, P15770	49	886	896	0	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 5	1995	373	6509					37	43		10.1038/373037a0	http://dx.doi.org/10.1038/373037a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800037				2022-12-24	WOS:A1995QA23900047
J	SCOTT, R; SCOTT, H				SCOTT, R; SCOTT, H			CROCODILE BITES AND TRADITIONAL BELIEFS IN KOROGWE DISTRICT, TANZANIA	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To investigate why fatal crocodile bites are increasing in a Tanzanian district and the importance of traditional beliefs and superstitions in determining the residents' response to the crocodiles. Design-Information about beliefs was obtained by interview of Korogwe residents. Human and crocodile fatality statistics were obtained from the Korogwe Department of Natural Resources. Setting-Villages within Korogwe District. Subjects-Population of Korogwe District. Results-Crocodiles have been responsible for 51 deaths in the 52 months from January 1990 to April 1994. Of these, 18 deaths occurred in the first four months of 1994. Conclusions-Local beliefs and superstitions about crocodiles include those about the taming of animals, with implications concerning the choice of victim and the penalties that may ensue if a crocodile is killed. The recent rise in human fatalities is thought to relate to increasing river pollution reducing the fish supply, together with a change in social mores at the riverside which has increased the crocodiles' displeasure. A reliable pumped water supply would reduce the need to draw water and bathe in the river, and eradication of superstition would empower the villagers in the fight against a common enemy.			SCOTT, R (corresponding author), ST RAPHAELS HOSP,POB 35,TANGA,TANZANIA.								0	13	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1691	1692		10.1136/bmj.309.6970.1691	http://dx.doi.org/10.1136/bmj.309.6970.1691			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819989	Green Published			2022-12-24	WOS:A1994PY71700015
J	STILLER, CA				STILLER, CA			POPULATION-BASED SURVIVAL RATES FOR CHILDHOOD-CANCER IN BRITAIN, 1980-91	BRITISH MEDICAL JOURNAL			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; NEURO-BLASTOMA; NEUROBLASTOMA; CHEMOTHERAPY; CHILDREN; LYMPHOMA; THERAPY; PROTOCOL; UKCCSG; TRIALS	Objectives-To investigate the survival of children with cancer diagnosed during 1980-91 in order to assess the impact of developments in medical care on a Population basis. Design-Retrospective cohort study. Setting-Great-Britain. Subjects-14973 children with cancer diagnosed during 1980-91 and included in the population based National Registry of Childhood Tumours. Main outcome measures-Actuarial survival rates. Results-For all cancers combined, two year survival increased from 66% to 76% between 1980-2 and 1989-91, and five year survival increased from 57% to 65% between 1980-2 and 1986-8. Significant increases in survival rates occurred among children with acute lymphoblastic leukaemia, acute nonlymphocytic leukaemia, retinoblastoma, osteosarcoma, Ewing's sarcoma, rhabdomyosarcoma, and malignant gonadal germ cell tumours. No trend in survival was seen for children with Hodgkin's disease, central nervous system tumours, neuroblastoma, or Wilms's tumour. Conclusions-Nearly two. thirds of children who have cancer diagnosed can now expect to survive at least 10 years.			STILLER, CA (corresponding author), UNIV OXFORD,DEPT PAEDIAT,CHILDHOOD CANC RES GRP,OXFORD OX2 6HJ,ENGLAND.			Stiller, Charles/0000-0002-3006-7869				BERTHOLD F, 1991, AM J PEDIAT HEMATOL, V13, P8; BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; BRAMWELL VHC, 1992, J CLIN ONCOL, V10, P1579, DOI 10.1200/JCO.1992.10.10.1579; CHESSELLS JM, 1992, LEUKEMIA, V6, P157; DUNST J, 1991, CANCER, V67, P2818, DOI 10.1002/1097-0142(19910601)67:11<2818::AID-CNCR2820671118>3.0.CO;2-Y; EDEN QB, 1992, BRIT J HAEMATOL, V82, P310, DOI 10.1111/j.1365-2141.1992.tb06423.x; HAAF H, 1993, JAHRESBERICHT 1992 D; HANAWA Y, 1990, MED PEDIATR ONCOL, V18, P472, DOI 10.1002/mpo.2950180607; HANN IM, 1990, BRIT J HAEMATOL, V76, P359, DOI 10.1111/j.1365-2141.1990.tb06368.x; HARTMANN O, 1988, J CLIN ONCOL, V6, P44, DOI 10.1200/JCO.1988.6.1.44; HAWKINS MM, 1991, J NATL CANCER I, V83, P1643, DOI 10.1093/jnci/83.22.1643; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; JONES PHM, 1991, BRIT J CANCER, V64, P1; KELLIE SJ, 1988, EUR J CANCER CLIN ON, V24, P903, DOI 10.1016/0277-5379(88)90200-3; MANN JR, 1989, CANCER-AM CANCER SOC, V63, P1657; MILLER BA, 1992, NIH922789 US DEP HLT; NAITO H, 1990, J PEDIATR SURG, V25, P245, DOI 10.1016/0022-3468(90)90410-B; Neglia J P, 1991, J Pediatr Oncol Nurs, V8, P59, DOI 10.1177/104345429100800207; PINKERTON CR, 1991, BRIT J CANCER, V64, P583, DOI 10.1038/bjc.1991.354; PINKERTON CR, 1990, BRIT J CANCER, V62, P319, DOI 10.1038/bjc.1990.286; PRITCHARD J, 1989, BRIT MED J, V299, P835, DOI 10.1136/bmj.299.6703.835; ROBERTSON CM, 1994, BRIT MED J, V309, P162, DOI 10.1136/bmj.309.6948.162; SANDERS BM, 1988, BRIT J OPHTHALMOL, V72, P576, DOI 10.1136/bjo.72.8.576; SANKILA R, 1993, EUR J CANCER, V29A, P122, DOI 10.1016/0959-8049(93)90588-7; SHAFFORD EA, 1993, BRIT J CANCER, V68, P1199, DOI 10.1038/bjc.1993.504; STEVENS M, 1993, MED PEDIATR ONCOL, V21, P554; STEVENS RF, 1992, LEUKEMIA, V6, P55; STILLER CA, 1988, ARCH DIS CHILD, V63, P23, DOI 10.1136/adc.63.1.23; STILLER CA, 1990, BRIT J CANCER, V62, P806, DOI 10.1038/bjc.1990.383; STILLER CA, 1994, ARCH DIS CHILD, V70, P219, DOI 10.1136/adc.70.3.219; STILLER CA, 1989, ARCH DIS CHILD, V64, P657, DOI 10.1136/adc.64.5.657; 1991, PEDIATRICS, V89, P597	32	120	120	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1612	1616		10.1136/bmj.309.6969.1612	http://dx.doi.org/10.1136/bmj.309.6969.1612			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819936	Green Published			2022-12-24	WOS:A1994PY22000016
J	WARREN, RW; NAGY, L; SELEGUE, J; GATES, J; CARROLL, S				WARREN, RW; NAGY, L; SELEGUE, J; GATES, J; CARROLL, S			EVOLUTION OF HOMEOTIC GENE-REGULATION AND FUNCTION IN FLIES AND BUTTERFLIES	NATURE			English	Article							BITHORAX-COMPLEX; DROSOPHILA; EXPRESSION	IT has been proposed that the evolution of homeotic genes parallels, and to some degree directs, the evolution of segment diversity in the myriapod-insect lineage(1-3). But the discovery of discrete Antennapedia complex (ANT-C) and bithorax complex (BX-C) gene members in crustacea(4) chelicerates(5), annelids(6-8) and various insects(9-11), as well as in vertebrates(12), indicates that the expansion and diversification of homeotic genes preceded the diversification of arthropods and insects. How, then, have these genes influenced the evolution of body plans? To address this question, we now examine homeotic gene expression and regulation in butterflies (Lepidoptera), which, unlike flies, possess larval abdominal limbs and two pairs of wings. We show that the difference in larval limb number between these insects results from striking changes in BX-C gene regulation in the butterfly abdomen, and we deduce that the wing-patterning genes regulated by Ultrabithorax have diverged in the course of butterfly and fly evolution. These findings have general implications for the role of homeotic genes in animal evolution.	UNIV WISCONSIN, HOWARD HUGHES MED INST, MADISON, WI 53706 USA; UNIV WISCONSIN, MOLEC BIOL LAB, MADISON, WI 53706 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								AKAM M, 1988, DEVELOPMENT, V104, P123; AKAM M, IN PRESS DEVELOPMENT; AVEROF M, 1993, CURR BIOL, V3, P73, DOI 10.1016/0960-9822(93)90158-K; Bateson W., 1894, MAT STUDY VARIATION, DOI [10.5962/bhl.title.1348, DOI 10.5962/BHL.TITLE.1348]; BEACHY PA, 1985, NATURE, V313, P545, DOI 10.1038/313545a0; BEEMAN RW, 1989, DEV BIOL, V133, P196, DOI 10.1016/0012-1606(89)90311-4; BIRKETSMITH SJR, 1984, PROLEGS LEGS WINGS I; CARTWRIGHT P, 1993, MOL PHYLOGENET EVOL, V2, P185, DOI 10.1006/mpev.1993.1019; DICK MH, 1994, MOL PHYLOGENET EVOL, V3, P146, DOI 10.1006/mpev.1994.1017; GARCIABELLIDO A, 1977, AM ZOOL, V17, P613; GARCIAFERNANDEZ J, 1994, NATURE, V370, P563, DOI 10.1038/370563a0; GOLDSCHMIDT RB, 1940, MATERIAL BASIS EVOLU; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KARCH F, 1985, CELL, V43, P81, DOI 10.1016/0092-8674(85)90014-5; KELSH R, 1994, DEV GENET, V15, P19, DOI 10.1002/dvg.1020150104; KELSH R, 1993, DEVELOPMENT, V117, P293; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LEWIS EB, 1963, AM ZOOL, V3, P33; MACIAS A, 1990, DEVELOPMENT, V110, P1197; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MORATA G, 1976, ROUX ARCH DEV BIOL, V179, P125, DOI 10.1007/BF00848298; PANGANIBAN G, 1994, CURR BIOL, V4, P671, DOI 10.1016/S0960-9822(00)00151-2; Raff R.A., 1983, EMBRYOS GENES EVOLUT; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHANKLAND M, 1991, DEVELOPMENT, P29; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; STUART JJ, 1993, DEVELOPMENT, V117, P233; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2; WYSOCKADILLER JW, 1989, NATURE, V341, P760, DOI 10.1038/341760a0	31	162	168	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 1	1994	372	6505					458	461		10.1038/372458a0	http://dx.doi.org/10.1038/372458a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7840822				2022-12-24	WOS:A1994PV01200055
J	FRIEDEN, TR; FUJIWARA, PI; WASHKO, RM; HAMBURG, MA				FRIEDEN, TR; FUJIWARA, PI; WASHKO, RM; HAMBURG, MA			TUBERCULOSIS IN NEW-YORK-CITY - TURNING THE TIDE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; INFECTION; CHEMOTHERAPY	Background. From 1978 through 1992, the number of patients with tuberculosis in New York City nearly tripled, and the proportion of such patients who had drug-resistant isolates of Mycobacterium tuberculosis more than doubled. Methods. We reviewed, confirmed, and analyzed data obtained during the surveillance of patients with tuberculosis. Results. From 1992 through 1994, there was a 21 percent decrease in reported cases of tuberculosis in New York City. An evaluation of the surveillance system revealed very few unreported cases. The number of cases decreased by more than 20 percent among blacks and Hispanics, persons with documented human immunodeficiency virus infection, homeless persons, and patients with multidrug-resistant tuberculosis; in all these groups, tuberculosis is likely to result from recent transmission. In contrast, the number of cases of tuberculosis increased among elderly and foreign-born persons, in whom the disease is likely to result from the reactivation of an infection acquired many years earlier. Enrollment in a program of directly observed therapy, in which health workers watch patients take their medications, increased from fewer than 100 patients to nearly 1300, with more than 32,000 patient-months of observation from 1992 through 1994. Conclusions. Epidemiologic patterns strongly suggest that the decrease in cases resulted from an interruption in the ongoing spread of M. tuberculosis infection, primarily because of better rates of completion of treatment and expanded use of directly observed therapy. Another contributing factor may have been efforts to reduce the spread of tuberculosis in institutional settings, such as hospitals, shelters, and jails. Expansion of measures to prevent and control tuberculosis and support of international control efforts are needed to ensure continued progress.	NEW YORK CITY DEPT HLTH, NEW YORK, NY 10013 USA; CTR DIS CONTROL & PREVENT, NATL CTR PREVENT SERV, DIV TB ELIMINAT, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, DIV FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30341 USA	New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; [Anonymous], 1994, MMWR MORB MORTAL WKL; Arno P S, 1993, J Law Med Ethics, V21, P317, DOI 10.1111/j.1748-720X.1993.tb01256.x; AZMEH W, 1993, 33RD INT C ANT AG CH, P229; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; BELLIN EY, 1993, JAMA-J AM MED ASSOC, V269, P2228, DOI 10.1001/jama.269.17.2228; BIGGS HM, 1908, BRIEF HIST CAMPAIGN; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BRICKNER PW, 1993, TUBERCULOSIS COMPREH, P433; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; JARLAIS DCD, 1994, JAMA-J AM MED ASSOC, V271, P121, DOI 10.1001/jama.271.2.121; KIM SJ, 1992, TUBERCLE LUNG DIS, V73, P219, DOI 10.1016/0962-8479(92)90090-7; LOWELL AM, 1961, TUBERCULOSIS NEW YOR; MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; STYBLO K, 1991, SELECTED PAPERS ROYA, V24, P52; VALWAY S, 1993, 33RD INT C ANT AG CH, P230; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; 1994, WHOTB94177; 1992, NEW YORK CITY TASK F; 1993, TUBERCULOSIS NEW YOR; 1990, MMWR-MORBID MORTAL W, V39, P9; 1995, MMWR-MORBID MORTAL W, V44, P81; 1994, AIDS SURVEILLANCE UP	35	580	593	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 27	1995	333	4					229	233		10.1056/NEJM199507273330406	http://dx.doi.org/10.1056/NEJM199507273330406			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK423	7791840				2022-12-24	WOS:A1995RK42300006
J	BATES, DW; CULLEN, DJ; LAIRD, N; PETERSEN, LA; SMALL, SD; SERVI, D; LAFFEL, G; SWEITZER, BJ; SHEA, BF; HALLISEY, R; VANDERVLIET, M; NEMESKAL, R; LEAPE, LL				BATES, DW; CULLEN, DJ; LAIRD, N; PETERSEN, LA; SMALL, SD; SERVI, D; LAFFEL, G; SWEITZER, BJ; SHEA, BF; HALLISEY, R; VANDERVLIET, M; NEMESKAL, R; LEAPE, LL			INCIDENCE OF ADVERSE DRUG EVENTS AND POTENTIAL ADVERSE DRUG EVENTS - IMPLICATIONS FOR PREVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITALIZED-PATIENTS; HEALTH-CARE; MEDICATION	Objectives.-To assess incidence and preventability of adverse drug events (ADEs) and potential ADEs. To analyze preventable events to develop prevention strategies. Design.-Prospective cohort study. Participants.-All 4031 adult admissions to a stratified random sample of 11 medical and surgical units in two tertiary care hospitals over a 6-month period. Units included two medical and three surgical intensive care units and four medical and two surgical general care units. Main Outcome Measures.-Adverse drug events and potential ADEs. Methods.-Incidents were detected by stimulated self-report by nurses and pharmacists and by daily review of all charts by nurse investigators. Incidents were subsequently classified by two independent reviewers as to whether they represented ADEs or potential ADEs and as to severity and preventability. Results.-Over 6 months, 247 ADEs and 194 potential ADEs were identified. Extrapolated event rates were 6.5 ADEs and 5.5 potential ADEs per 100 nonobstetrical admissions, for mean numbers per hospital per year of approximately 1900 ADEs and 1600 potential ADEs. Of all ADEs, 1% were fatal (none preventable), 12% life-threatening, 30% serious, and 57% significant. Twenty-eight percent were judged preventable. Of the life-threatening and serious ADEs, 42% were preventable, compared with 18% of significant ADEs, Errors resulting in preventable ADEs occurred most often at the stages of ordering (56%) and administration (34%); transcription (6%) and dispensing errors (4%) were less common. Errors were much more likely to be intercepted if the error occurred earlier in the process: 48% at the ordering stage vs 0% at the administration stage, Conclusion.-Adverse drug events were common and often preventable; serious ADEs were more likely to be preventable. Most resulted from errors at the ordering stage, but many also occurred at the administration stage. Prevention strategies should target both stages of the drug delivery process.	BRIGHAM & WOMENS HOSP, DEPT PHARM, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT ANESTHESIA, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT PHARM, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; APM INC, NEW YORK, NY USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	BATES, DW (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV GEN MED & PRIMARY CARE, 75 FRANCIS ST, BOSTON, MA 02115 USA.		Arán, Teodoro J Martínez/A-4568-2010	Arán, Teodoro J Martínez/0000-0002-5877-3941	AHRQ HHS [R01-HS07107-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Bates D W, 1994, Qual Manag Health Care, V2, P18; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1994, J AM MED INFORM ASSN, V1, P404, DOI 10.1136/jamia.1994.95153428; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BEERS M, 1988, JAMA-J AM MED ASSOC, V260, P3016, DOI 10.1001/jama.260.20.3016; BERRY LL, 1988, AM J HOSP PHARM, V45, P1534, DOI 10.1093/ajhp/45.7.1534; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; EVANS RS, 1994, ANN PHARMACOTHER, V28, P523, DOI 10.1177/106002809402800417; EVANS RS, 1993, P ANN S COMPUT APPL, V17, P161; FAICH GA, 1986, NEW ENGL J MED, V314, P1589, DOI 10.1056/NEJM198606123142427; FAICH GA, 1991, ARCH INTERN MED, V151, P1645, DOI 10.1001/archinte.151.8.1645; FOLLI HL, 1987, PEDIATRICS, V79, P718; FORRESTER JW, 1971, MIT TECHNOL REV, V73, P2; FUCHSBERG A, 1978, TRIAL LAWYERS Q, V12, P9; GOSNEY M, 1984, LANCET, V2, P564; GRASELA TH, 1993, AM J HOSP PHARM, V50, P1889, DOI 10.1093/ajhp/50.9.1889; HODDINOTT BC, 1967, CAN MED ASSOC J, V97, P1001; HURWITZ N, 1969, BMJ-BRIT MED J, V1, P531, DOI 10.1136/bmj.1.5643.531; JICK H, 1984, J ALLERGY CLIN IMMUN, V74, P555, DOI 10.1016/0091-6749(84)90106-4; KARCH FE, 1975, JAMA-J AM MED ASSOC, V234, P1236, DOI 10.1001/jama.234.12.1236; KEITH MR, 1989, AM J HOSP PHARM, V46, P1809, DOI 10.1093/ajhp/46.9.1809; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V269, P2765, DOI 10.1001/jama.269.21.2765; KOCH KE, 1990, AM J HOSP PHARM, V47, P1314, DOI 10.1093/ajhp/47.6.1314; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; MELMON KL, 1971, NEW ENGL J MED, V284, P1361; OGILVIE RI, 1967, CAN MED ASSOC J, V97, P1450; ONEIL AC, 1993, ANN INTERN MED, V119, P370, DOI 10.7326/0003-4819-119-5-199309010-00004; RIND DM, 1991, P ANN S COMPUT APPL, V15, P28; SEIDL LG, 1966, B JOHNS HOPKINS HOSP, V119, P299; Wan T T, 1987, QRB Qual Rev Bull, V13, P61; 1985, INJURY AM; 1991, STATXACT USER MANUAL; 1988, SAS RELEASE 6 03; 1980, MED MALPRACTICE CLOS	41	2208	2296	3	125	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					29	34		10.1001/jama.274.1.29	http://dx.doi.org/10.1001/jama.274.1.29			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG233	7791255				2022-12-24	WOS:A1995RG23300027
J	PEARSON, VAH; OWEN, MR; PHILLIPS, DR; GRAY, DJP; MARSHALL, MN				PEARSON, VAH; OWEN, MR; PHILLIPS, DR; GRAY, DJP; MARSHALL, MN			PREGNANT TEENAGERS KNOWLEDGE AND USE OF EMERGENCY CONTRACEPTION	BRITISH MEDICAL JOURNAL			English	Article									UNIV EXETER,INST POPULAT STUDIES,EXETER EX4 6DT,DEVON,ENGLAND; UNIV EXETER,POSTGRAD MED SCH,INST GEN PRACTICE,EXETER EX2 5DW,DEVON,ENGLAND	University of Exeter; University of Exeter	PEARSON, VAH (corresponding author), EXETER & N DEVON HLTH AUTHOR,SOUTHERNHAY E,EXETER EX1 1PQ,DEVON,ENGLAND.			PEREIRA GRAY, DENIS/0000-0001-7917-3841				BROMHAM DR, 1993, BRIT MED J, V306, P556, DOI 10.1136/bmj.306.6877.556; Bury J., 1984, TEENAGE PREGNANCY BR; DUNCAN G, 1990, BRIT J FAM PLANN, V15, P112; MELLANBY A, 1993, BRIT MED J, V307, P25, DOI 10.1136/bmj.307.6895.25; 1992, FMI21 OFF POP CENS S	5	47	49	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1644	1644		10.1136/bmj.310.6995.1644	http://dx.doi.org/10.1136/bmj.310.6995.1644			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RF698	7795453	Green Published			2022-12-24	WOS:A1995RF69800025
J	CASES, O; SEIF, I; GRIMSBY, J; GASPAR, P; CHEN, K; POURNIN, S; MULLER, U; AGUET, M; BABINET, C; SHIH, JC; DEMAEYER, E				CASES, O; SEIF, I; GRIMSBY, J; GASPAR, P; CHEN, K; POURNIN, S; MULLER, U; AGUET, M; BABINET, C; SHIH, JC; DEMAEYER, E			AGGRESSIVE-BEHAVIOR AND ALTERED AMOUNTS OF BRAIN-SEROTONIN AND NOREPINEPHRINE IN MICE LACKING MAOA	SCIENCE			English	Article							MONOAMINE OXIDASE-A; RAT-BRAIN; ORGANIZATION; EXPRESSION; GENES; IMMUNOCYTOCHEMISTRY; SEQUENCE; CORTEX; LIVER; MOTOR	Deficiency in monoamine oxidase A (MAOA), an enzyme that degrades serotonin and norepinephrine, has recently been shown to be associated with aggressive behavior in men of a Dutch family. A line of transgenic mice was isolated in which transgene integration caused a deletion in the gene encoding MAOA, providing an animal model of MAOA deficiency, in pup brains, serotonin concentrations were increased up to ninefold, and serotonin-like immunoreactivity was present. in catecholaminergic neurons, In pup and adult brains, norepinephrine concentrations were increased up to twofold, and I cytoarchitectural changes were observed in the somatosensory cortex. Pup behavioral alterations, including trembling, difficulty in righting, and fearfulness were reversed by the serotonin synthesis inhibitor parachlorophenylalanine. Adults manifested a distinct behavioral syndrome, including enhanced aggression in males.	INST CURIE,CNRS,URA 1343,F-91405 ORSAY,FRANCE; UNIV SO CALIF,DEPT MOLEC PHARMACOL & TOXICOL,LOS ANGELES,CA 90033; HOP LA PITIE SALPETRIERE,INSERM,U106,F-75651 PARIS,FRANCE; INST PASTEUR,CNRS,URA 361,F-75724 PARIS,FRANCE; UNIV ZURICH,INST MOLEC BIOL 1,CH-8093 ZURICH,SWITZERLAND; GENENTECH INC,S SAN FRANCISCO,CA 94080	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Southern California; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Zurich; Roche Holding; Genentech			cases, olivier/G-4882-2017; Gaspar, Patricia/G-8892-2011	cases, olivier/0000-0002-5678-7362; Gaspar, Patricia/0000-0003-4217-5717	NIMH NIH HHS [R01 MH 37020, K05 MH 00796, R37 MH039085-23, R37 MH 39085, R37 MH039085] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH000796, R01MH037020, R37MH039085] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BARINAGA M, 1994, SCIENCE, V264, P1690, DOI 10.1126/science.8209247; BENEDETTI MS, 1992, DEV PHARMACOL THERAP, V18, P191, DOI 10.1159/000480622; BENNETTCLARKE CA, 1993, P NATL ACAD SCI USA, V90, P153, DOI 10.1073/pnas.90.1.153; BORSINI F, 1988, PSYCHOPHARMACOLOGY, V94, P147; BROWN SDM, 1993, MAMM GENOME, V4, pS269, DOI 10.1007/BF00360846; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CASES O, UNPUB; CHEN C, 1994, SCIENCE, V266, P291, DOI 10.1126/science.7939668; CHEN ZY, 1992, GENOMICS, V14, P75, DOI 10.1016/S0888-7543(05)80286-1; COLLINS FA, 1992, AM J MED GENET, V42, P127, DOI 10.1002/ajmg.1320420126; DAMATO RJ, 1987, P NATL ACAD SCI USA, V84, P4322, DOI 10.1073/pnas.84.12.4322; GERSON SC, 1980, LIFE SCI, V27, P1435, DOI 10.1016/0024-3205(80)90368-9; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; HAEFELY WE, 1990, ADV NEUROL, V53, P505; KOIDE Y, 1984, NEUROCHEM RES, V9, P595, DOI 10.1007/BF00964506; KOLB B, 1983, CAN J PSYCHOL, V37, P211, DOI 10.1037/h0080724; KUWAHARA T, 1990, AGR BIOL CHEM TOKYO, V54, P253, DOI 10.1080/00021369.1990.10869903; LEVITT P, 1982, P NATL ACAD SCI-BIOL, V79, P6385, DOI 10.1073/pnas.79.20.6385; LICHTENSTEIGER W, 1967, J NEUROCHEM, V14, P489, DOI 10.1111/j.1471-4159.1967.tb09548.x; MANN CC, 1994, SCIENCE, V264, P1686, DOI 10.1126/science.8209246; Maxson Stephen C., 1992, V8, P349; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; OCHMAN H, 1988, GENETICS, V120, P621; OSTERHELDHAAS MC, 1994, DEV BRAIN RES, V77, P189, DOI 10.1016/0165-3806(94)90196-1; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; RHOADES RW, 1990, J COMP NEUROL, V293, P190, DOI 10.1002/cne.902930204; SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214; SEIF I, 1991, J VIROL, V65, P664, DOI 10.1128/JVI.65.2.664-671.1991; SHASKAN EG, 1970, J PHARMACOL EXP THER, V175, P404; STEINBUSCH HWM, 1982, CYTOCHEMICAL METHODS, P407; TSANG D, 1986, DEV NEUROSCI-BASEL, V8, P243, DOI 10.1159/000112258; WALLACE JA, 1982, BRAIN RES BULL, V9, P117, DOI 10.1016/0361-9230(82)90127-7; WESTLUND KN, 1985, SCIENCE, V230, P181, DOI 10.1126/science.3875898; WHISHAW IQ, 1981, J COMP PHYSIOL PSYCH, V95, P85, DOI 10.1037/h0077760; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; WU HF, 1993, MOL PHARMACOL, V43, P888	38	931	966	5	142	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1763	1766		10.1126/science.7792602	http://dx.doi.org/10.1126/science.7792602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792602	Green Accepted			2022-12-24	WOS:A1995RE66800045
J	DORIT, RL; AKASHI, H; GILBERT, W				DORIT, RL; AKASHI, H; GILBERT, W			ABSENCE OF POLYMORPHISM AT THE ZFY LOCUS ON THE HUMAN Y-CHROMOSOME	SCIENCE			English	Article							TESTIS-DETERMINING FACTOR; HUMAN MITOCHONDRIAL-DNA; GENE-CLUSTER; SEQUENCES; POPULATIONS; HAPLOTYPES; EVOLUTION; PATTERNS; PROTEIN; TISSUES	DNA polymorphism in the Y chromosome, examined at a 729-base pair intron located immediately upstream of the ZFY zinc-finger exon, revealed no sequence Variation in a worldwide sample of 38 human males. This finding cannot be explained by global constraint on the intron sequence, because interspecific comparisons with other nonhuman primates revealed phylogenetically informative sequence changes. The invariance likely results from either a recent selective sweep, a recent origin for modern Homo sapiens, recurrent male population bottlenecks, or historically small effective male population sizes. A coalescence model predicts an expected time to a most recent common ancestral male lineage of 270,000 years (95 percent confidence limits: 0 to 800,000 years).	UNIV CHICAGO,DEPT ECOL & EVOLUT,CHICAGO,IL 60637; HARVARD UNIV,CAMBRIDGE,MA 02138	University of Chicago; Harvard University	DORIT, RL (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511, USA.				NIGMS NIH HHS [GM 37997] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037997] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONARAKIS SE, 1988, HUM GENET, V80, P265, DOI 10.1007/BF01790095; AVRAMOPOULOS D, 1993, GENOMICS, V15, P98, DOI 10.1006/geno.1993.1015; AYALA FJ, 1994, P NATLA CAD SCI US, V91, P6786; BERRY AJ, 1991, GENETICS, V129, P1111; CHAKRAVARTI A, 1986, P NATL ACAD SCI USA, V83, P1045, DOI 10.1073/pnas.83.4.1045; CHAKRAVARTI A, 1984, P NATL ACAD SCI-BIOL, V81, P6085, DOI 10.1073/pnas.81.19.6085; CHAKRAVARTI A, 1981, AM J HUM GENET, V33, pA134; ELLIS N, 1990, NATURE, V344, P663, DOI 10.1038/344663a0; FRAYER DW, 1993, AM ANTHROPOL, V95, P14, DOI 10.1525/aa.1993.95.1.02a00020; HAMMER MF, 1994, MOL BIOL EVOL, V11, P749; HASEGAWA M, 1989, J HUM EVOL, V18, P461, DOI 10.1016/0047-2484(89)90075-4; HASEGAWA M, 1991, J MOL EVOL, V32, P37, DOI 10.1007/BF02099927; HUDSON RR, 1993, MECHANISMS OF MOLECULAR EVOLUTION, P23; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KREITMAN M, 1991, GENETICS, V127, P565; LAU YFC, 1989, AM J HUM GENET, V45, P942; LI WH, 1991, GENETICS, V129, P513; LUCOTTE G, 1985, NUCLEIC ACIDS RES, V13, P8285, DOI 10.1093/nar/13.22.8285; LUCOTTE G, 1988, HUMAN REVOLUTION BEH, P39; MALASPINA P, 1990, ANN HUM GENET, V54, P297, DOI 10.1111/j.1469-1809.1990.tb00385.x; MATTESON KJ, 1985, HUM GENET, V69, P263, DOI 10.1007/BF00293037; MCCOMBIE WR, 1992, NAT GENET, V1, P348, DOI 10.1038/ng0892-348; NAGAMINE CM, 1990, GENE DEV, V4, P63, DOI 10.1101/gad.4.1.63; NGO KY, 1986, AM J HUM GENET, V38, P407; OAKEY R, 1990, GENOMICS, V7, P325, DOI 10.1016/0888-7543(90)90165-Q; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PALMER MS, 1989, NATURE, V342, P937, DOI 10.1038/342937a0; ROEWER L, 1992, HUM GENET, V89, P389; SCHENIDERGADICK.A, 1989, CELL, V57, P1247; SHIMMIN LC, 1993, NATURE, V362, P745, DOI 10.1038/362745a0; SPRUDLE AB, 1991, AM J HUM GENET, V50, P107; SPURDLE AB, 1994, AM J HUM GENET, V54, P319; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; SU H, 1992, MOL REPROD DEV, V33, P252, DOI 10.1002/mrd.1080330304; TORRONI A, 1990, ANN HUM GENET, V54, P287; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WOLPOFF MH, 1989, HUMAN REVOLUTION, P62	37	168	171	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1183	1185		10.1126/science.7761836	http://dx.doi.org/10.1126/science.7761836			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761836				2022-12-24	WOS:A1995RA60400039
J	OGREN, M; HEDBLAD, B; ISACSSON, SO; JANZON, L; JUNGQUIST, G; LINDELL, SE				OGREN, M; HEDBLAD, B; ISACSSON, SO; JANZON, L; JUNGQUIST, G; LINDELL, SE			10-YEAR CEREBROVASCULAR MORBIDITY AND MORTALITY IN 68-YEAR-OLD MEN WITH ASYMPTOMATIC CAROTID STENOSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; ARTERY ATHEROSCLEROSIS; RISK-FACTORS; STROKE; POPULATION; PREVALENCE; BRUITS	Objective-To study the natural course of carotid artery stenosis detected by ultrasonography. Design-Prospective cohort study. Baseline examination in 1982-3 included ultrasound examination of carotid arteries, measurement of ankle-brachial blood pressure index, and detection of atrial fibrillation by 24 hour ambulatory electrocardiography. Setting-Malmo, a city in southern Sweden with 230 000 inhabitants. Subjects-470 men aged 68 years randomly selected hom the population. Main outcome measures-Incidence of stroke and transient ischaemic attack and all cause mortality during 10 years of follow up in relation to carotid stenosis, leg artery disease (ankle-brachial blood pressure index below 0.9), and atrial fibrillation. Results-Fifty men had a stroke; six of these were haemorrhagic. Another 11 had a transient ischaemic attack. Eighteen of the men with carotid stenosis (21.6 events/1000 person years) and 43 of the men with normal carotid arteries (14.8 events/1000 person years) had a stroke or transient ischaemic attack (P = 0.188). Men with atrial fibrillation had an increased rate of cerebrovascular events (36.7/1000 person years (P = 0.048). The highest rate was found in men with asymptomatic disease of the leg arteries (38.6/1000 person years) (P < 0.001). The increased risk of stroke or transient ischaemic attack in this group remained after multivariate analysis (relative risk 2.0; 95% confidence interval 1.1 to 3.7). Conclusions-In this cohort carotid stenosis was not associated with an increased risk of stroke. Part of this lack of association was explained by the high mortality from ischaemic heart disease in men with severe stenosis. Twenty seven of the 61 cerebrovascular events, however, occurred in men who had normal carotid arteries, normal ankle pressure, and no atrial fibrillation.	LUND UNIV, MALMO GEN HOSP, DEPT CLIN PHYSIOL, S-21401 MALMO, SWEDEN	Lund University	OGREN, M (corresponding author), LUND UNIV, MALMO GEN HOSP, DEPT COMMUNITY HLTH SCI, S-21401 MALMO, SWEDEN.							ANDERSON S, 1980, STATISTICAL METHODS; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; CARTER SA, 1968, CIRCULATION, V37, P624, DOI 10.1161/01.CIR.37.4.624; CHAMBERS BR, 1986, NEW ENGL J MED, V315, P860, DOI 10.1056/NEJM198610023151404; COX DR, 1972, J R STAT SOC B, V34, P187; CRAVEN TE, 1990, CIRCULATION, V82, P1230, DOI 10.1161/01.CIR.82.4.1230; Criqui M H, 1991, Drugs, V42 Suppl 5, P16; CULLEN SJ, 1983, CIRCULATION, V68, P83; DYKEN ML, 1984, STROKE, V15, P1105; FOWKES FGR, 1988, INT J EPIDEMIOL, V17, P248, DOI 10.1093/ije/17.2.248; GUNDERSEN J, 1972, ACTA CHIR SCAND S426, V26; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; ISACSSON SO, 1972, ACTA MED SCANDI S537, V192; JANZON L, 1981, CIRCULATION, V63, P1339, DOI 10.1161/01.CIR.63.6.1339; JUNGQUIST G, 1986, CLIN PHYSIOL, V6, P319, DOI 10.1111/j.1475-097X.1986.tb00237.x; JUNGQUIST G, 1989, STROKE, V20, P1327, DOI 10.1161/01.STR.20.10.1327; JUULMOLLER S, 1991, J INTERN MED, V230, P143, DOI 10.1111/j.1365-2796.1991.tb00422.x; LANDI G, 1992, LANCET, V339, P402, DOI 10.1016/0140-6736(92)90086-I; OGREN M, 1993, LANCET, V342, P1138, DOI 10.1016/0140-6736(93)92123-B; SALONEN R, 1988, ARTERIOSCLEROSIS, V8, P788, DOI 10.1161/01.ATV.8.6.788; SUTTON KC, 1987, STROKE, V18, P817, DOI 10.1161/01.STR.18.5.817; WILLEIT J, 1993, ARTERIOSCLER THROMB, V13, P661, DOI 10.1161/01.ATV.13.5.661; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561	23	62	63	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	1995	310	6990					1294	1298		10.1136/bmj.310.6990.1294	http://dx.doi.org/10.1136/bmj.310.6990.1294			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773042	Green Published			2022-12-24	WOS:A1995QZ86000020
J	DEMITRI, MS; POUSSIN, K; BACCARINI, P; PONTISSO, P; DERRICO, A; SIMON, N; GRIGIONI, W; ALBERTI, A; BEAUGRAND, M; PISI, E; BRECHOT, C; PATERLINI, P				DEMITRI, MS; POUSSIN, K; BACCARINI, P; PONTISSO, P; DERRICO, A; SIMON, N; GRIGIONI, W; ALBERTI, A; BEAUGRAND, M; PISI, E; BRECHOT, C; PATERLINI, P			HCV-ASSOCIATED LIVER-CANCER WITHOUT CIRRHOSIS	LANCET			English	Article							HEPATITIS-C VIRUS; POLYMERASE CHAIN-REACTION; B SURFACE-ANTIGEN; HEPATOCELLULAR-CARCINOMA; DNA; INTEGRATION; SEQUENCES; GENOMES; DISEASE	Chronic infection with hepatitis C virus (HCV) is regarded as a risk factor for hepatocellular cancer, mostly in patients with liver cirrhosis. We looked for HCV genomes in the livers of patients with hepatocellular cancer who did not have cirrhosis to see whether HCV was directly oncogenic. Cancerous and non-cancerous liver tissue, and serum samples from 19 patients negative for hepatitis B surface antigen were analysed by polymerase chain reaction for the presence of HCV genome, HCV replication, HCV genotyping, and HBV genome. 13 of 19 patients were HCV RNA-positive in cancerous and non-cancerous liver tissue; 8 of 17 tested were anti-HCV positive. Among the 13 HCV RNA-positive patients, 11 had genotype 1b and 2 had genotype 2a. 7 of 13 serum samples were HCV RNA positive. 7 of 19 patients were HBV DNA positive in cancerous and non-cancerous liver tissue, 5 of them anti-HBc positive. 4 patients were both HCV RNA and HBV DNA positive and 3 were both HCV RNA and HBV DNA negative. Our results provide evidence for the association of HCV, mostly genotype 1b, with hepatocellular cancer without the intermediate. step of cirrhosis.	FAC MED NECKER ENFANTS MALAD,INSERM,U370,F-75015 PARIS,FRANCE; UNIV BOLOGNA,DEPT INTERNAL MED,BOLOGNA,ITALY; UNIV BOLOGNA,DEPT PATHOL,BOLOGNA,ITALY; UNIV PADUA,DEPT INTERNAL MED,PADUA,ITALY; AURA,PARIS,FRANCE; HOP VERDIER,DEPT GASTROENTEROL,BONDY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Bologna; University of Bologna; University of Padua; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP			PONTISSO, PATRIZIA/K-3574-2018; Foschini, Maria P./A-6306-2016	PONTISSO, PATRIZIA/0000-0003-2077-9202; ALBERTI, ALFREDO/0000-0001-9926-2382; Foschini, Maria P./0000-0001-7079-7260				BLUM HE, 1994, HEPATOLOGY, V19, P251, DOI 10.1016/0270-9139(94)90078-7; BRECHOT C, 1985, NEW ENGL J MED, V312, P270, DOI 10.1056/NEJM198501313120503; Brouwer J. T., 1993, Journal of Hepatology, V18, pS10; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLOMBO M, 1994, PRIMARY LIVER CANC E, P49; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; FERAY C, IN PRESS GASTROENTER; GERBER MA, 1992, AM J PATHOL, V141, P1271; HERR W, 1993, CLIN INVESTIGATOR, V71, P49, DOI 10.1007/BF00210964; KAKLAMANI E, 1991, JAMA-J AM MED ASSOC, V265, P1974, DOI 10.1001/jama.265.15.1974; KATO N, 1993, HEPATOLOGY, V18, P16, DOI 10.1002/hep.1840180104; KEW MC, 1984, SEMIN LIVER DIS, V4, P136, DOI 10.1055/s-2008-1040653; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; MELIA WM, 1984, Q J MED, V211, P391; MIYAMURA T, 1994, PRIMARY LIVER CANC E, P125; NOUSBAUM J, IN PRESS ANN INTERN; PATERLINI P, 1993, HEPATOLOGY, V17, P20, DOI 10.1016/0270-9139(93)90186-Q; PATERLINI P, 1990, NEW ENGL J MED, V323, P80, DOI 10.1056/NEJM199007123230202; PATERLINI P, IN PRESS VIRAL HEPAT; PONTISSO P, 1993, GASTROENTEROLOGY, V105, P1529, DOI 10.1016/0016-5085(93)90161-5; POZZATO G, 1992, Journal of Hepatology, V16, pS3; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SBOLLI G, 1990, J MED VIROL, V30, P230, DOI 10.1002/jmv.1890300316; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; SIMMONDS P, 1993, J GEN VIROL, V74, P661, DOI 10.1099/0022-1317-74-4-661; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TAKADA N, 1992, J HEPATOL, V14, P35, DOI 10.1016/0168-8278(92)90128-C; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203	30	243	248	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					413	415		10.1016/S0140-6736(95)90400-X	http://dx.doi.org/10.1016/S0140-6736(95)90400-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7772123				2022-12-24	WOS:A1995QG90400008
J	KURZROCK, R; COHEN, PR				KURZROCK, R; COHEN, PR			ERYTHEMA-GYRATUM-REPENS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note									UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MED SPECIALTIES,DERMATOL SECT,HOUSTON,TX; UNIV TEXAS,SCH MED,DEPT DERMATOL,HOUSTON,TX; UNIV TEXAS,SCH MED,DEPT PATHOL,HOUSTON,TX	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System	KURZROCK, R (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN INVEST,BOX 302,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.		Kurzrock, Razelle/AAU-9782-2020					BARBER PV, 1978, BRIT J DERMATOL, V98, P465; BARRIERE H, 1978, ANN DERMATOL VENER, V105, P319; BOYD AS, 1992, J AM ACAD DERMATOL, V26, P757, DOI 10.1016/0190-9622(92)70107-Q; CHEESBROUGH MJ, 1985, CLIN EXP DERMATOL, V10, P466, DOI 10.1111/j.1365-2230.1985.tb00606.x; GAMMEL JA, 1952, AMA ARCH DERM SYPH, V66, P494, DOI 10.1001/archderm.1952.01530290070010; HOLT PJA, 1977, BRIT J DERMATOL, V96, P343, DOI 10.1111/j.1365-2133.1977.tb07127.x; INGBER A, 1983, Z HAUTKRANKHEITEN, V58, P1298; OLSEN TG, 1984, CUTIS, V34, P351; TYRING SK, 1993, CLIN DERMATOL, V11, P135, DOI 10.1016/0738-081X(93)90110-X	9	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					594	594		10.1001/jama.273.7.594	http://dx.doi.org/10.1001/jama.273.7.594			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF686	7837395				2022-12-24	WOS:A1995QF68600032
J	MAYER, A; NEUPERT, W; LILL, R				MAYER, A; NEUPERT, W; LILL, R			MITOCHONDRIAL PROTEIN IMPORT - REVERSIBLE BINDING OF THE PRESEQUENCE AT THE TRANS SIDE OF THE OUTER-MEMBRANE DRIVES PARTIAL TRANSLOCATION AND UNFOLDING	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; C HEME LYASE; PRECURSOR PROTEINS; INTERMEMBRANE SPACE; RECEPTOR COMPLEX; INNER MEMBRANE; CYTOCHROME-C; INSERTION; YEAST; MATRIX	The mechanism of translocation of matrix-targeted, cleavable preproteins across the mitochondrial outer membrane was studied using purified outer membrane vesicles. The N-terminal presequence interacts in a sequential and reversible fashion with two specific binding sites. The first one is provided by protease-sensitive receptors on the surface of the membrane (cis site); the second one is located at the inner face of the outer membrane (trans site). Binding to the trans site drives translocation of the N-terminal portion of the preprotein and, at the same time, unfolding of its mature part. We suggest that the outer membrane protein import machinery forms a translocation channel that permits reversible sliding of preproteins and prevents their lateral aggregation in the membrane. Although translocation can be initiated by the outer membrane, its completion requires coupling to the energetic system of the inner membrane. Our data assign an essential role to the presequence, not only for efficient targeting, but also for the translocation step.	UNIV MUNICH, INST PHYSIOL CHEM PHYS BIOCHMEM & ZELLBIOL, D-80336 MUNICH, GERMANY	University of Munich			Mayer, Andreas/AAE-4315-2020	Mayer, Andreas/0000-0001-6131-313X; Lill, Roland/0000-0002-8345-6518				ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; DOBBERSTEIN B, 1994, NATURE, V367, P599, DOI 10.1038/367599a0; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GLICK B, 1991, ANNU REV GENET, V25, P21; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; HWANG ST, 1991, J BIOL CHEM, V266, P21083; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MAYER A, 1994, CELL BIOL LABORATORY; NEUPERT W, 1993, PHILOS T ROY SOC B, V339, P355, DOI 10.1098/rstb.1993.0034; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NICHOLSON DW, 1987, EUR J BIOCHEM, V164, P147, DOI 10.1111/j.1432-1033.1987.tb11006.x; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SEGUIREAL B, 1992, FEBS LETT, V313, P2, DOI 10.1016/0014-5793(92)81171-H; SEQUIREAL B, 1993, EMBO J, V12, P2211, DOI 10.1002/j.1460-2075.1993.tb05869.x; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533	43	144	144	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 13	1995	80	1					127	137		10.1016/0092-8674(95)90457-3	http://dx.doi.org/10.1016/0092-8674(95)90457-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813008	Bronze			2022-12-24	WOS:A1995QB91000016
J	MITNIK, L; HELLER, C; PROST, J; VIOVY, JL				MITNIK, L; HELLER, C; PROST, J; VIOVY, JL			SEGREGATION IN DNA SOLUTIONS INDUCED BY ELECTRIC-FIELDS	SCIENCE			English	Article							ELECTROPHORESIS	DNA solutions subjected to an electric field exhibit an instability that leads to DNA segregation in aggregates tilted with regard to the field. With the use of epifluorescence videomicroscopy, the evolution of DNA patterns in capillaries as a function of DNA concentration, DNA size, field strength, and field frequency was studied. The field threshold for segregation was decreased when the frequency was lowered or when the DNA molecular weight or concentration was increased. Aggregation is attributed to an electrohydrodynamic instability triggered by the dipole-dipole interaction. This phenomenon explains the failure of earlier attempts to separate large DNA in capillaries.	ECOLE SUPER PHYS & CHIM IND VILLE PARIS, CNRS, UA 1382, PHYSICOCHIM THEOR LAB, F-75231 PARIS 05, FRANCE; ECOLE SUPER PHYS & CHIM IND VILLE PARIS, CNRS, UA 278, PHYSICOCHIM STRUCT & MACROMOLEC LAB, F-75231 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)				Viovy, Jean-Louis/0000-0002-8223-4040; Heller, Christoph/0000-0002-9434-8192				BROCHARDWYART F, 1988, CR ACAD SCI II, V307, P1497; Colburn J.C., 1992, CAPILLARY ELECTROPHO; GUSZCZYNSKI T, 1993, ELECTROPHORESIS, V14, P523, DOI 10.1002/elps.1150140180; HJERTEN S, 1991, FEB HIGH PERF CAP EL; HU Y, 1994, J CHEM PHYS, V100, P4674, DOI 10.1063/1.466250; JONSSON M, 1993, J CHEM SOC FARADAY T, V89, P2791, DOI 10.1039/ft9938902791; KRATKY O, 1949, RECL TRAV CHIM PAY B, V68, P1106; Mandel M, 1977, Ann N Y Acad Sci, V303, P74, DOI 10.1111/j.1749-6632.1977.tb55921.x; POHL HA, 1978, DIELECTROPHORESIS, P135; SONG L, 1991, J BIOMOL STRUCT DYN, V9, P87, DOI 10.1080/07391102.1991.10507895; WANG ZL, 1990, MACROMOLECULES, V23, P790, DOI 10.1021/ma00205a016	11	79	80	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 13	1995	267	5195					219	222		10.1126/science.7809626	http://dx.doi.org/10.1126/science.7809626			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809626				2022-12-24	WOS:A1995QB15300029
J	RANGELFRAUSTO, MS; PITTET, D; COSTIGAN, M; HWANG, T; DAVIS, CS; WENZEL, RP				RANGELFRAUSTO, MS; PITTET, D; COSTIGAN, M; HWANG, T; DAVIS, CS; WENZEL, RP			THE NATURAL-HISTORY OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) - A PROSPECTIVE-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS SYNDROME; CONTROLLED CLINICAL-TRIAL; GRAM-NEGATIVE BACTEREMIA; SEPTIC SHOCK; SEPSIS SYNDROME; MONOCLONAL-ANTIBODY; ENDOTOXIN; DISEASE	Objective.-Define the epidemiology of the four recently classified syndromes describing the biologic response to infection: systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic shock. Design.-Prospective cohort study with a follow-up of 28 days or until discharge if earlier. Setting.-Three intensive care units and three general wards in a tertiary health care institution. Methods.-Patients were included if they met at least two of the criteria for SI RS: fever or hypothermia, tachycardia, tachypnea, or abnormal white blood cell count. Main Outcomes Measures.-Development of any stage of the biologic response to infection: sepsis, severe sepsis, septic shock, end-organ dysfunction, and death. Results.-During the study period 3708 patients were admitted to the survey units, and 2527 (68%) met the criteria for SIRS. The incidence density rates for SIRS in the surgical, medical, and cardiovascular intensive care units were 857, 804, and 542 episodes per 1000 patient-days, respectively, and 671, 495, and 320 per 1000 patient-days for the medical, cardiothoracic, and general surgery wards, respectively. Among patients with SIRS, 649 (26%) developed sepsis, 467 (18%) developed severe sepsis, and 110 (4%) developed septic shock. The median interval from SIRS to sepsis was inversely correlated with the number of SIRS criteria (two, three, or all four) that the patients met. As the population of patients progressed from SIRS to septic shock, increasing proportions had adult respiratory distress syndrome, disseminated intravascular coagulation, acute renal failure, and shock. Positive blood cultures were found in 17% of patients with sepsis, in 25% with severe sepsis, and in 69% with septic shock, There were also stepwise increases in mortality rates in the hierarchy from SIRS, sepsis, severe sepsis, and septic shock: 7%, 16%, 20%, and 46%, respectively. Of interest, we also observed equal numbers of patients who appeared to have sepsis, severe sepsis, and septic shock but who had negative cultures. They had been prescribed empirical antibiotics for a median of 3 days, The cause of the systemic inflammatory response in these culture-negative populations is unknown, but they had similar morbidity and mortality rates as the respective culture-positive populations. Conclusions.-This prospective epidemiologic study of SIRS and related conditions provides, to our knowledge, the first evidence of a clinical progression from SIRS to sepsis to severe sepsis and septic shock.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,DIV GEN MED CLIN EPIDEMIOL & HLTH SERV RES,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PREVENT MED,DIV BIOSTAT,IOWA CITY,IA 52242; UNIV HOSP GENEVA,DEPT INTERNAL MED,DIV INFECT DIS,INFECT CONTROL GRP,GENEVA,SWITZERLAND	University of Iowa; University of Iowa; University of Geneva								[Anonymous], 1992, CRIT CARE MED, V20, P864; Bone R C, 1991, Infect Dis Clin North Am, V5, P793; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BONE RC, 1991, ANN INTERN MED, V114, P332, DOI 10.7326/0003-4819-114-4-332; BRODERICK A, 1990, AM J EPIDEMIOL, V131, P734, DOI 10.1093/oxfordjournals.aje.a115558; EXLEY AR, 1990, LANCET, V335, P1275, DOI 10.1016/0140-6736(90)91337-A; FREEMAN J, 1980, AM J EPIDEMIOL, V112, P707, DOI 10.1093/oxfordjournals.aje.a113043; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P10; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MCCABE WR, 1962, ARCH INTERN MED, V110, P856, DOI 10.1001/archinte.1962.03620240038007; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NIEDERMAN MS, 1990, CLIN CHEST MED, V11, P633; OPAL SM, 1992, OCT INT C ANT AG CHE, P372; OWENS WD, 1978, ANESTHESIOLOGY, V49, P239, DOI 10.1097/00000542-197810000-00003; PARKER MM, 1983, JAMA-J AM MED ASSOC, V250, P3324, DOI 10.1001/jama.250.24.3324; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; PITTET D, 1991, SEP INT C ANT AG CHE, P232; PITTET D, 1993, OCT INT C ANT AG CHE, P358; TEASDALE G, 1974, LANCET, V2, P81; WENZEL RP, 1992, NEW ENGL J MED, V326, P1151, DOI 10.1056/NEJM199204233261710; WHERRY J, 1993, OCT INT C ANT AG CHE, P246; WOOLSON RF, 1987, STATISTICAL METHODS, P252; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1993, MONTHLY VITAL STAT R, V41, P5; 1990, SAS STAT USERS GUIDE, V2	29	1408	1514	1	81	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 11	1995	273	2					117	123		10.1001/jama.273.2.117	http://dx.doi.org/10.1001/jama.273.2.117			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ687	7799491				2022-12-24	WOS:A1995PZ68700024
J	DOOLEY, CT; CHUNG, NN; WILKES, BC; SCHILLER, PW; BIDLACK, JM; PASTERNAK, GW; HOUGHTEN, RA				DOOLEY, CT; CHUNG, NN; WILKES, BC; SCHILLER, PW; BIDLACK, JM; PASTERNAK, GW; HOUGHTEN, RA			AN ALL D-AMINO-ACID OPIOID PEPTIDE WITH CENTRAL ANALGESIC ACTIVITY FROM A COMBINATORIAL LIBRARY	SCIENCE			English	Article							OPIATE RECEPTOR; LIGANDS	A synthetic combinatorial library containing 52,128,400 D-amino acid hexapeptides was used to identify a ligand for the mu opioid receptor. The peptide, Ac-rfwink-NH2, bears no resemblance to any known opioid peptide. Simulations using molecular dynamics, however, showed that three amino acid moieties have the same spatial orientation as the corresponding pharmacophoric groups of the opioid peptide PLO17. Ac-rfwink-NH2 was shown to be a potent agonist at the mu receptor and induced long-lasting analgesia in mice. Analgesia produced by intraperitoneally administered Ac-rfwink-NH2 was blocked by intracerebroventricular administration of naloxone, demonstrating that this peptide may cross the blood-brain barrier.	TORREY PINES INST MOLEC STUDIES,SAN DIEGO,CA 92121; HOUGHTEN PHARMACEUT INC,SAN DIEGO,CA 92121; CLIN RES INST MONTREAL,CHEM BIOL & PEPTIDE RES LAB,MONTREAL,PQ H2W 1R7,CANADA; UNIV ROCHESTER,MED CTR,DEPT PHARMACOL,ROCHESTER,NY 14642; MEM SLOAN KETTERING CANC CTR,DEPT NEUROL,NEW YORK,NY 10021	Torrey Pines Institute for Molecular Studies, California; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Rochester; Memorial Sloan Kettering Cancer Center					NIDA NIH HHS [DA-000138, DA-03742, DA-02615] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002615, R01DA003742, R56DA002615] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CLARK JA, 1988, MOL PHARMACOL, V34, P308; CLARK JA, 1989, J PHARMACOL EXP THER, V251, P461; DIMAIO J, 1982, J MED CHEM, V25, P1432, DOI 10.1021/jm00354a008; DOOLEY CT, 1993, P NATL ACAD SCI USA, V90, P10811, DOI 10.1073/pnas.90.22.10811; DOOLEY CT, 1993, LIFE SCI, V52, P1509, DOI 10.1016/0024-3205(93)90113-H; HENDERSON G, 1972, BRIT J PHARMACOL, V46, P764, DOI 10.1111/j.1476-5381.1972.tb06901.x; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HOUGHTEN RA, 1992, BIOTECHNIQUES, V13, P412; HOUGHTEN RA, 1993, BIOORG MED CHEM LETT, V3, P405, DOI 10.1016/S0960-894X(01)80222-5; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; JIANG Q, 1992, J PHARMACOL EXP THER, V262, P526; KOSTERLITZ HW, 1968, BRIT J PHARMACOL, V33, P266, DOI 10.1111/j.1476-5381.1968.tb00988.x; PATON WDM, 1957, BRIT J PHARM CHEMOTH, V12, P119, DOI 10.1111/j.1476-5381.1957.tb01373.x; SCHILLER PW, 1978, BIOCHEM BIOPH RES CO, V85, P1332, DOI 10.1016/0006-291X(78)91149-X; SCHILLER PW, 1983, PEPTIDES STRUCTURE F, P269; VAUGHN LK, 1993, LIFE SCI, V52, P1509; YAMAZAKI T, 1993, J MED CHEM, V36, P708, DOI 10.1021/jm00058a007; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	19	144	186	1	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					2019	2022		10.1126/science.7801131	http://dx.doi.org/10.1126/science.7801131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801131				2022-12-24	WOS:A1994PZ26700037
J	LIM, WA; RICHARDS, FM; FOX, RO				LIM, WA; RICHARDS, FM; FOX, RO			STRUCTURAL DETERMINANTS OF PEPTIDE-BINDING ORIENTATION AND OF SEQUENCE SPECIFICITY IN SH3 DOMAINS	NATURE			English	Article							CRYSTAL-STRUCTURE; TYROSINE KINASES; PROTEIN; SOS; ASSOCIATION; SEVENLESS; EXCHANGE; GRB2	THE Src-homology-3 (SH3) domains of the Caenorhabditis elegans protein SEM-5 and its human and Drosophila homologues, Grb2 and Drk (refs 1-4), bind proline-rich sequences found in the nucleotide-exchange factor Sos as part of their proposed function linking receptor tyrosine kinase activation to Ras activation(5-7). Here we report the crystal structure at 2.0 Angstrom resolution of the carboxy-terminal SH3 domain from SEM-5 complexed to the mSos-derived amino-acid sequence PPPVPPRRR. The peptide is found to bind in an orientation ('minus') that is precisely opposite to that observed previously ('plus' orientation) in other SH3-peptide complexes(8,9). This novel ability of peptide-recognition proteins to recognize peptides in two distinct modes may play an important role in the signalling specificity of pathways involving SH3 domains. Comparison of this structure with other SH3 complexes reveals how a conserved binding face can be used to recognize peptides in different orientations, and why the Sos peptide binds in this particular orientation.	YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06520	Howard Hughes Medical Institute; Yale University	LIM, WA (corresponding author), YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,POB 6666,NEW HAVEN,CT 06520, USA.							BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DUNBRACK RL, 1993, J MOL BIOL, V230, P542; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; LI N, 1993, NATURE, V363, P83; LIM WA, 1994, PROTEIN SCI, V3, P1261, DOI 10.1002/pro.5560030812; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NAVAZA J, 1987, ACTA CRYSTALLOGR A, V43, P645, DOI 10.1107/S0108767387098787; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICHARDS FM, 1993, Q REV BIOPHYS, V26, P423, DOI 10.1017/S0033583500002845; ROZAKISADOCK M, 1993, NATURE, V363, P79; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; TERASAWA H, IN PRESS NATURE STRU; WITTEKIND M, IN PRESS BIOCHEMISTR; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZVELEBIL MJJM, 1993, Q REV BIOPHYS, V26, P333, DOI 10.1017/S0033583500002870	28	475	482	1	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					375	379		10.1038/372375a0	http://dx.doi.org/10.1038/372375a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7802869				2022-12-24	WOS:A1994PU28700059
J	ENDERS, G; MILLER, E; CRADOCKWATSON, J; BOLLEY, I; RIDEHALGH, M				ENDERS, G; MILLER, E; CRADOCKWATSON, J; BOLLEY, I; RIDEHALGH, M			CONSEQUENCES OF VARICELLA AND HERPES-ZOSTER IN PREGNANCY - PROSPECTIVE-STUDY OF 1739 CASES	LANCET			English	Article							VIRUS-INFECTIONS; ZOSTER VIRUS	In a joint prospective study in Germany and the United Kingdom between 1980 and 1993, 1373 women who had varicella and 366 who had herpes tester during the first 36 weeks of gestation were followed up.	PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,DIV IMMUNISAT,LONDON NW9 5EQ,ENGLAND; INST VIROL INFEKTIOL & EPIDEMIOL,D-70192 STUTTGART,GERMANY; WITHINGTON HOSP,PUBL HLTH LAB,MANCHESTER M20 8LR,LANCS,ENGLAND	Public Health England								ALKALAY AL, 1987, J PEDIATR-US, V111, P320, DOI 10.1016/S0022-3476(87)80447-X; CRADOCKWATSON JE, 1991, CURRENT TOPICS CLIN, P1; DASILVA O, 1990, PEDIATR INFECT DIS J, V9, P854; ENDERS G, 1985, POSTGRAD MED J, V61, P23; GOTTARDI H, 1991, GEBURTSH FRAUENHEILK, V51, P63, DOI 10.1055/s-2008-1026335; HAAKE DA, 1990, REV INFECT DIS, V12, P788; HIGA K, 1987, OBSTET GYNECOL, V69, P214; KANGRO HO, 1988, EPIDEMIOL INFECT, V101, P187, DOI 10.1017/S0950268800029344; LAFORET EG, 1947, NEW ENGL J MED, V236, P534, DOI 10.1056/NEJM194704102361504; MEHRAEIN Y, 1991, GEBURTSH FRAUENHEILK, V51, P984, DOI 10.1055/s-2008-1026249; MICHIE CA, 1992, PEDIATR INFECT DIS J, V11, P1050, DOI 10.1097/00006454-199211120-00012; Miller E., 1993, Reviews in Medical Microbiology, V4, P222; MILLER E, 1989, LANCET, V2, P371; MILLER E, 1993, LANCET, V341, P308, DOI 10.1016/0140-6736(93)92663-E; PUCHHAMMERSTOCK.E, 1994, IN PRESS J PERINAT M, V22; SCHARF A, 1990, J PERINAT MED, V18, P317	16	335	357	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1548	1551		10.1016/S0140-6736(94)92943-2	http://dx.doi.org/10.1016/S0140-6736(94)92943-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7802767				2022-12-24	WOS:A1994NR32900013
J	WILCOX, CM; SCHWARTZ, DA; CLARK, WS				WILCOX, CM; SCHWARTZ, DA; CLARK, WS			ESOPHAGEAL ULCERATION IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - CAUSES, RESPONSE TO THERAPY, AND LONG-TERM OUTCOME	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNE-DEFICIENCY-SYNDROME; AVIUM COMPLEX INFECTION; CYTOMEGALOVIRUS VIREMIA; CD4 COUNT; SURVIVAL; AIDS; TRANSPLANTATION; HYBRIDIZATION; ZIDOVUDINE; SYMPTOMS	Objective: To determine the causes of esophageal ulceration, the response rate to currently available therapies, and the long-term outcome in patients with human immunodeficiency virus (HIV) infection. Design: Prospective cohort study. Setting: An urban county hospital. Patients: Consecutive patients with HIV infection and endoscopically detected esophageal ulceration during a 4-year period, Intervention: Causes of ulcers were determined from clinical, endoscopic, and pathologic findings. Standard medical therapies for the identified causes were instituted, and ulcer healing was endoscopically confirmed when possible. Measurements: Symptomatic and endoscopic response to therapy and long-term outcome, including survival. Results: 100 patients with esophageal ulcer were identified. Ulcers caused by cytomegalovirus alone were the most common (n = 45); idiopathic ulcers were almost as frequent (n = 40). Herpes simplex Virus esophagitis alone was identified as a cause in only 5 patients. Several potential causes of ulcer were found in 5 patients, including Candida esophagitis in 27 patients. Ten patients developed more than one cause of ulceration during long-term follow-up. Eighty-five patients had specific medical therapy for their identified disorders and had an overall response rate of 98%. Median survival from time of diagnosis was 8.9 months (range, 2 days to > 42 months). A difference in median survival was found between patients with cytomegalovirus esophagitis and those with idiopathic esophageal ulcer (7.6 months compared with 13.1 months; P = 0.03). Conclusions: Given I)the broad spectrum of causes of esophageal ulceration, 2) that each of these causes requires specific therapy, and 3) the apparent high response rate, it is important to do endoscopic evaluation with mucosal biopsy in patients with HIV infection so that a diagnosis can be established and appropriate therapy instituted. Despite effective therapy, long-term survival is poor; however, long-term remission and survival may occur in some patients.	EMORY UNIV, SCH MED, ATLANTA, GA USA; EMORY UNIV, SCH PUBL HLTH, ATLANTA, GA USA; GRADY MEM HOSP, ATLANTA, GA USA	Emory University; Emory University								ALEXANDER JA, 1988, DIGEST DIS SCI, V33, P1121, DOI 10.1007/BF01535788; BLANSHARD C, 1992, Q J MED, V85, P813; BONACINI M, 1991, ARCH INTERN MED, V151, P1567, DOI 10.1001/archinte.151.8.1567; CASABONA J, 1993, EUR J CANCER, V29A, P877, DOI 10.1016/S0959-8049(05)80430-7; CLAYTON F, 1989, ARCH PATHOL LAB MED, V113, P1124; CONNOLLY GM, 1989, GUT, V30, P1033, DOI 10.1136/gut.30.8.1033; DEGRUTTOLA V, 1993, J ACQ IMMUN DEF SYND, V6, P359; DOHN MN, 1992, ARCH INTERN MED, V152, P2465, DOI 10.1001/archinte.152.12.2465; EDWARDS P, 1990, ANN INTERN MED, V112, P65, DOI 10.7326/0003-4819-112-1-65; GERNA G, AIDS, V190, P1027; HORSBURGH CR, 1991, AM REV RESPIR DIS, V144, P557, DOI 10.1164/ajrccm/144.3_Pt_1.557; INDORF AS, 1992, ANN INTERN MED, V117, P133, DOI 10.7326/0003-4819-117-2-133; JACOBSON MA, 1991, J INFECT DIS, V164, P994, DOI 10.1093/infdis/164.5.994; KOTLER DP, 1992, J CLIN GASTROENTEROL, V15, P284, DOI 10.1097/00004836-199212000-00004; KUITERT LM, 1991, AIDS, V5, P1036, DOI 10.1097/00002030-199108000-00023; LEVINE AM, 1991, CANCER, V68, P2466, DOI 10.1002/1097-0142(19911201)68:11<2466::AID-CNCR2820681124>3.0.CO;2-G; LEVINE DS, 1991, GASTROINTEST ENDOSC, V37, P332, DOI 10.1016/S0016-5107(91)70726-8; MCDONALD GB, 1985, GASTROENTEROLOGY, V88, P1111, DOI 10.1016/S0016-5085(85)80068-8; MILES SA, 1994, J CLIN ONCOL, V12, P1910, DOI 10.1200/JCO.1994.12.9.1910; NELSON MR, 1991, AM J GASTROENTEROL, V86, P876; NIGHTINGALE SD, 1993, ARCH INTERN MED, V153, P1313, DOI 10.1001/archinte.153.11.1313; PHILLIPS AN, 1992, JAMA-J AM MED ASSOC, V268, P2662, DOI 10.1001/jama.268.19.2662; RABENECK L, 1990, JAMA-J AM MED ASSOC, V263, P2318, DOI 10.1001/jama.263.17.2318; RAGNI MV, 1993, BLOOD, V81, P1889; SALMON D, 1990, J MED VIROL, V32, P160, DOI 10.1002/jmv.1890320306; SCHWARTZ DA, 1992, HUM PATHOL, V23, P1019, DOI 10.1016/0046-8177(92)90263-3; SEGONDY M, 1990, SCAND J INFECT DIS, V22, P653, DOI 10.3109/00365549009027117; STONEBURNER R, 1992, ARCH INTERN MED, V152, P2033, DOI 10.1001/archinte.152.10.2033; WILCOX CM, 1995, AM J MED, V98, P169, DOI 10.1016/S0002-9343(99)80400-8; WILCOX CM, 1994, AM J GASTROENTEROL, V89, P2163; WILCOX CM, 1994, GASTROINTEST ENDOSC, V40, P481, DOI 10.1016/S0016-5107(94)70215-2; WILCOX CM, 1993, J CLIN GASTROENTEROL, V16, P251, DOI 10.1097/00004836-199304000-00019; WILCOX CM, 1993, AM J GASTROENTEROL, V88, P1459; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184	34	69	75	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1995	123	2					143	149		10.7326/0003-4819-123-2-199507150-00010	http://dx.doi.org/10.7326/0003-4819-123-2-199507150-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM435	7778827				2022-12-24	WOS:A1995RM43500010
J	MITCHELL, AA; VANBENNEKOM, CM; LOUIK, C				MITCHELL, AA; VANBENNEKOM, CM; LOUIK, C			A PREGNANCY-PREVENTION PROGRAM IN WOMEN OF CHILDBEARING AGE RECEIVING ISOTRETINOIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THALIDOMIDE	Background. Isotretinoin is effective in treating severe acne, but it is also teratogenic. To minimize pregnancies among exposed women, the manufacturer, together with the U.S. Food and Drug Administration, implemented a multicomponent Pregnancy Prevention Program in 1988. We report the results of an ongoing survey designed to assess compliance with this program. Methods. Treated women enrolled in the survey through their physician, by filling out a form in the medication package, or by calling a toll-free telephone number. They were randomly assigned to be followed by telephone or by mail. Telephone interviews were conducted at the start of therapy, in the middle of it, and 6 months after it ended; mailed questionnaires were completed 6 months after therapy ended (median duration of therapy, 20 weeks). Results. Between 1989 and 1993, 177,216 eligible women enrolled in the survey. Interviews with 24,503 women within one month of enrollment revealed that 99 percent had been told to avoid pregnancy. At that time, approximately 54 percent were not sexually active (of whom 37 percent used contraception) and 42 percent were sexually active (of whom 99 percent used contraception); 4 percent were infertile. Among 124,216 women with completed telephone or mail follow-up results, there were 402 pregnancies during therapy (3.4 per 1000 courses of isotretinoin); 72 percent of the pregnant women had elective abortions, 16 percent spontaneous abortions, 3 percent ectopic pregnancies, and 8 percent live births. Conclusions. The pregnancy rate among women receiving isotretinoin therapy was substantially lower than that in the general population and was compatible with the characteristics and behavior of the enrolled women.			MITCHELL, AA (corresponding author), BOSTON UNIV,SCH MED,SCH PUBL HLTH,SLONE EPIDEMIOL UNIT,1371 BEACON ST,BROOKLINE,MA 02146, USA.			Mitchell, Allen/0000-0003-0950-6799; Louik, Carol/0000-0001-5429-5084				DAI WS, 1992, J AM ACAD DERMATOL, V26, P599, DOI 10.1016/0190-9622(92)70088-W; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; FEAGAN BG, 1995, NEW ENGL J MED, V332, P292, DOI 10.1056/NEJM199502023320503; GORMAN C, 1994, TIME            0613, P67; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P287; LAMMER EJ, 1985, NEW ENGL J MED, V343, P837; MAKONKAWKEYOON S, 1993, P NATL ACAD SCI USA, V90, P5974, DOI 10.1073/pnas.90.13.5974; MOSHER WD, 1990, DHHS PHS901250 PUBL; SAMPAIO EP, 1993, J INFECT DIS, V168, P408, DOI 10.1093/infdis/168.2.408; STERN RS, 1989, NEW ENGL J MED, V320, P1007, DOI 10.1056/NEJM198904133201510; TRUSSELL J, 1987, STUD FAMILY PLANN, V18, P237, DOI 10.2307/1966856; UNDERWOOD AA, 1994, NEWSWEEK        0919, P58; VENTURA SJ, 1992, MON VITAL STAT REP S, V41; WEINBLATT ME, 1995, NEW ENGL J MED, V332, P330, DOI 10.1056/NEJM199502023320512	14	132	141	1	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 13	1995	333	2					101	106		10.1056/NEJM199507133330206	http://dx.doi.org/10.1056/NEJM199507133330206			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH225	7777014	Bronze			2022-12-24	WOS:A1995RH22500006
J	COCHI, SL; HULL, HF; WARD, NA				COCHI, SL; HULL, HF; WARD, NA			TO CONQUER POLIOMYELITIS FOREVER	LANCET			English	Editorial Material									WHO,EXPANDED PROGRAMME IMMUNIZAT,GENEVA,SWITZERLAND	World Health Organization	COCHI, SL (corresponding author), CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341, USA.							BART KJ, IN PRESS B WHO; HULL HF, 1994, LANCET, V343, P1331, DOI 10.1016/S0140-6736(94)92472-4; Smith Jane S., 1990, PATENTING SUN POLIO; YANG BP, 1995, PEDIATR INFECT DIS J, V14, P308, DOI 10.1097/00006454-199504000-00011; 1994, MMWR-MORBID MORTAL W, V13, P720; 1988, GLOBAL ERADICATION P; 1995, MMWR-MORBID MORTAL W, V44, P273	7	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1589	1590		10.1016/S0140-6736(95)90111-6	http://dx.doi.org/10.1016/S0140-6736(95)90111-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783533				2022-12-24	WOS:A1995RE67000004
J	THOMAS, JM				THOMAS, JM			GROIN STRAIN VERSUS OCCULT HERNIA - UNCOMFORTABLE ALTERNATIVES OR INCOMPATIBLE RIVALS	LANCET			English	Editorial Material							INGUINAL SURGERY; PAIN				THOMAS, JM (corresponding author), WATFORD DIST GEN HOSP,WATFORD,HERTS,ENGLAND.							ASHBY EC, 1977, ANN ROY COLL SURG, V59, P242; ASHBY EC, 1994, BRIT J SURG, V81, P1632, DOI 10.1002/bjs.1800811123; Carnett J., 1926, SURG GYNECOL OBSTET, P625; Cyriax EF, 1919, PRACTITIONER, V102, P314; EKBERG O, 1988, SPORTS MED, V6, P56, DOI 10.2165/00007256-198806010-00006; GALLEGOS NC, 1990, BRIT J SURG, V77, P1167, DOI 10.1002/bjs.1800771026; MALYCHA P, 1992, AUST NZ J SURG, V62, P123; POLGLASE AL, 1991, MED J AUSTRALIA, V155, P674, DOI 10.5694/j.1326-5377.1991.tb93958.x; Renstrom P, 1980, Br J Sports Med, V14, P30; SCOTT EM, 1993, GUT, V34, P1006, DOI 10.1136/gut.34.7.1006; SMEDBERG SGG, 1985, AM J SURG, V149, P378, DOI 10.1016/S0002-9610(85)80112-4; THOMSON H, 1977, LANCET, V2, P1053; UPPINGTON J, 1988, HOSP PRACT, V23, P37; Zimmerman G, 1988, Aust Fam Physician, V17, P1046	14	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1522	1523		10.1016/S0140-6736(95)91082-4	http://dx.doi.org/10.1016/S0140-6736(95)91082-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791435				2022-12-24	WOS:A1995RD79000004
J	CRAIG, AM; WYBORSKI, RJ; BANKER, G				CRAIG, AM; WYBORSKI, RJ; BANKER, G			PREFERENTIAL ADDITION OF NEWLY SYNTHESIZED MEMBRANE-PROTEIN AT AXONAL GROWTH CONES	NATURE			English	Article							SIMPLEX VIRUS AMPLICON; HIPPOCAMPAL-NEURONS; POLARITY ORIENTATION; PLASMA-MEMBRANE; GROWING AXONS; BREFELDIN-A; CULTURE; MICROTUBULES; DIFFUSION; MOVEMENT	THE addition of plasma membrane proteins to a growing axon could occur by preferential insertion at the tip (the growth cone), by uniform insertion along the axon, or by insertion at the cell body and bulk flow along the axon. To differentiate between these possibilities we used a defective herpesvirus vector to express an exogenous protein, the lymphocyte transmembrane protein CD8 alpha, in cultured rat hippocampal neurons. The newly synthesized protein first appeared on the axonal surface almost exclusively at the growth cone. Preferential addition at the growth cone was also observed in minor processes (immature dendrites), but not in mature dendrites. Over several hours, CD8 alpha reached a uniform distribution over the entire neuronal surface, presumably by diffusion within the membrane and possibly endocytic recycling. As well as providing materials for axonal growth, the selective addition of membrane vesicles at the growth cone may contribute to the polarized distribution of axonal surface molecules(1).	UNIV VIRGINIA,SCH MED,DEPT NEUROSCI,CHARLOTTESVILLE,VA 22908; PARKE DAVIS RES,DEPT BIOTECHNOL,ANN ARBOR,MI 48106	University of Virginia; Pfizer			Craig, Ann Marie/M-2054-2014					BAAS PW, 1989, J CELL BIOL, V109, P3085, DOI 10.1083/jcb.109.6.3085; BAAS PW, 1988, P NATL ACAD SCI USA, V85, P8335, DOI 10.1073/pnas.85.21.8335; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BRAY D, 1970, P NATL ACAD SCI USA, V65, P905, DOI 10.1073/pnas.65.4.905; DELUCA NA, 1985, J VIROL, V56, P558, DOI 10.1128/JVI.56.2.558-570.1985; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DOTTI CG, 1990, CELL, V62, P62; FELDMAN EL, 1981, J NEUROBIOL, V12, P591, DOI 10.1002/neu.480120607; FUTERMAN AH, 1993, NATURE, V362, P119, DOI 10.1038/362119a0; GELLER AI, 1988, SCIENCE, V241, P1667, DOI 10.1126/science.2843986; GOSLIN K, 1991, CULTURING NERVE CELL, P207; GRIFFIN JW, 1981, J CELL BIOL, V88, P205, DOI 10.1083/jcb.88.1.205; JUNG LJ, 1991, SCIENCE, V251, P1330, DOI 10.1126/science.2003219; KAPLITT M G, 1991, Molecular and Cellular Neuroscience, V2, P320, DOI 10.1016/1044-7431(91)90062-S; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KODA LY, 1976, J NEUROBIOL, V7, P157, DOI 10.1002/neu.480070208; KWONG AD, 1985, VIROLOGY, V142, P421, DOI 10.1016/0042-6822(85)90351-4; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MUNDIGL O, 1993, J CELL BIOL, V122, P1207, DOI 10.1083/jcb.122.6.1207; OKABE S, 1992, J CELL BIOL, V117, P105, DOI 10.1083/jcb.117.1.105; PFENNINGER KH, 1981, J CELL BIOL, V89, P547, DOI 10.1083/jcb.89.3.547; POPOV S, 1993, SCIENCE, V259, P244, DOI 10.1126/science.7678471; REINSCH SS, 1991, J CELL BIOL, V115, P365, DOI 10.1083/jcb.115.2.365; ROIZMAN B, 1990, VIROLOGY, V2, P1795; SMALL RK, 1984, J CELL BIOL, V98, P1434, DOI 10.1083/jcb.98.4.1434; SPAETE RR, 1982, CELL, V30, P295, DOI 10.1016/0092-8674(82)90035-6	26	154	155	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					592	594		10.1038/375592a0	http://dx.doi.org/10.1038/375592a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791876				2022-12-24	WOS:A1995RD28700052
J	CUENOUD, B; SZOSTAK, JW				CUENOUD, B; SZOSTAK, JW			A DNA METALLOENZYME WITH DNA-LIGASE ACTIVITY	NATURE			English	Article							HUMAN THROMBIN; RNA; BINDING; APTAMER; SELECTION; MOLECULES; INVITRO	SINGLE-STRANDED DNA can fold into well-defined sequence-dependent tertiary structures that specifically bind a variety of target molecules(1-10), raising the possibility that some folded single-stranded DNAs might exhibit catalytic activities similar to those of ribozymes and protein enzymes. Derivatives of the hammerhead ribozyme that contain a majority of deoxyribonucleotides retain the ability to cleave RNA(11), and a 'deoxyribozyme' was generated by leaving all essential ribonucleotides of the hammerhead on the RNA 'substrate'(12). Recently in vitro selection has been used to isolate a DNA sequence that shows Pb2+-dependent RNA-cleaving activity(13). Here we report the isolation by in vitro selection(14-17) of a small single-stranded DNA that is a Zn2+/Cu2+-dependent metalloenzyme. The enzyme catalyses the formation of a new phosphodiester bond by the condensation of the 5'-hydroxyl of one oligodeoxynucleotide and a 3'-phosphorimidazolide on another oligodeoxynucleotide, and shows multiple turnover ligation.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital								Ahrland S., 1973, COMPREHENSIVE INORGA, V5; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BRATTY J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P345, DOI 10.1016/0167-4781(93)90001-T; Breaker R R, 1994, Chem Biol, V1, P223, DOI 10.1016/1074-5521(94)90014-0; BREAKER RR, 1994, TRENDS BIOTECHNOL, V12, P268, DOI 10.1016/0167-7799(94)90138-4; CHAPMAN KB, 1994, CURR OPIN STRUC BIOL, V4, P618, DOI 10.1016/S0959-440X(94)90227-5; CHARTRAND P, 1994, RNA PROCESSING, V77; CHU BCF, 1986, NUCLEIC ACIDS RES, V14, P5591, DOI 10.1093/nar/14.14.5591; DAHM SC, 1993, BIOCHEMISTRY-US, V32, P13040, DOI 10.1021/bi00211a013; ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0; Fersht A., 1985, ENZYME STRUCTURE MEC; HUIZENGA DE, 1995, BIOCHEMISTRY-US, V34, P656, DOI 10.1021/bi00002a033; JOYCE GF, 1994, CURR OPIN STRUC BIOL, V4, P331, DOI 10.1016/S0959-440X(94)90100-7; KAO TH, 1980, P NATL ACAD SCI-BIOL, V77, P3360, DOI 10.1073/pnas.77.6.3360; KARLIN KD, 1993, SCIENCE, V261, P701, DOI 10.1126/science.7688141; KHAN AS, 1988, SCIENCE, V241, P74, DOI 10.1126/science.2455342; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LUEBKE KJ, 1989, J AM CHEM SOC, V111, P8733, DOI 10.1021/ja00205a033; ORGEL LE, 1994, SCI AM, V271, P77, DOI 10.1038/scientificamerican1094-76; PABORSKY LR, 1993, J BIOL CHEM, V268, P20808; PADMANABHAN K, 1993, J BIOL CHEM, V268, P17651; PAN T, 1994, BIOCHEMISTRY-US, V33, P9561, DOI 10.1021/bi00198a023; PERREAULT JP, 1989, EUR J BIOCHEM, V186, P87, DOI 10.1111/j.1432-1033.1989.tb15181.x; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; SHABAROVA ZA, 1988, BIOCHIMIE, V70, P1323, DOI 10.1016/0300-9084(88)90003-X; SZOSTAK JW, 1992, TRENDS BIOCHEM SCI, V17, P89, DOI 10.1016/0968-0004(92)90242-2; WANG KY, 1993, BIOCHEMISTRY-US, V32, P11285, DOI 10.1021/bi00093a004; WILSON C, 1995, NATURE, V374, P777, DOI 10.1038/374777a0; WYATT JR, 1994, P NATL ACAD SCI USA, V91, P1356, DOI 10.1073/pnas.91.4.1356	30	342	370	6	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 15	1995	375	6532					611	614		10.1038/375611a0	http://dx.doi.org/10.1038/375611a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791880				2022-12-24	WOS:A1995RD28700057
J	ADAMI, J; FRISCH, M; YUEN, J; GLIMELIUS, B; MELBYE, M				ADAMI, J; FRISCH, M; YUEN, J; GLIMELIUS, B; MELBYE, M			EVIDENCE OF AN ASSOCIATION BETWEEN NON-HODGKINS-LYMPHOMA AND SKIN-CANCER	BRITISH MEDICAL JOURNAL			English	Article							TRANSPLANT RECIPIENTS; UV-RADIATION; TIME TRENDS; RISK; MECHANISMS	Objective-To investigate a possible Link between exposure to ultraviolet light and the almost epidemic increase in non-Hodgkin's lymphoma worldwide. Because ultraviolet light is known to cause skin cancers, the association between non-Hodgkin's lymphoma and skin cancer was studied. Design-Secondary occurrence of either malignant melanoma or squamous cell skin cancer in cohorts of patients with a first diagnosis of either non-Hodgkin's lymphoma or chronic lymphocytic leukaemia, and vice versa, were studied. Expected numbers of subsequent cancers were calculated by sex, age, and period specific national incidence rates multiplied by the person years under observation in the cohorts. Setting-Denmark (1943-89) and Sweden (1958-89). Subjects-Four population based cohorts identified in the nationwide cancer registries (34641 people with non-Hodgkin's lymphoma, 17400 with chronic lymphocytic leukaemia, 34989 with malignant melanoma, 25980 with squamous cell skin cancer). A total of 562085 person years were accrued for the analysis. Main outcome measures-The ratios of observed to expected cancers (the standardised incidence ratio) served as a measure of the relative risk. Results-The relative risk for developing squamous cell skin cancer was 5.5 (95% confidence interval 4.6 to 6.6) among patients with non-Hodgkin's lymphoma and 8.6 (7.2 to 10.3) among patients with chronic lymphocytic leukaemia. The relative risks remained high over more than IS years of follow up. Relative risks for malignant melanoma were 2.4 (1.8 to 3.2) for patients with non-Hodgkin's lymphoma and 3.1 (2.1 to 4.4) for patients with chronic lymphocytic leukaemia. After aquamous cell skin cancer had been diagnosed there was a twofold excess risk for non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. By contrast, in each of the cohorts the general cancer risks excluding skin and lymphoproliferative malignancies were close to the expected. Conclusions-The occurrence of non-Hodgkin's lymphoma and skin cancer are strongly associated; this supports the hypothesis that the secular increase in exposure to ultraviolet light may have contributed to the increasing incidence of non-Hodgkin's lymphoma in recent decades	STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,DK-2300 COPENHAGEN S,DENMARK; UNIV UPPSALA HOSP,DEPT ONCOL,S-75185 UPPSALA,SWEDEN	Aarhus University; Statens Serum Institut; Uppsala University; Uppsala University Hospital	ADAMI, J (corresponding author), UNIV UPPSALA HOSP,DEPT CANC EPIDEMIOL,S-75185 UPPSALA,SWEDEN.		Yuen, Jonathan/AAI-2035-2021; Frisch, Morten/E-9206-2016	Frisch, Morten/0000-0002-3864-8860; Yuen, Jonathan/0000-0003-2944-9226; melbye, mads/0000-0001-8264-6785				BLOMBERG J, 1993, EUR J CANCER, V29A, P2101, DOI 10.1016/0959-8049(93)90042-E; BRESLOW N, 1987, STAT METHODS CANC RE, V2, P71; CARTWRIGHT R, 1994, LEUKEMIA LYMPHOMA, V14, P387, DOI 10.3109/10428199409049694; CASABONA J, 1991, INT J CANCER, V47, P49, DOI 10.1002/ijc.2910470110; CERHAN JR, 1993, ANN INTERN MED, V119, P8, DOI 10.7326/0003-4819-119-1-199307010-00002; COBEMAN M, 1985, ANN INTERN MED, V103, P140; DEVESA SS, 1992, CANCER RES, V52, pS5432; EBBESEN P, 1981, J NATL CANCER I, V67, P1077; FILIPOVICH AH, 1992, CANCER RES, V52, pS5465; FRISCH M, 1994, AM J EPIDEMIOL, V140, P12, DOI 10.1093/oxfordjournals.aje.a117154; GAIL MH, 1991, JNCI-J NATL CANCER I, V83, P695, DOI 10.1093/jnci/83.10.695; HAKULINEN T, 1985, AM J MED, V78, P29, DOI 10.1016/0002-9343(85)90242-6; HARTGE P, 1992, CANCER RES, V52, pS5566; HERSEY P, 1983, LANCET, V1, P545; HERSEY P, 1983, J IMMUNOL, V31, P171; HOOVER R, 1973, LANCET, V2, P55; KINLEN LJ, 1979, BRIT MED J, V2, P1461, DOI 10.1136/bmj.2.6203.1461; Kripke M L, 1981, Adv Cancer Res, V34, P69, DOI 10.1016/S0065-230X(08)60239-0; KRIPKE ML, 1990, J NATL CANCER I, V82, P1392, DOI 10.1093/jnci/82.17.1392; Lee JAH, 1982, CANC EPIDEMIOLOGY PR, P984; LENNERT K, 1978, HDB SPEZIELLEN PA 3B, V1, P84; MAGRATH I, 1992, CANCER RES, V52, pS5529; MARTINSSON U, 1992, ACTA ONCOL, V31, P275, DOI 10.3109/02841869209108173; MARTINSSON U, 1989, EUR J HAEMATOL, V43, P332; OPELZ G, 1993, LANCET, V342, P1514, DOI 10.1016/S0140-6736(05)80084-4; OSTERLIND A, 1991, Current Opinion in Oncology, V3, P355; PARKIN DM, 1993, INT J CANCER, V54, P594; PENN I, 1988, CANCER DETECT PREV, V12, P39; POTTER M, 1992, CANCER RES, V52, pS5522; ROMERDAHL CA, 1988, CANCER RES, V48, P4007; SCOTTO J, 1982, CANCER EPIDEMIOL, P996; STORM HH, 1992, CANCER INCIDENCE DEN; ZHENG TZ, 1992, CANCER, V70, P840, DOI 10.1002/1097-0142(19920815)70:4&lt;840::AID-CNCR2820700420&gt;3.0.CO;2-I; 1993, CANCER INCIDENCE SWE; 1992, IARC MONOGRAPHS EVAL, V55, P73	36	212	213	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1491	1495		10.1136/bmj.310.6993.1491	http://dx.doi.org/10.1136/bmj.310.6993.1491			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787593	Green Published			2022-12-24	WOS:A1995RD28500018
J	FRANKE, TF; YANG, SI; CHAN, TO; DATTA, K; KAZLAUSKAS, A; MORRISON, DK; KAPLAN, DR; TSICHLIS, PN				FRANKE, TF; YANG, SI; CHAN, TO; DATTA, K; KAZLAUSKAS, A; MORRISON, DK; KAPLAN, DR; TSICHLIS, PN			THE PROTEIN-KINASE ENCODED BY THE AKT PROTOONCOGENE IS A TARGET OF THE PDGF-ACTIVATED PHOSPHATIDYLINOSITOL 3-KINASE	CELL			English	Article							POLYMERASE CHAIN-REACTION; GROWTH-FACTOR; C-AKT; V-AKT; REGION; EXPRESSION; RECEPTORS; MICE	The serine/threonine protein kinase encoded by the Akt proto-oncogene is catalytically inactive in serum-starved primary and immortalized fibroblasts. Here we show that Akt and the Akt-related kinase AKT2 are activated by PDGF. The activation was rapid and specific, and it was abrogated by mutations in the Akt Pleckstrin homology (PH) domain. The Akt activation was also shown to depend on PDGFR beta tyrosines Y740 and Y751, which bind phosphatidylinositol 3-kinase (Pl 3-kinase) upon phosphorylation. Moreover, Akt activation was blocked by the Pl 3-kinase-specific inhibitor wortmannin and the dominant inhibitory N17Ras. Conversely, Akt activity was induced following the addition of phosphatidylinositol-3-phosphate to Akt immunoprecipitates from serum-starved cells in vitro, These results identify Akt as a novel target of Pl 3-kinase and suggest that the Akt PH domain may be a mediator of Pl 3-kinase signaling.	NCI, FREDERICK CANC RES FACIL & DEV CTR, ABL BASIC RES PROGRAM, EUKARYOT SIGNAL TRANSDUCT SECT, FREDERICK, MD 21702 USA; NATL JEWISH CTR IMMUNOL & RESP MED, DENVER, CO 80206 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Jewish Health	FRANKE, TF (corresponding author), FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA.			Chan, Tung/0000-0001-6574-9555	NCI NIH HHS [R01-CA57436, R01-CA38047, CA-55063] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055063, R01CA038047, R01CA057436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED NN, 1993, ONCOGENE, V8, P1957; BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DOWNWARD J, 1994, NATURE, V371, P378, DOI 10.1038/371378a0; FRANKE TF, 1994, ONCOGENE, V9, P141; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HENRIKSEN R, 1993, CANCER RES, V53, P4550; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; POWIS G, 1994, CANCER RES, V54, P2419; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STILES CD, 1979, J CELL PHYSIOL, V99, P395, DOI 10.1002/jcp.1040990314; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	31	1814	1867	3	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					727	736		10.1016/0092-8674(95)90534-0	http://dx.doi.org/10.1016/0092-8674(95)90534-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774014	Bronze			2022-12-24	WOS:A1995RB96100011
J	KUNDIG, TM; BACHMANN, MF; DIPAOLO, C; SIMARD, JJL; BATTEGAY, M; LOTHER, H; GESSNER, A; KUHLCKE, K; OHASHI, PS; HENGARTNER, H; ZINKERNAGEL, RM				KUNDIG, TM; BACHMANN, MF; DIPAOLO, C; SIMARD, JJL; BATTEGAY, M; LOTHER, H; GESSNER, A; KUHLCKE, K; OHASHI, PS; HENGARTNER, H; ZINKERNAGEL, RM			FIBROBLASTS AS EFFICIENT ANTIGEN-PRESENTING CELLS IN LYMPHOID ORGANS	SCIENCE			English	Article							CD8+ T-CELLS; INTERCELLULAR-ADHESION MOLECULE-1; FOOTPAD SWELLING REACTION; TUMOR-CELLS; LYMPHOCYTIC CHORIOMENINGITIS; ANTITUMOR IMMUNITY; TRANSGENIC MICE; GENE-TRANSFER; INVIVO; EXPRESSION	Only so-called ''professional'' antigen-presenting cells (APCs) of hematopoietic origin are believed capable of inducing T lymphocyte responses. However, fibroblasts transfected with viral proteins directly induced antiviral cytotoxic T lymphocyte responses in vivo, without involvement of host APCs. Fibroblasts induced T cells only in the milieu of lymphoid organs. Thus, antigen localization affects self-nonself discrimination and cell-based vaccine strategies.	ONTARIO CANC INST, DEPT MED BIOPHYS, TORONTO, ON M4X 1K9, CANADA; ONTARIO CANC INST, DEPT IMMUNOL, TORONTO, ON M4X 1K9, CANADA; UNIV HAMBURG, HEINRICH PETTE INST EXPTL VIROL & IMMUNOL, W-2000 HAMBURG, GERMANY	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Heinrich Pette Institute; University of Hamburg	KUNDIG, TM (corresponding author), UNIV ZURICH, INST EXPTL IMMUNOL, SCHMELZBERGSTR 12, CH-8091 ZURICH, SWITZERLAND.			Ohashi, Pamela S./0000-0003-2915-9317				BACHMANN MF, 1994, CURR OPIN IMMUNOL, V6, P320, DOI 10.1016/0952-7915(94)90108-2; Barker CF, 1967, TRANSPLANTATION, V5, P962; BASKAR S, 1993, P NATL ACAD SCI USA, V90, P5687, DOI 10.1073/pnas.90.12.5687; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; CHEN LP, 1994, J EXP MED, V179, P523, DOI 10.1084/jem.179.2.523; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; COLOMBO MP, 1991, J EXP MED, V173, P889, DOI 10.1084/jem.173.4.889; CROFT M, 1994, CURR OPIN IMMUNOL, V6, P431, DOI 10.1016/0952-7915(94)90123-6; DAMLE NK, 1992, J IMMUNOL, V148, P1985; DEBRICK JE, 1991, J IMMUNOL, V147, P2846; Deichman G I, 1969, Adv Cancer Res, V12, P101, DOI 10.1016/S0065-230X(08)60329-2; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; DIPAOLO C, THESIS U ZURICH; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FAUSTMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P5156, DOI 10.1073/pnas.78.8.5156; FAUSTMAN DL, 1984, P NATL ACAD SCI-BIOL, V81, P3864, DOI 10.1073/pnas.81.12.3864; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FREY JR, 1957, INT ARCH ALLER A IMM, V11, P81, DOI 10.1159/000228405; GANSBACHER B, 1990, CANCER RES, V50, P7820; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; GESSNER A, 1993, THESIS U HAMBURG; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GORELIK E, 1983, ADV CANCER RES, V39, P71, DOI 10.1016/S0065-230X(08)61033-7; GUERDER S, 1994, IMMUNITY, V1, P155; HANY M, 1989, EUR J IMMUNOL, V19, P417, DOI 10.1002/eji.1830190302; HARLAN DM, 1994, P NATL ACAD SCI USA, V91, P3137, DOI 10.1073/pnas.91.8.3137; HEATH WR, 1992, NATURE, V359, P547, DOI 10.1038/359547a0; HOCK H, 1991, J EXP MED, V174, P1291, DOI 10.1084/jem.174.6.1291; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; JANEWAY CA, 1989, COLD SH Q B, V54, P1; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KLEIN G, 1978, MANIPULATION IMMUNE, P339; KOSAKA H, 1992, J EXP MED, V176, P1291, DOI 10.1084/jem.176.5.1291; KUHLMAN P, 1991, J IMMUNOL, V146, P1773; LAFFERTY KJ, 1977, IMMUNOL REV, V35, P231, DOI 10.1111/j.1600-065X.1977.tb00241.x; LANE P, 1993, IMMUNOLOGY, V80, P56; LECHLER RI, 1982, J EXP MED, V155, P31, DOI 10.1084/jem.155.1.31; LEIST TP, 1987, J IMMUNOL, V138, P2278; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; MATZINGER P, 1977, CELL IMMUNOL, V33, P92, DOI 10.1016/0008-8749(77)90137-X; NISHIHARA K, 1988, CANCER RES, V48, P4730; NOSSAL GJV, 1989, SCIENCE, V245, P147, DOI 10.1126/science.2526369; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLD LJ, 1964, ANNU REV MED, V15, P167, DOI 10.1146/annurev.me.15.020164.001123; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PORGADOR A, 1992, CANCER RES, V52, P3679; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SIU G, 1989, J IMMUNOL, V143, P3813; SPRENT J, 1986, NATURE, V322, P541, DOI 10.1038/322541a0; SPRENT J, 1990, IMMUNOL REV, V117, P213, DOI 10.1111/j.1600-065X.1990.tb00574.x; TAHARA H, 1994, CANCER RES, V54, P182; TANAKA K, 1988, MOL CELL BIOL, V8, P1857, DOI 10.1128/MCB.8.4.1857; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WACHTEL SS, 1972, J EXP MED, V135, P388, DOI 10.1084/jem.135.2.388; WACHTEL SS, 1971, J EXP MED, V133, P921, DOI 10.1084/jem.133.4.921; ZINKERNAGEL RM, 1985, J EXP MED, V162, P2125, DOI 10.1084/jem.162.6.2125; ZINKERNAGEL RM, 1993, IMMUNOL REV, V133, P199, DOI 10.1111/j.1600-065X.1993.tb01517.x	65	263	273	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 2	1995	268	5215					1343	1347		10.1126/science.7761853	http://dx.doi.org/10.1126/science.7761853			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761853				2022-12-24	WOS:A1995RB19800037
J	KAUFFMANNZEH, A; THOMAS, GMH; BALL, A; PROSSER, S; CUNNINGHAM, E; COCKCROFT, S; HSUAN, JJ				KAUFFMANNZEH, A; THOMAS, GMH; BALL, A; PROSSER, S; CUNNINGHAM, E; COCKCROFT, S; HSUAN, JJ			REQUIREMENT FOR PHOSPHATIDYLINOSITOL TRANSFER PROTEIN IN EPIDERMAL GROWTH-FACTOR SIGNALING	SCIENCE			English	Article							PHOSPHOLIPASE-C-GAMMA; TYROSINE PHOSPHORYLATION; FACTOR RECEPTOR; EGF RECEPTOR; A431 CELLS; MONOCLONAL-ANTIBODY; PLASMA-MEMBRANES; BINDING-SITE; BOVINE BRAIN; KINASE	Stimulation of phosphatidylinositol-4,5-bisphosphate (PIP2) hydrolysis is a widespread mechanism for receptor-mediated signaling in eukaryotes. Cytosolic phosphatidylinositol transfer protein (PITP) is necessary for guanosine triphosphate (GTP)-dependent hydrolysis of PIP2 by phospholipase C-beta (PLC-beta), but the role of PITP is unclear. Stimulation of phospholipase C-gamma (PLC-gamma) in A431 human epidermoid carcinoma cells treated with epidermal growth factor (EGF) required PITP. Stimulation of PI-4 kinase in cells treated with EGF also required PITP. Coprecipitation studies revealed an EGF-dependent association of PITP with the EGF receptor, with PI-4 kinase, and with PLC-gamma.	UCL, SCH MED, LUDWIG INST CANC RES, PROT BIOCHEM GRP, LONDON W1P 8BT, ENGLAND; UCL, DEPT PHYSIOL, LONDON WC1E 6JJ, ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; University of London; University College London			Hsuan, Justin/C-8825-2009; Cockcroft, Shamshad/F-9480-2011	Hsuan, Justin/0000-0001-6083-7564; Cockcroft, Shamshad/0000-0002-5731-476X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALOUF JE, 1980, PHARMACOL THERAPEUT, V11, P661, DOI 10.1016/0163-7258(80)90045-5; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; COCHET C, 1991, J BIOL CHEM, V266, P637; COCKCROFT S, 1992, BIOCHEM J, V288, P1; Cunningham E. S., UNPUB; DOWNES CP, 1993, CURR BIOL, V3, P794; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HSUAN JJ, 1993, ANTICANCER RES, V13, P2521; KAUFFMANNZEH A, 1994, J BIOL CHEM, V269, P31243; KAUFFMANNZEH A, UNPUB; KIM JW, 1990, J BIOL CHEM, V265, P3940; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MICHELL RH, 1975, BIOCHIM BIOPHYS ACTA, V415, P81, DOI 10.1016/0304-4157(75)90017-9; MONACO ME, 1992, ENDOCR REV, V13, P707, DOI 10.1210/er.13.4.707; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PAYRASTRE B, 1991, BIOCHIM BIOPHYS ACTA, V1056, P19, DOI 10.1016/S0005-2728(05)80068-4; PAYRASTRE B, 1990, BIOCHEM J, V272, P665, DOI 10.1042/bj2720665; PIKE LJ, 1992, ENDOCR REV, V13, P692, DOI 10.1210/er.13.4.692; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1991, METHOD ENZYMOL, V197, P502; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; RYU SH, 1987, J BIOL CHEM, V262, P12511; SCHERMOLY MJ, 1983, BRAIN RES, V268, P197, DOI 10.1016/0006-8993(83)90410-9; SOLER C, 1994, J BIOL CHEM, V269, P12320; SORKIN A, 1992, J BIOL CHEM, V267, P8672; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; VANPARIDON PA, 1988, BIOCHIM BIOPHYS ACTA, V943, P76, DOI 10.1016/0005-2736(88)90348-3; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WALKER DH, 1987, P NATL ACAD SCI USA, V84, P7513, DOI 10.1073/pnas.84.21.7513; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.bi.60.070191.000445	40	149	157	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	1995	268	5214					1188	1190		10.1126/science.7761838	http://dx.doi.org/10.1126/science.7761838			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761838				2022-12-24	WOS:A1995RA60400041
J	ROSE, S				ROSE, S			THE RISE OF NEUROGENETIC DETERMINISM	NATURE			English	Editorial Material											ROSE, S (corresponding author), OPEN UNIV, DEPT BIOL, MILTON KEYNES MK7 6AA, BUCKS, ENGLAND.							BIGNAMI G, 1982, BIOL DETERMINISM, P94; BREGGIN PR, 1993, INT J PSYCHOL PSYCHO, V11, P59; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CHIPKIN RE, 1994, TRENDS NEUROSCI, V17, P50, DOI 10.1016/0166-2236(94)90070-1; COHEN D, 1994, OUT BLUE DEPRESSION; Dawkins R, 1976, SELFISH GENE; DELGADO JMW, 1971, PHYSICAL CONTROL MIN; GALANTER M, 1993, RECENT DEV ALCOHOLIS; Hamer D., 1994, SCI DESIRE SEARCH GA; HAMER DH, 1993, SCIENCE, V261, P321, DOI 10.1126/science.8332896; HARRISON G, 1990, SCHIZOPHRENIA BULL, V16, P663, DOI 10.1093/schbul/16.4.663; Herrnstein R.J., 1994, BELL CURVE INTELLIGE; Kitcher P, 1985, VALUING AMBITION; Kramer PD, 1994, LISTENING PROZAC; LeVay Simon, 1993, SEXUAL BRAIN; MANN CC, 1994, SCIENCE, V264, P1686, DOI 10.1126/science.8209246; Mark Vernon H., 1970, VIOLENCE BRAIN; Nelkin D, 1987, SELLING SCI; PERUTZ MF, 1988, TRENDS BIOCHEM SCI, V13, P206, DOI 10.1016/0968-0004(88)90083-7; Reiss A., 1993, UNDERSTANDING PREVEN; ROSE S, 1987, TRENDS NEUROSCI, V10, P152; Rose S, 1984, NOT IN OUR GENES; SWAAB DF, 1994, EUR J NEUROSCI, V7, P126; UHL G, 1993, TRENDS NEUROSCI, V16, P83, DOI 10.1016/0166-2236(93)90128-9; Wilson E.O., 1975, P1	25	76	76	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	1995	373	6513					380	382		10.1038/373380a0	http://dx.doi.org/10.1038/373380a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830787				2022-12-24	WOS:A1995QE67000026
J	NOUSBAUM, JB; POL, S; NALPAS, B; LANDAIS, P; BERTHELOT, P; BRECHOT, C; GIGOU, M; FERAY, C; THIERS, V; OKAMOTO, H; MISHIRO, S; POUSSIN, K; PATERLINI, P; RUMI, M; COLOMBO, M				NOUSBAUM, JB; POL, S; NALPAS, B; LANDAIS, P; BERTHELOT, P; BRECHOT, C; GIGOU, M; FERAY, C; THIERS, V; OKAMOTO, H; MISHIRO, S; POUSSIN, K; PATERLINI, P; RUMI, M; COLOMBO, M			HEPATITIS-C VIRUS TYPE-1B(II) INFECTION IN FRANCE AND ITALY	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS C VIRUS; HEPATITIS C; GENOTYPE; DNA, VIRAL; POLYMERASE CHAIN REACTION	RECOMBINANT INTERFERON-ALFA; POLYMERASE CHAIN-REACTION; HEPATOCELLULAR-CARCINOMA; B VIRUS; CONTROLLED TRIAL; GENOTYPES; SEQUENCE; LIVER; RNA; VARIABILITY	Objective: To analyze the distribution of hepatitis C virus (HCV) genotypes among patients positive for antibody to HCV (anti-HCV) according to age, severity of liver disease, and duration of infection; to investigate the influence of HCV genotypes on response to interferon-alpha therapy; and to study HCV viremia levels in relation to genotypes and severity of liver disease. Design: Cross-sectional study. Setting: 3 university hospitals and 2 research units. Patients: 3 groups of French and Italian patients with chronic HCV infection and detectable serum HCV RNA: Group 1 included 35 patients with hepatocellular carcinoma; group 2, 71 patients with cirrhosis who did not have hepatocellular carcinoma; and group 3, 114 patients with chronic active hepatitis. 106 of the patients with chronic hepatitis or cirrhosis were treated with interferon-alpha (3 MU subcutaneously 3 times/wk for greater than or equal to 6 months). Measurements: Genotyping by polymerase chain reaction with capsid-specific primers; serum HCV RNA by branched DNA (bDNA) signal amplification. Results: Hepatitis C virus genotype 1b (II) was the most prevalent genotype (61.8%). In a univariate analysis, it was associated with older age (<40 years, 47.4%; greater than or equal to 60 years, 80.4%; P = 0.001), longer duration of disease (less than or equal to 10 years, 40.4%; greater than or equal to 20 years, 86.7%; P = 0.005), and cirrhosis with or without hepatocellular carcinoma 78.4% compared with 53.8% for chronic hepatitis; P < 0.001). Viremia levels did not differ between patients infected with HCV type 1b (II) and those infected with other HCV genotypes. Patients with HCV type 1b (II) responded to interferon-alpha therapy significantly less than did patients with other HCV genotypes (P = 0.01). In a multivariate analysis, age and cirrhosis were independently associated with HCV genotype 1b (II). Genotype and HCV viremia level were independent predictors of response to interferon-alpha therapy. Conclusions: The prevalence of HCV genotypes in French and Italian patients has been changing; the prevalence of HCV type 1b (II) infection has progressively decreased, although it still accounts for most HCV-related cirrhosis and hepatocellular carcinoma. High HCV viremia levels and HCV genotype type 1b (II) are independent predictors for poor response to interferon-alpha therapy and should be considered in the management of patients with HCV infection.	HOP NECKER ENFANTS MALAD, F-75015 PARIS, FRANCE; INST PASTEUR, PARIS, FRANCE; JICHI MED SCH, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; UNIV MILAN, MILAN, ITALY; HOP P BROUSSE, PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Jichi Medical University; University of Milan			Feray, Cyrille/S-2559-2018; Okamoto, Hiroaki/H-4371-2011; Nalpas, Bertrand/M-4981-2018	Okamoto, Hiroaki/0000-0003-0827-0964; Nalpas, Bertrand/0000-0002-8215-2942				Brouwer J. T., 1993, Journal of Hepatology, V18, pS10; BUKH J, 1993, P NATL ACAD SCI USA, V90, P8234, DOI 10.1073/pnas.90.17.8234; CHA TA, 1992, P NATL ACAD SCI USA, V89, P7144, DOI 10.1073/pnas.89.15.7144; CHAN SW, 1992, J GEN VIROL, V73, P1131, DOI 10.1099/0022-1317-73-5-1131; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; COLLETT MS, 1989, J GEN VIROL, V70, P253, DOI 10.1099/0022-1317-70-2-253; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; ENOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021, DOI 10.1016/0006-291X(90)90494-8; FERAY C, 1993, GASTROENTEROLOGY, V104, P549, DOI 10.1016/0016-5085(93)90425-C; KATO N, 1993, J VIROL, V67, P3923, DOI 10.1128/JVI.67.7.3923-3930.1993; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; LI JS, 1991, GENE, V105, P167; LOK ASF, 1990, HEPATOLOGY, V12, P582, DOI 10.1002/hep.1840120322; MCOMISH F, 1993, TRANSFUSION, V33, P7, DOI 10.1046/j.1537-2995.1993.33193142314.x; NAKAO T, 1991, J GEN VIROL, V72, P2105, DOI 10.1099/0022-1317-72-9-2105; OKADA S, 1992, HEPATOLOGY, V16, P619, DOI 10.1002/hep.1840160302; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1992, VIROLOGY, V188, P331, DOI 10.1016/0042-6822(92)90762-E; OKAMOTO H, 1993, J GEN VIROL, V74, P2385, DOI 10.1099/0022-1317-74-11-2385; OKAMOTO H, 1992, VIROLOGY, V190, P894, DOI 10.1016/0042-6822(92)90933-G; PATERLINI P, 1993, HEPATOLOGY, V17, P20, DOI 10.1016/0270-9139(93)90186-Q; POZZATO G, 1991, LANCET, V338, P509, DOI 10.1016/0140-6736(91)90578-D; POZZATO G, 1992, Journal of Hepatology, V16, pS3; RAIMONDO G, 1988, VIROLOGY, V166, P103, DOI 10.1016/0042-6822(88)90151-1; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SHERMAN KE, 1993, J CLIN MICROBIOL, V31, P2679, DOI 10.1128/JCM.31.10.2679-2682.1993; SIMMONDS P, 1993, J GEN VIROL, V74, P661, DOI 10.1099/0022-1317-74-4-661; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TAKADA N, 1993, J HEPATOL, V17, P277, DOI 10.1016/S0168-8278(05)80205-3; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; Urdea M S, 1991, Nucleic Acids Symp Ser, P197; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203	39	516	528	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1995	122	3					161	+		10.7326/0003-4819-122-3-199502010-00001	http://dx.doi.org/10.7326/0003-4819-122-3-199502010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD733	7810932				2022-12-24	WOS:A1995QD73300001
J	SCHILLING, RF				SCHILLING, RF			ESTIMATING THE RISK FOR SEPSIS AFTER SPLENECTOMY IN HEREDITARY SPHEROCYTOSIS	ANNALS OF INTERNAL MEDICINE			English	Note							INFECTIONS; ADULTS				SCHILLING, RF (corresponding author), UNIV WISCONSIN, DEPT MED, 1300 UNIV AVE, MADISON, WI 53706 USA.							Gardner M, 1989, BRIT MED J; GARDNER MJ, 1989, BRIT MED J, P52; KING H, 1952, ANN SURG, V136, P239, DOI 10.1097/00000658-195208000-00006; KONRADSEN HB, 1991, ACTA PAEDIATR SCAND, V80, P423, DOI 10.1111/j.1651-2227.1991.tb11877.x; MACKINNEY AA, 1962, J CLIN INVEST, V41, P554, DOI 10.1172/JCI104509; ONEAL BJ, 1981, ANN SURG, V194, P775, DOI 10.1097/00000658-198112000-00020; SCHILLING RF, 1976, SEMIN HEMATOL, V13, P169; SCHWARTZ PE, 1982, JAMA-J AM MED ASSOC, V248, P2279, DOI 10.1001/jama.248.18.2279; Singer D B, 1973, Perspect Pediatr Pathol, V1, P285; TEARE L, 1992, LANCET, V340, P1362, DOI 10.1016/0140-6736(92)92555-T; ZARRABI MH, 1984, ARCH INTERN MED, V144, P1421, DOI 10.1001/archinte.144.7.1421	11	65	67	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1995	122	3					187	188		10.7326/0003-4819-122-3-199502010-00005	http://dx.doi.org/10.7326/0003-4819-122-3-199502010-00005			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD733	7810936				2022-12-24	WOS:A1995QD73300005
J	JO, SA; ZHU, XJ; MARCHIONNI, MA; BURDEN, SJ				JO, SA; ZHU, XJ; MARCHIONNI, MA; BURDEN, SJ			NEUREGULINS ARE CONCENTRATED AT NERVE-MUSCLE SYNAPSES AND ACTIVATE ACH-RECEPTOR GENE-EXPRESSION	NATURE			English	Article							ACETYLCHOLINE-RECEPTOR; SUBUNIT GENE; TRANSGENIC MICE; EPSILON-SUBUNIT; BASAL LAMINA; FAMILY; PROTEIN; MEMBER; NEU; HER4/P180(ERBB4)	Two different signalling pathways mediate the localization of acetylcholine receptors (AChRs) to synaptic sites in skeletal muscle. The signal for one pathway is agrin, a protein that triggers a redistribution of previously unlocalized cell surface AChRs to synaptic sites(1). The signal for the other pathway is not known, but this signal stimulates transcription of AChR genes in myofibre nuclei near the synaptic site(2). Neuregulins, identified originally as a potential ligand for erbB2 (Neu differentiation factor, NDF)(3), stimulate proliferation of Schwann cells (glial growth factor, GGF)(4), increase the rate of AChR synthesis in cultured muscle cells (AChR-inducing activity)(5) and are expressed in motor neurons(4,5). These results raise the possibility that neuregulin is the signal that activates AChR genes in synaptic nuclei. Here we show that neuregulin activates AChR gene expression in C2 muscle cells and that the neuregulin response element in the AChR delta-subunit gene is contained in the same 181 base pairs that confer synapse-specific expression in transgenic mice. We use antibodies to show that neuregulins are concentrated at synaptic sites and that, like the extracellular signal that stimulates synapse-specific expression, neuregulins remain at synaptic sites in the absence of nerve and muscle. We show that C2 muscle cells contain erbB2 and erbB3 messenger RNA but little or no erbB4 mRNA, and that neuregulin stimulates tyrosine phosphorylation of erbB2 and erbB3, indicating that neuregulin signalling in skeletal muscle may be mediated by a complex of erbB2 and erbB3.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; CAMBRIDGE NEUROSCI INC,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	JO, SA (corresponding author), HARVARD UNIV,SCH MED,CTR BLOOD RES,200 LONGWOOD AVE,BOSTON,MA 02115, USA.			Burden, Steven/0000-0002-3550-6891				BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BRENNER HR, 1992, DEVELOPMENT, V116, P41; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; BURDEN SJ, 1993, TRENDS GENET, V9, P12, DOI 10.1016/0168-9525(93)90066-Q; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GOLDMAN D, 1991, NEURON, V7, P649, DOI 10.1016/0896-6273(91)90377-C; GUNDERSEN K, 1993, J CELL BIOL, V123, P1535, DOI 10.1083/jcb.123.6.1535; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JO SA, 1992, DEVELOPMENT, V115, P673; KLARSFELD A, 1991, EMBO J, V10, P625, DOI 10.1002/j.1460-2075.1991.tb07990.x; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; MUDGE AW, 1993, CURR BIOL, V3, P361, DOI 10.1016/0960-9822(93)90201-X; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; SANES JR, 1991, DEVELOPMENT, V113, P1181; SANES JR, 1983, COLD SPRING HARB SYM, V48, P667, DOI 10.1101/SQB.1983.048.01.070; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SIMON AM, 1993, MOL CELL BIOL, V13, P5133, DOI 10.1128/MCB.13.9.5133; SIMON AM, 1992, DEVELOPMENT, V114, P545; TANG JC, 1994, DEVELOPMENT, V120, P1799; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	28	243	252	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					158	161						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816098				2022-12-24	WOS:A1995QB06300061
J	PACKER, C; COLLINS, DA; SINDIMWO, A; GOODALL, J				PACKER, C; COLLINS, DA; SINDIMWO, A; GOODALL, J			REPRODUCTIVE CONSTRAINTS ON AGGRESSIVE COMPETITION IN FEMALE BABOONS	NATURE			English	Article							OLIVE BABOONS; PAPIO-ANUBIS; PRIMATES; AGE	COMPETITIVE interaction between females of the same social group is characteristic of most primate species(1-3). In old World monkeys, females of high social rank maintain priority of access to scarce resources and harass low-ranking companions(1-6). But different field studies have found differing correlations between female dominance and reproductive success: several populations show an advantage of rank whereas others do not(1,3,5,7). Although such variation may reflect divergent levels of predation, food availability or social stress in different environments, female competitive ability may also be balanced by significant reproductive costs and thus be subject to strong stabilizing selection, We report here that high-ranking female baboons (Papio cynocephalus anubis) at Gombe National Park, Tanzania, enjoy shorter interbirth intervals, improved infant survival, and accelerated maturation of their daughters. These advantages, however, are countered by a significantly higher probability of miscarriage, and a proportion of high-ranking females suffer from reduced fertility.	UNIV EDINBURGH,INST CELL ANIM & POPULAT BIOL,ASHWORTH LAB,EDINBURGH EH9 3JT,MIDLOTHIAN,SCOTLAND; GOMBE STREAM RES CTR,KIGOMA,TANZANIA	University of Edinburgh	PACKER, C (corresponding author), UNIV MINNESOTA,DEPT EEB,1987 UPPER BUFORD CIRCLE,ST PAUL,MN 55108, USA.							ABBOTT DH, 1987, J ZOOL, V213, P455, DOI 10.1111/j.1469-7998.1987.tb03720.x; Altmann J., 1988, P403; Altmann J., 1970, LAB ANIM DIG, V6, P7; BERCOVITCH FB, 1993, BEHAV ECOL SOCIOBIOL, V33, P313; Chapais Bernard, 1992, P29; Collins DA, 1984, INFANTICIDE COMP EVO, P193; FAIRBANKS LA, 1986, ANIM BEHAV, V34, P1710, DOI 10.1016/S0003-3472(86)80258-5; Glickman Stephen E., 1993, Perspectives in Ethology, V10, P87; Goodall J, 1986, CHIMPANZEES GOMBE, DOI DOI 10.1002/AJPA.1330730313; Goy R W, 1972, Recent Prog Horm Res, V28, P707; HAUSFATER G, 1982, SCIENCE, V217, P752, DOI 10.1126/science.217.4561.752; HAUSFATER G, 1975, DOMINANCE REPRODUCTI; LEE PC, 1987, J ZOOL, V213, P409, DOI 10.1111/j.1469-7998.1987.tb03717.x; NASH LT, 1976, AM J PHYS ANTHROPOL, V44, P63, DOI 10.1002/ajpa.1330440109; OWENS NW, 1976, BEHAVIOUR, V57, P241, DOI 10.1163/156853976X00541; PACKER C, 1979, ANIM BEHAV, V27, P1, DOI 10.1016/0003-3472(79)90126-X; PACKER C, 1975, NATURE, V255, P219, DOI 10.1038/255219a0; Ransom TW., 1981, BEACH TROOP GOMBE; SACKETT GP, 1975, 5TH P INT C INT PRIM; Silk J.B., 1987, P318; SMUTS B, 1989, AM J PRIMATOL, V19, P229, DOI 10.1002/ajp.1350190405; STRUM SC, 1982, AM J PRIMATOL, V3, P61, DOI 10.1002/ajp.1350030106; vom Saal F S, 1989, J Reprod Fertil, V86, P457, DOI 10.1530/jrf.0.0860457; Walters J.R., 1987, P306; Wasser S.K., 1983, P349; WASSER SK, 1993, BEHAV ECOL SOCIOBIOL, V32, P273; YALCINKAYA TM, 1993, SCIENCE, V260, P1929, DOI 10.1126/science.8391165	27	136	139	2	47	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					60	63		10.1038/373060a0	http://dx.doi.org/10.1038/373060a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800039				2022-12-24	WOS:A1995QA23900054
J	HIRSCH, S; MUCKEL, E; HEEMEYER, F; VONHEIJNE, G; SOLL, J				HIRSCH, S; MUCKEL, E; HEEMEYER, F; VONHEIJNE, G; SOLL, J			A RECEPTOR COMPONENT OF THE CHLOROPLAST PROTEIN TRANSLOCATION MACHINERY	SCIENCE			English	Article							OUTER ENVELOPE MEMBRANE; SPINACH-CHLOROPLASTS; IMPORT APPARATUS; PEA-CHLOROPLASTS; CONTACT SITES; LOCALIZATION; IDENTIFICATION; MITOCHONDRIAL; POLYPEPTIDE; TRANSPORT	The chloroplast outer envelope protein OEP86 functions as a receptor in precursor protein translocation into chloroplasts. Sequence analysis suggests that the precursor of OEP86 is directed to the chloroplast outer envelope by a cleavable, negatively charged, and unusually long amino-terminal peptide. This presequence is unlike other potential targeting signals and suggests the existence of another membrane insertion pathway. insertion of precursor OEP86 required the hydrolysis of adenosine triphosphate and the existence of surface exposed chloroplast membrane components, and it was not competed by another precursor protein destined for the internal plastid compartments.	CHRISTIAN ALBRECHTS UNIV KIEL, INST BOT, D-24098 KIEL, GERMANY; KAROLINSKA INST, NOVUM, CTR STRUCT BIOCHEM, S-14157 HUDDINGE, SWEDEN	University of Kiel; Karolinska Institutet			von Heijne, Gunnar/AAH-9389-2019; von Heijne, Gunnar/F-5576-2011	von Heijne, Gunnar/0000-0002-4490-8569				ALEFSEN H, 1994, J PLANT PHYSIOL, V144, P339, DOI 10.1016/S0176-1617(11)81196-X; BLOCK MA, 1983, J BIOL CHEM, V258, P3281; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; FLUGGE UI, 1991, NATURE, V353, P364, DOI 10.1038/353364a0; HARLOW E, 1989, ANTIBODIES LABORATOR; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; JOYARD J, 1983, J BIOL CHEM, V258, P1; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KLEIN RR, 1992, PLANT PHYSIOL, V98, P546, DOI 10.1104/pp.98.2.546; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; SCHINDLER C, 1987, Z NATURFORSCH C, V42, P103; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SEEDORF M, IN PRESS PLANT J; SOLL J, 1989, PLANTA, V177, P393, DOI 10.1007/BF00403598; SOLL J, 1992, PLANT J, V2, P253, DOI 10.1111/j.1365-313X.1992.00253.x; SOLL J, 1993, PHYSIOL PLANTARUM, V87, P433, DOI 10.1111/j.1399-3054.1993.tb01752.x; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WAEGEMANN K, 1992, PLANTA, V187, P89, DOI 10.1007/BF00201628; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WAEGEMANN K, 1993, NATO ASI SERIES H, V74, P101	29	196	208	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					1989	1992		10.1126/science.7801125	http://dx.doi.org/10.1126/science.7801125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801125	Green Submitted			2022-12-24	WOS:A1994PZ26700029
J	CHRISTENSEN, K; SCHMIDT, MM; VETH, M; OLSEN, J				CHRISTENSEN, K; SCHMIDT, MM; VETH, M; OLSEN, J			ABSENCE OF AN ENVIRONMENTAL-EFFECT ON THE RECURRENCE OF FACIAL-CLEFT DEFECTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PALATE; LIP; GENE	Background. The rate of of a broad range of birth defects may decrease among women who change residence after the birth of their first infant, The aim of the present study was to determine the effect of changing residence on the recurrence of congenital facial-cleft defects. Methods. We identified 4189 women who had had infants with facial-cleft defects by linking a data base comprising the records of children with facial clefts born between 1952 and 1987 with the Central Person Registry in Denmark, Among the 4189 mothers, 1902 each had additional children after the first child with a facial-cleft defect. A total of 2692 younger siblings were identified. We compared the proportion of infants with facial-cleft defects among the younger siblings between mothers who had changed municipalities or sexual partners and those who had not. Results. Changing the municipality of residence did not decrease the frequency with which facial-cleft defects recurred in younger siblings. Among the 907 infants of mothers who changed municipalities but not partners, 29 (3.2 percent) had facial-cleft defects, as compared with 48 (3.4 percent) of 1425 infants of mothers who changed neither municipality nor partner (relative risk, 0.9; 95 percent confidence interval, 0.6 to 1.5), However, a change of partner reduced the recurrence risk significantly. Among 236 infants of mothers who changed partners, 1 (0.4 percent) had a facial-cleft defect, as compared with 77 (3.3 percent) of 2350 infants of mothers who did not change partners (relative risk, 0.1; 95 percent confidence interval, 0.02 to 0.9). Conclusions. Recurrence of facial-cleft defects is not linked to the residence of the mother, but having a different partner reduced a woman's risk of having a second child with this defect.	ODENSE UNIV, SCH MED, ODENSE, DENMARK; AARHUS UNIV, DEPT BIOSTAT, AARHUS, DENMARK	University of Southern Denmark; Aarhus University	CHRISTENSEN, K (corresponding author), STENO INST PUBL HLTH, DEPT EPIDEMIOL & SOCIAL MED, DANISH EPIDEMIOL SCI CTR, RES UNIT, DK-8000 AARHUS C, DENMARK.		Christensen, Kaare/C-2360-2009	Christensen, Kaare/0000-0002-5429-5292				ARDINGER HH, 1989, AM J HUM GENET, V45, P348; BAIRD PA, 1994, TERATOLOGY, V49, P448, DOI 10.1002/tera.1420490604; CARTER CO, 1982, J MED GENET, V19, P246, DOI 10.1136/jmg.19.4.246; CHENEVIXTRENCH G, 1992, AM J HUM GENET, V51, P1377; CHRISTENSEN K, 1993, AM J MED GENET, V47, P910, DOI 10.1002/ajmg.1320470620; CHRISTENSEN K, 1992, AM J HUM GENET, V51, P654; CHRISTENSEN K, 1994, CLIN GENET, V46, P329; FRIIS ML, 1989, ACTA NEUROL SCAND, V79, P433, DOI 10.1111/j.1600-0404.1989.tb03814.x; GOLDBERG R, 1993, AM J MED GENET, V45, P313, DOI 10.1002/ajmg.1320450307; KALLEN B, 1986, ACTA PAEDIATR SCAND, P1; KHOURY MJ, 1987, AM J PUBLIC HEALTH, V77, P623, DOI 10.2105/AJPH.77.5.623; LIE RT, 1994, NEW ENGL J MED, V331, P1, DOI 10.1056/NEJM199407073310101; MARAZITA ML, 1986, J CRAN GENET DEV BIO, P89; MOORE GE, 1987, NATURE, V326, P91, DOI 10.1038/326091a0; OLSEN J, 1982, UGESKRIFT LAEGER, V4, P1333; PRADAT P, 1994, GENET EPIDEMIOL, V11, P131, DOI 10.1002/gepi.1370110204; WALD N, 1991, LANCET, V338, P131; WANG JH, 1988, AM J HUM GENET, V42, P772; WERLER MM, 1991, AM J EPIDEMIOL, V134, P691, DOI 10.1093/oxfordjournals.aje.a116145	19	45	45	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 20	1995	333	3					161	164		10.1056/NEJM199507203330305	http://dx.doi.org/10.1056/NEJM199507203330305			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK917	7791818	Bronze			2022-12-24	WOS:A1995RK91700005
J	LEVY, JA				LEVY, JA			HIV RESEARCH - A NEED TO FOCUS ON THE RIGHT TARGET	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; T-LYMPHOCYTES; INFECTION; EFFICACY; LEUKEMIA; VACCINE; CELLS				LEVY, JA (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143, USA.							ADA G, 1992, NATURE, V359, P572, DOI 10.1038/359572a0; ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; CLERICI M, 1994, IMMUNOL TODAY, V15, P575, DOI 10.1016/0167-5699(94)90220-8; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAST PE, 1993, AIDS, V7, pS147, DOI 10.1097/00002030-199301001-00020; FOWKE KR, 1995, 5TH P ANN C HIV AIDS; FULTZ PN, 1992, SCIENCE, V256, P1687, DOI 10.1126/science.256.5064.1687; GARDNER MB, 1994, RETROVIRIDAE, V3, P133; HANSON CV, 1994, AIDS RES HUM RETROV, V10, P645, DOI 10.1089/aid.1994.10.645; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HUNSMANN G, 1975, VIROLOGY, V66, P327, DOI 10.1016/0042-6822(75)90203-2; KERKAU T, 1989, AIDS RES HUM RETROV, V5, P613, DOI 10.1089/aid.1989.5.613; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KREISS J, 1992, JAMA-J AM MED ASSOC, V268, P477, DOI 10.1001/jama.268.4.477; LAYNE SP, 1992, VIROLOGY, V189, P695, DOI 10.1016/0042-6822(92)90593-E; LEVY JA, 1993, AIDS, V7, P1401, DOI 10.1097/00002030-199311000-00001; Levy JA, 1994, HIV PATHOGENESIS AID; LOVEDAY C, 1995, LANCET, V345, P820, DOI 10.1016/S0140-6736(95)92963-0; MACKEWICZ CE, 1994, LANCET, V344, P1671, DOI 10.1016/S0140-6736(94)90459-6; MACKEWICZ CE, 1994, CLIN IMMUNOL IMMUNOP, V73, P80, DOI 10.1006/clin.1994.1172; MURTHY KK, 1994, 7TH P ANN M NAT COOP; PEDERSEN NC, 1993, J VET INTERN MED, V7, P34, DOI 10.1111/j.1939-1676.1993.tb03166.x; PHILLIPS DM, 1994, AIDS, V8, P719, DOI 10.1097/00002030-199406000-00001; ROWLANDJONES S, 1993, SEMIN VIROL, V4, P83, DOI 10.1006/smvy.1993.1002; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ULRICH PP, 1989, J INFECT DIS, V160, P1; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	28	22	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1619	1621		10.1016/S0140-6736(95)90121-3	http://dx.doi.org/10.1016/S0140-6736(95)90121-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783542				2022-12-24	WOS:A1995RE67000014
J	PIERIBONE, VA; SHUPLIAKOV, O; BRODIN, L; HILFIKERROTHENFLUH, S; CZERNIK, AJ; GREENGARD, P				PIERIBONE, VA; SHUPLIAKOV, O; BRODIN, L; HILFIKERROTHENFLUH, S; CZERNIK, AJ; GREENGARD, P			DISTINCT POOLS OF SYNAPTIC VESICLES IN NEUROTRANSMITTER RELEASE	NATURE			English	Article							SYNAPSIN-I; SHORT-TERM; PROTEIN; PHOSPHOPROTEINS; SYNAPTOTAGMIN; PLASTICITY; NEURONS	NERVE terminals are unique among cellular secretory systems in that they can sustain vesicular release at a high rate. Although little is known about the mechanisms that account for the distinctive features of neurotransmitter release, it can be assumed that neuron-specific proteins are involved. One such protein family, the synapsins, are believed to regulate neurotransmitter release through phosphorylation-dependent interactions with synaptic vesicles and cytoskeletal elements(1). Here we show that clusters of vesicles at synaptic release sites are composed of two pools, a distal pool containing synapsin and a proximal pool devoid of synapsin and located adjacent to the presynaptic membrane. Presynaptic injection of synapsin antibodies resulted in the loss of the distal pool, without any apparent effect on the proximal pool. Depletion of this distal pool,vas associated with a marked depression of neurotransmitter release evoked by high-frequency (18-20 Hz) but not by low-frequency (0.2 Hz) stimulation. Thus the availability of the synapsin-associated pool of vesicles seems to be required to sustain release of neurotransmitter in response to high-frequency bursts of impulses.	KAROLINSKA INST, DEPT NEUROSCI, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet	PIERIBONE, VA (corresponding author), ROCKEFELLER UNIV, MOLEC & CELLULAR NEUROSCI LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Shupliakov, Oleg/R-9148-2016; Hilfiker, Sabine N/L-6369-2014	Shupliakov, Oleg/0000-0001-5352-6848; Hilfiker, Sabine N/0000-0002-5167-7682; Pieribone, Vincent/0000-0002-5836-5454				ATWOOD HL, 1986, INT REV NEUROBIOL, V28, P275, DOI 10.1016/S0074-7742(08)60111-7; BENFENATI F, 1993, J CELL BIOL, V123, P1845, DOI 10.1083/jcb.123.6.1845; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BRODIN L, 1994, J NEUROPHYSIOL, V72, P592, DOI 10.1152/jn.1994.72.2.592; BRODIN L, 1994, ADV SEC MESS PHOSPH, V29, P205; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUCHANAN JT, 1992, BIOL CYBERN, V67, P123, DOI 10.1007/BF00201019; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Katz B., 1969, RELEASE NEURAL TRANS; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; MANDELL JW, 1992, J NEUROSCI, V12, P1736; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; Peters A, 1991, FINE STRUCTURE NERVO; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; ROVAINEN CM, 1979, PHYSIOL REV, V59, P1007, DOI 10.1152/physrev.1979.59.4.1007; RUBENSTEIN JL, 1993, SYNAPSE, V13, P161, DOI 10.1002/syn.890130207; SHUPLIAKOV O, 1995, EUR J NEUROSCI, V7, P1111, DOI 10.1111/j.1460-9568.1995.tb01099.x; SHUPLIAKOV O, 1992, J NEUROSCI, V12, P3789; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; WICKELGREN WO, 1985, J NEUROSCI, V5, P1188	24	423	429	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 8	1995	375	6531					493	497		10.1038/375493a0	http://dx.doi.org/10.1038/375493a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777058				2022-12-24	WOS:A1995RC18800049
J	GRIEDER, NC; NELLEN, D; BURKE, R; BASLER, K; AFFOLTER, M				GRIEDER, NC; NELLEN, D; BURKE, R; BASLER, K; AFFOLTER, M			SCHNURRI IS REQUIRED FOR DROSOPHILA DPP SIGNALING AND ENCODES A ZINC-FINGER PROTEIN SIMILAR TO THE MAMMALIAN TRANSCRIPTION FACTOR PRDII-BF1	CELL			English	Article							DECAPENTAPLEGIC GENE; GERM LAYERS; BINDING PROTEIN; LARVAL CUTICLE; ZYGOTIC LOCI; BETA FAMILY; PATTERN; EMBRYO; MELANOGASTER; EXPRESSION	Cytokines of the TGF beta superfamily regulate many aspects of cellular function by activating receptor complexes consisting of two distantly related serine/threonine kinases. Previous studies have indicated that Drosophila dpp uses similar signaling complexes and strictly requires the punt and thick veins receptors to transduce the signal across the membrane. Here, we show that the schnurri (shn) gene is required for many aspects of dpp signaling, Genetic epistasis experiments indicate that shn functions downstream of the dpp signal and its receptors. The shn gene encodes a large protein similar to a family of mammalian zinc finger transcription factors. The shn protein might therefore act as a nuclear target in the dpp signaling pathway directly regulating the expression of dpp-responsive genes.	UNIV ZURICH, INST ZOOL, CH-8057 ZURICH, SWITZERLAND	University of Zurich	GRIEDER, NC (corresponding author), UNIV BASEL, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND.			Basler, Konrad/0000-0003-3534-1529; Affolter, Markus/0000-0002-5171-0016; Burke, Richard/0000-0003-0086-0767				AFFOLTER M, 1994, DEVELOPMENT, V120, P3105; AFFOLTER M, 1993, DEVELOPMENT, V117, P1199; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CHOU TB, 1993, DEVELOPMENT, V119, P1359; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; CRABTREE GR, 1992, TRANSCRIPTIONAL REGU, P1063; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; HAUPTMANN G, 1994, TRENDS GENET, V10, P266, DOI 10.1016/0168-9525(90)90008-T; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; JACKSON PD, 1994, DEV DYNAM, V199, P28, DOI 10.1002/aja.1001990104; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KARPEN GH, 1992, GENETICS, V132, P737; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; NAKAMURA T, 1990, MOL CELL BIOL, V10, P3700, DOI 10.1128/MCB.10.7.3700; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NOMURA N, 1991, J BIOL CHEM, V266, P8590; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; REUTER R, 1990, DEVELOPMENT, V110, P1031; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; ROOP DR, 1978, CELL, V15, P671, DOI 10.1016/0092-8674(78)90035-1; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; SEGAL D, 1985, GENETICS, V109, P119; STAEHLINGHAMPTON K, 1994, DEV BIOL, V164, P502, DOI 10.1006/dbio.1994.1219; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; THURINGER F, 1993, EMBO J, V12, P2419, DOI 10.1002/j.1460-2075.1993.tb05896.x; THURINGER F, 1993, P NATL ACAD SCI USA, V90, P3899, DOI 10.1073/pnas.90.9.3899; TREMML G, 1992, DEVELOPMENT, V116, P447; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANTVEER LJ, 1992, P NATL ACAD SCI USA, V89, P8971, DOI 10.1073/pnas.89.19.8971; WALL NA, 1994, CURR OPIN GENET DEV, V4, P517, DOI 10.1016/0959-437X(94)90066-C; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; WINICK J, 1993, DEVELOPMENT, V119, P1055; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; ZECCA M, 1995, IN PRESS DEVELOPMENT	49	168	173	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					791	800		10.1016/0092-8674(95)90540-5	http://dx.doi.org/10.1016/0092-8674(95)90540-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774018	Green Accepted, Bronze			2022-12-24	WOS:A1995RB96100017
J	ROBERTS, TL; WOOD, DA; RIEMERSMA, RA; GALLAGHER, PJ; LAMPE, FC				ROBERTS, TL; WOOD, DA; RIEMERSMA, RA; GALLAGHER, PJ; LAMPE, FC			TRANS ISOMERS OF OLEIC AND LINOLEIC ACIDS IN ADIPOSE-TISSUE AND SUDDEN CARDIAC DEATH	LANCET			English	Article							CORONARY HEART-DISEASE; TRANSUNSATURATED FATTY-ACIDS; BODY TISSUE; LIPIDS; WOMEN; RISK; OILS; MEN	Trans isomers of unsaturated fatty acids are formed by biological or industrial hydrogenation. A population case-control study of sudden cardiac death in men was done to test the hypothesis that trans isomers of oleic acid and linoleic acid increase the risk of sudden cardiac death due to coronary artery disease. In adipose tissue obtained at necropsy from 66 cases of sudden cardiac death and taken from 286 healthy age and sex matched controls, the proportions of trans isomers of oleic and linoleic acid were measured by gas-liquid chromatography. In cases, the mean (SE) percentage of total trans fatty acids (C18:1 plus C18:2), expressed as a proportion of all fatty acids, was significantly lower (2.68 [0.08]%) than in healthy controls (2.86 [0.04]%; p<0.05). Trans C18:1 was 2.1 (0.7)% in cases compared with 2.27 (0.04)% (p<0.05) in controls. The proportion of all trans isomers of linoleic acid was 0.58 (0.02)% in cases compared with 0.59 (0.01)% in controls (p=0.98). The estimated relative risk for sudden cardiac death of trans C18:1 and C18:2 fatty acids combined did not differ significantly from 1.0 in relation to the distribution of these trans isomers by quintile in the control population. The relative risk (95% CI) of sudden cardiac death in the top quintile was 0.40 (0.15-1.02) for C18:1 and 1.08 (0.48-2.74) for C18:2 compared with the bottom quintiles of their respective control distributions. When these univariate relations for irans fatty acids were adjusted for coronary risk factors, smoking was the only factor that remained independently associated with risk of sudden cardiac death (2.27 [1.23-4.17]). Overall, there was no evidence of a relation between trans isomers of oleic and linoleic acids combined and sudden cardiac death. However, trans oleic acid was negatively associated with risk of sudden cardiac death, whereas no association with trans forms of linoleic acid was seen. This study does not support the hypothesis that trans isomers increase the risk of sudden cardiac death.	ROYAL BROMPTON HOSP,NATL HEART & LUNG INST,DEPT CLIN EPIDEMIOL,LONDON SW3 6LY,ENGLAND; UNIV EDINBURGH,CARDIOVASC RES UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND; SOUTHAMPTON UNIV HOSP,SOUTHAMPTON GEN HOSP,DEPT PATHOL,SOUTHAMPTON,HANTS,ENGLAND; SOUTHAMPTON UNIV HOSP,SOUTHAMPTON GEN HOSP,DEPT MED STAT & COMP,SOUTHAMPTON,HANTS,ENGLAND	Imperial College London; Royal Brompton Hospital; University of Edinburgh; University of Southampton; University of Southampton			Robles-Sardin, Alma E/M-7714-2015; Lampe, Fiona/I-5826-2019	Robles-Sardin, Alma E/0000-0003-2044-7793; Lampe, Fiona/0000-0001-6851-5471	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		HOLMAN RT, 1956, P SOC EXP BIOL MED, V93, P175, DOI 10.3181/00379727-93-22699; LONDON SJ, 1991, AM J CLIN NUTR, V54, P340, DOI 10.1093/ajcn/54.2.340; MACINTYRE DE, 1984, BLOOD, V63, P848; MANN GV, 1994, LANCET, V343, P1268, DOI 10.1016/S0140-6736(94)92157-1; MCLENNAN PL, 1988, AM HEART J, V116, P709, DOI 10.1016/0002-8703(88)90328-6; MCLENNAN PL, 1985, CAN J PHYSIOL PHARM, V63, P1411, DOI 10.1139/y85-232; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1991, EUR J CLIN NUTR, V45, P375; PRIVETT OS, 1955, ARCH BIOCHEM BIOPHYS, V57, P156, DOI 10.1016/0003-9861(55)90188-0; ROBERTS TL, 1993, BRIT HEART J, V70, P524; SARGENT CA, 1990, BIOCHEM SOC T, V18, P1077, DOI 10.1042/bst0181077; THOMAS LH, 1983, J EPIDEMIOL COMMUN H, V37, P22, DOI 10.1136/jech.37.1.22; THOMAS LH, 1992, J EPIDEMIOL COMMUN H, V46, P78, DOI 10.1136/jech.46.1.78; THOMAS LH, 1981, AM J CLIN NUTR, V34, P877, DOI 10.1093/ajcn/34.5.877; THOMAS LH, 1983, J EPIDEMIOL COMMUN H, V37, P16, DOI 10.1136/jech.37.1.16; THOMAS LH, 1981, J EPIDEMIOL COMMUNIT, V35, P252; VESTER I, 1991, P SCAND FORUM LIP RE, V1, P39; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; WOOD DA, 1987, LANCET, V1, P177; WOOD DA, 1984, LANCET, V2, P117, DOI 10.1016/S0140-6736(84)91044-4; WOOD R, 1993, J LIPID RES, V34, P1; 1987, REPORT BRIT NUTRITIO	22	122	127	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					278	282		10.1016/S0140-6736(95)90274-0	http://dx.doi.org/10.1016/S0140-6736(95)90274-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7837861				2022-12-24	WOS:A1995QE73100008
J	COFFIN, JM				COFFIN, JM			HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RETROVIRAL SHUTTLE VECTOR; SINGLE REPLICATION CYCLE; REVERSE-TRANSCRIPTASE; T-CELL; INSITU HYBRIDIZATION; MUTATIONAL HOTSPOTS; BROAD-SPECTRUM; INFECTION; TYPE-1	Several recent reports indicate that the long, clinically latent phase that characterizes human immunodeficiency virus (HIV) infection of humans is not a period of viral inactivity, but an active process in which cells are being infected and dying at a high rate and in large numbers. These results lead to a simple steady-state model in which infection, cell death, and cell replacement are in balance, and imply that the unique feature of HIV is the extraordinarily large number of replication cycles that occur during infection of a single individual. This turnover drives both the pathogenic process and (even more than mutation rate) the development of genetic variation. This variation includes the inevitable and, in principle, predictable accumulation of mutations such as those conferring resistance to antiviral drugs whose presence before therapy must be considered in the design of therapeutic strategies,			COFFIN, JM (corresponding author), TUFTS UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,136 HARRISON AVE,BOSTON,MA 02111, USA.				NATIONAL CANCER INSTITUTE [R35CA044385] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 44385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURNS DPW, 1991, J VIROL, V65, P1843, DOI 10.1128/JVI.65.4.1843-1854.1991; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; Coffin J M, 1980, Ann N Y Acad Sci, V354, P410, DOI 10.1111/j.1749-6632.1980.tb27982.x; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; COFFIN JP, UNPUB; CRISE B, 1992, J VIROL, V66, P2296, DOI 10.1128/JVI.66.4.2296-2301.1992; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DOOLITTLE RF, 1990, CURR TOP MICROBIOL, V157, P1; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; ELGEN M, 1990, AIDS S1, V4, P585; ELGEN M, 1988, RNA GENETICS, V3, P3; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EMBRETSON J, 1993, P NATL ACAD SCI USA, V90, P357, DOI 10.1073/pnas.90.1.357; EVANS LA, 1993, HIV MOL ORG PATHOGEN, P29; FAUCI AS, 1993, J ACQ IMMUN DEF SYND, V6, P655; FENYO EM, 1988, J VIROL, V62, P4414; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FOLKS T, 1986, SCIENCE, V231, P600, DOI 10.1126/science.3003906; GAO Q, 1992, J VIROL, V66, P12, DOI 10.1128/JVI.66.1.12-19.1992; GOJOBORI T, 1990, P NATL ACAD SCI USA, V87, P10015, DOI 10.1073/pnas.87.24.10015; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOLLAND JJ, 1992, CURR TOP MICROBIOL, V176, P1; JOHNSON PR, 1991, VIROLOGY, V185, P217, DOI 10.1016/0042-6822(91)90769-8; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOZAL MJ, 1993, J INFECT DIS, V167, P526, DOI 10.1093/infdis/167.3.526; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; LINETTE GP, 1988, SCIENCE, V241, P573, DOI 10.1126/science.2899908; LOVEDAY C, COMMUNICATION; MERRILL JE, 1989, J VIROL, V63, P4404, DOI 10.1128/JVI.63.10.4404-4408.1989; MERRILL JE, 1992, CLIN IMMUNOL IMMUNOP, V64, P23, DOI 10.1016/0090-1229(92)90054-R; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MOHRI H, 1993, P NATL ACAD SCI USA, V90, P25, DOI 10.1073/pnas.90.1.25; MONK RJ, 1992, J VIROL, V66, P3683, DOI 10.1128/JVI.66.6.3683-3689.1992; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; MYERS G, 1992, RETROVIRIDAE, P51; NAJERA I, 1995, J VIROL, V69, P23; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9839; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6024, DOI 10.1073/pnas.87.16.6024; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; RICHMAN D, COMMUNICATION; RICHMAN DD, 1992, CURR TOP MICROBIOL, V176, P131; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SALSELA K, 1993, J VIROL, V67, P7423; SCHINAZI R, 1994, INT ANTIVIRAL NEWS, V2, P72; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUURMANN R, UNPUB; SCHWARTZ S, 1989, P NATL ACAD SCI USA, V86, P7200, DOI 10.1073/pnas.86.18.7200; SMITH TF, 1988, NATURE, V333, P573, DOI 10.1038/333573a0; TANTILLO J, 1994, J MOL BIOL, V243, P364; TARPLEY WG, COMMUNICATION; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; VARELAECHAVARRIA A, 1992, J BIOL CHEM, V267, P24681; WAINHOBSON S, 1992, CURR TOP MICROBIOL, V176, P181; WEI X, 1995, NATURE, V373, P17; WOLINSKY SM, COMMUNICATION; 1994, LANCET, V343, P871	69	1630	1704	3	111	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 27	1995	267	5197					483	489		10.1126/science.7824947	http://dx.doi.org/10.1126/science.7824947			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824947				2022-12-24	WOS:A1995QD40300031
J	GILBERT, RE; WIGFIELD, RE; FLEMING, PJ; BERRY, PJ; RUDD, PT				GILBERT, RE; WIGFIELD, RE; FLEMING, PJ; BERRY, PJ; RUDD, PT			BOTTLE-FEEDING AND THE SUDDEN-INFANT-DEATH-SYNDROME	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SLEEPING POSITION; UNEXPECTED DEATH; RISK-FACTORS; BREAST-MILK; COT DEATH; EPIDEMIOLOGY; CHILDREN; PRETERM	Objective-To determine whether the risk of the sudden infant death syndrome is increased in bottle fed babies. Design-Population based case-control study matching for age and time. Subjects-All babies aged 1 week to 1 year dying of sudden infant death syndrome during November 1987 to April 1989 or February 1990 to June 1991 and two live controls. Setting-Avon and north Somerset. Main outcome measures-Breast or bottle feeding, sleeping position, maternal smoking, parental employment, and length of gestation. Results-Compared with being fully breast fed, the crude odds ratio for sudden infant death in fully bottle fed babies was 3.1 and for mixed breast and bottle fed babies 1.5. These odds ratios fell to 1.8 (95% confidence interval 0.7 to 4.8) and 1.2 (0.5 to 2.7) respectively after maternal smoking, parental employment, preterm gestation, and sleeping position had been adjusted for. Sleeping position partly masked the effect of being bottle fed on sudden infant death as breast fed babies were more likely to have slept prone than bottle fed babies. Conclusions-Bottle feeding is not a significant independent risk factor for the sudden infant death syndrome. Patterns of maternal smoking, preterm gestation, and parental employment status account for most of the apparent association with bottle feeding.	ST MICHAELS HOSP, DEPT CHILD HLTH, BRISTOL BS2 8EG, AVON, ENGLAND; ROYAL UNITED HOSP, BATH UNIT RES PAEDIAT, BATH BA1 3NG, AVON, ENGLAND; ST MICHAELS HOSP, DEPT PAEDIAT PATHOL, BRISTOL BS2 8EG, AVON, ENGLAND		GILBERT, RE (corresponding author), INST CHILD HLTH, DEPT EPIDEMIOL & BIOSTAT, LONDON WC1N 1EH, ENGLAND.		Fleming, Peter J/A-9081-2010; Fleming, Peter/O-3231-2019	Fleming, Peter J/0000-0003-2521-5764; Fleming, Peter/0000-0003-2521-5764; Gilbert, Ruth/0000-0001-9347-2709	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEAL SM, 1986, AUST PAEDIATR J, V22, P13; BIERINGSORENSEN F, 1978, ACTA PAEDIATR SCAND, V67, P129, DOI 10.1111/j.1651-2227.1978.tb16292.x; BROOKS JG, 1994, PEDIATRICS, V94, P456; CARPENTE.RG, 1965, BRIT J PREV SOC MED, V19, P1; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; ENGELBERTS AC, 1991, THESIS; FEDRICK J, 1974, BRIT J PREV SOC MED, V28, P164; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; FORD RPK, 1993, INT J EPIDEMIOL, V22, P885, DOI 10.1093/ije/22.5.885; FROGART P, 1971, BR J PREV SOC MED, V49, P119; HARRIS JDC, 1982, J EPIDEMIOL COMMUN H, V36, P162, DOI 10.1136/jech.36.3.162; HOFFMAN HJ, 1988, ANN NY ACAD SCI, V533, P13, DOI 10.1111/j.1749-6632.1988.tb37230.x; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; KNOWELDEN J, 1984, MULTICENTRE STUDY PO; KRAUS AS, 1971, C J PUBLIC HEALTH, V62, P210; KRAUS JF, 1989, INT J EPIDEMIOL, V18, P113, DOI 10.1093/ije/18.1.113; LUCAS A, 1990, LANCET, V336, P1519, DOI 10.1016/0140-6736(90)93304-8; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; LUCAS A, 1990, BRIT MED J, V300, P837, DOI 10.1136/bmj.300.6728.837; MCGLASHAN ND, 1989, SOC SCI MED, V29, P1015, DOI 10.1016/0277-9536(89)90059-2; MITCHELL EA, 1992, AUST J PUBLIC HEALTH, V16, P158; MURPHY JF, 1982, J EPIDEMIOL COMMUN H, V36, P17, DOI 10.1136/jech.36.1.17; POLLOCK JI, 1992, EFFECTS SMOKING FETU, P108; PROTESTOS CD, 1973, ARCH DIS CHILD, V48, P835, DOI 10.1136/adc.48.11.835; RHEAD WJ, 1973, BMJ-BRIT MED J, V4, P548, DOI 10.1136/bmj.4.5891.548-d; SAVAGE F, 1992, MIDIRS MIDWIFERY DIG, V2, P3; WATSON E, 1981, MED SCI LAW, V21, P78, DOI 10.1177/002580248102100202; WHITE AS, 1992, INFANT FEEDING 1990; WIGFIELD RE, 1992, BRIT MED J, V304, P282, DOI 10.1136/bmj.304.6822.282; WILLIAMS AF, 1994, ARCH DIS CHILD, V71, P376; 1993, REPORT CHIEF MED OFF	31	47	48	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 14	1995	310	6972					88	90		10.1136/bmj.310.6972.88	http://dx.doi.org/10.1136/bmj.310.6972.88			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC223	7833732	Green Published			2022-12-24	WOS:A1995QC22300018
J	SVEJSTRUP, JQ; WANG, ZG; FEAVER, WJ; WU, XH; BUSHNELL, DA; DONAHUE, TF; FRIEDBERG, EC; KORNBERG, RD				SVEJSTRUP, JQ; WANG, ZG; FEAVER, WJ; WU, XH; BUSHNELL, DA; DONAHUE, TF; FRIEDBERG, EC; KORNBERG, RD			DIFFERENT FORMS OF TFIIH FOR TRANSCRIPTION AND DNA-REPAIR - HOLO-TFIIH AND A NUCLEOTIDE EXCISION REPAIROSOME	CELL			English	Article							RNA POLYMERASE-II; FACTOR-B; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; CTD KINASE; DHFR GENE; YEAST; PURIFICATION; RECOMBINATION; DOMAIN	Yeast TFIIH that is active in transcription can be dissociated into three components: a 5-subunit core, the SSL2 gene product, and a complex of 47 kDa, 45 kDa, and 33 kDa polypeptides that possesses protein kinase activity directed towards the C-terminal repeat domain of RNA polymerase II. These three components can reconstitute fully functional TFIIH, and all three are required for transcription in vitro. By contrast, TFIIH that is highly active in nucleotide excision repair (NER) lacks the kinase complex and instead contains the products of all other genes known to be required for NER in yeast: RAD1, RAD2, RAD4, RAD10, and RAD14. This repairosome is not active in reconstituted transcription in vitro and is significantly more active than any of the constituent polypeptides in correcting defective repair in extracts from strains mutated in NER genes.	STANFORD UNIV,SCH MED,DEPT BIOL STRUCT,STANFORD,CA 94305; UNIV TEXAS,SW MED CTR,DEPT PATHOL,MOLEC PATHOL LAB,DALLAS,TX 75235; INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Indiana University System; Indiana University Bloomington				Svejstrup, Jesper/0000-0003-4964-6147	NATIONAL CANCER INSTITUTE [R01CA012428, R37CA012428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM032263, R01GM036659] Funding Source: NIH RePORTER; NCI NIH HHS [CA12428] Funding Source: Medline; NIGMS NIH HHS [GM36659, GM32263] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BARDWELL L, 1994, P NATL ACAD SCI USA, V91, P3926, DOI 10.1073/pnas.91.9.3926; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CLEAVER JE, 1994, CELL, V76, P1, DOI 10.1016/0092-8674(94)90165-1; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLORES O, 1992, J BIOL CHEM, V267, P2786; Friedberg E.C., 1991, MOL CELLULAR BIOL TE, P147; GERARD M, 1991, J BIOL CHEM, V266, P20940; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; NAEGELI H, 1992, BIOCHEMISTRY-US, V32, P613; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; Qui H., 1993, GENE DEV, V7, P2161; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SONG JM, 1990, J BACTERIOL, V172, P6620, DOI 10.1128/jb.172.12.6620-6630.1990; SUNG P, 1984, P NATL ACAD SCI USA, V84, P8951; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; VANGOOL AJ, 1994, IN PRESS EMBO J; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WANG ZG, 1993, P NATL ACAD SCI USA, V90, P4907, DOI 10.1073/pnas.90.11.4907	55	248	252	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					21	28		10.1016/0092-8674(95)90447-6	http://dx.doi.org/10.1016/0092-8674(95)90447-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813015	Bronze			2022-12-24	WOS:A1995QB91000006
J	SAKIMURA, K; KUTSUWADA, T; ITO, I; MANABE, T; TAKAYAMA, C; KUSHIYA, E; YAGI, T; AIZAWA, S; INOUE, Y; SUGIYAMA, H; MISHINA, M				SAKIMURA, K; KUTSUWADA, T; ITO, I; MANABE, T; TAKAYAMA, C; KUSHIYA, E; YAGI, T; AIZAWA, S; INOUE, Y; SUGIYAMA, H; MISHINA, M			REDUCED HIPPOCAMPAL LTP AND SPATIAL-LEARNING IN MICE LACKING NMDA RECEPTOR EPSILON-1 SUBUNIT	NATURE			English	Article							LONG-TERM POTENTIATION; II MUTANT MICE; CHANNEL; CLONING; ANTAGONIST; EXPRESSION; MODULATION; NEURONS	THE NMDA (N-methyl-D-aspartate) receptor channel is important for synaptic plasticity, which is thought to underlie learning, memory and development(1,2). The NMDA receptor channel is formed by at least two members of the glutamate receptor (GluR) channel subunit families, the GluR epsilon (NR2) and GluR zeta (NR1) subunit families(3-8). The four epsilon subunits are distinct in distribution, properties and regulation(5-14). On the basis of the Mg2+ sensitivity and expression patterns, we have proposed that the epsilon 1 (NR2A) and epsilon 2 (NR2B) subunits play a role in synaptic plasticity(6,14). Here we show that targeted disruption of the mouse epsilon 1 subunit gene resulted in significant reduction of the NMDA receptor channel current and long-term potentiation at the hippocampal CA1 synapses. The mutant mice also showed a moderate deficiency in spatial learning. These results support the notion that the NMDA receptor channel-dependent synaptic plasticity is the cellular basis of certain forms of learning.	UNIV TOKYO,FAC MED,DEPT PHARMACOL,BUNKYO KU,TOKYO 113,JAPAN; NIIGATA UNIV,BRAIN RES INST,DEPT NEUROPHARMACOL,NIIGATA 951,JAPAN; KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT NEUROPHYSIOL,TOKYO 113,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT ANAT,SAPPORO,HOKKAIDO 060,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC ONCOL LAB,TSUKUBA,IBARAKI 305,JAPAN	University of Tokyo; Niigata University; Kyushu University; University of Tokyo; Hokkaido University; RIKEN								ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; ARAKI K, 1993, BIOCHEM BIOPH RES CO, V197, P1267, DOI 10.1006/bbrc.1993.2614; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; COLEMAN PA, 1989, J NEUROPHYSIOL, V61, P218, DOI 10.1152/jn.1989.61.1.218; DAVIS S, 1992, J NEUROSCI, V12, P21; GRANT SG, 1992, SCIENCE, V259, P1903; IKEDA K, 1992, FEBS LETT, V313, P34, DOI 10.1016/0014-5793(92)81178-O; ISHII T, 1993, J BIOL CHEM, V268, P2836; ITO I, 1991, NEUROREPORT, V2, P333, DOI 10.1097/00001756-199106000-00008; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MISHINA M, 1993, ANN NY ACAD SCI, V707, P136, DOI 10.1111/j.1749-6632.1993.tb38049.x; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORI H, 1993, NEUROREPORT, V4, P519, DOI 10.1097/00001756-199305000-00014; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; WATANABE M, 1993, J COMP NEUROL, V338, P337; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; YAMAZAKI M, 1992, FEBS LETT, V300, P39, DOI 10.1016/0014-5793(92)80160-I; ZHANG YX, 1994, BRAIN RES, V658, P127, DOI 10.1016/S0006-8993(09)90018-X	30	659	679	1	41	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					151	155		10.1038/373151a0	http://dx.doi.org/10.1038/373151a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816096				2022-12-24	WOS:A1995QB06300059
J	DYDA, F; HICKMAN, AB; JENKINS, TM; ENGELMAN, A; CRAIGIE, R; DAVIES, DR				DYDA, F; HICKMAN, AB; JENKINS, TM; ENGELMAN, A; CRAIGIE, R; DAVIES, DR			CRYSTAL-STRUCTURE OF THE CATALYTIC DOMAIN OF HIV-1 INTEGRASE - SIMILARITY TO OTHER POLYNUCLEOTIDYL TRANSFERASES	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; ESCHERICHIA-COLI; DNA INTEGRATION; ANGSTROM RESOLUTION; NUCLEOTIDE-SEQUENCE; PROTEIN INVITRO; RIBONUCLEASE-H; AIDS VIRUS; IDENTIFICATION	HIV integrase is the enzyme responsible for inserting the viral DNA into the host chromosome; it is essential for HIV replication. The crystal structure of the catalytically active core domain (residues 50 to 212) of HIV-7 integrase was determined at 2.5 Angstrom resolution. The central feature of the structure is a five-stranded beta sheet flanked by helical regions. The overall topology reveals that this domain of integrase belongs to a superfamily of polynucleotidyl transferases that includes ribonuclease H and the Holliday junction resolvase RuvC. The active site region is identified by the position of two of the conserved carboxylate residues essential for catalysis, which are located at similar positions in ribonuclease H. In the crystal, two molecules form a dimer with an extensive solvent-inaccessible interface of 1300 Angstrom(2) per monomer.	NIDDK,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								[Anonymous], COMMUNICATION; ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; ARTYMIUK PJ, 1993, FEBS LETT, V324, P15, DOI 10.1016/0014-5793(93)81523-3; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1994, GENE DEV, V8, P2416, DOI 10.1101/gad.8.20.2416; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CARTEAU S, 1993, BIOCHEM BIOPH RES CO, V192, P1409, DOI 10.1006/bbrc.1993.1573; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CRAIGIE R, 1991, NUCLEIC ACIDS RES, V19, P2729, DOI 10.1093/nar/19.10.2729; CROUCH R J, 1990, New Biologist, V2, P771; Crouch R. J., 1982, NUCLEASES, P211; CUSHMAN M, 1992, BIOCHEM BIOPH RES CO, V185, P85, DOI 10.1016/S0006-291X(05)80958-1; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DAVIES JF, 1994, CELL, V7623, P1123; Doublie S., 1992, CRYSTALLIZATION NUCL, P311; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; FESEN MR, 1993, P NATL ACAD SCI USA, V90, P2399, DOI 10.1073/pnas.90.6.2399; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FUREY W, 1990, AM CRYSTALLOGRAPHIC; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; HAZUDA DJ, 1994, NUCLEIC ACIDS RES, V22, P1121, DOI 10.1093/nar/22.6.1121; HICKMAN AB, 1994, J BIOL CHEM, V269, P29279; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JENKINS TC, UNPUB; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREMENSTOVA E, COMMUNICATION; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LEAVITT AD, 1993, J BIOL CHEM, V268, P2113; LIN TH, 1991, PROTEIN ENG, V4, P435, DOI 10.1093/protein/4.4.435; MAZUMDER A, 1994, P NATL ACAD SCI USA, V91, P5771, DOI 10.1073/pnas.91.13.5771; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; MURZIN AG, 1992, CURR OPIN STRUC BIOL, V2, P895; NUCLEASES, 1967, DAVI, P93; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; RADSTROM P, 1994, J BACTERIOL, V176, P3257, DOI 10.1128/jb.176.11.3257-3268.1994; RAMAKRISHNAN V, 1993, NATURE, V262, P219; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROWLAND SJ, 1990, MOL MICROBIOL, V4, P961, DOI 10.1111/j.1365-2958.1990.tb00669.x; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SCHAUER M, 1992, BIOCHEM BIOPH RES CO, V185, P874, DOI 10.1016/0006-291X(92)91708-X; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SHERRATT D, 1989, MOBILE DNA, P163; STARNES MC, 1989, J BIOL CHEM, V264, P7073; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; VINCENT KA, 1990, NUCLEIC ACIDS RES, V18, P6045, DOI 10.1093/nar/18.20.6045; VINK C, 1991, J VIROL, V65, P4636, DOI 10.1128/JVI.65.9.4636-4644.1991; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; VINK C, 1994, NUCLEIC ACIDS RES, V22, P2176, DOI 10.1093/nar/22.11.2176; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; VINK C, 1990, J VIROL, V64, P5626, DOI 10.1128/JVI.64.11.5626-5627.1990; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; WOERNER AM, 1993, NUCLEIC ACIDS RES, V21, P3507, DOI 10.1093/nar/21.15.3507; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	81	680	712	0	33	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					1981	1986		10.1126/science.7801124	http://dx.doi.org/10.1126/science.7801124			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801124				2022-12-24	WOS:A1994PZ26700027
J	SALLES, FJ; LIEBERFARB, ME; WREDEN, C; GERGEN, JP; STRICKLAND, S				SALLES, FJ; LIEBERFARB, ME; WREDEN, C; GERGEN, JP; STRICKLAND, S			COORDINATE INITIATION OF DROSOPHILA DEVELOPMENT BY REGULATED POLYADENYLATION OF MATERNAL MESSENGER-RNAS	SCIENCE			English	Article							XENOPUS OOCYTE MATURATION; RECEPTOR TYROSINE KINASE; CYTOPLASMIC POLYADENYLATION; TRANSLATIONAL CONTROL; MEIOTIC MATURATION; ANTERIOR PATTERN; MOUSE OOCYTES; BODY PATTERN; EMBRYO; GENE	Pattern formation in Drosophila depends initially on the translational activation of maternal messenger RNAs (mRNAs) whose protein products determine cell fate. Three mRNAs that dictate anterior, dorsoventral, and terminal specification-bicoid, Toll, and torso, respectively-showed increases in polyadenylate [poly(A)] tail length concomitant with translation. In contrast, posteriorly localized nanos mRNA, although also translationally activated, was not regulated by poly(A) status. These results implicate at least two mechanisms of mRNA activation in flies. Studies with bicoid mRNA showed that cytoplasmic polyadenylation is necessary for translation, establishing this pathway as essential for embryogenesis. Combined, these experiments identify a regulatory pathway that can coordinate initiation of maternal pattern formation systems in Drosophila.	SUNY STONY BROOK, MED CTR, DEPT PHARMACOL, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NIGMS NIH HHS [GM51584] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051584] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; DRIEVER W, 1989, NATURE, V342, P149, DOI 10.1038/342149a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1990, DEVELOPMENT, V109, P811; EPHRUSSI A, COMMUNICATION; FERRANDON D, IN PRESS CELL; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0; GAY NJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P290, DOI 10.1016/0167-4781(92)90163-T; GOTTLIEB E, 1992, P NATL ACAD SCI USA, V89, P7164, DOI 10.1073/pnas.89.15.7164; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HUARTE J, 1987, GENE DEV, V1, P1201, DOI 10.1101/gad.1.10.1201; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KUHN R, 1991, MECH DEVELOP, V35, P143, DOI 10.1016/0925-4773(91)90064-D; MACDONALD PM, 1991, GENE DEV, V5, P2455, DOI 10.1101/gad.5.12b.2455; MARTIN JR, 1994, NATURE, V367, P741, DOI 10.1038/367741a0; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MCGREW LL, 1990, EMBO J, V9, P3743, DOI 10.1002/j.1460-2075.1990.tb07587.x; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; PARIS J, 1990, MOL CELL BIOL, V10, P5634, DOI 10.1128/MCB.10.11.5634; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; SALLES F, UNPUB; SALLES FJ, 1992, GENE DEV, V6, P1202, DOI 10.1101/gad.6.7.1202; SCHAFER M, 1990, EMBO J, V9, P4519, DOI 10.1002/j.1460-2075.1990.tb07903.x; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; Standart Nancy, 1992, Seminars in Developmental Biology, V3, P367; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STJOHNSTON D, 1992, CELL, V68, P201; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; VERROTTI AC, UNPUB; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WHARTON RP, 1992, SEMINARS DEV BIOL, V3, P391; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WNAG LK, 1994, DEV DYNAM, V199, P103	43	205	208	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 23	1994	266	5193					1996	1999		10.1126/science.7801127	http://dx.doi.org/10.1126/science.7801127			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801127				2022-12-24	WOS:A1994PZ26700031
J	MALGAROLI, A; TING, AE; WENDLAND, B; BERGAMASCHI, A; VILLA, A; TSIEN, RW; SCHELLER, RH				MALGAROLI, A; TING, AE; WENDLAND, B; BERGAMASCHI, A; VILLA, A; TSIEN, RW; SCHELLER, RH			PRESYNAPTIC COMPONENT OF LONG-TERM POTENTIATION VISUALIZED AT INDIVIDUAL HIPPOCAMPAL SYNAPSES	SCIENCE			English	Article							FROG NEUROMUSCULAR-JUNCTION; MINIATURE SYNAPTIC CURRENTS; RELEASE; ENHANCEMENT; PROBABILITY; INDUCTION; TRANSMISSION; MECHANISM; FREQUENCY; NEURONS	Long-term potentiation has previously been studied with electrophysiological techniques that do not readily separate presynaptic and postsynaptic contributions. Changes in exocytotic-endocytotic cycling have now been monitored at synapses between cultured rat hippocampal neurons by measuring the differential uptake of antibodies that recognize the intraluminal domain of the synaptic vesicle protein synaptotagmin. Vesicular cycling increased markedly during glutamate-induced long-term potentiation. The degree of potentiation was heterogeneous, appearing greater at synapses at which the initial extent of vesicular turnover was low. Thus, changes in presynaptic activity were visualized directly and the spatial distribution of potentiation could be determined at the level of single synaptic boutons.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305; UNIV MILAN,DIPARTIMENTO FARMACOL,I-20132 MILAN,ITALY	Howard Hughes Medical Institute; Stanford University; University of Milan	MALGAROLI, A (corresponding author), SCI INST SAN RAFFAELE,DIBIT,I-20132 MILAN,ITALY.		Bergamaschi, Andrea/AAN-3705-2020; Malgaroli, Antonio/I-5090-2013; Villa, Antonello/B-4781-2012	Malgaroli, Antonio/0000-0003-3758-7477; Ting, Anthony/0000-0002-5058-9576	Telethon [D.016] Funding Source: Medline	Telethon(Fondazione Telethon)		BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; COAN EJ, 1989, NEUROSCI LETT, V105, P205, DOI 10.1016/0304-3940(89)90038-4; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CORMIER RJ, 1993, NEURON, V10, P907, DOI 10.1016/0896-6273(93)90206-7; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LEVTOV A, 1980, J PHYSIOL-LONDON, V309, P247, DOI 10.1113/jphysiol.1980.sp013507; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LYNCH MA, 1986, BRAIN RES, V369, P405, DOI 10.1016/0006-8993(86)90561-5; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1994, SCIENCE, V265, P1888, DOI 10.1126/science.7916483; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; Matteoli M, 1991, Curr Opin Neurobiol, V1, P91, DOI 10.1016/0959-4388(91)90015-Y; MCPHERSON PS, 1994, SEMIN NEUROSCI, V6, P137; MELDOLESI J, 1988, CURR TOP MEMBR TRANS, V32, P139; MURPHY TH, 1994, SCIENCE, V263, P529, DOI 10.1126/science.7904774; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; RANDALL A, 1995, J NEUROSCI, V15, P2995; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; YANG XD, 1991, P NATL ACAD SCI USA, V88, P4299, DOI 10.1073/pnas.88.10.4299; ZHENG W, 1991, MOL PHARMACOL, V40, P734	37	148	148	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 16	1995	268	5217					1624	1628		10.1126/science.7777862	http://dx.doi.org/10.1126/science.7777862			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7777862				2022-12-24	WOS:A1995RD45900040
J	KIMURA, Y; YAHARA, I; LINDQUIST, S				KIMURA, Y; YAHARA, I; LINDQUIST, S			ROLE OF THE PROTEIN CHAPERONE YDJ1 IN ESTABLISHING HSP90-MEDIATED SIGNAL-TRANSDUCTION PATHWAYS	SCIENCE			English	Article							HEAT-SHOCK PROTEIN; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; YEAST HOMOLOG; HSP90; KINASE; TEMPERATURES; COMPLEXES; BINDING; GROWTH	The substrate-specific protein chaperone Hsp90 (heat shock protein 90) from Saccharomyces cerevisiae functions in diverse signal transduction pathways. A mutation in YDJ1, a member of the DnaJ chaperone family, was recovered in a synthetic-lethal screen with Hsp90 mutants. in an otherwise wild-type background, the ydj1 mutation exerted strong and specific effects an three Hsp90 substrates, derepressing two (the estrogen and glucocorticoid receptors) and reducing the function of the third (the tyrosine kinase p60(v-src)). Analysis of one of these substrates, the glucocorticoid receptor, indicated that Ydj1 exerts its effects through physical interaction with Hsp90 substrates.	UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; TOKYO METROPOLITAN INST MED SCI,TOKYO 113,JAPAN	University of Chicago; Howard Hughes Medical Institute; University of Chicago; Tokyo Metropolitan Institute of Medical Science			Kimura, Yoko/E-6845-2013	Kimura, Yoko/0000-0002-3054-9753				ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BOHEN SP, UNPUB; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRISCO PRG, 1990, J BIOL CHEM, V265, P11667; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CAPLAN A, COMMUNICATION; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; CHANG H, UNPUB; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; CUTTFORTH T, 1994, CELL, V77, P1027; DOYLE HJ, 1993, GENE DEV, V7, P633, DOI 10.1101/gad.7.4.633; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JOHNSON JL, 1994, J BIOL CHEM, V263, P24989; KIMURA Y, 1994, MOL GEN GENET, V242, P517, DOI 10.1007/BF00285275; KIMURA Y, UNPUB; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; NATHAN DF, UNPUB; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1993, J BIOL CHEM, V268, P21455; SANCHEZ Y, 1993, J BACTERIOL, V175, P6484, DOI 10.1128/jb.175.20.6484-6491.1993; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	34	218	226	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1362	1365		10.1126/science.7761857	http://dx.doi.org/10.1126/science.7761857			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761857				2022-12-24	WOS:A1995RB19800042
J	SCHNITZLER, GR; BRISCOE, C; BROWN, JM; FIRTEL, RA				SCHNITZLER, GR; BRISCOE, C; BROWN, JM; FIRTEL, RA			SERPENTINE CAMP RECEPTORS MAY ACT THROUGH A G-PROTEIN-INDEPENDENT PATHWAY TO INDUCE POSTAGGREGATIVE DEVELOPMENT IN DICTYOSTELIUM	CELL			English	Article							MOLECULAR-GENETIC-ANALYSIS; CYCLIC-AMP; SIGNAL-TRANSDUCTION; MULTICELLULAR DEVELOPMENT; CELL-DIFFERENTIATION; KINASE ACTIVATION; PRESTALK GENE; EXPRESSION; DISCOIDEUM; SUBUNITS	The transcription factor G box-binding factor (GBF) is required for the developmental switch between aggregative and postaggregative gene expression, cell-type differentiation, and morphogenesis. We show that constitutive expression of GBF allows ectopic expression of postaggregative genes, but only in response to exogenous cAMP. GBF activation requires the serpentine cAMP receptors required for aggregation, but not the coupled G alpha 2 or the GP subunit, suggesting a novel signaling pathway. in response to high cAMP, g alpha 2-null cells can bypass the aggregation stage, expressing cell type-specific genes and forming fruiting bodies. Our results demonstrate that the same receptors regulate aggregation and cell-type differentiation, but via distinct pathways depending upon whether the receptor perceives a pulsatile or sustained signal.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego								ABE K, 1983, DEV BIOL, V95, P200, DOI 10.1016/0012-1606(83)90018-0; BERKS M, 1990, DEVELOPMENT, V110, P977; BLUMBERG DD, 1988, DEV GENET, V9, P359, DOI 10.1002/dvg.1020090417; BLUMBERG DD, 1989, DIFFERENTIATION, V41, P14, DOI 10.1111/j.1432-0436.1989.tb00727.x; CARREL F, 1994, MOL BIOL CELL, V5, P7, DOI 10.1091/mbc.5.1.7; CECCARELLI A, 1992, DEV BIOL, V152, P188, DOI 10.1016/0012-1606(92)90169-H; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CUBITT AB, 1992, COLD SPRING HARB SYM, V57, P177, DOI 10.1101/SQB.1992.057.01.023; DATTA S, 1988, GENE DEV, V2, P294, DOI 10.1101/gad.2.3.294; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; DHARMAWARDHANE S, 1994, DEVELOPMENT, V120, P3549; DYNES JL, 1994, GENE DEV, V8, P948, DOI 10.1101/gad.8.8.948; FOSNAUGH KL, 1993, DEV BIOL, V157, P38, DOI 10.1006/dbio.1993.1110; GOMER RH, 1985, COLD SPRING HARB SYM, V50, P801, DOI 10.1101/SQB.1985.050.01.098; HABERSTROH L, 1990, GENE DEV, V4, P596, DOI 10.1101/gad.4.4.596; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HADWIGER JA, 1994, P NATL ACAD SCI USA, V91, P10566, DOI 10.1073/pnas.91.22.10566; HARIBABU B, 1986, MOL CELL BIOL, V6, P2402, DOI 10.1128/MCB.6.7.2402; HJORTH AL, 1989, GENE DEV, V3, P747, DOI 10.1101/gad.3.6.747; HJORTH AL, 1990, GENE DEV, V4, P419, DOI 10.1101/gad.4.3.419; INSALL RH, 1994, MOL BIOL CELL, V5, P703, DOI 10.1091/mbc.5.6.703; JACKSON CL, 1991, CELL, V67, P389, DOI 10.1016/0092-8674(91)90190-A; JERMYN KA, 1987, DEVELOPMENT, V100, P745; JOHNSON RL, 1992, J BIOL CHEM, V267, P4600; JOHNSON RL, 1993, GENE DEV, V7, P273, DOI 10.1101/gad.7.2.273; Kay Robert R., 1992, Current Opinion in Cell Biology, V4, P934, DOI 10.1016/0955-0674(92)90121-R; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; KUBOHARA Y, 1994, FASEB J, V11, P869; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; KUMAGAI A, 1988, COLD SPRING HARB SYM, V2, P675; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LILLY PJ, 1994, J BIOL CHEM, V259, P14123; MANN SKO, 1987, MOL CELL BIOL, V7, P458, DOI 10.1128/MCB.7.1.458; MANN SKO, 1989, P NATL ACAD SCI USA, V86, P1924, DOI 10.1073/pnas.86.6.1924; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; MEHDY MC, 1983, CELL, V32, P763, DOI 10.1016/0092-8674(83)90062-4; MILNE JLS, 1995, IN PRESS J BIOL CHEM; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; OYAMA M, 1986, P NATL ACAD SCI USA, V83, P4819, DOI 10.1073/pnas.83.13.4819; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PEARS CJ, 1988, NUCLEIC ACIDS RES, V16, P8467, DOI 10.1093/nar/16.17.8467; PEARS CJ, 1987, EMBO J, V6, P195, DOI 10.1002/j.1460-2075.1987.tb04738.x; POWELLCOFFMAN JA, 1994, MOL CELL BIOL, V14, P5840, DOI 10.1128/MCB.14.9.5840; SARAN S, 1994, FEBS LETT, V337, P43, DOI 10.1016/0014-5793(94)80626-8; SCHAAP P, 1986, DEV BIOL, V118, P52, DOI 10.1016/0012-1606(86)90072-2; SCHAAP P, 1985, EXP CELL RES, V159, P388, DOI 10.1016/S0014-4827(85)80012-4; SCHLATTERER C, 1992, EUR J CELL BIOL, V58, P172; SCHNITZLER GR, 1994, GENE DEV, V8, P502, DOI 10.1101/gad.8.4.502; SEGALL J, 1995, IN PRESS J CELL BIOL; SOEDE RDM, 1994, DEVELOPMENT, V120, P1997; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; TOWN C, 1978, DEV BIOL, V63, P412, DOI 10.1016/0012-1606(78)90145-8; Williams JG, 1991, CURR OPIN GENET DEV, V1, P358, DOI 10.1016/S0959-437X(05)80300-4; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; WU L, 1994, HDB EXPT PHARM, V108, P335; WU LJ, 1991, BIOCHEM BIOPH RES CO, V179, P1141, DOI 10.1016/0006-291X(91)91690-E; WU LJ, 1994, MOL BIOL CELL, V5, P691, DOI 10.1091/mbc.5.6.691; WU LJ, 1995, IN PRESS J CELL BIOL	59	55	56	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					737	745		10.1016/0092-8674(95)90535-9	http://dx.doi.org/10.1016/0092-8674(95)90535-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774015	Bronze			2022-12-24	WOS:A1995RB96100012
J	FRAGNETO, G; THOMAS, RK; RENNIE, AR; PENFOLD, J				FRAGNETO, G; THOMAS, RK; RENNIE, AR; PENFOLD, J			NEUTRON REFLECTION STUDY OF BOVINE BETA-CASEIN ADSORBED ON OTS SELF-ASSEMBLED MONOLAYERS	SCIENCE			English	Article							AQUEOUS PERMANGANATE INTERACTION; PENETRATION-CONTROLLED REACTIONS; LANGMUIR-BLODGETT MONOLAYERS; SILICA WATER INTERFACE; LONG-CHAIN SURFACTANTS; PROTEIN ADSORPTION; POLYSTYRENE LATEX; SPECULAR REFLECTION; ORGANIC MONOLAYERS; SERUM-ALBUMIN	Specular neutron reflection has been used to determine the structure and composition of bovine beta-casein adsorbed on a solid surface from an aqueous phosphate-buffered solution at pH 7. The protein was adsorbed on a hydrophobic monolayer self-assembled from deuterated octadecyltrichlorosilane solution on a silicon (111) surface. A two-layer structure formed consisting of one dense layer of thickness 23 +/- 1 angstroms and a surface coverage of 1.9 milligrams per square meter adjacent to the surface and an external layer protruding into the solution of thickness 35 +/- 1 angstroms and 12 percent protein volume fraction. The structure of the (beta-casein) layer is explained in terms of the charge distribution in the protein.	UNIV CAMBRIDGE,CAVENDISH LAB,CAMBRIDGE CB3 OHE,ENGLAND; UNIV OXFORD,PHYS CHEM LAB,OXFORD OX1 3QZ,ENGLAND; RUTHERFORD APPLETON LAB,DIDCOT OX11 0QX,OXON,ENGLAND	University of Cambridge; University of Oxford; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory								BENJAMINS J, 1975, FARADAY DISCUSS, V59, P218, DOI 10.1039/dc9755900218; BORETOS JW, 1980, SYNTHETIC BIOMEDICAL, P187; BRASH JL, 1985, MAKROMOL CHEM S, V9, P69; BROOKSBANK DV, 1993, J CHEM SOC FARADAY T, V89, P3419, DOI 10.1039/ft9938903419; CALDWELL KD, 1992, J CHROMATOGR, V604, P63, DOI 10.1016/0021-9673(92)85529-3; CARLES C, 1988, FEBS LETT, V229, P265, DOI 10.1016/0014-5793(88)81138-4; CUYPERS PA, 1978, ANAL BIOCHEM, V84, P56, DOI 10.1016/0003-2697(78)90483-9; DICKINSON E, 1993, LANGMUIR, V9, P242, DOI 10.1021/la00025a046; DILLMAN WJ, 1973, J COLLOID INTERF SCI, V44, P221, DOI 10.1016/0021-9797(73)90215-4; FAIR BD, 1980, J COLLOID INTERF SCI, V77, P525, DOI 10.1016/0021-9797(80)90325-2; Feijter J. A. D., 1978, BIOPOLYMERS, V17, P1759; FRAGNETO G, UNPUB; GAN CS, 1994, J COLLOID INTERF SCI, V162, P214; GRAHAM DE, 1979, J COLLOID INTERF SCI, V70, P415, DOI 10.1016/0021-9797(79)90049-3; GUN J, 1984, J COLLOID INTERF SCI, V101, P201, DOI 10.1016/0021-9797(84)90020-1; Heavens O.S, 1991, OPTICAL PROPERTIES T; HENCKEVORT HJ, 1984, J COLLOID INTERF SCI, V98, P138; Horbett T. A., 2019, HYDROGELS MED PHARM, P127; IVARSSON B, 1986, CRIT REV BIOCOMPAT, V2, P1; JENNISSEN HP, 1989, BER BUNSEN PHYS CHEM, V93, P948, DOI 10.1002/bbpc.19890930905; JONSSON U, 1985, J COLLOID INTERF SCI, V103, P60; KERN W, 1990, J ELECTROCHEM SOC, V137, P1887, DOI 10.1149/1.2086825; LEE EM, 1989, CHEM PHYS LETT, V162, P196, DOI 10.1016/0009-2614(89)85124-3; LEE EM, 1990, EUROPHYS LETT, V13, P135, DOI 10.1209/0295-5075/13/2/007; MACKIE AR, 1991, J CHEM SOC FARADAY T, V87, P3043, DOI 10.1039/ft9918703043; MAOZ R, 1987, LANGMUIR, V3, P1045, DOI 10.1021/la00078a028; MAOZ R, 1987, LANGMUIR, V3, P1034, DOI 10.1021/la00078a027; MAOZ R, 1984, J COLLOID INTERF SCI, V100, P465, DOI 10.1016/0021-9797(84)90452-1; MATRITCHIE F, 1972, J COLLOID INTERF SCI, V38, P484; MCDERMOTT DB, UNPUB; MCDERMOTT DC, 1994, J COLLOID INTERF SCI, V162, P304, DOI 10.1006/jcis.1994.1043; MCDERMOTT DC, 1992, LANGMUIR, V8, P1204, DOI 10.1021/la00040a031; MIZUTANI T, 1985, J LIQ CHROMATOGR, V8, P925, DOI 10.1080/01483918508067122; NETZER L, 1983, J AM CHEM SOC, V105, P674, DOI 10.1021/ja00341a087; NETZER L, 1983, THIN SOLID FILMS, V99, P235, DOI 10.1016/0040-6090(83)90386-3; NETZER L, 1983, THIN SOLID FILMS, V100, P67, DOI 10.1016/0040-6090(83)90230-4; NORDE W, 1978, J COLLOID INTERF SCI, V66, P257, DOI 10.1016/0021-9797(78)90303-X; NYLANDER T, 1994, J COLLOID INTERF SCI, V162, P151, DOI 10.1006/jcis.1994.1020; PENFOLD J, 1990, J PHYS-CONDENS MAT, V2, P1369, DOI 10.1088/0953-8984/2/6/001; PORATH J, 1987, BIOTECHNOL PROGR, V3, P14, DOI 10.1002/btpr.5420030104; PRIME KL, 1993, J AM CHEM SOC, V115, P10714, DOI 10.1021/ja00076a032; PRIME KL, 1991, SCIENCE, V252, P1164, DOI 10.1126/science.252.5009.1164; RENNIE AR, 1990, LANGMUIR, V6, P1031, DOI 10.1021/la00095a025; SAGIV J, 1980, J AM CHEM SOC, V102, P92, DOI 10.1021/ja00521a016; SCHMIDT DG, 1972, J COLLOID INTERF SCI, V39, P655, DOI 10.1016/0021-9797(72)90073-2; SEARS VF, 1993, NEUTRON NEWS, V3, P26; SEVASTIANOV VI, 1988, CRIT REV BIOCOMPAT, V4, P109; SODERQUIST ME, 1980, J COLLOID INTERF SCI, V75, P386, DOI 10.1016/0021-9797(80)90463-4; SUZAWA T, 1982, J COLLOID INTERF SCI, V86, P144, DOI 10.1016/0021-9797(82)90049-2; TIDSWELL IM, 1990, PHYS REV B, V41, P1111, DOI 10.1103/PhysRevB.41.1111; WATANABE N, 1986, COLLOID POLYM SCI, V264, P903, DOI 10.1007/BF01410642; WEAST RC, 1973, HDB CHEM PHYSICS B; WEAST RC, 1973, HDB CHEM PHYSICS C; WU XZ, 1993, PHYS REV LETT, V70, P958, DOI 10.1103/PhysRevLett.70.958	54	136	137	0	26	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					657	660		10.1126/science.7839141	http://dx.doi.org/10.1126/science.7839141			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839141				2022-12-24	WOS:A1995QE73300032
J	TOMAC, A; LINDQVIST, E; LIN, LFH; OGREN, SO; YOUNG, D; HOFFER, BJ; OLSON, L				TOMAC, A; LINDQVIST, E; LIN, LFH; OGREN, SO; YOUNG, D; HOFFER, BJ; OLSON, L			PROTECTION AND REPAIR OF THE NIGROSTRIATAL DOPAMINERGIC SYSTEM BY GDNF IN-VIVO	NATURE			English	Article							CENTRAL CATECHOLAMINE NEURONS; FIBROBLAST GROWTH-FACTOR; NEUROTROPHIC FACTOR; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; SUBSTANTIA-NIGRA; MICE; CULTURE; RAT	GLIAL-CELL-LINE-DERIVED neurotrophic factor (GDNF), a recently cloned new member of the transforming growth factor-beta superfamily, promotes survival of cultured fetal mesencephalic dopamine neurons(1) and is expressed in the developing striatum(2,3). There have, however, been no reports about effects of GDNF in situ. We have used the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which produces parkinsonian symptoms in man, to determine whether GDNF might exert protective or regenerative effects in vivo in the adult nigrostriatal dopamine system in C57/Bl mice. GDNF injected over the substantia nigra or in striatum before MPTP potently protects the dopamine system, as shown by numbers of mesencephalic dopamine nerve cell bodies, dopamine nerve terminal densities and dopamine levels. When GDNF is given after MPTP, dopamine levels and fibre densities are significantly restored. In both cases, motor behaviour is increased above,normal levels. We conclude that intracerebral GDNF administration exerts both protective and reparative effects on the nigrostriatal dopamine system, which may have implications for the development of new treatment strategies for Parkinson's disease.	SYNERGEN INC,BOULDER,CO 80301; UNIV COLORADO,DEPT PREVENT MED & BIOSTAT,DENVER,CO 80217	University of Colorado System; University of Colorado Denver	TOMAC, A (corresponding author), KAROLINSKA INST,DEPT NEUROSCI,S-17177 STOCKHOLM,SWEDEN.			Ogren, Sven Ove/0000-0003-2573-5276				BECK KD, 1993, NEUROSCIENCE, V52, P855, DOI 10.1016/0306-4522(93)90534-M; DAHLSTROM A, 1964, ACTA PHYSIOL SCAND, V62, P1; FERRARI G, 1991, J NEUROSCI RES, V30, P493, DOI 10.1002/jnr.490300306; HEIKKILA RE, 1984, SCIENCE, V224, P1451, DOI 10.1126/science.6610213; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Hudson J., 1993, Society for Neuroscience Abstracts, V19, P652; HUMPEL C, 1994, NEUROSCIENCE, V59, P791, DOI 10.1016/0306-4522(94)90284-4; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; JONSSON G, 1985, N-S ARCH PHARMACOL, V331, P1, DOI 10.1007/BF00498844; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MAGAL E, 1993, NEUROSCIENCE, V52, P867, DOI 10.1016/0306-4522(93)90535-N; NIKKHAH G, 1993, EXP BRAIN RES, V92, P516; OGREN SO, 1979, DOPAMINERGIC ERGOT D, P187; OTTO D, 1990, J NEUROSCI, V10, P1912; SCHAAR DG, 1993, EXP NEUROL, V124, P368, DOI 10.1006/exnr.1993.1207; SCHMIDTKASTNER R, 1994, MOL BRAIN RES, V26, P325, DOI 10.1016/0169-328X(94)90106-6; SPINA MB, 1992, J NEUROCHEM, V59, P99, DOI 10.1111/j.1471-4159.1992.tb08880.x; STROMBERG I, 1993, EXP NEUROL, V124, P401, DOI 10.1006/exnr.1993.1214; SUNDSTROM E, 1987, BRAIN RES, V405, P26; SUNDSTROM E, 1990, BRAIN RES, V528, P181, DOI 10.1016/0006-8993(90)91656-2	21	1002	1079	0	29	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					335	339		10.1038/373335a0	http://dx.doi.org/10.1038/373335a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830766	Bronze			2022-12-24	WOS:A1995QD40400057
J	KNOWLES, S				KNOWLES, S			A PASSAGE THROUGH GRIEF - THE WESTERN-AUSTRALIAN RURAL PREGNANCY LOSS TEAM	BRITISH MEDICAL JOURNAL			English	Article											KNOWLES, S (corresponding author), KING EDWARD MEM HOSP WOMEN,SUBIACO,WA 6008,AUSTRALIA.								0	11	11	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1705	1708		10.1136/bmj.309.6970.1705	http://dx.doi.org/10.1136/bmj.309.6970.1705			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819995	Green Published			2022-12-24	WOS:A1994PY71700024
J	LINDBACK, S; BROSTROM, C; KARLSSON, A; GAINES, H				LINDBACK, S; BROSTROM, C; KARLSSON, A; GAINES, H			DOES SYMPTOMATIC PRIMARY HIV-1 INFECTION ACCELERATE PROGRESSION TO CDC STAGE-IV DISEASE, CD4 COUNT BELOW 200 X 10(6)/1, AIDS, AND DEATH FROM AIDS	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; BISEXUAL MEN; ILLNESS; SEROCONVERTERS; PREDICTORS; ANTIBODY; COHORT; RISK	Objective-To investigate the prognostic significance of symptomatic primary HIV-1 infection. Design-Prospective study of homosexual men seroconverting to HIV in 1985 and 1986. Patients were followed up at least three times yearly with clinical examinations and T cell subset determinations for an average of 7.2 years. Setting-Research project centred on attenders for treatment and screening for HIV at the Karolinska Institute, Stockholm. Subjects-19 patients presenting with a glandular-fever-like illness associated with seroconversion to HIV and 29 asymptomatic seroconverters. Main outcome measures-Progression to Centers for Disease Control and Prevention stage IV disease, CD4 cell count below 200 x 10(6)/1, AIDS, and death from AIDS. Results-Symptomatic seroconverters were significantly more likely to develop Centers for Disease Control and Prevention stage IV disease (95% v 66%), CD4 cell counts below 200 x 10(6)/1 (84% v 55%), and AIDS (58% v 28%) and die of AIDS (53% v 7%). Conclusion-A glandular-fever-like illness associated with seroconversion to HIV-1 predicts accelerated progression to AIDS and other HIV related diseases.	KAROLINSKA INST,HUDDINGE HOSP,DEPT INFECT DIS,STOCKHOLM,SWEDEN; KAROLINSKA INST,SODER SJUKHUSET,DEPT DERMATOVENEREOL,STOCKHOLM,SWEDEN; SWEDISH INST INFECT DIS CONTROL,DEPT CLIN IMMUNOL,STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska Institutet; Sodersjukhuset Hospital; Swedish Institute for Infectious Disease Control								ALBERT J, 1987, J MED VIROL, V23, P67, DOI 10.1002/jmv.1890230108; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; COOPER DA, 1985, LANCET, V1, P537; GAINES H, 1987, LANCET, V1, P1249; GAINES H, 1988, BRIT MED J, V297, P1363, DOI 10.1136/bmj.297.6660.1363; GAINES H, 1990, AIDS, V4, P995, DOI 10.1097/00002030-199010000-00008; GAINES H, 1988, AIDS, V2, P11, DOI 10.1097/00002030-198802000-00002; HESSOL NA, 1989, AM J EPIDEMIOL, V130, P1167, DOI 10.1093/oxfordjournals.aje.a115445; JASON J, 1989, JAMA-J AM MED ASSOC, V261, P725, DOI 10.1001/jama.261.5.725; KEET IPM, 1993, AIDS, V7, P51, DOI 10.1097/00002030-199301000-00008; LANGE JMA, 1988, AIDS, V2, P31, DOI 10.1097/00002030-198802000-00005; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; MARCUS R, 1989, B WORLD HEALTH ORGAN, V67, P577; NIU MT, 1993, AIDS RES HUM RETROV, V9, P913, DOI 10.1089/aid.1993.9.913; PEDERSEN C, 1989, BRIT MED J, V299, P154, DOI 10.1136/bmj.299.6692.154; REZZA G, 1992, AIDS, V6, P421, DOI 10.1097/00002030-199204000-00010; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SIMMONDS P, 1991, LANCET, V338, P1159, DOI 10.1016/0140-6736(91)92029-2; SINICCO A, 1993, J ACQ IMMUN DEF SYND, V6, P575; TINDALL B, 1988, ARCH INTERN MED, V148, P945, DOI 10.1001/archinte.148.4.945; VONSYDOW M, 1988, BMJ-BRIT MED J, V296, P238, DOI 10.1136/bmj.296.6617.238; 1987, MMWR-MORBID MORTAL W, V36, P3; 1994, LANCET, V343, P871; 1986, MMWR-MORBID MORTAL W, V35, P334	24	77	77	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1535	1537		10.1136/bmj.309.6968.1535	http://dx.doi.org/10.1136/bmj.309.6968.1535			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819891	Green Published			2022-12-24	WOS:A1994PX56400017
J	THAM, KY; EVANS, RJ; RUBYTHON, EJ; KINNAIRD, TD				THAM, KY; EVANS, RJ; RUBYTHON, EJ; KINNAIRD, TD			MANAGEMENT OF VENTRICULAR-FIBRILLATION BY DOCTORS IN CARDIAC-ARREST TEAMS	BRITISH MEDICAL JOURNAL			English	Article							RESUSCITATION SKILLS; CARDIOPULMONARY		CARDIFF ROYAL INFIRM,DEPT ACCID & EMERGENCY,CARDIFF CF2 1SZ,S GLAM,WALES	Cardiff Royal Infirmary								DAVID J, 1993, BRIT MED J, V306, P1578, DOI 10.1136/bmj.306.6892.1578; MORRIS F, 1991, BRIT MED J, V302, P626, DOI 10.1136/bmj.302.6777.626; TUNSTALLPEDOE H, 1992, BRIT MED J, V304, P1347, DOI 10.1136/bmj.304.6838.1347; 1992, RESUSCITATION, V24, P111; 1993, BRIT MED J, V306, P1589	5	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1408	1409		10.1136/bmj.309.6966.1408a	http://dx.doi.org/10.1136/bmj.309.6966.1408a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819848	Green Published			2022-12-24	WOS:A1994PU76400021
J	FEDER, HM; HUNT, MS				FEDER, HM; HUNT, MS			PITFALLS IN THE DIAGNOSIS AND TREATMENT OF LYME-DISEASE IN CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ERYTHEMA MIGRANS; SEROLOGIC TESTS; REFERRAL CENTER; BORRELIOSIS; DOXYCYCLINE	Objective.-To define pitfalls of diagnosis and treatment of Lyme disease in children. Design.-Case series. Setting.-A university Lyme disease clinic in a Lyme disease endemic area. Patients. A total of 146 pediatric patients (mean age, 9.9 years) referred with possible Lyme disease. Main Outcome Measures.-Of the 146 patients, 56 (38%) were overdiagnosed, 12 (8%) were underdiagnosed, and 75 (51%) were correctly diagnosed with Lyme disease. Treatment errors were made for 19 (25%) of these 75 patients. In addition, three patients (2%) with tick bites were misdiagnosed or mistreated. Frequent pitfalls included misidentifying rashes as erythema migrans, ascribing nonspecific symptoms to Lyme disease, failing to ascribe fleeting objective symptoms to Lyme disease, and inappropriate antibiotic therapy for patients with Lyme disease. Conclusions.-Errors in the diagnosis and treatment of Lyme disease in children are common.	UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,FARMINGTON,CT	University of Connecticut	FEDER, HM (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT FAMILY MED,MC 3960,FARMINGTON,CT 06030, USA.							BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BURDGE DR, 1993, CLIN INFECT DIS, V16, P558, DOI 10.1093/clind/16.4.558; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; FEDER HM, 1993, PEDIATRICS, V91, P456; FEDER HM, 1992, CLIN INFECT DIS, V15, P788, DOI 10.1093/clind/15.5.788; FEDER HM, 1995, J INFECT DIS, V171, P1371, DOI 10.1093/infdis/171.5.1371; FISTER RD, 1984, J CLIN MICROBIOL, V27, P2834; HALPERIN JJ, 1992, NEUROLOGY, V42, P1268, DOI 10.1212/WNL.42.7.1268; Krause P J, 1994, Adv Pediatr Infect Dis, V9, P183; LUGER SW, 1990, ARCH INTERN MED, V150, P761, DOI 10.1001/archinte.150.4.761; MAGNARELLI LA, 1990, J CLIN MICROBIOL, V28, P1276, DOI 10.1128/JCM.28.6.1276-1279.1990; MALANE MS, 1991, ANN INTERN MED, V114, P490, DOI 10.7326/0003-4819-114-6-490; NADELMAN RB, 1992, ANN INTERN MED, V117, P273, DOI 10.7326/0003-4819-117-4-273; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; SHAPIRO ED, 1992, NEW ENGL J MED, V327, P1769, DOI 10.1056/NEJM199212173272501; SIGAL LH, 1990, AM J MED, V88, P577, DOI 10.1016/0002-9343(90)90520-N; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; 1993, MMWR-MORBID MORTAL W, V42, P345	20	26	26	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					66	68		10.1001/jama.274.1.66	http://dx.doi.org/10.1001/jama.274.1.66			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG233	7791260				2022-12-24	WOS:A1995RG23300032
J	OCONNOR, N				OCONNOR, N			NEW CLASSIFICATION FOR LYMPHOMAS	LANCET			English	Editorial Material											OCONNOR, N (corresponding author), ROYAL SHREWSBURY HOSP NHS TRUST,SHREWSBURY,SALOP,ENGLAND.							[Anonymous], 1982, CANCER, V49, P2112; [Anonymous], 1975, BRIT J HAEMATOL, DOI DOI 10.1111/J.1365-2141.1975.TB00911.X; CHAN JKC, 1994, HISTOPATHOLOGY, V25, P517, DOI 10.1111/j.1365-2559.1994.tb01371.x; CHAN JKC, IN PRESS AM J CLIN P; HARRIS NL, 1994, BLOOD, V84, P1361; KAY HEM, 1974, LANCET, V2, P586; Lennert K, 1992, HISTOPATHOLOGY NON H; MACLENNAN KA, 1989, CANCER-AM CANCER SOC, V64, P1686, DOI 10.1002/1097-0142(19891015)64:8<1686::AID-CNCR2820640822>3.0.CO;2-I; OCONNOR NTJ, 1987, J PATHOL, V151, P185, DOI 10.1002/path.1711510305; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430	11	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1521	1522		10.1016/S0140-6736(95)91081-6	http://dx.doi.org/10.1016/S0140-6736(95)91081-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791434				2022-12-24	WOS:A1995RD79000003
J	NASSAR, M; HORN, G; HERRMANN, C; SCHERER, A; MCCORMICK, F; WITTINGHOFER, A				NASSAR, M; HORN, G; HERRMANN, C; SCHERER, A; MCCORMICK, F; WITTINGHOFER, A			THE 2.2-ANGSTROM CRYSTAL-STRUCTURE OF THE RAS-BINDING DOMAIN OF THE SERINE THREONINE KINASE C-RAF1 IN COMPLEX WITH RAP1A AND A GTP ANALOG	NATURE			English	Article							RAS-P21 GTPASE; GENE-PRODUCT; HA-RAS; PROTEIN; TARGET; RAF-1; RECOGNITION; INHIBITION; RESOLUTION; HYDROLYSIS	The X-ray crystal structure of the complex between the Ras-related protein Rap1A in the GTP-analogue (GppNHp) form and the pas-binding domain (RED) of the Ras effector molecule c-Raf1, a ser/Thr-specific protein kinase, has been solved to a resolution of 2.2 Angstrom. It shows that RED has the ubiquitin superfold and that the structure of Rap1A is very similar to that of Ras. The interaction between the two proteins is mediated by an apparent central antiparallel beta-sheet formed by strands B1-B2 from RED and strands beta 2-beta 3 from Rap1A. Complex formation is mediated by main-chain and side-chain interactions of the so-called effector residues in the switch I region of Rap1A.	MAX PLANCK INST MED RES,BIOPHYS ABT,D-69119 HEIDELBERG,GERMANY; ONYX PHARMACEUT,RICHMOND,CA 94806	Max Planck Society	NASSAR, M (corresponding author), MAX PLANCK INST MOLEK PHYSIOL,STRUKTURELLE BIOL ABT,POSTFACH 102664,D-44026 DORTMUND,GERMANY.							AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Barnard D, 1995, ONCOGENE, V10, P1283; BOKOCH G, 1993, GTPASES BIOL 1, V108, P377; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER TA, 1993, XPLOR VERSION 3 1; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; COOK S, 1993, EMBO J, V12, P3485; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; EMERSON SD, 1994, BIOCHEMISTRY-US, V33, P7745, DOI 10.1021/bi00191a001; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HATA Y, 1990, J BIOL CHEM, V265, P7104; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LU XY, 1994, EMBO J, V13, P2592, DOI 10.1002/j.1460-2075.1994.tb06549.x; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WHITE MA, 1995, CELL, V80, P1; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	49	549	564	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					554	560		10.1038/375554a0	http://dx.doi.org/10.1038/375554a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791872				2022-12-24	WOS:A1995RD28700042
J	ANNEST, JL; MERCY, JA; GIBSON, DR; RYAN, GW				ANNEST, JL; MERCY, JA; GIBSON, DR; RYAN, GW			NATIONAL ESTIMATES OF NONFATAL FIREARM-RELATED INJURIES - BEYOND THE TIP OF THE ICEBERG	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUN OWNERSHIP; HOMICIDE; HOME	Objective.-To describe the magnitude and characteristics of nonfatal firearm-related injuries treated in hospital emergency departments in the United States and to compare nonfatal injury rates with firearm-related fatality rates. Design.-Data were obtained from medical records for all firearm-related injury cases identified using the National Electronic Injury Surveillance System (NEISS) from June 1, 1992, through May 31, 1993. Setting.-NEISS comprises 91 hospitals that are a stratified probability sample of all hospitals in the United States and its territories that have at least six beds and provide 24-hour emergency service. Main Outcome Measures.-Numbers and population rates for nonfatal and fatal firearm-related injuries. Results.-An estimated 99 025 (95% confidence interval [CI], 56 325 to 141 725) persons (or 38.6 per 100 000 population; 95% CI, 22.0 to 55.2) were treated for nonfatal firearm-related injuries in US hospital emergency departments during the study period. The rate of nonfatal firearm-related injuries treated was 2.6 (95% CI, 1.5 to 3.7) times the national rate of fatal firearm-related injuries for 1992. Conclusions.-Nonfatal firearm-related injuries contribute substantially to the overall public health burden of firearm-related injuries. NEISS can be useful to monitor the number of nonfatal firearm-related injuries in the United States. A national surveillance system is needed to provide uniform data on firearm-related injury morbidity and mortality for use in research and prevention efforts.			ANNEST, JL (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,OFF STAT & PROGRAMMING K59,ATLANTA,GA 30341, USA.							ASKRANT AP, 1968, ACCIDENTS HOMICIDE; BRICK M, 1992, STATISTICAL EVALUATI; BURT CW, 1995, ADVANCE DATA VITAL H, V261, P1; Cook P.J., 1991, CRIME JUSTICE, V14, P1, DOI [10.1086/449183, DOI 10.1086/449183]; COOK PJ, 1985, J QUANTITATIVE CRIMI, V0001; FINGERHUT LA, 1992, JAMA-J AM MED ASSOC, V267, P3048, DOI 10.1001/jama.267.22.3048; FINGERHUT LA, 1994, ADV DATA VITAL HLTH, V242, P1; FINGERHUT LA, 1991, MONTHLY VITAL STAT R, V39, P1; JAGGER J, 1986, JAMA-J AM MED ASSOC, V255, P3143, DOI 10.1001/jama.255.22.3143; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; KOCHANEK KD, 1994, MONTHLY VITAL STAT S, V43, P56; LEE RK, 1991, AM J EPIDEMIOL, V134, P511, DOI 10.1093/oxfordjournals.aje.a116123; MARKER D, 1988, CPSCC871144 US CONS; RAND MR, 1994, NCJ147003 US DEP JUS, P1; Rice DP, 1989, COST INJURY US REPOR; SALTZMAN LE, 1992, JAMA-J AM MED ASSOC, V267, P3043, DOI 10.1001/jama.267.22.3043; TERET SP, 1992, JAMA-J AM MED ASSOC, V267, P3073, DOI 10.1001/jama.267.22.3073; WINTEMUTE G, 1993, JAMA-J AM MED ASSOC, V269, P2213, DOI 10.1001/jama.1993.03500170043026; WRIGHT JD, 1981, WEAPONS CRIME VIOLEN, P293; ZWERLING C, 1993, AM J PREV MED, V3, P1; 1991, MMWR-MORBID MORTAL W, V43, P609; 1976, VITAL HLTH STAT 10, V105; 1964, VITAL HLTH STAT 10, V6; 1994, NATIONAL ELECTRONIC; 1994, MMWR-MORBID MORTAL W, V43, P37; 1993, NATIONAL ELECTRONIC; 1994, TIP ICEBERG WEAPON I, P5	28	227	227	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	1995	273	22					1749	1754		10.1001/jama.273.22.1749	http://dx.doi.org/10.1001/jama.273.22.1749			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB800	7769767				2022-12-24	WOS:A1995RB80000026
J	ROSAHL, TW; SPILLANE, D; MISSLER, M; HERZ, J; SELIG, DK; WOLFF, JR; HAMMER, RE; MALENKA, RC; SUDHOF, TC				ROSAHL, TW; SPILLANE, D; MISSLER, M; HERZ, J; SELIG, DK; WOLFF, JR; HAMMER, RE; MALENKA, RC; SUDHOF, TC			ESSENTIAL FUNCTIONS OF SYNAPSIN-I AND SYNAPSIN-II IN SYNAPTIC VESICLE REGULATION	NATURE			English	Article							PROTEIN; PHOSPHOPROTEINS; ASSOCIATION; PLASTICITY; ACTIN; MICE	SYNAPTIC vesicles are coated by synapsins, phosphoproteins that account for 9% of the vesicle protein(1-3). To analyse the functions of these proteins, we have studied knockout mice lacking either synapsin I, synapsin II, or both. Mice lacking synapsins are viable and fertile with no gross anatomical abnormalities, but experience seizures with a frequency proportional to the number of mutant alleles. Synapsin-II and double knockouts, but not synapsin-I knockouts, exhibit decreased post-tetanic potentiation and severe synaptic depression upon repetitive stimulation. Intrinsic synaptic-vesicle membrane proteins, but not peripheral membrane proteins or other synaptic proteins, are slightly decreased in individual knockouts and more severely reduced in double knockouts, as is the number of synaptic vesicles. Thus synapsins are not required for neurite outgrowth, synaptogenesis or the basic mechanics of synaptic vesicle traffic, but are essential for accelerating this traffic during repetitive stimulation. The phenotype of the synapsin knockouts could be explained either by deficient recruitment of synaptic vesicles to the active zone, or by impaired maturation of vesicles at the active zone, both of which could lead to a secondary destabilization of synaptic vesicles.	UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV CALIF SAN FRANCISCO, CTR NEUROBIOL & PSYCHIAT, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CTR NEUROBIOL & PSYCHIAT, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; GOTHENBURG UNIV, ZENTRUM ANAT, D-37075 GOTTINGEN, GERMANY	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Hammer, Robert E./0000-0001-5487-7551; Missler, Markus/0000-0001-8008-984X				ADAMS JC, 1981, J HISTOCHEM CYTOCHEM, V29, P775, DOI 10.1177/29.6.7252134; [Anonymous], 1979, STEREOLOGICAL METHOD; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAINES AJ, 1985, NATURE, V315, P410, DOI 10.1038/315410a0; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; GEPPERT M, 1994, EMBO J, V13, P3720, DOI 10.1002/j.1460-2075.1994.tb06681.x; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Imaizumi K, 1959, EXP ANIM TOKYO, V8, P6; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; MANDELL JW, 1990, NEURON, V5, P19, DOI 10.1016/0896-6273(90)90030-J; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MISSLER M, 1993, J COMP NEUROL, V333, P53, DOI 10.1002/cne.903330105; PETRUCCI TC, 1987, J CELL BIOL, V105, P1355, DOI 10.1083/jcb.105.3.1355; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; RUSAKOV DA, 1991, NEUROSCI LETT, V131, P156, DOI 10.1016/0304-3940(91)90602-P; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEINER JP, 1987, J BIOL CHEM, V262, P905; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; WOOLSON RF, 1987, STATISTICAL METHODS, P344; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	24	608	614	2	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 8	1995	375	6531					488	493		10.1038/375488a0	http://dx.doi.org/10.1038/375488a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777057				2022-12-24	WOS:A1995RC18800048
J	COLLINS, K; KOBAYASHI, R; GREIDER, CW				COLLINS, K; KOBAYASHI, R; GREIDER, CW			PURIFICATION OF TETRAHYMENA TELOMERASE AND CLONING OF GENES ENCODING THE 2 PROTEIN-COMPONENTS OF THE ENZYME	CELL			English	Article							RNA; ELONGATION; SENESCENCE; SEQUENCES; ELEMENTS; MOTIFS; DNA	Telomerase is a ribonucleoprotein DNA polymerase that catalyzes the de novo synthesis of telomeric simple sequence repeats. We describe the purification of telomerase and the cloning of cDNAs encoding two protein subunits from the ciliate Tetrahymena. Two proteins of 80 and 95 kDa copurified and coimmunoprecipitated with telomerase activity and the previously identified Tetrahymena telomerase RNA. The p95 subunit specifically cross-linked to a radiolabeled telomeric DNA primer, while the p80 subunit specifically bound to radiolabeled telomerase RNA. At the primary sequence level, the two telomerase proteins share only limited homologies with other polymerases and polymerase accessory factors.			COLLINS, K (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Greider, Carol/0000-0002-5494-8126	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043080] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43080] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1992, CURRENT PROTOCOLS MO; AUTEXIER C, 1994, GENE DEV, V8, P563, DOI 10.1101/gad.8.5.563; BHATTACHARYYA A, 1994, EMBO J, V13, P5721, DOI 10.1002/j.1460-2075.1994.tb06910.x; BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; CAVARELLI J, 1994, EMBO J, V13, P327, DOI 10.1002/j.1460-2075.1994.tb06265.x; CHERRY JM, 1985, CELL, V43, P747, DOI 10.1016/0092-8674(85)90248-X; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; HARLEY CB, 1994, COLD SPRING HARB SYM, V66, P1; HARRINGTON L, 1995, J BIOL CHEM, V270, P8893, DOI 10.1074/jbc.270.15.8893; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; MAIZELS N, 1993, RNA WORLD, P577; MARTINDALE DW, 1989, J PROTOZOOL, V36, P29; MELEK M, 1994, MOL CELL BIOL, V14, P7827, DOI 10.1128/MCB.14.12.7827; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PETERSON MG, 1991, NATURE, V354, P369; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; PRESCOTT DM, 1994, MICROBIOL REV, V58, P233, DOI 10.1128/MMBR.58.2.233-267.1994; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; Sambrook J., 1989, MOL CLONING LAB MANU; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; TAKEMASA T, 1989, J BIOL CHEM, P19293; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	37	241	265	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					677	686		10.1016/0092-8674(95)90529-4	http://dx.doi.org/10.1016/0092-8674(95)90529-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774009	Bronze			2022-12-24	WOS:A1995RB96100006
J	WALLACE, L; BERNATH, P; LIVINGSTON, W; HINKLE, K; BUSLER, J; GUO, BJ; ZHANG, KQ				WALLACE, L; BERNATH, P; LIVINGSTON, W; HINKLE, K; BUSLER, J; GUO, BJ; ZHANG, KQ			WATER ON THE SUN	SCIENCE			English	Article							HYDROGEN FLAME SPECTRA; RO-VIBRATIONAL LEVELS; MILLIMETER-WAVE; H2O; MOLECULES; CM-1	High-resolution infrared spectra of sunspot umbrae have been recorded with the 1-meter Fourier transform spectrometer on Kitt Peak. The spectra contain a very large number of water absorption features originating on the sun. These lines have been assigned to the pure rotation and the vibration-rotation transitions of hot water by comparison with high-temperature laboratory emission spectra.	UNIV WATERLOO, DEPT CHEM, WATERLOO, ON N2L 3G1, CANADA; KITT PEAK NATL OBSERV, NATL OPT ASTRON OBSERV, TUCSON, AZ 85726 USA; UNIV ARIZONA, DEPT CHEM, TUCSON, AZ 85721 USA; NATL OPT ASTRON OBSERV, NATL SOLAR OBSERV, TUCSON, AZ 85726 USA; UNIV WATERLOO, DEPT CHEM, WATERLOO, ON N2L 3G1, CANADA	University of Waterloo; National Optical Astronomy Observatory; University of Arizona; National Optical Astronomy Observatory; University of Waterloo			Bernath, Peter F/B-6567-2012	Bernath, Peter F/0000-0002-1255-396X				ALLARD F, 1994, ASTROPHYS J, V426, pL39, DOI 10.1086/187334; AMANO T, 1991, CHEM PHYS LETT, V182, P93, DOI 10.1016/0009-2614(91)80109-B; BRAY RJ, 1979, SUNSPOTS, P107; CAMPBELL JC, UNPUB; CAMYPEYRET C, 1977, MOL PHYS, V33, P1641, DOI 10.1080/00268977700101361; CHEUNG AC, 1969, NATURE, V221, P626, DOI 10.1038/221626a0; FLAUD JM, 1976, MOL PHYS, V32, P499, DOI 10.1080/00268977600103251; GELLER M, 1992, NASA REF PUBL, V1224, P92; GLENAR DA, 1985, J MOL SPECTROSC, V111, P403, DOI 10.1016/0022-2852(85)90015-3; HALL DNB, 1972, ASTROPHYS J, V175, pL95, DOI 10.1086/180993; HALL DNB, 1970, THESIS HARVARD U; HINKLE KH, 1979, ASTROPHYS J, V227, P923, DOI 10.1086/156801; JORGENSEN UG, 1993, J MOL SPECTROSC, V161, P219, DOI 10.1006/jmsp.1993.1228; KLEINMANN SG, 1986, ASTROPHYS J SUPPL S, V62, P501, DOI 10.1086/191149; LEBLANC RB, 1994, J MOL SPECTROSC, V164, P574, DOI 10.1006/jmsp.1994.1100; LIEBERT J, 1994, MOL STELLAR ENV, P62; LIVINGSTON W, 1991, NATURE, V350, P45, DOI 10.1038/350045a0; PEARSON JC, 1991, ASTROPHYS J, V379, pL41, DOI 10.1086/186149; Polyansky OL, 1996, J MOL SPECTROSC, V176, P305, DOI 10.1006/jmsp.1996.0091; POLYANSKY OL, 1994, J CHEM PHYS, V101, P7651, DOI 10.1063/1.468258; POLYANSKY OL, 1985, J MOL SPECTROSC, V112, P79, DOI 10.1016/0022-2852(85)90193-6; SINHA K, 1991, P ASTRON SOC AUST, V9, P32, DOI 10.1017/S1323358000024814; SPINARD H, 1969, ANNU REV ASTRON ASTR, V7, P249, DOI 10.1146/annurev.aa.07.090169.001341; TOTH RA, 1994, APPL OPTICS, V33, P4851, DOI 10.1364/AO.33.004851; TSUJI T, IN PRESS ELEMENTARY; TYUTEREV VG, 1992, J MOL SPECTROSC, V151, P97, DOI 10.1016/0022-2852(92)90009-D; WALLACE L, 1992, 92001 NAT OPT ASTR O; WALLACE L, 1994, 199401 NAT OPT ASTR	28	111	113	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1155	1158		10.1126/science.7761830	http://dx.doi.org/10.1126/science.7761830			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761830				2022-12-24	WOS:A1995RA60400030
J	VANDERMEER, ALH; VANDERWEEL, FR; LEE, DN				VANDERMEER, ALH; VANDERWEEL, FR; LEE, DN			THE FUNCTIONAL-SIGNIFICANCE OF ARM MOVEMENTS IN NEONATES	SCIENCE			English	Article							VISUAL GUIDANCE; AFFORDANCES	Arm movements made by newborn babies are usually dismissed as unintentional, purposeless, or reflexive, Spontaneous arm-waving movements were recorded while newborns lay supine facing to one side. They were allowed to see only the arm they were facing, only the opposite arm on a video monitor, or neither arm. Small forces pulled on their wrists in the direction of the toes. The babies opposed the perturbing force so as to keep an arm up and moving normally, but only when they could see the arm, either directly or on the video monitor. The findings indicate that newborns can purposely control their arm movements in the face of external forces and that development of visual control of arm movement is underway soon after birth.			VANDERMEER, ALH (corresponding author), UNIV EDINBURGH,DEPT PSYCHOL,PERCEPT ACT LABS,7 GEORGE SQ,EDINBURGH EH8 9JZ,MIDLOTHIAN,SCOTLAND.							Bernstein N.A., 1967, COORDINATION REGULAT; BOWER TGR, 1970, NATURE, V228, P679, DOI 10.1038/228679a0; BUTTERWORTH G, 1988, BRIT J DEV PSYCHOL, V6, P303, DOI 10.1111/j.2044-835X.1988.tb01103.x; Fraiberg S., 1977, INSIGHTS BLIND; Gesell A., 1947, DEV DIAGNOSIS; GIBSON EJ, 1988, ANNU REV PSYCHOL, V39, P1, DOI 10.1146/annurev.ps.39.020188.000245; Gibson J. J, 1979, ECOLOGICAL APPROACH; LEE DN, 1974, PERCEPT PSYCHOPHYS, V15, P529, DOI 10.3758/BF03199297; Piaget Jean, 1952, ORIGINS INTELLIGENCE; THELEN E, 1990, SENSORY MOTOR ORG DE, V1, P39; TREVARTHEN C, 1974, Neurosciences Research Program Bulletin, V12, P570; VONHOFSTEN C, 1982, DEV PSYCHOL, V18, P450, DOI 10.1037/0012-1649.18.3.450; WARREN WH, 1984, J EXP PSYCHOL HUMAN, V10, P683, DOI 10.1037/0096-1523.10.5.683; WARREN WH, 1987, J EXP PSYCHOL HUMAN, V13, P371, DOI 10.1037/0096-1523.13.3.371; WHITE BL, 1964, CHILD DEV, V35, P349, DOI 10.1111/j.1467-8624.1964.tb05944.x; Winter DA, 1979, BIOMECHANICS HUMAN M	16	151	153	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					693	695		10.1126/science.7839147	http://dx.doi.org/10.1126/science.7839147			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QE733	7839147				2022-12-24	WOS:A1995QE73300042
J	SHA, WC; LIOU, HC; TUOMANEN, EI; BALTIMORE, D				SHA, WC; LIOU, HC; TUOMANEN, EI; BALTIMORE, D			TARGETED DISRUPTION OF THE P50 SUBUNIT OF NF-KAPPA-B LEADS TO MULTIFOCAL DEFECTS IN IMMUNE-RESPONSES	CELL			English	Article							DNA-BINDING SUBUNIT; TRANSCRIPTION FACTORS; ENHANCER; PROMOTER; GENE; REL; INHIBITION; EXPRESSION; DORSAL; INVOLVEMENT	NF-kappa B, a heterodimeric transcription factor composed of p50 and p65 subunits, can be activated in many cell types and is thought to regulate a wide variety of genes involved in immune function and development, Mice lacking the p50 subunit of NF-kappa B show no developmental abnormalities, but exhibit multifocal defects in immune responses involving B lymphocytes and nonspecific responses to infection. B cells do not proliferate in response to bacterial lipopolysaccharide and are defective in basal and specific antibody production. Mice lacking p50 are unable effectively to clear L. monocytogenes and are more susceptible to infection with S. pneumoniae, but are more resistant to infection with murine encephalomyocarditis virus. These data support the role of NF-kappa B as a vital transcription factor for both specific and nonspecific immune responses, but do not indicate a developmental role for the factor.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; CORNELL UNIV,COLL MED,DEPT CELL BIOL,DIV ALLERGY & IMMUNOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MED,DIV ALLERGY & IMMUNOL,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOLEC INFECT DIS LAB,NEW YORK,NY 10021	Massachusetts Institute of Technology (MIT); Cornell University; Cornell University; Rockefeller University			Tuomanen, Elaine I/N-3081-2018	Tuomanen, Elaine I/0000-0003-0349-8716	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039458] Funding Source: NIH RePORTER; NIAID NIH HHS [AI08724-02] Funding Source: Medline; NIGMS NIH HHS [GM39458] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BANCROFT GJ, 1991, IMMUNOL REV, V124, P5, DOI 10.1111/j.1600-065X.1991.tb00613.x; Coligan J.E., 1993, CURRENT PROTOCOLS IM; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOODBOURN S, 1985, CELL, V41, P509, DOI 10.1016/S0092-8674(85)80024-6; GRILLI M, 1991, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LIEBERMANN TA, 1990, MOL CELL BIOL, V10, P2327; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIU JL, 1991, J IMMUNOL, V146, P1685; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MANIATIS T, 1992, POSITIVE NEGATIVE RE; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PESSARA U, 1990, MOL CELL BIOL, V10, P4146, DOI 10.1128/MCB.10.8.4146; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SEN R, 1987, MOL CELL BIOL, V7, P1989, DOI 10.1128/MCB.7.5.1989; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6	38	1021	1048	1	20	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 27	1995	80	2					321	330		10.1016/0092-8674(95)90415-8	http://dx.doi.org/10.1016/0092-8674(95)90415-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834752	hybrid			2022-12-24	WOS:A1995QD92400015
J	OPPENHEIM, RW; HOUENOU, LJ; JOHNSON, JE; LIN, LFH; LI, LX; LO, AC; NEWSOME, AL; PREVETTE, DM; WANG, SW				OPPENHEIM, RW; HOUENOU, LJ; JOHNSON, JE; LIN, LFH; LI, LX; LO, AC; NEWSOME, AL; PREVETTE, DM; WANG, SW			DEVELOPING MOTOR-NEURONS RESCUED FROM PROGRAMMED AND AXOTOMY-INDUCED CELL-DEATH BY GDNF	NATURE			English	Article							NEUROTROPHIC FACTOR; NERVOUS-SYSTEM; SURVIVAL; MUSCLE; MOTONEURONS; SUPPORT; CULTURE; INVIVO	DURING normal development of the vertebrate nervous system, large numbers of neurons in the central and peripheral nervous system undergo naturally occurring cell death(1). For example, about half of all spinal motor neurons die over a period of a few days in developing avian, rat and mouse embryos(1). Previous studies have shown that extracts from muscle and brain, secreted factors from glia, as well as several growth factors and neurotrophic agents, including muscle-derived factors, can promote the survival of developing motor neurons in vitro and in vivo(2-15). But because neurotrophins and other known trophic agents administered alone or in combination are insufficient to rescue all developing motor neurons from cell deaths(8), other neurotrophic molecules are probably essential for the survival and differentiation of motor neurons. Here we report that glial-cell-line-derived neurotrophic factor (GDNF), a potent neurotrophic factor that enhances survival of mammalian midbrain dopaminergic neurons(16,17), rescues developing avian motor neurons from natural programmed cell death in vivo and promotes the survival of enriched populations of cultured motor neurons. Furthermore, treatment with this agent in vivo also prevents the induced death and atrophy of both avian and mouse spinal motor neurons following peripheral axotomy.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,NEUROSCI PROGRAM,WINSTON SALEM,NC 27157; SYNERGEN INC,BOULDER,CO 80301	Wake Forest University; Wake Forest Baptist Medical Center	OPPENHEIM, RW (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT NEUROBIOL & ANAT,WINSTON SALEM,NC 27157, USA.							ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BLOCHGALLEGO E, 1993, DEVELOPMENT, V111, P221; DOHRMANN U, 1987, DEV BIOL, V124, P145, DOI 10.1016/0012-1606(87)90467-2; DOHRMANN U, 1986, DEV BIOL, V118, P209, DOI 10.1016/0012-1606(86)90089-8; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HOUENOU LJ, 1994, PROG BRAIN RES, V102, P209; JOHNSON J, 1994, CURR BIOL, V4, P662, DOI 10.1016/S0960-9822(00)00149-4; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; LANCEJONES C, 1982, DEV BRAIN RES, V4, P473, DOI 10.1016/0165-3806(82)90192-4; LI LX, 1994, J NEUROBIOL, V25, P759, DOI 10.1002/neu.480250702; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MILLIGAN CE, 1994, J NEUROBIOL, V25, P1005, DOI 10.1002/neu.480250809; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; OPPENHEIM RW, 1993, J NEUROBIOL, V24, P1065, DOI 10.1002/neu.480240806; OPPENHEIM RW, 1988, SCIENCE, V240, P919, DOI 10.1126/science.3363373; OPPENHEIM RW, 1986, DEV BIOL, V114, P425; OPPENHEIM RW, 1991, SCIENCE, V257, P1616; RIECKE GK, 1982, PHYSIOL BEHAV, V28, P755; SCHAAR DG, 1993, EXP NEUROL, V124, P368, DOI 10.1006/exnr.1993.1207; SENDTNER M, 1992, NATURE, V360, P755; SPRINGER JE, 1994, Q EXPL NEUROL, V127, P167; STOMBERG I, 1993, EXP NEUROL, V124, P401; VONBARTHELD CS, 1994, NEURON, V12, P639, DOI 10.1016/0896-6273(94)90219-4; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; YIN QW, 1994, J NEUROSCI, V14, P7629	30	620	674	1	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					344	346		10.1038/373344a0	http://dx.doi.org/10.1038/373344a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830769				2022-12-24	WOS:A1995QD40400060
J	FERRICK, DA; SCHRENZEL, MD; MULVANIA, T; HSIEH, B; FERLIN, WG; LEPPER, H				FERRICK, DA; SCHRENZEL, MD; MULVANIA, T; HSIEH, B; FERLIN, WG; LEPPER, H			DIFFERENTIAL PRODUCTION OF INTERFERON-GAMMA AND INTERLEUKIN-4 IN RESPONSE TO TH1-STIMULATING AND TH2-STIMULATING PATHOGENS BY GAMMA-DELTA T-CELLS IN-VIVO	NATURE			English	Article							ALPHA-BETA; LISTERIA-MONOCYTOGENES; PROTECTIVE IMMUNITY; INFECTION; CYTOKINES; MICE; TUBERCULOSIS; EOSINOPHILIA; APPEARANCE; ELEVATION	EXPOSURE to various pathogens can stimulate at least two patterns of cytokine production by CD4-positive T cells(1-4) Responses that result in secretion of interferon-gamma (IFN-gamma), lymphotoxin and interleukin-2 (IL-2) are classified as T-helper-1 (Th1)(5,6); CD4(+) T-cell production of IL-4, IL-5, IL-9, IL-10 and IL-13 is called a T-helper-2 response (Th2)(5,6). Differentiation of CD4(+) T cells into either Th1 or Th2 cells is influenced by the cytokine milieu in which the initial antigen priming occurs(7-9). Here we use flow cytometry to identify the presence of intracellular cytokines (cytoflow) and analyse T-cell production of IFN-gamma and IL-4 from mice infected with Listeria monocytogenes or Nippostrongylus brasiliensis. We show that T cells bearing ya receptors discriminate early in infection between these two pathogens by producing cytokines associated with the appropriate T-helper response. Our results demonstrate that gamma delta T cells are involved in establishing primary immune responses.			FERRICK, DA (corresponding author), UNIV CALIF DAVIS,SCH VET MED,DEPT PATHOL MICROBIOL & IMMUNOL,DAVIS,CA 95616, USA.							BARNES PF, 1992, J INFECT DIS, V165, P506, DOI 10.1093/infdis/165.3.506; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; ENSOR JE, 1994, AM J PHYSIOL, V266, P967; FU YX, 1994, J IMMUNOL, V153, P3101; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HIROMATSU K, 1992, J EXP MED, V175, P49, DOI 10.1084/jem.175.1.49; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; KATONA IM, 1988, J IMMUNOL, V140, P3206; KELSO A, 1988, P NATL ACAD SCI USA, V85, P9189, DOI 10.1073/pnas.85.23.9189; LOCKSLEY RM, 1994, J EXP MED, V179, P1405, DOI 10.1084/jem.179.5.1405; MOMBAERTS P, 1993, NATURE, V365, P53, DOI 10.1038/365053a0; MOSER R, 1993, J LAB CLIN MED, V122, P567; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; OBRIEN RL, 1989, CELL, V57, P667, DOI 10.1016/0092-8674(89)90135-9; OHGA S, 1990, EUR J IMMUNOL, V20, P533, DOI 10.1002/eji.1830200311; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; ROCKEN M, 1992, J IMMUNOL, V148, P1031; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SCOTT P, 1991, IMMUNOL TODAY, V12, P346, DOI 10.1016/0167-5699(91)90063-Y; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; SVETIC A, 1993, J IMMUNOL, V150, P3434; TWOMEY BM, 1993, CLIN EXP IMMUNOL, V93, P178; URBAN JF, 1992, IMMUNOL REV, V127, P205, DOI 10.1111/j.1600-065X.1992.tb01415.x; WEN L, 1994, NATURE, V369, P654, DOI 10.1038/369654a0; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	30	590	599	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					255	257		10.1038/373255a0	http://dx.doi.org/10.1038/373255a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816142				2022-12-24	WOS:A1995QC27800067
J	MARTINEZ, FD; WRIGHT, AL; TAUSSIG, LM; HOLBERG, CJ; HALONEN, M; MORGAN, WJ; BEAN, J; BIANCHI, H; CURTISS, J; EY, J; SANGUINETI, A; SMITH, B; VONDRAK, T; WEST, N; MCLELLAN, M				MARTINEZ, FD; WRIGHT, AL; TAUSSIG, LM; HOLBERG, CJ; HALONEN, M; MORGAN, WJ; BEAN, J; BIANCHI, H; CURTISS, J; EY, J; SANGUINETI, A; SMITH, B; VONDRAK, T; WEST, N; MCLELLAN, M			ASTHMA AND WHEEZING IN THE FIRST 6 YEARS OF LIFE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS-SPECIFIC IGE; RESPIRATORY ILLNESS; PULMONARY-FUNCTION; LUNG-FUNCTION; SERUM IGE; AIRWAY RESPONSIVENESS; 1ST YEAR; CHILDREN; SUBSEQUENT; CHILDHOOD	Background. Many young children wheeze during viral respiratory infections, but the pathogenesis of these episodes and their relation to the development of asthma later in life are not well understood. Methods. In a prospective study, we investigated the factors affecting wheezing before the age of three years and their relation to wheezing at six years of age. Of 1246 newborns in the Tucson, Arizona, area enrolled between May 1980 and October 1984, follow-up data at both three and six years of age were available for 826. For these children, assessments in infancy included measurement of cord-serum IgE levels (measured in 750 children), pulmonary-function testing before any lower respiratory tract illness had occurred (125), measurement of serum IgE levels at nine months of age (672), and questionnaires completed by the children's parents when the children were one year old (800), Assessments at six years of age included measurement of serum IgE levels (in 460), pulmonary-function testing (526), and skin allergy testing (629). Results. At the age of six years, 425 children (51.5 percent) had never wheezed, 164 (19.9 percent) had had at least one lower respiratory tract illness with wheezing during the first three years of life but had no wheezing at six years of age, 124 (15.0 percent) had no wheezing before the age of three years but had wheezing at the age of six years, and 113 (13.7 percent) had wheezing both before three years of age and at six years of age. The children who had wheezing before three years of age but not at the age of six had diminished airway function (length-adjusted maximal expiratory flow at functional residual capacity [V(max)FRC]) both before the age of one year and at the age of six years, were more likely than the other children to have mothers who smoked but not mothers with asthma, and did not have elevated serum IgE levels or skin-test reactivity. Children who started wheezing in early life and continued to wheeze at the age of six were more likely than the children who never wheezed to have mothers with a history of asthma (P<0.001), to have elevated serum IgE levels (P<0.01) and normal lung function in the first year of life, and to have elevated serum IgE levels (P<0.001) and diminished values for V(max)FRC (P<0.01) at six years of age. Conclusions. The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life, In a substantial minority of infants, however, wheezing episodes are probably related to a predisposition to asthma.	UNIV ARIZONA, COLL MED, DEPT PEDIAT, TUCSON, AZ USA	University of Arizona	MARTINEZ, FD (corresponding author), UNIV ARIZONA, ARIZONA HLTH SCI CTR, COLL MED, CTR RESP SCI, 1501 N CAMPBELL AVE, TUCSON, AZ 85724 USA.			Halonen, Marilyn/0000-0001-9606-935X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMITAGE P, 1987, STATISTICAL METHODS; BERBERICH MA, 1993, AM REV RESPIR DIS, V148, P1105; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; HALONEN M, 1992, AM REV RESPIR DIS, V146, P866, DOI 10.1164/ajrccm/146.4.866; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518, DOI 10.1164/ajrccm/138.3.518; MARTINEZ FD, 1991, AM REV RESPIR DIS, V143, P312, DOI 10.1164/ajrccm/143.2.312; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; MARTINEZ FD, 1994, 5 P BRONCH INT S GRO, P161; MERKUS PJFM, 1993, AM REV RESPIR DIS, V148, P1484, DOI 10.1164/ajrccm/148.6_Pt_1.1484; PATTEMORE PK, 1993, CLIN EXP ALLERGY, V23, P886, DOI 10.1111/j.1365-2222.1993.tb00273.x; REDLINE S, 1989, AM REV RESPIR DIS, V140, P179, DOI 10.1164/ajrccm/140.1.179; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; SAMET JM, 1983, AM REV RESPIR DIS, V127, P508, DOI 10.1164/arrd.1983.127.4.508; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811, DOI 10.1164/ajrccm/147.4.811; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; TAUSSIG LM, 1977, AM REV RESPIR DIS, V116, P1031; TEPPER RS, 1987, AM REV RESPIR DIS, V136, P800; WEISS ST, 1992, AM REV RESPIR DIS, V145, P58, DOI 10.1164/ajrccm/145.1.58; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WELLIVER RC, 1993, PEDIATR PULM, V15, P19, DOI 10.1002/ppul.1950150104; WELLIVER RC, 1982, J PEDIATR-US, V101, P889, DOI 10.1016/S0022-3476(82)80005-X; Woolf B, 1954, ANN HUM GENET, V19, P251; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232, DOI 10.1093/oxfordjournals.aje.a115243	24	2826	2904	7	286	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 19	1995	332	3					133	138		10.1056/NEJM199501193320301	http://dx.doi.org/10.1056/NEJM199501193320301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB160	7800004				2022-12-24	WOS:A1995QB16000001
J	BURGER, MPM; HOLLEMA, H; PIETERS, WJLM; QUINT, WGV				BURGER, MPM; HOLLEMA, H; PIETERS, WJLM; QUINT, WGV			PREDICTIVE VALUE OF HUMAN PAPILLOMAVIRUS TYPE FOR HISTOLOGICAL DIAGNOSIS OF WOMEN WITH CERVICAL CYTOLOGICAL ABNORMALITIES	BRITISH MEDICAL JOURNAL			English	Article									SSZOG,PATHOL LAB,9675 HJ WINSCHOTEN,NETHERLANDS; SSDZ,CTR DIAGNOST,2625 AD DELFT,NETHERLANDS		BURGER, MPM (corresponding author), UNIV GRONINGEN HOSP,DEPT OBSTET & GYNAECOL,ONCOL GYNAECOL SECT,OOSTERSINGEL 59,9713 EZ GRONINGEN,NETHERLANDS.							BURGER MPM, 1993, BRIT MED J, V306, P749, DOI 10.1136/bmj.306.6880.749; CUZICK J, 1994, BRIT J CANCER, V69, P167, DOI 10.1038/bjc.1994.28; GENEST DR, 1993, HUM PATHOL, V24, P760; LORINCZ AT, 1992, OBSTET GYNECOL, V79, P328, DOI 10.1097/00006250-199203000-00002; VANRANST M, 1992, J GEN VIROL, V73, P2653, DOI 10.1099/0022-1317-73-10-2653	5	26	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					94	95		10.1136/bmj.310.6972.94	http://dx.doi.org/10.1136/bmj.310.6972.94			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC223	7833734	Green Published			2022-12-24	WOS:A1995QC22300020
J	HARPER, CL; NYQUIST, LE; BANSAL, B; WIESMANN, H; SHIH, CY				HARPER, CL; NYQUIST, LE; BANSAL, B; WIESMANN, H; SHIH, CY			RAPID ACCRETION AND EARLY DIFFERENTIATION OF MARS INDICATED BY ND-142 ND-144 IN SNC METEORITES	SCIENCE			English	Article							ND ISOTOPIC EVOLUTION; SM-ND; MARTIAN ORIGIN; PB SYSTEMATICS; SHERGOTTITES; PLANET; AGE; ACHONDRITES; CHONDRITES; ABUNDANCES	Small differences in the ratio of neodymium-142 to neodymium-144 in early formed mantle reservoirs in planetary bodies are the result of in situ decay of the extinct radionuclide samarium-146 and can be used to constrain early planetary differentiation and therefore the time scale of planetary accretion. The martian meteorite Nakhla (similar to 1.3 billion years old), the type sample of the nakhlite subgroup of the Shergottite-Nakhlite-Chassigny (SNC) meteorites, exhibits a 59 +/- 13 parts per million excess in the ratio of neodymium-142 to neodymium-144 relative to normal neodymium. This anomaly records differentiation in the martian mantle before 4539 million years ago and implies that Mars experienced no giant impacts at any time later than 27 million years after the origin of the solar system.	NASA, LYNDON B JOHNSON SPACE CTR, HOUSTON, TX 77058 USA; LOCKHEED ENGN & SCI CO, HOUSTON, TX 77058 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; Lockheed Martin	HARPER, CL (corresponding author), HARVARD UNIV, DEPT EARTH & PLANETARY SCI, 20 OXFORD ST, CAMBRIDGE, MA 02138 USA.							AARSETH SJ, 1993, ASTROPHYS J, V403, P351, DOI 10.1086/172208; BOGARD DD, 1984, GEOCHIM COSMOCHIM AC, V48, P1723, DOI 10.1016/0016-7037(84)90028-0; BOGARD DD, 1977, GEOPHYS RES LETT, V4, P69, DOI 10.1029/GL004i002p00069; BOGARD DD, 1979, METEORITICS, V14, P356; CHEN JH, 1986, GEOCHIM COSMOCHIM AC, V50, P955, DOI 10.1016/0016-7037(86)90376-5; DONES L, 1993, ICARUS, V103, P67, DOI 10.1006/icar.1993.1059; GALE NH, 1975, EARTH PLANET SC LETT, V26, P195, DOI 10.1016/0012-821X(75)90087-4; GOPEL C, 1994, EARTH PLANET SC LETT, V121, P153, DOI 10.1016/0012-821X(94)90038-8; HARPER CL, 1992, NATURE, V360, P728, DOI 10.1038/360728a0; HARPER CL, UNPUB; HARPER CL, 1994, LPS, V25, P509; HARPER CL, 1993, LUNAR PLANET SCI, V24, P607; JACOBSEN SB, 1980, EARTH PLANET SC LETT, V50, P139, DOI 10.1016/0012-821X(80)90125-9; JACOBSEN SB, 1984, EARTH PLANET SC LETT, V67, P137, DOI 10.1016/0012-821X(84)90109-2; JAGOUTZ E, 1991, SPACE SCI REV, V56, P13, DOI 10.1007/BF00178386; JAGOUTZ E, 1989, GEOCHIM COSMOCHIM AC, V53, P2429, DOI 10.1016/0016-7037(89)90363-3; JONES JH, 1986, GEOCHIM COSMOCHIM AC, V50, P969, DOI 10.1016/0016-7037(86)90377-7; JONES JH, 1989, P LUNAR PLANET SCI C, V19, P465; JONES JH, 1990, 9004 LUN PLAN I TECH, P35; LARSON RB, 1989, FORMATION EVOLUTION, P31; Lee T, 1974, GEOPHYS RES LETT, V1, P225, DOI 10.1029/GL001i006p00225; LISSAUER JJ, 1993, ANNU REV ASTRON ASTR, V31, P129, DOI 10.1146/annurev.aa.31.090193.001021; LISSAUER JJ, 1987, ICARUS, V69, P249, DOI 10.1016/0019-1035(87)90104-7; LISSAUER JJ, 1991, ICARUS, V93, P288, DOI 10.1016/0019-1035(91)90213-D; LISSAUER JJ, IN PRESS NEPTUNE TRI; LONGHI J, 1991, P LUNAR PLANET SCI, V21, P695; MCSWEEN HY, 1985, REV GEOPHYS, V23, P391, DOI 10.1029/RG023i004p00391; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MOUGINISMARK PJ, 1992, J GEOPHYS RES-PLANET, V97, P10213, DOI 10.1029/92JE00612; MUSSELWHITE DS, 1991, NATURE, V352, P697, DOI 10.1038/352697a0; NAKAMURA N, 1982, GEOCHIM COSMOCHIM AC, V46, P1555, DOI 10.1016/0016-7037(82)90314-3; NAKAMURA N, 1982, METEORITICS, V17, P257; NORMAN MD, 1992, LUNAR PLANET SCI, V23, P999; NYQUIST LE, 1990, GEOCHIM COSMOCHIM AC, V54, P2195, DOI 10.1016/0016-7037(90)90045-M; NYQUIST LE, 1994, METEORITICS, V29, P872, DOI 10.1111/j.1945-5100.1994.tb01102.x; NYQUIST LE, 1991, METEORITICS, V26, P381; NYQUIST LE, 1994, LUNAR PLANET SCI, V25, P1017; NYQUIST LE, UNPUB; OTT U, 1988, GEOCHIM COSMOCHIM AC, V52, P1937, DOI 10.1016/0016-7037(88)90017-8; PAL DK, 1986, GEOCHIM COSMOCHIM AC, V50, P2405, DOI 10.1016/0016-7037(86)90022-0; PODOSEK FA, 1973, EARTH PLANET SC LETT, V19, P135, DOI 10.1016/0012-821X(73)90108-8; PRINZHOFER A, 1992, GEOCHIM COSMOCHIM AC, V56, P797, DOI 10.1016/0016-7037(92)90099-5; SHIH CY, 1982, GEOCHIM COSMOCHIM AC, V46, P2323, DOI 10.1016/0016-7037(82)90205-8; SLEEP NH, 1994, J GEOPHYS RES-PLANET, V99, P5639, DOI 10.1029/94JE00216; SPAUTE D, 1991, ICARUS, V92, P147, DOI 10.1016/0019-1035(91)90041-Q; STEVENSON DJ, 1988, ICARUS, V75, P146, DOI 10.1016/0019-1035(88)90133-9; STEWART BW, 1994, GEOCHIM COSMOCHIM AC, V58, P3487, DOI 10.1016/0016-7037(94)90100-7; TONKS WB, 1993, J GEOPHYS RES-PLANET, V98, P5319, DOI 10.1029/92JE02726; WADHWA M, 1994, GEOCHIM COSMOCHIM AC, V58, P4213, DOI 10.1016/0016-7037(94)90274-7; WASSERBURG GJ, 1981, GEOCHIM COSMOCHIM AC, V45, P2311, DOI 10.1016/0016-7037(81)90085-5; Wetherill G. W, 1986, ORIGIN MOON, P519; WETHERILL GW, 1990, ANNU REV EARTH PL SC, V18, P205, DOI 10.1146/annurev.ea.18.050190.001225; WETHERILL GW, 1989, ICARUS, V77, P330, DOI 10.1016/0019-1035(89)90093-6; WETHERILL GW, 1993, ICARUS, V106, P190, DOI 10.1006/icar.1993.1166; WETHERILL GW, 1992, ICARUS, V100, P307, DOI 10.1016/0019-1035(92)90103-E; WIENS RC, 1986, EARTH PLANET SC LETT, V77, P149, DOI 10.1016/0012-821X(86)90156-1; [No title captured]; [No title captured]; [No title captured]	59	131	131	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 13	1995	267	5195					213	217		10.1126/science.7809625	http://dx.doi.org/10.1126/science.7809625			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809625				2022-12-24	WOS:A1995QB15300027
J	PINK, G				PINK, G			THE PRICE OF TRUTH	BRITISH MEDICAL JOURNAL			English	Article																			0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1700	1705		10.1136/bmj.309.6970.1700	http://dx.doi.org/10.1136/bmj.309.6970.1700			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819994	Green Published			2022-12-24	WOS:A1994PY71700023
J	PAZIN, MJ; KAMAKAKA, RT; KADONAGA, JT				PAZIN, MJ; KAMAKAKA, RT; KADONAGA, JT			ATP-DEPENDENT NUCLEOSOME RECONFIGURATION AND TRANSCRIPTIONAL ACTIVATION FROM PREASSEMBLED CHROMATIN TEMPLATES	SCIENCE			English	Article							RNA POLYMERASE-II; GAL4 DERIVATIVES; DROSOPHILA EMBRYOS; DNA-REPLICATION; DISRUPTION; INVITRO; YEAST; GAL4-VP16; ANTIREPRESSION; MECHANISM	GAL4-VP16-mediated nucleosome reconfiguration and transcriptional activation were observed with preassembled chromatin templates that contained regular and physiological nucleosome spacing. Both processes were dependent on adenosine triphosphate (ATP), although binding of GAL4-VP16 to the chromatin was ATP-independent. Factor-mediated nucleosome reconfiguration was not, however, sufficient for transcriptional activation. These experiments recreate in vitro the active participation of nucleosomal cores in the regulation of transcription that occurs in vivo, and they suggest a multistep pathway for transcriptional activation in which factor- and ATP-dependent nucleosome reconfiguration is followed by facilitation by the DNA-bound activator of transcription from the repressed chromatin template.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOLEC,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego			Kamakaka, Rohinton/K-3140-2019	Kamakaka, Rohinton/0000-0003-1931-7000; Pazin, Michael/0000-0002-7561-3640				AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; Bulger M., 1994, METH MOL G, V5, P241; BULGER MD, UNPUB; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CAVILLI G, 1993, EMBO J, V12, P4603; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GRALLA JD, 1985, P NATL ACAD SCI USA, V82, P3078, DOI 10.1073/pnas.82.10.3078; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; IMBALZANO AN, 1991, NATURE, V370, P481; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; KAMAKAKA RT, 1994, METHOD CELL BIOL, V44, P225, DOI 10.1016/S0091-679X(08)60916-4; KAMAKAKA RT, UNPUB; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAYBOURN PJ, 1992, SCIENCE, V257, P1682, DOI 10.1126/science.1388287; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; MORSE RH, 1993, SCIENCE, V262, P1563, DOI 10.1126/science.8248805; NEDOSPASOV SA, 1980, BIOCHEM BIOPH RES CO, V92, P532, DOI 10.1016/0006-291X(80)90366-6; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PAZIN MJ, UNPUB; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; WOLFFE AP, 1994, CURR OPIN GENET DEV, V4, P245, DOI 10.1016/S0959-437X(05)80051-6; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	41	135	137	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					2007	2011		10.1126/science.7801129	http://dx.doi.org/10.1126/science.7801129			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801129				2022-12-24	WOS:A1994PZ26700034
J	IRIBARREN, C; REED, DM; BURCHFIEL, CM; DWYER, JH				IRIBARREN, C; REED, DM; BURCHFIEL, CM; DWYER, JH			SERUM TOTAL CHOLESTEROL AND MORTALITY - CONFOUNDING FACTORS AND RISK MODIFICATION IN JAPANESE-AMERICAN MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; MIDDLE-AGED MEN; FACTOR INTERVENTION TRIAL; CANCER MORTALITY; FOLLOW-UP; CARDIOVASCULAR-DISEASE; INVERSE RELATIONSHIP; PLASMA-CHOLESTEROL; HEMOSTATIC FACTORS; VITAMIN-E	Objective.-To further investigate the relationship between serum total cholesterol CTG) level and mortality due to major causes. in particular, is the elevated mortality among persons with low TC levels due to confounding conditions that both lower TC level and increase the risk of mortality, and is the association between low or high TC level and mortality homogeneous in the population or, alternatively, restricted to persons with other risk factors? Study Design.-Prospective cohort study. Setting.-Free-living population in Oahu, Hawaii. Participants.-A total of 7049 middle-aged men of Japanese ancestry. Main Outcome Measures.-Age- and risk factor-adjusted mortality due to coronary heart disease, hemorrhagic stroke, cancer, chronic obstructive pulmonary disease, nonmalignant liver disease, trauma, miscellaneous and unknown; and all causes. Results.-During 23 years of follow-up, a total of 1954 deaths were documented (38% cancer, 25% cardiovascular, and 37% other). Men with low serum TC levels (<4.66 mmol/L [<180 mg/dL]) were found to have several adverse health characteristics, including a higher prevalence of current smoking, heavy drinking, and certain gastrointestinal conditions. In an age-adjusted model, and in relation to the reference group (4.66 to 6.19 mmol/L [180 to 239 mg/dL]), those in the lowest TC group (<4.66 mmol/L [<180 mg/dL]) were at significantly higher risk of mortality due to hemorrhagic stroke (relative risk [RR], 2.41; 95% confidence interval [Ci], 1.45 to 4.00), cancer (RR, 1.41; 95% CI, 1.17 to 1.69), and all causes (RR, 1.23; 95% Cl, 1.09 to 1.38). Adjustment for confounders in multivariate analysis (and exclusion of cases with prevalent disease at baseline and deaths through year 5) did not explain the risk of fatal hemorrhagic stroke but reduced the excess risk of cancer mortality by 51% (to 1.20 from 1.41) and reduced the excess risk of all-cause mortality by 56% (to 1.10 from 1.32) in the low TC group. In addition, there were clear differences in the patterns of risk when comparing men with and without selected risk factors tie, smoking, alcohol consumption, and untreated hypertension). Conclusions.-We conclude that the excess mortality at low TC levels can be partially explained by confounding with other determinants of death and by preexisting disease at baseline, and TC-mortality associations are not homogeneous in the population. In our study, TC level was not associated with increased cancer or all-cause mortality in the absence of smoking, high alcohol consumption, and untreated hypertension.	UNIV SO CALIF,SCH MED,INST HLTH PROMOT & DIS PREVENT RES,DEPT PREVENT MED,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MED,INST ARTERIOSCLEROSIS RES,LOS ANGELES,CA 90033; BUCK CTR RES AGING,NOVATO,CA; NHLBI,BETHESDA,MD 20892; HONOLULU HAWAII HEART PROGRAM,HONOLULU,HI	University of Southern California; University of Southern California; Buck Institute for Research on Aging; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NHLBI NIH HHS [N01-HV-02901, N01-HC-02901] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC002901] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AIKEN LS, 1991, MULTIPLE REGRESSION, P67; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; BAPTISTE MS, 1992, INT J EPIDEMIOL, V21, P16, DOI 10.1093/ije/21.1.16; BELSKY JL, 1971, 1271 AT BOM CAS COMM; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; BONITHONKOPP C, 1988, ATHEROSCLEROSIS, V71, P71, DOI 10.1016/0021-9150(88)90303-6; Breslow N. E., 1987, STATISTICAL METHODS, VII; CHEN ZM, 1993, BMJ-BRIT MED J, V306, P890, DOI 10.1136/bmj.306.6882.890; Clayton D., 1992, STAT MODELS LONGITUD, P301; COWAN LD, 1990, AM J EPIDEMIOL, V131, P468, DOI 10.1093/oxfordjournals.aje.a115521; DYER AR, 1981, J CHRON DIS, V34, P249, DOI 10.1016/0021-9681(81)90030-8; FRANK JW, 1992, J CLIN EPIDEMIOL, V45, P333, DOI 10.1016/0895-4356(92)90034-K; GARCIAPALMIERI MR, 1981, AM J EPIDEMIOL, V114, P29, DOI 10.1093/oxfordjournals.aje.a113171; GOLDBERG RJ, 1994, CIRCULATION, V89, P651, DOI 10.1161/01.CIR.89.2.651; HARRIS T, 1992, J CLIN EPIDEMIOL, V45, P595, DOI 10.1016/0895-4356(92)90131-6; Higgins M, 1992, Ann Epidemiol, V2, P69, DOI 10.1016/1047-2797(92)90039-S; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; ISO H, 1994, J CLIN EPIDEMIOL, V47, P961, DOI 10.1016/0895-4356(94)90110-4; ISO H, 1989, AM J EPIDEMIOL, V130, P925, DOI 10.1093/oxfordjournals.aje.a115425; KAGAN A, 1981, AM J EPIDEMIOL, V114, P11, DOI 10.1093/oxfordjournals.aje.a113157; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KARK JD, 1982, BRIT MED J, V284, P152, DOI 10.1136/bmj.284.6310.152; KARK JD, 1980, J CHRON DIS, V33, P311, DOI 10.1016/0021-9681(80)90026-0; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; KOZAREVIC D, 1981, AM J EPIDEMIOL, V114, P21, DOI 10.1093/oxfordjournals.aje.a113170; LAW MR, 1991, CANCER CAUSE CONTROL, V2, P253, DOI 10.1007/BF00052142; MANOLIO TA, 1993, CIRCULATION, V87, P728, DOI 10.1161/01.CIR.87.3.728; MARTIN MJ, 1986, LANCET, V2, P933; MEADE TW, 1985, BRIT MED J, V290, P428, DOI 10.1136/bmj.290.6466.428; MENKES MS, 1986, NEW ENGL J MED, V315, P1250, DOI 10.1056/NEJM198611133152003; MIETTINEN OS, 1981, AM J EPIDEMIOL, V114, P593, DOI 10.1093/oxfordjournals.aje.a113225; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; PETERSON B, 1981, JAMA-J AM MED ASSOC, V245, P2056, DOI 10.1001/jama.245.20.2056; REED DM, 1990, AM J EPIDEMIOL, V131, P579, DOI 10.1093/oxfordjournals.aje.a115542; ROGERS S, 1988, EUR J CLIN NUTR, V42, P197; ROSE G, 1980, LANCET, V1, P523; RUSSELLBRIEFEL R, 1985, AM J EPIDEMIOL, V122, P741, DOI 10.1093/oxfordjournals.aje.a114157; SALMOND CE, 1985, BMJ-BRIT MED J, V290, P422, DOI 10.1136/bmj.290.6466.422; SCHATZKIN A, 1988, CANCER RES, V48, P452; SCHATZKIN A, 1987, LANCET, V2, P298; SCHUIT AJ, 1993, AM J EPIDEMIOL, V137, P966, DOI 10.1093/oxfordjournals.aje.a116769; SINHA R, 1993, CANCER EPIDEM BIOMAR, V2, P473; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; STAHELIN HB, 1991, AM J EPIDEMIOL, V133, P766; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; STEMMERMANN GN, 1984, INT J EPIDEMIOL, V13, P299, DOI 10.1093/ije/13.3.299; TILLOTSON JL, 1973, AM J CLIN NUTR, V26, P177, DOI 10.1093/ajcn/26.2.177; WALD NJ, 1989, BRIT J CANCER, V59, P938; WESTLUND K, 1972, SCAND J CLIN LA S127, V30, P2; White A D, 1992, Ann Epidemiol, V2, P85, DOI 10.1016/1047-2797(92)90041-N; WILLIAMS RR, 1981, JAMA-J AM MED ASSOC, V245, P247, DOI 10.1001/jama.245.3.247; WORTH RM, 1970, J CHRON DIS, V23, P389, DOI 10.1016/0021-9681(70)90022-6; YAARI S, 1981, LANCET, V1, P1011; 1988, ARCH INTERN MED, V148, P36; [No title captured]; [No title captured]; 1987, SAS STAT SOFTWARE VE	58	82	83	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1926	1932		10.1001/jama.273.24.1926	http://dx.doi.org/10.1001/jama.273.24.1926			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783302				2022-12-24	WOS:A1995RE35400028
J	MARTIN, K; TROUCHE, D; HAGEMEIER, C; SORENSEN, TS; LATHANGUE, NB; KOUZARIDES, T				MARTIN, K; TROUCHE, D; HAGEMEIER, C; SORENSEN, TS; LATHANGUE, NB; KOUZARIDES, T			STIMULATION OF E2F1/DP1 TRANSCRIPTIONAL ACTIVITY BY MDM2 ONCOPROTEIN	NATURE			English	Article							BINDING PROTEIN; RETINOBLASTOMA PROTEIN; ACTIVATION DOMAIN; GENE-PRODUCT; P53; TRANSACTIVATION; EXPRESSION; E2F-1; COMPLEX; FORMS	THE MDM2 proto-oncogene is found amplified in a variety of tumours(1). The oncogenic capacity of the MDM2 protein is attributed to its ability to bind the p53 tumour-suppressor protein and mask its transcriptional activation potential(2,3). Here we show that MDM2 makes a functional contact with two cooperating transcription factors, E2F1 and DP1 (refs 4, 5), which are involved in S-phase progression(6). MDM2 contacts the activation domain of E2F1 using residues conserved in the activation domain of p53. However, in contrast to its repression of p53 activity, MDM2 stimulates the activation capacity of E2F1/DP1. These results indicate that MDM2 not only releases a proliferative block by silencing the tumour suppressor p53, it also positively augments proliferation by stimulating the S-phase inducing transcription factors E2F1/DP1.	WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE,ENGLAND; NATL INST MED RES,MRC,LONDON NW7 1AA,ENGLAND	University of Cambridge; MRC National Institute for Medical Research			Trouche, Didier/B-2854-2008	Kouzarides, Tony/0000-0002-8918-4162; Trouche, Didier/0000-0003-1398-6481	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	22	446	466	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					691	694		10.1038/375691a0	http://dx.doi.org/10.1038/375691a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791903				2022-12-24	WOS:A1995RE57600063
J	BOUJRAD, N; OGWUEGBU, SO; GARNIER, M; LEE, CH; MARTIN, BM; PAPADOPOULOS, V				BOUJRAD, N; OGWUEGBU, SO; GARNIER, M; LEE, CH; MARTIN, BM; PAPADOPOULOS, V			IDENTIFICATION OF A STIMULATOR OF STEROID-HORMONE SYNTHESIS ISOLATED FROM TESTIS	SCIENCE			English	Article							LEYDIG-CELL STEROIDOGENESIS; RAT SERTOLI CELLS; TISSUE INHIBITOR; SEMINIFEROUS TUBULES; MATRIX METALLOPROTEINASES; TESTICULAR FUNCTION; GRANULOSA-CELLS; INVITRO; PROTEIN; PURIFICATION	Gonadal steroidogenesis is regulated by pituitary gonadotropins and a locally produced, unidentified factor. A 70-kilodalton (kD) protein complex secreted from rat Serloli cells was isolated. The complex, composed of 28- and 38-kD proteins, stimulated steroidogenesis by Leydig cells and ovarian granulosa cells in a dose-dependent and adenosine 3',5'-monophosphate-independent manner. The follicle-stimulating hormone-induced 28-kD protein appeared to be responsible for the bioactivity, but the 38-kD protein was indispensable for maximal activity. The 28- and 38-kD proteins were shown to be identical to the tissue inhibitor of metalloproteinase-1 (TIMP-1) and the proenzyme form of cathepsin L, respectively. Thus, a TIMP-1-procathepsin L complex is a potent activator of steroidogenesis and may regulate steroid concentrations and, thus, germ cell development in both males and females.	GEORGETOWN UNIV, MED CTR, DEPT CELL BIOL, WASHINGTON, DC 20007 USA; NIMH, CLIN NEUROSCI BRANCH, MOLEC NEUROGENET SECT, BETHESDA, MD 20892 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			Papadopoulos, Vassilios/AAI-2613-2019; BOUJRAD, Noureddine/L-1367-2015	Papadopoulos, Vassilios/0000-0002-1183-8568; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024633] Funding Source: NIH RePORTER; NICHD NIH HHS [HD01031, HD24633] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AOKI A, 1978, BIOL REPROD, V19, P144, DOI 10.1095/biolreprod19.1.144; BENAHMED M, 1985, AM J PHYSIOL, V248, pE176, DOI 10.1152/ajpendo.1985.248.2.E176; BENNETT B, 1992, J IMMUNOL METHODS, V153, P31, DOI 10.1016/0022-1759(92)90302-A; BENZEEV A, 1987, DIFFERENTIATION, V34, P222, DOI 10.1111/j.1432-0436.1987.tb00070.x; BERGH A, 1982, INT J ANDROL, V5, P325, DOI 10.1111/j.1365-2605.1982.tb00261.x; BERTAUX B, 1991, J INVEST DERMATOL, V97, P679, DOI 10.1111/1523-1747.ep12483956; CHEN YDI, 1976, P SOC EXP BIOL MED, V153, P473; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEKRETSER DM, 1987, INT REV CYTOL, V109, P89, DOI 10.1016/S0074-7696(08)61720-9; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; DYM M, 1991, ENDOCRINOLOGY, V128, P1167, DOI 10.1210/endo-128-2-1167; ERICKSONLAWRENCE M, 1991, MOL ENDOCRINOL, V5, P1789, DOI 10.1210/mend-5-12-1789; Gamier M., 1994, MOL PHARM, V45, P201; GROTJAN HE, 1982, ANN NY ACAD SCI, V383, P456, DOI 10.1111/j.1749-6632.1982.tb23198.x; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; HSUEH AJW, 1984, J CLIN ENDOCR METAB, V15, P117; JANSZ GF, 1990, J ANDROL, V11, P131; JOHNSON BH, 1971, SCIENCE, V173, P635, DOI 10.1126/science.173.3997.635; JOHNSON MD, 1987, MOL CELL BIOL, V7, P2821, DOI 10.1128/MCB.7.8.2821; Kane S E, 1990, Semin Cancer Biol, V1, P127; KERR JB, 1985, ENDOCRINOLOGY, V116, P2592, DOI 10.1210/endo-116-6-2592; KRETSER DMD, 1979, ENDOCRINOLOGY, V105, P135, DOI 10.1210/endo-105-1-135; MANN JS, 1991, ENDOCRINOLOGY, V128, P1825, DOI 10.1210/endo-128-4-1825; Matsudaira P, 1989, PRACTICAL GUIDE PROT; MELSERT R, 1988, MOL CELL ENDOCRINOL, V59, P221, DOI 10.1016/0303-7207(88)90107-4; MELSERT R, 1967, J ENDOCRINOL, V115, pR17; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ONODA M, 1991, MOL CELL ENDOCRINOL, V77, P207, DOI 10.1016/0303-7207(91)90076-5; PAPADOPOULOS V, 1985, FEBS LETT, V188, P312, DOI 10.1016/0014-5793(85)80393-8; PAPADOPOULOS V, 1987, J ENDOCRINOL, V114, P459, DOI 10.1677/joe.0.1140459; PAPADOPOULOS V, 1991, J CLIN ENDOCR METAB, V72, P1332, DOI 10.1210/jcem-72-6-1332; PAPADOPOULOS V, UNPUB; PARVINEN M, 1984, MOL CELL ENDOCRINOL, V37, P331, DOI 10.1016/0303-7207(84)90103-5; RICH KA, 1979, MOL CELL ENDOCRINOL, V13, P123, DOI 10.1016/0303-7207(79)90013-3; RISBRIDGER GP, 1986, J REPROD FERTIL, V77, P239, DOI 10.1530/jrf.0.0770239; RISBRIDGER GP, 1981, ENDOCRINOLOGY, V109, P1234, DOI 10.1210/endo-109-4-1234; ROSWIT WT, 1992, ARCH BIOCHEM BIOPHYS, V292, P402, DOI 10.1016/0003-9861(92)90009-L; SAEZ JM, 1987, J STEROID BIOCHEM, V27, P317, DOI 10.1016/0022-4731(87)90323-2; Setchell B.P., 1978, THE MAMMALIAN TESTIS; SHARPE RM, 1984, MOL CELL ENDOCRINOL, V37, P159, DOI 10.1016/0303-7207(84)90048-0; SKINNER MK, 1991, ENDOCR REV, V12, P45, DOI 10.1210/edrv-12-1-45; SMITH GW, 1994, ENDOCRINOLOGY, V134, P344, DOI 10.1210/en.134.1.344; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; TEERDS KJ, 1989, J ENDOCRINOL, V120, P97, DOI 10.1677/joe.0.1200097; TROEN BR, 1987, BIOCHEM J, V246, P731, DOI 10.1042/bj2460731; VERHOEVEN G, 1986, J STEROID BIOCHEM, V25, P393, DOI 10.1016/0022-4731(86)90252-9; WELGUS HG, 1985, COLLAGEN REL RES, V5, P167; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; ZHU C, 1991, BIOL REPROD, V45, P334, DOI 10.1095/biolreprod45.2.334	50	144	154	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 16	1995	268	5217					1609	1612		10.1126/science.7777858	http://dx.doi.org/10.1126/science.7777858			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7777858				2022-12-24	WOS:A1995RD45900035
J	SEN, D; OSBORNE, K				SEN, D; OSBORNE, K			GENERAL-PRACTITIONERS KNOWLEDGE OF NOTIFIABLE, REPORTABLE, AND PRESCRIBED DISEASES	BRITISH MEDICAL JOURNAL			English	Article									HLTH & SAFETY EXECUT,EPIDEMIOL & MED STAT UNIT,BOOTLE L20 3QZ,MERSEYSIDE,ENGLAND		SEN, D (corresponding author), HLTH & SAFETY EXECUT,MERSEYSIDE & CHESHIRE AREA OFF,BOOTLE L20 3PG,MERSEYSIDE,ENGLAND.							BOILLAT MA, 1994, OCCUP MED-OXFORD, V44, P123, DOI 10.1093/occmed/44.3.123; 1991, N12 BEN AG LEAFL; 1992, COMPENDIUM HLTH STAT; 1986, HSR23 OFF SAF EC	4	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	1995	310	6990					1299	1299		10.1136/bmj.310.6990.1299	http://dx.doi.org/10.1136/bmj.310.6990.1299			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773043	Green Published			2022-12-24	WOS:A1995QZ86000021
J	JOHNSTON, SL; PATTEMORE, PK; SANDERSON, G; SMITH, S; LAMPE, F; JOSEPHS, L; SYMINGTON, P; OTOOLE, S; MYINT, SH; TYRRELL, DAJ; HOLGATE, ST				JOHNSTON, SL; PATTEMORE, PK; SANDERSON, G; SMITH, S; LAMPE, F; JOSEPHS, L; SYMINGTON, P; OTOOLE, S; MYINT, SH; TYRRELL, DAJ; HOLGATE, ST			COMMUNITY STUDY OF ROLE OF VIRAL-INFECTIONS IN EXACERBATIONS OF ASTHMA IN 9-11 YEAR-OLD CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							WHEEZY BRONCHITIS; RESPIRATORY-INFECTIONS; VIRUSES; SYMPTOMS; ADULTS; PRECIPITANTS; ASSOCIATION; CORONAVIRUS; CHILDHOOD	Objective-To study the association between upper and lower respiratory viral infections and acute exacerbations of asthma in schoolchildren in the community. Design-Community based 13 month longitudinal study using diary card respiratory symptom and peak expiratory flow monitoring to allow early sampling for viruses. Subjects-1O8 Children aged 9-11 years who had reported wheeze or cough, or both, in a questionnaire. Setting-Southampton and surrounding community. Main outcome measures-Upper and lower respiratory viral infections detected by polymerase chain reaction or conventional methods, reported exacerbations of asthma, computer identified episodes of respiratory tract symptoms or peak flow reductions. Results-Viruses were detected in 80% of reported episodes of reduced peak expiratory flow, 80% of reported episodes of wheeze, and in 85% of reported episodes of upper respiratory symptoms, cough, wheeze, and a fall in peak expiratory flow. The median duration of reported falls in peak expiratory flow was 14 days, and the median maximum fall in peak expiratory flow was 81 1/min. The most commonly identified virus type was rhinovirus. Conclusions-This study supports the hypothesis that upper respiratory viral infections are associated with 80-85% of asthma exacerbations in school age children.	UNIV SOUTHAMPTON,DEPT MED STAT & COMP,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND; UNIV LEICESTER,DEPT MICROBIOL,LEICESTER LE1 9HN,LEICS,ENGLAND; MRC,COMMON COLD UNIT,SALISBURY,WILTS,ENGLAND	University of Southampton; University of Leicester	JOHNSTON, SL (corresponding author), UNIV MED SOUTHAMPTON,SOUTHAMPTON GEN HOSP,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.		Lampe, Fiona/I-5826-2019; Fahimifar, Sepideh/M-5303-2019; Johnston, Sebastian Lennox/I-2423-2012	Lampe, Fiona/0000-0001-6851-5471; Johnston, Sebastian Lennox/0000-0003-3009-9200; Josephs, Lynn/0000-0002-7157-2992; Pattemore, Philip/0000-0002-4968-1287				BEASLEY R, 1988, THORAX, V43, P679, DOI 10.1136/thx.43.9.679; CARLSEN KH, 1984, ARCH DIS CHILD, V59, P310, DOI 10.1136/adc.59.4.310; CLOUGH JB, 1994, AM J RESP CRIT CARE, V150, P48, DOI 10.1164/ajrccm.150.1.8025771; CLOUGH JB, 1991, AM REV RESPIR DIS, V143, P755, DOI 10.1164/ajrccm/143.4_Pt_1.755; Gwaltney J.M., 1979, PRINCIPLES PRACTICE, V1st ed., P429; Hamparian W, 1979, DIAGNOSTIC PROCEDURE, P562; HENDERSON FW, 1979, J PEDIATR-US, V95, P183; HORN MEC, 1975, J HYG-CAMBRIDGE, V74, P157, DOI 10.1017/S0022172400024220; HORN MEC, 1979, THORAX, V34, P23, DOI 10.1136/thx.34.1.23; HORN MEC, 1979, ARCH DIS CHILD, V54, P587, DOI 10.1136/adc.54.8.587; HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393; JENNINGS LC, 1987, NEW ZEAL MED J, V100, P488; JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993; JOHNSTON SL, 1993, THESIS U SOUTHAMPTON, P99; KRAAIJEVELD CA, 1980, J CLIN MICROBIOL, V12, P493, DOI 10.1128/JCM.12.4.493-497.1980; LARSON HE, 1980, J MED VIROL, V5, P221, DOI 10.1002/jmv.1890050306; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MERTSOLA J, 1991, ARCH DIS CHILD, V66, P124, DOI 10.1136/adc.66.1.124; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MITCHELL I, 1976, ARCH DIS CHILD, V51, P707, DOI 10.1136/adc.51.9.707; MITCHELL I, 1978, ARCH DIS CHILD, V53, P106, DOI 10.1136/adc.53.2.106; MYINT S, 1994, MOL CELL PROBE, V8, P357, DOI 10.1006/mcpr.1994.1052; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; PHILLPOTTS RJ, 1983, J VIROL METHODS, V6, P267, DOI 10.1016/0166-0934(83)90041-1; PICADO C, 1992, THORAX, V47, P197, DOI 10.1136/thx.47.3.197; POTTER PC, 1984, S AFR MED J, V66, P397; ROLDAAN AC, 1982, EUR J RESPIR DIS, V63, P140; SCHMIDT NJ, 1979, DIAGNOSTIC PROCEDURE, P67; STORR J, 1989, ARCH DIS CHILD, V64, P103, DOI 10.1136/adc.64.1.103; WILSON NM, 1989, ARCH DIS CHILD, V64, P1194, DOI 10.1136/adc.64.8.1194	31	1471	1525	0	99	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	1995	310	6989					1225	1229		10.1136/bmj.310.6989.1225	http://dx.doi.org/10.1136/bmj.310.6989.1225			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY877	7767192	Green Published			2022-12-24	WOS:A1995QY87700015
J	LOWE, CJ; RAYNOR, DK; COURTNEY, EA; PURVIS, J; TEALE, C				LOWE, CJ; RAYNOR, DK; COURTNEY, EA; PURVIS, J; TEALE, C			EFFECTS OF SELF-MEDICATION PROGRAM ON KNOWLEDGE OF DRUGS AND COMPLIANCE WITH TREATMENT IN ELDERLY PATIENTS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether a programme of self medication for inpatients improves compliance with treatment and knowledge of their drugs after discharge from hospital. Design-Patients were prospectively recruited from four wards: two with a self medication programme and two acting as controls. Ten days after discharge the patients were visited at home. They were questioned about their drugs, and a tablet count was undertaken. Setting-The pharmacy department and four medical wards with an interest in elderly patients at a district general hospital, and the patients' homes. Patients-88 patients discharged to their own homes who were regularly taking one or more drugs. Intervention-A hospital self medication programme in which patients are educated about their medicines and given increasing responsibility for taking them in hospital. Main outcome measure-Compliance with and knowledge of the purpose of their medicines 10 days after discharge from hospital. Results-The mean compliance score in patients taking part in the self medication programme was 95% compared with 83% in the control group (difference 12%, 95% confidence interval 4% to 21%; P<0.02). Of the patients in the self medication group, 90% (38/42) knew the purpose of their drugs compared with 46% (17/37) in the control group (difference 44%, 26% to 63%; P<0.001). Conclusion-A self medication programme is an effective aid for improving compliance with and knowledge of patients' drugs after discharge.	SEACROFT HOSP,PRACTICE DEV UNIT,LEEDS LS14 6UH,W YORKSHIRE,ENGLAND; UNIV BRADFORD,PHARM PRACTICE RES UNIT,BRADFORD BD7 1DP,W YORKSHIRE,ENGLAND	University of Bradford	LOWE, CJ (corresponding author), SEACROFT HOSP,DEPT PHARM,LEEDS LS14 6UH,W YORKSHIRE,ENGLAND.							ASPLUND J, 1984, BRIT J CLIN PHARMACO, V17, P547, DOI 10.1111/j.1365-2125.1984.tb02388.x; BAXENDALEC, 1978, BRIT MED J, V2, P1278; Bird C, 1988, Nurs Times, V84, P28; FOSTER H, 1993, AGE AGEING S3, V22, P23; GARDNER MJ, 1989, CONFIDENCE INTERVAL; Ley P., 1988, COMMUNICATING PATIEN; MAZZUCA SA, 1982, J CHRON DIS, V35, P521, DOI 10.1016/0021-9681(82)90071-6; PARKIN DM, 1976, BMJ-BRIT MED J, V2, P686, DOI 10.1136/bmj.2.6037.686; RAYNOR DK, 1993, BRIT MED J, V306, P1158, DOI 10.1136/bmj.306.6886.1158; RUDD P, 1979, CLIN PHARMACOL THER, V25, P257; SACKET DL, 1979, COMPLIANCE HEALTHCAR; SANDLER DA, 1989, BRIT MED J, V298, P870, DOI 10.1136/bmj.298.6677.870; Webb C, 1990, Nurs Times, V86, P46; Wood SI, 1992, INT J PHARM PRAC, V1, P240; WRIGHT EC, 1993, LANCET, V342, P909, DOI 10.1016/0140-6736(93)91951-H	15	80	82	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	1995	310	6989					1229	1231		10.1136/bmj.310.6989.1229	http://dx.doi.org/10.1136/bmj.310.6989.1229			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY877	7767193	Green Published			2022-12-24	WOS:A1995QY87700016
J	GRONBAEK, M; DEIS, A; SORENSEN, TIA; BECKER, U; SCHNOHR, P; JENSEN, G				GRONBAEK, M; DEIS, A; SORENSEN, TIA; BECKER, U; SCHNOHR, P; JENSEN, G			MORTALITY ASSOCIATED WITH MODERATE INTAKES OF WINE, BEER, OR SPIRITS	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; ALCOHOL-CONSUMPTION; RED WINE; RISK; WOMEN; MEN	Objective-To examine the association between intake of different types of alcoholic drinks and mortality. Design-Prospective population study with baseline assessment of alcohol intake, smoking habit, income, education, and body mass index, and 10-12 years' follow up of mortality. Setting-Copenhagen city heart study, Denmark. Subjects-6051 men and 7234 women aged 30-70 years. Main outcome measure-Number and time of cause-specific deaths from 1976 to 1988. Results-The risk of dying steadily decreased with an increasing intake of wine-from a relative risk of 1.00 for the subjects who never drank wine to 0.51 (95% confidence interval 0.32 to 0.81) for those who drank three to five glasses a day. Intake of neither beer nor spirits, however, was associated with reduced risk. For spirits intake the relative risk of dying increased from 1.00 for those who never drank to 1.34 (1.05 to 1.71) for those with an intake of three to five drinks a day. The effects of the three types of alcoholic drinks seemed to be independent of each other, and no significant interactions existed with sex, age, education, income, smoking, or body mass index. Wine drinking showed the same relation to risk of death from cardiovascular and cerebrovascular disease as to risk of death from all causes. Conclusion-Low to moderate intake of wine is associated with lower mortality from cardiovascular and cerebrovascular disease and other causes. Similar intake of spirits implied an increased risk, while beer drinking did not affect mortality.	COPENHAGEN HOSP CORP,INST PREVENT MED,DANISH EPIDEMIOL SCI CTR,COPENHAGEN,DENMARK; DANISH COMM ASSESSMENT SUBSTAND LIVES,COPENHAGEN,DENMARK; UNIV COPENHAGEN,HVIDOVRE HOSP,DEPT MED GASTROENTEROL,ALCOHOL UNIT,DK-1168 COPENHAGEN,DENMARK; UNIV COPENHAGEN,RIGSHOSP,DEPT 7117,COPENHAGEN CITY HEART STUDY,DK-2100 COPENHAGEN,DENMARK	Aarhus University; University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen			Becker, Ulrik/D-2657-2012	Becker, Ulrik/0000-0002-1678-7771; Gronbaek, Morten Klocker/0000-0002-8473-6474				Appleyard M., 1989, SCAND J SOC MED, V41, P1; BOFFETTA P, 1990, EPIDEMIOLOGY, V1, P337; Carnacini A, 1994, ALCOLOGIA, V6, P41; CHEN J, 1992, INT J EPIDEMIOL, V2, P625; CRIQUI MH, 1990, BRIT J ADDICT, V85, P854; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; Gerdes L U, 1992, Ugeskr Laeger, V154, P3580; GRONBAEK M, 1994, BRIT MED J, V308, P302, DOI 10.1136/bmj.308.6924.302; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; HENNEKENS CH, 1979, JAMA-J AM MED ASSOC, V242, P1973, DOI 10.1001/jama.242.18.1973; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; JACKSON R, 1991, BRIT MED J, V303, P211, DOI 10.1136/bmj.303.6796.211; KIMBALL AW, 1992, AM J EPIDEMIOL, V135, P1287, DOI 10.1093/oxfordjournals.aje.a116235; KLATSKY AL, 1986, AM J CARDIOL, V58, P710, DOI 10.1016/0002-9149(86)90342-5; KLATSKY AL, 1993, AM J CARDIOL, V71, P467, DOI 10.1016/0002-9149(93)90460-T; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KOZARAREVIC DJ, 1980, LANCET, V1, P613; MARMOT MG, 1981, LANCET, V1, P580; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; MIDANIK LT, 1988, BRIT J ADDICT, V83, P1019; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROSENBERG L, 1981, AM J PUBLIC HEALTH, V71, P82, DOI 10.2105/AJPH.71.1.82; SAELAN H, 1993, ALCOHOL DRUG ABUSE 1; SEIGNEUR M, 1990, J APPL CARDIOL, V5, P215; SHAPER AG, 1988, LANCET, V1, P1267; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STLEGER AS, 1979, LANCET, V1, P1017, DOI 10.1016/S0140-6736(79)92765-X; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801	31	495	504	2	39	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1165	1169		10.1136/bmj.310.6988.1165	http://dx.doi.org/10.1136/bmj.310.6988.1165			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX566	7767150	Green Published			2022-12-24	WOS:A1995QX56600021
J	KEMPIN, SA; SAVIDGE, B; YANOFSKY, MF				KEMPIN, SA; SAVIDGE, B; YANOFSKY, MF			MOLECULAR-BASIS OF THE CAULIFLOWER PHENOTYPE IN ARABIDOPSIS	SCIENCE			English	Article							HOMEOTIC GENE; FLOWER DEVELOPMENT; INFLORESCENCE DEVELOPMENT; THALIANA; APETALA1; LEAFY	Genetic studies demonstrate that two Arabidopsis genes, CAULIFLOWER and APETALA1, encode partially redundant activities involved in the formation of floral meristems, the first step in the development of flowers. Isolation of the CAULIFLOWER gene from Arabidopsis reveals that it is closely related in sequence to APETALA1. Like APETALA1, CAULIFLOWER is expressed in young flower primordia and encodes a MADS-domain, indicating that it may function as a transcription factor. Analysis of the cultivated garden variety of cauliflower (Brassica oleracea var. botrytis) reveals that its CAULIFLOWER gene homolog is not functional, suggesting a molecular basis for one of the oldest recognized flower abnormalities.	UNIV CALIF SAN DIEGO,DEPT BIOL,SAN DIEGO,CA; UNIV CALIF SAN DIEGO,CTR GENET MOLEC,SAN DIEGO,CA	University of California System; University of California San Diego; University of California System; University of California San Diego					NIGMS NIH HHS [GM07313] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOWMAN JL, 1993, DEVELOPMENT, V119, P721; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; GUSTAFSONBROWN C, 1994, CELL, V76, P131, DOI 10.1016/0092-8674(94)90178-3; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MANDEL M, UNPUB; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; RIETER RS, 1992, P NATL ACAD SCI USA, V89, P1477; SADIK S, 1962, AM J BOT, V49, P290, DOI 10.2307/2439552; SAVIDGE B, UNPUB; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHANNON S, 1993, PLANT CELL, V5, P639, DOI 10.1105/tpc.5.6.639; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WILLIAMS PH, 1986, SCIENCE, V232, P1385, DOI 10.1126/science.232.4756.1385; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0; YARNELL SH, 1956, BOT REV, V22, P81, DOI 10.1007/BF02872468	20	393	437	2	82	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 27	1995	267	5197					522	525		10.1126/science.7824951	http://dx.doi.org/10.1126/science.7824951			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824951				2022-12-24	WOS:A1995QD40300041
J	TRACEY, KJ				TRACEY, KJ			TNF AND WEST,MAE OR - DEATH FROM TOO MUCH OF A GOOD THING	LANCET			English	Editorial Material							TUMOR-NECROSIS-FACTOR; PLASMODIUM-FALCIPARUM; FACTOR-ALPHA; CACHECTIN; SHOCK; INTERLEUKIN-1; INFECTION; RECEPTOR; MALARIA; SERUM		PICOWER INST MED RES,MANHASSET,NY	Northwell Health	TRACEY, KJ (corresponding author), N SHORE UNIV HOSP,DEPT SURG,BIOMED SCI LAB,MANHASSET,NY 11030, USA.							BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; CLARK IA, 1992, LANCET, V340, P894, DOI 10.1016/0140-6736(92)93295-X; GIRARDIN E, 1988, NEW ENGL J MED, V319, P397, DOI 10.1056/NEJM198808183190703; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P1233, DOI 10.1073/pnas.87.3.1233; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; MARANO MA, 1990, SURG GYNECOL OBSTET, V170, P32; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; MOLVIG J, 1988, SCAND J IMMUNOL, V27, P705, DOI 10.1111/j.1365-3083.1988.tb02404.x; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PICOT F, 1993, EUR J IMMUNOL, V23, P224; Tracey K.J., 1992, TUMOR NECROSIS FACTO, P255; TRACEY KJ, 1989, LANCET, V1, P1122; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; WILSON AG, 1994, BR J RHEUMATOL S1, V33, P89	15	33	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					75	76		10.1016/S0140-6736(95)90055-1	http://dx.doi.org/10.1016/S0140-6736(95)90055-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815882				2022-12-24	WOS:A1995QB80400002
J	HARWOOD, AJ; PLYTE, SE; WOODGETT, J; STRUTT, H; KAY, RR				HARWOOD, AJ; PLYTE, SE; WOODGETT, J; STRUTT, H; KAY, RR			GLYCOGEN-SYNTHASE KINASE-3 REGULATES CELL FATE IN DICTYOSTELIUM	CELL			English	Article							CYCLIC-AMP; GENE-EXPRESSION; STALK-CELL; PRESTALK CELLS; DISCOIDEUM; DIFFERENTIATION; INDUCTION; PRESPORE; PHOSPHORYLATION; TRANSFORMATION	Extracellular cyclic AMP (cAMP) induces the formation of prespore cells in Dictyostelium but inhibits stalk cell formation. We have cloned gskA, which encodes the Dictyostelium homolog of glycogen synthase kinase 3 (GSK-3), and discovered that it is required for both cAMP effects. Disruption of gskA creates a mutant that aggregates but forms few spores and an abnormally high number of stalk cells. These stalk cells probably arise from an expanded prestalk B (pstB) cell population, which normally produces the basal disc of the fruiting body. In cultured mutant cells, cAMP neither inhibits pstB cell differentiation nor induces efficient prespore cell differentiation. We propose that cAMP acts through a common pathway that requires GSK-3 and determines the proportion of prespore and pstB cells.	PRINCESS MARGARET HOSP,ONTARIO CANC INST,TORONTO,ON M4X 1K9,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	HARWOOD, AJ (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Harwood, Adrian/A-4350-2010; Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797; Strutt, Helen/0000-0003-4365-2271; Kay, Robert R/0000-0001-9836-7967; Harwood, Adrian/0000-0003-3124-5169				BARKLIS E, 1983, CELL, V32, P1139, DOI 10.1016/0092-8674(83)90297-0; BERKS M, 1988, DEV BIOL, V126, P108, DOI 10.1016/0012-1606(88)90244-8; BERKS M, 1990, DEVELOPMENT, V110, P977; BIANCHI MW, 1993, GENE, V134, P51, DOI 10.1016/0378-1119(93)90173-Z; BIANCHI MW, 1994, MOL GEN GENET, V242, P337, DOI 10.1007/BF00280424; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CECCARELLI A, 1991, CELL, V65, P983, DOI 10.1016/0092-8674(91)90550-I; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DEGROOT RP, 1993, ONCOGENE, V8, P841; DIAZBENJUMEE F, 1994, GENE, V85, P353; EARLY AE, 1987, GENE, V59, P99, DOI 10.1016/0378-1119(87)90270-8; EARLY AE, 1988, DEVELOPMENT, V103, P519; EARLY AE, 1993, DEVELOPMENT, V118, P353; HANKS S, 1991, METHOD ENZYMOL, V300, P38; HARLOW E, 1988, ANTIBODIES LABORATOR; HARWOOD AJ, 1991, DIFFERENTIATION, V46, P7, DOI 10.1111/j.1432-0436.1991.tb00860.x; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; JERMYN KA, 1991, DEVELOPMENT, V111, P779; JERMYN KA, 1989, NATURE, V340, P144, DOI 10.1038/340144a0; JOLY E, 1993, TRENDS GENET, V9, P157, DOI 10.1016/0168-9525(93)90152-8; KAY RR, 1992, BIOCHEM J, V281, P155, DOI 10.1042/bj2810155; KAY RR, 1978, NATURE, V271, P58, DOI 10.1038/271058a0; KAY RR, 1983, NATURE, V303, P242, DOI 10.1038/303242a0; KAY RR, 1989, DEVELOPMENT, V105, P753; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; KOPACHIK WJ, 1985, DIFFERENTIATION, V28, P209, DOI 10.1111/j.1432-0436.1985.tb00827.x; KUSPA A, 1992, P NATL ACAD SCI USA, V89, P8803, DOI 10.1073/pnas.89.18.8803; MANN SKO, 1987, MOL CELL BIOL, V7, P458, DOI 10.1128/MCB.7.1.458; MEHDY MC, 1983, CELL, V32, P763, DOI 10.1016/0092-8674(83)90062-4; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; PUZISS JW, 1994, MOL CELL BIOL, V14, P831, DOI 10.1128/MCB.14.1.831; SAXE CL, 1991, DEV GENET, V12, P6, DOI 10.1002/dvg.1020120104; SCHAAP P, 1986, DEV BIOL, V118, P52, DOI 10.1016/0012-1606(86)90072-2; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V354, P825; SIMPSON P, 1993, DEVELOPMENT, P29; STERNFELD J, 1982, DEV BIOL, V93, P111, DOI 10.1016/0012-1606(82)90244-5; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; THEISEN H, 1994, DEVELOPMENT, V120, P347; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x	49	180	188	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					139	148		10.1016/0092-8674(95)90458-1	http://dx.doi.org/10.1016/0092-8674(95)90458-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813009	Bronze			2022-12-24	WOS:A1995QB91000017
J	WYATT, JP				WYATT, JP			SQUIRREL BITES	BRITISH MEDICAL JOURNAL			English	Article											WYATT, JP (corresponding author), ROYAL HOSP SICK CHILDREN,EDINBURGH EH9 1LF,MIDLOTHIAN,SCOTLAND.							BRACKENBURY PH, 1989, ARCH EMERG MED, V6, P251; LAWTON J, 1990, NATURE, V343, P595, DOI 10.1038/343595a0; MAGEE JS, 1989, PEDIATR INFECT DIS J, V8, P123; RUSSO PK, 1981, NEW ENGL J MED, V304, P1166, DOI 10.1056/NEJM198105073041911	4	6	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1694	1694		10.1136/bmj.309.6970.1694	http://dx.doi.org/10.1136/bmj.309.6970.1694			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819992	Green Published			2022-12-24	WOS:A1994PY71700018
J	ALLEN, K; BLASCOVICH, J				ALLEN, K; BLASCOVICH, J			EFFECTS OF MUSIC ON CARDIOVASCULAR REACTIVITY AMONG SURGEONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							RESPONSES; STRESS	Objective.-To determine the effects of surgeon-selected and experimenter-selected music on performance and autonomic responses of surgeons during a standard laboratory psychological stressor. Design.-Within-subjects laboratory experiment. Setting.-Hospital psychophysiology laboratory. Participants.-A total of 50 male surgeons aged 31 to 61 years, who reported that they typically listen to music during surgery, volunteered for the study. Main Outcome Measurements.-Cardiac responses, hemodynamic measures, electrodermal autonomic responses, task speed, and accuracy. Results.-Autonomic reactivity for all physiological measures was significantly less in the surgeon-selected music condition than in the experimenter-selected music condition, which in turn was significantly less than in the no-music control condition. Likewise, speed and accuracy of task performance were significantly better in the surgeon-selected music condition than in the experimenter-selected music condition, which was also significantly better than the no-music control condition. Conclusion.-Surgeon-selected music was associated with reduced autonomic reactivity and improved performance of a stressful nonsurgical laboratory task in study participants.	SUNY BUFFALO,DEPT PSYCHOL,AMHERST,NY	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	ALLEN, K (corresponding author), SUNY BUFFALO,CTR STUDY BIOBEHAV & SOCIAL ASPECTS HLTH,PK HALL,AMHERST,NY 14260, USA.							ALLEN KM, 1991, J PERS SOC PSYCHOL, V61, P582, DOI 10.1037/0022-3514.61.4.582; ALLEN MT, 1987, PSYCHOPHYSIOLOGY, V24, P648, DOI 10.1111/j.1469-8986.1987.tb00345.x; BARGER DA, 1979, J MUSIC THER, V16, P158, DOI 10.1093/jmt/16.4.158; Beck S L, 1991, Oncol Nurs Forum, V18, P1327; BLASCOVICH J, 1992, J PERS SOC PSYCHOL, V63, P164, DOI 10.1037/0022-3514.63.1.164; BLASCOVICH J, 1993, J PERS SOC PSYCHOL, V64, P165, DOI 10.1037/0022-3514.64.2.165; CHETTA HD, 1981, J MUSIC THER, V18, P74, DOI 10.1093/jmt/18.2.74; DAINOW E, 1977, J RES MUSIC EDUC, V25, P211, DOI 10.2307/3345305; DAVISROLLINS C, 1987, HEART LUNG, V19, P29; DEGOOD DE, 1976, BIOFEEDBACK SELF-REG, V1, P373; GUZZETTA CE, 1989, HEART LUNG, V18, P606; Heitz L, 1992, J Post Anesth Nurs, V7, P22; Katkin E. S., 1993, CARDIOVASCULAR REACT; KELSEY RM, 1991, PSYCHOPHYSIOLOGY, V28, P619, DOI 10.1111/j.1469-8986.1991.tb01005.x; LANDRETH JE, 1974, J RES MUSIC EDUC, V22, P4, DOI 10.2307/3344613; LEVY O, 1964, TWILIGHT IDOLS, V16, P6; LOCSIN RGRAC, 1981, J ADV NURS, V6, P19, DOI 10.1111/j.1365-2648.1981.tb03091.x; MATTHEWS KA, 1986, HDB STRESS REACTIVIT; ORNSTEIN R, 1989, HLTH PLEASURES; OYAMA T, 1987, MUSIK MED MUSIC MED, P223; PERETTI PO, 1975, J PSYCHOL, V89, P183, DOI 10.1080/00223980.1975.9915750; PERETTI PO, 1974, J RES MUSIC EDUC, V22, P278, DOI 10.2307/3344765; RAUSCHER FH, 1993, NATURE, V365, P6; SHAPIRO AG, 1987, MUSIK MED, P227; SIFER KJ, 1991, AJR AM J ROENTGENOL, V156, P403; STEVENS K, 1990, J ADV NURS, V15, P1045, DOI 10.1111/j.1365-2648.1990.tb01985.x; STOUDENMIRE J, 1975, J CLIN PSYCHOL, V31, P490, DOI 10.1002/1097-4679(197507)31:3<490::AID-JCLP2270310328>3.0.CO;2-E; TANIOKA F, 1987, MUSIK MED, P199; Thayer J., 1983, PSYCHOMUSICOLOGY, V3, P44, DOI DOI 10.1037/H0094256; TOMAKA J, 1993, J PERS SOC PSYCHOL, V65, P248, DOI 10.1037/0022-3514.65.2.248; TOMAKA J, 1992, PERS SOC PSYCHOL B, V18, P616, DOI 10.1177/0146167292185012; Turner J., 1992, INDIVIDUAL DIFFERENC; UPDIKE PA, 1987, ANN PLAS SURG, V19, P29, DOI 10.1097/00000637-198707000-00004; WEBSTER C, 1973, AUST OCCUP THER J, V20, P9; Whipple B, 1992, Sch Inq Nurs Pract, V6, P43; ZIMNY GH, 1963, AM J PSYCHOL, V76, P311, DOI 10.2307/1419170	36	120	120	1	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					882	884		10.1001/jama.272.11.882	http://dx.doi.org/10.1001/jama.272.11.882			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PG182	7811324				2022-12-24	WOS:A1994PG18200028
J	PATEL, P; MENDALL, MA; KHULUSI, S; MOLINEAUX, N; LEVY, J; MAXWELL, JD; NORTHFIELD, TC				PATEL, P; MENDALL, MA; KHULUSI, S; MOLINEAUX, N; LEVY, J; MAXWELL, JD; NORTHFIELD, TC			SALIVARY ANTIBODIES TO HELICOBACTER-PYLORI - SCREENING DYSPEPTIC PATIENTS BEFORE ENDOSCOPY	LANCET			English	Note								Diagnostic tests on saliva have advantages compared with those on serum. In 119 consecutive dyspeptic patients referred for endoscopy we developed and validated an enzyme-linked immunosorbent assay to detect salivary immunoglobulins to Helicobacter pylori. Salivary IgG distinguished positive and negative cases (p < 0.0001), but salivary IgA did not. The optimum performance of salivary IgG (85%) was similar to that of serum IgG (90%) and better than that of salivary IgA. Using our assay and a history of regular use of non-steroidal anti-inflammatories in screening patients under 45 years, we detected all peptic ulcers while saving 39% of endoscopies.	UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT MED,LONDON SW17 0RE,ENGLAND	St Georges University London								ALEMOHAMMAD MM, 1993, J CLIN MICROBIOL, V31, P2174, DOI 10.1128/JCM.31.8.2174-2177.1993; HOLDSTOCK G, 1979, BRIT MED J, V1, P457, DOI 10.1136/bmj.1.6161.457; MARSHALL BJ, 1984, LANCET, V1, P1311; MENDALL MA, 1992, EUR J GASTROEN HEPAT, V4, P713; PARRY JV, 1987, LANCET, V2, P72, DOI 10.1016/S0140-6736(87)92737-1; PATEL P, 1993, GUT, V34, pS36; RATHBONE BJ, 1986, GUT, V27, P642, DOI 10.1136/gut.27.6.642; WILLIAMS B, 1988, LANCET, V2, P1349; 1993, LANCET, V341, P1359; 1988, LANCET, V1, P576	10	95	96	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					511	512		10.1016/S0140-6736(94)91899-6	http://dx.doi.org/10.1016/S0140-6736(94)91899-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7802777				2022-12-24	WOS:A1994PC53500010
J	FREEMANTLE, N; HOUSE, A; SONG, F; MASON, JM; SHELDON, TA				FREEMANTLE, N; HOUSE, A; SONG, F; MASON, JM; SHELDON, TA			PRESCRIBING SELECTIVE SEROTONIN REUPTAKE INHIBITORS AS STRATEGY FOR PREVENTION OF SUICIDE	BRITISH MEDICAL JOURNAL			English	Article							ANTIDEPRESSANTS; OVERDOSE; TOXICITY; RATES; TRIAL; RISK; CARE	Objective-To evaluate a policy to reduce the incidence of suicide by means of changing the prescribing of antidepressants from the older tricycle antidepressants to the routine first line use of selective serotonin reuptake inhibitors or newer tricyclic and related antidepressants. Design-Cost effectiveness analysis with sensitivity analyses using observational data on costs, volume of prescribing, deaths, and toxicity. Setting-United Kingdom primary care. Interventions-Selective serotonin reuptake inhibitors or newer tricyclic and related antidepressants compared with the use of older tricyclics. Main outcome measures-Cost per life saved and cost per Life year saved. Results-The potential number of lives which may be saved from a switch to the routine first line use of selective serotonin reuptake inhibitors is between 300 and 450 each year. The cost per life year gained ranges from pound 19 000 to pound 173 000, depending on the assumptions used. The cost per life year gained through the use of the newer tricyclic and related antidepressants is considerably lower. Conclusions-The cost per life year gained through avoiding suicides by the routine first line use of serotonin reuptake inhibitors is likely to be high. The new tricyclics and related drugs are of similar toxicity to the serotonin reuptake inhibitors but are considerably cheaper and so are more cost effective for this purpose. Further research is required on such prescribing. Because of the great uncertainties the shift to considerably more expensive options must be further investigated.	UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND; LEEDS GEN INFIRM,DEPT LIASON PSYCHIAT,LEEDS,W YORKSHIRE,ENGLAND	University of York - UK; Leeds General Infirmary; University of Leeds	FREEMANTLE, N (corresponding author), UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Mason, James M/D-9904-2011; Sheldon, Trevor/AAK-7088-2021; Song, Fujian/B-3516-2013; anand, amit/A-7222-2009	Mason, James M/0000-0001-9210-4082; Sheldon, Trevor/0000-0002-7479-5913; Freemantle, Nick/0000-0001-5807-5740; House, Allan/0000-0001-8721-8026				BEASLEY CM, 1991, BMJ-BRIT MED J, V303, P685, DOI 10.1136/bmj.303.6804.685; CASSIDY S, 1987, BRIT MED J, V295, P1021, DOI 10.1136/bmj.295.6605.1021; CLARKE PR, 1991, EC ANAL SCREENING BR; CLARKE RV, 1987, J EPIDEMIOL COMMUN H, V41, P114, DOI 10.1136/jech.41.2.114; DIEKSTRA RFW, 1989, ACTA PSYCHIAT SCAND, V79, P268, DOI 10.1111/j.1600-0447.1989.tb10257.x; EDWARDS JG, 1992, BRIT MED J, V304, P1644, DOI 10.1136/bmj.304.6843.1644; FARMER RDT, 1989, ACTA PSYCHIAT SCAND, V80, P25, DOI 10.1111/j.1600-0447.1989.tb03044.x; FAWCETT J, 1987, AM J PSYCHIAT, V144, P35; FRADD SO, 1992, BRIT MED J, V305, P366, DOI 10.1136/bmj.305.6849.366-c; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; GOLDSTEIN RB, 1991, ARCH GEN PSYCHIAT, V48, P618; HENRY J, 1989, ACTA PSYCHIAT S S354, V90, P37; Henry J A, 1992, Eur J Med, V1, P343; JAAKKIMAINEN L, 1990, J CLIN ONCOL, V8, P1301, DOI 10.1200/JCO.1990.8.8.1301; KAPUR S, 1992, JAMA-J AM MED ASSOC, V268, P3441, DOI 10.1001/jama.268.24.3441; KREITMAN N, 1976, BRIT J PREV SOC MED, V30, P86; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; LIN EHB, 1989, J GEN INTERN MED, V4, P1, DOI 10.1007/BF02596482; MILNE S, 1993, BRIT MED J, V306, P1126, DOI 10.1136/bmj.306.6885.1126-b; MONTGOMERY S, 1992, GENERAL PRACTIT 0522, P68; MONTGOMERY SA, 1988, INT CLIN PSYCHOPHARM, V3, P15; POKORNY AD, 1983, ARCH GEN PSYCHIAT, V40, P249; ROY A, 1983, ARCH GEN PSYCHIAT, V40, P971; SAINSBURY P, 1980, SUICIDE SYNDROME, P38; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; TUBMAN TRJ, 1990, BRIT MED J, V301, P842, DOI 10.1136/bmj.301.6756.842; 1992, BMA RPS24 BRIT NED A; 1993, EFFECTIVE HLTH CARE, V5; 1993, DRUG THER B, V31, P57; 1990, MORTALITY STATISTICS; 1992, GUIDELINES TREATING; 1992, HLTH NATION; 1993, ANATOMICAL THERAPEUT; 1986, BREAST CANCER SCREEN; 1993, HLTH NATION KEY AREA	35	85	84	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					249	253		10.1136/bmj.309.6949.249	http://dx.doi.org/10.1136/bmj.309.6949.249			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NZ180	7832842	Green Published			2022-12-24	WOS:A1994NZ18000021
J	BENOWITZ, NL; HENNINGFIELD, JE				BENOWITZ, NL; HENNINGFIELD, JE			ESTABLISHING A NICOTINE THRESHOLD FOR ADDICTION - THE IMPLICATIONS FOR TOBACCO REGULATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CIGARETTE-SMOKING; CARBON-MONOXIDE; TAR; YIELDS; EXPOSURE; BIOAVAILABILITY; SMOKERS		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94110; NATL INST DRUG ABUSE,BALTIMORE,MD 21224	University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)					NIDA NIH HHS [DA01696, DA02277] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA002277, P50DA001696, R01DA002277] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		[Anonymous], 1994, PREVENTING TOBACCO U; BENOWITZ NL, 1982, CLIN PHARMACOL THER, V32, P758, DOI 10.1038/clpt.1982.233; BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; BENOWITZ NL, 1984, CLIN PHARMACOL THER, V35, P499, DOI 10.1038/clpt.1984.67; BENOWITZ NL, 1986, NEW ENGL J MED, V315, P1310, DOI 10.1056/NEJM198611203152102; BENOWITZ NL, 1991, CLIN PHARMACOL THER, V49, P270, DOI 10.1038/clpt.1991.28; BENOWITZ NL, IN PRESS CLIN PHARM; COULTAS DB, 1993, AM REV RESPIR DIS, V148, P435, DOI 10.1164/ajrccm/148.2.435; FIORE MC, 1992, MED CLIN N AM, V76, P289, DOI 10.1016/S0025-7125(16)30354-6; GORI GB, 1985, REGUL TOXICOL PHARM, V5, P314, DOI 10.1016/0273-2300(85)90045-5; GUYATT AR, 1989, PSYCHOPHARMACOLOGY, V99, P80, DOI 10.1007/BF00634457; HENNINGFIELD JE, 1990, BRIT J ADDICT, V85, P279; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; ROBINSON JH, 1992, PSYCHOPHARMACOLOGY, V108, P466, DOI 10.1007/BF02247423; ROBINSON JH, 1992, PSYCHOPHARMACOLOGY, V108, P397, DOI 10.1007/BF02247412; RUSSELL MAH, 1976, BRIT MED J, V1, P1430, DOI 10.1136/bmj.1.6023.1430; RUSSELL MAH, 1982, BRIT J ADDICT, V77, P145; SHIFFMAN S, 1989, PSYCHOPHARMACOLOGY, V97, P539, DOI 10.1007/BF00439561; SHIFFMAN S, 1990, ARCH GEN PSYCHIAT, V47, P333; STEPNEY R, 1980, BRIT J ADDICT, V75, P81; 1988, DHHS PHS CDC888406 P	21	378	387	0	28	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 14	1994	331	2					123	125		10.1056/NEJM199407143310212	http://dx.doi.org/10.1056/NEJM199407143310212			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NW712	7818638				2022-12-24	WOS:A1994NW71200012
J	ROBERTS, RJ; SANDIFER, QD; EVANS, MR; NOLANFARRELL, MZ; DAVIS, PM				ROBERTS, RJ; SANDIFER, QD; EVANS, MR; NOLANFARRELL, MZ; DAVIS, PM			REASONS FOR NON-UPTAKE OF MEASLES, MUMPS, AND RUBELLA CATCH-UP IMMUNIZATION IN A MEASLES EPIDEMIC AND SIDE-EFFECTS OF THE VACCINE	BRITISH MEDICAL JOURNAL			English	Article							IMMUNIZATION; CHILDREN; OUTBREAK; TRANSMISSION; POPULATION; COLLEGE	Objectives-To investigate the reasons for poor uptake of immunisation (non-immunisation) and the possible side effects of measles, mumps, and rubella vaccine in a catch up immunisation campaign during a community outbreak of measles. Design-Descriptive study of reasons for non-immunisation and retrospective cohort study of side effects of the vaccine. Setting-Secondary schools in South Glamorgan. Subjects-Random cluster sample of the parents of 500 children targeted but not immunised and a randomised sample of 2866 of the children targeted. Main outcome measures-Reasons for non-immunisation; symptoms among immunised and non-immunised children. Results-Immunisation coverage of the campaign was only 43.4% (7633/17 595). The practical problems experienced included non-return of consent forms (6698/17 595), refusal of immunisation (2061/10 897 forms returned), and absence from school on day of immunisation (1203/8836 children with consent for immunisation). The most common reasons cited for non-immunisation were previous measles infection (145/232), previous immunisation against measles (78/232), and concern about side effects (55/232). Symptoms were equally common among immunised and non-immunised subjects. However, significantly more immunised boys than non-immunised boys reported fever (relative risk 2.31 (95% confidence interval 1.36 to 3.93)), rash (2.00 (1.10 to 3.64), joint symptoms (1.58; 1.05 to 2.38), and headache (1.31 (1.04 to 1.65)). Conclusions-Many of the objections raised by parents could be overcome by emphasising that primary immunisation does not necessarily confer immunity and that diagnosis of measles is unreliable. Measles, mumps, and rubella vaccine is safe in children aged 11-15.	S GLAMORGAN HLTH AUTHOR,DEPT PUBL HLTH MED,CARDIFF CF1 3NW,S GLAM,WALES; LANSDOWNE HOSP,CARDIFF COMMUNITY HLTH CARE,CARDIFF CF1 8UL,S GLAM,WALES		ROBERTS, RJ (corresponding author), CTR COMMUNICABLE DIS SURVEILLANCE,PUBL HLTH LAB SERV,WELSH UNIT,ABTON HOUSE,CARDIFF CF4 3QX,S GLAM,WALES.		Morgan, Maria/D-3379-2009; Evans, Meirion/C-2990-2008	Evans, Meirion/0000-0003-3578-1866; Morgan, Maria/0000-0002-5182-7222				BARRETT G, 1993, BRIT MED J, V307, P681, DOI 10.1136/bmj.307.6905.681-b; BAXTER DN, 1990, PUBLIC HEALTH, V104, P267, DOI 10.1016/S0033-3506(05)80476-7; BENJAMIN CM, 1992, BMJ-BRIT MED J, V304, P1075, DOI 10.1136/bmj.304.6834.1075; BROWN DWG, 1994, BRIT MED J, V308, P1015, DOI 10.1136/bmj.308.6935.1015; Calvert N, 1994, Commun Dis Rep CDR Rev, V4, pR70; CHEN RT, 1991, VACCINE, V9, P297, DOI 10.1016/0264-410X(91)90053-9; CHEN RT, 1989, AM J EPIDEMIOL, V129, P173, DOI 10.1093/oxfordjournals.aje.a115106; Dean A. G., 1990, EPI INFO VERSION 5 W; GUSTAFSON TL, 1987, NEW ENGL J MED, V316, P771, DOI 10.1056/NEJM198703263161303; HERSH BS, 1991, AM J PUBLIC HEALTH, V81, P360, DOI 10.2105/AJPH.81.3.360; HULL D, 1987, J ROY COLL PHYS LOND, V21, P28; KLEIN N, 1989, BRIT MED J, V298, P1687, DOI 10.1136/bmj.298.6689.1687; LI J, 1993, BRIT MED J, V307, P168, DOI 10.1136/bmj.307.6897.168; LOCHHEAD YJ, 1991, J ADV NURS, V16, P130, DOI 10.1111/j.1365-2648.1991.tb01616.x; LYONS R, IN PRESS EPIDEMIOL I; MARKOWITZ LE, 1989, NEW ENGL J MED, V320, P75, DOI 10.1056/NEJM198901123200202; MILLER C, 1989, PRACTITIONER, V223, P69; MORGANCAPNER P, 1988, BRIT MED J, V297, P770, DOI 10.1136/bmj.297.6651.770; PELTOLA H, 1986, LANCET, V1, P939; Richardson J A, 1994, Commun Dis Rep CDR Rev, V4, pR73; SEAGER C, 1994, VACCINE, V82, P1018; SPRUANCE SL, 1977, ARTHRITIS RHEUM, V20, P741, DOI 10.1002/art.1780200216; 1994, COMMUN DIS REP CDR W, V4, P147; 1980, MMWR-MORBID MORTAL W, V29, P549; 1994, INFECTIOUS DISEASES	25	39	39	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1629	1632		10.1136/bmj.310.6995.1629	http://dx.doi.org/10.1136/bmj.310.6995.1629			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF698	7795447	Green Published			2022-12-24	WOS:A1995RF69800017
J	BARTEL, B; FINK, GR				BARTEL, B; FINK, GR			ILR1, AN AMIDOHYDROLASE THAT RELEASES ACTIVE INDOLE-3-ACETIC-ACID FROM CONJUGATES	SCIENCE			English	Article							ARABIDOPSIS-THALIANA; RESISTANT MUTANTS; AUXIN; TISSUES; CLONING; GROWTH; YEAST	In plants, the growth regulator indole-3-acetic acid (IAA) is found both free and conjugated to a variety of amino acids, peptides, and carbohydrates. IAA conjugated to leucine has effects in Arabidopsis thaliana similar to those of free IAA. The ilr1 mutant is insensitive to exogenous IAA-Leu and was used to positionally clone the Arabidopsis ILR1 gene. ILR1 encodes a 48-kilodalton protein that cleaves IAA-amino acid conjugates in vitro and is homologous to bacterial amidohydrolase enzymes. DNA sequences similar to that of ILR1 are found in other plant species.	MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			Bartel, Bonnie/O-8119-2019; Bartel, Bonnie/D-3550-2011	Bartel, Bonnie/0000-0002-6367-346X; Bartel, Bonnie/0000-0002-6367-346X				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARTEL B, UNPUB; BEDNAREK SY, 1992, PLANT MOL BIOL, V20, P133, DOI 10.1007/BF00029156; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BIALEK K, 1983, PLANT PHYSIOL, V73, P130, DOI 10.1104/pp.73.1.130; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; COHEN JD, 1982, ANNU REV PLANT PHYS, V33, P403, DOI 10.1146/annurev.pp.33.060182.002155; COHEN JD, 1988, BIOMECHANISMS REGULA, P229; Davies P. J., 1987, PLANT HORMONES THEIR; ESTELLE MA, 1987, MOL GEN GENET, V206, P200, DOI 10.1007/BF00333575; HANI EK, 1995, J BACTERIOL, V177, P2396, DOI 10.1128/jb.177.9.2396-2402.1995; HAUGHN GW, 1986, MOL GEN GENET, V204, P430, DOI 10.1007/BF00331020; HERMANSON GG, 1991, NUCLEIC ACIDS RES, V19, P4943, DOI 10.1093/nar/19.18.4943; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; JAKUBOWSKA A, 1993, J PLANT PHYSIOL, V142, P61, DOI 10.1016/S0176-1617(11)80108-2; Koncz C., 1992, METHODS ARABIDOPSIS; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; LIU CM, 1993, PLANT CELL, V5, P621, DOI 10.1105/tpc.5.6.621; MAHER EP, 1980, BIOCHEM GENET, V18, P1041, DOI 10.1007/BF00484337; MINET M, 1992, PLANT J, V2, P417; NORMANLY J, 1993, P NATL ACAD SCI USA, V90, P10355, DOI 10.1073/pnas.90.21.10355; SAKANYAN V, 1993, APPL ENVIRON MICROB, V59, P3878, DOI 10.1128/AEM.59.11.3878-3888.1993; STASINOPOULOS TC, 1990, PLANT PHYSIOL, V93, P1365, DOI 10.1104/pp.93.4.1365; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SZERSZEN JB, 1994, SCIENCE, V265, P1699, DOI 10.1126/science.8085154; WILSON AK, 1990, MOL GEN GENET, V222, P377, DOI 10.1007/BF00633843	26	196	200	5	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 23	1995	268	5218					1745	1748		10.1126/science.7792599	http://dx.doi.org/10.1126/science.7792599			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792599				2022-12-24	WOS:A1995RE66800041
J	XIAO, ZX; CHEN, JD; LEVINE, AJ; MODJTAHEDI, N; XING, J; SELLERS, WR; LIVINGSTON, DM				XIAO, ZX; CHEN, JD; LEVINE, AJ; MODJTAHEDI, N; XING, J; SELLERS, WR; LIVINGSTON, DM			INTERACTION BETWEEN THE RETINOBLASTOMA PROTEIN AND THE ONCOPROTEIN MDM2	NATURE			English	Article							GENE-PRODUCT; TRANSCRIPTION FACTOR; GROWTH SUPPRESSION; COMPLEX-FORMATION; P53; TRANSACTIVATION; IDENTIFICATION; AMPLIFICATION; EXPRESSION; REPRESSION	INACTIVATION of tumour-suppressor genes leads to deregulated cell proliferation and is a key factor in human tumorigenesis. Both p53 and retinoblastoma genes are frequently mutated in human cancers(1,2), and the simultaneous inactivation of RB and p53 is frequently observed in a variety of naturally occurring human tumours(3). Furthermore, three distinct DNA tumour virus groups papovaviruses, adenoviruses and human papillomaviruses-transform cells by targeting and inactivating certain functions of both the p53 and retinoblastoma proteins(1,2). The cellular oncoprotein, Mdm2, binds to and downmodulates p53 function(4-6); its human homologue, MDM2, is amplified in certain human tumours, including sarcomas(7-9) and gliomas(10). Overproduction of Mdm2 is both tumorigenic(4) and capable of immortalizing primary rat embryo fibroblasts(11). Here we show that MDM2 interacts physically and functionally with pRB and, as with p53, inhibits pRB growth regulatory function. Therefore, both pRB and p53 can be subjected to negative regulation by the product of a single cellular proto-oncogene.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Harvard University; Harvard Medical School; Princeton University	XIAO, ZX (corresponding author), DANA FARBER CANC INST,BOSTON,MA 02115, USA.		MODJTAHEDI, Nazanine/D-4377-2017					CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORDONCARDO C, 1994, CANCER RES, V54, P794; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; HAMEL PA, 1992, ONCOGENE, V7, P693; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LEACH FS, 1993, CANCER RES, V53, P2231; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	30	548	568	1	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					694	698		10.1038/375694a0	http://dx.doi.org/10.1038/375694a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791904				2022-12-24	WOS:A1995RE57600064
J	CUZICK, J; SZAREWSKI, A; TERRY, G; HO, L; HANBY, A; MADDOX, P; ANDERSON, M; KOCJAN, G; STEELE, ST; GUILLEBAUD, J				CUZICK, J; SZAREWSKI, A; TERRY, G; HO, L; HANBY, A; MADDOX, P; ANDERSON, M; KOCJAN, G; STEELE, ST; GUILLEBAUD, J			HUMAN PAPILLOMAVIRUS TESTING IN PRIMARY CERVICAL SCREENING	LANCET			English	Article							TYPE-16; WOMEN; DNA	Several studies have examined the role of tests for human papillomavirus (HPV) We looked at HPV testing for types 16, 18, 31, and 33 on material taken at the time of a cervical smear in 2009 eligible women having routine screening. Women with any degree of dyskaryosis or high levels of one of these HPV types were referred for colposcopy. 44% of the cervical intraepithelial neoplasia (CIN) lesions of grade 2/3 detected had negative cytology and were found only by HPV testing. A further 22% of the CIN 2/3 lesions were positive for HPV but showed only borderline or mild cytological changes. The positive predictive value of HPV testing was 42%, which was similar to that for moderate dyskaryosis. HPV types 16 and 31 were more sensitive and specific for CIN 2/3 than were types 18 or 33. However, 25% of the CIN 2/3 lesions were not detected by these four HPV tests. We suggest that HPV testing could usefully augment but not replace conventional cytology. These results should stimulate a much larger randomised trial to assess the impact of these improved CIN 2/3 detection rates on the subsequent incidence of invasive cancer.	IMPERIAL CANC RES FUND, DEPT HISTOPATHOL, LONDON WC2A 3PX, ENGLAND; UNIV NOTTINGHAM HOSP, DEPT HISTOPATHOL, NOTTINGHAM NG7 2UH, ENGLAND; UCL, SCH MED, DEPT HISTOPATHOL, LONDON W1N 8AA, ENGLAND; UCL, SCH MED, DEPT CYTOL, LONDON W1N 8AA, ENGLAND; UNIV COLL & MIDDLESEX SCH MED, DEPT OBSTET & GYNAECOL, LONDON, ENGLAND; MARGARET PYKE CTR FAMILY PLANNING & REPROD HLTH C, LONDON, ENGLAND	Cancer Research UK; University of Nottingham; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London	CUZICK, J (corresponding author), IMPERIAL CANC RES FUND, DEPT MATH STAT & EPIDEMIOL, LONDON WC2A 3PX, ENGLAND.							BAVIN PJ, 1993, BRIT J CANCER, V67, P602, DOI 10.1038/bjc.1993.110; COX JT, 1992, OBSTET GYNECOL, V80, P389; COX JT, 1995, AM J OBSTET GYNECOL, V172, P946, DOI 10.1016/0002-9378(95)90026-8; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; CUZICK J, 1994, BRIT J CANCER, V69, P167, DOI 10.1038/bjc.1994.28; HECHT JL, 1995, INT J CANCER, V60, P369, DOI 10.1002/ijc.2910600317; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; Meijer C J, 1992, IARC Sci Publ, P271; REID R, 1991, AM J OBSTET GYNECOL, V164, P1461, DOI 10.1016/0002-9378(91)91425-V; SLATER DN, 1994, J CLIN PATHOL, V47, P27, DOI 10.1136/jcp.47.1.27; SZAREWSKI A, 1993, ACTA CYTOL, V37, P457; TERRY G, 1994, CLIN CHEM, V40, P1890; VANWIJNGAARDEN WJ, 1993, BRIT MED J, V306, P967, DOI 10.1136/bmj.306.6883.967; VANWIJNGAARDEN WJ, 1995, BRIT J OBSTET GYNAEC, V102, P137	14	289	296	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 17	1995	345	8964					1533	1536		10.1016/S0140-6736(95)91086-7	http://dx.doi.org/10.1016/S0140-6736(95)91086-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791438				2022-12-24	WOS:A1995RD79000008
J	LUKAS, J; PARRY, D; AAGAARD, L; MANN, DJ; BARTKOVA, J; STRAUSS, M; PETERS, G; BARTEK, J				LUKAS, J; PARRY, D; AAGAARD, L; MANN, DJ; BARTKOVA, J; STRAUSS, M; PETERS, G; BARTEK, J			RETINOBLASTOMA-PROTEIN-DEPENDENT CELL-CYCLE INHIBITION BY THE TUMOR-SUPPRESSOR P16	NATURE			English	Article							GENE; OVEREXPRESSION; PROGRESSION; FIBROBLASTS; G(1); D1	D-TYPE cyclins, in association with the cyclin-dependent kinases Cdk4 or Cdk6, promote progression through the G1 phase of the cell cycle(1-6) by phosphorylating the retinoblastoma protein (RB)(7,8). The activities of Cdk4 and Cdk6 are constrained by inhibitors(9-12) such as p16, the product of the CDKN2 gene on human chromosome 9p21 (refs 12-14). The frequent deletion or mutation of CDKN2 in tumour cells suggests that p16 acts as a tumour suppressor. We show that wild-type p16 arrests normal diploid cells in late G1, whereas a tumour-associated mutant of p16 does not. Significantly, the ability of p16 to induce cell-cycle arrest is lost in cells lacking functional RB, including primary fibroblasts from Rb--/- mouse embryos. Thus, loss of p16, overexpression of D-cyclins and loss of RB have similar effects on G1 progression, and may represent a common pathway to tumorigenesis.	DANISH CANC SOC,DIV CANC BIOL,DK-2100 COPENHAGEN 0,DENMARK; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; MAX PLANCK GESELL,D-13122 BERLIN,GERMANY	Danish Cancer Society; Cancer Research UK; Max Planck Society			Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEN J, 1994, CANCER RES, V54, P6353; JIANG W, 1993, ONCOGENE, V8, P3447; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, IN PRESS ONCOGENE; LUKAS J, 1994, J ONCOGENE, V9, P707; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAM SW, 1994, CANCER RES, V54, P5816; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103	26	863	888	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					503	506		10.1038/375503a0	http://dx.doi.org/10.1038/375503a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777060				2022-12-24	WOS:A1995RC18800052
J	SICHERI, F; YANG, DSC				SICHERI, F; YANG, DSC			ICE-BINDING STRUCTURE AND MECHANISM OF AN ANTIFREEZE PROTEIN FROM WINTER FLOUNDER	NATURE			English	Article							MOLECULAR-DYNAMICS; GLOBULAR-PROTEINS; ALPHA-HELICES; POLYPEPTIDE; ADSORPTION	ANTIFREEZE proteins provide fish with protection against the freezing effect of polar environments by binding to ice surfaces and inhibiting growth of ice crystals. We present the X-ray crystal structure at 1.5 Angstrom resolution of a lone alpha-helical antifreeze protein from winter flounder, which provides a detailed look at its ice-binding features. These consist of four repeated ice-binding motifs, the side chains of which are inherently rigid or restrained by pairwise side-chain interactions to form a flat binding surface. Elaborate amino- and carboxy-terminal cap structures are also present, which explain the protein's rich alpha-helical content in solution. We propose an ice-binding model that accounts for the binding specificity of the antifreeze protein along the [01 (1) over bar 2] axes of the {20 (2) over bar 1} ice planes(1).	MCMASTER UNIV,FAC HLTH SCI,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA; VET ADM MED CTR,BIOCRYSTALLOG LAB,PITTSBURGH,PA 15240	McMaster University; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Sicheri, Frank/F-8856-2013					ANANTHANARAYANA.VS, 1977, BIOCHEM BIOPH RES CO, V74, P685; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAKRABARTTY A, 1991, EUR J BIOCHEM, V202, P1057, DOI 10.1111/j.1432-1033.1991.tb16470.x; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11307; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; HEW CL, 1986, EUR J BIOCHEM, V160, P267, DOI 10.1111/j.1432-1033.1986.tb09966.x; HEW CL, 1987, INTEGRATION CONTROL, P299; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN H, 1993, PROTEIN ENG, V6, P19, DOI 10.1093/protein/6.1.19; KNIGHT CA, 1993, BIOPHYS J, V64, P252, DOI 10.1016/S0006-3495(93)81361-4; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; LAL M, 1993, J FARADAY DISCUSS, V95, P299; MADURA JD, 1994, J AM CHEM SOC, V116, P417, DOI 10.1021/ja00080a066; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; PIELA L, 1987, BIOPOLYMERS, V26, P1273, DOI 10.1002/bip.360260805; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; THANKI N, 1988, J MOL BIOL, V202, P637, DOI 10.1016/0022-2836(88)90292-6; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2; WEN DY, 1992, J BIOL CHEM, V267, P14102; YANG DSC, 1986, J MOL BIOL, V189, P725, DOI 10.1016/0022-2836(86)90504-8; YANG DSC, 1988, NATURE, V333, P232, DOI 10.1038/333232a0	23	325	346	7	117	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					427	431		10.1038/375427a0	http://dx.doi.org/10.1038/375427a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760940	Green Submitted			2022-12-24	WOS:A1995RB10100060
J	HORTON, R				HORTON, R			WOMEN AS WOMEN WITH HIV	LANCET			English	Editorial Material																		CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; MILNICK SL, 1994, JAMA-J AM MED ASSOC, V272, P1915; 1994, LANCET, V344, P207; 1995, MMWR-MORBID MORTAL W, V44, P81	4	5	5	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					531	532		10.1016/S0140-6736(95)90458-1	http://dx.doi.org/10.1016/S0140-6736(95)90458-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776767	Bronze			2022-12-24	WOS:A1995QK44400003
J	LIVINGSTON, MG				LIVINGSTON, MG			INTERACTIONS WITH SELECTIVE MAOIS	LANCET			English	Editorial Material							OXIDASE; PSEUDOPHAEOCHROMOCYTOMA; MOCLOBEMIDE; INHIBITORS; SELEGILINE				LIVINGSTON, MG (corresponding author), UNIV GLASGOW,GARTNAVEL ROYAL HOSP,DEPT PSYCHOL MED,GLASGOW,LANARK,SCOTLAND.							BASS C, 1989, BRIT MED J, V298, P345, DOI 10.1136/bmj.298.6670.345; FREEMAN H, 1993, LANCET, V342, P1528, DOI 10.1016/S0140-6736(05)80090-X; KNOLL J, 1978, BIOCHEM PHARMACOL, V27, P1739, DOI 10.1016/0006-2952(78)90550-6; LEFEBVRE H, 1995, CLIN ENDOCRINOL, V42, P95, DOI 10.1111/j.1365-2265.1995.tb02604.x; LEFEBVRE H, 1993, LANCET, V341, P555, DOI 10.1016/0140-6736(93)90314-7; MANN JJ, 1989, ARCH GEN PSYCHIAT, V46, P45; MCGRATH PJ, 1989, J CLIN PSYCHOPHARM, V9, P310; MONTASTRUC JL, 1993, LANCET, V341, P555, DOI 10.1016/0140-6736(93)90313-6; NEUVONEN PJ, 1993, LANCET, V342, P1419, DOI 10.1016/0140-6736(93)92774-N; ZORNBERG GL, 1991, LANCET, V337, P246, DOI 10.1016/0140-6736(91)92219-R; 1989, DRUG THER B, V27, P63	11	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					533	534		10.1016/S0140-6736(95)90460-3	http://dx.doi.org/10.1016/S0140-6736(95)90460-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776769				2022-12-24	WOS:A1995QK44400005
J	PAUL, WE				PAUL, WE			REEXAMINING AIDS RESEARCH PRIORITIES	SCIENCE			English	Editorial Material							MECHANISM; INFECTION; VACCINE; CELLS; GENE; HIV				PAUL, WE (corresponding author), NIH, OFF AIDS RES, BETHESDA, MD 20892 USA.							BABA TW, IN PRESS SCIENCE; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; CAO Y, IN PRESS N ENGL J ME; CLERICI M, 1994, JAMA-J AM MED ASSOC, V271, P42, DOI 10.1001/jama.271.1.42; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; CZERKINSKY C, 1993, CLIN INFECT DIS, V16, pS106, DOI 10.1093/clinids/16.Supplement_2.S106; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FIELDS BN, 1994, NATURE, V369, P95, DOI 10.1038/369095a0; GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KLUGMAN KP, 1987, LANCET, V2, P1165; LAZARO I, 1994, J VIROL, V68, P6535, DOI 10.1128/JVI.68.10.6535-6546.1994; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; MERSON MH, 1994, INT C AIDS, V10, P4; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; PANTALEO G, IN PRESS N ENGL J ME; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PLUMMER FA, 1993, INT C AIDS, V9, P23; ROMAGNANI S, 1994, AIDS RES HUM RETROV, V10, pR3, DOI 10.1089/aid.1994.10.iii; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; UMLAUF SW, 1993, IMMUNOL REV, V133, P177, DOI 10.1111/j.1600-065X.1993.tb01516.x; WALKER CM, 1991, J VIROL, V65, P5921, DOI 10.1128/JVI.65.11.5921-5927.1991; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WINKELSTEIN WJ, 1993, INT C AIDS, V9, P88; 1994, HIV AIDS SURVEILLANC, V6, P1	29	31	34	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	1995	267	5198					633	636		10.1126/science.7839138	http://dx.doi.org/10.1126/science.7839138			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839138				2022-12-24	WOS:A1995QE73300025
J	WADA, A				WADA, A			A SPACE-TIME SLIDE-RULE (VOL 373, PG R39, 1995)	NATURE			English	Correction, Addition								Akiyoshi Wada retired some years ago as a professor of physics at Tokyo University, where he was for many years one of those in Japan urging the fuller use of physical techniques in molecular biology, notably in the automatic sequencing of DNA. Now he is the director of the interdisciplinary Sagami Chemical Research Center near Tokyo. The Wadarules reproduced on these pages (together with an explanatory note by Professor Wada) do not arise directly from the author's professional work but are the product of a fertile tile and ingenious imagination exercised, in part no doubt, on long aircraft journeys. They are offered without restriction to those who may have use for them. It is simply necessary to photocopy the diagrams, to separate the main rule from the reference rule and to mount each part on stiff card in such a way as to be able to slide the latter against the former. While the Wadarules may have a general heuristic value for those who have the time to play with them, they may have a particular educational value for young children and may be particularly useful for, say, science writers forever seeking graphic wars of dramatizing the large or small scale of some phenomenon (as in the phrase ''seems no bigger than a dime at a distance of 1 mile''). The rules can readily be amended to include objects with dimensions other than those shown. The annotation of the time rule leaves ample room for the addition of extra items, such as the average duration of the human heart-beat, the period of oscillation of ''middle C'' (0.00178 seconds) and the like.			WADA, A (corresponding author), SAGAMI CHEM RES CTR,4-4-1 NISHIOHNUMA,SAGAMIHARA,KANAGAWA 229,JAPAN.							WADA A, 1995, NATURE, V373, pR39	1	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					R35	R36						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830774				2022-12-24	WOS:A1995QE67000065
J	MUIR, KW; SQUIRE, IB; ALWAN, W; LEES, KR				MUIR, KW; SQUIRE, IB; ALWAN, W; LEES, KR			ANTICARDIOLIPIN ANTIBODIES IN AN UNSELECTED STROKE POPULATION	LANCET			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTIPHOSPHOLIPID SYNDROME; CEREBRAL-ISCHEMIA; ANTI-CARDIOLIPIN; ASSOCIATION; THROMBOSIS; INFARCTION; COAGULATION; PREVALENCE; FEATURES	A pathogenetic role in thrombotic disease, particularly in young people, has been postulated for anticardiolipin antibody (ACA). We have carried out a prospective controlled study of 262 unselected patients with acute stroke and 226 controls to assess the prevalence and relation to age and vascular risk factors of ACA. Titres of IgG, IgA, or IgM ACA were above the upper normal limit in 38% of patients. The proportions of patients and controls with raised titres did not differ significantly (13 vs 8% IgG, 22 vs 29% IgA, 11 vs 7% IgM). IgG titres were higher among patients than among controls (mean 3.88 vs 2.86 u/mL [95% CI for difference 0.62-0.87], p=0.0004), whereas IgA and IgM titres were lower in patients than in controls (IgA 4.82 vs 5.98 u/mL [1.12-1.60], p = 0.01; IgM 3.00 vs 3.64 u/mL [1.01-1.45], p = 0.04). However, within age tertiles the only significant difference between patients and controls for IgG ACA was in the oldest tertile. Analysis by number of risk factors for stroke showed a significant difference between the groups only for subjects with one risk factor. IgA and IgM ACA titres were higher among controls only in those with no vascular risk factors.	UNIV GLASGOW,WESTERN INFIRM,DEPT IMMUNOL,GLASGOW G11 6NT,SCOTLAND	University of Glasgow	MUIR, KW (corresponding author), UNIV GLASGOW,WESTERN INFIRM,DEPT MED & THERAPEUT,GLASGOW G11 6NT,SCOTLAND.		Muir, Keith W/A-7670-2011	Muir, Keith W/0000-0001-9535-022X				ASHERSON RA, 1991, ANN RHEUM DIS, V50, P805, DOI 10.1136/ard.50.11.805; ASHERSON RA, 1992, ANN RHEUM DIS, V51, P147, DOI 10.1136/ard.51.2.147; BABIKIAN VL, 1990, STROKE, V21, P1268; BABIKIAN VL, 1992, STROKE S1, V23, P133; BAKIMER R, 1992, J CLIN INVEST, V89, P1558, DOI 10.1172/JCI115749; BREY RL, 1990, NEUROLOGY, V40, P1190, DOI 10.1212/WNL.40.8.1190; CHAKRAVARTY KK, 1991, Q J MED, V79, P397; CHANCELLOR AM, 1991, J NEUROL, V238, P401, DOI 10.1007/BF00319860; CZLONKOWSKA A, 1992, ACTA NEUROL SCAND, V86, P304, DOI 10.1111/j.1600-0404.1992.tb05090.x; GINSBURG KS, 1992, ANN INTERN MED, V117, P997, DOI 10.7326/0003-4819-117-12-997; GREAVES M, 1993, J NEUROL NEUROSUR PS, V56, P433, DOI 10.1136/jnnp.56.5.433; HAMSTEN A, 1986, LANCET, V1, P113; HARRIS E N, 1987, British Journal of Rheumatology, V26, P19; HARRIS EN, 1983, LANCET, V2, P1211; HARRIS EN, 1990, AM J CLIN PATHOL, V94, P476, DOI 10.1093/ajcp/94.4.476; HART RG, 1984, STROKE, V15, P114, DOI 10.1161/01.STR.15.1.114; HESS DC, 1991, NEUROLOGY, V41, P525, DOI 10.1212/WNL.41.4.525; HUGHES GRV, 1993, LANCET, V342, P341, DOI 10.1016/0140-6736(93)91477-4; KUSHNER MJ, 1990, STROKE, V21, P295, DOI 10.1161/01.STR.21.2.295; LEVINE SR, 1990, NEUROLOGY, V40, P1181, DOI 10.1212/WNL.40.8.1181; MANOUSSAKIS MN, 1987, CLIN EXP IMMUNOL, V69, P557; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; MONTALBAN J, 1991, STROKE, V22, P750, DOI 10.1161/01.STR.22.6.750; MUEH JR, 1980, ANN INTERN MED, V92, P156, DOI 10.7326/0003-4819-92-2-156; NENCINI P, 1992, STROKE, V23, P189, DOI 10.1161/01.STR.23.2.189; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TRIMBLE M, 1990, AM J MED, V88, P593, DOI 10.1016/0002-9343(90)90523-G; VLACHOYIANNOPOULOS PG, 1992, EUR J CLIN INVEST, V22, P482, DOI 10.1111/j.1365-2362.1992.tb01494.x; 1993, STROKE S1, V24, P120	29	91	93	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					452	456		10.1016/S0140-6736(94)91775-2	http://dx.doi.org/10.1016/S0140-6736(94)91775-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7818647				2022-12-24	WOS:A1994PB76100015
J	MATSUMOTO, A; OGURA, K; HIRATA, Y; KAKOKI, M; WATANABE, F; TAKENAKA, K; SHIRATORI, Y; MOMOMURA, S; OMATA, M				MATSUMOTO, A; OGURA, K; HIRATA, Y; KAKOKI, M; WATANABE, F; TAKENAKA, K; SHIRATORI, Y; MOMOMURA, S; OMATA, M			INCREASED NITRIC-OXIDE IN THE EXHALED AIR OF PATIENTS WITH DECOMPENSATED LIVER-CIRRHOSIS	ANNALS OF INTERNAL MEDICINE			English	Note							SYNTHASE; EXPRESSION; ENDOTOXIN; CYTOKINES; CELLS; RATS	Objective: To determine if nitric oxide output in exhaled air is increased in patients with liver cirrhosis. Design: Cross-sectional study. Setting: A university hospital. Patients: 50 patients with liver cirrhosis, 6 patients with chronic hepatitis, and 15 healthy controls. Measurements: Nitric oxide in exhaled air was measured using a chemiluminescence analyzer. Cardiac index was determined using echocardiography. Results: Patients with decompensated liver cirrhosis had higher levels of exhaled nitric oxide output (Child C patients, 190 +/- 11 nL/min per m(2) body surface area) than controls (97 +/- 8 nL/min per m(2) body surface area; P < 0.001), whereas patients with compensated liver cirrhosis or chronic hepatitis had levels of nitric oxide output similar to those found in controls. Cardiac index was greater in patients with liver cirrhosis (Child C patients, 4.3 +/- 0.3 L/min per m(2) body surface area) than in controls (2.9 +/- 0.2 L/min per m(2) body surface area; P < 0.001). Cardiac index correlated with nitric oxide levels (r = 0.621; P < 0.001). Conclusions: Increased nitric oxide output in exhaled air is associated with systemic circulatory disturbances in patients with liver cirrhosis.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 2, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CLARIA J, 1992, HEPATOLOGY, V15, P343, DOI 10.1002/hep.1840150227; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GUARNER C, 1993, HEPATOLOGY, V18, P1139; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KHORUTS A, 1991, HEPATOLOGY, V13, P267, DOI 10.1016/0270-9139(91)92439-F; LEE FY, 1992, HEPATOLOGY, V16, P1043, DOI 10.1002/hep.1840160430; LUMSDEN AB, 1988, HEPATOLOGY, V8, P232, DOI 10.1002/hep.1840080207; MATSUMOTO A, 1994, LANCET, V343, P849, DOI 10.1016/S0140-6736(94)92047-8; MIDGLEY S, 1991, LANCET, V338, P1590, DOI 10.1016/0140-6736(91)92407-S; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURRAY JF, 1958, AM J MED, V24, P358, DOI 10.1016/0002-9343(58)90322-X; PERSSON MG, 1994, LANCET, V343, P146, DOI 10.1016/S0140-6736(94)90935-0; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; ROLLA G, 1994, NEW ENGL J MED, V331, P1098, DOI 10.1056/NEJM199410203311617; SPITZER JA, 1994, HEPATOLOGY, V19, P217, DOI 10.1002/hep.1840190132; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; TEICHHOLZ LE, 1976, AM J CARDIOL, V37, P7, DOI 10.1016/0002-9149(76)90491-4; TILG H, 1992, GASTROENTEROLOGY, V103, P264, DOI 10.1016/0016-5085(92)91122-K; VALLANCE P, 1991, LANCET, V337, P776, DOI 10.1016/0140-6736(91)91384-7	21	99	103	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1995	123	2					110	113		10.7326/0003-4819-123-2-199507150-00005	http://dx.doi.org/10.7326/0003-4819-123-2-199507150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM435	7778822				2022-12-24	WOS:A1995RM43500005
J	WOO, D				WOO, D			APOPTOSIS AND LOSS OF RENAL TISSUE IN POLYCYSTIC KIDNEY-DISEASES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL-DEATH; VITRONECTIN RECEPTOR; TRANSGENIC MICE; NEOPLASIA; ATROPHY; EVENTS; MODEL; RAT	Background. Polycystic kidney disease is characterized by the enlargement of renal cysts, interstitial fibrosis, and gradual loss of normal renal tissue in association with progressive deterioration of renal function. The process causing the progressive loss of renal tissue is unknown, but it could be the result of a form of programmed cell death known as apoptosis. Methods. We assayed apoptotic DNA fragmentation in normal and polycystic kidneys biochemically by gel electrophoresis and histochemically by in situ end-labeling. A DNA-specific dye, Hoechst 33258, was used to detect morphologic apoptosis in renal samples from patients with normal kidneys, polycystic kidney disease, and other kidney diseases. Results. Apoptotic DNA fragmentation was detected in polycystic kidneys from 5 patients without renal failure and 11 patients with renal failure but not in kidneys from 12 patients with no renal disease. In situ end-labeling revealed apoptotic cells in glomeruli, in cyst walls, and in both cystic and noncystic tubules of the polycystic kidneys. No tubular apoptosis was detected in renal-biopsy specimens from five patients with IgA nephropathy, three patients with nephrosclerosis, two patients with focal glomerulosclerosis, one patient with diabetic nephropathy, six patients with acute tubular necrosis, or four patients with acute and four patients with chronic renal-transplant rejection. The capacity of polycystic kidney cells to undergo apoptosis was retained in vitro in the absence of uremia, ischemia, and other confounding pathologic conditions. Conclusions. Apoptotic loss of renal tissue may be associated with the progressive deterioration of renal function that occurs in patients with polycystic kidney disease.			WOO, D (corresponding author), UNIV CALIF LOS ANGELES,DEPT MED,DIV NEPHROL,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040700, R01DK045663] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40700, DK45663] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVNER ED, 1992, P NATL ACAD SCI USA, V89, P7447, DOI 10.1073/pnas.89.16.7447; BAERT L, 1978, KIDNEY INT, V13, P519, DOI 10.1038/ki.1978.75; BAKER AJ, 1994, J CLIN INVEST, V94, P2105, DOI 10.1172/JCI117565; BASERGA R, 1968, LAB INVEST, V19, P92; CARONE FA, 1993, LAB INVEST, V68, P413; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; COLES HSR, 1993, DEVELOPMENT, V118, P777; CUPPAGE FE, 1980, KIDNEY INT, V17, P372, DOI 10.1038/ki.1980.43; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FADOK VA, 1992, J IMMUNOL, V149, P4029; FINE LG, 1989, ANNU REV PHYSIOL, V51, P19, DOI 10.1146/annurev.ph.51.030189.000315; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOBE GC, 1990, LAB INVEST, V63, P770; GOBE GC, 1987, LAB INVEST, V56, P273; GRANTHAM JJ, 1995, J CLIN INVEST, V95, P195, DOI 10.1172/JCI117638; GRANTHAM JJ, 1990, AM J KIDNEY DIS, V15, P110, DOI 10.1016/S0272-6386(12)80507-5; HEGG O, 1966, J PATHOL BACTERIOL, V91, P311, DOI 10.1002/path.1700910204; KAMADA S, 1995, CANCER RES, V55, P354; KELLEY KA, 1991, J AM SOC NEPHROL, V2, P84; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; LEDDACOLUMBANO GM, 1989, AM J PATHOL, V135, P657; MAJNO G, 1995, AM J PATHOL, V146, P3; MIGHELI A, 1994, J NEUROPATH EXP NEUR, V53, P606, DOI 10.1097/00005072-199411000-00008; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; PREMINGER GM, 1982, J UROLOGY, V127, P556, DOI 10.1016/S0022-5347(17)53911-7; Sambrook J., 1989, MOL CLONING LAB MANU; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAWCZUK IS, 1989, KIDNEY INT, V35, P1315, DOI 10.1038/ki.1989.128; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; TAKAHASHI H, 1986, J UROLOGY, V135, P1280, DOI 10.1016/S0022-5347(17)46074-5; TRUDEL M, 1991, KIDNEY INT, V39, P665, DOI 10.1038/ki.1991.80; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILSON PD, 1991, AM J PHYSIOL, V260, pF420, DOI 10.1152/ajprenal.1991.260.3.F420; WOO DDL, 1994, NATURE, V368, P750, DOI 10.1038/368750a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	41	288	304	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 6	1995	333	1					18	25		10.1056/NEJM199507063330104	http://dx.doi.org/10.1056/NEJM199507063330104			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG735	7776989	Bronze			2022-12-24	WOS:A1995RG73500004
J	COYLE, A; MCGRELLIS, S				COYLE, A; MCGRELLIS, S			STRATEGIES FOR DEALING WITH PROBLEMS ASSOCIATED WITH USE OF SERVICES FOR HIV-INFECTION AND AIDS OUT OF REGION - VIEWS OF PROVIDERS AND USERS	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONER	Objectives-To identify reasons why people with HIV infection and AIDS living within the former South West Thames Regional Health Authority use HIV and AIDS services outside the region, and to identify strategies for dealing with the problems associated with such use. Design-Qualitative study consisting of interviews with individual subjects and focus groups. Setting-Providers of services for patients with HIV infection and AIDS in South West Thames, central London, and Brighten. Users of such services resident in South West Thames. Subjects-Thirty four South West Thames residents with HIV infection and AIDS who use or used services outside the former region; and 70 providers of services within and beyond South West Thames. Results-Principal reasons for use of services out of the region were accessibility (15) and negative appraisals of local services (14). Three main strategies for dealing with the problems of such use were suggested by providers. These entailed introducing users of services outside the region to services in their locality (16); sharing the responsibility for care between providers in specialist centres and in the person's locality (10); and involving the person's general practitioner in their care (12). These strategies were deemed acceptable by 29, 30, and 20 service users respectively. Conclusion-The reasons underlying use of services for patients with HIV infection and AIDS outside the region offer suggestions for developing services in areas with a high incidence of such use. The suggestions advanced by service providers offer an acceptable framework for dealing with the problems.			COYLE, A (corresponding author), UNIV SURREY,DEPT NURSING & MIDWIFERY,GUILDFORD GU2 5XH,SURREY,ENGLAND.			Coyle, Adrian/0000-0002-5340-9817				ADLER M, 1993, BRIT MED J, V307, P1010, DOI 10.1136/bmj.307.6910.1010; BEARDSELL S, 1995, HIV TESTING SERVICES; COYLE A, 1993, NEED LISTEN SERVICE; KING MB, 1988, BRIT MED J, V297, P182, DOI 10.1136/bmj.297.6642.182; Krueger R. A., 1988, FOCUS GROUPS PRACTIC; MANSFIELD SJ, 1989, J ROY COLL GEN PRACT, V39, P104; Miles M., 1994, QUALITATIVE DATA ANA; SAUNDERS P, 1994, BRIT MED J, V308, P2, DOI 10.1136/bmj.308.6920.2; SMITH S, 1993, BRIT MED J, V307, P801, DOI 10.1136/bmj.307.6907.801-c; 1993, HIV AIDS 1992 1993 S	10	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1636	1638		10.1136/bmj.310.6995.1636	http://dx.doi.org/10.1136/bmj.310.6995.1636			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF698	7795449	Green Published			2022-12-24	WOS:A1995RF69800019
J	NOOR, MA				NOOR, MA			SPECIATION DRIVEN BY NATURAL-SELECTION IN DROSOPHILA	NATURE			English	Article							GENE FLOW; REINFORCEMENT	REINFORCEMENT is the process by which natural selection strengthens sexual isolation between incipient species, reducing the frequency of maladaptive hybridization and hence completing reproductive isolation. Although this model of speciation was once widely accepted(1,2), its plausibility(3,4) and experimental support(5-7) have been recently attacked. Here we provide an example of speciation by reinforcement, in the North American fruitfly Drosophila pseudoobscura. The results suggest that females of D. pseudoobscura evolved increased sexual isolation from their sibling species, D. persimilis, by natural selection against maladaptive hybridization.			NOOR, MA (corresponding author), UNIV CHICAGO,DEPT ECOL & EVOLUT,1101 E 57TH ST,CHICAGO,IL 60637, USA.			Noor, Mohamed/0000-0002-5400-4408				BROWN RGB, 1963, BEHAVIOUR, V23, P61; Butlin R., 1989, P158; BUTLIN R, 1987, TRENDS ECOL EVOL, V2, P8, DOI 10.1016/0169-5347(87)90193-5; COYNE JA, 1987, AM NAT, V129, P847, DOI 10.1086/284679; COYNE JA, 1992, NATURE, V355, P511, DOI 10.1038/355511a0; DOBZHANSKY T, 1973, AM NAT, V107, P312, DOI 10.1086/282833; Dobzhansky T., 1935, PHILOS SCI, V2, P344, DOI DOI 10.1086/286379; Dobzhansky T., 1952, COPEIA, V1952, P287; Dobzhansky T., 1975, INVERTEBRATES GENETI, P537; HOWARD DJ, 1993, HYBRID ZONES AND THE EVOLUTIONARY PROCESS, P46; Lewontin RC, 1974, GENETIC BASIS EVOLUT; MAYR E, 1946, P NATL ACAD SCI USA, V32, P128, DOI 10.1073/pnas.32.5.128; Mayr E., 1942, SYSTEMATICS ORIGIN S; Noor M.A., 1994, Drosophila Information Service, V75, P67; NOOR MA, 1995, PAN-PAC ENTOMOL, V71, P71; POWELL JR, 1983, P NATL ACAD SCI-BIOL, V80, P492, DOI 10.1073/pnas.80.2.492; SANDERSON N, 1989, EVOLUTION, V43, P1223, DOI [10.2307/2409358, 10.1111/j.1558-5646.1989.tb02570.x]; SCHAEFFER SW, 1992, GENETICS, V132, P471; SPENCER HG, 1986, AM NAT, V128, P241, DOI 10.1086/284557; TAKAHATA N, 1984, P NATL ACAD SCI-BIOL, V81, P1764, DOI 10.1073/pnas.81.6.1764; TEMPLETON AR, 1981, ANNU REV ECOL SYST, V12, P23, DOI 10.1146/annurev.es.12.110181.000323	21	262	266	0	41	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					674	675		10.1038/375674a0	http://dx.doi.org/10.1038/375674a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791899				2022-12-24	WOS:A1995RE57600057
J	DANZIG, LE; SHORT, LJ; COLLINS, K; MAHONEY, W; SEPE, S; BLAND, L; JARVIS, WR				DANZIG, LE; SHORT, LJ; COLLINS, K; MAHONEY, W; SEPE, S; BLAND, L; JARVIS, WR			BLOOD-STREAM INFECTIONS ASSOCIATED WITH A NEEDLELESS INTRAVENOUS-INFUSION SYSTEM IN PATIENTS RECEIVING HOME INFUSION THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.- To determine risk factors for bloodstream infections (BSIs) in an outbreak among patients receiving home intravenous infusion therapy. Design.- Case-control and retrospective cohort studies. Setting - Home health agency. Patients.- Patients receiving home intravenous infusion therapy from Rhode Island Home Therapeutics (RIHT) from January through December 1993. Main Outcome Measure.- Development of primary BSI. Methods.- We compared patients with BSI (ie, case patients) with randomly selected noninfected RIHT patients receiving intravenous therapy, conducted a cohort study of all RIHT patients receiving intravenous therapy via a central venous catheter (CVC), and conducted a culture survey of injection cap luminal fluid. Results.- Case patients were more likely than controls to have had therapy via a CVC (11/11 vs 14/32; odds ratio [OR] undefined; P<.001) or total parenteral nutrition and intralipid therapy (TPN/IL) (9/11 vs 3/32; OR, 43.5; 95% confidence interval [CI], 4.9 to 510.0). Among RIHT patients with CVCs, risk factors for BSI were receipt of TPN/IL (9/35 vs 2/67; rate ratio [RR], 8.6; 95% CI, 2.0 to 37.7) or use of a needleless infusion system (10/41 vs 1/61; RR, 14.9; 95% CI, 2.0 to 111.8). Only the combination of both exposures was significantly associated with development of a BSI (P<.001). Luminal fluid from injection caps of needleless devices was significantly more likely to be culture positive than fluid from protected-needle devices (5/23 vs 0/18; RR undefined; P=.04). Conclusions.- Our data suggest that a needleless device used for TPN/IL was associated with increased risk of BSI when injection caps were changed every 7 days.	RHODE ISL HOME THERAPEUT,E PROVIDENCE,RI		DANZIG, LE (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,1600 CLIFTON RD NE,ATLANTA,GA 30333, USA.		Mahoney, William/GQB-0802-2022					BENSON JS, 1992, FDA SAFETY ALERT NEE; DEAN AG, 1991, EPIINFO VERSION 5 01; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GARTNER K, 1993, AM J INFECT CONTROL, V20, P75; GOLDMANN DA, 1993, CLIN MICROBIOL REV, V6, P176, DOI 10.1128/CMR.6.2.176-192.1993; GRAHAM DR, 1991, AM J MED, V91, pS95, DOI 10.1016/0002-9343(91)90351-W; IPPOLITO G, 1994, JAMA-J AM MED ASSOC, V272, P607, DOI 10.1001/jama.272.8.607; JARVIS WR, 1991, AM J MED, V91, pS101, DOI 10.1016/0002-9343(91)90352-X; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MAKI DG, 1992, HOSP INFECT, P849; MENDELSON H, 1992, 33RD INT C ANT AG CH; SIMMONS BP, 1982, GUIDELINE PREVENTION; SKOLNICK R, 1993, AM J INFECT CONTROL, V21, P39, DOI 10.1016/0196-6553(93)90206-J; WILLIAMS WW, 1985, JPEN-PARENTER ENTER, V9, P735, DOI 10.1177/0148607185009006735; 1990, SAS PROCEDURES GUIDE	15	101	102	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	1995	273	23					1862	1864		10.1001/jama.273.23.1862	http://dx.doi.org/10.1001/jama.273.23.1862			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD116	7776503				2022-12-24	WOS:A1995RD11600029
J	HARDEN, PN; GEDDES, C; ROWE, PA; MCILROY, JH; BOULTONJONES, M; RODGER, RSC; JUNOR, BJR; BRIGGS, JD; CONNELL, JMC; JARDINE, AG				HARDEN, PN; GEDDES, C; ROWE, PA; MCILROY, JH; BOULTONJONES, M; RODGER, RSC; JUNOR, BJR; BRIGGS, JD; CONNELL, JMC; JARDINE, AG			POLYMORPHISMS IN ANGIOTENSIN-CONVERTING-ENZYME GENE AND PROGRESSION OF IGA NEPHROPATHY	LANCET			English	Note							QUESTIONNAIRE; SUGARS; WOMEN	We have investigated the influence of the functional insertion (I) and deletion (D) polymorphism in intron 16 of the gene for angiotensin-converting enzyme (ACE) in a retrospective study of 100 patients with IgA nephropathy. There was no difference in genotype frequency compared with normal subjects. However, patients homozygous for the D allele tended to present at an earlier age (medians: DD, 33; ID, 34; II, 42 years) and to require renal replacement therapy at a younger age (medians 37, 42, and 48 years, respectively). The rate of progression was significantly worse in patients homozygous for the D allele. The DD genotype is associated with increased severity of disease in patients with IgA nephropathy.	WESTERN INFIRM & ASSOCIATED HOSP,RENAL UNIT,GLASGOW,LANARK,SCOTLAND; ROYAL INFIRM,RENAL UNIT,GLASGOW,LANARK,SCOTLAND; ROYAL INFIRM,DEPT CLIN BIOCHEM,GLASGOW,LANARK,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,DEPT MED,GLASGOW G11 6NT,LANARK,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,DEPT THERAPEUT,GLASGOW G11 6NT,LANARK,SCOTLAND	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; University of Glasgow; University of Glasgow			Jardine, Alan/L-5770-2019	Jardine, Alan/0000-0001-5815-9370				ADAMSON AJ, 1980, J HUM NUTRDIET, V5, P371; BARKER M E, 1988, Journal of Human Nutrition and Dietetics, V1, P179, DOI 10.1111/j.1365-277X.1988.tb00187.x; BINGHAM S, 1991, P NUTR SOC, V50, pA32; BLACK AE, 1991, EUR J CLIN NUTR, V45, P583; EMMETT P, 1992, J HUM NUTR DIET, V5, P245, DOI 10.1111/j.1365-277X.1992.tb00159.x; EMMETT PM, 1993, EUR J CLIN NUTR, V47, P20; GIBNEY MJ, 1980, J HUM NUTR DIET, V3, P245; Gregory F., 1990, DIETARY NUTR SURVEY; HEATON KW, 1991, GUT, V32, P316, DOI 10.1136/gut.32.3.316; MANN GV, 1994, LANCET, V343, P1268, DOI 10.1016/S0140-6736(94)92157-1; Paul A.A., 1978, MCCANCE WIDDOWSONS C; PRENTICE AM, 1986, BRIT MED J, V292, P983, DOI 10.1136/bmj.292.6526.983; Pryer J. A., 1994, Proceedings of the Nutrition Society, V53, p235A; RUGGGUNN AJ, 1993, J HUM NUTR DIET, V6, P419, DOI 10.1111/j.1365-277X.1993.tb00387.x; WILES SJ, 1980, J HUM NUTR, V34, P189; WILLETT WC, 1994, AM J PUBLIC HEALTH, V84, P722, DOI 10.2105/AJPH.84.5.722; YARNELL JWG, 1983, HUM NUTR-APPL NUTR, V37, P103; 1992, GOOD DIETARY PRACTIC, V3, P1; 1992, HLTH NATION STRATEGY; 1991, REPORTS HLTH SOCIAL, V41; 1989, REPORTS HLTH SOCIAL, V37	21	225	232	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1540	1542		10.1016/S0140-6736(95)91088-3	http://dx.doi.org/10.1016/S0140-6736(95)91088-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791440				2022-12-24	WOS:A1995RD79000010
J	MAYFORD, M; WANG, J; KANDEL, ER; ODELL, TJ				MAYFORD, M; WANG, J; KANDEL, ER; ODELL, TJ			CAMKII REGULATES THE FREQUENCY-RESPONSE FUNCTION OF HIPPOCAMPAL SYNAPSES FOR THE PRODUCTION OF BOTH LTD AND LTP	CELL			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; SQUID GIANT SYNAPSE; II MUTANT MICE; VISUAL-CORTEX; CA-2+-INDEPENDENT ACTIVITY; AUTOPHOSPHORYLATION SITES; NEUROTRANSMITTER RELEASE; AREA CA1; CALMODULIN	To investigate the function of the autophosphorylated form of CaMKII in synaptic plasticity, we generated transgenic mice that express a kinase that is Ca2+ independent as a result of a point mutation of Thr-286 to aspartate, which mimics autophosphorylation. Mice expressing the mutant form of the kinase show an increased level of Ca2+-independent CaMKII activity similar to that seen following LTP. The mice nevertheless exhibit normal LTP in response to stimulation at 100 Hz. However, at lower frequencies, in the range of 1-10 Hz, there is a systematic shift in the size and direction of the resulting synaptic change in the transgenic animals that favors LTD. The regulation of this frequency-response function by Ca2+-independent CaMKII activity seems to account for two previously unexplained synaptic phenomena, the relative loss of LTD in adult animals compared with juveniles and the enhanced capability for depression of facilitated synapses.			MAYFORD, M (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,HOWARD HUGHES MED INST,NEW YORK,NY 10032, USA.			Mayford, Mark/0000-0002-9001-5024	NIMH NIH HHS [MH50733] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; BACH ME, 1995, CELL, V81; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; BEAR MF, 1990, J NEUROSCI, V10, P909; BEARMF, 1994, CURR OPIN NEUROBIOL, V4, P389; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; CLINE HT, 1990, J NEUROSCI, V10, P1197; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; DUDEK SM, 1993, J NEUROSCI, V13, P2910; FONG YL, 1989, J BIOL CHEM, V264, P16759; FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; GOODMAN CS, 1993, NEURON S, V10, P77; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HEBB DO, 1949, ORG BEHAVIOR; KAMIYA H, 1994, NATURE, V371, P603, DOI 10.1038/371603a0; LIN JW, 1990, P NATL ACAD SCI USA, V87, P8257, DOI 10.1073/pnas.87.21.8257; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LOU LL, 1989, J NEUROSCI, V9, P2020; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1992, NEURON, V9, P121, DOI 10.1016/0896-6273(92)90227-5; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MILLER SG, 1985, J BIOL CHEM, V260, P9039; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; MULLER D, 1989, DEV BRAIN RES, V49, P105, DOI 10.1016/0165-3806(89)90063-1; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; O'Dell T J, 1994, Learn Mem, V1, P129; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SEJNOWSKI TJ, 1977, J MATH BIOL, V4, P303, DOI 10.1007/BF00275079; SHATZ CJ, 1928, SCIENCE, V242, P87; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STAUBLI U, 1990, BRAIN RES, V513, P113, DOI 10.1016/0006-8993(90)91096-Y; STEVENS CF, 1994, CURR BIOL, V4, P687, DOI 10.1016/S0960-9822(00)00153-6; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; STRYKER MP, 1986, J NEUROSCI, V6, P2117; SUNYER T, 1990, P NATL ACAD SCI USA, V87, P278, DOI 10.1073/pnas.87.1.278; TAN SE, 1994, J NEUROSCI, V14, P1123, DOI 10.1523/JNEUROSCI.14-03-01123.1994; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002	61	431	459	0	16	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					891	904		10.1016/0092-8674(95)90009-8	http://dx.doi.org/10.1016/0092-8674(95)90009-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781066	hybrid			2022-12-24	WOS:A1995RD76800010
J	VANDIJK, MR; WATERS, AP; JANSE, CJ				VANDIJK, MR; WATERS, AP; JANSE, CJ			STABLE TRANSFECTION OF MALARIA PARASITE BLOOD STAGES	SCIENCE			English	Article							PLASMODIUM-BERGHEI; TRYPANOSOMA-BRUCEI; HOMOLOGOUS RECOMBINATION; PYRIMETHAMINE RESISTANCE; TOXOPLASMA-GONDII; GENE REPLACEMENT; TRANSFORMATION; EXPRESSION; FALCIPARUM; MUTATIONS	Genetic manipulation of malaria parasites would revolutionize the study of this group of pathogens and have implications for vaccine and drug development. This report describes the stable, drug-selectable genetic transformation of the clinically relevant intracellular blood stages of a malaria parasite. A plasmid transfection vector carrying the gene locus that encodes a drug-resistant form of the bifunctional enzyme dihydrofolate reductase-thymidylate synthase from the rodent malaria parasite Plasmodium berghei was constructed. Derivatives of this vector were introduced into merozoites of P. berghei by electroporation, and parasites were selected for successful transformation in the rodent host on the basis of resistance to pyrimethamine. The plasmids were present in a circular, unrearranged form that replicated episomally to an observed maximum of 15 copies per cell in drug-resistant populations.	LEIDEN UNIV,DEPT PARASITOL,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC			Waters, Andy P/C-9377-2009	Waters, Andy P/0000-0001-8900-2982; Janse, Chris J/0000-0002-6410-6205				BELLOFATTO V, 1991, P NATL ACAD SCI USA, V88, P6711, DOI 10.1073/pnas.88.15.6711; COWMAN AF, 1988, P NATL ACAD SCI USA, V85, P9109, DOI 10.1073/pnas.85.23.9109; COWMAN AF, 1990, MOL BIOCHEM PARASIT, V42, P21, DOI 10.1016/0166-6851(90)90109-Y; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; DONALD RGK, 1993, P NATL ACAD SCI USA, V90, P11703, DOI 10.1073/pnas.90.24.11703; DONALD RGK, 1993, MOL BIOCHEM PARASIT, V63, P243; DORE E, 1990, MOL CELL BIOL, V10, P2423, DOI 10.1128/MCB.10.5.2423; EID J, 1991, P NATL ACAD SCI USA, V88, P2118, DOI 10.1073/pnas.88.6.2118; GOONEWARDENE R, 1993, P NATL ACAD SCI USA, V90, P5234, DOI 10.1073/pnas.90.11.5234; JANSE CJ, 1989, INT J PARASITOL, V19, P509, DOI 10.1016/0020-7519(89)90080-5; JANSE CJ, 1984, INT J PARASITOL, V14, P317, DOI 10.1016/0020-7519(84)90083-3; JANSE CJ, 1986, MOL BIOCHEM PARASIT, V20, P173, DOI 10.1016/0166-6851(86)90029-0; JANSE CJ, 1994, METHOD CELL BIOL, V42, P296; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KIM K, 1993, SCIENCE, V262, P911, DOI 10.1126/science.8235614; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; LONG CA, 1993, CURR OPIN IMMUNOL, V5, P548, DOI 10.1016/0952-7915(93)90036-R; MONS B, 1985, PARASITOLOGY, V91, P423, DOI 10.1017/S0031182000062673; NARDIN EH, 1993, ANNU REV IMMUNOL, V11, P687, DOI 10.1146/annurev.iy.11.040193.003351; PAPADOPOULOU B, 1994, MOL BIOCHEM PARASIT, V65, P39, DOI 10.1016/0166-6851(94)90113-9; PATON MG, 1993, MOL BIOCHEM PARASIT, V59, P263, DOI 10.1016/0166-6851(93)90224-L; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114; TANAKA M, 1990, MOL BIOCHEM PARASIT, V39, P127, DOI 10.1016/0166-6851(90)90015-E; TENASBROEK ALMA, 1993, MOL BIOCHEM PARASIT, V59, P133, DOI 10.1016/0166-6851(93)90014-O; VANDIJK MR, 1994, MOL BIOCHEM PARASIT, V68, P167, DOI 10.1016/0166-6851(94)00163-4; VANDIJK MR, UNPUB; VINKENOOG R, IN PRESS MOL BIOCH P; WU Y, 1995, P NATL ACAD SCI USA, V91, P973	29	192	197	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1358	1362		10.1126/science.7761856	http://dx.doi.org/10.1126/science.7761856			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761856				2022-12-24	WOS:A1995RB19800041
J	HINTON, GE; DAYAN, P; FREY, BJ; NEAL, RM				HINTON, GE; DAYAN, P; FREY, BJ; NEAL, RM			THE WAKE-SLEEP ALGORITHM FOR UNSUPERVISED NEURAL NETWORKS	SCIENCE			English	Article								An unsupervised learning algorithm for a multilayer network of stochastic neurons is described. Bottom-up ''recognition'' connections convert the input into representations in successive hidden layers, and top-down ''generative'' connections reconstruct the representation in one layer from the representation in the layer above. In the ''wake'' phase, neurons are driven by recognition connections, and generative connections are adapted to increase the probability that they would reconstruct the correct activity vector in the layer below. In the ''sleep'' phase, neurons are driven by generative connections, and recognition connections are adapted to increase the probability that they would produce the correct activity vector in the layer above.			HINTON, GE (corresponding author), UNIV TORONTO, DEPT COMP SCI, 6 KINGS COLL RD, TORONTO, ON M5S 1A4, CANADA.			Dayan, Peter/0000-0003-3476-1839				Barlow HB, 1989, NEURAL COMPUT, V1, P295, DOI 10.1162/neco.1989.1.3.295; CARPENTER GA, 1987, COMPUT VISION GRAPH, V37, P54, DOI 10.1016/S0734-189X(87)80014-2; DAYAN P, IN PRESS NEURAL COMP; GRENANDER U, 1976, LECTURES PATTERN THE; HASSELMO ME, 1993, TRENDS NEUROSCI, V16, P218, DOI 10.1016/0166-2236(93)90159-J; Hinton G.E., 1994, ADV NEURAL INFORM PR, P3, DOI DOI 10.1021/jp906511z; JORDAN MI, 1992, COGNITIVE SCI, V16, P307, DOI 10.1207/s15516709cog1603_1; KAWATO M, 1993, NETWORK-COMP NEURAL, V4, P415, DOI 10.1088/0954-898X/4/4/001; MUMFORD D, 1994, LARGE SCALE NEURONAL, P125; Rissanen J., 1989, STOCHASTIC COMPLEXIT; ULLMAN S, 1994, LARGE SCALE THEORIES, P257	11	520	572	1	99	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	1995	268	5214					1158	1161		10.1126/science.7761831	http://dx.doi.org/10.1126/science.7761831			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761831				2022-12-24	WOS:A1995RA60400031
J	KELLY, DA; STANTON, A				KELLY, DA; STANTON, A			JAUNDICE IN BABIES - IMPLICATIONS FOR COMMUNITY SCREENING FOR BILIARY ATRESIA	BRITISH MEDICAL JOURNAL			English	Article								Although prompt referral of babies with biliary atresia ensures early surgery and improves outcome,(1) late referral persists in the United Kingdom, leading to calls for systematic screening of babies with neonatal jaundice persisting beyond 14 days.(2) This would entail reviewing the baby, establishing whether the stool is pigmented, testing urine for bilirubin, and measuring blood concentrations of conjugated and unconjugated bilirubin.(2 3) To evaluate the feasibility of systematic screening, we ascertained the prevalence of (a) jaundice in babies aged 2, 4, and 6 weeks, and (b) dark urine or pale stools as reported by the parents or a health visitor. We also established how often stools or urine of jaundiced babies were noted by health visitors at their first visit to gauge the effect on workload.	SOLIHULL HEALTHCARE NATL HLTH SERV TRUST,BIRMINGHAM B37 7XR,W MIDLANDS,ENGLAND; CHILDRENS HOSP,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND									FRIEDMAN L, 1978, BRIT MED J, V1, P1235, DOI 10.1136/bmj.1.6122.1235; HUSSEIN M, 1991, ARCH DIS CHILD, V66, P1177, DOI 10.1136/adc.66.10.1177; MACKINLAY GA, 1993, BRIT MED J, V306, P1426, DOI 10.1136/bmj.306.6890.1426; NELSON R, 1989, BRIT MED J, V298, P1471, DOI 10.1136/bmj.298.6686.1471; WINFIELD CR, 1978, ARCH DIS CHILD, V53, P506, DOI 10.1136/adc.53.6.506	5	35	38	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1172	1173		10.1136/bmj.310.6988.1172	http://dx.doi.org/10.1136/bmj.310.6988.1172			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX566	7767152	Green Published			2022-12-24	WOS:A1995QX56600029
J	STOOP, R; POO, MM				STOOP, R; POO, MM			POTENTIATION OF TRANSMITTER RELEASE BY CILIARY NEUROTROPHIC FACTOR REQUIRES SOMATIC SIGNALING	SCIENCE			English	Article							LEUKEMIA INHIBITORY FACTOR; SPINAL-CORD NEURONS; NEUROMUSCULAR SYNAPSES; SYMPATHETIC NEURONS; RECEPTOR COMPONENT; SCIATIC-NERVE; FACTOR CNTF; ADULT-RAT; CULTURE; EXPRESSION	Neurotrophic factors participate in the development and maintenance of the nervous system. Application of ciliary neurotrophic factor (CNTF), a protein that promotes survival of motor neurons, resulted in an immediate potentiation of spontaneous and impulse-evoked transmitter release at developing neuromuscular synapses in Xenopus cell cultures. When CNTF was applied al the synapse, the onset of the potentiation was slower than that produced by application at the cell body of the presynaptic neuron. The potentiation effect was abolished when-the neurite shaft was severed from the cell body. Thus, transmitter secretion from the nerve terminals is under immediate somatic control and can be regulated by CNTF.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University								ADLER R, 1979, SCIENCE, V204, P1434, DOI 10.1126/science.451576; ALLEN RD, 1982, SCIENCE, V218, P1127, DOI 10.1126/science.6183744; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BLAIR LAC, 1983, J NEUROSCI, V3, P1430; BLOTTNER D, 1989, NEUROSCI LETT, V105, P316, DOI 10.1016/0304-3940(89)90640-X; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; COHEN MW, 1987, J NEUROSCI, V7, P2849; CURTIS R, 1993, NATURE, V365, P253, DOI 10.1038/365253a0; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; DAN Y, 1992, NATURE, V359, P733, DOI 10.1038/359733a0; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Davis S, 1993, Curr Opin Neurobiol, V3, P20, DOI 10.1016/0959-4388(93)90030-3; ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7; EVERS J, 1989, J NEUROSCI, V9, P1523; FRIEDMAN B, 1992, NEURON, V9, P295, DOI 10.1016/0896-6273(92)90168-D; GRAFI G, 1993, FEBS LETT, V336, P403, DOI 10.1016/0014-5793(93)80846-M; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; IP NY, 1991, J NEUROSCI, V11, P3124; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KALBERG C, 1993, J NEUROCHEM, V60, P145, DOI 10.1111/j.1471-4159.1993.tb05832.x; Kandel E.R., 1991, PRINC NEUROSCI; KIDOKORO Y, 1988, P NATL ACAD SCI USA, V85, P1978, DOI 10.1073/pnas.85.6.1978; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; ODOWD DK, 1983, NATURE, V303, P619, DOI 10.1038/303619a0; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; POPOV S, 1992, J NEUROSCI, V12, P77; Purves, 1985, PRINCIPLES NEURAL DE; RENDE M, 1992, GLIA, V5, P25, DOI 10.1002/glia.440050105; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SKAPER SD, 1986, DEV BRAIN RES, V24, P39, DOI 10.1016/0165-3806(86)90171-9; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; Tabti N., 1991, CULTURING NERVE CELL, P137; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0	44	119	121	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	1995	267	5198					695	699		10.1126/science.7839148	http://dx.doi.org/10.1126/science.7839148			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839148				2022-12-24	WOS:A1995QE73300043
J	KOMIYAMA, NH; MIYAZAKI, G; TAME, J; NAGAI, K				KOMIYAMA, NH; MIYAZAKI, G; TAME, J; NAGAI, K			TRANSPLANTING A UNIQUE ALLOSTERIC EFFECT FROM CROCODILE INTO HUMAN HEMOGLOBIN	NATURE			English	Article							ESCHERICHIA-COLI; CARBON-DIOXIDE; HEMOGLOBIN; BINDING	CROCODILES are able to remain under water for more than one hour without surfacing to breathe(1,2) and often kill their prey by drowning it. How do crocodiles stay under water for a long time? When they hold their breath, bicarbonate ions, the final product of respiration, accumulate and drastically reduce the oxygen affinity of haemoglobin, releasing it large fraction of haemoglobin-bound oxygen into the tissues(3,4). We have now located the bicarbonate-ion-binding site at the alpha(1) beta(2)-subunit interface by making various human-crocodile chimaeric haemoglobins. Furthermore, we have been able to transplant the bicarbonate effect into human haemoglobin by replacing only a few residues, even though the amino-acid sequence identity between crocodile (Crocodylus niloticus) and human haemoglobins is only 68% for the alpha- and 51% for the beta-subunit(5). These results indicate that an entirely new function which enables species to adapt to a new environment could evolve in a protein by a relatively small number of amino-acid substitutions in key positions(6).	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS,TOYONAKA,OSAKA 560,JAPAN	MRC Laboratory Molecular Biology; Osaka University				Tame, Jeremy/0000-0002-9341-7280				ANDERSEN HT, 1961, ACTA PHYSIOL SCAND, V53, P23, DOI 10.1111/j.1748-1716.1961.tb02261.x; BAUER C, 1977, NATURE, V269, P825, DOI 10.1038/269825a0; BAUER C, 1981, J BIOL CHEM, V256, P8429; COTT H. B., 1961, TRANS ZOOL SOC LONDON, V29, P211; FEMI G, 1981, ATLAS MOL STRUCTURE, V2; GRIGG GC, 1993, J EXP BIOL, V175, P15; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; IKEMURA T, 1982, J MOL BIOL, V158, P573, DOI 10.1016/0022-2836(82)90250-9; Imai K, 1981, Methods Enzymol, V76, P438; KIMURA M, 1971, SCI AM, V241, P94; KOMIYAMA NH, 1991, NATURE, V352, P349, DOI 10.1038/352349a0; Kooyman G.L., 1989, DIVERSE DIVERS PHYSL; LECLERCQ F, 1981, H-S Z PHYSIOL CHEM, V362, P1151; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1981, NATURE, V291, P682, DOI 10.1038/291682a0; PERUTZ MF, 1983, MOL BIOL EVOL, V1, P1; TAME JRH, 1989, THESIS U CAMBRIDGE; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4	19	72	73	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					244	246		10.1038/373244a0	http://dx.doi.org/10.1038/373244a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816138				2022-12-24	WOS:A1995QC27800063
J	SPRAY, JG; THOMPSON, LM				SPRAY, JG; THOMPSON, LM			FRICTION MELT DISTRIBUTION IN A MULTIRING IMPACT BASIN	NATURE			English	Article							SUDBURY STRUCTURE; VREDEFORT DOME; COESITE	IT is generally accepted that multi-ring basins are the consequence of very large impacts, but the mechanism by which they form is still a matter of contention(1,2). Most of what is currently known about multi-ring basins is based on remote studies of the Moon(3-5) and, to a lesser extent, Mars and Mercury(4,6). But at least two multi-ring impact basins have been recognized on Earth(7)-the Sudbury(8) (Canada) and Vredefort(9) (South Africa) impact structures-providing an opportunity to study their properties directly. Here we describe the distribution of friction melt (pseudotachylyte) in the floor of the Sudbury impact basin. Although the veins and dykes of pseudotachylyte decrease in both thickness and frequency of occurrence towards the basin periphery, the greatest volumes of friction melt appear to define four rings around the central impact melt sheet. Field evidence indicates that the rings originated as zones of large displacement, which facilitated localized frictional melting of the basin floor during the modification (collapse) stage of the cratering process. By analogy, we argue that the rings of other multi-ring impact basins are also likely to be the remnants of such large-displacement fault zones.			SPRAY, JG (corresponding author), UNIV NEW BRUNSWICK,DEPT GEOL,FREDERICTON,NB E3B 5A3,CANADA.		Spray, John/J-7504-2013	Spray, John/0000-0003-3418-6862				[Anonymous], 1984, ONTARIO GEOLOGICAL S, V1, P97; Baldwin R. B., 1972, Physics of the Earth and Planetary Interiors, V6, P327, DOI 10.1016/0031-9201(72)90056-8; Baldwin R. B., 1963, MEASURE MOON, P488; BUTLER HR, IN PRESS LARGE METEO; CHUBB PT, IN PRESS CAN J EARTH; Dence M.R., 1977, IMPACT EXPLOSION CRA, P247; DENCE MR, 1972, SPEC PAP GEOL ASS CA, V10, P7; DIETZ RS, 1964, J GEOL, V72, P412, DOI 10.1086/626999; Dressler B.O., 1987, RES TERRESTRIAL IMPA, P39; DRESSLER BO, 1984, GEOL ORE DEPOSIT+, P97; DRESSLER BO, 1980, 196 ONT MIN NAT RES; FAGGART BE, 1985, SCIENCE, V230, P436, DOI 10.1126/science.230.4724.436; Grieve R. B., 1981, Proceedings of the Heartworm Symposium '80, Dallas, Texas, 23-24 February 1980., P37; GRIEVE RAF, 1991, J GEOPHYS RES-PLANET, V96, P22753, DOI 10.1029/91JE02513; Hartmann W. K., 1971, Moon, V3, P3, DOI 10.1007/BF00620390; Hartmann W.K., 1962, COMMUN LUNAR PLANET, V1, P51; HARTMANN WK, 1969, SKY TELESCOPE, V37, P4; HODGES CA, 1978, ICARUS, V34, P294, DOI 10.1016/0019-1035(78)90169-0; LAMBERT P, 1981, P LUNAR PLANET SCI, V12, P59; MARTINI JEJ, 1992, J METAMORPH GEOL, V10, P517, DOI 10.1111/j.1525-1314.1992.tb00102.x; MARTINI JEJ, 1991, EARTH PLANET SC LETT, V103, P285, DOI 10.1016/0012-821X(91)90167-G; Melosh H. J, 1989, IMPACT CRATERING GEO, DOI DOI 10.1103/PHYSREVB.46.10411; MELOSH HJ, 1978, GEOPHYS RES LETT, V5, P985, DOI 10.1029/GL005i011p00985; MELOSH HJ, 1979, J GEOPHYS RES, V84, P7513, DOI 10.1029/JB084iB13p07513; MILKEREIT B, 1992, GEOLOGY, V20, P807, DOI 10.1130/0091-7613(1992)020<0807:DGOTSS>2.3.CO;2; PEREDERY WV, 1984, GEOLOGY ORE DEPOSITS, P491; PIKE RJ, 1987, EARTH MOON PLANETS, V39, P129, DOI 10.1007/BF00054060; Shand S.J., 1916, Q J GEOL SOC, V72, P198, DOI [10.1144/GSL.JGS.1916.072.01-04.12, DOI 10.1144/GSL.JGS.1916.072.01-04.12]; SHANKS WS, 1991, CAN J EARTH SCI, V28, P1677, DOI 10.1139/e91-149; SPEERS EC, 1947, J GEOL, V65, P497; SPRAY JG, 1993, J GEOPHYS RES-SOL EA, V98, P8053, DOI 10.1029/93JB00020; SPRAY JG, 1992, TECTONOPHYSICS, V204, P205, DOI 10.1016/0040-1951(92)90308-S; SPRAY JG, 1987, J STRUCT GEOL, V7, P49; SPUDIS PD, 1993, GEOLOGY MULTIRING IM, P263; THOMPSON LM, 1993, EOS, V74, P389; WICHMAN RW, 1993, METEORITICS, V28, P222, DOI 10.1111/j.1945-5100.1993.tb00760.x; Wood C.A., 1976, P LUNAR PLANET SCI C, P3629	37	116	117	1	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					130	132		10.1038/373130a0	http://dx.doi.org/10.1038/373130a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816095				2022-12-24	WOS:A1995QB06300051
J	SEUFERT, W; FUTCHER, B; JENTSCH, S				SEUFERT, W; FUTCHER, B; JENTSCH, S			ROLE OF A UBIQUITIN-CONJUGATING ENZYME IN DEGRADATION OF S-PHASE AND M-PHASE CYCLINS	NATURE			English	Article							YEAST-CELL CYCLE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; PROTEOLYSIS; ENCODES; KINASE; CDC28; ANAPHASE; PATHWAY; MITOSIS	CELL cycle progression in eukaryotes is controlled by the p34(cdc2/CDC28) protein kinase and its short-lived, phase-specific regulatory subunits called cyclins(1,2). In Xenopus oocytes, degradation of M-phase (B-type) cyclins is required for exit from mitosis and is mediated by the ubiquitin-dependent proteolytic system(3). Here we show that B-type-cyclin degradation in yeast involves an essential nuclear ubiquitin-conjugating enzyme, UBC9. Repression of UBC9 synthesis prevents cell cycle progression at the G2 or early M phase, causing the accumulation of large budded cells with a single nucleus, a short spindle and replicated DNA. In ubc9 mutants both CLB5, an S-phase cyclin(4,5), and CLB2, an M-phase cyclin(6,7), are stabilized. In wild-type cells the CLB5 protein is unstable throughout the cell cycle, whereas CLB2 turnover occurs only at a specific cell-cycle stage(8). Thus distinct degradation signals or regulated interaction,vith the ubiquitin-protein ligase system may determine the cell-cycle specificity of cyclin proteolysis.	MAX PLANCK GESELL,FRIEDRICH MIESCHER LAB,D-72076 TUBINGEN,GERMANY; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Eberhard Karls University of Tubingen; Max Planck Society; Cold Spring Harbor Laboratory			Seufert, Wolfgang/F-7136-2019	Seufert, Wolfgang/0000-0001-8938-9064				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Ausubel FM, 1994, CURRENT PROTOCOLS MO; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; ELLISON KS, 1991, J BIOL CHEM, V266, P24116; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1992, ANNU REV GENET, V26, P177; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0	30	440	454	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					78	81		10.1038/373078a0	http://dx.doi.org/10.1038/373078a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800043				2022-12-24	WOS:A1995QA23900060
J	SUGAWARA, N; IVANOV, EL; FISHMANLOBELL, J; RAY, BL; WU, X; HABER, JE				SUGAWARA, N; IVANOV, EL; FISHMANLOBELL, J; RAY, BL; WU, X; HABER, JE			DNA STRUCTURE-DEPENDENT REQUIREMENTS FOR YEAST RAD GENES IN GENE CONVERSION	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; MATING-TYPE; NUCLEOTIDE-SEQUENCE; REPAIR; RECOMBINATION; CASSETTE; PROTEIN	IN Saccharomyces cerevisiae, HO endonuclease-induced mating-type (MAT) switching is a specialized mitotic recombination event in which MAT sequences are replaced by those copied from a distant, unexpressed donor (HML or HMR)(1,2). The donors have a chromatin structure inaccessible for both transcription and HO cleavage(1,2). Here we use physical monitoring of DNA to show that MAT switching is completely blocked at an early step in recombination in strains deleted for the DNA repair genes RAD51, RAD52, RAD54, RAD55 or RAD57. We find, however, that only RAD52 is required when the donor sequence is simultaneously not silenced and located on a plasmid. RAD51, RAD54, RAD55 and RAD57 are still required when the same transcribed donor is on the chromosome. We conclude that recombination in vivo occurs between DNA molecules in chromatin, whose structure significantly influences the outcome. RAD51, RAD54, RAD55 and RAD57 are all required to facilitate strand invasion into otherwise inaccessible donor sequences.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254	Brandeis University; Brandeis University				Haber, James/0000-0002-1878-0610				ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; BANG DD, 1992, NUCLEIC ACIDS RES, V20, P3925, DOI 10.1093/nar/20.15.3925; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; BRAND AH, 1985, CELL, P41; COLLINS I, 1994, MOL CELL BIOL, V14, P3524, DOI 10.1128/MCB.14.5.3524; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; HABER JE, 1993, P NATL ACAD SCI USA, V90, P3363, DOI 10.1073/pnas.90.8.3363; HABER JE, 1992, TRENDS GENET, V8, P446, DOI 10.1016/0168-9525(92)90329-3; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; JENSEN RE, 1984, COLD SPRING HARB SYM, V49, P97, DOI 10.1101/SQB.1984.049.01.013; KANS JA, 1991, GENE, V105, P139, DOI 10.1016/0378-1119(91)90527-I; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; LOVETT ST, 1987, GENETICS, V116, P547; MAHONEY DJ, 1989, MOL CELL BIOL, V9, P4621, DOI 10.1128/MCB.9.11.4621; MALONE RE, 1980, P NATL ACAD SCI-BIOL, V77, P503, DOI 10.1073/pnas.77.1.503; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; NICKOLOFF JA, 1989, J MOL BIOL, V207, P527, DOI 10.1016/0022-2836(89)90462-2; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RATTRAY A, IN PRESS GENETICS; RAVEH D, 1989, MOL GEN GENET, V220, P33; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, P202; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SIMPSON RT, 1993, PROGR NUCLEIC ACIDS, V40, P1896; STRATHERN JN, 1989, GENETIC RECOMBINATIO, P445; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; [No title captured]	30	160	164	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					84	86		10.1038/373084a0	http://dx.doi.org/10.1038/373084a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800045				2022-12-24	WOS:A1995QA23900062
J	WADE, MJ; CHANG, NW				WADE, MJ; CHANG, NW			INCREASED MALE-FERTILITY IN TRIBOLIUM-CONFUSUM BEETLES AFTER INFECTION WITH THE INTRACELLULAR PARASITE WOLBACHIA	NATURE			English	Article							CYTOPLASMIC INCOMPATIBILITY; DROSOPHILA-SIMULANS; FLOUR BEETLES; INHERITANCE; POPULATIONS; SPECIATION; SYMBIONT; SPREAD	THE cytoplasmically inherited microorganism Wolbachia pipientis behaves like a sexually selected trait in its host, the flour beetle Tribolium confusum, enhancing male fertility at the expense of female fecundity. Here we show that infected females have fewer offspring than uninfected females but infected males have a large fertility advantage over uninfected males within multiply-inseminated infected or uninfected females. The male fertility effect accelerates the spread of the Wolbachia through the host population and expands the initial opportunity for hitch-hiking of host nuclear genes. Sperm competition in a host, mediated by endosymbionts, has not been previously described.			WADE, MJ (corresponding author), UNIV CHICAGO,DEPT ECOL & EVOLUT,1101 E 57TH ST,CHICAGO,IL 60637, USA.							Breeuwer J.A.J., 1992, Insect Molecular Biology, V1, P25, DOI 10.1111/j.1365-2583.1993.tb00074.x; BREEWUER JAJ, 1990, NATURE, V348, P558; HOFFMANN AA, 1988, GENETICS, V119, P435; HOLDEN PR, 1993, GENET RES, V62, P23, DOI 10.1017/S0016672300031529; KAMBHAMPATI S, 1993, EVOLUTION, V47, P673, DOI [10.2307/2410079, 10.1111/j.1558-5646.1993.tb02121.x]; LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/pnas.78.6.3721; MONTCHAMPMOREAU C, 1991, GENETICS, V129, P399; MORAN N, 1994, TRENDS ECOL EVOL, V9, P15, DOI 10.1016/0169-5347(94)90226-7; ONEILL SL, 1990, NATURE, V348, P178, DOI 10.1038/348178a0; ONEILL SL, 1992, P NATL ACAD SCI USA, V89, P2649; PARK T, 1933, EXP ZOOL, V65, P17; RICHARDSON PM, 1987, J INVERTEBR PATHOL, V50, P176, DOI 10.1016/0022-2011(87)90080-2; ROBINSON T, 1994, HEREDITY, V73, P155, DOI 10.1038/hdy.1994.114; ROUSSET F, 1991, TRENDS ECOL EVOL, V6, P54, DOI 10.1016/0169-5347(91)90123-F; ROUSSET F, 1993, HEREDITY, V72, P325; STEVENS L, 1990, GENETICS, V124, P367; STEVENS L, 1993, ANIM BEHAV, V46, P305, DOI 10.1006/anbe.1993.1191; STOUTHAMER R, 1993, NATURE, V361, P66, DOI 10.1038/361066a0; SUBBARAO SK, RECENT DEV GENETICS, P313; THOMPSON JN, 1987, BIOL J LINN SOC, V32, P385, DOI 10.1111/j.1095-8312.1987.tb00439.x; TRPIS MJ, 1993, J HERED, V72, P313; TURELLI M, 1992, GENETICS, V132, P713; TURELLI M, 1991, NATURE, V353, P440, DOI 10.1038/353440a0; WADE MJ, 1985, SCIENCE, V227, P527, DOI 10.1126/science.3966160; WADE MJ, 1994, J THEOR BIOL, V167, P81, DOI 10.1006/jtbi.1994.1052; WADE MJ, 1994, HEREDITY, V72, P163, DOI 10.1038/hdy.1994.23; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443	28	102	108	1	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					72	74		10.1038/373072a0	http://dx.doi.org/10.1038/373072a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800041				2022-12-24	WOS:A1995QA23900058
J	ZHAO, C; EMMONS, SW				ZHAO, C; EMMONS, SW			A TRANSCRIPTION FACTOR CONTROLLING DEVELOPMENT OF PERIPHERAL SENSE-ORGANS IN C-ELEGANS	NATURE			English	Article							CAENORHABDITIS-ELEGANS; DROSOPHILA-MELANOGASTER; NERVOUS-SYSTEM; CELL LINEAGES; MYC HOMOLOGY; DNA-BINDING; GENE; NEMATODE; ACHAETE; REGION	THE basic-helix-loop-helix (bHLH) proteins constitute a class of transcription factors thought to be important in the control of cell-type determination(1). These transcription factors are believed to activate the expression of cell-type-specific genes to generate stable differentiated cell types(2). The expression of bHLH proteins, in turn, is regulated by spatial cues, so that switches in cell type occur in a reproducible pattern(3). We report here that the lin-32 gene of Caenorhabditis elegans, which encodes a bHLH protein of the Drosophila achaete-scute family of transcription factors, is necessary and in some cells sufficient for specification of the neuroblast cell fate. Similarity in the function and structure of the lin-32 protein (LIN-32) to transcription factors of the achaete-scute gene family in Drosophila and vertebrates implies that this class of transcription factors functioned in a primitive ancestral form to specify neuronal cell fate, supporting the proposition that certain basic mechanisms of cell-type determination have been conserved through metazoan evolution(1).			ZHAO, C (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC GENET,1300 MORRIS PK AVE,BRONX,NY 10461, USA.							ALBERTSON DG, 1993, GENETICS, V134, P211; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; BAIRD SE, 1991, DEVELOPMENT, V113, P515; BEGLEY CG, 1989, P NATL ACAD SCI USA, V88, P10128; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; GONZALEZ F, 1989, EMBO J, V8, P3553, DOI 10.1002/j.1460-2075.1989.tb08527.x; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; HODGKIN J, 1983, NATURE, V304, P267, DOI 10.1038/304267a0; HORVITZ HR, 1983, COLD SPRING HARB SYM, V43, P453; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PLENEFISCH JD, 1989, GENETICS, V121, P57; RUVKUN G, 1989, GENETICS, V121, P501; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	30	108	112	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					74	78		10.1038/373074a0	http://dx.doi.org/10.1038/373074a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800042				2022-12-24	WOS:A1995QA23900059
J	CURREY, J				CURREY, J			COME BACK DDT - ALL IS FORGIVEN	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1692	1692		10.1136/bmj.309.6970.1692	http://dx.doi.org/10.1136/bmj.309.6970.1692			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819990	Green Published			2022-12-24	WOS:A1994PY71700016
J	RICHARD, P; DELVALLE, GA; MOREAU, P; MILPIED, N; FELICE, MP; DAESCHLER, T; HAROUSSEAU, JL; RICHET, H				RICHARD, P; DELVALLE, GA; MOREAU, P; MILPIED, N; FELICE, MP; DAESCHLER, T; HAROUSSEAU, JL; RICHET, H			VIRIDANS STREPTOCOCCAL BACTEREMIA IN PATIENTS WITH NEUTROPENIA	LANCET			English	Note							MARROW TRANSPLANT RECIPIENTS; SEPTICEMIA; SEPSIS	Viridans streptococcal bacteraemia is frequent in neutropenic patients. 25 neutropenic patients with viridans streptococcal bacteraemia were compared with 64 control patients. Exposure to repeated chemotherapy or cytarabine were independent risk-factors for streptococcal bacteraemia. The use of carboxyureidopenicillins and stay in laminar-airflow rooms were protective. In a further cohort study of 49 patients, oral streptococci with the same ribotype as blood isolates were recovered from all 7 bacteraemic patients. The oral cavity is a portal of entry for viridans streptococci bacteraemia in neutropenic patients, especially after oral mucosal damage induced by repeated chemotherapy.	HOP HOTEL DIEU,FAC CHIRURG DENT,F-44035 NANTES,FRANCE; HOP HOTEL DIEU,SERV HEMATOL,F-44035 NANTES,FRANCE	Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes	RICHARD, P (corresponding author), HOP HOTEL DIEU,INST MED BIOL,BACTERIOL LAB A,F-44035 NANTES,FRANCE.			moreau, philippe/0000-0003-1780-8746; Milpied, Noel/0000-0002-5177-014X				BOCHUD PY, 1994, CLIN INFECT DIS, V1, P25; BOSTROM B, 1984, LANCET, V1, P1120; CLASSEN DC, 1990, AM J MED, V89, P441, DOI 10.1016/0002-9343(90)90373-L; COHEN J, 1983, LANCET, V2, P1452, DOI 10.1016/S0140-6736(83)90799-7; ELTING LS, 1994, CLIN INFECT DIS, V14, P1201; HENSLEE J, 1984, LANCET, V1, P393; MASCRET B, 1984, LANCET, V1, P1185; RINGDEN O, 1984, LANCET, V1, P744; VALTEAU D, 1991, BONE MARROW TRANSPL, V7, P415	9	81	82	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1607	1609		10.1016/S0140-6736(95)90117-5	http://dx.doi.org/10.1016/S0140-6736(95)90117-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783538				2022-12-24	WOS:A1995RE67000010
J	DATTA, A; JINKSROBERTSON, S				DATTA, A; JINKSROBERTSON, S			ASSOCIATION OF INCREASED SPONTANEOUS MUTATION-RATES WITH HIGH-LEVELS OF TRANSCRIPTION IN YEAST	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; INDUCED MUTAGENESIS; GENE; RAD6; RECOMBINATION; DISRUPTION; RADIATION; STRAINS; CELLS; CONSTRUCTION	Complex processes such as transcription, replication, repair, and recombination require changes in chromatin structure and the interactions of numerous trans-acting factors with DNA sequences, raising the possibility that these processes may be interrelated. Here the effect of transcription on the rate of spontaneous mutation in the yeast Saccharomyces cerevisiae was examined. With the use of a lys2 frameshift allele under the control of a highly inducible promoter, the rate of spontaneous reversion was shown to increase when the mutant gene was highly transcribed. Thus, transcriptionally active DNA and enhanced spontaneous mutation rates are associated in yeast.	EMORY UNIV, GRAD PROGRAM BIOCHEM & MOLEC BIOL, ATLANTA, GA 30322 USA; EMORY UNIV, DEPT BIOL, ATLANTA, GA 30322 USA	Emory University; Emory University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038464, R29GM038464] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38464] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; BALBINDER E, 1970, GENETICS, V66, P31; BARTLETT JD, 1991, MUTAT RES, V255, P247, DOI 10.1016/0921-8777(91)90028-N; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; CASSIERCHAUVAT C, 1991, MUTAT RES, V254, P247, DOI 10.1016/0921-8777(91)90063-U; CHATTOO BB, 1979, GENETICS, V93, P51; Datta A., UNPUB; DAVIS BD, 1989, P NATL ACAD SCI USA, V86, P5005, DOI 10.1073/pnas.86.13.5005; DERR LK, 1993, NATURE, V361, P170, DOI 10.1038/361170a0; DERR LK, 1991, CELL, V67, P355, DOI 10.1016/0092-8674(91)90187-4; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; FLEIG UN, 1986, GENE, V46, P237, DOI 10.1016/0378-1119(86)90408-7; FOX MS, 1994, EXPERIENTIA, V50, P253, DOI 10.1007/BF01924008; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; GANGLOFF S, 1994, EXPERIENTIA, V50, P261, DOI 10.1007/BF01924009; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HERMAN RK, 1971, J BACTERIOL, V106, P543, DOI 10.1128/JB.106.2.543-550.1971; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, P193; KOMBERG RD, 1992, ANN REV CELL BIOL, V8, P563; KOROGODIN VI, 1991, YEAST, V7, P105, DOI 10.1002/yea.320070204; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; LAWRENCE CW, 1984, MOL GEN GENET, V195, P487, DOI 10.1007/BF00341451; LAWRENCE CW, 1976, GENETICS, V82, P207; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Luria SE, 1943, GENETICS, V28, P491; MELAMED C, 1992, MOL CELL BIOL, V12, P1613, DOI 10.1128/MCB.12.4.1613; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; PALOMBO F, 1992, J MOL BIOL, V223, P587, DOI 10.1016/0022-2836(92)90974-O; PLATT T, 1984, MOL CELL BIOL, V4, P994, DOI 10.1128/MCB.4.5.994; PRAKASH L, 1976, GENETICS, V83, P285; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; QUAH SK, 1980, GENETICS, V96, P819; RATTRAY AJ, 1994, GENETICS, V138, P587; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SAVIC DJ, 1972, MOL GEN GENET, V118, P45, DOI 10.1007/BF02428331; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; STEELE DF, 1992, GENETICS, V132, P9; STEELE DF, 1991, GENETICS, V127, P53; STRATHEM JN, IN PRESS GENETICS; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; TORCHIA TE, 1984, MOL CELL BIOL, V4, P1521, DOI 10.1128/MCB.4.8.1521; VONBORSTEL RC, 1971, GENETICS, V69, P17; WARTERS RL, 1987, MUTAT RES, V180, P21, DOI 10.1016/0027-5107(87)90063-7; WATKINS JF, 1993, GENE DEV, V7, P250, DOI 10.1101/gad.7.2.250	50	207	212	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 16	1995	268	5217					1616	1619		10.1126/science.7777859	http://dx.doi.org/10.1126/science.7777859			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7777859				2022-12-24	WOS:A1995RD45900037
J	NEED, AG; WISHART, JM; SCOPACASA, F; HOROWITZ, M; MORRIS, HA; NORDIN, BEC				NEED, AG; WISHART, JM; SCOPACASA, F; HOROWITZ, M; MORRIS, HA; NORDIN, BEC			EFFECT OF PHYSICAL-ACTIVITY ON FEMORAL BONE-DENSITY IN MEN	BRITISH MEDICAL JOURNAL			English	Article									ROYAL ADELAIDE HOSP,DEPT MED,ADELAIDE,SA 5000,AUSTRALIA; UNIV ADELAIDE,DEPT PATHOL,ADELAIDE,SA 5001,AUSTRALIA	Royal Adelaide Hospital; University of Adelaide	NEED, AG (corresponding author), INST MED & VET SCI,DIV CLIN BIOCHEM,ADELAIDE,SA 5000,AUSTRALIA.		Morris, Howard A/G-4564-2010; Morris, Howard/L-6272-2019					MCARDLE WD, 1986, EXERCISE PHYSL ENERG, P642; SLEMENDA CW, 1993, BONE MINER, V20, P125, DOI 10.1016/S0169-6009(08)80021-9; SNOWHARTER C, 1992, J BONE MINER RES, V7, P1291; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; WISHART JM, IN PRESS CLIN ENDOCR	5	14	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1501	1502		10.1136/bmj.310.6993.1501	http://dx.doi.org/10.1136/bmj.310.6993.1501			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787597	Green Published			2022-12-24	WOS:A1995RD28500022
J	FLOR, H; ELBERT, T; KNECHT, S; WIENBRUCH, C; PANTEV, C; BIRBAUMER, N; LARBIG, W; TAUB, E				FLOR, H; ELBERT, T; KNECHT, S; WIENBRUCH, C; PANTEV, C; BIRBAUMER, N; LARBIG, W; TAUB, E			PHANTOM-LIMB PAIN AS A PERCEPTUAL CORRELATE OF CORTICAL REORGANIZATION FOLLOWING ARM AMPUTATION	NATURE			English	Article							CORTEX	ALTHOUGH phantom-limb pain is a frequent consequence of the amputation of an extremity, little is known about its origin(1-4). On the basis of the demonstration of substantial plasticity of the somatosensory cortex after amputation(5) or somatosensory deafferentation in adult monkeys(6), it has been suggested that cortical reorganization could account for some non-painful phantom-limb phenomena in amputees and that cortical reorganization has an adaptive (that is, pain-preventing) function(2,5,7,8). Theoretical and empirical work on chronic back pain(9,10) has revealed a positive relationship between the amount of cortical alteration and the magnitude of pain, so we predicted that cortical reorganization and phantom-limb pain should be positively related. Using non-invasive neuromagnetic imaging techniques to determine cortical reorganization in humans(11-13), we report a very strong direct relationship (r = 0.93) between the amount of cortical reorganization and the magnitude of phantom limb pain (but not non-painful phantom phenomena) experienced after arm amputation. These data indicate that phantom-limb pain is related to, and may be a consequence of, plastic changes in primary somatosensory cortex.	UNIV KONSTANZ,DEPT PSYCHOL,D-78434 CONSTANCE,GERMANY; UNIV MUNSTER,DEPT NEUROL,D-48129 MUNSTER,GERMANY; UNIV MUNSTER,INST EXPTL AUDIOL,D-48129 MUNSTER,GERMANY; UNIV TUBINGEN,INST MED PSYCHOL & BEHAV NEUROBIOL,D-72074 TUBINGEN,GERMANY; UNIV ALABAMA,DEPT PSYCHOL,BIRMINGHAM,AL 35294	University of Konstanz; University of Munster; University of Munster; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Alabama System; University of Alabama Birmingham	FLOR, H (corresponding author), HUMBOLDT UNIV BERLIN,DEPT PSYCHOL,HAUSVOGTEIPL 5-7,D-10117 BERLIN,GERMANY.		Elbert, Thomas/C-8556-2009	Elbert, Thomas/0000-0003-1332-4939; Knecht, Stefan/0000-0003-1056-9228; Flor, Herta/0000-0003-4809-5398; Birbaumer, Niels/0000-0002-6786-5127				CALFORD MB, 1991, P ROY SOC B-BIOL SCI, V243, P269, DOI 10.1098/rspb.1991.0041; Casey K., 1991, PAIN CENTRAL NERVOUS; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; ELBERT T, 1994, NEUROREPORT, V5, P2593, DOI 10.1097/00001756-199412000-00047; Flor H, 1990, Schmerz, V4, P82, DOI 10.1007/BF02527839; FLOR H, 1994, AM PAIN SOC J, V3, P1187; FLOR H, IN PRESS RECENT ADV; GEISSNER E, IN PRESS SCHMERZEMPF; Gilbert C D, 1993, Curr Opin Neurobiol, V3, P100, DOI 10.1016/0959-4388(93)90042-W; Jensen TS., 1994, TXB PAIN, P651; KATZ J, 1992, CAN J PSYCHIAT, V37, P282, DOI 10.1177/070674379203700502; KERNS RD, 1985, PAIN, V23, P345, DOI 10.1016/0304-3959(85)90004-1; LUND JP, 1994, SCIENCE, V265, P546, DOI 10.1126/science.8036500; LUTKENHONER B, IN PRESS BRAIN TOPOG; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; MELZACK R, 1989, CAN PSYCHOL, V30, P1, DOI 10.1037/h0079793; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RAMACHANDRAN VS, 1992, SCIENCE, V258, P1159, DOI 10.1126/science.1439826; RAMACHANDRAN VS, 1992, NEUROREPORT, V3, P583, DOI 10.1097/00001756-199207000-00009; SHERMAN RA, 1989, BIOFEEDBACK SELF-REG, V14, P267, DOI 10.1007/BF00999118; WILLIS WD, 1994, 7TH P WORLD C PAIN, P301; YANG TT, 1994, NATURE, V368, P592, DOI 10.1038/368592b0; YANG TT, 1994, NEUROREPORT, V5, P701, DOI 10.1097/00001756-199402000-00010	24	1253	1284	2	184	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					482	484		10.1038/375482a0	http://dx.doi.org/10.1038/375482a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777055	Green Submitted			2022-12-24	WOS:A1995RC18800046
J	TENNANT, A; FEAR, J; PICKERING, A; HILLMAN, M; CUTTS, A; CHAMBERLAIN, MA				TENNANT, A; FEAR, J; PICKERING, A; HILLMAN, M; CUTTS, A; CHAMBERLAIN, MA			PREVALENCE OF KNEE PROBLEMS IN THE POPULATION AGED 55 YEARS AND OVER - IDENTIFYING THE NEED FOR KNEE ARTHROPLASTY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OSTEOARTHRITIS; GUIDELINES; ARTHRITIS; HIP	Objective-To determine the prevalence of knee problems in people aged 55 years and over and identify those who should be considered for knee arthroplasty. Design-Postal survey; questionnaires were sent to a multistage stratified probability sample of residents of North Yorkshire Health Authority aged 55 and over. Setting-A health district with a population of 210 000 aged 55 and over. Results-An initial four page postal questionnaire produced an 86% response rate among 18 827 eligible patients. A subsequent detailed questionnaire sent to 1277 patients with knee problems (with a response rate of 78%) then determined the prevalence of severe pain and severe disability. Pain and disability consistent with the need to consider arthroplasty was found in 20.4/1000 (95% confidence interval 18.0 to 23.1); of these, 4.1 (2.7 to 5.8)/1000 had extreme disability. Age and sex specific rates in men who might benefit from arthroplasty were, in those aged 55-64, 12.9 (8.4 to 19.0)/1000; aged 65-74, 12.1 (7.4 to 18.4)/1000; aged 75 and over, 20.3 (12.9 to 30.5)/ 1000. In women aged 55-64 the rates were 12.9 (8.6 to 18.7)/1000; aged 65-74, 19.6 (13.9 to 26.7)/1000; aged 75 years and over, 42.6 (34.3 to 52.4)/1000. Conclusions-Total knee replacement has until recently been considered unreliable and often seen as a last resort for many with severe knee problems. Advances in prosthesis design and surgical and anaesthetic techniques have transformed this procedure into a reliable option with a potential for reducing disability and dependency in a large number of people in the community. Understandably, the prevalence pool of those who may benefit is large; health authorities and, increasingly, general practitioners should consider purchasing more total knee replacement surgery to offer real choice to those in need.	N YORKSHIRE HLTH, PUBL HLTH MED, YORK YO1 1PE, N YORKSHIRE, ENGLAND		TENNANT, A (corresponding author), UNIV LEEDS, RES SCH MED, RHEUMATOL & REHABIL RES UNIV, LEEDS LS2 9NZ, W YORKSHIRE, ENGLAND.							COOPER C, 1994, ANN RHEUM DIS, V53, P90, DOI 10.1136/ard.53.2.90; CROFT P, 1992, SCAND J WORK ENV HEA, V18, P59, DOI 10.5271/sjweh.1608; FERTIG A, 1993, BRIT MED J, V307, P1467, DOI 10.1136/bmj.307.6917.1467; HARRIS AI, 1971, SAMPLE SURVEYS LOCAL; Harris Amelia I, 1971, HANDICAPPED IMPAIRED; KIRWAN JR, 1994, BRIT J RHEUMATOL, V33, P357; KIRWAN JR, 1986, BRIT J RHEUMATOL, V25, P206; LEQUESNE MG, 1987, SCAND J RHEUMATOL, P85; LIANG MH, 1986, ARTHRITIS RHEUM, V29, P937, DOI 10.1002/art.1780290801; MARTIN J, 1988, OPCS1 SURV DIS GREAT; RAND JA, 1991, J BONE JOINT SURG AM, V73A, P397, DOI 10.2106/00004623-199173030-00011; SCHOENBERG B S, 1983, Neuroepidemiology, V2, P257, DOI 10.1159/000110529; SCOTT DL, 1993, J ROY COLL PHYS LOND, V27, P391; STEVENS A, 1994, HLTH NEEDS ASSESSMEN, V1; TENNANT A, 1991, J EPIDEMIOL COMMUN H, V45, P81, DOI 10.1136/jech.45.1.81; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILKIN D, 1992, HOSPITAL REFERRALS, P76; WILLIAMS MH, 1994, HLTH CARE NEEDS ASSE, V1, P448; 1971, SERVICES HANDICAPPED	19	80	81	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	1995	310	6990					1291	1293		10.1136/bmj.310.6990.1291	http://dx.doi.org/10.1136/bmj.310.6990.1291			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773041	Green Published			2022-12-24	WOS:A1995QZ86000019
J	PETO, J; HODGSON, JT; MATTHEWS, FE; JONES, JR				PETO, J; HODGSON, JT; MATTHEWS, FE; JONES, JR			CONTINUING INCREASE IN MESOTHELIOMA MORTALITY IN BRITAIN	LANCET			English	Article							ASBESTOS WORKERS	Mesothelioma is closely related to exposure to asbestos, and mesothelioma mortality can be taken as an index of past exposure to asbestos in the population. We analysed mesothelioma mortality since 1968 to assess the current state of the mesothelioma epidemic, and to predict its future course. We found that rates of mesothelioma in men formed a clear pattern defined by age and date of birth. Rates rose steeply with age showing a very similar pattern in all five-year birth cohorts. By date of birth, rates increased from mid-1893 to mid-1948, and then fell. Relative to the 1943-48 cohort, the risk for the 1948-53 cohort is 0.79 and for the 1953-58 cohort 0.48. Despite these falls, if the age profile of rates for these cohorts follows the pattern of past cohorts, their predicted lifetime mesothelioma risks will be 1.3%, 1.0%, and 0.6%. Combining projections for all cohorts results in a peak of annual male mesothelioma deaths in about the year 2020 of between 2700 and 3300 deaths. If diagnostic trend is responsible for a 20% growth in recorded cases every 5 years-an extreme but arguable case-and if this trend has now ceased, the peak of annual male deaths will be reduced to 1300, reached around the year 2010. Analysis of occupations recorded on death certificates indicate that building workers, especially plumbers and gas fitters, carpenters and electricians are the largest high-risk group. These data indicate that mesothelioma deaths will continue to increase for at least 15 and more likely 25 years. For the worst affected cohorts-men born in the 1940s-mesothelioma may account for around 1% of all deaths. Asbestos exposure at work in construction and building maintenance will account for a large proportion of these deaths, and it is important that such workers should be aware of the risks and take appropriate precautions.	HLTH & SAFETY EXECUT,EPIDEMIOL & MED STAT UNIT,BOOTLE,MERSEYSIDE,ENGLAND		PETO, J (corresponding author), INST CANC RES,EPIDEMIOL SECT,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		Hodgson, John/HGD-6550-2022; Matthews, Fiona/O-6932-2015	Matthews, Fiona/0000-0002-1728-2388				BERRY G, 1991, BRIT J IND MED, V48, P793; Burdett GJ, 1989, IARC SCI PUBL, V90, P277; CARBONE M, 1994, ONCOGENE, V9, P781; DINI S, 1992, AM J IND MED, V21, P569, DOI 10.1002/ajim.4700210412; HODGSON JT, 1986, BRIT J IND MED, V43, P158; JONES RD, 1988, SCAND J WORK ENV HEA, V14, P145, DOI 10.5271/sjweh.1938; NEWHOUSE ML, 1985, BRIT J IND MED, V42, P4; PETO J, 1982, BRIT J CANCER, V45, P124, DOI 10.1038/bjc.1982.15; PETO J, 1981, BANBURY REPORT, V9; Selikoff I J, 1979, Ann N Y Acad Sci, V330, P91, DOI 10.1111/j.1749-6632.1979.tb18711.x; Wagner JC, 1960, BR J IND MED, V17, P266; [No title captured]; 1995, IN PRESS OCCUPATIO S; 1968, ANN OCCUP HYG, V11, P47	14	457	463	0	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					535	539		10.1016/S0140-6736(95)90462-X	http://dx.doi.org/10.1016/S0140-6736(95)90462-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776771				2022-12-24	WOS:A1995QK44400007
J	DEKOK, YJM; VANDERMAAREL, SM; BITNERGLINDZICZ, M; HUBER, I; MONACO, AP; MALCOLM, S; PEMBREY, ME; ROPERS, HH; CREMERS, FPM				DEKOK, YJM; VANDERMAAREL, SM; BITNERGLINDZICZ, M; HUBER, I; MONACO, AP; MALCOLM, S; PEMBREY, ME; ROPERS, HH; CREMERS, FPM			ASSOCIATION BETWEEN X-LINKED MIXED DEAFNESS AND MUTATIONS IN THE POU DOMAIN GENE POU3F4	SCIENCE			English	Article							PERILYMPHATIC GUSHER; STAPES SURGERY; EXPRESSION; CHOROIDEREMIA; LINKAGE; COMPLEX; BRAIN; XQ21	Deafness with fixation of the stapes (DFN3) is the most frequent X-linked form of hearing impairment. The underlying gene has been localized to a 500-kilobase segment of the Xq21 band. Here, it is reported that a candidate gene for this disorder, Brain 4 (POU3F4), which encodes a transcription factor with a POU domain, maps to the same interval. In five unrelated patients with DFN3 but not in 50 normal controls, small mutations were found that result in truncation of the predicted protein or in nonconservative amino acid substitutions. These findings indicate that POU3F4 mutations are a molecular cause of DFN3.	UNIV NIJMEGEN HOSP, DEPT HUMAN GENET, 6500 HB NIJMEGEN, NETHERLANDS; UNIV LONDON, INST CHILD HLTH, LONDON WC1N 1EH, ENGLAND; UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, OXFORD OX3 9DU, ENGLAND	Radboud University Nijmegen; University of London; University College London; University of Oxford			Monaco, Anthony P/A-4495-2010; Bitner-Glindzicz, Maria/A-4231-2009; Cremers, Frans/A-5625-2014	Monaco, Anthony P/0000-0001-7480-3197; Cremers, Frans/0000-0002-4954-5592; van der Maarel, Silvere/0000-0001-8103-711X				BACH I, 1992, AM J HUM GENET, V51, P38; BACH I, 1992, HUM GENET, V89, P620; Bergstrom L, 1971, Otolaryngol Clin North Am, V4, P369; BITNERGLINDZICZ M, 1994, J MED GENET, V31, P916, DOI 10.1136/jmg.31.12.916; BRUNNER HG, 1988, HUM GENET, V80, P337, DOI 10.1007/BF00273647; COTTER PD, 1992, GENOMICS, V13, P211, DOI 10.1016/0888-7543(92)90223-F; COUCKE P, 1994, NEW ENGL J MED, V331, P425, DOI 10.1056/NEJM199408183310702; CREMERS CWRJ, 1985, ARCH OTOLARYNGOL, V111, P249; CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0; CREMERS FPM, 1989, GENOMICS, V4, P41, DOI 10.1016/0888-7543(89)90312-1; DEKOK YJM, UNPUB; DOUVILLE PJ, 1994, MAMM GENOME, V5, P180, DOI 10.1007/BF00352353; FRIEDMAN TB, 1994, AM J HUM GENET, V55; GLASSCOC.ME, 1973, ARCH OTOLARYNGOL, V98, P82; GUILFORD P, 1994, HUM MOL GENET, V3, P989, DOI 10.1093/hmg/3.6.989; GUILFORD P, 1994, NAT GENET, V6, P24, DOI 10.1038/ng0194-24; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HUBER I, 1994, HUM MOL GENET, V3, P1151, DOI 10.1093/hmg/3.7.1151; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LALWANI AK, 1993, AM J HUM GENET, V53, P1027; LEMOINE C, 1992, P NATL ACAD SCI USA, V89, P3285, DOI 10.1073/pnas.89.8.3285; LEON PE, 1992, P NATL ACAD SCI USA, V89, P5181, DOI 10.1073/pnas.89.11.5181; MATHIS JM, 1992, EMBO J, V11, P2551, DOI 10.1002/j.1460-2075.1992.tb05320.x; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; NANCE W E, 1971, Birth Defects Original Article Series, V7, P64; OKAMOTO K, 1993, J BIOL CHEM, V268, P7449; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PHELPS PD, 1991, NEURORADIOLOGY, V33, P326, DOI 10.1007/BF00587816; PIUSSAN C, IN PRESS AM J HUM GE; REARDON W, 1991, GENOMICS, V11, P885, DOI 10.1016/0888-7543(91)90011-3; RYAN AF, 1991, ANN NY ACAD SCI, V630, P129, DOI 10.1111/j.1749-6632.1991.tb19581.x; SCHOENHAUT DS, 1986, GENE, V48, P55, DOI 10.1016/0378-1119(86)90351-3; SHAVERARNOS K, COMMUNICATION; THORPE P, 1974, S AFR MED J, V48, P587; WALLIS C, 1988, GENOMICS, V3, P299, DOI 10.1016/0888-7543(88)90119-X	37	319	329	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	1995	267	5198					685	688		10.1126/science.7839145	http://dx.doi.org/10.1126/science.7839145			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839145	Green Submitted			2022-12-24	WOS:A1995QE73300040
J	CASSE, M; LEHOUCQ, R; VANGIONIFLAM, E				CASSE, M; LEHOUCQ, R; VANGIONIFLAM, E			PRODUCTION AND EVOLUTION OF LIGHT-ELEMENTS IN ACTIVE STAR-FORMING REGIONS	NATURE			English	Article							MASSIVE STARS; COSMIC-RAYS; GAMMA-RAYS; SOLAR; MODELS	COLLISIONS between cosmic rays (energetic protons and alpha-particles) and carbon, nitrogen and oxygen in the interstellar medium have been considered(1) to be the main source of lithium, beryllium and boron, through fragmentation of the larger nuclei. But this mechanism is unable to account for the observed Solar System abundances of the isotopes Li-7 and B-11. The recent detection of an excess of gamma-rays(2) in the direction of the star-forming region in the Orion cloud has been interpreted(3) as arising from the excitation of carbon and oxygen nuclei ejected from supernovae when they collide with the surrounding gas, which is primarily molecular and atomic hydrogen. Here we investigate the consequences of the two-body interactions of the ejected carbon and oxygen nuclei (and the alpha-particles ejected with them) with the hydrogen and helium in the surrounding gas, using a model developed previously(4-6). We show that these interactions offer a way to make lithium, beryllium and boron that is independent of the abundance of heavy elements in the surrounding medium. Such supernova-driven interactions, combined with the effect of galactic cosmic rays, can explain the observed Solar System abundances of these light elements.	CNRS,INST ASTROPHYS PARIS,F-75014 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	CASSE, M (corresponding author), CTR ETUD SACLAY,DSM,DAPNIA,SERV ASTROPHYS,F-91191 GIF SUR YVETTE,FRANCE.							ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BLOCMEN H, 1984, ASTRON ASTROPHYS, V139, P37; BLOEMEN H, 1994, ASTRON ASTROPHYS, V281, pL5; BROWN AGA, 1994, ASTRON ASTROPHYS, V289, P101; BURROWS DN, 1993, ASTROPHYS J, V406, P97, DOI 10.1086/172423; BYKOV A, 1994, ASTRON ASTROPHYS, V283, pL1; CASSE M, IN PRESS NCULEI COSM; CLAYTON DD, 1994, NATURE, V368, P222, DOI 10.1038/368222a0; CUNHA K, 1994, ASTROPHYS J, V426, P170, DOI 10.1086/174053; DUNCAN DK, 1992, ASTROPHYS J, V401, P584, DOI 10.1086/172088; EDVARDSSON B, IN PRESS ASTR ASTROP; FIELDS BD, IN PRESS ASTROPHYS J; GILMORE G, 1992, NATURE, V357, P379, DOI 10.1038/357379a0; KOZLOVSKY B, 1974, ASTROPHYS J, V191, pL43, DOI 10.1086/181542; MARTI K, IN PRESS NUCLEI COSM; MENEGUZZI M, 1971, ASTRON ASTROPHYS, V15, P337; MENEGUZZI M, 1975, ASTRON ASTROPHYS, V40, P99; MURPHY RJ, 1990, ASTROPHYS J, V351, P299, DOI 10.1086/168466; RAMATY R, 1979, ASTROPHYS J SUPPL S, V40, P487, DOI 10.1086/190596; RAMATY R, 1975, SPACE SCI REV, V18, P341, DOI 10.1007/BF00212911; RAMATY R, IN PRESS ASTROPHYS J; READ SM, 1984, ATOM DATA NUCL DATA, V31, P359, DOI 10.1016/0092-640X(84)90009-3; REEVES H, 1994, REV MOD PHYS, V66, P193, DOI 10.1103/RevModPhys.66.193; RYAN S, 1994, APJ, V388, P184; SPITE F, 1993, ORIGIN EVOLUTION ELE, P201; VANGIONIFLAM E, 1990, ASTROPHYS J, V364, P568, DOI 10.1086/169439; WEAVER TA, 1993, PHYS REP, V227, P65, DOI 10.1016/0370-1573(93)90058-L; WOOSLEY SE, 1993, ASTROPHYS J, V411, P823, DOI 10.1086/172886	28	114	114	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					318	319		10.1038/373318a0	http://dx.doi.org/10.1038/373318a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830765				2022-12-24	WOS:A1995QD40400050
J	HOLLANDER, GA; WANG, BP; NICHOGIANNOPOULOU, A; PLATENBURG, PP; VANEWIJK, W; BURAKOFF, SJ; GUTIERREZRAMOS, JC; TERHORST, C				HOLLANDER, GA; WANG, BP; NICHOGIANNOPOULOU, A; PLATENBURG, PP; VANEWIJK, W; BURAKOFF, SJ; GUTIERREZRAMOS, JC; TERHORST, C			DEVELOPMENTAL CONTROL POINT IN INDUCTION OF THYMIC CORTEX REGULATED BY A SUBPOPULATION OF PROTHYMOCYTES	NATURE			English	Article							T-CELL DEVELOPMENT; LYMPHOCYTES-T; MICE; MICROENVIRONMENT; DIFFERENTIATION; RESTORATION; RECEPTOR	T LYMPHOCYTES Of the alpha/beta T-cell receptor (TCR) lineage mature in the thymus, where they undergo a series of differentiation, expansion and selection events(1-7). For normal T-cell ontogeny to occur, thymocytes must interact physically with cortical and medullary thymic stroma cells(8-10). In parallel, interactions of the thymic stromal cells with TCR-positive thymocytes are necessary for the development of the thymic medulla(10-12). Comparable requirements for the differentiation of the cortex have not been defined, however. Here me analyse mutant mouse strains to assess the function of early prothymocytes in the induction of the thymic cortex. We find that animals with a developmental block at the earliest stage of T-lineage commitment lack a functional thymic cortex. This abnormality could be corrected in fetal but not adult animals by transplantation of either fetal or adult wild-type haematopoietic stem cells. Thus a developmentally restricted interaction of fetal stromal cells with early prothymocytes is required for the induction of a cortical microenvironment. In addition, a normal thymic architecture is necessary for sustained T-cell ontogeny.	BETH ISRAEL HOSP,DIV IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; ERASMUS UNIV ROTTERDAM,DEPT IMMUNOL,3000 DR ROTTERDAM,NETHERLANDS	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Erasmus University Rotterdam	HOLLANDER, GA (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115, USA.			Hollander, Georg/0000-0002-8790-0874				BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; BOYD RL, 1993, IMMUNOL TODAY, V14, P445, DOI 10.1016/0167-5699(93)90248-J; BRADLEY LM, 1992, J IMMUNOL, V148, P324; BUDD RC, 1987, J IMMUNOL, V138, P3120; GODFREY DI, 1994, J IMMUNOL, V152, P4783; GODFREY DI, 1993, J IMMUNOL, V150, P4244; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; IKUTA K, 1992, ANNU REV IMMUNOL, V10, P759; Jenkinson E J, 1990, Semin Immunol, V2, P51; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NEZELOF C, 1992, HISTOPATHOLOGY, V21, P499, DOI 10.1111/j.1365-2559.1992.tb00437.x; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; RITTER MA, 1993, IMMUNOL TODAY, V14, P462, DOI 10.1016/0167-5699(93)90250-O; ROBERTS R, 1990, MOUSE ITS REPRODUCTI, P253; SCOLLAY R, 1991, CURR OPIN IMMUNOL, V3, P204, DOI 10.1016/0952-7915(91)90051-2; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHORES EW, 1991, EUR J IMMUNOL, V21, P1657, DOI 10.1002/eji.1830210711; Shortman K, 1990, Semin Immunol, V2, P3; VANEWIJK W, 1984, AM J ANAT, V170, P311, DOI 10.1002/aja.1001700307; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; VANEWIJK W, 1994, IMMUNOL TODAY, V15, P214, DOI 10.1016/0167-5699(94)90246-1; VANVLIET E, 1984, EUR J IMMUNOL, V14, P524, DOI 10.1002/eji.1830140608; VANVLIET E, 1985, EUR J IMMUNOL, V15, P677; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WANG B, IN PRESS INT IMMUN; WANG BP, 1994, P NATL ACAD SCI USA, V91, P9402, DOI 10.1073/pnas.91.20.9402; YOKOYAMA WM, 1988, J IMMUNOL, V141, P369	27	236	239	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					350	353		10.1038/373350a0	http://dx.doi.org/10.1038/373350a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830770				2022-12-24	WOS:A1995QD40400062
J	WADA, A				WADA, A			A SPACE-TIME SLIDE-RULE	NATURE			English	Article								Akiyoshi Wada retired some years ago as a professor of physics at Tokyo University, where he was for many years one of those in Japan urging the fuller use of physical techniques in molecular biology notably in the automatic sequencing of DNA. Now he is the director of the interdisciplinary Sagami Chemical Research Center near Tokyo. The Wadarules reproduced on these pages (together with an explanatory note by Professor Wada) do not arise directly from the author's professional work, but are the product of a fertile and ingenious imagination exercised, in part no doubt, on long aircraft journeys. They are offered without restriction to those who may have use for them. It is simply necessary to photocopy the diagrams, to separate the main rule from the reference rule and to mount each part on stiff card in such a way as to be able to slide the latter against the former. While the Wadarules may have a general heuristic value for those who have the time to play with them, they mag have a particular educational value for young children and may be particularly useful for, say, science writers forever seeking graphic ways of dramatizing the large or small scale of some phenomenon (as in the phrase ''seems no bigger than a dime at a distance of 1 mile''). The rules can readily be amended to include objects with dimensions other than those shown. The annotation of the time rule leaves ample room for the addition of extra items, such as the average duration of the human heart-beat, the period of oscillation of ''middle C'' (0.00178 seconds) and the like.			WADA, A (corresponding author), SAGAMI CHEM RES CTR,4-4-1 NISHIOHNUMA,SAGAMIHARA,KANAGAWA 229,JAPAN.								0	1	1	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					R39	R40						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830749				2022-12-24	WOS:A1995QD40400047
J	FRYER, CJH				FRYER, CJH			PELVIC RHABDOMYOSARCOMA - PAYING THE PRICE OF BLADDER PRESERVATION	LANCET			English	Editorial Material							SEQUELAE		BRITISH COLUMBIA CHILDRENS HOSP,VANCOUVER,BC,CANADA	BC Childrens Hospital; University of British Columbia	FRYER, CJH (corresponding author), UNIV BRITISH COLUMBIA,DIV PEDIAT HEMATOL ONCOL,VANCOUVER,BC,CANADA.							ATRA A, 1994, BRIT J CANCER, V70, P1004, DOI 10.1038/bjc.1994.438; DONALDSON S, 1994, MED PEDIATR ONCOL, V23, P3; FLAMANT F, 1990, J CLIN ONCOL, V8, P1847, DOI 10.1200/JCO.1990.8.11.1847; FONTANESI J, 1991, ENDOCURIETH HYPERTH, V7, P195; HAYS DM, IN PRESS AM J PEDIAT; HAYS DM, 1991, MED PEDIATR ONCOL, V19, P423; RANEY B, 1993, CANCER, V71, P2387, DOI 10.1002/1097-0142(19930401)71:7<2387::AID-CNCR2820710734>3.0.CO;2-A; YEUNG CK, 1994, BRIT J CANCER, V70, P1000, DOI 10.1038/bjc.1994.437	8	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					141	142		10.1016/S0140-6736(95)90162-0	http://dx.doi.org/10.1016/S0140-6736(95)90162-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823666				2022-12-24	WOS:A1995QC55000005
J	FINZI, L; GELLES, J				FINZI, L; GELLES, J			MEASUREMENT OF LACTOSE REPRESSOR-MEDIATED LOOP FORMATION AND BREAKDOWN IN SINGLE DNA-MOLECULES	SCIENCE			English	Article							LAC REPRESSOR; OPERATORS; STABILITY; COMPLEX; PROTEIN; INVITRO; OPERON	In gene regulatory systems in which proteins bind to multiple sites on a DNA molecule, the characterization of chemical mechanisms and single-step reaction rates is difficult because many chemical species may exist simultaneously in a molecular ensemble. This problem was circumvented by detecting DNA looping by the lactose repressor protein of Escherichia coli in single DNA molecules. The looping was detected by monitoring the nanometer-scale Brownian motion of microscopic particles linked to the ends of individual DNA molecules. This allowed the determination of the rates of formation and breakdown of a protein-mediated DNA loop in vitro. The measurements reveal that mechanical strain stored in the loop does not substantially accelerate loop breakdown, and the measurements also show that subunit dissociation of tetrameric repressor is not the predominant loop breakdown pathway.	BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254; BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254	Brandeis University; Brandeis University								BERLINER E, 1994, J BIOL CHEM, V269, P8610; BERLINER E, IN PRESS NATURE; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BRENOWITZ M, 1990, BIOCHEMISTRY-US, V29, P3374, DOI 10.1021/bi00465a033; BRENOWITZ M, 1993, BIOCHEMISTRY-US, V32, P8693, DOI 10.1021/bi00084a041; BRENOWITZ M, 1991, BIOCHEMISTRY-US, V30, P5986, DOI 10.1021/bi00238a024; COLQUHOUN D, 1981, PROC R SOC SER B-BIO, V211, P205, DOI 10.1098/rspb.1981.0003; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; EISMANN E, 1987, J MOL BIOL, V195, P949, DOI 10.1016/0022-2836(87)90499-2; FINZI L, UNPUB; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HSIEH WT, 1987, J BIOL CHEM, V262, P14583; KRAMER H, 1987, EMBO J, V6, P1481, DOI 10.1002/j.1460-2075.1987.tb02390.x; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; MOSSING MC, 1986, SCIENCE, V233, P889, DOI 10.1126/science.3090685; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; YIN H, 1994, BIOPHYS J, V67, P2468, DOI 10.1016/S0006-3495(94)80735-0	19	182	191	0	20	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 20	1995	267	5196					378	380		10.1126/science.7824935	http://dx.doi.org/10.1126/science.7824935			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7824935				2022-12-24	WOS:A1995QC27300035
J	GLOVER, JNM; HARRISON, SC				GLOVER, JNM; HARRISON, SC			CRYSTAL-STRUCTURE OF THE HETERODIMERIC BZIP TRANSCRIPTION FACTOR C-FOS-C-JUN BOUND TO DNA	NATURE			English	Article							X-RAY STRUCTURE; LEUCINE ZIPPER; BASIC REGION; BINDING DOMAINS; COILED-COIL; PROTEIN; COMPLEX; RECOGNITION; SPECIFICITY; EXPRESSION	THE FOS and Jun families of eukaryotic transcription factors heterodimerize to form complexes capable of binding 5'-TGAGTCA-3' DNA elements. We have determined the X-ray crystal structure of a heterodimer of the bZIP regions of c-Fos and c-Jun bound to DNA. Both subunits form continuous alpha-helices. The carboxy-terminal regions form an asymmetric coiled-coil, and the amino-terminal regions make base-specific contacts with DNA in the major groove. Comparison of the two crystallographically distinct protein-DNA complexes show that the coiled-coil is flexibly joined to the basic regions and that the Fos-Jun heterodimer does not recognize the asymmetric 5'-TGAGTCA-3' recognition element in a unique orientation. There is an extensive network of electrostatic interactions between subunits within the coiled-coil, consistent with proposals that these interactions determine preferential formation of the heterodimer over either of the homodimers.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University	GLOVER, JNM (corresponding author), HARVARD UNIV,HOWARD HUGHES MED INST,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ABATE C, 1990, SCIENCE, V248, P1157; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; 1979, CCP 4 SUITE PROGRAMS	28	653	691	1	43	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					257	261		10.1038/373257a0	http://dx.doi.org/10.1038/373257a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816143				2022-12-24	WOS:A1995QC27800068
J	VRIELINK, H; VANDERPOEL, CL; REESINK, HW; ZAAIJER, HL; SCHOLTEN, E; KREMER, LCM; CUYPERS, HTM; LELIE, PN; VANOERS, MHJ				VRIELINK, H; VANDERPOEL, CL; REESINK, HW; ZAAIJER, HL; SCHOLTEN, E; KREMER, LCM; CUYPERS, HTM; LELIE, PN; VANOERS, MHJ			LOOK-BACK STUDY OF INFECTIVITY OF ANTI-HCV ELISA-POSITIVE BLOOD COMPONENTS	LANCET			English	Note							HEPATITIS-C VIRUS; RECOMBINANT IMMUNOBLOT ASSAY	The infectivity of blood components from donors who were later found to be anti-HCV ELISA-positive was investigated in recipients who were enrolled in a look-back programme. Recipients received ELISA-positive blood components from donors who were PCR-positive and/or RIBA-2-positive (n=22, group A) or PCR-negative and indeterminate or negative on RIBA-2 (n=105, group B). 26 of 32 (81%) recipients of group A donors and none of 140 of group B were HCV-infected. All stored serum samples of previous donations (n=172) of group A donors were anti-HCV-positive in RIBA-3, indicating a chronic carrier state of HCV in these donors.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam	VRIELINK, H (corresponding author), NETHERLANDS RED CROSS,BLOOD BANK AMSTERDAM,POSTBOX 9137,PLESMANLAAN 125,1066 CX AMSTERDAM,NETHERLANDS.			Kremer, Leontien/0000-0001-7422-3248				BUSCH MP, 1991, TRANSFUSION, V31, P655, DOI 10.1046/j.1537-2995.1991.31791368346.x; CUYPERS HTM, 1992, J CLIN MICROBIOL, V30, P3220, DOI 10.1128/JCM.30.12.3220-3224.1992; EBELING F, 1990, LANCET, V335, P982, DOI 10.1016/0140-6736(90)91055-F; SAMSON S, 1990, TRANSFUSION, V30, P214, DOI 10.1046/j.1537-2995.1990.30390194339.x; UYTTENDAELE S, 1994, VOX SANG, V66, P122, DOI 10.1111/j.1423-0410.1994.tb00293.x; VANDERPOEL C, 1991, TRANSFUSION, V31, P777; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; ZAAIJER HL, 1994, TRANSFUSION, V34, P603, DOI 10.1046/j.1537-2995.1994.34794330015.x	8	56	56	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					95	96		10.1016/S0140-6736(95)90063-2	http://dx.doi.org/10.1016/S0140-6736(95)90063-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815889				2022-12-24	WOS:A1995QB80400010
J	FAKLER, B; BRANDLE, U; GLOWATZKI, E; WEIDEMANN, S; ZENNER, HP; RUPPERSBERG, JP				FAKLER, B; BRANDLE, U; GLOWATZKI, E; WEIDEMANN, S; ZENNER, HP; RUPPERSBERG, JP			STRONG VOLTAGE-DEPENDENT INWARD RECTIFICATION OF INWARD RECTIFIER K+ CHANNELS IS CAUSED BY INTRACELLULAR SPERMINE	CELL			English	Article							GUINEA-PIG HEART; POTASSIUM CHANNEL; IK(A) CHANNELS; CELL-MEMBRANE; INACTIVATION; MAGNESIUM; IONS; POLYAMINES; EXPRESSION; COMPLEX	Inward rectifier K+ channels mediate the K+ conductance at resting potential in many types of cell. Since these K+ channels do not pass outward currents (inward rectification) when the cell membrane is depolarized beyond a trigger threshold, they play an important role in controlling excitability. Both a highly voltage-dependent block by intracellular Mg2+ and an endogenous gating process are presently assumed to underly inward rectification. It is shown that strong voltage dependence of rectification found under physiological conditions is predominantly due to the effect of intracellular spermine. Physiological concentrations of free spermine mediate strong rectification of IRK1 inward rectifier K+ channels even in the absence of free Mg2+ and in IRK1 mutant channels that have no endogenous rectification.	UNIV TUBINGEN HOSP, EAR NOSE & THROAT CLIN, DEPT SENSORY BIOPHYS, D-72076 TUBINGEN, GERMANY	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital				Glowatzki, Elisabeth/0000-0003-3135-658X				BOND CT, 1994, RECEPTOR CHANNEL, V2, P183; CHO SW, 1991, EUR J BIOCHEM, V202, P107, DOI 10.1111/j.1432-1033.1991.tb16350.x; ELAM TR, 1993, BIOPHYS J, V64, pA227; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FAKLER B, 1994, NEURON, V13, P1413, DOI 10.1016/0896-6273(94)90426-X; FAKLER B, 1994, FEBS LETT, V356, P199, DOI 10.1016/0014-5793(94)01258-X; GIANNAKOUROS T, 1990, MOL CELL BIOCHEM, V99, P9, DOI 10.1007/BF01261388; GUTTERIDGE JMC, 1990, BIOCHEM J, V269, P169, DOI 10.1042/bj2690169; HAGIWARA S, 1976, J GEN PHYSIOL, V67, P621, DOI 10.1085/jgp.67.6.621; HEBY O, 1981, DIFFERENTIATION, V19, P1, DOI 10.1111/j.1432-0436.1981.tb01123.x; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; Hille B, 1992, IONIC CHANNELS EXCIT, P127; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; KELLY MEM, 1992, J MEMBRANE BIOL, V126, P171; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KURACHI Y, 1985, J PHYSIOL-LONDON, V366, P365, DOI 10.1113/jphysiol.1985.sp015803; LEECH CA, 1981, J PHYSIOL-LONDON, V319, P295, DOI 10.1113/jphysiol.1981.sp013909; LOPATIN AN, 1994, J PHYSL, V477, P86; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MATSUDA H, 1991, J PHYSIOL-LONDON, V435, P83, DOI 10.1113/jphysiol.1991.sp018499; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; RUPPERSBERG JP, 1994, SEMIN NEUROSCI, V6, P87; SILVER MR, 1990, J GEN PHYSIOL, V96, P109, DOI 10.1085/jgp.96.1.109; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WATANABE S, 1991, J BIOL CHEM, V266, P20803	30	313	314	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 13	1995	80	1					149	154		10.1016/0092-8674(95)90459-X	http://dx.doi.org/10.1016/0092-8674(95)90459-X			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813010	Bronze			2022-12-24	WOS:A1995QB91000018
J	PHILLIPS, DM				PHILLIPS, DM			MYCOPLASMA-PNEUMONIAE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PHILLIPS, DM (corresponding author), POPULAT COUNCIL,1230 YORK AVE,NEW YORK,NY 10021, USA.								0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1421	1421						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU533	7772108				2022-12-24	WOS:A1994PU53300005
J	MACALLAN, DC; NOBLE, C; BALDWIN, C; JEBB, SA; PRENTICE, AM; COWARD, WA; SAWYER, MB; MCMANUS, TJ; GRIFFIN, GE				MACALLAN, DC; NOBLE, C; BALDWIN, C; JEBB, SA; PRENTICE, AM; COWARD, WA; SAWYER, MB; MCMANUS, TJ; GRIFFIN, GE			ENERGY-EXPENDITURE AND WASTING IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BODY-COMPOSITION; WEIGHT CHANGE; MEN	Background. Increased expenditure of energy at rest has been considered a contributing factor to the negative energy balance and weight loss that occur in patients with human immunodeficiency virus (HIV) infection. However, the true determinant of energy balance is not resting but total energy expenditure. We sought to determine the contribution of total energy expenditure to weight changes in patients with HIV-associated wasting. Methods. We performed 51 assessments of energy metabolism in 27 men with HIV infection at different stages of disease, including periods of both rapid and slow weight loss. Resting energy expenditure was measured by indirect calorimetry, total energy expenditure by the doubly-labeled-water technique, and energy intake by recording the weight of food consumed. The results were compared with the rate of weight loss or gain. Results. The mean (+/-SD) total energy expended by the HIV-infected men was 2750+/-670 kcal per day, no more than that expended by normal men. There was a significant positive relation between total energy expenditure and the rate of weight change (r=0.61, P<0.001); thus, during rapid weight loss, total energy expenditure was reduced to 2180+/-580 kcal per day (P = 0.009), primarily because of reduced physical activity. During rapid weight loss, the negative energy balance (-8501+/-580 kcal per day) was primarily the result of the reduction in energy intake, to 1330+/-610 kcal per day; intake correlated strongly with the rate of weight change (r=0.84, P<0.001). Conclusions. In patients with HIV infection, total energy expenditure is reduced during episodes of weight loss. Reduced energy intake, not elevated energy expenditure, is the prime determinant of weight loss in HIV-associated wasting.	KINGS HEALTHCARE,DEPT GENITOURINARY MED,LONDON,ENGLAND; DUNN CLIN NUTR CTR,CAMBRIDGE,ENGLAND		MACALLAN, DC (corresponding author), ST GEORGE HOSP,SCH MED,DIV INFECT DIS,LONDON SW17 0RE,ENGLAND.		Prentice, Andrew/AAG-1961-2019	Macallan, Derek/0000-0002-3014-7148; Jebb, Susan/0000-0001-9190-2920				BLACK AE, IN PRESS EUR J CLIN; COLE TJ, 1992, AM J PHYSIOL, V263, pE965, DOI 10.1152/ajpendo.1992.263.5.E965; Coward W, 1991, NEW TECHNIQUES NUTR, P139; DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060; FOSKETT M, 1991, J HUM NUTR DIET, V4, P149, DOI 10.1111/j.1365-277X.1991.tb00092.x; GORAN MI, 1993, METABOLISM, V42, P487, DOI 10.1016/0026-0495(93)90108-Z; GRUNFELD C, 1991, AM J MED, V90, P154, DOI 10.1016/0002-9343(91)80154-E; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; GRUNFELD C, 1992, AM J CLIN NUTR, V55, P455, DOI 10.1093/ajcn/55.2.455; HOMMES MJT, 1991, METABOLISM, V40, P651, DOI 10.1016/0026-0495(91)90059-6; KOTLER DP, 1985, AM J CLIN NUTR, V42, P1255, DOI 10.1093/ajcn/42.6.1255; KOTLER DP, 1990, JPEN-PARENTER ENTER, V14, P454, DOI 10.1177/0148607190014005454; MACALLAN DC, 1995, AM J CLIN NUTR, V61, P818, DOI 10.1093/ajcn/61.4.818; MACALLAN DC, 1993, AM J CLIN NUTR, V58, P417, DOI 10.1093/ajcn/58.3.417; Paul A.A., 1978, MCCANCE WIDDOWSONS C; Prentice A.M., 1991, NEW TECHNIQUES NUTR, P177; RAVUSSIN E, 1989, AM J CLIN NUTR, V49, P968, DOI 10.1093/ajcn/49.5.968; Schofield W N, 1985, Hum Nutr Clin Nutr, V39 Suppl 1, P5; STEIN TP, 1990, METABOLISM, V39, P876, DOI 10.1016/0026-0495(90)90136-Z; SUTTMANN U, 1994, CLIN SCI, V86, P461; 1987, MMWR CDC SURVEILL S3, V36, pS3; 1990, DOUBLY LABELLED WATE	22	295	298	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 13	1995	333	2					83	88		10.1056/NEJM199507133330202	http://dx.doi.org/10.1056/NEJM199507133330202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH225	7777033	Bronze			2022-12-24	WOS:A1995RH22500002
J	LOTKE, M				LOTKE, M			SHE WONT LOOK AT ME	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								Early-onset hearing impairment is a common disability in the United States. Persons with hearing loss, whether they use American Sign Language or lip-read, must look at those with whom they are speaking. Lip reading is not a reliable method of communication for most deaf persons. Reading and writing also limit the amount of communication between health care providers and deaf patients. The best way to communicate with most deaf persons is through a qualified American Sign Language interpreter. This paper discusses communication with deaf persons and ways in which health care providers and hospitals can improve their interactions with deaf patients.	STANFORD UNIV, ROBERT WOOD JOHNSON CLIN SCHOLAR PROGRAM, STANFORD, CA USA	Robert Wood Johnson Foundation (RWJF); Stanford University								MCEWEN E, 1988, J FAM PRACTICE, V26, P289; Schein J.D., 1974, DEAF POPULATION US	2	17	17	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1995	123	1					54	57		10.7326/0003-4819-123-1-199507010-00008	http://dx.doi.org/10.7326/0003-4819-123-1-199507010-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE665	7762915				2022-12-24	WOS:A1995RE66500009
J	GOSSEN, M; FREUNDLIEB, S; BENDER, G; MULLER, G; HILLEN, W; BUJARD, H				GOSSEN, M; FREUNDLIEB, S; BENDER, G; MULLER, G; HILLEN, W; BUJARD, H			TRANSCRIPTIONAL ACTIVATION BY TETRACYCLINES IN MAMMALIAN-CELLS	SCIENCE			English	Article							GENE	A transcriptional transactivator was developed that fuses the VP16 activation domain with a mutant Tet repressor from Escherichia coli. This transactivator requires certain tetracycline (Tc) derivatives for specific DNA binding. Thus, addition of doxycycline to HeLa cells that constitutively synthesized the transactivator and that contained an appropriate, stably integrated reporter unit rapidly induced gene expression more than a thousandfold. The specificity of the Tet repressor-operator-effector interaction and the pharmacological characteristics of Tc's make this regulatory system well suited for the control of gene activities in vivo, such as in transgenic animals and possibly in gene therapy.	UNIV ERLANGEN NURNBERG,INST MIKROBIOL & BIOCHEM,D-91058 ERLANGEN,GERMANY	University of Erlangen Nuremberg	GOSSEN, M (corresponding author), UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.		Wilson, Matthew H/K-3193-2013; Gossen, Manfred/K-9602-2013	Gossen, Manfred/0000-0002-1761-4063				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; HECHT B, 1993, J BACTERIOL, V175, P1206, DOI 10.1128/JB.175.4.1206-1210.1993; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; KISTNER A, UNPUB; MULLER G, 1995, THESIS U ERLANGEN NU; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLEICHER, 1984, P NATL ACAD SCI USA, V81, P1991; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WEINMANN P, 1994, PLANT J, V5, P559, DOI 10.1046/j.1365-313X.1994.5040559.x; Yarranton Geoffrey T., 1992, Current Opinion in Biotechnology, V3, P506, DOI 10.1016/0958-1669(92)90078-W	16	1963	2319	3	129	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1766	1769		10.1126/science.7792603	http://dx.doi.org/10.1126/science.7792603			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792603				2022-12-24	WOS:A1995RE66800046
J	PIMENTA, W; KORYTKOWSKI, M; MITRAKOU, A; JENSSEN, T; YKIJARVINEN, H; EVRON, W; DAILEY, G; GERICH, J				PIMENTA, W; KORYTKOWSKI, M; MITRAKOU, A; JENSSEN, T; YKIJARVINEN, H; EVRON, W; DAILEY, G; GERICH, J			PANCREATIC BETA-CELL DYSFUNCTION AS THE PRIMARY GENETIC LESION IN NIDDM - EVIDENCE FROM STUDIES IN NORMAL GLUCOSE-TOLERANT INDIVIDUALS WITH A FIRST-DEGREE NIDDM RELATIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENT DIABETES-MELLITUS; INDUCED INSULIN RELEASE; BODY-FAT DISTRIBUTION; PIMA-INDIANS; GLYCOGEN-SYNTHASE; INCREASED RISK; ISLET FUNCTION; RESISTANCE; SENSITIVITY; SECRETION	Objective.- To test the hypothesis that insulin resistance precedes impaired insulin secretion in individuals genetically predisposed to non-insulin-dependent diabetes mellitus (NIDDM). Design.- Case-control study. Setting.- Outpatient facility of clinical research center. Participants.- One hundred volunteers of European ancestry having normal glucose tolerance, 50 with and 50 without a first-degree NIDDM relative, matched for age, sex, and degree of obesity. Main Outcome Measures.- Insulin secretion and insulin sensitivity assessed by hyperglycemic (N=100) and euglycemic-hyperinsulinemic (N=62) clamp experiments. Results.- The individuals with a first-degree NIDDM relative had reduced first-and second-phase insulin responses (mean+/-SEM, 939+/-68 vs 1209+/-82 pmol/L, and 322+/-19 vs 407+/-24 pmol/L, respectively, P=.001 and .01), but their insulin sensitivity (148+/-6 and 92+/-6 nmol . kg(-1). min(-1)/pmol . L(-1) in hyperglycemic and euglycemic clamp studies) did not differ from that of the control group (126+/-5 and 81+/-7 nmol . kg(-1). min(-1)/pmol . L(-1), in hyperglycemic and euglycemic clamp studies, P=.07 and .24, respectively). In some individuals only first- or only second-phase insulin responses were reduced. Conclusion.- In this study population, heterogeneous defects in insulin secretion were demonstrated, while defects in insulin sensitivity were not evident. We therefore conclude that since the earliest defects identified in a group genetically at high risk to develop NIDDM are those related to insulin secretion, defects in insulin secretion rather than insulin sensitivity are likely the major genetic factor predisposing to development of NIDDM.	UNIV PITTSBURGH,DEPT MED,PITTSBURGH,PA; UNIV ATHENS,DEPT INTERNAL MED PROPAEDEUT 2,ATHENS,GREECE; UNIV TROMSO HOSP,DEPT MED,TROMSO,NORWAY; HELSINKI UNIV,DEPT MED 2,HELSINKI,FINLAND; SCRIPPS CLIN & RES FDN,LA JOLLA,CA 92037	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National & Kapodistrian University of Athens; UiT The Arctic University of Tromso; University Hospital of North Norway; University of Helsinki; Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000044, M01RR000056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020411, R37DK020411] Funding Source: NIH RePORTER; NCRR NIH HHS [M501 RR00044, M501 RR00056] Funding Source: Medline; NIDDK NIH HHS [DK20411] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNER P, 1991, DIABETOLOGIA, V34, P483, DOI 10.1007/BF00403284; ARONOFF SL, 1977, DIABETES, V26, P827, DOI 10.2337/diabetes.26.9.827; BAK JF, 1992, DIABETOLOGIA, V35, P777; BANERJI MA, 1989, DIABETES, V38, P784, DOI 10.2337/diabetes.38.6.784; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BARNETT AH, 1981, BRIT MED J, V282, P1656, DOI 10.1136/bmj.282.6277.1656; BEARD JC, 1987, J CLIN ENDOCR METAB, V65, P59, DOI 10.1210/jcem-65-1-59; Berntorp K, 1985, Diabetes Res, V2, P151; BOBERG J, 1976, SCAND J CLIN LAB INV, V36, P145, DOI 10.3109/00365517609055241; BODEN G, 1968, J CLIN INVEST, V47, P729, DOI 10.1172/JCI105768; BOGARDUS C, 1989, DIABETES, V38, P1423, DOI 10.2337/diabetes.38.11.1423; BONORA E, 1984, DIABETES METAB, V10, P250; CAMPBELL PJ, 1988, METABOLISM, V37, P15, DOI 10.1016/0026-0495(88)90023-6; CARLES M, 1991, DIABETES, V40, P796; CERASI E, 1967, ACTA ENDOCRINOL-COP, V55, P330, DOI 10.1530/acta.0.0550330; CERASI E, 1972, DIABETES, V21, P224, DOI 10.2337/diab.21.4.224; COLWELL JA, 1967, DIABETES, V16, P560, DOI 10.2337/diab.16.8.560; DAWKE H, 1968, DIABETOLOGIA, V4, P349; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; EFENDIC S, 1971, METABOLISM, V20, P568, DOI 10.1016/0026-0495(71)90005-9; ELBEIN SC, 1991, DIABETES, V40, P1024, DOI 10.2337/diabetes.40.8.1024; ENSINCK JW, 1976, CLIN RES, V24, pA155; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FUJITA Y, 1975, DIABETES, V24, P17, DOI 10.2337/diabetes.24.1.17; GERICH JE, 1988, BAILLIERE CLIN ENDOC, V2, P307, DOI 10.1016/S0950-351X(88)80034-X; GINSBERG H, 1981, DIABETES, V30, P739, DOI 10.2337/diab.30.9.739; GOTTLIEB MS, 1974, DIABETES, V23, P684, DOI 10.2337/diab.23.8.684; GRODSKY GM, 1965, LANCET, V1, P290; GULLI G, 1992, DIABETES, V41, P1575, DOI 10.2337/diabetes.41.12.1575; HAFFNER SM, 1986, NEW ENGL J MED, V315, P220, DOI 10.1056/NEJM198607243150403; HAMMAN RF, 1992, DIABETES METAB REV, V8, P287, DOI 10.1002/dmr.5610080402; HANDBERG A, 1993, DIABETOLOGIA, V36, P668, DOI 10.1007/BF00404079; HARRIS H, 1950, ANN EUGENIC, V15, P95; HENIKSEN J, 1994, J CLIN INVEST, V94, P1196; HO LT, 1989, DIABETIC MED, V7, P31; HOSKER JP, 1989, METABOLISM, V38, P767, DOI 10.1016/0026-0495(89)90064-4; ISELIUS L, 1985, CLIN GENET, V28, P8; JACKSON WPU, 1972, LANCET, V1, P1040; JOHNSTON C, 1990, DIABETIC MED, V7, P119, DOI 10.1111/j.1464-5491.1990.tb01345.x; KALANT N, 1979, DIABETOLOGIA, V16, P365, DOI 10.1007/BF01223156; KELLER U, 1979, SCHWEIZ MED WSCHR, V109, P595; KOBBERLING J, 1990, WORLD REV NUTR DIET, P102; KROTKIEWSKI M, 1983, J CLIN INVEST, V72, P1150, DOI 10.1172/JCI111040; LAWS A, 1989, J CLIN ENDOCR METAB, V69, P343, DOI 10.1210/jcem-69-2-343; LEMIEUX S, 1992, DIABETOLOGIA, V35, P653, DOI 10.1007/BF00400258; LERNER RL, 1972, J CLIN INVEST, V51, P1624, DOI 10.1172/JCI106963; LESLIE RDG, 1988, DIABETES NUTR METAB, V3, P235; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; LUNDGREN H, 1990, DIABETIC MED, V7, P407, DOI 10.1111/j.1464-5491.1990.tb01415.x; MANDARINO L, 1984, DIABETOLOGIA, V27, P358, DOI 10.1007/BF00304850; MARTIN BC, 1992, DIABETES, V41, P850, DOI 10.2337/diabetes.41.7.850; MITRAKOU A, 1992, J CLIN ENDOCR METAB, V75, P379, DOI 10.1210/jc.75.2.379; NESHER R, 1987, EUR J CLIN INVEST, V17, P266, DOI 10.1111/j.1365-2362.1987.tb01247.x; ORAHILLY S, 1988, NEW ENGL J MED, V318, P1225, DOI 10.1056/NEJM198805123181902; ORAHILLY SP, 1986, LANCET, V2, P360; OSEI K, 1991, DIABETES CARE, V14, P890, DOI 10.2337/diacare.14.10.890; PAULSEN EP, 1968, DIABETES, V17, P261, DOI 10.2337/diab.17.5.261; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; POZEFSKY T, 1973, J CLIN INVEST, V52, P1608, DOI 10.1172/JCI107338; PYKE DA, 1967, BRIT MED J, V4, P21, DOI 10.1136/bmj.4.5570.21; RAMACHANDRAN A, 1990, DIABETIC MED, V7, P331, DOI 10.1111/j.1464-5491.1990.tb01400.x; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RICKETTS HT, 1966, DIABETES, V15, P880, DOI 10.2337/diab.15.12.880; ROJAS L, 1969, J CLIN ENDOCR METAB, V29, P1569, DOI 10.1210/jcem-29-12-1569; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; RULL AJ, 1970, DIABETES, V19, P1; SAAD MF, 1991, AM J MED, V90, P229; SAAD MF, 1994, DIABETES, V43, P1114, DOI 10.2337/diabetes.43.9.1114; SCHALINJANTTI C, 1992, DIABETES, V41, P598, DOI 10.2337/diabetes.41.5.598; SELTZER HS, 1967, J CLIN INVEST, V46, P323, DOI 10.1172/JCI105534; SERRANORIOS M, 1970, DIABETOLOGIA, V6, P392, DOI 10.1007/BF01212071; SICREE RA, 1987, DIABETES, V36, P179, DOI 10.2337/diabetes.36.2.179; SIMPSON RG, 1968, DIABETES, V17, P684, DOI 10.2337/diab.17.11.684; SIPERSTEIN MD, 1968, J CLIN INVEST, V47, P1973, DOI 10.1172/JCI105886; SKARFORS ET, 1991, BRIT MED J, V303, P755, DOI 10.1136/bmj.303.6805.755; SOELDNER S, 1968, DIABETES, V17, P17; SONKSEN PH, 1973, DIABETOLOGIA, V9, P426, DOI 10.1007/BF01239440; STAFFEL M, 1992, NATURE, V2, P153; TAYLOR S, 1994, DIABETES, V43, P785; TURNER RC, 1988, BAILLIERE CLIN ENDOC, V2, P327, DOI 10.1016/S0950-351X(88)80035-1; VAAG A, 1992, J CLIN INVEST, V89, P782, DOI 10.1172/JCI115656; VAAG A, 1995, J CLIN INVEST, V95, P690, DOI 10.1172/JCI117715; VIGNERI R, 1976, DIABETES, V25, P167, DOI 10.2337/diabetes.25.3.167; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; WELBORN TA, 1966, LANCET, V1, P280; YKIJARVINEN H, 1990, ANN MED, V22, P197, DOI 10.3109/07853899009147269; YKIJARVINEN H, 1994, LANCET, V343, P91, DOI 10.1016/S0140-6736(94)90821-4; YKIJARVINEN H, 1992, ENDOCR REV, V13, P415; Zar JH., 1999, BIOSTAT ANAL; 1985, WHO TECH REP SER, V727, P9	93	314	327	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	1995	273	23					1855	1861		10.1001/jama.273.23.1855	http://dx.doi.org/10.1001/jama.273.23.1855			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD116	7776502				2022-12-24	WOS:A1995RD11600028
J	KHAW, KT; WOODHOUSE, P				KHAW, KT; WOODHOUSE, P			INTERRELATION OF VITAMIN-C, INFECTION, HEMOSTATIC FACTORS, AND CARDIOVASCULAR-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; MYOCARDIAL-INFARCTION; SEASONAL-VARIATION; E CONSUMPTION; RISK FACTOR; MORTALITY; STROKE; POPULATION; PREVENTION; FIBRINOGEN	Objective-To examine the hypothesis that the increase in fibrinogen concentration and respiratory infections in winter is related to seasonal variations in vitamin C status (assessed with serum ascorbate concentration). Design-Longitudinal study of individuals seen at intervals of two months over one year. Setting-Cambridge. Subjects-96 men and women aged 65-74 years living in their own homes. Main outcome measures-Haemostatic factors fibrinogen and factor VIIC; acute phase proteins; respiratory symptoms; respiratory function. Results-Mean dietary intake of vitamin C varied from about 65 mg/24 h in winter to 90 mg/24 h in summer; mean serum ascorbate concentration ranged from 50 mu mol/l in winter to 60 mu mol/l in summer. Serum ascorbate concentration was strongly inversely related to haemostatic factors fibrinogen and factor VIIC as well as to acute phase proteins but not to self reported respiratory symptoms or neutrophil count. Serum ascorbate concentration was also related positively to forced expiratory volume in one second. An increase in dietary vitamin C of 60 mg daily (about one orange) was associated with a decrease in fibrinogen concentrations of 0.15 g/l, equivalent (according to prospective studies) to a decline of approximately 10% in risk of ischaemic heart disease. Conclusion-High intake of vitamin C has been suggested as being protective both for respiratory infection and for cardiovascular disease. These findings support the hypothesis that vitamin C may protect against cardiovascular disease through an effect on haemostatic factors at least partly through the response to infection; this may have implications both for our understanding of the pathogenetic mechanisms in respiratory and cardiovascular disease and for the prevention of such conditions.			KHAW, KT (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN MED,CLIN GERONTOL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND.		Khaw, Kay-Tee/AAZ-3209-2021					AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ALEXANDER RW, 1994, NEW ENGL J MED, V331, P468, DOI 10.1056/NEJM199408183310709; BLOCK G, 1991, AM J CLIN NUTR, V53, pS270, DOI 10.1093/ajcn/53.1.270S; CALVIN J, 1986, ANN CLIN BIOCHEM, V23, P206, DOI 10.1177/000456328602300212; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; Curwen M., 1991, HLTH TRENDS, V22, P169; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; GILLMAN M, 1994, AM J EPIDEMIOL, V139, pS47; GORDON DJ, 1988, J CLIN EPIDEMIOL, V41, P679, DOI 10.1016/0895-4356(88)90120-5; GREGORY J, 1990, DIETARY NUTRITIONAL, P126; HEMILA H, 1992, BRIT J NUTR, V67, P3, DOI 10.1079/BJN19920004; KANNEL WB, 1992, JAMA-J AM MED ASSOC, V267, P1253, DOI 10.1001/jama.267.9.1253; KHAW KT, 1987, AM J EPIDEMIOL, V126, P1093, DOI 10.1093/oxfordjournals.aje.a114748; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MILLER GJ, 1985, BRIT J HAEMATOL, V59, P249, DOI 10.1111/j.1365-2141.1985.tb02991.x; Nyyssonen K., 1994, European Heart Journal, V15, P168; Paul A.A., 1978, MCCANCE WIDDOWSONS C; Pauling L., 1970, VITAMIN C COMMON COL; QIZILBASH N, 1991, BRIT MED J, V303, P605, DOI 10.1136/bmj.303.6803.605; RAO CR, 1973, LINEAR STATISTICAL I, P418; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SCHWARTZ J, 1994, AM J CLIN NUTR, V59, P110, DOI 10.1093/ajcn/59.1.110; SIMON JA, 1992, J AM COLL NUTR, V11, P107; SPODICK DH, 1984, AM J CARDIOL, V53, P481, DOI 10.1016/0002-9149(84)90016-X; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STRACHAN DP, 1992, J EPIDEMIOL COMMUN H, V46, P66, DOI 10.1136/jech.46.1.66; SYRJANEN J, 1988, BRIT MED J, V296, P1156, DOI 10.1136/bmj.296.6630.1156; VOLLSET SE, 1983, LANCET, V2, P742; VUILLEUMIER JP, 1989, J MICRONUTR ANAL, V5, P25; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WILSONT W, 1993, AM J EPIDEMIOL, V137, P292; WOODHOUSE PR, 1993, J HYPERTENS, V11, P1267; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	38	90	91	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1559	1563		10.1136/bmj.310.6994.1559	http://dx.doi.org/10.1136/bmj.310.6994.1559			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787643	Green Published			2022-12-24	WOS:A1995RE35300017
J	GARGAS, A; DEPRIEST, PT; GRUBE, M; TEHLER, A				GARGAS, A; DEPRIEST, PT; GRUBE, M; TEHLER, A			MULTIPLE ORIGINS OF LICHEN SYMBIOSES IN FUNGI SUGGESTED BY SSU RDNA PHYLOGENY	SCIENCE			English	Article							CLADISTIC OUTLINE	Phylogenetic hypotheses provide a context for examining the evolution of heterotrophic lifestyles. The lichen lifestyle, which is the symbiotic association of fungi with algae, is found in various representatives of Dicaryomycotina, both Ascomycetes and Basidiomycetes. A highly resolved parsimony analysis of small subunit ribosomal DNA (SSU rDNA) sequences suggests at least five independent origins of the lichen habit in disparate groups of Ascomycetes and Basidiomycetes. Because lichen associations arose from parasitic, mycorrhizal, or free-living saprobic fungi, neither mutualism nor parasitism should be construed as endpoints in symbiont evolution.	GRAZ UNIV,INST BOT,A-8010 GRAZ,AUSTRIA; UNIV STOCKHOLM,INST BOT,S-10691 STOCKHOLM,SWEDEN	University of Graz; Stockholm University	GARGAS, A (corresponding author), SMITHSONIAN INST,NATL MUSEUM NAT HIST,DEPT BOT,NHB-166,WASHINGTON,DC 20560, USA.		DePriest, Paula T./K-6633-2015	DePriest, Paula T./0000-0002-6079-7870; Grube, Martin/0000-0001-6940-5282				Ahmadjian V, 1983, ALGAL SYMBIOSIS, P147; Ahmadjian V., 1967, LICHEN SYMBIOSIS; BERBEE ML, 1992, MOL BIOL EVOL, V9, P278; BLACKWELL M, 1994, MYCOLOGIA, V86, P1, DOI 10.2307/3760716; Bruns TD, 1992, MOL PHYLOGENET EVOL, V1, P231, DOI 10.1016/1055-7903(92)90020-H; Caullery M., 1952, PARASITISM SYMBIOSIS; De Bary A, 1879, ERSCHEINUNG SYMBIOSE; ERIKSSON OE, 1993, SYST ASCOMYCETUM, V12, P52; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FUTUYAMA DJ, 1991, GENES ECOLOGY, P139; GARGAS A, 1995, EXP MYCOL, V19, P7, DOI 10.1006/emyc.1995.1002; Hawksworth D.L., 1982, J HATTORI BOT LAB, V52, P323; Hawksworth David L., 1994, Cryptogamic Botany, V4, P117; HAWKSWORTH DL, 1978, ESSAYS PLANT TAXONOM, P122; Henssen A, 1973, LICHENES; HONEGGER R, 1991, ANNU REV PLANT PHYS, V42, P553, DOI 10.1146/annurev.pp.42.060191.003005; Kappen Ludger, 1994, Cryptogamic Botany, V4, P193; Landvik Sara, 1993, Systema Ascomycetum, V11, P107; Margulis L., 1988, 5 KINGDOMS ILLUSTRAT; NISHIDA H, 1993, MOL BIOL EVOL, V10, P431; Oberwinkler F., 1984, NOVA HEDWIGIA S, V79, P739; POELT J, 1958, PLANTA, V51, P288, DOI 10.1007/BF02125723; Rambold G., 1992, BIBLIOTHECA LICHENOL, V48, P1; SAENZ GS, 1994, MYCOLOGIA, V86, P212, DOI 10.2307/3760639; SPATAFORA JW, 1993, MYCOLOGIA, V85, P912, DOI 10.2307/3760674; SWANN EC, 1993, MYCOLOGIA, V85, P923, DOI 10.2307/3760675; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; TEHLER A, 1990, CAN J BOT, V68, P2458, DOI 10.1139/b90-312; TEHLER A, 1988, CLADISTICS, V4, P227, DOI 10.1111/j.1096-0031.1988.tb00474.x; Tucker S. C., 1991, TROPICAL LICHENS THE, P171; WAINRIGHT PO, 1993, SCIENCE, V260, P340, DOI 10.1126/science.8469985; WIRTH V, 1995, FLECHTEN BADEN WURTL, P137	32	245	251	2	63	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1492	1495		10.1126/science.7770775	http://dx.doi.org/10.1126/science.7770775			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770775				2022-12-24	WOS:A1995RC19000039
J	KIEFHABER, T; LABHARDT, AM; BALDWIN, RL				KIEFHABER, T; LABHARDT, AM; BALDWIN, RL			DIRECT NMR EVIDENCE FOR AN INTERMEDIATE PRECEDING THE RATE-LIMITING STEP IN THE UNFOLDING OF RIBONUCLEASE-A	NATURE			English	Article							STRUCTURAL CHARACTERIZATION; TRANSITION-STATE; PROTEIN; LYSOZYME	IT is commonly believed that there are no detectable intermediates in the kinetic unfolding reactions of small proteins(1-6). If such intermediates could be found, they would give important information about the nature of the transition state for unfolding, which is thought to occur close to the native state. We report here that one-dimensional proton magnetic resonance spectra recorded during the unfolding of ribonuclease A provide direct evidence for at least one unfolding intermediate in which side chains are free to rotate. This intermediate appears to be a 'dry molten globule' of the kind hypothesized by Shakhnovich and Finkelstein(7).	F HOFFMANN LA ROCHE & CO LTD,PHARMA RES NEW TECHNOL,CH-4002 BASEL,SWITZERLAND; STANFORD UNIV,MED CTR,DEPT BIOCHEM,STANFORD,CA 94305	Roche Holding; Stanford University	KIEFHABER, T (corresponding author), UNIV BASEL,BIOCTR,BIOPHYS CHEM ABT,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.		Kiefhaber, Thomas/A-3028-2010					CHEN BL, 1989, BIOCHEMISTRY-US, V28, P691, DOI 10.1021/bi00428a042; CHEN XW, 1994, BIOCHEMISTRY-US, V33, P6356, DOI 10.1021/bi00186a040; DOBSON CM, 1994, TRENDS BIOCHEM SCI, V19, P31, DOI 10.1016/0968-0004(94)90171-6; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; JENG MF, 1990, BIOCHEMISTRY-US, V29, P10433, DOI 10.1021/bi00498a001; KIEFHABER T, 1995, P NATL ACAD SCI USA, V92, P2657, DOI 10.1073/pnas.92.7.2657; KUWAJIMA K, 1989, J MOL BIOL, V206, P547, DOI 10.1016/0022-2836(89)90500-7; MUCKE M, 1994, BIOCHEMISTRY-US, V33, P12930; PITITSYN GB, 1992, PROTEIN FOLDING, P243; RICO M, 1989, EUR J BIOCHEM, V183, P623, DOI 10.1111/j.1432-1033.1989.tb21092.x; ROBERTSON AD, 1989, BIOCHEMISTRY-US, V28, P5930, DOI 10.1021/bi00440a033; Schmid Franz X., 1992, P197; SEGAWA SI, 1984, BIOPOLYMERS, V23, P2473; SERRANO L, 1992, J MOL BIOL, V224, P805, DOI 10.1016/0022-2836(92)90563-Y; SHAKHNOVICH EI, 1989, BIOPOLYMERS, V28, P1667, DOI 10.1002/bip.360281003; VANDAEL H, 1993, BIOCHEMISTRY-US, V32, P11886, DOI 10.1021/bi00095a018; Wuthrich K., 1986, NMR PROTEINS NUCL AC	17	146	146	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					513	515		10.1038/375513a0	http://dx.doi.org/10.1038/375513a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777063				2022-12-24	WOS:A1995RC18800055
J	ARNOW, P; CHAMBERLIN, W				ARNOW, P; CHAMBERLIN, W			DEBUGGING COMPUTER-ASSISTED ANTIBIOTIC PRESCRIBING	LANCET			English	Editorial Material									MICHAEL REESE HOSP & MED CTR,CHICAGO,IL 60616	Michael Reese Hospital & Medical Center	ARNOW, P (corresponding author), UNIV CHICAGO HOSP & CLIN,DEPT MED,CHICAGO,IL 60637, USA.							EVANS RS, 1994, ARCH INTERN MED, V154, P878, DOI 10.1001/archinte.154.8.878; GARDNER FT, 1979, ARCH SURG-CHICAGO, V114, P883; GROSS PA, 1994, CLIN INFECT DIS, V18, P421, DOI 10.1093/clinids/18.3.421; HIRSCHMAN SZ, 1988, ARCH INTERN MED, V148, P2001, DOI 10.1001/archinte.148.9.2001; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; MOSS FM, 1981, LANCET, V2, P407; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; STURM AW, 1988, J ANTIMICROB CHEMOTH, V22, P257, DOI 10.1093/jac/22.2.257; YU VI, 1976, JAMA-J AM MED ASSOC, V242, P1279; YU VL, 1991, AM J MED SCI, V301, P165, DOI 10.1097/00000441-199103000-00003; 1994, J ANTIMICROB CHEMOTH, V34, P21	11	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					207	208		10.1016/S0140-6736(95)90219-8	http://dx.doi.org/10.1016/S0140-6736(95)90219-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823711				2022-12-24	WOS:A1995QD53200005
J	HAWTON, K; WARE, C; MISTRY, H; HEWITT, J; KINGSBURY, S; ROBERTS, D; WEITZEL, H				HAWTON, K; WARE, C; MISTRY, H; HEWITT, J; KINGSBURY, S; ROBERTS, D; WEITZEL, H			WHY PATIENTS CHOOSE PARACETAMOL FOR SELF-POISONING AND THEIR KNOWLEDGE OF ITS DANGERS	BRITISH MEDICAL JOURNAL			English	Article									JOHN RADCLIFFE HOSP,DEPT PSYCHOL MED,BARNES UNIT,OXFORD OX3 9DX,ENGLAND	University of Oxford	HAWTON, K (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND.							BRAY GP, 1993, BRIT MED J, V306, P157, DOI 10.1136/bmj.306.6871.157; GAZZARD BG, 1976, BRIT MED J, V1, P212, DOI 10.1136/bmj.1.6003.212; HAWTON K, 1992, BRIT MED J, V304, P1409, DOI 10.1136/bmj.304.6839.1409; OGRADY JG, 1991, BRIT MED J, V303, P221, DOI 10.1136/bmj.303.6796.221; SPOONER JB, 1993, PHARM J, V250, P706	5	84	85	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 21	1995	310	6973					164	164		10.1136/bmj.310.6973.164	http://dx.doi.org/10.1136/bmj.310.6973.164			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD201	7833757	Green Published			2022-12-24	WOS:A1995QD20100023
J	CHEN, J; MAKINO, CL; PEACHEY, NS; BAYLOR, DA; SIMON, MI				CHEN, J; MAKINO, CL; PEACHEY, NS; BAYLOR, DA; SIMON, MI			MECHANISMS OF RHODOPSIN INACTIVATION IN-VIVO AS REVEALED BY A COOH-TERMINAL TRUNCATION MUTANT	SCIENCE			English	Article							DOMINANT RETINITIS-PIGMENTOSA; ROD OUTER SEGMENTS; COUPLED RECEPTOR KINASES; PHOSPHORYLATION SITES; TRANSGENIC MICE; PROTEIN; GENE; DESENSITIZATION; PHOTORECEPTORS; TRANSDUCTION	Although biochemical experiments suggest that rhodopsin and other receptors coupled to heterotrimeric guanosine triphosphate-binding proteins (G proteins) are inactivated by phosphorylation near the carboxyl (COOH)-terminus and the subsequent binding of a capping protein, little is known about the quenching process in vivo. Flash responses were recorded from rods of transgenic mice in which a fraction of the rhodopsin molecules lacked the COOH-terminal phosphorylation sites. In the single photon regime, abnormally prolonged responses, attributed to activation of individual truncated rhodopsins, occurred interspersed with normal responses. The occurrence of the prolonged responses suggests that phosphorylation is required for normal shutoff. Comparison of normal and prolonged single photon responses indicated that rhodopsin begins to be quenched before the peak of the electrical response and that quenching limits the response amplitude.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; EDWARD HINES JR VET ADM HOSP,HINES,IL 60141; LOYOLA UNIV,STRITCH SCH MED,DEPT NEUROL,MAYWOOD,IL 60153	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Loyola University Chicago	CHEN, J (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.		Makino, Clint Lawrence/H-8428-2019; Peachey, Neal/G-5533-2010	Makino, Clint Lawrence/0000-0002-6005-9069; Peachey, Neal/0000-0002-4419-7226	NATIONAL EYE INSTITUTE [F32EY006405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012288] Funding Source: NIH RePORTER; NEI NIH HHS [F32 EY06405, EY0570] Funding Source: Medline; NIA NIH HHS [AG12288] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; APFELSTEDTSYLLA E, 1993, BRIT J OPHTHALMOL, V77, P495, DOI 10.1136/bjo.77.8.495; BAUMANN C, 1973, J PHYSIOL-LONDON, V235, P761, DOI 10.1113/jphysiol.1973.sp010415; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BENNETT N, 1980, BIOCHEM BIOPH RES CO, V96, P1695, DOI 10.1016/0006-291X(80)91369-8; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BRETON ME, 1994, INVEST OPHTH VIS SCI, V35, P295; CHEN J, 1993, INVEST OPHTH VIS SCI, V34, P768; CONE RA, 1969, NATURE, V221, P820, DOI 10.1038/221820a0; EBREY TG, 1968, VISION RES, V8, P965, DOI 10.1016/0042-6989(68)90071-0; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; HARGRAVE PA, 1992, INT REV CYTOL, V137B, P49; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HOOD DC, 1990, VISUAL NEUROSCI, V5, P379, DOI 10.1017/S0952523800000468; HORN M, 1992, HUM GENET, V90, P255; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KIM RY, 1993, ARCH OPHTHALMOL-CHIC, V111, P1518, DOI 10.1001/archopht.1993.01090110084030; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MCDOWELL JH, 1985, INVEST OPHTH VIS SCI, V26, P291; MILLER JL, 1984, VISION RES, V24, P1509, DOI 10.1016/0042-6989(84)90313-4; NEWTON AC, 1991, J BIOL CHEM, V266, P17725; NEWTON AC, 1993, J BIOL CHEM, V268, P18181; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PEACHEY NS, UNPUB; PENN RD, 1969, NATURE, V223, P201, DOI 10.1038/223201a0; RESTAGNO G, 1993, HUM MOL GENET, V2, P207, DOI 10.1093/hmg/2.2.207; SUNG CH, 1994, J NEUROSCI, V14, P5818; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; WEHNER M, 1987, ADV BIOSCI, V62, P345; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; WILLIAMS DS, 1989, EXP EYE RES, V49, P439, DOI 10.1016/0014-4835(89)90052-3; WILSON CJ, 1993, CURR BIOL, V3, P683, DOI 10.1016/0960-9822(93)90068-Y	39	258	262	1	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 20	1995	267	5196					374	377		10.1126/science.7824934	http://dx.doi.org/10.1126/science.7824934			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7824934				2022-12-24	WOS:A1995QC27300034
J	HYNES, M; POULSEN, K; TESSIERLAVIGNE, M; ROSENTHAL, A				HYNES, M; POULSEN, K; TESSIERLAVIGNE, M; ROSENTHAL, A			CONTROL OF NEURONAL DIVERSITY BY THE FLOOR PLATE - CONTACT-MEDIATED INDUCTION OF MIDBRAIN DOPAMINERGIC-NEURONS	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; TYROSINE-HYDROXYLASE; CELL PATTERN; SUBSTANTIA-NIGRA; RAT; DIFFERENTIATION; EXPRESSION; SIGNALS; LOCALIZATION; RECEPTORS	The notochord and floor plate contribute to patterning the ventral neural tube in part by expressing a diffusible factor that induces motoneurons. To determine the mechanisms that direct the development of other classes of ventral neurons, we studied the development of dopaminergic neurons that reside near motoneurons in the ventral midbrain. We provide evidence that dopaminergic neurons develop in the vicinity of the floor plate and that they can be specified by the floor plate in vitro and in vivo. Unlike motoneurons, efficient induction of dopaminergic neurons requires contact with floor plate cells. These results suggest that neuronal diversification along the dorsal-ventral axis may be achieved partly through the concerted action of diffusible and contact-dependent signals from a single organizing center, the floor plate.	GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080; UNIV CALIF SAN FRANCISCO,DEPT ANAT,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM CELL BIOL,SAN FRANCISCO,CA 94143	Roche Holding; Genentech; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco				Hynes, Mary/0000-0001-6623-6727				ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ALTMAN J, 1981, J COMP NEUROL, V198, P677, DOI 10.1002/cne.901980409; BANERJEE SA, 1992, J NEUROSCI, V12, P4460; BAPTISTA CA, 1994, NEURON, V12, P243, DOI 10.1016/0896-6273(94)90268-2; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; DONIACH T, 1993, J NEUROBIOL, V24, P1256, DOI 10.1002/neu.480241003; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; GAO WQ, 1992, CELL, V68, P841, DOI 10.1016/0092-8674(92)90028-B; GAO WQ, 1991, NEURON, V6, P705, DOI 10.1016/0896-6273(91)90168-Y; GREENBERG D, 1974, SCIENCE, V184, P1243; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0; JESSELL TM, 1992, HARVEY LECT, V86, P87; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAUDER JM, 1974, J COMP NEUROL, V155, P469, DOI 10.1002/cne.901550407; LUMSDEN A, 1994, DEVELOPMENT, V120, P1581; LUSKIN MB, 1993, J NEUROSCI, V13, P1730; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MARCHAND R, 1983, NEUROSCIENCE, V9, P373, DOI 10.1016/0306-4522(83)90300-7; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7772, DOI 10.1073/pnas.91.16.7772; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; PICKEL VM, 1975, J HISTOCHEM CYTOCHEM, V23, P1, DOI 10.1177/23.1.234988; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PUELLES L, 1993, TRENDS NEUROSCI, V16, P472, DOI 10.1016/0166-2236(93)90080-6; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SEEMAN P, 1993, NATURE, V365, P441, DOI 10.1038/365441a0; SMITH JC, 1994, CELL, V76, P193, DOI 10.1016/0092-8674(94)90325-5; SPECHT LA, 1981, J COMP NEUROL, V199, P255, DOI 10.1002/cne.901990208; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; VOORN P, 1988, NEUROSCIENCE, V25, P857, DOI 10.1016/0306-4522(88)90041-3; WATANABE T, 1990, NEURON, V2, P461; YAGINUMA H, 1991, J COMP NEUROL, V304, P78, DOI 10.1002/cne.903040107; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	41	204	212	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					95	101		10.1016/0092-8674(95)90454-9	http://dx.doi.org/10.1016/0092-8674(95)90454-9			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813022	Bronze			2022-12-24	WOS:A1995QB91000013
J	COURIEL, JM				COURIEL, JM			GLUE EAR - PRESCRIBE, OPERATE, OR WAIT	LANCET			English	Editorial Material							CHILDREN				COURIEL, JM (corresponding author), BOOTH HALL CHILDRENS HOSP,DEPT MED,MANCHESTER,LANCS,ENGLAND.							BERMAN S, 1994, PEDIATRICS, V93, P353; BLACK NA, 1990, BRIT MED J, V300, P1551, DOI 10.1136/bmj.300.6739.1551; DEMELKER RA, 1993, BRIT MED J, V306, P5, DOI 10.1136/bmj.306.6869.5; GATES GA, 1987, NEW ENGL J MED, V317, P1441; MAW AR, 1994, CLIN OTOLARYNGOL, V19, P125, DOI 10.1111/j.1365-2273.1994.tb01195.x; MAW R, 1993, BMJ-BRIT MED J, V306, P756, DOI 10.1136/bmj.306.6880.756; Paradise J L, 1992, Adv Pediatr, V39, P157; 1992, EFFECTIVE HLTH CARE	8	7	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					3	4		10.1016/S0140-6736(95)91144-8	http://dx.doi.org/10.1016/S0140-6736(95)91144-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799705				2022-12-24	WOS:A1995QA29000003
J	ZOMERDIJK, JCBM; BECKMANN, H; COMAI, L; TJIAN, R				ZOMERDIJK, JCBM; BECKMANN, H; COMAI, L; TJIAN, R			ASSEMBLY OF TRANSCRIPTIONALLY ACTIVE RNA-POLYMERASE-I INITIATION-FACTOR SL1 FROM RECOMBINANT SUBUNITS	SCIENCE			English	Article							FACTOR-TIF-IA; TATA-BINDING-PROTEIN; VACCINIA VIRUS; EXPRESSION SYSTEM; III TRANSCRIPTION; RIBOSOMAL DNA; MOUSE RDNA; PROMOTER; COMPLEX; SEQUENCES	Initiation of ribosomal RNA synthesis by RNA polymerase I requires the promoter selec tivity factor SL1, which consists of the TATA-binding protein, TBP, and three associated factors, TAF(I)s 110, 63, and 48. Here the in vivo and in vitro assembly of functional SL1 complexes from recombinant TAF(I)s and TBP are reported. Complexes containing TBP and all three TAF(I)s were as active in supporting transcription from the human ribosomal RNA gene promoter as endogenous SL1, whereas partial complexes without TBP did not efficiently direct transcription in vitro. These results suggest that TAF(I)s 110, 63, and 48, together with TBP, are necessary and sufficient to reconstitute a transcriptionally active SL1 complex.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley			Comai, Lucio/H-9524-2019; Zomerdijk, Joost/A-5142-2008; Comai, Lucio/L-5905-2019	Comai, Lucio/0000-0003-3109-1841; Zomerdijk, Joost/0000-0003-1865-729X				BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BUTTGEREIT D, 1985, NUCLEIC ACIDS RES, V13, P8165, DOI 10.1093/nar/13.22.8165; CAVANAUGH AH, 1985, NUCLEIC ACIDS RES, V13, P3357, DOI 10.1093/nar/13.9.3357; CLOS J, 1986, P NATL ACAD SCI USA, V83, P604, DOI 10.1073/pnas.83.3.604; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; MCSTAY B, 1991, EMBO J, V10, P2297, DOI 10.1002/j.1460-2075.1991.tb07766.x; MISHIMA Y, 1982, NUCLEIC ACIDS RES, V10, P6659, DOI 10.1093/nar/10.21.6659; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; REEDER RH, 1992, REGULATION TRANSCRIP, V1, P315; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SCHNAPP A, 1993, MOL CELL BIOL, V13, P6723, DOI 10.1128/MCB.13.11.6723; SCHNAPP G, 1994, EMBO J, V13, P4028, DOI 10.1002/j.1460-2075.1994.tb06719.x; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; TOWER J, 1987, CELL, V50, P873, DOI 10.1016/0092-8674(87)90514-9; TOWER J, 1986, MOL CELL BIOL, V6, P3451, DOI 10.1128/MCB.6.10.3451	26	97	99	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					2015	2018		10.1126/science.7801130	http://dx.doi.org/10.1126/science.7801130			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801130				2022-12-24	WOS:A1994PZ26700036
J	WRIGHT, N; CAPLAN, R; PAYNE, S				WRIGHT, N; CAPLAN, R; PAYNE, S			COMMUNITY SURVEY OF LONG-TERM DAYTIME USE OF BENZODIAZEPINES	BRITISH MEDICAL JOURNAL			English	Article									LINCOLN CTY HOSP,PETER HODGKINSON CTR,LINCOLN LN2 5QY,ENGLAND; MAPPERLEY HOSP,NOTTINGHAM NG3 6AA,ENGLAND									ASHTON H, 1989, BRIT J ADDICT, V84, P541; TAYLOR D, 1987, BENZODIAZEPINES CURR, P13; TYRER P, 1990, J AFFECT DISORDERS, V19, P53, DOI 10.1016/0165-0327(90)90009-W; Tyrer P J, 1984, Br Med J (Clin Res Ed), V288, P1101; 1988, CURRENT PROBLEMS, V21, P1	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 2	1994	309	6946					27	28		10.1136/bmj.309.6946.27	http://dx.doi.org/10.1136/bmj.309.6946.27			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NV891	7802775	Green Published			2022-12-24	WOS:A1994NV89100020
J	CRAVATT, BF; PROSPEROGARCIA, O; SIUZDAK, G; GILULA, NB; HENRIKSEN, SJ; BOGER, DL; LERNER, RA				CRAVATT, BF; PROSPEROGARCIA, O; SIUZDAK, G; GILULA, NB; HENRIKSEN, SJ; BOGER, DL; LERNER, RA			CHEMICAL CHARACTERIZATION OF A FAMILY OF BRAIN LIPIDS THAT INDUCE SLEEP	SCIENCE			English	Article							FATTY-ACID AMIDES	A molecule isolated from the cerebrospinal fluid of sleep-deprived cats has been chemically characterized and identified as cis-9,10-octadecenoamide. Other fatty acid primary amides in addition to cis-9,10-octadecenoamide were identified as natural constituents of the cerebrospinal fluid of cat, rat, and human, indicating that these compounds compose a distinct family of brain lipids. Synthetic cis-9,10-octadecenoamide induced physiological sleep when injected into rats. Together, these results suggest that fatty acid primary amides may represent a previously unrecognized class of biological signaling molecules.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute			Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604; Siuzdak, Gary/0000-0002-4749-0014	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR007273] Funding Source: NIH RePORTER; NCRR NIH HHS [1 S10 RR07273-01] Funding Source: Medline; NIDA NIH HHS [R01 DA015648] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ARAFAT ES, 1989, LIFE SCI, V45, P1679, DOI 10.1016/0024-3205(89)90278-6; CHRISTIE WW, 1973, LIPID ANAL, P128; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; GENARD S, 1991, B SOC CHIM FR, P397; INOUE S, 1989, BIOL SLEEP SUBSTANCE; JAIN MK, 1992, J MED CHEM, V35, P3584, DOI 10.1021/jm00097a018; LERNER RA, 1994, P NATL ACAD SCI USA, V91, P9505, DOI 10.1073/pnas.91.20.9505; PRIVETT OS, 1966, PROGR CHEMISTRY FATS, V9, P91; PROSPEROGARCIA O, 1994, PHARMACOL BIOCHEM BE, V49, P413, DOI 10.1016/0091-3057(94)90442-1; SCHOENENBERGER GA, 1984, EUR NEUROL, V23, P321, DOI 10.1159/000115711; UENO R, 1982, BIOCHEM BIOPH RES CO, V109, P576, DOI 10.1016/0006-291X(82)91760-0; WAKAMATSU K, 1990, BIOCHEM BIOPH RES CO, V168, P423, DOI 10.1016/0006-291X(90)92338-Z	14	535	565	1	35	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1506	1509		10.1126/science.7770779	http://dx.doi.org/10.1126/science.7770779			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770779				2022-12-24	WOS:A1995RC19000043
J	WHITE, N; COHEN, S				WHITE, N; COHEN, S			TRADEMARKS MUST NOT GO GENERIC	NATURE			English	Editorial Material											WHITE, N (corresponding author), TAYLOR JOYNSON GARRETT,50 VICTORIA EMBANKMENT,LONDON EC4Y 0DX,ENGLAND.							1995, NATURE, V373, P370; 1995, NATURE, V374, P208	2	1	1	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					432	432		10.1038/375432a0	http://dx.doi.org/10.1038/375432a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760941	Bronze			2022-12-24	WOS:A1995RB10100063
J	CHIANG, CM; ROEDER, RG				CHIANG, CM; ROEDER, RG			CLONING OF AN INTRINSIC HUMAN TFIID SUBUNIT THAT INTERACTS WITH MULTIPLE TRANSCRIPTIONAL ACTIVATORS	SCIENCE			English	Article							RNA POLYMERASE-II; TATA-BINDING PROTEIN; NF-KAPPA-B; FUNCTIONAL-ANALYSIS; LESS PROMOTER; EXPRESSION; COMPLEX; VP16; IDENTIFICATION; COACTIVATORS	TFIID is a multisubunit protein complex comprised of the TATA-binding protein (TBP) and multiple TBP-associated factors (TAFs). The TAFs in TFIID are essential for activator-dependent transcription, The cloning of a complementary DNA encoding a human TFIID TAF, TAF(II)55, that has no known homolog in Drosophila TFIID is now described. TAF(II)55 is shown to interact with the largest subunit(TAF(II)230) of human TFIID through its central region and with multiple activators-including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins-through a distinct amino-terminal domain. The TAF(II)55-interacting region of Sp1 was localized to its DNA-binding domain, which is distinct from the glutamine-rich activation domains previously shown to interact with Drosophila TAF(II)110. Thus, this human TFIID TAF may be a co-activator that mediates a response to multiple activators through a distinct mechanism.	ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021	Rockefeller University								BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; Chiang C M, 1993, Methods Mol Biol, V15, P189, DOI 10.1385/0-89603-244-2:189; Chiang C.-W., UNPUB; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1993, PEPTIDE RES, V6, P62; CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOFFMANN A, UNPUB; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; KAULEN H, 1991, MOL CELL BIOL, V11, P412, DOI 10.1128/MCB.11.1.412; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1993, J BIOL CHEM, V268, P17554; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; REINBERG D, 1987, J BIOL CHEM, V262, P3310; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	49	362	369	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 27	1995	267	5197					531	536		10.1126/science.7824954	http://dx.doi.org/10.1126/science.7824954			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824954				2022-12-24	WOS:A1995QD40300044
J	LUESCHER, IF; VIVIER, E; LAYER, A; MAHIOU, J; GODEAU, F; MALISSEN, B; ROMERO, P				LUESCHER, IF; VIVIER, E; LAYER, A; MAHIOU, J; GODEAU, F; MALISSEN, B; ROMERO, P			CD8 MODULATION OF T-CELL ANTIGEN RECEPTOR-LIGAND INTERACTIONS ON LIVING CYTOTOXIC T-LYMPHOCYTES	NATURE			English	Article							PHYSICAL ASSOCIATION; BETA-CHAIN; MOLECULES; BINDING; ACTIVATION; EXPRESSION; COMPLEX; KINASE; CD45	THYMOCYTES and class I major histocompatibility complex (MHC)-restricted cytotoxic T lymphocytes express predominantly heterodimeric alpha/beta CD8(1,2). By interacting with non-polymorphic regions of MHC class I molecules CD8 can mediate adhesion(3-6) or by binding the same MHC molecules that interact with the T-cell antigen receptor (TCR) function as coreceptor in TCR-ligand binding and T-cell activation(1,2). Using TCR photoaffinity labelling with a soluble, monomeric photoreactive H-2K(d)-peptide derivative complex(7), we report here that the avidity of TCR-ligand interactions on cloned cytotoxic T cells is very greatly strengthened by CD8. This is primarily explained by coordinate binding of ligand molecules by CD8 and TCR, because substitution of Asp 227 of K-d with LYS severely impaired the TCR-ligand binding on CD8(+), but not CD8(-) cells. Kinetic studies on CD8(+) and CD8(-) cells further showed that CD8 imposes distinct dynamics and a remarkable temperature dependence on TCR-ligand interactions. We propose that the ability of CD8 to act as coreceptor can be modulated by CD8-TCR interactions.	CTR IMMUNOL,INSERM CNRS MARSEILLE LUMINY,F-13288 MARSEILLE 9,FRANCE; FAC MED NECKER ENFANTS MALAD,INSERM,U373,F-75730 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	LUESCHER, IF (corresponding author), UNIV LAUSANNE,LUDWIG INST CANC RES,LAUSANNE BRANCH,CH-1066 EPALINGES,SWITZERLAND.		Vivier, Eric/F-8939-2010; Romero, Pedro/S-6015-2017; Malissen, Bernard/AAK-4659-2020	Vivier, Eric/0000-0001-7022-8287; Romero, Pedro/0000-0002-9688-2882; Malissen, Bernard/0000-0003-1340-9342				BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; CARBONE AM, 1988, J IMMUNOL, V141, P1369; DIANZANI U, 1992, EUR J IMMUNOL, V22, P365, DOI 10.1002/eji.1830220212; DIANZANI U, 1992, J IMMUNOL, V148, P678; EICHMANN K, 1991, J IMMUNOL, V147, P2075; GALLAGHER PF, 1989, P NATL ACAD SCI USA, V86, P10044, DOI 10.1073/pnas.86.24.10044; GOLSTEIN P, 1982, IMMUNOL REV, V68, P5, DOI 10.1111/j.1600-065X.1982.tb01058.x; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; KARAKI S, 1992, J IMMUNOL, V149, P1613; LUESCHER IF, 1994, J BIOL CHEM, V269, P5574; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MICELI MC, 1993, ADV IMMUNOL, V53, P59, DOI 10.1016/S0065-2776(08)60498-8; NAKAYAMA K, 1994, SCIENCE, V263, P1131, DOI 10.1126/science.8108731; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; OROURKE AM, 1993, IMMUNOL TODAY, V14, P183; OROURKE AM, 1990, NATURE, V346, P187, DOI 10.1038/346187a0; RATNOFSKY SE, 1987, J EXP MED, V166, P1747, DOI 10.1084/jem.166.6.1747; ROMERO P, 1993, J EXP MED, V177, P1247, DOI 10.1084/jem.177.5.1247; ROMERO P, 1993, J IMMUNOL, V150, P3825; ROMERO P, 1994, J IMMUNOL METHODS, V171, P73, DOI 10.1016/0022-1759(94)90230-5; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; SUZUKI S, 1992, EUR J IMMUNOL, V22, P2475, DOI 10.1002/eji.1830221002; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TOMONARI K, 1990, INT IMMUNOL, V2, P1189, DOI 10.1093/intimm/2.12.1189; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WHEELER CJ, 1992, NATURE, V357, P247, DOI 10.1038/357247a0; WHITE J, 1989, J IMMUNOL, V143, P1822; YAMANE Y, 1991, CELL IMMUNOL, V136, P496, DOI 10.1016/0008-8749(91)90370-Q	30	207	211	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					353	356		10.1038/373353a0	http://dx.doi.org/10.1038/373353a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830771				2022-12-24	WOS:A1995QD40400063
J	RUDEL, T; SCHEUERPFLUG, I; MEYER, TF				RUDEL, T; SCHEUERPFLUG, I; MEYER, TF			NEISSERIA PILC PROTEIN IDENTIFIED AS TYPE-4 PILUS TIP LOCATED ADHESIN	NATURE			English	Article							HUMAN EPITHELIAL-CELLS; ANTIGENIC VARIATION; ESCHERICHIA-COLI; VIBRIO-CHOLERAE; PHASE VARIATION; GONORRHOEAE; SEQUENCE; GENE; MENINGITIDIS; ORGANIZATION	TYPE-4 pilus-mediated adherence of Neisseria gonorrhoeae and Neisseria meningitidis is considered to be a crucial early event in neisserial infections(1,2). In addition to the principal pilus subunit (pilin or PilE), both pathogens produce low quantities of a phase-variable PilC protein which is implicated in pilus biogenesis and pilus-mediated epithelial cell adherence(3,4). The identity, however, of the pilus adhesin has remained obscure(4,5). Here we describe the isolation of a PilC protein from a gonococcal overproducing strain and demonstrate its specific interaction with human epithelial cells. Our results are consistent with the cell and species tropisms of neisserial infections. Binding of PilC effectively competes with pilus-mediated, but not Opa-mediated(6), attachment of N. gonorrhoeae and of N. meningitidis, indicating that both pathogens interact with identical or very similar epithelial cell receptors. Immunogold electron microscopy using antisera raised against purified PilC and synthetic peptides locates PilC at the tip of gonococcal pill. PilC thus represents an essential pilus-associated adhesin, providing a rationale for selective protection against neisserial infections.	MAX PLANCK INST INFEKT BIOL,D-10117 BERLIN,GERMANY	Max Planck Society	RUDEL, T (corresponding author), MAX PLANCK INST BIOL,INFEKT BIOL ABT,SPEMANNSTR 34,D-72076 TUBINGEN,GERMANY.		Meyer, Thomas F. F/J-2485-2013	Meyer, Thomas F. F/0000-0002-6120-8679				GIRON JA, 1994, MOL MICROBIOL, V12, P71, DOI 10.1111/j.1365-2958.1994.tb00996.x; GIRON JA, 1991, SCIENCE, V254, P710, DOI 10.1126/science.1683004; HAAS R, 1992, MOL MICROBIOL, V6, P197, DOI 10.1111/j.1365-2958.1992.tb02001.x; HAGBLOM P, 1985, NATURE, V315, P156, DOI 10.1038/315156a0; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; JOHNSON SC, 1991, J INFECT DIS, V163, P128, DOI 10.1093/infdis/163.1.128; JONSSON AB, 1991, EMBO J, V10, P477, DOI 10.1002/j.1460-2075.1991.tb07970.x; KELLOGG DS, 1968, J BACTERIOL, V96, P596, DOI 10.1128/JB.96.3.596-605.1968; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; LEE KK, 1994, MOL MICROBIOL, V11, P705, DOI 10.1111/j.1365-2958.1994.tb00348.x; MAKINO S, 1991, EMBO J, V10, P1307, DOI 10.1002/j.1460-2075.1991.tb07649.x; Meyer T F, 1994, Curr Top Microbiol Immunol, V192, P283; MEYER TF, 1984, P NATL ACAD SCI-BIOL, V81, P6110, DOI 10.1073/pnas.81.19.6110; MUIR LL, 1988, INFECT IMMUN, V56, P1743, DOI 10.1128/IAI.56.7.1743-1747.1988; NASSIF X, 1994, P NATL ACAD SCI USA, V91, P3769, DOI 10.1073/pnas.91.9.3769; NASSIF X, 1993, MOL MICROBIOL, V8, P719, DOI 10.1111/j.1365-2958.1993.tb01615.x; OGIERMAN MA, 1993, GENE, V126, P51, DOI 10.1016/0378-1119(93)90589-U; PARGE HE, 1990, J BIOL CHEM, V265, P2278; POHLNER J, 1993, GENE, V130, P121, DOI 10.1016/0378-1119(93)90354-6; ROTHBARD JB, 1985, P NATL ACAD SCI USA, V82, P915, DOI 10.1073/pnas.82.3.915; RUDEL T, 1992, MOL MICROBIOL, V6, P3439, DOI 10.1111/j.1365-2958.1992.tb02211.x; SASTRY PA, 1983, FEBS LETT, V151, P253, DOI 10.1016/0014-5793(83)80080-5; SHAW CE, 1990, INFECT IMMUN, V58, P3042, DOI 10.1128/IAI.58.9.3042-3049.1990; SWANSON J, 1987, J EXP MED, V165, P1016, DOI 10.1084/jem.165.4.1016; VIRJI M, 1992, MOL MICROBIOL, V6, P1271, DOI 10.1111/j.1365-2958.1992.tb00848.x; VIRJI M, 1993, MOL MICROBIOL, V10, P10131; WANG JF, 1992, INFECT IMMUN, V60, P5267, DOI 10.1128/IAI.60.12.5267-5282.1992	27	240	248	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					357	359		10.1038/373357a0	http://dx.doi.org/10.1038/373357a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830772				2022-12-24	WOS:A1995QD40400064
J	MCNAMARA, RM; MONTI, S; KELLY, JJ				MCNAMARA, RM; MONTI, S; KELLY, JJ			REQUESTING CONSENT FOR AN INVASIVE PROCEDURE IN NEWLY DECEASED ADULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							INTUBATION; INFANTS; TEACH; DEAD	Objective.-Ethical concerns exist over the performance of medical procedures, such as endotracheal intubation, on newly deceased patients without family consent. This study examined the process of obtaining consent for the purpose of performing an invasive procedure in newly deceased adults. Design.-A prospective case series. Participants.-The families of patients who died during a 5-month period were requested to provide consent to perform wire-guided retrograde tracheal intubation. Main Outcome Measures.-Differences between success and failure in obtaining consent including information on the deceased, family reasons for their decision, and the experience of those requesting consent. Results.-Consent was requested from 44 families and 26 (59%) agreed to the procedure. This success rate was achieved despite the lack of a prior relationship with the family by the persons requesting consent. Consent was obtained more frequently in unexpected than expected deaths (77% vs 41%, P=.03). There were no differences in success rates for consent for age, race, sex, or do-not-resuscitate status of the deceased. Spouses consented more frequently than children (77% vs 50%, P=.25). The two physicians reported greater comfort in requesting consent than the nurse anesthetist investigator. In one instance, the consent process may have increased the emotional distress of the family. Conclusion.-Consent can frequently be obtained from families for an invasive procedure in newly deceased adults. Physicians should reconsider the practice of performing postmortem procedures without obtaining family consent.	MED COLL PENN,DEPT ANESTHESIOL,PHILADELPHIA,PA 19129	Drexel University	MCNAMARA, RM (corresponding author), MED COLL PENN,DEPT EMERGENCY MED,3300 HENRY AVE,PHILADELPHIA,PA 19129, USA.							BENFIELD DG, 1991, JAMA-J AM MED ASSOC, V265, P2360, DOI 10.1001/jama.265.18.2360; BURNS JP, 1994, NEW ENGL J MED, V331, P1652, DOI 10.1056/NEJM199412153312411; ISERSON KV, 1986, HASTINGS CENT REP, V16, P28, DOI 10.2307/3563273; ISERSON KV, 1993, J MED ETHICS, V19, P92, DOI 10.1136/jme.19.2.92; MCNAMARA RM, 1987, ANN EMERG MED, V16, P680, DOI 10.1016/S0196-0644(87)80071-9; MORHAIM D K, 1991, Journal of Emergency Medicine, V9, P515, DOI 10.1016/0736-4679(91)90233-6; ORLOWSKI JP, 1988, NEW ENGL J MED, V319, P439, DOI 10.1056/NEJM198808183190710; REITZ NN, 1993, J NATL MED ASSOC, V85, P353; SCHILLACI RF, 1976, NEW ENGL J MED, V295, P488, DOI 10.1056/NEJM197608262950907; TACHAKRA SS, 1991, JAMA-J AM MED ASSOC, V266, P1649, DOI 10.1001/jama.1991.03470120051027; TOLLE SW, 1984, ARCH INTERN MED, V144, P2389, DOI 10.1001/archinte.144.12.2389; TONKS A, 1992, BRIT MED J, V305, P332	12	47	47	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					310	312		10.1001/jama.273.4.310	http://dx.doi.org/10.1001/jama.273.4.310			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC057	7815659				2022-12-24	WOS:A1995QC05700030
J	JOHNSON, RP; CRAIG, SW				JOHNSON, RP; CRAIG, SW			F-ACTIN BINDING-SITE MASKED BY THE INTRAMOLECULAR ASSOCIATION OF VINCULIN HEAD AND TAIL DOMAINS	NATURE			English	Article							SELF-ASSOCIATION; ESCHERICHIA-COLI; ALPHA-ACTININ; SMOOTH-MUSCLE; PURIFICATION; PROTEINS; METAVINCULIN; FILAMENTS; SEQUENCE; CDNA	ALTHOUGH vinculin is present at all sites of F-actin attachment to plasma membranes(1) acid is required for linkage of myofibrils to sarcolemma(2), it is unclear how it promotes attachment of actin to membranes. Because biochemical evidence for a direct interaction of vinculin with F-actin is controversial(3-9), current models of actin-membrane linkages depict only an indirect role for vinculin, as a tether for alpha-actinin(10). We demonstrate here that an intramolecular association between the 95K head and 30K tail domains of vinculin(11) masks an F-actin binding site present in the carboxyterminal tail domain. Cosedimentation and crosslinking assays, and direct visualization by transmission electron microscopy, reveal an interaction between F-actin and a bacterially expressed fusion protein containing amino acids 811-1066 of vinculin, and between F-actin and a proteolytic fragment of vinculin containing amino acids 858-1066. Vinculin itself neither cosediments with nor crosslinks F-actin. The amino-terminal 95K head fragment of vinculin, but not intact vinculin, inhibits both cosedimentation and crosslinking. We propose that assembly of vinculin into an adherens junction involves disruption of the head-tail interaction, revealing a site that mediates microfilament attachment.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University								BARSTEAD RJ, 1991, J CELL BIOL, V114, P715, DOI 10.1083/jcb.114.4.715; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; CRITCHLEY DR, 1991, BIOCHEM SOC T, V19, P1028, DOI 10.1042/bst0191028; EVANS RR, 1984, J BIOL CHEM, V259, P3916; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FRORATH B, 1992, BIOTECHNIQUES, V12, P558; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; GIMONA M, 1988, EMBO J, V7, P2329, DOI 10.1002/j.1460-2075.1988.tb03076.x; GROESCH ME, 1990, CELL MOTIL CYTOSKEL, V15, P41, DOI 10.1002/cm.970150107; JOCKUSCH BM, 1981, P NATL ACAD SCI-BIOL, V78, P3005, DOI 10.1073/pnas.78.5.3005; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; MENKEL AR, 1993, EUR J CELL BIOL S37, V60, P38; MILAM LM, 1985, J MOL BIOL, V184, P543, DOI 10.1016/0022-2836(85)90301-8; MOLONY L, 1985, J CELL BIOCHEM, V29, P31, DOI 10.1002/jcb.240290104; OTTO JJ, 1986, CELL MOTIL CYTOSKEL, V6, P48, DOI 10.1002/cm.970060107; PRICE GJ, 1987, BIOCHEM J, V245, P595, DOI 10.1042/bj2450595; PRICE GJ, 1989, BIOCHEM J, V259, P453, DOI 10.1042/bj2590453; RUHNAU K, 1988, FEBS LETT, V228, P105, DOI 10.1016/0014-5793(88)80595-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; WESTMEYER A, 1990, EMBO J, V9, P2071, DOI 10.1002/j.1460-2075.1990.tb07374.x; WILKINS JA, 1982, CELL, V28, P83, DOI 10.1016/0092-8674(82)90377-4; WILKINS JA, 1986, J CELL BIOL, V102, P1085, DOI 10.1083/jcb.102.3.1085	30	322	323	1	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					261	264		10.1038/373261a0	http://dx.doi.org/10.1038/373261a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816144				2022-12-24	WOS:A1995QC27800069
J	RHIND, NR; MILLER, LM; KOPCZYNSKI, JB; MEYER, BJ				RHIND, NR; MILLER, LM; KOPCZYNSKI, JB; MEYER, BJ			XOL-1 ACTS AS AN EARLY SWITCH IN THE C-ELEGANS MALE HERMAPHRODITE DECISION	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; SEX DETERMINATION SIGNAL; X-CHROMOSOME DOSAGE; GENE-EXPRESSION; DROSOPHILA; COMPENSATION; MORPHOGEN; DOMAINS	xol-1 is the earliest-acting gene in the known hierarchy that controls C. elegans sex determination and dosage compensation. We show that the primary sex-determining signal (the WA ratio) directs the choice of sexual fate by regulating xol-1 transcript levels: high xol-1 expression during gastrulation triggers male development, whereas low expression at that time permits hermaphrodite development. Inappropriately high xol-1 expression causes hermaphrodites to activate the male program of development and die from a disruption in dosage compensation. These results demonstrate that xol-1 functions as an early developmental switch to set the choice of sexual fate and suggest that assessment of the WA ratio occurs only early in embryogenesis to determine sex. Moreover, sdc-2, a gene that must be repressed by xol-1 to ensure male development, may be a direct target of negative regulation by xol-1.			RHIND, NR (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,229 STANLEY HALL,BERKELEY,CA 94720, USA.			Meyer, Barbara/0000-0002-6530-4588; Rhind, Nicholas/0000-0003-1758-7736	NIGMS NIH HHS [GM30702, R01 GM030702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030702, R01GM030702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERIB CC, 1994, GENETICS, V138, P1105; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELOTE JM, 1983, DEV BIOL, V95, P512, DOI 10.1016/0012-1606(83)90054-4; Bull J. J., 1983, EVOLUTION SEX DETERM; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; CLINE TW, 1993, TRENDS GENET, V9, P385, DOI 10.1016/0168-9525(93)90138-8; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HODGES D, 1994, ADV GENET, V31, P243; HODGKIN J, 1979, GENETICS, V91, P67; Hsu David R., 1993, Seminars in Developmental Biology, V4, P93, DOI 10.1006/sedb.1993.1012; HSU DR, 1994, GENETICS, V137, P999; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KLEIN RD, 1993, CELL, V72, P349, DOI 10.1016/0092-8674(93)90113-5; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; KRAUSE M, 1989, J MOL BIOL, V208, P381, DOI 10.1016/0022-2836(89)90503-2; KUWABARA PE, 1992, TRENDS GENET, V8, P164, DOI 10.1016/0168-9525(92)90218-S; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; Sambrook J., 1989, MOL CLONING LAB MANU; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; VILLENEUVE AM, 1990, GENETICS, V124, P91	25	75	79	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					71	82		10.1016/0092-8674(95)90452-2	http://dx.doi.org/10.1016/0092-8674(95)90452-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813020	Bronze			2022-12-24	WOS:A1995QB91000011
J	BURNS, JP; REARDON, FE; TRUOG, RD				BURNS, JP; REARDON, FE; TRUOG, RD			USING NEWLY DECEASED PATIENTS TO TEACH RESUSCITATION PROCEDURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CONSENT; INFANTS		HASSAN & REARDON, BOSTON, MA 02116 USA; CHILDRENS HOSP, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital	BURNS, JP (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DIV PEDIAT CRIT CARE, NEMC 93, 750 WASHINGTON ST, BOSTON, MA 02111 USA.		Burns, Jeffrey P/AAW-8474-2021					ABRAMSON NS, 1981, JAMA-J AM MED ASSOC, V246, P2828; BENFIELD DG, 1991, JAMA-J AM MED ASSOC, V265, P2360, DOI 10.1001/jama.265.18.2360; BRATTEBO G, 1988, LANCET, V2, P1078; Clayton M., 1992, DRAWINGS COLLECTION; FEINBERG J, 1985, HASTINGS CENT REP, V15, P31, DOI 10.2307/3561915; Iserson K V, 1991, J Emerg Med, V9, P509, DOI 10.1016/0736-4679(91)90225-5; ISERSON KV, 1986, HASTINGS CENT REP, V16, P28, DOI 10.2307/3563273; MAY WF, 1985, HASTINGS CENT REP, V15, P38, DOI 10.2307/3561916; MORHAIM D K, 1991, Journal of Emergency Medicine, V9, P515, DOI 10.1016/0736-4679(91)90233-6; Orlowski J P, 1990, J Clin Ethics, V1, P201; ORLOWSKI JP, 1988, NEW ENGL J MED, V319, P439, DOI 10.1056/NEJM198808183190710; ROELS L, 1991, TRANSPLANT P, V23, P903; ROSNER F, 1991, MODERN MED JEWISH ET, P313; TACHAKRA SS, 1991, JAMA-J AM MED ASSOC, V266, P1649, DOI 10.1001/jama.1991.03470120051027; 1991, JAMA-J AM MED ASSOC, V266, P2837; 1993, AM MED NEWS     0322, P10	16	46	46	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 15	1994	331	24					1652	1655		10.1056/NEJM199412153312411	http://dx.doi.org/10.1056/NEJM199412153312411			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW446	7772111				2022-12-24	WOS:A1994PW44600011
J	THOMSON, JA; DAVIES, DL; MCLAREN, EH; TEASDALE, GM				THOMSON, JA; DAVIES, DL; MCLAREN, EH; TEASDALE, GM			10-YEAR FOLLOW-UP OF MICROPROLACTINOMA TREATED BY TRANSSPHENOIDAL SURGERY	BRITISH MEDICAL JOURNAL			English	Article							HYPERPROLACTINEMIA; PROLACTINOMA		WESTERN INFIRM & ASSOCIATED HOSP,DEPT MED & THERAPEUT,GLASGOW G11 6NT,LANARK,SCOTLAND; STOBHILL GEN HOSP,DEPT MED,GLASGOW G21 3UW,LANARK,SCOTLAND; SO GEN HOSP,INST NEUROL SCI,GLASGOW G51 4TF,LANARK,SCOTLAND	University of Glasgow	THOMSON, JA (corresponding author), UNIV GLASGOW,GLASGOW ROYAL INFIRM,DEPT MED,GLASGOW G31 2ER,LANARK,SCOTLAND.							BEVAN JS, 1987, CLIN ENDOCRINOL, V26, P541, DOI 10.1111/j.1365-2265.1987.tb00809.x; SCANLON MF, 1985, BRIT MED J, V291, P1547, DOI 10.1136/bmj.291.6508.1547; SERRI O, 1983, NEW ENGL J MED, V309, P280, DOI 10.1056/NEJM198308043090505; SERRI O, 1993, NEW ENGL J MED, V329, P1357, DOI 10.1056/NEJM199310283291817; THOMSON JA, 1985, BRIT MED J, V291, P1550, DOI 10.1136/bmj.291.6508.1550	5	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1409	1410		10.1136/bmj.309.6966.1409	http://dx.doi.org/10.1136/bmj.309.6966.1409			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819849	Green Published			2022-12-24	WOS:A1994PU76400022
J	ROACH, PL; CLIFTON, IJ; FULOP, V; HARLOS, K; BARTON, GJ; HAJDU, J; ANDERSSON, I; SCHOFIELD, CJ; BALDWIN, JE				ROACH, PL; CLIFTON, IJ; FULOP, V; HARLOS, K; BARTON, GJ; HAJDU, J; ANDERSSON, I; SCHOFIELD, CJ; BALDWIN, JE			CRYSTAL-STRUCTURE OF ISOPENICILLIN N-SYNTHASE IS THE FIRST FROM A NEW STRUCTURAL FAMILY OF ENZYMES	NATURE			English	Article							X-RAY-ABSORPTION; ACTIVE-SITE; SUBSTRATE; ISOZYMES; ERRORS; MAPS	PENICILLIN antibiotics are all produced from fermentation-derived penicillins because their chemical synthesis is not commercially viable. The key step in penicillin biosynthesis, in which both the beta-lactam and thiazolidine rings of the nucleus are created, is mediated by isopenicillin N synthase (IPNS), which binds ferrous iron-and uses dioxygen as a cosubstrate, In a unique enzymatic step, with no chemical precedent, IPNS catalyses the transfer of four hydrogen atoms from its tripeptide substrate to dioxygen forming, in a single reaction, the complete bicyclic nucleus of the penicillins(1). We now report the structure of IPNS complexed with manganese, which reveals the active site is unusually buried within a 'jelly-roll' motif and lined by hydrophobic residues, and suggest hem this structure permits the process of penicillin formation. Sequence analyses indicate IPNS, 1-aminocyclopropane-1-carboxylic acid oxidase and many of the 2-oxo-acid-dependent oxygenases contain a conserved jelly-roll motif, forming a new structural family of enzymes.	UNIV OXFORD, DYSON PERRINS LAB, OXFORD OX1 3QY, ENGLAND; SWEDISH UNIV AGR SCI, UPPSALA BIOMED CTR, DEPT BIOL MOLEC, S-75124 UPPSALA, SWEDEN; UNIV OXFORD, OXFORD CTR MOLEC SCI, OXFORD OX1 3QY, ENGLAND; UNIV OXFORD, LAB MOLEC BIOPHYS, OXFORD OX1 3QY, ENGLAND	University of Oxford; Swedish University of Agricultural Sciences; University of Oxford; University of Oxford			Roach, Peter/C-6248-2013; Roach, Peter/AAW-7071-2021; Barton, Geoffrey/N-1037-2019; Barton, Geoffrey J/C-6267-2011	Barton, Geoffrey/0000-0002-9014-5355; Schofield, Christopher/0000-0002-0290-6565				BALDWIN JE, 1991, TETRAHEDRON, V47, P5991, DOI 10.1016/S0040-4020(01)86491-7; BALDWIN JE, 1990, CHEM REV, V90, P1079, DOI 10.1021/cr00105a001; BALDWIN JE, 1992, CHEM BETA LACTAMS, pCH1; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEN VJ, 1989, J BIOL CHEM, V264, P21677; COWTAN K, 1994, ACTA CRYSTALLOGR D, V50, P760; Crowfoot D., 1949, CHEM PENICILLIN, P310; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; Fleming A, 1929, BRIT J EXP PATHOL, V10, P226; FLOREY HW, 1949, ANTIBIOTICS, V2; FUJISHIMA Y, 1994, J MOL BIOL, V242, P712, DOI 10.1006/jmbi.1994.1622; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARSH EN, 1992, BIOCHEMISTRY-US, V31, P12648, DOI 10.1021/bi00165a015; NORRIS GE, 1994, STRUCTURE, V2, P1049, DOI 10.1016/S0969-2126(94)00108-1; ORVILLE AM, 1992, BIOCHEMISTRY-US, V31, P4602, DOI 10.1021/bi00134a010; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; PANG CP, 1984, BIOCHEM J, V222, P789, DOI 10.1042/bj2220789; PRESCOTT AG, 1993, J EXP BOT, V44, P849, DOI 10.1093/jxb/44.5.849; RANDALL CR, 1993, BIOCHEMISTRY-US, V32, P6664, DOI 10.1021/bi00077a020; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RETEY J, 1990, ANGEW CHEM INT EDIT, V29, P355, DOI 10.1002/anie.199003551; ROACH PL, 1995, PROTEIN SCI, V4, P1007; SCOTT RA, 1992, BIOCHEMISTRY-US, V31, P4596, DOI 10.1021/bi00134a009; SRINIVASAN N, 1994, STRUCTURE, V2, P1017, DOI 10.1016/S0969-2126(94)00105-7; STUART D, 1993, CURR OPIN STRUC BIOL, V3, P167, DOI 10.1016/S0959-440X(05)80148-4; [No title captured]	30	373	386	0	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 22	1995	375	6533					700	704		10.1038/375700a0	http://dx.doi.org/10.1038/375700a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791906				2022-12-24	WOS:A1995RE57600066
J	YUSTE, R; DENK, W				YUSTE, R; DENK, W			DENDRITIC SPINES AS BASIC FUNCTIONAL UNITS OF NEURONAL INTEGRATION	NATURE			English	Article							CALCIUM; TRANSMISSION; POTENTIATION; RESPONSES; SLICES; BRAIN	MOST excitatory synaptic connections occur on dendritic spines(1). Calcium imaging experiments have suggested that spines constitute individual calcium compartments(2,3), but recent results have challenged this idea(4,5). Using two-photon microscopy(6) to image fluorescence with high resolution in strongly scattering tissue, we measured calcium dynamics in spines from CA1 pyramidal neurons in slices of rat hippocampus. Subthreshold synaptic stimulation and spontaneous synaptic events produced calcium accumulations that were localized to isolated spines, showed stochastic failure, and were abolished by postsynaptic blockers, Single somatic spikes induced fast-peaking calcium accumulation in spines throughout the cell. Pairing of spikes with synaptic stimulation was frequently cooperative, that is, it resulted in supralinear calcium accumulations. We conclude: (1) calcium channels exist in spine heads; (2) action potentials invade the spines; (3) spines are individual calcium compartments; and (4) spines can individually detect the temporal coincidence of pre- and postsynaptic activity, and thus serve as basic functional units of neuronal integration.	AT&T BELL LABS,BIOL COMPUTAT RES DEPT,MURRAY HILL,NJ 07974	AT&T; Nokia Corporation; Nokia Bell Labs			denk, winfried/I-6627-2012					ALFORD S, 1993, J PHYSIOL-LONDON, V469, P693, DOI 10.1113/jphysiol.1993.sp019838; ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; ANDERSEN P, 1977, NATURE, V266, P736, DOI 10.1038/266736a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P553, DOI 10.1113/jphysiol.1954.sp005128; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DENK W, 1994, J NEUROSCI METH, V54, P151, DOI 10.1016/0165-0270(94)90189-9; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EILERS J, 1995, NATURE, V373, P155, DOI 10.1038/373155a0; GAMBLE E, 1987, SCIENCE, V236, P1311, DOI 10.1126/science.3495885; Goppert-Mayer M., 1931, ANN PHYS-LEIPZIG, V401, P273, DOI DOI 10.1002/ANDP.19314010303; GUTHRIE PB, 1991, NATURE, V354, P78; JAFFE DB, 1994, J NEUROBIOL, V25, P220, DOI 10.1002/neu.480250303; LEVY WB, 1979, BRAIN RES, V175, P233, DOI 10.1016/0006-8993(79)91003-5; LEVY WB, 1985, ELECTRICAL ACTIVITY; LLANO I, 1994, NEURON, V12, P663, DOI 10.1016/0896-6273(94)90221-6; MAJOR G, 1993, BIOPHYS J, V65, P423, DOI 10.1016/S0006-3495(93)81037-3; Marty A., 1983, SINGLE CHANNEL RECOR, P107; MCNAUGHTON BL, 1977, J COMP NEUROL, V175, P439, DOI 10.1002/cne.901750404; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; MURPHY TH, 1994, NATURE, V263, P529; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; OTMAKHOV N, 1993, NEURON, V10, P1101, DOI 10.1016/0896-6273(93)90058-Y; Peters A, 1991, FINE STRUCTURE NERVO; SOBEL EC, 1994, SCIENCE, V263, P823, DOI 10.1126/science.263.5148.823; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; SVAASAND LO, 1983, PHOTOCHEM PHOTOBIOL, V38, P293, DOI 10.1111/j.1751-1097.1983.tb02674.x; TANK DW, IN PRESS J NEUROSCI; YUSTE R, 1994, NEURON, V13, P23, DOI 10.1016/0896-6273(94)90457-X	31	689	706	0	52	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					682	684		10.1038/375682a0	http://dx.doi.org/10.1038/375682a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791901				2022-12-24	WOS:A1995RE57600060
J	PEPPELENBOSCH, MP; QIU, RG; DEVRIESSMITS, AMM; TERTOOLEN, LGJ; DELAAT, SW; MCCORMICK, F; HALL, A; SYMONS, MH; BOS, JL				PEPPELENBOSCH, MP; QIU, RG; DEVRIESSMITS, AMM; TERTOOLEN, LGJ; DELAAT, SW; MCCORMICK, F; HALL, A; SYMONS, MH; BOS, JL			RAC MEDIATES GROWTH FACTOR-INDUCED ARACHIDONIC-ACID RELEASE	CELL			English	Article							SIGNAL-REGULATED KINASE-2; RHO GENE-PRODUCT; PROTEIN; ACTIN; PHOSPHOLIPASE-A2; ACTIVATION; P21RAS; CELLS; IDENTIFICATION; FIBROBLASTS	Growth factor-induced stress fiber formation involves signal transduction through Rac and Rho proteins and production of leukotrienes from arachidonic acid metabolism. In exploring the relationship between these pathways, we found that Rac is essential for EGF-induced arachidonic acid production and subsequent generation of leukotrienes and that Rac V12, a constitutively activated mutant of Rac, generates leukotrienes in a growth factor-independent manner. Leukotrienes generated by EGF or Rac V12 are necessary and sufficient for stress fiber formation. Furthermore, leukotriene-dependent stress fiber formation requires Rho proteins. We have therefore identified elements of a pathway from growth factor receptors that includes Rac, arachidonic acid production, arachidonic acid metabolism to leukotrienes, and leukotriene-dependent Rho activation. This appears to be the major pathway by which Rac influences Rho-dependent cytoskeleton rearrangements.	UNIV UTRECHT, PHYSIOL CHEM LAB, 3584 CG UTRECHT, NETHERLANDS; ONYX PHARMACEUT, RICHMOND, CA 94806 USA; NETHERLANDS INST DEV BIOL, HUBRECHT LAB, 3584 CT UTRECHT, NETHERLANDS; UCL, MRC, MOLEC CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND; UCL, DEPT BIOCHEM, LONDON WC1E 6BT, ENGLAND	Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); University of London; University College London; University of London; University College London				Peppelenbosch, Maikel/0000-0001-9112-6028				AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BRETCHER A, 1989, J CELL BIOL, V64, P573; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DOMIN J, 1993, J BIOL CHEM, V268, P8927; DOWNEY GP, 1990, J CELL BIOL, V110, P1975, DOI 10.1083/jcb.110.6.1975; GILLARD J, 1989, CAN J PHYSIOL PHARM, V67, P456, DOI 10.1139/y89-073; GOLDBERG H, 1994, BIOCHEM BIOPH RES CO, V198, P220, DOI 10.1006/bbrc.1994.1031; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GROTENDORST GR, 1984, CELL, V36, P279, DOI 10.1016/0092-8674(84)90221-6; HABETS GGM, 1994, CELL, V77, P539; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; NOBES CD, 1995, J CELL SCI, V108, P225; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHLESSINGER J, 1981, EXP CELL RES, V134, P273, DOI 10.1016/0014-4827(81)90426-2; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SPAARGAREN M, 1992, BIOCHEM J, V287, P37, DOI 10.1042/bj2870037; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; WARNER LC, 1993, ONCOGENE, V8, P3249; XU XX, 1994, J BIOL CHEM, V269, P31693	34	197	198	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 16	1995	81	6					849	856		10.1016/0092-8674(95)90005-5	http://dx.doi.org/10.1016/0092-8674(95)90005-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781062	Bronze			2022-12-24	WOS:A1995RD76800006
J	STENTON, SC; SANDHU, PS; HENDRICK, DJ				STENTON, SC; SANDHU, PS; HENDRICK, DJ			INDUSTRIAL INJURY BENEFIT FOR OCCUPATIONAL ASTHMA IN NORTH-EAST OF ENGLAND	BRITISH MEDICAL JOURNAL			English	Article									NEWCASTLE GEN HOSP,REG UNIT OCCUPAT LUNG DIS,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle General Hospital	STENTON, SC (corresponding author), NEWCASTLE GEN HOSP,CHEST UNIT,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND.							CHANYEUNG M, 1987, J ALLERGY CLIN IMMUN, V79, P792, DOI 10.1016/0091-6749(87)90212-0; LUCMALO J, 1991, AM REV RESPIR DIS, V143, P528; MEREDITH SK, 1994, OCCUP MED-OXFORD, V44, P183, DOI 10.1093/occmed/44.4.183; 1989, NI226 DEP HLTH SOC S	4	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	1995	310	6990					1299	1300		10.1136/bmj.310.6990.1299a	http://dx.doi.org/10.1136/bmj.310.6990.1299a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773044	Green Published			2022-12-24	WOS:A1995QZ86000022
J	QUAGLIARELLO, VJ; VISCOLI, C; HORWITZ, RI				QUAGLIARELLO, VJ; VISCOLI, C; HORWITZ, RI			PRIMARY PREVENTION OF CRYPTOCOCCAL MENINGITIS BY FLUCONAZOLE IN HIV-INFECTED PATIENTS	LANCET			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PRIMARY PROPHYLAXIS; AMPHOTERICIN-B; AIDS	To evaluate whether oral fluconazole reduces the risk of a first episode of cryptococcal meningitis in HIV-infected patients, we conducted a case-control study of patients cared for in a university teaching hospital and two urban HIV-outpatient clinics. Cases consisted of HIV-infected patients with CD4 cell counts less than 250/mu L who developed a first episode of cryptococcal meningitis between July 1, 1990, and June 30, 1993. For each case (n=18), 4 control subjects were chosen from HIV-infected patients (CD4 count < 250/mu L) whose cerebrospinal fluid was negative for cryptococcal antigen and culture, and who were matched by age, sex, and time of lumbar puncture. There were no significant differences between cases and controls in age, sex, insurance status, mean CD4 count, history of oral candidosis, presence of a previous AIDS-defining illness, the number of visits to the HIV-outpatient clinic, or use of antiretroviral therapy. In the 6 months before lumbar puncture, 2 of 18 cases (11%) and 26 of 72 controls (36%) were exposed to fluconazole, a finding that gives a matched odds ratio (adjusted for race, route of HIV infection, and CD4 count) of 0.08 (95% CI 0.01-0.84; p=0.035) and indicates a 92% protective efficacy. We conclude that fluconazole reduces the risk of a first episode of cryptococcal meningitis in HIV-infected patients with a CD4 count less than 250/mu L. Although the optimum dose and duration of fluconazole could not be determined, our results suggest that less than daily use was effective in the prevention of cryptococcal meningitis.			QUAGLIARELLO, VJ (corresponding author), YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510, USA.							Breslow N, 1980, STAT METHODS CANC RE, P248; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; Cotton D., 1992, AIDS Clinical Care, V4, P85; FEINSTEIN AR, 1988, J CLIN INVEST, V81, P1, DOI 10.1172/JCI113279; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P118; GALGIANI JN, 1990, ANN INTERN MED, V113, P177, DOI 10.7326/0003-4819-113-3-177; GIRARD PM, 1993, NEW ENGL J MED, V328, P1514, DOI 10.1056/NEJM199305273282102; HAYDEN GF, 1982, JAMA-J AM MED ASSOC, V247, P326, DOI 10.1001/jama.247.3.326; IMPERIALE TF, 1990, AM J MED, V88, P131, DOI 10.1016/0002-9343(90)90461-L; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; NIGHTINGALE SD, 1992, AIDS, V6, P191, DOI 10.1097/00002030-199202000-00008; POWDERLY WG, 1992, NEW ENGL J MED, V326, P793, DOI 10.1056/NEJM199203193261203; POWDERLY WG, 1993, CLIN INFECT DIS, V17, P837, DOI 10.1093/clinids/17.5.837; SAAG MS, 1992, NEW ENGL J MED, V326, P83, DOI 10.1056/NEJM199201093260202; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P171; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; Wheat L. J., 1994, AIDS Clinical Care, V6, P27; 1992, MMWR-MORBID MORTAL W, V41, P1	18	42	43	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					548	552		10.1016/S0140-6736(95)90465-4	http://dx.doi.org/10.1016/S0140-6736(95)90465-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776774	hybrid			2022-12-24	WOS:A1995QK44400010
J	BRUNO, A; JONES, WL; AUSTIN, JK; CARTER, S; QUALLS, C				BRUNO, A; JONES, WL; AUSTIN, JK; CARTER, S; QUALLS, C			VASCULAR OUTCOME IN MEN WITH ASYMPTOMATIC RETINAL CHOLESTEROL EMBOLI - A COHORT STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						EMBOLISM, CHOLESTEROL; RETINA; CEREBROVASCULAR DISORDERS; MYOCARDIAL INFARCTION; CEREBRAL INFARCTION	CEREBRAL INFARCTION; RISK-FACTORS; ARTERY; CONCOMITANTS; STENOSIS	Objective: To determine whether asymptomatic retinal cholesterol embolism is a risk factor for vascular events. Design: Cohort study with retrospectively selected controls. Setting: A Veterans Affairs medical center. Patients: 70 consecutive patients with asymptomatic retinal cholesterol emboli on dilated ocular examination in an eye clinic and 70 controls without retinal emboli. Controls were matched to patients for sex; age; prevalence of hypertension, diabetes mellitus, and ischemic heart disease; serum cholesterol level; and smoking history. Measurements: Stroke, myocardial infarction, and death. Results: During a mean follow-up of 3.4 years, stroke occurred at an annual rate of 8.5% among patients and 0.8% among controls (adjusted relative risk, 9.9; 95% Cl, 2.3 to 43.1; P = 0.002). Nineteen strokes occurred, 17 in patients and 2 in controls; all were nonfatal cerebral infarctions. Twelve of the 17 that occurred in patients were in a carotid artery territory ipsilateral to the qualifying retinal cholesterol embolus and 5 were in another vascular territory. Ocular infarction or hemorrhagic stroke did not occur. Nonfatal myocardial infarction or vascular death occurred at an annual rate of 7.7% among patients and 4.9% among controls (adjusted relative risk, 1.4; 95% Cl, 0.7 to 2.9; P = 0.39). Conclusion: Asymptomatic retinal cholesterol embolism is an important risk factor for cerebral infarction independent of commonly recognized vascular risk factors.	VET AFFAIRS MED CTR, OPTOMETRY SECT 112A, ALBUQUERQUE, NM 87108 USA; VET AFFAIRS MED CTR, NEUROL SERV 127, ALBUQUERQUE, NM 87108 USA; UNIV NEW MEXICO, DEPT MATH & STAT, ALBUQUERQUE, NM 87131 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of New Mexico					NCRR NIH HHS [MO1 RR00997] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000997] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BEAL MF, 1981, NEUROLOGY, V31, P860, DOI 10.1212/WNL.31.7.860; BOGOUSSLAVSKY J, 1985, ARCH NEUROL-CHICAGO, V42, P864, DOI 10.1001/archneur.1985.04060080042014; BRUNO A, 1992, STROKE, V23, P900, DOI 10.1161/01.STR.23.6.900; BULL DA, 1992, J CARDIOVASC SURG, V33, P401; BUNT TJ, 1986, J VASC SURG, V4, P559; CROUSE JR, 1987, STROKE, V18, P990, DOI 10.1161/01.STR.18.6.990; DAVID NJ, 1963, NEUROLOGY, V13, P708, DOI 10.1212/WNL.13.8.708; EHRENFEL.WK, 1966, ARCH SURG-CHICAGO, V93, P787; FABRIS F, 1994, STROKE, V25, P1133, DOI 10.1161/01.STR.25.6.1133; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GARRAWAY WM, 1979, STROKE, V10, P657, DOI 10.1161/01.STR.10.6.657; MAURIZI CP, 1968, ARCH PATHOL, V86, P528; PFAFFENBACH DD, 1973, AM J OPHTHALMOL, V75, P66, DOI 10.1016/0002-9394(73)90653-3; RICHARDS AM, 1965, AM J CARDIOL, V15, P696, DOI 10.1016/0002-9149(65)90359-0; RUSSELL RWR, 1968, LANCET, V2, P789; SAVINO PJ, 1977, ARCH OPHTHALMOL-CHIC, V95, P1185, DOI 10.1001/archopht.1977.04450070083005; SAVINO PJ, 1988, AMAUROSIS FUGAX, P90; SAYRE GP, 1959, ARCH INTERN MED, V103, P799, DOI 10.1001/archinte.1959.00270050121019; THURLBECK WM, 1957, NEW ENGL J MED, V257, P442, DOI 10.1056/NEJM195709052571002; 1990, SAS STAT USERS GUIDE, P1027	20	62	65	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					249	253		10.7326/0003-4819-122-4-199502150-00002	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825759				2022-12-24	WOS:A1995QF76900002
J	MADDUX, BA; SBRACCIA, P; KUMAKURA, S; SASSON, S; YOUNGREN, J; FISHER, A; SPENCER, S; GRUPE, A; HENZEL, W; STEWART, TA; REAVEN, GM; GOLDFINE, ID				MADDUX, BA; SBRACCIA, P; KUMAKURA, S; SASSON, S; YOUNGREN, J; FISHER, A; SPENCER, S; GRUPE, A; HENZEL, W; STEWART, TA; REAVEN, GM; GOLDFINE, ID			MEMBRANE GLYCOPROTEIN PC-1 AND INSULIN-RESISTANCE IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NATURE			English	Article							RECEPTOR TYROSINE KINASE; NUCLEOTIDE PYROPHOSPHATASE; FIBROBLASTS; MECHANISMS; EXPRESSION; GLUCOSE; CLONING; NIDDM; GENE	MOST patients with non-insulin-dependent diabetes mellitus are resistant to both endogenous and exogenous insulin(1). Insulin resistance precedes the onset of this disease(2-4), suggesting that it may be an initial abnormality. Insulin-receptor kinase activity is impaired in muscle, fibroblasts and other tissues of many patients with non-insulin-dependent diabetes mellitus(5), but abnormalities in the insulin-receptor gene do not appear to be the cause of this decreased kinase activity(6,7). Skin fibroblasts from certain insulin-resistant patients contain an inhibitor of insulin-receptor tyrosine kinase(8,9). Here we show that this inhibitor is a membrane glycoprotein, termed PC-1 (refs 10,11). We find that PC-1 activity is increased in fibroblasts from seven of nine patients with typical non-insulin-dependent diabetes mellitus. In addition, overexpression of PC-1 in transfected cultured cells reduces insulin-stimulated tyrosine kinase activity. These studies raise the possibility that PC-1 has a role in the insulin resistance of non-insulin-dependent diabetes mellitus.	UNIV CALIF SAN FRANCISCO,MT ZION MED CTR,DIV DIABET & ENDOCRINE RES,SAN FRANCISCO,CA 94115; GENENTECH INC,S SAN FRANCISCO,CA 94080; STANFORD UNIV,VET ADM MED CTR,PALO ALTO,CA 94304	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; Roche Holding; Genentech; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Sasson, Shlomo/0000-0002-9343-526X; Henzel, William/0000-0003-2940-3797				BOGARDUS C, 1989, DIABETES, V38, P1423, DOI 10.2337/diabetes.38.11.1423; BUCKLEY MF, 1990, J BIOL CHEM, V265, P17506; FORSAYETH J, 1986, DIABETES, V35, P837, DOI 10.2337/diabetes.35.7.837; FUNAKOSHI I, 1992, ARCH BIOCHEM BIOPHYS, V295, P180, DOI 10.1016/0003-9861(92)90504-P; Greene S F, 1994, Obes Res, V2, P432; HARING H, 1989, DIABETES METAB REV, V5, P431; HARTMANN KKP, 1990, ENDOCRINOLOGY, V127, P2038, DOI 10.1210/endo-127-4-2038; HUANG R, 1994, J CLIN INVEST, V94, P560, DOI 10.1172/JCI117370; MADDUX BA, 1993, J CLIN ENDOCR METAB, V77, P73, DOI 10.1210/jc.77.1.73; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MILAZZO G, 1992, CANCER RES, V52, P3924; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; ODA Y, 1991, J BIOL CHEM, V266, P16791; REAVEN GM, 1988, DIABETES, V35, P1595; REBBE NF, 1993, MOL IMMUNOL, V30, P87, DOI 10.1016/0161-5890(93)90429-F; SBRACCIA P, 1991, DIABETES, V40, P295, DOI 10.2337/diabetes.40.2.295; SUVA LJ, 1989, GENE, V77, P95, DOI 10.1016/0378-1119(89)90363-6; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; YOSHIDA H, 1983, J BIOCHEM-TOKYO, V93, P1641, DOI 10.1093/oxfordjournals.jbchem.a134303	21	288	299	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					448	451		10.1038/373448a0	http://dx.doi.org/10.1038/373448a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830796				2022-12-24	WOS:A1995QE67000062
J	GUARINO, LA; SMITH, G; DONG, W				GUARINO, LA; SMITH, G; DONG, W			UBIQUITIN IS ATTACHED TO MEMBRANES OF BACULOVIRUS PARTICLES BY A NOVEL TYPE OF PHOSPHOLIPID ANCHOR	CELL			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; FATTY-ACID ACYLATION; CAPSID PROTEIN VP4; RNA-POLYMERASE; GLYCOSYL-PHOSPHATIDYLINOSITOL; NUCLEOTIDE-SEQUENCE; GENE REGION; IDENTIFICATION; SITE; CHROMATOGRAPHY	Purified budded virions of Autographa californica nuclear polyhedrosis virus (AcNPV) contain abundant amounts of free ubiquitin, which has an altered electrophoretic mobility on SDS gels as compared with standard ubiquitin. Phase extraction of virion proteins with Triton X-114 indicated that the modified form of ubiquitin behaved as an integral membrane protein. The membrane-bound form of ubiquitin was labeled with both phosphate and palmitate, and its electrophoretic mobility was altered by treatment with phospholipase A2 and a phosphatidylcholine-specific phospholipase D. Mild trypsin digestion indicated that the acyl group was not linked to the C-terminus of the protein. Acylated ubiquitin could not be radiolabeled with a membrane-impermeable Bolton-Hunter reagent unless virus was pretreated with detergent. Together, these experiments suggest that ubiquitin is attached to the inner face of the viral membrane by a novel type of phospholipid anchor.	INST BIOSCI & TECHNOL, CTR ADV INVERTEBRATE MOLEC SCI, COLLEGE STN, TX 77843 USA		GUARINO, LA (corresponding author), TEXAS A&M UNIV, DEPT ENTOMOL, COLLEGE STN, TX 77843 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044055] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44055] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGER M, 1984, EMBO J, V3, P713, DOI 10.1002/j.1460-2075.1984.tb01874.x; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRAUNAGEL SC, 1994, VIROLOGY, V202, P315, DOI 10.1006/viro.1994.1348; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; COX MJ, 1986, ANAL BIOCHEM, V154, P345, DOI 10.1016/0003-2697(86)90535-X; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967; DITMER JC, 1969, METHOD ENZYMOL, V14, P482; DRISCOLL J, 1992, CELL, V68, P823, DOI 10.1016/0092-8674(92)90024-7; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; DUNIGAN DD, 1988, VIROLOGY, V165, P310, DOI 10.1016/0042-6822(88)90691-5; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GAEDIGKNITSCHKO K, 1990, VIROLOGY, V175, P282, DOI 10.1016/0042-6822(90)90210-I; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; GUARINO LA, 1990, P NATL ACAD SCI USA, V87, P409, DOI 10.1073/pnas.87.1.409; GUARINO LA, 1990, VIROLOGY, V179, P1, DOI 10.1016/0042-6822(90)90266-T; HAAS AL, 1985, J BIOL CHEM, V260, P4694; HARLOW E, 1988, ANTIBODIES LABORATOR; HINGAMP PM, 1995, IN PRESS J VIROL, V69; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KEMP LM, 1988, VIROLOGY, V166, P258, DOI 10.1016/0042-6822(88)90170-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOEB KR, 1992, J BIOL CHEM, V267, P7806; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MEYERS G, 1991, VIROLOGY, V180, P602, DOI 10.1016/0042-6822(91)90074-L; OREILLY DR, 1992, BACULOVIRUS EXPRESSI; PAUL AV, 1987, P NATL ACAD SCI USA, V84, P7827, DOI 10.1073/pnas.84.22.7827; PUTTERMAN D, 1990, VIROLOGY, V176, P633, DOI 10.1016/0042-6822(90)90035-P; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; REIN A, 1986, P NATL ACAD SCI USA, V83, P7246, DOI 10.1073/pnas.83.19.7246; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROBERTS TE, 1989, VIROLOGY, V172, P377, DOI 10.1016/0042-6822(89)90145-1; RODRIGUEZ JM, 1992, VIROLOGY, V186, P40, DOI 10.1016/0042-6822(92)90059-X; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUSSELL RLQ, 1993, J GEN VIROL, V74, P1191, DOI 10.1099/0022-1317-74-6-1191; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; Sambrook J., 1989, MOL CLONING; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TAKAYAMA M, 1977, CLIN CHIM ACTA, V79, P93, DOI 10.1016/0009-8981(77)90465-X; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WELLS MA, 1969, METHOD ENZYMOL, V14, P178; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	49	67	86	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	1995	80	2					301	309		10.1016/0092-8674(95)90413-1	http://dx.doi.org/10.1016/0092-8674(95)90413-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834750	Bronze			2022-12-24	WOS:A1995QD92400013
J	ROY, N; MAHADEVAN, MS; MCLEAN, M; SHUTLER, G; YARAGHI, Z; FARAHANI, R; BAIRD, S; BESNERJOHNSTON, A; LEFEBVRE, C; KANG, XL; SALIH, M; AUBRY, H; TAMAI, K; GUAN, XP; IOANNOU, P; CRAWFORD, TO; DEJONG, PJ; SURH, L; IKEDA, JE; KORNELUK, RG; MACKENZIE, A				ROY, N; MAHADEVAN, MS; MCLEAN, M; SHUTLER, G; YARAGHI, Z; FARAHANI, R; BAIRD, S; BESNERJOHNSTON, A; LEFEBVRE, C; KANG, XL; SALIH, M; AUBRY, H; TAMAI, K; GUAN, XP; IOANNOU, P; CRAWFORD, TO; DEJONG, PJ; SURH, L; IKEDA, JE; KORNELUK, RG; MACKENZIE, A			THE GENE FOR NEURONAL APOPTOSIS INHIBITORY PROTEIN IS PARTIALLY DELETED IN INDIVIDUALS WITH SPINAL MUSCULAR-ATROPHY	CELL			English	Article							WERDNIG-HOFFMANN DISEASE; LINKAGE ANALYSIS; REGION; LOCUS; 5Q13; POLYMORPHISMS; CHROMOSOME-5; BACULOVIRUS; INTERVAL; MARKERS	The spinal muscular atrophies (SMAs), characterized by spinal cord motor neuron depletion, are among the most common autosomal recessive disorders. One model of SMA pathogenesis invokes an inappropriate persistence of normally occurring motor neuron apop tosis. Consistent with this hypothesis, the novel gene for neuronal apoptosis inhibitory protein (NAIP) has been mapped to the SMA region of chromosome 5q13.1 and is homologous with baculoviral apoptosis inhibitor proteins. The two first coding exons of this gene are deleted in approximately 67% of type I SMA chromosomes compared with 2% of non-SMA chromosomes. Furthermore, RT-PCR analysis reveals internally deleted and mutated forms of the NAIP transcript in type I SMA individuals and not in unaffected individuals. These findings suggest that mutations in the NAIP locus may lead to a failure of a normally occurring inhibition of motor neuron apoptosis resulting in or contributing to the SMA phenotype.	CHILDRENS HOSP EASTERN ONTARIO, GENET MOLEC LAB, OTTAWA, ON K1H 8L1, CANADA; UNIV OTTAWA, DEPT BIOCHEM, OTTAWA, ON K1H 8M5, CANADA; UNIV OTTAWA, DEPT PEDIAT, OTTAWA, ON K1H 8M5, CANADA; UNIV OTTAWA, IKEDA GENOSPHERE PROJECT, OTTAWA, ON K1H 8M5, CANADA; UNIV OTTAWA, DEPT MICROBIOL, OTTAWA, ON K1H 8M5, CANADA; UNIV OTTAWA, DEPT IMMUNOL, OTTAWA, ON K1H 8M5, CANADA; ROSWELL PK CANC INST, DEPT HUMAN GENET, BUFFALO, NY 14263 USA; JOHNS HOPKINS UNIV, DEPT NEUROL, BALTIMORE, MD 21205 USA; TOKAI UNIV, INST MED SCI, DEPT MED & MOLEC GENET, ISEHARA, KANAGAWA 25911, JAPAN	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; Roswell Park Cancer Institute; Johns Hopkins University; Tokai University			Crawford, Thomas/E-6307-2012; Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911	CSR NIH HHS [1R01RG01165-01] Funding Source: Medline	CSR NIH HHS		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3583; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BRAHE C, 1994, HUM GENET, V93, P494, DOI 10.1007/BF00202811; BROOKE MH, 1986, CLIN VIEW NEUROMUSCU; BRZUSTOWICZ LM, 1992, GENOMICS, V13, P991, DOI 10.1016/0888-7543(92)90012-H; BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; BURGHES AHM, 1994, GENOMICS, V21, P394, DOI 10.1006/geno.1994.1282; BURGHES AHM, 1994, HUM GENET, V93, P305, DOI 10.1007/BF00212028; CHEN EY, 1993, GENOMICS, V17, P651, DOI 10.1006/geno.1993.1385; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; CLEM RJ, 1993, J VIROL, V67, P3730, DOI 10.1128/JVI.67.7.3730-3738.1993; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; CLEM RJ, 1994, APOPTOSIS, V2, P89; CLERMONT O, 1994, AM J HUM GENET, V54, P687; COLLIER S, 1993, NAT GENET, V3, P260, DOI 10.1038/ng0393-260; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DIDONATO CJ, 1994, AM J HUM GENET, V55, P1218; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; EVANS BA, 1985, EMBO J, V4, P133, DOI 10.1002/j.1460-2075.1985.tb02327.x; FRANCIS MJ, 1993, HUM MOL GENET, V2, P1161, DOI 10.1093/hmg/2.8.1161; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; GILLIAM TC, 1990, NATURE, V345, P823, DOI 10.1038/345823a0; GILLIAM TC, 1989, GENOMICS, V5, P940, DOI 10.1016/0888-7543(89)90138-9; GLATT K, 1994, GENOMICS, V19, P157, DOI 10.1006/geno.1994.1027; GLEESON R, 1991, NUCLEIC ACIDS RES, V19, P6491; HEDRICK PW, 1987, GENETICS, V117, P331; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; KLEYN PW, 1993, P NATL ACAD SCI USA, V90, P6801, DOI 10.1073/pnas.90.14.6801; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LIEN LL, 1991, P NATL ACAD SCI USA, V88, P7873, DOI 10.1073/pnas.88.17.7873; MACKENZIE A, 1993, HUM GENET, V90, P501; MCLEAN MD, 1994, HUM MOL GENET, V3, P1951; MELKI J, 1990, NATURE, V344, P767, DOI 10.1038/344767a0; MELKI J, 1994, SCIENCE, V264, P1474, DOI 10.1126/science.7910982; MURAYAMA S, 1991, ACTA NEUROPATHOL, V81, P408, DOI 10.1007/BF00293462; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PERESS NS, 1986, CLIN NEUROPATHOL, V5, P69; Podolsky L., 1994, American Journal of Human Genetics, V55, pA161; ROY N, 1995, IN PRESS GENOMICS; SARNAT HB, 1983, PROGR SPINAL MUSCULA, P91; SHETH P, 1991, AM J HUM GENET, V48, P764; SOARES VM, 1993, GENOMICS, V15, P365, DOI 10.1006/geno.1993.1069; THOMPSON TG, 1993, HUM MOL GENET, V2, P1169, DOI 10.1093/hmg/2.8.1169; TOWFIGHI J, 1985, ACTA NEUROPATHOL, V65, P270, DOI 10.1007/BF00687008; WEDELL A, 1993, HUM GENET, V91, P236; WIRTH B, 1993, GENOMICS, V15, P113, DOI 10.1006/geno.1993.1018; WIRTH B, 1994, GENOMICS, V20, P84, DOI 10.1006/geno.1994.1130; [No title captured]; [No title captured]	53	825	869	0	18	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 13	1995	80	1					167	178		10.1016/0092-8674(95)90461-1	http://dx.doi.org/10.1016/0092-8674(95)90461-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813013	hybrid			2022-12-24	WOS:A1995QB91000020
J	KLINE, SE; HEDEMARK, LL; DAVIES, SF				KLINE, SE; HEDEMARK, LL; DAVIES, SF			OUTBREAK OF TUBERCULOSIS AMONG REGULAR PATRONS OF A NEIGHBORHOOD BAR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PULMONARY TUBERCULOSIS; ADULT; HOMELESS; SEQUENCE; SHELTER; COMPLEX	Background. Outbreaks of tuberculosis have been reported in prisons, nursing homes, urban homeless shelters, and other crowded settings. We report a nonresidential outbreak of tuberculosis that originated in a neighborhood bar. Methods. A homeless patient with highly infectious pulmonary tuberculosis was a regular patron of a neighborhood bar during a long symptomatic interval before diagnosis. We investigated 97 other regular customers and employees of the bar through interviews, tuberculin skin testing, and chest roentgenography, We performed DNA fingerprinting on isolates from the index patient and 11 other patients. Results. The index patient apparently infected 41 of 97 contacts (42 percent), resulting in 14 cases of active tuberculosis and 27 cases of infection but no disease (indicated by positive tuberculin skin tests). Four other cases of active tuberculosis occurred among regular customers of the bar who were missed by the contact investigation. There were also two secondary cases. Radiographic findings in active cases included upper-lobe disease in seven cases (three cavitary) and negative chest films at the time of diagnosis in four cases. All 12 culture isolates we tested had the same chromosomal-DNA restriction pattern. Conclusions. The spread of tuberculosis in a neighborhood bar can be a major public health problem. The high rate of infection and disease among the contacts was unexpected and was not due to coinfection with the human immunodeficiency virus. Possible explanations include heavy alcohol use among the contacts, high infectivity of the index case, or both. Sputum cultures must be performed in tuberculin-positive contacts who have symptoms, even if the chest films are normal.	HENNEPIN CTY MED CTR,DEPT MED,DIV PULM & CRIT CARE MED,MINNEAPOLIS,MN 55415; UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55455; TB CONTROL CLIN HENNEPIN CTY,MINNEAPOLIS,MN; UNIV MINNESOTA HOSP & CLIN,DEPT MED,DIV INFECT DIS,MINNEAPOLIS,MN	Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital								ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BARZA M, 1972, POSTGRAD MED, V51, P143, DOI 10.1080/00325481.1972.11698136; BROWN KE, 1961, BRIT J DIS CHEST, V55, P150, DOI 10.1016/S0007-0971(61)80109-5; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; CHOYKE PL, 1983, RADIOLOGY, V148, P357, DOI 10.1148/radiology.148.2.6867325; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; FEINGOLD AO, 1976, SOUTHERN MED J, V69, P1336, DOI 10.1097/00007611-197610000-00024; FRIEDMAN L H, 1992, American Review of Respiratory Disease, V145, pA107; FRIEDMAN LN, 1987, AM REV RESPIR DIS, V136, P1188, DOI 10.1164/ajrccm/136.5.1188; HADLOCK FP, 1980, AM J ROENTGENOL, V134, P1015, DOI 10.2214/ajr.134.5.1015; HUSEN L, 1971, CHEST, V60, P540, DOI 10.1378/chest.60.6.540; KHAN MA, 1977, AM J MED, V62, P31, DOI 10.1016/0002-9343(77)90346-1; MILLER W T, 1978, AJR (American Journal of Roentgenology), V130, P867; MILLER WT, 1993, SEMIN ROENTGENOL, V28, P109, DOI 10.1016/S0037-198X(05)80100-2; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; OLIN JS, 1966, CAN MED ASSOC J, V94, P999; PEDROBOTET J, 1992, AIDS, V6, P91, DOI 10.1097/00002030-199201000-00012; SCHMIDEK HH, 1967, CAN MED ASSOC J, V97, P178; SIDDIQUI F, 1989, BACTEC SYSTEM PRODUC; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; STEAD WW, 1981, ANN INTERN MED, V94, P606, DOI 10.7326/0003-4819-94-5-606; TABET SR, 1994, J INFECT DIS, V169, P189, DOI 10.1093/infdis/169.1.189; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; WOODRING JH, 1986, AM J ROENTGENOL, V146, P497, DOI 10.2214/ajr.146.3.497; 1991, MMWR-MORBID MORTAL W, V40, P869; 1990, AM REV RESPIR DIS, V142, P725; 1990, AM REV RESPIR DIS, V142, P1470; 1992, MMWR-MORBID MORTAL W, V41, P507	31	186	187	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 27	1995	333	4					222	227		10.1056/NEJM199507273330404	http://dx.doi.org/10.1056/NEJM199507273330404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK423	7791838				2022-12-24	WOS:A1995RK42300004
J	BENNETT, SN; MCNEIL, MM; BLAND, LA; ARDUINO, MJ; VILLARINO, ME; PERROTTA, DM; BURWEN, DR; WELBEL, SF; PEGUES, DA; STROUD, L; ZEITZ, PS; JARVIS, WR				BENNETT, SN; MCNEIL, MM; BLAND, LA; ARDUINO, MJ; VILLARINO, ME; PERROTTA, DM; BURWEN, DR; WELBEL, SF; PEGUES, DA; STROUD, L; ZEITZ, PS; JARVIS, WR			POSTOPERATIVE INFECTIONS TRACED TO CONTAMINATION OF AN INTRAVENOUS ANESTHETIC, PROPOFOL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTENSIVE-CARE UNITS; NOSOCOMIAL INFECTIONS; STAPHYLOCOCCUS-AUREUS; ENDOTOXIN PRODUCTION; CANDIDA-ALBICANS; MICROBIAL-GROWTH; BACTERIAL-GROWTH; SYRINGES; INFUSION; OUTBREAK	Background. Between June 1990 and February 1993, the Centers for Disease Control and Prevention conducted investigations at seven hospitals because of unusual outbreaks of bloodstream infections, surgical-site infections, and acute febrile episodes after surgical procedures. Methods. We conducted case-control or cohort studies, or both, to identify risk factors. A case patient was defined as any patient who had an organism-specific infection or acute febrile episode after a surgical procedure during the study period in that hospital. The investigations also included reviews of procedures, cultures, and microbiologic studies of infecting, contaminating, and colonizing strains. Results. Sixty-two case patients were identified, 49 (79 percent) of whom underwent surgery during an epidemic period. Postoperative complications were more frequent during the epidemic period than before it. Only exposure to propofol, a lipid-based anesthetic agent, was significantly associated with the postoperative complications at all seven hospitals. In six of the outbreaks, an etiologic agent (Staphylococcus aureus, Candida albicans, Moraxella osloensis, Enterobacter agglomerans, or Serratia marcescens) was identified, and the same strains were isolated from the case patients. Although cultures of unopened containers of propofol were negative, at two hospitals cultures of propofol from syringes currently in use were positive. At one hospital, the recovered organism was identical to the organism isolated from the case patients. Interviews with and observation of anesthesiology personnel documented a wide variety of lapses in aseptic techniques. Conclusions. With the increasing use of lipid-based medications, which support rapid bacterial growth at room temperature, strict aseptic techniques are essential during the handling of these agents to prevent extrinsic contamination and dangerous infectious complications.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, HOSP INFECT PROGRAM, ATLANTA, GA 30333 USA; CTR DIS CONTROL & PREVENT, DIV BACTERIAL & MYCOT DIS, ATLANTA, GA 30333 USA; CTR DIS CONTROL & PREVENT, DIV FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30333 USA; TEXAS DEPT HLTH, AUSTIN, TX USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Texas Department of State Health Services			Arduino, Matthew/C-1461-2012	Arduino, Matthew/0000-0001-7072-538X; McNeil, Michael/0000-0003-0713-8312; Zeitz, Paul/0000-0002-0865-088X				ALTER MJ, 1983, ANN INTERN MED, V99, P330, DOI 10.7326/0003-4819-99-3-330; ARDUINO MJ, 1991, INFECT CONT HOSP EP, V12, P535; BERRY CB, 1993, ANAESTHESIA, V48, P30; BLAIR JE, 1961, B WORLD HEALTH ORGAN, V24, P771; CORBETT JJ, 1971, NEUROLOGY, V21, P946, DOI 10.1212/WNL.21.9.946; CROCKER KS, 1984, JPEN-PARENTER ENTER, V8, P391, DOI 10.1177/0148607184008004391; Dean A. G., 1990, EPI INFO VERSION 5 W; EDWARDS PR, 1986, IDENTIFICATION ENTER, P431; FROGGATT JW, 1991, 31ST INT C ANT AG CH; Garner J. S., 1985, GUIDELINE PREVENTION; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GREENE ES, 1990, ANESTHESIOLOGY, V73, pA1061; HARRISON CA, 1990, ANAESTHESIA, V45, P831, DOI 10.1111/j.1365-2044.1990.tb14564.x; JACKSON PG, 1981, TUBERCLE, V62, P277, DOI 10.1016/S0041-3879(81)80008-6; JARVIS WR, 1991, AM J MED, V91, pS185, DOI 10.1016/0002-9343(91)90367-7; JARVIS WR, 1984, J CLIN MICROBIOL, V19, P17, DOI 10.1128/JCM.19.1.17-20.1984; KANTOR RJ, 1983, AM J MED, V74, P449, DOI 10.1016/0002-9343(83)90978-6; KEMPEN P M, 1989, Anesthesiology (Hagerstown), V71, pA948, DOI 10.1097/00000542-198909001-00948; KEMPEN PM, 1989, CAN J ANAESTH, V36, P730, DOI 10.1007/BF03005435; KEMPEN PM, 1990, ANESTH ANALG       S, V70, pS199; KOEPKE JW, 1985, ANN ALLERGY, V55, P776; KOEPKE JW, 1984, NEW ENGL J MED, V311, P1188; LASKER BA, 1989, NUCLEIC ACIDS RES, V17, P3783, DOI 10.1093/nar/17.10.3783; LUTZ CT, 1984, NEW ENGL J MED, V310, P1335, DOI 10.1056/NEJM198405173102024; MAKI DG, 1974, APPL MICROBIOL, V28, P778, DOI 10.1128/AEM.28.5.778-784.1974; Maniatis T., 1982, MOL CLONING; MASON MM, 1987, J CLIN MICROBIOL, V25, P563, DOI 10.1128/JCM.25.3.563-566.1987; MASTRO TD, 1990, NEW ENGL J MED, V323, P968, DOI 10.1056/NEJM199010043231406; NORTH JB, 1979, AUST NZ J SURG, V49, P484, DOI 10.1111/j.1445-2197.1979.tb05847.x; ODONNELL NG, 1992, ANAESTHESIA, V47, P923, DOI 10.1111/j.1365-2044.1992.tb03191.x; PARLOW JL, 1989, CAN J ANAESTH, V36, pS61; PETERSEN NJ, 1973, HEALTH LAB SCI, V10, P18; REMILLARD JF, 1987, DETECTION BACTERIAL, V231, P197; ROSENBERG A D, 1989, Anesthesiology (Hagerstown), V71, pA949, DOI 10.1097/00000542-198909001-00949; ROSENBERG AD, 1991, ANESTH ANALG, V72, pS228; RUDNICK JR, 1992, 2ND ANN M SOC HOSP E; SCHAFFNER W, 1969, NEW ENGL J MED, V280, P1224, DOI 10.1056/NEJM196905292802209; SOSIS MB, 1993, ANESTH ANALG, V77, P766; STEERE AC, 1978, TRANSFUSION, V18, P102, DOI 10.1046/j.1537-2995.1978.18178118551.x; TESSLER M, 1992, CAN J ANAESTH, V39, P509, DOI 10.1007/BF03008718; THOMAS DV, 1991, BRIT J ANAESTH, V66, P274, DOI 10.1093/bja/66.2.274-a; TRAUB WH, 1977, J CLIN MICROBIOL, V5, P115; TREPANIER CA, 1990, CAN J ANAESTH, V37, P156, DOI 10.1007/BF03005462; WEINSTEIN RA, 1991, AM J MED, V91, pS179, DOI 10.1016/0002-9343(91)90366-6; ZACHER AN, 1991, ANESTHESIOLOGY, V75, P893, DOI 10.1097/00000542-199111000-00022; 1993, RECOMMENDATIONS INFE; 1985, US PHARMACOPEIA, P1165; 1976, MMWR-MORBID MORTAL W, V25, P141; 1990, MMWR-MORBID MORTAL W, V39, P426; 1993, INFECTION CONTROL GU; 1993, DIPRIVAN INJECTION; 1985, STANDARD METHODS EXA, P869	52	362	374	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 20	1995	333	3					147	154		10.1056/NEJM199507203330303	http://dx.doi.org/10.1056/NEJM199507203330303			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK917	7791816				2022-12-24	WOS:A1995RK91700003
J	ZHONG, Y				ZHONG, Y			MEDIATION OF PACAP-LIKE NEUROPEPTIDE TRANSMISSION BY COACTIVATION OF RAS/RAF AND CAMP SIGNAL-TRANSDUCTION PATHWAYS IN DROSOPHILA	NATURE			English	Article							PROTEIN-TYROSINE KINASE; ADENYLATE-CYCLASE; RECEPTOR; RUTABAGA; CURRENTS; GENE; RAS1	MUCH work on the signal transduction mechanisms underlying neurotransmission has been directed towards studying the roles of the cyclic AMP and phosphoinositide pathways1-3. Upon ligand binding, the transmitter receptors interact with heterotrimeric G proteins, allowing G(alpha) and G(beta gamma) subunits to disengage(2,3). The free G(alpha) then modulates the activity of adenylyl cyclase and phospholipase C1-3. It has been suggested that the G(beta gamma), complex which is activated through muscarinic or neuropeptide receptors can stimulate mitogen-activated protein kinase (MAPK) via activation of the small guanine-nucleotide-binding protein Ras(4,5). Sequential activation of the intermediates in the Ras/Raf serine-threonine protein kinase/MAPK kinase/MAPK/transcription factor pathway has emerged as a central mechanism for controlling cell proliferation and differentiation in yeast, worms, fruitflies and mammals(6-11). Here we show, by analysis of Drosophila mutants, that synaptic current and modulation of K+ current, triggered by a pituitary adenylyl cyclase-activating polypeptide-like neuropeptide(12), are mediated by coactivation of the Ras/Raf and Rutabaga-adenylyl cyclase pathways. Thus the Ras/Raf pathway also appears to be essential for G-protein-coupled neurotransmission.			ZHONG, Y (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.			Zhong, Yi/0000-0001-7810-9899; Zhong, Yi/0000-0002-7927-5976				ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EXTON JH, 1994, ANNU REV PHYSIOL, V56, P349; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hille B., 1992, IONIC CHANNELS EXCIT; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEUMANSILBERBER, 1984, CELL, V0037; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STEWART BA, 1994, J COMP PHYSIOL A, V175, P179, DOI 10.1007/BF00215114; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; YATANI A, 1991, CELL, V61, P769; ZHAO ML, 1995, J NEUROSCI, V15, P1406; ZHONG Y, 1993, J NEUROGENET, V9, P15, DOI 10.3109/01677069309167273; ZHONG Y, 1995, NEURON, V14, P527, DOI 10.1016/0896-6273(95)90309-7; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	30	97	98	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					588	592		10.1038/375588a0	http://dx.doi.org/10.1038/375588a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791875				2022-12-24	WOS:A1995RD28700051
J	RAFFLE, AE; ALDEN, B; MACKENZIE, EFD				RAFFLE, AE; ALDEN, B; MACKENZIE, EFD			DETECTION RATES FOR ABNORMAL CERVICAL SMEARS - WHAT ARE WE SCREENING FOR	LANCET			English	Article							CARCINOMA INSITU; MORTALITY; CANCER; TRENDS; DNA	We analysed rates of detection for smear abnormalities in 255 000 women served by the Bristol screening programme. The programme began in 1966 with the aim of eradicating the 30-40 deaths each year in Bristol from cervical cancer. Organisation has been good and population uptake has been high for the past 15 years. Records were computerised in 1977. During the 1988 to 1993 screening round, 225 974 women were tested. New smear abnormalities were found in 15 551, of whom nearly 6000 were referred for colposcopy. These numbers are excessively high in comparison with the incidence of the malignancy we are trying to prevent. The effect of screening on death rates in Bristol is too small to detect. Our conclusion is that despite good organisation of the service, much of our effort in Bristol is devoted to limiting the harm done to healthy women and to protecting our staff from litigation as cases of serious disease continue to occur. The real lesson from 30 years' cervical screening is that no matter how obvious the predicted benefit may seem for any screening test, introduction should never take place without adequate prior evaluation of both positive and negative effects in controlled trials.	UNITED BRISTOL HEALTHCARE TRUST,DEPT INFORMAT TECHNOL,BRISTOL,AVON,ENGLAND; SOUTHMEAD HLTH SERV TRUST,BRISTOL,AVON,ENGLAND		RAFFLE, AE (corresponding author), BRISTOL & DIST HLTH AUTHOR,10 DIGHTON ST,BRISTOL BS2 8EE,AVON,ENGLAND.							ADELSTEIN AM, 1971, BRIT J PREV SOC MED, V25, P186; ANDERSON CM, 1994, BRIT MED J, V309, P953, DOI 10.1136/bmj.309.6959.953a; AUSTOKER J, 1994, CANCER CERVIX UTERI; BUCKLEY CH, 1994, J CLIN PATHOL, V47, P481; CREASMAN WT, 1972, OBSTET GYNECOL, V39, P373; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; DUNCAN ID, 1993, GUIDELINES CLIN PRAC; EVANS DMD, 1986, J CLIN PATHOL, V39, P933, DOI 10.1136/jcp.39.9.933; FLANNELLY G, 1994, BRIT MED J, V308, P1399, DOI 10.1136/bmj.308.6941.1399; KOLSTAD P, 1976, OBSTET GYNECOL, V48, P125; MACGREGOR JE, 1994, BMJ-BRIT MED J, V308, P1407, DOI 10.1136/bmj.308.6941.1407; MACGREGOR JE, 1978, LANCET, V2, P774; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; PARTINGTON CK, 1991, CANCER, V67, P3104, DOI 10.1002/1097-0142(19910615)67:12<3104::AID-CNCR2820671227>3.0.CO;2-L; SASIENI P, 1991, LANCET, V338, P818, DOI 10.1016/0140-6736(91)90701-P; SIGURDSSON K, 1991, INT J CANCER, V48, P523, DOI 10.1002/ijc.2910480408; 1965, REPORT MED OFFICER H; 1994, REPORT 1ST 5 YEARS N	18	111	111	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 10	1995	345	8963					1469	1473		10.1016/S0140-6736(95)91036-0	http://dx.doi.org/10.1016/S0140-6736(95)91036-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC189	7769901				2022-12-24	WOS:A1995RC18900008
J	MAINEN, ZF; SEJNOWSKI, TJ				MAINEN, ZF; SEJNOWSKI, TJ			RELIABILITY OF SPIKE TIMING IN NEOCORTICAL NEURONS	SCIENCE			English	Article							CAT VISUAL-CORTEX; SINGLE NEURONS; RESPONSES; MONKEY; VARIABILITY; STIMULUS; PATTERNS; CELLS; BRAIN; TRANSMISSION	It is not known whether the variability of neural activity in the cerebral cortex carries information or reflects noisy underlying mechanisms. In an examination of the reliability of spike generation using recordings from neurons in rat neocortical slices, the precision of spike timing was found to depend on stimulus transients. Constant stimuli led to imprecise spike trains, whereas stimuli with fluctuations resembling synaptic activity produced spike trains with timing reproducible to less than 1 millisecond. These data suggest a low intrinsic noise level in spike generation, which could allow cortical neurons to accurately transform synaptic input into spike sequences, supporting a possible role for spike timing in the processing of cortical information by the neocortex.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	MAINEN, ZF (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037, USA.		Sejnowski, Terrence/AAV-5558-2021	Mainen, Zachary/0000-0001-7913-9109				Abeles M, 1991, CORTICONICS NEURAL C, DOI DOI 10.1017/CBO9780511574566; ADRIAN ED, 1926, J PHYSIOL-LONDON, V61, P47; ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; BAIR W, 1994, SOC NEUR ABSTR, V20, P1229; Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; BARLOW HB, 1963, KYBERNETIK, V2, P1, DOI 10.1007/BF00292103; BERGMAN H, 1993, J NEUROPHYSIOL, V70, P1629; BRYANT HL, 1976, J PHYSIOL-LONDON, V260, P279, DOI 10.1113/jphysiol.1976.sp011516; BULLOCK TH, 1970, J GEN PHYSIOL, V55, P565, DOI 10.1085/jgp.55.5.565; Burns BD, 1968, UNCERTAIN NERVOUS SY; CALVIN WH, 1968, J NEUROPHYSIOL, V31, P574, DOI 10.1152/jn.1968.31.4.574; CARR CE, 1990, J NEUROSCI, V10, P3227; CRONER LJ, 1993, P NATL ACAD SCI USA, V90, P8128, DOI 10.1073/pnas.90.17.8128; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P659, DOI 10.1113/jphysiol.1991.sp018730; ENGEL AK, 1992, TRENDS NEUROSCI, V15, P218, DOI 10.1016/0166-2236(92)90039-B; FERSTER D, 1992, J NEUROSCI, V12, P1262; Gray C M, 1994, J Comput Neurosci, V1, P11, DOI 10.1007/BF00962716; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; Hines M, 1993, NEURAL SYSTEMS ANAL, P127; JAGADEESH B, 1992, SCIENCE, V257, P552, DOI 10.1126/science.1636094; KORENBERG MJ, 1989, J NEUROPHYSIOL, V61, P1110, DOI 10.1152/jn.1989.61.6.1110; KRUGER J, 1991, TRENDS NEUROSCI, V14, P282, DOI 10.1016/0166-2236(91)90138-K; LASS Y, 1975, BIOL CYBERN, V19, P61, DOI 10.1007/BF00364102; LESTIENNE R, 1987, BRAIN RES, V437, P214, DOI 10.1016/0006-8993(87)91638-6; LEVINE MW, 1988, VISUAL NEUROSCI, V1, P31, DOI 10.1017/S0952523800001000; MacKAY DONALD M., 1952, BULL MATH BIOPHYS, V14, P127, DOI 10.1007/BF02477711; MAINEN ZF, UNPUB; MALNEN ZF, UNPUB; Marmarelis P.Z., 1978, ANAL PHYSL SYSTEMS; MAUNSELL JHR, 1992, J NEUROPHYSIOL, V68, P1332, DOI 10.1152/jn.1992.68.4.1332; MCCLURKIN JW, 1991, SCIENCE, V253, P675, DOI 10.1126/science.1908118; MIDDLEBROOKS JC, 1994, SCIENCE, V264, P842, DOI 10.1126/science.8171339; NODA H, 1970, BRAIN RES, V18, P513, DOI 10.1016/0006-8993(70)90134-4; OTMAKHOV N, 1993, NEURON, V10, P1101, DOI 10.1016/0896-6273(93)90058-Y; PECHER C, 1939, ARCH INTERN PHYSIOL, V49, P129; PHILLIPS JR, 1992, J NEUROSCI, V12, P827; Rice SO, 1954, SELECTED PAPERS NOIS, P133; RICHMOND BJ, 1990, J NEUROPHYSIOL, V64, P370, DOI 10.1152/jn.1990.64.2.370; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; SCHREINER RC, 1978, J NEUROPHYSIOL, V41, P338, DOI 10.1152/jn.1978.41.2.338; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; SNOWDEN RJ, 1992, EXP BRAIN RES, V88, P389, DOI 10.1007/BF02259114; SOFTKY WR, 1993, J NEUROSCI, V13, P334; STEIN RB, 1967, BIOPHYS J, V7, P797, DOI 10.1016/S0006-3495(67)86623-2; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; SUGA N, 1990, COLD SPRING HARB SYM, V55, P585; THOMSON AM, 1993, J NEUROPHYSIOL, V70, P2354, DOI 10.1152/jn.1993.70.6.2354; TOLHURST DJ, 1983, VISION RES, V23, P775, DOI 10.1016/0042-6989(83)90200-6; TOMKO GJ, 1974, BRAIN RES, V79, P405, DOI 10.1016/0006-8993(74)90438-7; TOVEE MJ, 1993, J NEUROPHYSIOL, V70, P640, DOI 10.1152/jn.1993.70.2.640; VANSTEVENINCK RD, 1988, PROC R SOC SER B-BIO, V234, P379; WERNER G, 1963, J NEUROPHYSIOL, V26, P958, DOI 10.1152/jn.1963.26.6.958; WHITSEL BL, 1977, J NEUROPHYSIOL, V40, P589, DOI 10.1152/jn.1977.40.3.589; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	55	1429	1442	2	51	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1503	1506		10.1126/science.7770778	http://dx.doi.org/10.1126/science.7770778			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770778				2022-12-24	WOS:A1995RC19000042
J	STRATER, N; KLABUNDE, T; TUCKER, P; WITZEL, H; KREBS, B				STRATER, N; KLABUNDE, T; TUCKER, P; WITZEL, H; KREBS, B			CRYSTAL-STRUCTURE OF A PURPLE ACID-PHOSPHATASE CONTAINING A DINUCLEAR FE(III)-ZN(II) ACTIVE-SITE	SCIENCE			English	Article							REACTION-MECHANISM; BOVINE SPLEEN; PROTEIN; UTEROFERRIN; CATALYZES	Kidney bean purple acid phosphatase (KBPAP) is an Fe(III)-Zn(II) metalloenzyme resembling the mammalian Fe(III)-Fe(II) purple acid phosphatases. The structure of the homodimeric III-kilodalton KBPAP was determined at a resolution of 2.9 angstroms. The enzyme contains two domains in each subunit. The active site is located in the carboxyl-terminal terminal domain at the carboxy end of two sandwiched beta alpha beta alpha beta motifs. The two metal ions are 3.1 angstroms apart and bridged monodentately by Asp(164) The iron is further coordinated by Tyr(167), His(325), and Asp(135), and the zinc by His(286), His(323), and Asn(201). The active-site structure is consistent with previous proposals regarding the mechanism of phosphate ester hydrolysis involving nucleophilic attack on the phosphate group by an Fe(III)coordinated hydroxide ion.	EUROPEAN MOLEC BIOL LAB, D-69117 HEIDELBERG, GERMANY; UNIV MUNSTER, INST BIOCHEM, D-48149 MUNSTER, GERMANY	European Molecular Biology Laboratory (EMBL); University of Munster	STRATER, N (corresponding author), UNIV MUNSTER, INST ANORGAN CHEM, D-48149 MUNSTER, GERMANY.		Krebs, Bernt/B-9068-2011; Strater, Norbert/P-4856-2018	Strater, Norbert/0000-0002-2001-0500				AQUINO MAS, 1994, J CHEM SOC DALTON, P429, DOI 10.1039/dt9940000429; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BECK JL, 1986, BIOCHIM BIOPHYS ACTA, V869, P61, DOI 10.1016/0167-4838(86)90310-9; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER TA, 1993, XPLOR VERSION 3 1 MA; DIETRICH M, 1991, EUR J BIOCHEM, V199, P105, DOI 10.1111/j.1432-1033.1991.tb16097.x; Doi K., 1988, STRUCT BONDING BERLI, V70, P1; HAYMAN AR, 1994, J BIOL CHEM, V269, P1294; HOLMES MA, 1991, J MOL BIOL, V218, P583, DOI 10.1016/0022-2836(91)90703-9; HOLZ RC, 1992, J AM CHEM SOC, V114, P4434, DOI 10.1021/ja00037a079; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT; KAUZLARICH SM, 1986, INORG CHEM, V25, P2781, DOI 10.1021/ic00236a025; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KLABUNDE T, 1994, EUR J BIOCHEM, V226, P369, DOI 10.1111/j.1432-1033.1994.tb20061.x; KLEYWEGT GJ, IN PRESS ACTA CRYS D; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MUELLER EG, 1993, J AM CHEM SOC, V115, P2974, DOI 10.1021/ja00060a055; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; PRIGGEMEYER S, 1995, INORG CHEM, V34, P1445, DOI 10.1021/ic00110a024; QUE L, 1990, PROG INORG CHEM, V38, P97; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; STAHL B, 1994, EUR J BIOCHEM, V220, P321, DOI 10.1111/j.1432-1033.1994.tb18628.x; STRATER N, 1992, J MOL BIOL, V224, P511, DOI 10.1016/0022-2836(92)91012-E; SUERBAUM H, 1993, EUR J BIOCHEM, V214, P313, DOI 10.1111/j.1432-1033.1993.tb17926.x; TRUE AE, 1993, J AM CHEM SOC, V115, P4246, DOI 10.1021/ja00063a047; VINCENT JB, 1990, CHEM REV, V90, P1447, DOI 10.1021/cr00106a004; WANG ZG, 1992, BIOCHEMISTRY-US, V31, P5263, DOI 10.1021/bi00138a004	28	404	413	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 9	1995	268	5216					1489	1492		10.1126/science.7770774	http://dx.doi.org/10.1126/science.7770774			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770774				2022-12-24	WOS:A1995RC19000038
J	CHIARA, MD; REED, R				CHIARA, MD; REED, R			A 2-STEP MECHANISM FOR 5' AND 3' SPLICE-SITE PAIRING	NATURE			English	Article							MESSENGER-RNA PRECURSORS; ACTIVE-SITE; U6 SNRNA; SELECTION; SEQUENCES; INVITRO	A FUNDAMENTAL question in the splicing of precursor messenger RNA is how the 5' and 3' splice sites are recognized and paired during the splicing reaction. It has been proposed that spliceosome assembly in metazoan pre-mRNAs can be initiated through interaction between the 3' splice site and specific sequence elements on the downstream exon (an exonic enhancer or a 5' splice site)(1). Pairing of the intronic 5' and 3' splice sites occurs subsequently. We report here that 5' and 3' splice sites located on separate synthetic pre-mRNA substrates can be efficiently trans-spliced if the 3' trans-splicing substrate contains these downstream sequence elements. Moreover, selection of the trans 5' splice site can occur after the second pre-spliceosomal complex A has assembled on the 3' trans-splicing substrate. Thus our data demonstrate that 5' and 3' splice-site pairing in metazoans can occur in two distinct steps.			CHIARA, MD (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		Chiara, María Dolores/AAG-5765-2019	Chiara, María Dolores/0000-0002-1112-1583				DATTA B, 1993, MOL CELL BIOL, V13, P5377, DOI 10.1128/MCB.13.9.5377; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; KONARSKA MM, 1985, CELL, V42, P165, DOI 10.1016/S0092-8674(85)80112-4; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KUO HC, 1992, SCIENCE, V251, P1045; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SOLNICK D, 1986, CELL, V44, P211, DOI 10.1016/0092-8674(86)90752-X; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WOLFF T, 1994, P NATL ACAD SCI USA, V91, P903, DOI 10.1073/pnas.91.3.903	17	93	97	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					510	513		10.1038/375510a0	http://dx.doi.org/10.1038/375510a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777062				2022-12-24	WOS:A1995RC18800054
J	ERICSON, J; MUHR, J; PLACZEK, M; LINTS, T; JESSELL, TM; EDLUND, T				ERICSON, J; MUHR, J; PLACZEK, M; LINTS, T; JESSELL, TM; EDLUND, T			SONIC HEDGEHOG INDUCES THE DIFFERENTIATION OF VENTRAL FOREBRAIN NEURONS - A COMMON SIGNAL FOR VENTRAL PATTERNING WITHIN THE NEURAL-TUBE	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; FLOOR PLATE; CELL PATTERN; PROTEIN ISL-1; CHICK-EMBRYO; EXPRESSION; NOTOCHORD; INDUCTION; HOMEODOMAIN; HOMEOBOX	The vertebrate hedgehog-related gene Sonic hedgehog (Shh) is expressed in ventral domains along the entire rostrocaudal length of the neural tube, including the forebrain. We show here that SHH induces the differentiation of ventral neuronal cell types in explants derived from prospective forebrain regions of the neural plate. Neurons induced in explants derived from both diencephalic and telencephalic levels of the neural plate express the LIM homeodomain protein Isl-1, and these neurons possess distinct identities that match those of the ventral neurons generated in these two subdivisions of the forebrain in vivo. A single inducing molecule, SHH, therefore appears to mediate the induction of distinct ventral neuronal cell types along the entire rostrocaudal extent of the embryonic central nervous system.	NATL INST MED RES, LONDON NW7 1AA, ENGLAND; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	MRC National Institute for Medical Research; Columbia University; Howard Hughes Medical Institute; Columbia University	ERICSON, J (corresponding author), UMEA UNIV, DEPT MICROBIOL, S-90187 UMEA, SWEDEN.		Placzek, Marysia/E-6172-2010; Lints, Thierry/K-4408-2012	Ericson, Johan/0000-0002-8019-7127; Placzek, Marysia/0000-0002-4106-9229	NINDS NIH HHS [NS-33245, NS-30532] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033245, P01NS030532] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTABA ARI, 1992, DEVELOPMENT, V116, P67; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BARTH KA, 1995, IN PRESS DEVELOPMENT, V121; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; CHANG DT, 1994, DEVELOPMENT, V120, P3339; COULY GF, 1987, DEV BIOL, V120, P198, DOI 10.1016/0012-1606(87)90118-7; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; DONIACH T, 1992, SCIENCE, V257, P542, DOI 10.1126/science.1636091; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATTA K, 1994, P NATL ACAD SCI USA, V91, P2061, DOI 10.1073/pnas.91.6.2061; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; INOUE A, 1994, DEV DYNAM, V199, P1, DOI 10.1002/aja.1001990102; JACOBSON CO, 1964, ZOOL BIDR UPPS, V36, P73; JESSELL TM, 1992, HARVEY LECT, V86, P87; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; Kingsbury BF, 1930, J COMP NEUROL, V50, P177, DOI 10.1002/cne.900500109; KORZH V, 1993, DEVELOPMENT, V118, P417; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MACDONALD R, 1994, NEURON, V13, P1039, DOI 10.1016/0896-6273(94)90044-2; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1991, DEVELOPMENT, P105; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; PUELLES L, 1987, J COMP NEUROL, V266, P247, DOI 10.1002/cne.902660210; PUELLES L, 1993, TRENDS NEUROSCI, V16, P472, DOI 10.1016/0166-2236(93)90080-6; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROACH FC, 1945, J EXP ZOOL, V99, P53, DOI 10.1002/jez.1400990203; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SIMON H, 1995, CURR BIOL, V5, P205, DOI 10.1016/S0960-9822(95)00041-8; SIMON H, 1994, J NEUROBIOL, V25, P1129, DOI 10.1002/neu.480250908; SMITH JC, 1993, CURR BIOL, V3, P582, DOI 10.1016/0960-9822(93)90003-7; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TANABE Y, 1995, IN PRESS CURR BIOL; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	51	454	476	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					747	756		10.1016/0092-8674(95)90536-7	http://dx.doi.org/10.1016/0092-8674(95)90536-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774016	Bronze			2022-12-24	WOS:A1995RB96100013
J	TEWARI, M; QUAN, LT; OROURKE, K; DESNOYERS, S; ZENG, Z; BEIDLER, DR; POIRIER, GG; SALVESEN, GS; DIXIT, VM				TEWARI, M; QUAN, LT; OROURKE, K; DESNOYERS, S; ZENG, Z; BEIDLER, DR; POIRIER, GG; SALVESEN, GS; DIXIT, VM			YAMA/CPP32-BETA, A MAMMALIAN HOMOLOG OF CED-3, IS A CRMA-INHIBITABLE PROTEASE THAT CLEAVES THE DEATH SUBSTRATE POLY(ADP-RIBOSE) POLYMERASE	CELL			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; CELL-DEATH; C-ELEGANS; ALPHA-1-PROTEINASE INHIBITOR; GENE CED-3; INDUCTION; APOPTOSIS; ENCODES	Although the mechanism of mammalian apoptosis has not been elucidated, a protease of the CED-3/ICE family is anticipated to be a component of the death machinery. Several lines of evidence predict that this protease cleaves the death substrate poly(ADP-ribose) polymerase (PARP) to a specific 85 kDa form observed during apoptosis, is inhibitable by the CrmA protein, and is distinct from ICE, We cloned a ced-3/ICE-related gene, designated Yama, that encodes a protein identical to CPP32 beta. Purified Yama was a zymogen that, when activated, cleaved PARP to generate the 85 kDa apoptotic fragment. Cleavage of PARP by Yama was inhibited by CrmA but not by an inactive point mutant of CrmA. Furthermore, CrmA blocked cleavage of PARP in cells undergoing apoptosis. We propose that Yama may represent an effector component of the mammalian cell death pathway and suggest that CrmA blocks apoptosis by inhibiting Yama.	UNIV MICHIGAN,SCH MED,GRAD PROGRAM CELLULAR & MOLEC BIOL,ANN ARBOR,MI 48109; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; CHU LAVAL,RES CTR,MOLEC ENDOCRINOL LAB,POLY ADPRIBOSE METAB GRP,ST FOY,PQ G1V 4G2,CANADA; UNIV LAVAL,ST FOY,PQ G1V 4G2,CANADA	University of Michigan System; University of Michigan; Duke University; Laval University; Laval University	TEWARI, M (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109, USA.		dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; Poirier, Guy/0000-0002-4869-1424	NATIONAL CANCER INSTITUTE [R01CA064803] Funding Source: NIH RePORTER; NCI NIH HHS [CA64803] Funding Source: Medline; NHLBI NIH HHS [HL07517] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DAVIS AE, 1992, NAT GENET, V1, P354, DOI 10.1038/ng0892-354; DESNOYERS S, 1994, ANAL BIOCHEM, V218, P470, DOI 10.1006/abio.1994.1212; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HU HM, 1994, J BIOL CHEM, V269, P30069; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KOMIYAMA T, 1994, TECHNIQUES PROTEIN C, V5, P305; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RON D, 1992, BIOTECHNIQUES, V13, P866; SCHULZE AJ, 1991, EUR J BIOCHEM, V202, P1147, DOI 10.1111/j.1432-1033.1991.tb16483.x; SHAO HN, 1994, J BIOL CHEM, V269, P26606; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZAHRADKA P, 1984, EUR J BIOCHEM, V142, P503, DOI 10.1111/j.1432-1033.1984.tb08314.x	38	2291	2361	1	32	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					801	809		10.1016/0092-8674(95)90541-3	http://dx.doi.org/10.1016/0092-8674(95)90541-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774019	Bronze			2022-12-24	WOS:A1995RB96100018
J	KANG, CH; CHAN, R; BERGER, I; LOCKSHIN, C; GREEN, L; GOLD, L; RICH, A				KANG, CH; CHAN, R; BERGER, I; LOCKSHIN, C; GREEN, L; GOLD, L; RICH, A			CRYSTAL-STRUCTURE OF THE T4 REGA TRANSLATIONAL REGULATOR PROTEIN AT 1.9-ANGSTROM RESOLUTION	SCIENCE			English	Article							BACTERIOPHAGE-T4; REPRESSOR; BINDING	The translational regulator protein regA is encoded by the T4 bacteriophage and binds to a region of messenger RNA (mRNA) that includes the initiator codon, RegA is unusual in that it represses the translation of about 35 early T4 mRNAs but does not affect nearly 200 other mRNAs. The crystal structure of regA was determined at 1.9 Angstrom resolution; the protein was shown to have an alpha-helical core and two regions with antiparallel beta sheets. One of these beta sheets has four antiparallel strands and has some sequence homology to RNP-1 and RNP-2, which are believed to be RNA-binding motifs and are found in a number of known RNA-binding proteins. Structurally guided mutants may help to uncover the basis for this variety of RNA interaction.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HANNOVER MED SCH,DEPT BIOPHYS CHEM,D-30623 HANNOVER,GERMANY; NEXAGEN INC,BOULDER,CO 80302; UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80302	Massachusetts Institute of Technology (MIT); Hannover Medical School; University of Colorado System; University of Colorado Boulder				Berger, Imre/0000-0001-7518-9045				BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRUNGER AT, XPLOR; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAVARELLI J, 1991, NATURE, V352, P181; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; JOZWIK CE, 1992, P NATL ACAD SCI USA, V89, P5053, DOI 10.1073/pnas.89.11.5053; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MILLER ES, 1985, J BIOL CHEM, V260, P3053; MILLER ES, 1994, MOL BIOL BACTERIOP T, V4, P193; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Pflugrath J. W., 1984, Methods and Applications in Crystallographic Computing. International Summer School on Crystallographic Computing, P404; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; STEIGMANN W, 1982, PROTEIN PACKAGE CRYS; TROJANOWSKA M, 1984, NUCLEIC ACIDS RES, V12, P5979, DOI 10.1093/nar/12.15.5979; UNNITHAN S, 1990, NUCLEIC ACIDS RES, V18, P7083, DOI 10.1093/nar/18.23.7083; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEBSTER KR, 1990, J BIOL CHEM, V265, P19007; WEBSTERKR, 1992, J BIOL CHEM, V267, P26097; WINTER RB, 1987, P NATL ACAD SCI USA, V84, P7822, DOI 10.1073/pnas.84.22.7822	21	21	22	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1170	1173		10.1126/science.7761833	http://dx.doi.org/10.1126/science.7761833			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761833				2022-12-24	WOS:A1995RA60400035
J	KALE, R				KALE, R			SOUTH-AFRICA HEALTH - TRADITIONAL HEALERS IN SOUTH-AFRICA - A PARALLEL HEALTH-CARE SYSTEM	BRITISH MEDICAL JOURNAL			English	Article							MEDICINES											FREEMAN M, 1992, SOC SCI MED, V34, P1183, DOI 10.1016/0277-9536(92)90311-D; GRAHAM R, 1993, WHITE WOMAN WITCH DO, V229, P234; KARIM SSA, 1992, BRINDGING GAP PROJEC; MCVANN A, 1992, S AFR MED J, V81, P139; SEGAL I, 1994, BARAGWANATH HOSPITAL, P17; VANRENSBURG HCJ, 1982, PROFILE DISEASE HLTH, P180; VEALE DJH, 1992, J ETHNOPHARMACOL, V36, P185, DOI 10.1016/0378-8741(92)90043-Q; WOOD R, 1990, S AFR MED J, V77, P640	8	116	119	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1182	1185		10.1136/bmj.310.6988.1182	http://dx.doi.org/10.1136/bmj.310.6988.1182			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX566	7767156	Green Published			2022-12-24	WOS:A1995QX56600030
J	CHESTER, MR; BARNETT, DB				CHESTER, MR; BARNETT, DB			CARDIAC CHAMBER-SPECIFIC BETA-ADRENOCEPTOR REGULATION AND SYMPATHETIC INNERVATION	LANCET			English	Note							HEART-FAILURE; DOWN-REGULATION; BETA-1-ADRENOCEPTOR; BETA-2-ADRENOCEPTOR; CARDIOMYOPATHY	We assessed by radioligand binding techniques the effect of cardiac failure on beta-adrenoceptor density in 5 hearts from patients undergoing repeat transplantation and 5 normal (unused donor) hearts. Right ventricular total and subtype beta-adrenoceptors in the denervated repeat-transplant hearts were down-regulated compared with the normally innervated controls. Within the denervated hearts, beta(1)-adrenoceptors were selectively down-regulated in the right ventricle compared with the left ventricle. Tissue noradrenaline content confirmed sympathetic denervation in the transplantd hearts. Thus, regional sympathetic innervation is not necessary for chamber-specific beta-adrenoceptor down-regulation; other mechanisms for this process should be sought.	NATL HEART & LUNG INST, LONDON, ENGLAND; LEICESTER ROYAL INFIRM, DEPT PHARMACOL, LEICESTER LE2 7LX, LEICS, ENGLAND	Imperial College London; University of Leicester								BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; BRODDE OE, 1989, J AM COLL CARDIOL, V14, P323, DOI 10.1016/0735-1097(89)90181-2; CHESTER MR, 1992, BRIT J CLIN PHARMACO, V33, P417, DOI 10.1111/j.1365-2125.1992.tb04061.x; GILBERT EM, 1989, CIRCULATION, V79, P344, DOI 10.1161/01.CIR.79.2.344; KAWAI C, 1983, J AM COLL CARDIOL, V2, P834, DOI 10.1016/S0735-1097(83)80229-0; LIANG CS, 1989, J CLIN INVEST, V84, P1267, DOI 10.1172/JCI114294; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; WAAGSTEIN F, 1989, CIRCULATION, V80, P551, DOI 10.1161/01.CIR.80.3.551; YOSHIKAWA T, 1994, J AM COLL CARDIOL, V24, P210, DOI 10.1016/0735-1097(94)90565-7	10	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	1995	345	8949					553	555		10.1016/S0140-6736(95)90467-0	http://dx.doi.org/10.1016/S0140-6736(95)90467-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776776				2022-12-24	WOS:A1995QK44400012
J	AUGER, J; KUNSTMANN, JM; CZYGLIK, F; JOUANNET, P				AUGER, J; KUNSTMANN, JM; CZYGLIK, F; JOUANNET, P			DECLINE IN SEMEN QUALITY AMONG FERTILE MEN IN PARIS DURING THE PAST 20 YEARS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPERM COUNTS; REPRODUCTIVE-TRACT; HUMAN TESTIS; DIETHYLSTILBESTROL	Background. Several studies have suggested a population-wide decline in the quality of semen over the past 50 years, but clear evidence of decreasing semen quality in recent decades is lacking. Methods. From 1973 through 1992 we measured the volume of seminal fluid, the sperm concentration, and the percentages of motile and morphologically normal spermatozoa in 1351 healthy fertile men. The data on the semen samples were collected at one sperm bank in Paris. The data in each calendar year were analyzed as a function of the year of donation, the age of each patient, the year of birth, and the duration of sexual abstinence before semen collection. Results. There was no change in semen volume during the study period, The mean concentration of sperm decreased by 2.1 percent per year, from 89x10(6) per milliliter in 1973 to 60x10(6) per milliliter in 1992 (P<0.001). During the same period the percentages of motile and normal spermatozoa decreased by 0.6 percent and 0.5 percent per year, respectively (both P<0.001). After adjustment in multiple regression analyses for age and the duration of sexual abstinence, each successive calendar year of birth accounted for 2.6 percent of the yearly decline in the sperm concentration and for 0.3 percent and 0.7 percent, respectively, of the yearly declines in the percentages of motile and normal spermatozoa (all P<0.001). Conclusions. During the past 20 years, there has been a decline in the concentration and motility of sperm and in the percentage of morphologically normal spermatozoa in fertile men that is independent of the age of the men.	UNIV PARIS SUD,CTR HOSP,CTR ETUD & CONSERVAT OEUFS & SPERME HUMAINS,F-94275 LE KREMLIN BICETR,FRANCE	UDICE-French Research Universities; Universite Paris Saclay			Auger, Jacques/AAA-1375-2019	Auger, Jacques/0000-0002-4521-3363				BENDVOLD E, 1989, INT J FERTIL, V34, P401; BOSTOFTE E, 1983, INT J FERTIL, V28, P91; BOYLE P, 1987, EUR J CANCER CLIN ON, V23, P827, DOI 10.1016/0277-5379(87)90286-0; BROMWICH P, 1994, BRIT MED J, V309, P19, DOI 10.1136/bmj.309.6946.19; CANLORBE P, 1966, ANN PEDIATR-PARIS, V42, P969; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; COLEMAN MP, 1993, IARC SCI PUBL, V121, P521; COOPER TG, 1992, FERTIL STERIL, V58, P172; David G., 1975, J GYN OBST BIOL R S1, V1, P17; DIXON WJ, 1988, BMDP STATISTICAL SOF; FARROW S, 1994, BRIT MED J, V309, P1; GINSBURG J, 1994, LANCET, V343, P230, DOI 10.1016/S0140-6736(94)91012-X; GIWERCMAN A, 1992, INT J ANDROL, V15, P373, DOI 10.1111/j.1365-2605.1992.tb01351.x; GIWERCMAN A, 1993, ENVIRON HEALTH PERSP, V101, P65, DOI 10.2307/3431378; IRVINE DS, 1994, BRIT MED J, V309, P476, DOI 10.1136/bmj.309.6952.476; JACKSON MB, 1988, HORM RES, V30, P153, DOI 10.1159/000181052; JAMES WH, 1980, ANDROLOGIA, V12, P381; JARDIN A, 1992, Journal of Urology, V147, p386A; JOHNSON L, 1986, J ANDROL, V7, P331; JOUANNET P, 1977, ANDROLOGIA, V9, P36; JOUANNET P, 1981, INT J ANDROL, V4, P440, DOI 10.1111/j.1365-2605.1981.tb00728.x; MIEUSSET R, 1989, J CLIN ENDOCR METAB, V68, P419, DOI 10.1210/jcem-68-2-419; MIEUSSET R, 1991, TEMPERATURE ENV EFFE, P233; SCHWARTZ D, 1983, FERTIL STERIL, V39, P530; SHARPE RM, 1993, J ENDOCRINOL, V136, P357, DOI 10.1677/joe.0.1360357; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SPIRA A, 1983, REV EPIDEMIOL SANTE, V31, P249; STILLMAN RJ, 1982, AM J OBSTET GYNECOL, V142, P905, DOI 10.1016/S0002-9378(16)32540-6; 1992, WHO LABORATORY MANUA	29	835	883	1	46	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	1995	332	5					281	285		10.1056/NEJM199502023320501	http://dx.doi.org/10.1056/NEJM199502023320501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD396	7816062				2022-12-24	WOS:A1995QD39600001
J	CHEN, C; NAGY, Z; RADIC, MZ; HARDY, RR; HUSZAR, D; CAMPER, SA; WEIGERT, M				CHEN, C; NAGY, Z; RADIC, MZ; HARDY, RR; HUSZAR, D; CAMPER, SA; WEIGERT, M			THE SITE AND STAGE OF ANTI-DNA B-CELL DELETION	NATURE			English	Article							REACTIVE LYMPHOCYTES-B; SOMATIC MUTATION; ESCAPE TOLERANCE; AUTOIMMUNE MICE; CLONAL DELETION; BONE-MARROW; MOUSE; ANTIBODIES; AUTOANTIBODIES; ELIMINATION	ANTIBODIES to DNA and nucleoproteins are found in sera of individuals with systemic autoimmune disease. In the population (and in the autoimmune mouse strain MRL/lpr) there is a great variety of such antinuclear antibodies, but individuals with systemic lupus erythematosus or single MRL mice express a subset only of the antinuclear specificities found in the population. These observations have been interpreted to mean that these antibodies arise by immunization(1) The oligoclonal nature of the autoantibody response and the evidence of selection acting on somatically mutated autoantibodies favour this interpretation(2,3). Specific activation of autoantibodies in disease implies either that autoantibodies are regulated in non-diseased individuals or that autoantigen availability is variable. The former has been demonstrated in anti-DNA transgenic mice. In normal mice, transgene-encoded antibodies against double-stranded (ds) DNA are not expressed in serum or on B cells(4-6). Here we describe modified anti-dsDNA transgenic mice which allow us to study the site and developmental stage at which such B-cell regulation occurs. This model shows that in normal mice B cells expressing anti-DNA specificity are deleted in the bone marrow at a pre-B to immature B transitional stage.	MED COLL PENN,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19129; FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111; GENPHARM INT INC,MT VIEW,CA 94043; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109	Drexel University; Fox Chase Cancer Center; University of Michigan System; University of Michigan	CHEN, C (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.			Camper, Sally/0000-0001-8556-3379; Radic, Marko/0000-0002-8004-282X				ALLMAN DM, 1993, J IMMUNOL, V151, P4431; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; CHEN C, 1994, J IMMUNOL, V152, P1970; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; EILAT D, 1988, J IMMUNOL, V141, P1745; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HARDIN JA, 1986, ARTHRITIS RHEUM, V29, P457, DOI 10.1002/art.1780290401; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; MARION TN, 1990, J IMMUNOL, V145, P2322; NEMAZEE D, 1991, IMMUNOL REV, V122, P117, DOI 10.1111/j.1600-065X.1991.tb00600.x; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; RADIC MZ, 1991, J IMMUNOL, V146, P176; RADIC MZ, 1993, J IMMUNOL, V150, P4966; RADIC MZ, 1993, J EXP MED, V177, P1165, DOI 10.1084/jem.177.4.1165; RADIC MZ, 1994, REV IMMUNOL, V12, P487; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; SHLOMCHIK MJ, 1987, P NATL ACAD SCI USA, V84, P9150, DOI 10.1073/pnas.84.24.9150; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009	24	261	264	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					252	255		10.1038/373252a0	http://dx.doi.org/10.1038/373252a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816141	Green Submitted			2022-12-24	WOS:A1995QC27800066
J	JONES, PH; HARPER, S; WATT, FM				JONES, PH; HARPER, S; WATT, FM			STEM-CELL PATTERNING AND FATE IN HUMAN EPIDERMIS	CELL			English	Article							INTEGRINS ALPHA-3-BETA-1; FIBRONECTIN RECEPTOR; MESSENGER-RNA; ADHESION; EXPRESSION; KERATINOCYTES; MIGRATION; CYTOSKELETAL; ANTIGEN; ROLES	Within human epidermis there are two types of proliferating keratinocyte: stem cells, which have high proliferative potential, and transit-amplifying cells, which are destined to undergo terminal differentiation after a few rounds of division. We show that, in vivo, stem cells express higher levels of the alpha(2) beta(1) and alpha(3) beta(1) integrins than transit-amplifying cells and that this can be used both to determine the location of stem cells within the epidermis and to isolate them directly from the tissue. The distribution of stem cells and transit-amplifying cells is not random: patches of integrin-bright and integrin-dull cells have a specific location with respect to the epidermal-dermal junction that varies between body sites and that correlates with the distribution of S phase cells. Stem cell patterning can be recreated in culture, in the absence of dermis, and appears to be subject to autoregulation.	IMPERIAL CANC RES FUND, KERATINOCYTE LAB, LONDON WC2A 3PX, ENGLAND; LEICESTER GEN HOSP, DEPT NEPHROL, LEICESTER LE5 4PW, LEICS, ENGLAND	Cancer Research UK; University Hospitals of Leicester NHS Trust; Leicester General Hospital			Jones, Philip/D-2464-2009; Watt, Fiona/AHB-0226-2022	Jones, Philip/0000-0002-5904-795X; Watt, Fiona/0000-0001-9151-5154	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BARRANDON Y, 1988, J INVEST DERMATOL, V91, P315, DOI 10.1111/1523-1747.ep12475646; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; CHEN FA, 1991, J EXP MED, V173, P1111, DOI 10.1084/jem.173.5.1111; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; DESTROOPER B, 1988, CELL BIOL INT REP, V12, P9, DOI 10.1016/0309-1651(88)90106-3; GERMAIN L, 1993, BURNS, V19, P99, DOI 10.1016/0305-4179(93)90028-7; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HALL PA, 1989, DEVELOPMENT, V106, P619; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; HERTLE MD, 1991, DEVELOPMENT, V112, P193; HODIVALA KJ, 1994, J CELL BIOL, V124, P589, DOI 10.1083/jcb.124.4.589; Holbrook K.A., 1991, PHYSL BIOCH MOL BIOL, P63; HOTCHIN NA, 1993, J CELL SCI, V106, P1131; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; LANE EB, 1991, ANN NY ACAD SCI, V642, P197; LAVKER RM, 1983, J INVEST DERMATOL, V81, pS121, DOI 10.1111/1523-1747.ep12540880; OFARRELL PH, 1994, NATURE, V368, P188, DOI 10.1038/368188a0; POTTEN CS, 1988, J CELL SCI, P45; POTTEN CS, 1974, CELL TISSUE KINET, V7, P77, DOI 10.1111/j.1365-2184.1974.tb00401.x; PRINGLE JH, 1990, J PATHOL, V162, P197, DOI 10.1002/path.1711620305; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; ROCHAT A, 1994, INT J DEV BIOL, V76, P1063; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; UCHIDA N, 1993, CURR OPIN IMMUNOL, V5, P177, DOI 10.1016/0952-7915(93)90002-A; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WATT FM, 1993, J CELL SCI, V106, P175; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; YANG JS, 1993, J INVEST DERMATOL, V101, P652, DOI 10.1111/1523-1747.ep12371671; ZHONG R, 1983, NUCLEIC ACIDS RES, V11, P7409, DOI 10.1093/nar/11.21.7409	37	675	733	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 13	1995	80	1					83	93		10.1016/0092-8674(95)90453-0	http://dx.doi.org/10.1016/0092-8674(95)90453-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813021	Bronze			2022-12-24	WOS:A1995QB91000012
J	POMERANTZ, JL; SHARP, PA; PABO, CO				POMERANTZ, JL; SHARP, PA; PABO, CO			STRUCTURE-BASED DESIGN OF TRANSCRIPTION FACTORS	SCIENCE			English	Article							DNA-BINDING SPECIFICITY; POU-DOMAIN; PROTEIN; REPRESSOR; SEQUENCE	Computer modeling suggested that transcription factors with novel sequence specificities could be designed by combining known DNA binding domains. This structure-based strategy was tested by construction of a fusion protein, ZFHD1,that contained zinc fingers 1 and 2 from Zif268, a short polypeptide linker, and the homeodomain from Oct-1. The fusion protein bound optimally to a sequence containing adjacent homeodomain (TA-ATTA) and zinc finger (NGGGNG) subsites. When fused to an activation domain, ZFHD1 regulated promoter activity in vivo in a sequence-specific manner. Analysis of known protein-DNA complexes suggests that many other DNA binding proteins could be designed in a similar fashion.	MIT,HARVARD DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139; MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	POMERANTZ, JL (corresponding author), MIT,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139, USA.			Pomerantz, Joel L./0000-0002-5030-1018	NATIONAL CANCER INSTITUTE [P01CA042063, P30CA014051] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA42063, P30-CA14051] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; PAVIETICH NP, 1991, SCIENCE, V252, P809; PELLETT PE, 1985, P NATL ACAD SCI USA, V82, P5870, DOI 10.1073/pnas.82.17.5870; POMERANTZ JL, 1994, BIOCHEMISTRY-US, V33, P10851, DOI 10.1021/bi00202a001; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; POMERANTZ JL, UNPUB; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUCKOW M, 1994, NUCLEIC ACIDS RES, V22, P2198, DOI 10.1093/nar/22.12.2198; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; WHARTON RP, 1985, NATURE, V316, P601, DOI 10.1038/316601a0; YOUDERIAN P, 1983, CELL, V35, P777, DOI 10.1016/0092-8674(83)90110-1	20	121	179	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 6	1995	267	5194					93	96		10.1126/science.7809612	http://dx.doi.org/10.1126/science.7809612			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7809612				2022-12-24	WOS:A1995QA23500037
J	ANGELINI, GD; IZZAT, MB; BRYAN, AJ; WEST, RR				ANGELINI, GD; IZZAT, MB; BRYAN, AJ; WEST, RR			HOW SENSITIVE ARE CARDIAC-SURGEONS FINGERS	BRITISH MEDICAL JOURNAL			English	Article									UNIV WALES COLL MED, CTR PUBL HLTH STUDIES, CARDIFF CF4 4XN, S GLAM, WALES	Cardiff University	ANGELINI, GD (corresponding author), UNIV BRISTOL, DEPT CARDIAC SURG, BRISTOL BS2 8HW, AVON, ENGLAND.		Izzat, Mohammad Bashar/I-1987-2019	Izzat, Mohammad Bashar/0000-0001-6758-8716; angelini, gianni/0000-0002-1753-3730				BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; LOWE CR, 1962, LANCET, V1, P1086; PAUCA AL, 1989, ANESTHESIOLOGY, V70, P935, DOI 10.1097/00000542-198906000-00009; URZUA J, 1990, ANESTHESIOLOGY, V73, P191, DOI 10.1097/00000542-199007000-00035	4	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1685	1686		10.1136/bmj.309.6970.1685	http://dx.doi.org/10.1136/bmj.309.6970.1685			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819985	Green Published			2022-12-24	WOS:A1994PY71700009
J	CLARK, LR				CLARK, LR			TEEN SEX BLUES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1969	1970						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783311				2022-12-24	WOS:A1995RE35400040
J	TANG, WJ; GILMAN, AG				TANG, WJ; GILMAN, AG			CONSTRUCTION OF A SOLUBLE ADENYLYL-CYCLASE ACTIVATED BY G(S)ALPHA AND FORSKOLIN	SCIENCE			English	Article							GLUCOSE-TRANSPORT; ESCHERICHIA-COLI; GS-ALPHA; SITE; CAMP; RAT; ADIPOCYTES; INHIBITION	A soluble adenylyl cyclase was constructed by linkage of portions of the cytosolic domains of the mammalian type I and type II enzymes. The soluble enzyme was stimulated by both forskolin and the alpha subunit of the heterotrimeric guanine nucleotide-binding protein (G protein) G(s) (G(s) alpha). Expression of the construct complemented the catabolic defect in a strain of Escherichia coli that is deficient in adenylyl cyclase activity. The active, approximately 60-kilodalton enzyme accumulated in the cytoplasmic fraction of E. coli to yield activities in excess of 1 nanomole per minute per milligram of protein. The two sets of transmembrane helices of mammalian adenylyl cyclases are thus not necessary for the catalytic or the most characteristic regulatory activities of the enzyme. This system may be useful for both genetic and biochemical analysis of G protein-regulated adenylyl cyclases.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Tang, Wei-Jen/0000-0002-8267-8995	NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BEUVE A, 1990, J BACTERIOL, V172, P2614, DOI 10.1128/jb.172.5.2614-2621.1990; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DESSAUER C, UNPUB; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HEUSCHNEIDER G, 1989, P NATL ACAD SCI USA, V86, P2938, DOI 10.1073/pnas.86.8.2938; HOSHI T, 1988, SCIENCE, V240, P1652, DOI 10.1126/science.2454506; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; JOOST HG, 1988, MOL PHARMACOL, V33, P449; KASHIWAGI A, 1983, J BIOL CHEM, V258, P3685; KNOLL LJ, 1993, J BIOL CHEM, V268, P4281; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; MORRIS DI, 1991, BIOCHEMISTRY-US, V30, P8371, DOI 10.1021/bi00098a014; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PERLMAN RL, 1969, BIOCHEM BIOPH RES CO, V37, P151, DOI 10.1016/0006-291X(69)90893-6; ROY A, 1982, MOL GEN GENET, V188, P465, DOI 10.1007/BF00330050; SEAMON KB, 1983, J MED CHEM, V26, P436, DOI 10.1021/jm00357a021; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SUTKOWSKI EM, 1994, BIOCHEMISTRY-US, V33, P12852, DOI 10.1021/bi00209a017; Tang W. J., UNPUB; TANG WJ, 1992, COLD SPRING HARB SYM, V57, P135, DOI 10.1101/SQB.1992.057.01.017; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; WADLER S, 1988, CANCER RES, V48, P539; WADZINSKI BE, 1990, BIOCHEM J, V272, P151, DOI 10.1042/bj2720151; WAGONER PK, 1988, SCIENCE, V240, P1655, DOI 10.1126/science.2454507	29	148	153	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 23	1995	268	5218					1769	1772		10.1126/science.7792604	http://dx.doi.org/10.1126/science.7792604			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7792604				2022-12-24	WOS:A1995RE66800047
J	BESSEN, RA; KOCISKO, DA; RAYMOND, GJ; NANDAN, S; LANSBURY, PT; CAUGHEY, B				BESSEN, RA; KOCISKO, DA; RAYMOND, GJ; NANDAN, S; LANSBURY, PT; CAUGHEY, B			NONGENETIC PROPAGATION OF STRAIN-SPECIFIC PROPERTIES OF SCRAPIE PRION PROTEIN	NATURE			English	Article							TRANSMISSIBLE MINK ENCEPHALOPATHY; DISEASES; BIOLOGY; MODEL; AGENT	THE infectious agents causing scrapie and other transmissible spongiform encephalopathies have been postulated to consist solely of the protease-resistant form of prion protein (PrPSc)(1-6). One unprecedented requirement of the protein-only model is that the 'inheritance' of pathogen strain differences must be mediated by stable variations in PrPSc structure(2,7,8), rather than mutations in an agent-specific nucleic acid(9). Strain differences in PrPSc structure have been described for the hyper (HY) and drowsy (DY) strains of hamster transmissible mink encephalopathy (TME)(7,8), a a scrapie-like disease originating in mink. Although HY and DY PrPSc are both post-translationally derived from the precursor prion protein (PrPc) they are cleaved at different amino-terminal sites by proteinase K (ref. 8). Here we investigate whether this strain-specific property of PrPSc is transmitted to PrPc during formation of new PrPSc. PrPSc from the HY and DY TME strains converted the protease-sensitive PrPc into two distinct sets of protease-resistant PrP products in a cell-free system. These data provide evidence that self-propagation of PrPSc polymers with distinct three-dimensional structures could be the molecular basis of scrapie strains.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	BESSEN, RA (corresponding author), NIAID,ROCKY MT LABS,PERSISTENT VIRAL DIS LAB,HAMILTON,MT 59840, USA.							BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J GEN VIROL, V73, P329, DOI 10.1099/0022-1317-73-2-329; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; BOLTON DC, 1988, CIBA F SYMP, V135, P164; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; BRUCE ME, 1987, J GEN VIROL, V68, P79, DOI 10.1099/0022-1317-68-1-79; CASPAR DLD, 1980, BIOPHYS J, V32, P101; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0	14	450	465	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					698	700		10.1038/375698a0	http://dx.doi.org/10.1038/375698a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7791905				2022-12-24	WOS:A1995RE57600065
J	EMMETT, PM; HEATON, KW				EMMETT, PM; HEATON, KW			IS EXTRINSIC SUGAR A VEHICLE FOR DIETARY-FAT	LANCET			English	Article							11-12-YEAR-OLD ENGLISH CHILDREN; ENERGY; QUESTIONNAIRE; WOMEN	Although many guidelines to healthy eating recommend restriction of the intake of extrinsic (refined) sugar, there are concerns that such restriction might result in an increase in the amount and the proportion of dietary fats with a consequent possible increase in the risk of cardiovascular disease. We used regression analysis to examine the determinants of fat intake in subjects from a population survey who had weighed their food for 4 days. In men (n=77) acid women (n=83), fat eaten was positively related to the intake of extrinsic sugar. When intakes were expressed as percent of calories the relation became negative. A survey in a semi-random sample of 739 men aged 40-69 yr and 976 women aged 25-69 yr showed that, in both sexes, an increase in extrinsic sugar was a linear increase in the intake of and hence of fat combined with carbohydrate. This was due mainly to a higher intake of cakes and biscuits. Foods containing sugar and fat provided an extra 12.0 g per day of fat in the men and 13.8 g per day in the women when the highest quartile of extrinsic sugar consumers were compared with the lowest quartile. We conclude that lowering the intake of extrinsic sugar is unlikely to be associated with higher fat intake. Instead extrinsic sugar may act as a vehicle for fat intake, encouraging consumption by making the fat more palatable.	UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,BRISTOL BS2 8HW,AVON,ENGLAND	Bristol Royal Infirmary; University of Bristol			Emmett, Pauline/AAL-6815-2021	Emmett, Pauline/0000-0003-1076-4779				ADAMSON AJ, 1992, J HUM NUTR DIET, V5, P371, DOI 10.1111/j.1365-277X.1992.tb00177.x; BARKER M E, 1988, Journal of Human Nutrition and Dietetics, V1, P179, DOI 10.1111/j.1365-277X.1988.tb00187.x; BINGHAM S, 1991, P NUTR SOC, V50, pA32; BLACK AE, 1991, EUR J CLIN NUTR, V45, P583; EMMETT P, 1992, J HUM NUTR DIET, V5, P245, DOI 10.1111/j.1365-277X.1992.tb00159.x; EMMETT PM, 1993, EUR J CLIN NUTR, V47, P20; GIBNEY MJ, 1980, J HUM NUTR DIET, V3, P245; Gregory F., 1990, DIETARY NUTR SURVEY; HEATON KW, 1991, GUT, V32, P316, DOI 10.1136/gut.32.3.316; MANN GV, 1994, LANCET, V343, P1268, DOI 10.1016/S0140-6736(94)92157-1; Paul A.A., 1978, MCCANCE WIDDOWSONS C; PRENTICE AM, 1986, BRIT MED J, V292, P983, DOI 10.1136/bmj.292.6526.983; Pryer J. A., 1994, Proceedings of the Nutrition Society, V53, p235A; RUGGGUNN AJ, 1993, J HUM NUTR DIET, V6, P419, DOI 10.1111/j.1365-277X.1993.tb00387.x; WILES SJ, 1980, J HUM NUTR, V34, P189; WILLETT WC, 1994, AM J PUBLIC HEALTH, V84, P722, DOI 10.2105/AJPH.84.5.722; YARNELL JWG, 1983, HUM NUTR-APPL NUTR, V37, P103; 1992, GOOD DIETARY PRACTIC, V3, P1; 1992, HLTH NATION STRATEGY; 1991, REPORTS HLTH SOCIAL, V41; 1989, REPORTS HLTH SOCIAL, V37	21	46	46	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1537	1540		10.1016/S0140-6736(95)91087-5	http://dx.doi.org/10.1016/S0140-6736(95)91087-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791439				2022-12-24	WOS:A1995RD79000009
J	RANGANATHAN, R; STEVENS, CF				RANGANATHAN, R; STEVENS, CF			ARRESTIN BINDING DETERMINES THE RATE OF INACTIVATION OF THE G-PROTEIN-COUPLED RECEPTOR RHODOPSIN IN-VIVO	CELL			English	Article							LIGHT-INDUCED PHOSPHORYLATION; 48-KDA PROTEIN; DROSOPHILA PHOTORECEPTOR; PHOTOEXCITED RHODOPSIN; RETINAL RODS; INVIVO; DESENSITIZATION; KINASE; DEACTIVATION; ACTIVATION	G protein-coupled receptor inactivation is a crucial feature of cellular signaling systems; this process determines the catalytic lifetime of the activated receptor and is necessary for response termination. Although previous work has indicated a class of models in which several sequential steps are required for receptor inactivation, the rate-limiting event is still unclear. In this paper, we develop a theory that describes the kinetics of inactivation of the G protein-coupled receptor rhodopsin based on the rate of arrestin binding and test the theory using a combination of genetic and electrophysiological techniques in Drosophila photoreceptors. The theory quantitatively describes the inactivation kinetics of activated rhodopsin in vivo and can be independently tested with molecular and spectroscopic data. The results demonstrate that the rate of arrestin binding determines the kinetics of receptor inactivation in vivo and thus is the event that controls signal amplification at the first step of this G protein-coupled transduction cascade.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; SALK INST BIOL STUDIES,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Salk Institute	RANGANATHAN, R (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115, USA.							BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; COLLINS S, 1990, BIOCHEM SOC T, V18, P541, DOI 10.1042/bst0180541; Dartnall H. J. A., 1972, HDB SENSORY PHYSIOLO, V7, P122; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; Goodeve CF, 1938, PROC R SOC LON SER-A, V166, P0342, DOI 10.1098/rspa.1938.0097; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; KUHN H, 1987, J RECEPTOR RES, V7, P283, DOI 10.3109/10799898709054990; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; LEVINE H, 1990, MECH DEVELOP, V33, P19, DOI 10.1016/0925-4773(90)90131-5; MAKINO CL, 1991, J PHYSIOL-LONDON, V442, P761, DOI 10.1113/jphysiol.1991.sp018818; MATSUMOTO H, 1991, BIOCHEM BIOPH RES CO, V177, P1306, DOI 10.1016/0006-291X(91)90683-X; MATSUMOTO H, 1984, SCIENCE, V223, P184, DOI 10.1126/science.6419348; MCDOWELL JH, 1977, BIOCHEMISTRY-US, V16, P4054, DOI 10.1021/bi00637a018; MINKE B, 1986, MOL MECHANISM PHOTOR, P241; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; RANGANATHAN R, 1991, ANN REV NEUROL, V18, P283; RICHARD EA, 1992, NATURE, V356, P336, DOI 10.1038/356336a0; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SCHWEMER J, 1984, J COMP PHYSIOL, V154, P535, DOI 10.1007/BF00610167; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; THOMPSON P, 1984, BIOCHEM J, V220, P773, DOI 10.1042/bj2200773; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; YAMAMOTO K, 1983, BIOPHYS STRUCT MECH, V9, P259, DOI 10.1007/BF00535661	29	49	50	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					841	848		10.1016/0092-8674(95)90004-7	http://dx.doi.org/10.1016/0092-8674(95)90004-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781061	Bronze			2022-12-24	WOS:A1995RD76800005
J	KELCE, WR; STONE, CR; LAWS, SC; GRAY, LE; KEMPPAINEN, JA; WILSON, EM				KELCE, WR; STONE, CR; LAWS, SC; GRAY, LE; KEMPPAINEN, JA; WILSON, EM			PERSISTENT DDT METABOLITE P,P'-DDE IS A POTENT ANDROGEN RECEPTOR ANTAGONIST	NATURE			English	Article							ESTROGENIC ACTIVITY; RAT; BINDING; PROSTATE; ANALOGS	THE increase in the number of reports of abnormalities in male sex development in wildlife and humans coincided with the introduction of 'oestrogenic' chemicals such as DDT (1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane) into the environment, Although these phenotypic alterations are thought to be mediated by the oestrogen receptor, they are also consistent with inhibition of androgen receptor-mediated events, Here we report that the major and persistent DDT metabolite, p,p'-DDE (1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene), has little ability to bind the oestrogen receptor, but inhibits androgen binding to the androgen receptor, androgen-induced transcriptional activity, and androgen action in developing, pubertal and adult male rats, The results suggest that abnormalities in male sex development induced by p,p'-DDE and related environmental chemicals may be mediated at the level of the androgen receptor.	UNIV N CAROLINA,REPROD BIOL LABS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	KELCE, WR (corresponding author), US EPA,HLTH EFFECTS RES LAB,DIV DEV TOXICOL,REPROD TOXICOL BRANCH,RES TRIANGLE PK,NC 27711, USA.			gray jr, leon earl/0000-0002-1111-4754				BITMAN J, 1970, J AGR FOOD CHEM, V18, P1108, DOI 10.1021/jf60172a019; BOUWMAN H, 1991, J TOXICOL ENV HEALTH, V33, P141, DOI 10.1080/15287399109531514; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; CLEMENS LG, 1978, HORM BEHAV, V10, P40, DOI 10.1016/0018-506X(78)90023-5; CURLEY A, 1969, ARCH ENVIRON HEALTH, V19, P628, DOI 10.1080/00039896.1969.10666901; DURNBERGER H, 1980, CELL, V19, P465, DOI 10.1016/0092-8674(80)90521-8; Dustman E H, 1969, Ann N Y Acad Sci, V160, P162, DOI 10.1111/j.1749-6632.1969.tb15828.x; GELLERT RJ, 1972, ENDOCRINOLOGY, V91, P1095, DOI 10.1210/endo-91-4-1095; GRAY LE, 1994, TOXICOL APPL PHARM, V129, P46, DOI 10.1006/taap.1994.1227; GUILLETTE LJ, 1994, ENVIRON HEALTH PERSP, V102, P680, DOI 10.2307/3432198; IMPERATOMCGINLEY J, 1992, ENDOCRINOLOGY, V131, P1149, DOI 10.1210/en.131.3.1149; KELCE W R, 1988, Steroids, V52, P217, DOI 10.1016/0039-128X(88)90005-0; KELCE WR, 1994, TOXICOL APPL PHARM, V126, P276, DOI 10.1006/taap.1994.1117; KORENBROT CC, 1977, BIOL REPROD, V17, P298, DOI 10.1095/biolreprod17.2.298; KUPFER D, 1975, Critical Reviews in Toxicology, V4, P83; LEGER JG, 1988, PROSTATE, V13, P131, DOI 10.1002/pros.2990130205; MORGAN DP, 1971, ARCH ENVIRON HEALTH, V22, P301, DOI 10.1080/00039896.1971.10665848; NELSON J A, 1978, Journal of Toxicology and Environmental Health, V4, P325; NELSON JA, 1974, BIOCHEM PHARMACOL, V23, P447, DOI 10.1016/0006-2952(74)90436-5; Neumann F, 1970, Recent Prog Horm Res, V26, P337; PAGE MJ, 1982, MOL CELL ENDOCRINOL, V27, P343, DOI 10.1016/0303-7207(82)90099-5; ROBISON AK, 1985, J TOXICOL ENV HEALTH, V16, P493, DOI 10.1080/15287398509530758; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; STONE CR, 1995, J ANDROL S, V16, P42; WELCH RM, 1969, TOXICOL APPL PHARM, V14, P358, DOI 10.1016/0041-008X(69)90117-3; WILSON EM, 1976, J BIOL CHEM, V251, P5620; WOOLLEY DE, 1971, TOXICOL APPL PHARM, V18, P907, DOI 10.1016/0041-008X(71)90238-9; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	29	1257	1317	7	187	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					581	585		10.1038/375581a0	http://dx.doi.org/10.1038/375581a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7791873				2022-12-24	WOS:A1995RD28700049
J	CORTES, J; WIESMANN, KEH; ROBERTS, GA; BROWN, MJB; STAUNTON, J; LEADLAY, PF				CORTES, J; WIESMANN, KEH; ROBERTS, GA; BROWN, MJB; STAUNTON, J; LEADLAY, PF			REPOSITIONING OF A DOMAIN IN A MODULAR POLYKETIDE SYNTHASE TO PROMOTE SPECIFIC CHAIN CLEAVAGE	SCIENCE			English	Article							SACCHAROPOLYSPORA-ERYTHRAEA; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; BIOSYNTHESIS; GENES; ORGANIZATION; EXPRESSION; CLUSTER	Macrocyclic polyketides exhibit an impressive range of medically useful activities, and there is great interest in manipulating the genes that govern their synthesis. The 6-deoxyerythronolide B synthase (DEBS) of Saccharopolyspora erythraea, which synthesizes the aglycone core of the antibiotic erythromycin A, has been modified by repositioning of a chain-terminating cyclase domain to the carboxyl-terminus of DEBS1, the multienzyme that catalyzes the first two rounds of polyketide chain extension. The resulting mutant markedly accelerates formation of the predicted triketide lactone, compared to a control in which the repositioned domain is inactive. Repositioning of the cyclase should be generally useful for redirecting polyketide synthesis to obtain polyketides of specified chain lengths.	UNIV CAMBRIDGE,CAMBRIDGE CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1QW,ENGLAND; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND; UNIV CAMBRIDGE,DEPT ORGAN CHEM,CAMBRIDGE CB2 1EW,ENGLAND; UNIV CAMBRIDGE,CAMBRIDGE CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1EW,ENGLAND	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge				Leadlay, Peter/0000-0002-3247-509X; Roberts, Gareth/0000-0002-3726-390X; Cortes, Jesus/0000-0002-2475-6983				APARICIO JF, 1994, J BIOL CHEM, V269, P8524; BECK J, 1990, EUR J BIOCHEM, V192, P487, DOI 10.1111/j.1432-1033.1990.tb19252.x; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; CAFFREY P, 1991, EUR J BIOCHEM, V195, P823, DOI 10.1111/j.1432-1033.1991.tb15771.x; CAFFREY P, 1992, FEBS LETT, V304, P225, DOI 10.1016/0014-5793(92)80624-P; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; CUTTER A, UNPUB; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DONADIO S, 1992, GENE, V115, P97, DOI 10.1016/0378-1119(92)90546-2; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; JOSHI AK, 1993, J BIOL CHEM, V268, P22508; KANEDA T, 1962, J BIOL CHEM, V237, P322; KAO CM, 1994, J AM CHEM SOC, V116, P11612, DOI 10.1021/ja00104a069; KAO CM, 1994, J BIOL CHEM, V265, P509; LEADLAY PF, 1993, BIOCHEM SOC T, V21, P218, DOI 10.1042/bst0210218; MACNEIL DJ, 1992, GENE, V115, P97; MARSDEN AFA, 1994, SCIENCE, V263, P378, DOI 10.1126/science.8278811; ROBERTS GA, 1993, EUR J BIOCHEM, V214, P305, DOI 10.1111/j.1432-1033.1993.tb17925.x; ROBERTS GB, UNPUB; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; STAUNTON J, 1991, ANGEW CHEM INT EDIT, V30, P1302, DOI 10.1002/anie.199113021; WEBER JM, 1990, J BACTERIOL, V172, P2372, DOI 10.1128/jb.172.5.2372-2383.1990; YE JS, 1994, J BACTERIOL, V176, P6270, DOI 10.1128/jb.176.20.6270-6280.1994	25	226	248	1	28	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1487	1489		10.1126/science.7770773	http://dx.doi.org/10.1126/science.7770773			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770773				2022-12-24	WOS:A1995RC19000037
J	KOENIG, HL; SCHUMACHER, M; FERZAZ, B; DOTHI, AN; RESSOUCHES, A; GUENNOUN, R; JUNGTESTAS, I; ROBEL, P; AKWA, Y; BAULIEU, EE				KOENIG, HL; SCHUMACHER, M; FERZAZ, B; DOTHI, AN; RESSOUCHES, A; GUENNOUN, R; JUNGTESTAS, I; ROBEL, P; AKWA, Y; BAULIEU, EE			PROGESTERONE SYNTHESIS AND MYELIN FORMATION BY SCHWANN-CELLS	SCIENCE			English	Article							NEUROACTIVE STEROIDS; SCIATIC-NERVES; TREMBLER MOUSE; BASAL LAMINA; NEUROSTEROIDS; BRAIN; PREGNENOLONE; DIFFERENTIATION; PHOSPHOLIPIDS; REGENERATION	Progesterone is shown here to be produced from pregnenolone by Schwann cells in peripheral nerves, After cryolesion of the sciatic nerve in male mice, axons regenerate and become myelinated. Blocking either the local synthesis or the receptor-mediated action of progesterone impaired remyelination. Administration of progesterone or its precursor, pregnenolone, to the lesion site increased the extent of myelin sheath formation. Myelination of axons was also increased when progesterone was added to cultures of rat dorsal root ganglia. These observations indicate a role for locally produced progesterone in myelination, demonstrate that progesterone is not simply a sex steroid, and suggest a new therapeutic approach to promote myelin repair.	INSERM,U33,HORMONES LAB,F-94276 LE KREMLIN BICETR,FRANCE; UNIV BORDEAUX 1,DEV NEUROBIOL LAB,F-33405 TALENCE,FRANCE; COLL FRANCE,CNRS,U1115,F-75231 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France			Schumacher, Michael/G-3581-2013; Messier, Claude/A-2322-2008; Guennoun, Rachida/F-2420-2011; Akwa, Yvette/I-5223-2018	Schumacher, Michael/0000-0001-6117-5371; Messier, Claude/0000-0002-4791-1763; Guennoun, Rachida/0000-0002-9219-7300; Akwa, Yvette/0000-0003-2181-4612				AKWA Y, 1993, CR ACAD SCI III-VIE, V316, P410; AKWA Y, 1993, J CELL BIOL, V121, P135, DOI 10.1083/jcb.121.1.135; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; Baulieu E. -E., 1981, STEROID HORMONE REGU, P3; BAULIEU EE, 1991, BIOL CELL, V71, P3, DOI 10.1016/0248-4900(91)90045-O; BIZZOZERO OA, 1991, J BIOL CHEM, V266, P17092; BOLIN LM, 1993, J CELL BIOL, V123, P237, DOI 10.1083/jcb.123.1.237; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; CHADWICK D, 1990, CIBA F S, V153; CORPECHOT C, 1993, ENDOCRINOLOGY, V133, P1003, DOI 10.1210/en.133.3.1003; DROZ B, 1981, BRAIN RES, V219, P57, DOI 10.1016/0006-8993(81)90267-5; ELDRIDGE CF, 1987, J CELL BIOL, V105, P1023, DOI 10.1083/jcb.105.2.1023; ELDRIDGE CF, 1989, J NEUROSCI, V9, P625; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; FERZAZ B, 1989, CR ACAD SCI III-VIE, V309, P377; FUXE K, 1981, STEROID HORMONE REGU; GUENNOUN R, IN PRESS MOL BRAIN R; HILDEBRAND C, 1994, PROG NEUROBIOL, V43, P85, DOI 10.1016/0301-0082(94)90010-8; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JUNGTESTAS I, 1994, J STEROID BIOCHEM, V48, P145, DOI 10.1016/0960-0760(94)90261-5; JUNGTESTAS I, 1989, ENDOCRINOLOGY, V125, P2083; Kleitman N, 1991, CULTURING NERVE CELL, P337; KOENIG H, UNPUB; LEGOASCOGNE C, 1987, SCIENCE, V237, P1212, DOI 10.1126/science.3306919; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; MCEWEN BS, 1991, TRENDS ENDOCRIN MET, V2, P62, DOI 10.1016/1043-2760(91)90042-L; MELLON SH, 1994, J CLIN ENDOCR METAB, V78, P1003, DOI 10.1210/jc.78.5.1003; MORFIN R, 1992, P NATL ACAD SCI USA, V89, P6790, DOI 10.1073/pnas.89.15.6790; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; RAISINGHANI KH, 1968, ACTA ENDOCRINOL-COP, V57, P393; ROBEL P, 1994, TRENDS ENDOCRIN MET, V5, P1, DOI 10.1016/1043-2760(94)90114-7; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; SALZER JL, 1980, J CELL BIOL, V84, P739, DOI 10.1083/jcb.84.3.739; SCHUMACHER M, 1990, SCIENCE, V250, P691, DOI 10.1126/science.2173139; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; TOEWS AD, 1988, J NEUROSCI, V8, P593; VERDI JM, 1990, J BIOL CHEM, V265, P20314	37	402	414	0	24	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1500	1503		10.1126/science.7770777	http://dx.doi.org/10.1126/science.7770777			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770777				2022-12-24	WOS:A1995RC19000041
J	FULLER, SD; BERRIMAN, JA; BUTCHER, SJ; GOWEN, BE				FULLER, SD; BERRIMAN, JA; BUTCHER, SJ; GOWEN, BE			LOW PH INDUCES SWIVELING OF THE GLYCOPROTEIN HETERODIMERS IN THE SEMLIKI-FOREST VIRUS SPIKE COMPLEX	CELL			English	Article							HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; SINDBIS VIRUS; ELECTRON-MICROGRAPHS; INFLUENZA-VIRUS; FUSION PROCESS; PROTEIN; ENVELOPE; RECONSTRUCTION; MECHANISM; CELLS	Time-resolved cryoelectron microscopy reveals the first step in the conformational changes that enable membrane fusion in Semliki Forest virus. The neutral pH structure reveals a central cavity within the spike complex, plate-like extensions forming a layer above the membrane, and the paths of the paired transmembrane domains connecting the trimeric spikes and pentamer-hexamer clustered capsid subunits. Low pH treatment results in centrifugal movement of E2, the receptor-binding subunit, centripetal movement of E1 to narrow the central cavity initiating the formation of an E1 trimer, and the extension of the E1 fusion sequence toward the target membrane.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	FULLER, SD (corresponding author), EUROPEAN MOLEC BIOL LAB,STRUCT BIOL PROGRAMME,MEYERHOFSTR 1,D-69012 HEIDELBERG,GERMANY.		Butcher, Sarah J/H-5579-2012	Butcher, Sarah/0000-0001-7060-5871	NIGMS NIH HHS [GM41449] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041449] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1994, STRUCTURE, V2, P907, DOI 10.1016/S0969-2126(94)00091-3; BERRIMAN J, 1994, ULTRAMICROSCOPY, V156, P241; BRON R, 1993, EMBO J, V12, P693, DOI 10.1002/j.1460-2075.1993.tb05703.x; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHENG RH, 1995, CELL, V80, P621; DUBUISSON J, 1993, J VIROL, V67, P3363, DOI 10.1128/JVI.67.6.3363-3374.1993; FULLER S, 1994, STRUCTURE, V2, P903, DOI 10.1016/S0969-2126(94)00090-5; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; GAROFF H, 1980, NATURE, V288, P221; HELENIUS A, 1980, J CELL BIOL, V84, P404, DOI 10.1083/jcb.84.2.404; JAIN SK, 1991, J BIOL CHEM, V266, P5756; JUSTMAN J, 1993, J VIROL, V67, P7597, DOI 10.1128/JVI.67.12.7597-7607.1993; KENNEY JM, 1994, STRUCTURE, V2, P823, DOI 10.1016/S0969-2126(94)00083-2; Kielian M, 1986, TOGAVIRIDAE FLAVIVIR, P91; KIELIAN N, 1994, ADV VIRUS RES, V45, P113; LEVYMINTZ P, 1991, J VIROL, V65, P4292, DOI 10.1128/JVI.65.8.4292-4300.1991; LOBIGS M, 1990, J VIROL, V64, P4346, DOI 10.1128/JVI.64.9.4346-4355.1990; PAREDES AM, 1993, P NATL ACAD SCI USA, V90, P9095, DOI 10.1073/pnas.90.19.9095; SALMINEN A, 1992, J CELL BIOL, V116, P349, DOI 10.1083/jcb.116.2.349; SCHLESINGER MJ, 1986, TOGAVIRIDAE FLAVIVIR, P21; SIMONS K, 1980, J GEN VIROL, V50, P1, DOI 10.1099/0022-1317-50-1-1; Singh I., 1992, SEMIN VIROL, V3, P511; STEWART PL, 1991, CELL, V67, P145, DOI 10.1016/0092-8674(91)90578-M; STEWART PL, 1993, EMBO J, V72, P2589; STUBBS MJ, 1991, J MOL BIOL, V221, P39, DOI 10.1016/0022-2836(91)80200-E; TUCKER PC, 1991, J VIROL, V65, P1551, DOI 10.1128/JVI.65.3.1551-1557.1991; VENIENBRYAN C, 1994, J MOL BIOL, V236, P572, DOI 10.1006/jmbi.1994.1166; VOGEL RH, 1986, NATURE, V320, P533, DOI 10.1038/320533a0; VOGEL RH, 1988, ULTRAMICROSCOPY, V25, P223, DOI 10.1016/0304-3991(88)90017-4; WAHLBERG JM, 1992, J CELL BIOL, V116, P339, DOI 10.1083/jcb.116.2.339; WAHLBERG JM, 1992, J VIROL, V66, P7309, DOI 10.1128/JVI.66.12.7309-7318.1992; WHITE J, 1980, J CELL BIOL, V87, P264, DOI 10.1083/jcb.87.1.264; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.biochem.56.1.365; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	36	119	119	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					715	725		10.1016/0092-8674(95)90533-2	http://dx.doi.org/10.1016/0092-8674(95)90533-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774013	Bronze			2022-12-24	WOS:A1995RB96100010
J	NICOLELIS, MAL; BACCALA, LA; LIN, RCS; CHAPIN, JK				NICOLELIS, MAL; BACCALA, LA; LIN, RCS; CHAPIN, JK			SENSORIMOTOR ENCODING BY SYNCHRONOUS NEURAL ENSEMBLE ACTIVITY AT MULTIPLE LEVELS OF THE SOMATOSENSORY SYSTEM	SCIENCE			English	Article							SOMATIC SENSORY TRANSMISSION; MOTOR CORTEX STIMULATION; AWAKE RATS; AFFERENT MODULATION; RECEPTIVE-FIELDS; PARIETAL RHYTHMS; DIRECT RESPONSES; SINGLE NEURONS; SI-CORTEX; MOVEMENT	Neural ensemble processing of sensorimotor information during behavior was investigated by simultaneously recording up to 48 single neurons at multiple relays of the rat trigeminal somatosensory system. Cortical, thalamic, and brainstem neurons exhibited widespread 7- to 12-hertz synchronous oscillations, which began during attentive immobility and reliably predicted the imminent onset of rhythmic whisker twitching. Each oscillatory cycle began as a traveling wave of neural activity in the cortex that then spread to the thalamus. Just before the onset of rhythmic whisker twitching, the oscillations spread to the spinal trigeminal brainstem complex. Thereafter, the oscillations at all levels were synchronous with whisker protraction. Neural structures manifesting these rhythms also exhibited distributed spatiotemporal patterns of neuronal ensemble activity in response to tactile stimulation, thus, multilevel synchronous activity in this system may encode not only sensory information but also the onset and temporal domain of tactile exploratory movements.	MED COLL PENN, DEPT ANAT & NEUROBIOL, PHILADELPHIA, PA 19102 USA; HAHNEMANN UNIV, PHILADELPHIA, PA 19102 USA; UNIV PENN, DEPT ELECT ENGN, PHILADELPHIA, PA 19104 USA; UNIV SAO PAULO, DEPT ELECTR ENGN, BR-05508 SAO PAULO, BRAZIL	Drexel University; Drexel University; University of Pennsylvania; Universidade de Sao Paulo			Baccala, Luiz Antonio/A-3370-2008	Baccala, Luiz Antonio/0000-0002-2668-6747	NIDCR NIH HHS [DE11121-01] Funding Source: Medline; NINDS NIH HHS [NS-29161, NS-26722] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026722, R01NS029161] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONGJAMES M, 1991, J COMP NEUROL, V303, P211, DOI 10.1002/cne.903030204; BOUYER JJ, 1981, ELECTROEN CLIN NEURO, V51, P244, DOI 10.1016/0013-4694(81)90138-3; BUZSAKI G, 1991, NEUROSCIENCE, V41, P351, DOI 10.1016/0306-4522(91)90332-I; CARVELL GE, 1990, J NEUROSCI, V10, P2638; CHAPIN JK, 1982, EXP NEUROL, V78, P654, DOI 10.1016/0014-4886(82)90082-6; CHAPIN JK, 1986, EXP BRAIN RES, V62, P549; CHAPIN JK, 1982, EXP NEUROL, V78, P670, DOI 10.1016/0014-4886(82)90083-8; CHAPIN JK, 1984, J COMP NEUROL, V229, P199, DOI 10.1002/cne.902290206; CHMIELOWSKA J, 1989, J COMP NEUROL, V285, P325, DOI 10.1002/cne.902850304; Churchland P. S., 1992, COMPUTATIONAL BRAIN, DOI 10.7551/mitpress/2010.001.0001; COULTER JD, 1974, J NEUROPHYSIOL, V37, P831, DOI 10.1152/jn.1974.37.5.831; DIAMOND IT, 1969, SCIENCE, V164, P251, DOI 10.1126/science.164.3877.251; ERICKSON RP, 1968, PSYCHOL REV, V75, P447, DOI 10.1037/h0026752; FREEMAN WJ, 1987, BEHAV NEUROSCI, V101, P393, DOI 10.1037/0735-7044.101.3.393; Freeman WJ, 1975, MASS ACTION NERVOUS; GASTAUT MH, 1952, REV NEUROL, V87, P176; HOPFIELD JJ, 1986, SCIENCE, V233, P625, DOI 10.1126/science.3755256; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; KAAS JH, 1990, HUMAN NERVOUS SYSTEM, P813; KRISTEVAFEIGE R, 1993, NEUROREPORT, V4, P1291, DOI 10.1097/00001756-199309150-00001; LAURENT G, 1994, SCIENCE, V265, P1872, DOI 10.1126/science.265.5180.1872; LIN RCS, 1993, SOC NEUR ABSTR, V19, P106; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; NELSON RJ, 1984, BRAIN RES, V304, P143, DOI 10.1016/0006-8993(84)90870-9; Nicolelis M. A. L., 1994, Society for Neuroscience Abstracts, V20, P125; NICOLELIS MAL, 1993, NATURE, V361, P533, DOI 10.1038/361533a0; NICOLELIS MAL, 1993, P NATL ACAD SCI USA, V90, P2212, DOI 10.1073/pnas.90.6.2212; NICOLELIS MAL, 1994, J NEUROSCI, V14, P3511; ROUGEUL A, 1979, ELECTROEN CLIN NEURO, V46, P310, DOI 10.1016/0013-4694(79)90205-0; SALMELIN R, 1994, NEUROSCIENCE, V60, P537, DOI 10.1016/0306-4522(94)90263-1; SANES JN, 1993, P NATL ACAD SCI USA, V90, P4470, DOI 10.1073/pnas.90.10.4470; SEMBA K, 1984, NEUROSCIENCE, V12, P761, DOI 10.1016/0306-4522(84)90168-4; SEMBA K, 1980, BRAIN RES, V195, P281, DOI 10.1016/0006-8993(80)90065-7; SHERMAN SM, 1990, SYNAPTIC ORG BRAIN, P246; SHIN HC, 1990, NEUROSCI LETT, V108, P116, DOI 10.1016/0304-3940(90)90716-M; SHIN HC, 1990, BRAIN RES BULL, V24, P257; SHIN HC, 1989, BRAIN RES BULL, V22, P245, DOI 10.1016/0361-9230(89)90049-X; SOMPOLINSKY H, 1991, PHYS REV A, V43, P6990, DOI 10.1103/PhysRevA.43.6990; Steriade M., 1990, THALAMIC OSCILLATION	39	450	464	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 2	1995	268	5215					1353	1358		10.1126/science.7761855	http://dx.doi.org/10.1126/science.7761855			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761855				2022-12-24	WOS:A1995RB19800040
J	FAIRWEATHERTAIT, SJ; FOX, TE; MALLILLIN, A				FAIRWEATHERTAIT, SJ; FOX, TE; MALLILLIN, A			BALTI CURRIES AND IRON	BRITISH MEDICAL JOURNAL			English	Article							FOOD				FAIRWEATHERTAIT, SJ (corresponding author), INST FOOD RES,NORWICH LAB,NORWICH NR4 7UA,NORFOLK,ENGLAND.		Fairweather-Tait, Susan J/K-4251-2012	Fairweather-Tait, Susan/0000-0002-1413-5569				BRITTIN HC, 1986, J AM DIET ASSOC, V86, P897; FAIRWEATHERTAIT SJ, 1990, BRIT J NUTR, V64, P547, DOI 10.1079/BJN19900054; Gregory F., 1990, DIETARY NUTR SURVEY; MARTINEZ FE, 1986, NUTR RES, V6, P421, DOI 10.1016/S0271-5317(86)80183-X	4	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1368	1368		10.1136/bmj.310.6991.1368	http://dx.doi.org/10.1136/bmj.310.6991.1368			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB005	7787541	Green Published			2022-12-24	WOS:A1995RB00500024
J	MUGLIA, L; JACOBSON, L; DIKKES, P; MAJZOUB, JA				MUGLIA, L; JACOBSON, L; DIKKES, P; MAJZOUB, JA			CORTICOTROPIN-RELEASING HORMONE DEFICIENCY REVEALS MAJOR FETAL BUT NOT ADULT GLUCOCORTICOID NEED	NATURE			English	Article							RESPIRATORY-DISTRESS SYNDROME; SURFACTANT; DEXAMETHASONE; EXPRESSION; SECRETION; STRESS	The body responds to stress by activation of the hypothalamic-pituitary-adrenal (HPA) axis and release of glucocorticoids. Glucocorticoid production in the adult regulates carbohydrate and amino-acid metabolism, maintains blood pressure, and restrains the inflammatory response(1). In the fetus, exogenous glucocorticoids accelerate maturation of lung(2) and gastrointestinal enzyme systems(3) and promote hepatic glycogen deposition(4). Corticotropin-releasing hormone (CRH), a 41-amino-acid neuropeptide produced in the paraventricular nucleus of the hypothalamus and many regions of the cerebral cortex(5,6), has been implicated in both the HPA axis(7) and behavioural responses(8) to stress. To define the importance of CRH in the response of the HPA axis to stress and fetal development, we have constructed a mammalian model of CRH deficiency by targeted mutation in embryonic stem (ES) cells(9). We report here that corticotropin-releasing hormone-deficient mice reveal a fetal glucocorticoid requirement for lung maturation. Postnatally, despite marked glucocorticoid deficiency, these mice exhibit normal growth, fertility and longevity, suggesting that the major role of glucocorticoid is during fetal rather than postnatal life.	HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School	MUGLIA, L (corresponding author), HARVARD UNIV, SCH MED, DIV ENDOCRINOL, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.							AVERY ME, 1984, J PEDIATR-US, V104, P240, DOI 10.1016/S0022-3476(84)81000-8; BALLARD PL, 1989, ENDOCR REV, V10, P165, DOI 10.1210/edrv-10-2-165; BALLARD PL, 1979, GLUCOCORTICOID HORMO, P493; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRITCHLOW V, 1963, AM J PHYSIOL, V205, P807, DOI 10.1152/ajplegacy.1963.205.5.807; CROWLEY P, 1990, BRIT J OBSTET GYNAEC, V97, P11, DOI 10.1111/j.1471-0528.1990.tb01711.x; DALLMAN MF, 1993, FRONT NEUROENDOCRIN, V14, P303, DOI 10.1006/frne.1993.1010; DALLMAN MF, 1987, RECENT PROG HORM RES, V43, P113; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; GERTZ BJ, 1987, ENDOCRINOLOGY, V120, P381, DOI 10.1210/endo-120-1-381; JACOBSON L, 1989, ENDOCRINOLOGY, V124, P2144, DOI 10.1210/endo-124-5-2144; KOOB GF, 1993, CIBA F SYMP, V172, P277; LIGGINS GC, 1972, PEDIATRICS, V50, P515; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; MOOG F, 1953, J EXP ZOOL, V124, P329, DOI 10.1002/jez.1401240209; MUGLIA LJ, 1994, J CLIN INVEST, V93, P2066, DOI 10.1172/JCI117201; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; Orth DN, 1992, WILLIAMS TXB ENDOCRI, P489; PHELPS DS, 1991, AM J PHYSIOL, V260, pL146, DOI 10.1152/ajplung.1991.260.2.L146; POST M, 1986, J BIOL CHEM, V261, P2179; ROBERTS MM, 1993, NEUROENDOCRINOLOGY, V57, P388, DOI 10.1159/000126384; SASAKI A, 1984, J CLIN ENDOCR METAB, V59, P812; SEASHOLTZ A F, 1991, Molecular and Cellular Neuroscience, V2, P266, DOI 10.1016/1044-7431(91)90054-R; SPINEDI E, 1992, ENDOCRINOLOGY, V131, P2430, DOI 10.1210/en.131.5.2430; SUDA T, 1984, J CLIN ENDOCR METAB, V59, P861, DOI 10.1210/jcem-59-5-861; THOMPSON RC, 1987, MOL ENDOCRINOL, V1, P363, DOI 10.1210/mend-1-5-363; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAMVAKOPOULOS NC, 1994, ENDOCR REV, V15, P409, DOI 10.1210/er.15.4.409; VENKATESH VC, 1993, AM J RESP CELL MOL, V8, P222, DOI 10.1165/ajrcmb/8.2.222	30	428	430	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					427	432		10.1038/373427a0	http://dx.doi.org/10.1038/373427a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830793				2022-12-24	WOS:A1995QE67000056
J	WENGER, PN; OTTEN, J; BREEDEN, A; ORFAS, D; BECKSAGUE, CM; JARVIS, WR				WENGER, PN; OTTEN, J; BREEDEN, A; ORFAS, D; BECKSAGUE, CM; JARVIS, WR			CONTROL OF NOSOCOMIAL TRANSMISSION OF MULTIDRUG-RESISTANT MYCOBACTERIUM-TUBERCULOSIS AMONG HEALTH-CARE WORKERS AND HIV-INFECTED PATIENTS	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; OUTBREAK; RISK	From 1988 to 1990, an outbreak of multidrug-resistant tuberculosis (MDR-TB) among patients, and an increased number of tuberculin-skin-test conversions among healthcare workers, occurred on the HIV ward of Jackson Memorial Hospital, Miami, Florida, USA. Measures similar to those subsequently recommended in the 1990 Centers for Disease Control and Prevention guidelines were implemented on the HIV ward by June, 1990, and in September, 1992, we evaluated the efficacy of these control measures. Among MDR-TB patients and healthcare workers with tuberculin-skin-test conversions on the HIV ward, we looked for evidence of exposure to HIV ward MDR-TB patients positive for acid-fast bacilli in sputum during initial January-May, 1990) and follow-up (June, 1990-June, 1992) periods. Exposure before implementation of control measures to an infectious MDR-TB patient on the HIV ward was recorded in 12 of 15 (80%) MDR-TB patients during the initial period and 5 of 11(45%) MDR-TB patients during follow-up. After implementation of control measures, no episodes of MDR-TB could be traced to contact with infectious MDR-TB patients on the HIV ward. Skin-test conversions among workers on the HIV ward declined from 7 of 25 (28%) during the initial period to 3 of 17 (18%) in the early (June, 1990-February, 1998) and 0 of 23 in the late (March, 1991-June, 1992) follow-up periods (p<0.01). Skin-test conversions among healthcare workers were not associated with increased exposure to MDR-TB patients, and were not significantly higher among workers on the HIV ward than on a control ward without tuberculosis patients (3/27 vs 0/16). These data demonstrate that implementation of measures similar to the Centers for Disease Control and Prevention 1990 tuberculosis-control guidelines were effective in halting transmission of MDR-TB to healthcare workers and HIV-infected patients.	JACKSON MEM HOSP,OFF TB CONTROL,MIAMI,FL 33136; JACKSON MEM HOSP,OFF EMPLOYEE HLTH,MIAMI,FL 33136					Beck-Sague, Consuelo/0000-0001-9082-0165				BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; EHRENKRA.NJ, 1972, ANN INTERN MED, V77, P377, DOI 10.7326/0003-4819-77-3-377; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540; JARVIS WR, 1993, RES MICROBIOL, V144, P117, DOI 10.1016/0923-2508(93)90025-W; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RUDNIK J, 1993, 3RD ANN M SOC HOSP E; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; 1990, MMWR-MORBID MORTAL W, V39, P1; 1990, MMWR MORB MORTAL WKL, V39; 1990, AM REV RESPIR DIS, V142, P725; 1991, MMWR-MORBID MORTAL W, V40, P585	19	149	149	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					235	240		10.1016/S0140-6736(95)90228-7	http://dx.doi.org/10.1016/S0140-6736(95)90228-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823719	Bronze			2022-12-24	WOS:A1995QD53200014
J	CHAPMAN, T; LIDDLE, LF; KALB, JM; WOLFNER, MF; PARTRIDGE, L				CHAPMAN, T; LIDDLE, LF; KALB, JM; WOLFNER, MF; PARTRIDGE, L			COST OF MATING IN DROSOPHILA-MELANOGASTER FEMALES IS MEDIATED BY MALE ACCESSORY-GLAND PRODUCTS	NATURE			English	Article							REPRODUCTIVE-BEHAVIOR; EXPRESSION; GENE; PEPTIDE; EXPOSURE; SPERM	FEMALE Drosophila melanogaster with environmentally(1-3) or genetically(4) elevated rates of mating die younger than controls. This cost of mating is not attributable to receipt of sperm(5). We demonstrate here that seminal fluid products from the main cells of the male accessory gland are responsible for the cost of mating in females, and that increasing exposure to these products increases female death rate. Main-cell products are also involved in elevating the rate of female egg-laying, in reducing female receptivity to further matings and in removing or destroying sperm of previous mates(6-12). The cost of mating to females may therefore represent a side-effect of evolutionary conflict between males(13).	UNIV LONDON UNIV COLL,DEPT GENET & BIOMETRY,LONDON NW1 2HE,ENGLAND; UNIV EDINBURGH,INST CELL ANIM & POPULAT BIOL,EDINBURGH EH9 3JT,MIDLOTHIAN,SCOTLAND; CORNELL UNIV,GENET & DEV SECT,ITHACA,NY 14853	University of London; University College London; University of Edinburgh; Cornell University			Partridge, Linda/A-5501-2010; Chapman, Tracey/E-5100-2011	Partridge, Linda/0000-0001-9615-0094				AGUADE M, 1992, GENETICS, V132, P755; AIGAKI T, 1991, NEURON, V7, P557, DOI 10.1016/0896-6273(91)90368-A; BALRATI A, 1970, DROSOPHILA INFORMATI, V45, P67; BERTRAM MJ, 1992, MECH DEVELOP, V38, P33, DOI 10.1016/0925-4773(92)90036-J; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; CAVENER DR, 1983, P NATL ACAD SCI-BIOL, V80, P6286, DOI 10.1073/pnas.80.20.6286; CHAPMAN T, 1994, J EVOLUTION BIOL, V7, P51, DOI 10.1046/j.1420-9101.1994.7010051.x; CHAPMAN T, 1992, J INSECT PHYSIOL, V38, P223, DOI 10.1016/0022-1910(92)90070-T; CHAPMAN T, 1993, P ROY SOC B-BIOL SCI, V253, P211, DOI 10.1098/rspb.1993.0105; CHEN PS, 1988, CELL, V54, P291, DOI 10.1016/0092-8674(88)90192-4; DIBENEDETTO AJ, 1990, DEV BIOL, V139, P134, DOI 10.1016/0012-1606(90)90284-P; DIXON WJ, 1988, BMDP STATISTICAL SOF, V2; FOWLER K, 1989, NATURE, V338, P760, DOI 10.1038/338760a0; HARSHMAN LG, IN PRESS EVOLUTION; HIHARA F, 1981, Zoological Magazine (Tokyo), V90, P307; KALB JM, 1993, P NATL ACAD SCI USA, V90, P8093, DOI 10.1073/pnas.90.17.8093; LUDWIG MZ, 1991, BIOCHEM GENET, V29, P215, DOI 10.1007/BF00590103; MANNING A, 1967, ANIM BEHAV, V15, P239, DOI 10.1016/0003-3472(67)90006-1; MEIKLE DB, 1990, J INSECT PHYSIOL, V36, P93, DOI 10.1016/0022-1910(90)90179-J; MONSMA SA, 1988, GENE DEV, V2, P1063, DOI 10.1101/gad.2.9.1063; PARTRIDGE L, 1990, J INSECT PHYSIOL, V36, P419, DOI 10.1016/0022-1910(90)90059-O; PARTRIDGE L, 1987, J INSECT PHYSIOL, V33, P745, DOI 10.1016/0022-1910(87)90060-6; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x; SCOTT D, 1987, ANIM BEHAV, V35, P142, DOI 10.1016/S0003-3472(87)80219-1; TREVITT S, 1988, J INSECT PHYSIOL, V34, P821, DOI 10.1016/0022-1910(88)90157-6; TREVITT S, 1989, THESIS U EDINBURGH; Trivers R. L., 1972, SEXUAL SELECTION DES, P136, DOI DOI 10.1002/AJPA.1330400226; VANVALEN LM, 1985, EVOL THEOR, V7, P93	28	1072	1093	1	248	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					241	244		10.1038/373241a0	http://dx.doi.org/10.1038/373241a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816137				2022-12-24	WOS:A1995QC27800062
J	DREVETS, WC; BURTON, H; VIDEEN, TO; SNYDER, AZ; SIMPSON, JR; RAICHLE, ME				DREVETS, WC; BURTON, H; VIDEEN, TO; SNYDER, AZ; SIMPSON, JR; RAICHLE, ME			BLOOD-FLOW CHANGES IN HUMAN SOMATOSENSORY CORTEX DURING ANTICIPATED STIMULATION	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; SOMATIC SENSORY TRANSMISSION; PET IMAGES; SELECTIVE ATTENTION; BRAIN; RESPONSES; MOVEMENT; PERFORMANCE; (H2O)-O-15; MODULATION	POSITRON emission tomography (PET) measurements of brain blood flow were used to monitor changes in the human primary and secondary somatosensory cortices during the period when somatosensory stimuli were expected. In anticipation of either focal or innocuous touching, or localized, painful shocks, blood flow decreased in parts of the primary somatosensory cortex map located outside the representation of the skin area that was the target of the expected stimulus. Specifically, attending to an impending stimulus to the fingers produced a significant decrease in blood flow in the somatosensory zones for the face, whereas attending to stimulation of the toe produced decreases in the zones for the fingers and face. Decreases were more prominent in the side ipsilateral to the location of the expected stimulus. No significant changes in blood flow occurred in the region of the cortex representing the skin locus of the awaited stimulation. These results are concurrent with a model of spatial attention in which potential signal enhancement may rely on, generalized suppression of background activity(1).	ST LOUIS UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110; ST LOUIS UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; ST LOUIS UNIV,SCH MED,DEPT NEUROL & NEUROL SURG NEUROL,ST LOUIS,MO 63110	Saint Louis University; Saint Louis University; Saint Louis University	DREVETS, WC (corresponding author), ST LOUIS UNIV,SCH MED,MALLINCKRODT INST RADIOL,DIV RADIAT SCI,ST LOUIS,MO 63110, USA.							BURTON H, 1993, SOMATOSENS MOT RES, V10, P297, DOI 10.3109/08990229309028839; CHAPIN JK, 1982, EXP NEUROL, V78, P654, DOI 10.1016/0014-4886(82)90082-6; CHAPIN JK, 1982, EXP NEUROL, V78, P670, DOI 10.1016/0014-4886(82)90083-8; CHAPMAN CE, 1988, EXP BRAIN RES, V72, P316; CHAPMAN CE, 1987, EXP BRAIN RES, V68, P516; CHAPMAN CE, 1991, EXP BRAIN RES, V87, P319; COQUERY J M, 1971, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V165, P1946; Coquery J-M, 1978, ACTIVE TOUCH MECHANI, P161; DREVETS WC, 1992, SCIENCE, V256, P1696, DOI 10.1126/science.256.5064.1696; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1989, J NUCL MED, V30, P141; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; FOX PT, 1987, J NEUROSURG, V67, P34, DOI 10.3171/jns.1987.67.1.0034; HERSCOVITCH P, 1983, J NUCL MED, V14, P782; NELSON RJ, 1980, J COMP NEUROL, V192, P611, DOI 10.1002/cne.901920402; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.neuro.13.1.25; RAICHLE ME, 1983, J NUCL MED, V24, P790; ROLAND PE, 1981, J NEUROPHYSIOL, V46, P744, DOI 10.1152/jn.1981.46.4.744; SATHIAN K, 1991, PERCEPT PSYCHOPHYS, V50, P237, DOI 10.3758/BF03206747; SINCLAIR RJ, 1991, J NEUROPHYSIOL, V66, P153, DOI 10.1152/jn.1991.66.1.153; SPIELBERGER CD, 1970, MANUAL STATE TRAIT A; Talairach J., 1988, COPLANAR STEREOTAXIC, P1; WHANG KC, 1991, PERCEPT PSYCHOPHYS, V50, P157, DOI 10.3758/BF03212216; YAMAMOTO M, 1982, IEEE T NUCL SCI, V29, P529, DOI 10.1109/TNS.1982.4335901	24	231	238	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					249	252		10.1038/373249a0	http://dx.doi.org/10.1038/373249a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816140				2022-12-24	WOS:A1995QC27800065
J	COLBRIDGE, MJ; BAILY, GG; DUNBAR, EM; ONG, ELC				COLBRIDGE, MJ; BAILY, GG; DUNBAR, EM; ONG, ELC			ANTIBIOTICS CARRIED IN GENERAL-PRACTITIONERS EMERGENCY BAGS - 4 YEARS ON	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,NEWCASTLE GEN HOSP,SCH MED,INFECT DIS UNIT,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND; N MANCHESTER GRP HOSP,DEPT TROP MED & INFECT DIS,MANCHESTER M8 6RB,LANCS,ENGLAND	Newcastle General Hospital; Newcastle University - UK				Ong, Edmund/0000-0002-6594-0509				BEGG N, 1992, BRIT MED J, V305, P133, DOI 10.1136/bmj.305.6846.133; CARTWRIGHT K, 1992, BRIT MED J, V305, P1343; ONG ELC, 1988, BRIT MED J, V297, P901, DOI 10.1136/bmj.297.6653.901; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141	4	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					29	30		10.1136/bmj.310.6971.29	http://dx.doi.org/10.1136/bmj.310.6971.29			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827551	Green Published			2022-12-24	WOS:A1995QB06000028
J	ROONEY, CM; SMITH, CA; NG, CYC; LOFTIN, S; LI, CF; KRANCE, RA; BRENNER, MK; HESLOP, HE				ROONEY, CM; SMITH, CA; NG, CYC; LOFTIN, S; LI, CF; KRANCE, RA; BRENNER, MK; HESLOP, HE			USE OF GENE-MODIFIED VIRUS-SPECIFIC T-LYMPHOCYTES TO CONTROL EPSTEIN-BARR-VIRUS-RELATED LYMPHOPROLIFERATION	LANCET			English	Article							MARROW TRANSPLANT RECIPIENTS; BONE-MARROW; IMMUNITY	Reactivation of Epstein-Barr virus (EBV) after bone-marrow transplantation leads in many cases to lymphoproliferative disease that responds poorly to standard therapy and is usually fatal. To prevent or central this complication, we prepared EBV-specific cytotoxic T-lymphocyte (CTL) lines from donor leucocytes and infused them into ten allograft recipients. Three of the patients had shown signs of EBV reactivation, with or without overt lymphoproliferation, and the others received CTL infusions as prophylaxis. No patient developed any complication that could be attributed to the CTL infusions. in the three patients with EBV reactivation, EBV DNA concentrations (measured by semiquantitative polymerase chain reaction [PCR]), which had increased 1000-fold or more, returned to the control range within 3-4 weeks of immunotherapy. The most striking consequence was the resolution of immunoblastic lymphoma in a 17-year-old patient who received four CTL infusions (two 1x10(7)/m(2) and two 5x10(7)/m(2)). Because the CTL had been genetically marked before infusion, we were able to show by PCR analysis that they persisted for 10 weeks after administration. EBV-specific donor-type T-cell lines seem to offer safe and effective therapy for control of EBV-associated lymphoproliferation.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOLEC BIOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, DIV BONE MARROW TRANSPLANTAT, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, COLL MED, DEPT PATHOL, MEMPHIS, TN USA; UNIV TENNESSEE, COLL MED, DEPT MED, MEMPHIS, TN USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center			Rooney, Cliona/ABD-5475-2021; Heslop, Helen/AAC-9500-2020; Brenner, Malcolm/Y-2509-2019		NATIONAL CANCER INSTITUTE [P30CA021765, R01CA061384, P01CA020180, U01CA061384] Funding Source: NIH RePORTER; NCI NIH HHS [CA 61384, CA 21765, CA 20180] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOURGAULT I, 1991, CLIN EXP IMMUNOL, V84, P501; BOYLE MJ, 1991, BLOOD, V78, P3004; BRENNER MK, 1993, LANCET, V342, P1134, DOI 10.1016/0140-6736(93)92122-A; BURROWS SR, 1994, J EXP MED, V179, P1155, DOI 10.1084/jem.179.4.1155; COHEN KI, 1991, P NATL ACAD SCI USA, V86, P9558; CRAWFORD DH, 1986, TRANSPLANTATION, V42, P50, DOI 10.1097/00007890-198607000-00010; DUNCOMBE AS, 1992, BLOOD, V79, P3059; FISCHER A, 1991, NEW ENGL J MED, V324, P1451, DOI 10.1056/NEJM199105233242102; HESLOP HE, 1994, BLOOD, V83, P1706, DOI 10.1182/blood.V83.6.1706b.bloodjournal8361706b; HESLOP HE, 1994, HUM GENE THER, V5, P381, DOI 10.1089/hum.1994.5.3-381; HESLOP HE, 1994, NEW ENGL J MED, V331, P679; JOSKE D, 1993, BLOOD REV, V7, P215, DOI 10.1016/0268-960X(93)90008-R; KHANNA R, 1992, J EXP MED, V176, P169, DOI 10.1084/jem.176.1.169; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; LIEBERMAN J, 1994, NEW ENGL J MED, V330, P1231, DOI 10.1056/NEJM199404283301711; LIST AF, 1987, J CLIN ONCOL, V5, P1673, DOI 10.1200/JCO.1987.5.10.1673; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; PRENTICE HG, 1984, LANCET, V1, P472; RICKINSON AB, 1981, CANCER RES, V41, P4216; RIDDELL SR, 1992, SCIENCE, V257, P238; RIDDLER SA, 1994, BLOOD, V84, P972; ROONEY CM, IN PRESS BR J HAEMAT; SAVOIE A, 1994, BLOOD, V83, P2715; STRAUS SE, 1992, ANN INTERN MED, V118, P45; VANRHEE F, 1994, BLOOD, V83, P3377; Young L S, 1992, Semin Cancer Biol, V3, P273; ZIMBER U, 1986, VIROLOGY, V154, P56, DOI 10.1016/0042-6822(86)90429-0	29	951	985	1	24	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 7	1995	345	8941					9	13		10.1016/S0140-6736(95)91150-2	http://dx.doi.org/10.1016/S0140-6736(95)91150-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799740				2022-12-24	WOS:A1995QA29000008
J	STANLEY, P; PACKMAN, LC; KORONAKIS, V; HUGHES, C				STANLEY, P; PACKMAN, LC; KORONAKIS, V; HUGHES, C			FATTY ACYLATION OF 2 INTERNAL LYSINE RESIDUES REQUIRED FOR THE TOXIC ACTIVITY OF ESCHERICHIA-COLI HEMOLYSIN	SCIENCE			English	Article							NUCLEOTIDE-SEQUENCE; ACTINOBACILLUS-PLEUROPNEUMONIAE; CHROMOSOMAL HEMOLYSIN; VIRUS GLYCOPROTEINS; GENE; SECRETION; PROTEIN; PROHAEMOLYSIN; ACTIVATION; HLYC	Hemolysin of Escherichia coli is activated by fatty acylation of the protoxin, directed by the putative acyl transferase HlyC and by acyl carrier protein (ACP). Mass spectrometry and Edman degradation of proteolytic products from mature toxin activated in vitro with tritium-labeled acylACP revealed two fatty-acylated internal lysine residues, lysine 564 and lysine 690. Resistance of the acylation to chemical treatments suggested that fatty acid was amide linked. Substitution of the two lysines confirmed that they were the only sites of acylation and showed that although each was acylated in the absence of the other, both sites were required for in vivo toxin activity.	UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND	University of Cambridge; University of Cambridge				Koronakis, Vassilis/0000-0002-1353-1092				CHANG YF, 1989, DNA-J MOLEC CELL BIO, V8, P635, DOI 10.1089/dna.1.1989.8.635; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; FORESTIER C, 1991, INFECT IMMUN, V59, P4212, DOI 10.1128/IAI.59.11.4212-4220.1991; FORESTIER C, 1990, INFECT IMMUN, V58, P828, DOI 10.1128/IAI.58.3.828-832.1990; FREY J, 1991, INFECT IMMUN, V59, P3026, DOI 10.1128/IAI.59.9.3026-3032.1991; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GYGI D, 1990, MOL MICROBIOL, V4, P123, DOI 10.1111/j.1365-2958.1990.tb02021.x; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HARDIE KR, 1991, MOL MICROBIOL, V5, P1669, DOI 10.1111/j.1365-2958.1991.tb01914.x; HEDO JA, 1987, J BIOL CHEM, V262, P954; HESS J, 1986, FEMS MICROBIOL LETT, V34, P1, DOI 10.1016/0378-1097(86)90261-2; HUGHES C, 1992, BIOESSAYS, V14, P519, DOI 10.1002/bies.950140804; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; KORONAKIS V, 1988, NUCLEIC ACIDS RES, V16, P4789, DOI 10.1093/nar/16.11.4789; KRAIG E, 1990, INFECT IMMUN, V58, P920, DOI 10.1128/IAI.58.4.920-929.1990; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LO RYC, 1987, INFECT IMMUN, V55, P1987, DOI 10.1128/IAI.55.9.1987-1996.1987; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MCWHINNEY DR, 1992, J BACTERIOL, V174, P291, DOI 10.1128/jb.174.1.291-297.1992; OLSON EN, 1984, J BIOL CHEM, V259, P5364; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; PELLETT S, 1990, INFECT IMMUN, V58, P822, DOI 10.1128/IAI.58.3.822-827.1990; PILLAI S, 1987, P NATL ACAD SCI USA, V84, P7654, DOI 10.1073/pnas.84.21.7654; ROWE GE, 1994, INFECT IMMUN, V62, P579, DOI 10.1128/IAI.62.2.579-588.1994; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT MFG, 1979, P NATL ACAD SCI USA, V76, P1687, DOI 10.1073/pnas.76.4.1687; STANLEY P, 1991, MOL MICROBIOL, V5, P2391, DOI 10.1111/j.1365-2958.1991.tb02085.x; STANLEY P, UNPUB; STANLEY PLD, 1993, MOL MICROBIOL, V10, P781, DOI 10.1111/j.1365-2958.1993.tb00948.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUTTORP N, 1990, INFECT IMMUN, V58, P3796, DOI 10.1128/IAI.58.11.3796-3801.1990	34	167	173	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					1992	1996		10.1126/science.7801126	http://dx.doi.org/10.1126/science.7801126			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801126				2022-12-24	WOS:A1994PZ26700030
J	WILLIAMS, A; SHAW, WC; DEVLIN, HB				WILLIAMS, A; SHAW, WC; DEVLIN, HB			PROVISION OF SERVICES FOR CLEFT-LIP AND PALATE IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article									UNIV MANCHESTER,TURNER DENT SCH,DEPT ORAL HLTH & DEV,MANCHESTER M15 6FH,LANCS,ENGLAND	University of Manchester	WILLIAMS, A (corresponding author), ROYAL COLL SURGEONS ENGLAND,SURG AUDIT UNIT,LONDON WC2A 3PN,ENGLAND.							Congenital Malformations Worldwide, 1993, CONGENITAL MALFORMAT; DEVLIN HB, 1990, ANN R COLL SURG EN S, V73, P3; SHAW WC, 1994, FINAL REPORT REGIONA; SHAW WC, 1992, RECENT ADV PLASTICS, V4, P1; 1994, REPORT STANDING DENT	5	28	28	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1552	1552		10.1136/bmj.309.6968.1552	http://dx.doi.org/10.1136/bmj.309.6968.1552			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819898	Green Published			2022-12-24	WOS:A1994PX56400024
J	RAEBURN, JA				RAEBURN, JA			SCREENING FOR CARRIERS OF CYSTIC-FIBROSIS - SCREENING BEFORE PREGNANCY IS NEEDED	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE				RAEBURN, JA (corresponding author), CITY HOSP NOTTINGHAM,CTR GENET MED,NOTTINGHAM NG5 1PD,ENGLAND.							BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; MARTEAU TM, 1992, J MED GENET, V29, P24, DOI 10.1136/jmg.29.1.24; MATTHEWS P, 1993, INDEPENDENT SUND AUG, P42; MENNIE ME, 1992, LANCET, V340, P214, DOI 10.1016/0140-6736(92)90476-J; MODELL M, 1993, BRIT MED J, V307, P849, DOI 10.1136/bmj.307.6908.849; QURESHI N, 1993, BRIT MED J, V307, P816, DOI 10.1136/bmj.307.6908.816; SCRIVER CR, 1992, AM J HUM GENET, V51, P943; WALD NJ, 1993, LANCET, V342, P1307, DOI 10.1016/0140-6736(93)92403-G; 1993, GENETIC SCREENING ET, P15; 1992, CYSTIC FIBROSIS DNA	10	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1428	1429		10.1136/bmj.309.6966.1428	http://dx.doi.org/10.1136/bmj.309.6966.1428			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819857	Green Published			2022-12-24	WOS:A1994PU76400032
